







## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>G01N 33/48</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/22430</b> (43) International Publication Date: <b>20 April 2000 (20.04.00)</b>
(21) International Application Number: <b>PCT/US99/23573</b> (22) International Filing Date: <b>8 October 1999 (08.10.99)</b> (30) Priority Data: 60/103,794                      9 October 1998 (09.10.98)    US 60/132,068                    30 April 1999 (30.04.99)    US (71) Applicant (for all designated States except US): <b>CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>FRAZER, Claire, M. [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). HICKEY, Erin [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). PETERSON, Jeremy [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). TETTELIN, Herve [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). VENTER, J., Craig [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). MASIGNANI, Vega [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). GALEOTTI, Cesira [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). MORA, Marirossa [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). RATTI, Giulio [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100</b>		Siena (IT). SCARSELLI, Maria [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). SCARLATO, Vincenzo [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). RAPPUOLI, Rino [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). PIZZA, Mariagrazia [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). (74) Agent: <b>HARBIN, Ailsa, A.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).</b> (81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b> <b>Published</b> Without international search report and to be republished upon receipt of that report.
(54) Title: <b>NEISSERIA GENOMIC SEQUENCES AND METHODS OF THEIR USE</b> (57) Abstract		
The invention provides methods of obtaining immunogenic proteins from genomic sequences including <i>Neisseria</i> , including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of <i>Neisseria meningitidis B</i> . The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.		    <p><b>Figure A: Purification of protein 919 (46 kDa)</b> Purification M 919</p> <p><b>Figure B: Western blot of protein 919 (46 kDa)</b> Western blot O M V T P PP</p> <p><b>Figure C: HPLC chromatogram of protein 919 (46 kDa)</b> 919 (46 kDa) PACS</p> <p><b>Figure D: Bactericidal assay</b> 919 (46 kDa) BACTERICIDAL ASSAY Legend: <math>\square</math> preimmune, <math>\triangle</math> GP, <math>\bullet</math> 919 Y-axis: colonies X-axis: time (t0 to t1)</p> <p><b>Figure E: ELISA assay</b> 919 (46 kDa) ELISA assay: positive</p>

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

## NEISSERIA GENOMIC SEQUENCES AND METHODS OF THEIR USE

This application claims priority to provisional U.S. applications serial nos. 60/103,794, filed 9 October, 1998 and 60/132,068, filed 30 April, 1999, both of which are  
5 incorporated in full herein by reference.

This invention relates to methods of obtaining antigens and immunogens, the antigens and immunogens so obtained, and nucleic acids from the bacterial species: *Neisseria meningitidis*. In particular, it relates to genomic sequences from the bacterium; more particularly its "B" serogroup.

10

## BACKGROUND

*Neisseria meningitidis* is a non-motile, gram negative diplococcus human pathogen. It colonizes the pharynx, causing meningitis and, occasionally, septicaemia in the absence of meningitis. It is closely related to *N. gonorrhoea*, although one feature that clearly  
15 differentiates meningococcus from gonococcus is the presence of a polysaccharide capsule that is present in all pathogenic meningococci.

*N. meningitidis* causes both endemic and epidemic disease. In the United States the attack rate is 0.6-1 per 100,000 persons per year, and it can be much greater during outbreaks. (see Lieberman *et al.* (1996) Safety and Immunogenicity of a Serogroups A/C *Neisseria*  
20 *meningitidis* Oligosaccharide-Protein Conjugate Vaccine in Young Children. *JAMA* 275(19):1499-1503; Schuchat *et al* (1997) Bacterial Meningitis in the United States in 1995. *N Engl J Med* 337(14):970-976). In developing countries, endemic disease rates are much higher and during epidemics incidence rates can reach 500 cases per 100,000 persons per year. Mortality is extremely high, at 10-20% in the United States, and much higher in  
25 developing countries. Following the introduction of the conjugate vaccine against *Haemophilus influenzae*, *N. meningitidis* is the major cause of bacterial meningitis at all ages in the United States (Schuchat *et al* (1997) *supra*).

Based on the organism's capsular polysaccharide, 12 serogroups of *N. meningitidis* have been identified. Group A is the pathogen most often implicated in epidemic disease in  
30 sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in the United States and in most developed countries. Serogroups W135 and Y are responsible for

- 2 -

the rest of the cases in the United States and developed countries. The meningococcal vaccine currently in use is a tetravalent polysaccharide vaccine composed of serogroups A, C, Y and W135. Although efficacious in adolescents and adults, it induces a poor immune response and short duration of protection, and cannot be used in infants (e.g., Morbidity and Mortality weekly report, Vol. 46, No. RR-5 (1997)). This is because polysaccharides are T-cell independent antigens that induce a weak immune response that cannot be boosted by repeated immunization. Following the success of the vaccination against *H. influenzae*, conjugate vaccines against serogroups A and C have been developed and are at the final stage of clinical testing (Zollinger WD "New and Improved Vaccines Against Meningococcal Disease". In: *New Generation Vaccines*, supra, pp. 469-488; Lieberman *et al* (1996) supra; Costantino *et al* (1992) Development and phase I clinical testing of a conjugate vaccine against meningococcus A (menA) and C (menC) (*Vaccine* 10:691-698)).

Meningococcus B (MenB) remains a problem, however. This serotype currently is responsible for approximately 50% of total meningitis in the United States, Europe, and South America. The polysaccharide approach cannot be used because the MenB capsular polysaccharide is a polymer of  $\alpha(2-8)$ -linked *N*-acetyl neuraminic acid that is also present in mammalian tissue. This results in tolerance to the antigen; indeed, if an immune response were elicited, it would be anti-self, and therefore undesirable. In order to avoid induction of autoimmunity and to induce a protective immune response, the capsular polysaccharide has, for instance, been chemically modified substituting the *N*-acetyl groups with *N*-propionyl groups, leaving the specific antigenicity unaltered (Romero & Outschoorn (1994) Current status of Meningococcal group B vaccine candidates: capsular or non-capsular? *Clin Microbiol Rev* 7(4):559-575).

Alternative approaches to MenB vaccines have used complex mixtures of outer membrane proteins (OMPs), containing either the OMPs alone, or OMPs enriched in porins, or deleted of the class 4 OMPs that are believed to induce antibodies that block bactericidal activity. This approach produces vaccines that are not well characterized. They are able to protect against the homologous strain, but are not effective at large where there are many antigenic variants of the outer membrane proteins. To overcome the antigenic variability, multivalent vaccines containing up to nine different porins have been constructed (e.g., Poolman JT (1992) Development of a meningococcal vaccine. *Infect. Agents Dis.* 4:13-28).



- 3 -

Additional proteins to be used in outer membrane vaccines have been the opa and opc proteins, but none of these approaches have been able to overcome the antigenic variability (e.g., Ala' Aldeen & Borriello (1996) The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. *Vaccine* 14(1):49-53).

A certain amount of sequence data is available for meningococcal and gonococcal genes and proteins (e.g., EP-A-0467714, WO96/29412), but this is by no means complete. The provision of further sequences could provide an opportunity to identify secreted or surface-exposed proteins that are presumed targets for the immune system and which are not antigenically variable or at least are more antigenically conserved than other and more variable regions. Thus, those antigenic sequences that are more highly conserved are preferred sequences. Those sequences specific to *Neisseria meningitidis* or *Neisseria gonorrhoeae* that are more highly conserved are further preferred sequences. For instance, some of the identified proteins could be components of efficacious vaccines against meningococcus B, some could be components of vaccines against all meningococcal serotypes, and others could be components of vaccines against all pathogenic *Neisseriae*. The identification of sequences from the bacterium will also facilitate the production of biological probes, particularly organism-specific probes.

It is thus an object of the invention is to provide Neisserial DNA sequences which (1) encode proteins predicted and/or shown to be antigenic or immunogenic, (2) can be used as probes or amplification primers, and (3) can be analyzed by bioinformatics.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the products of protein expression and purification of the predicted ORF 919 as cloned and expressed in *E. coli*.

Fig. 2 illustrates the products of protein expression and purification of the predicted ORF 279 as cloned and expressed in *E. coli*.

Fig. 3 illustrates the products of protein expression and purification of the predicted ORF 576-1 as cloned and expressed in *E. coli*.

Fig. 4 illustrates the products of protein expression and purification of the predicted ORF 519-1 as cloned and expressed in *E. coli*.

Fig. 5 illustrates the products of protein expression and purification of the predicted ORF 121-1 as cloned and expressed in *E. coli*.

Fig. 6 illustrates the products of protein expression and purification of the predicted ORF 128-1 as cloned and expressed in *E. coli*.

5 Fig. 7 illustrates the products of protein expression and purification of the predicted ORF 206 as cloned and expressed in *E. coli*.

Fig. 8 illustrates the products of protein expression and purification of the predicted ORF 287 as cloned and expressed in *E. coli*.

10 Fig. 9 illustrates the products of protein expression and purification of the predicted ORF 406 as cloned and expressed in *E. coli*.

Fig. 10 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 919 as cloned and expressed in *E. coli*.

Fig. 11 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 279 as cloned and expressed in *E. coli*.

15 Fig. 12 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 576-1 as cloned and expressed in *E. coli*.

Fig. 13 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 519-1 as cloned and expressed in *E. coli*.

20 Fig. 14 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 121-1 as cloned and expressed in *E. coli*.

Fig. 15 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 128-1 as cloned and expressed in *E. coli*.

Fig. 16 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 206 as cloned and expressed in *E. coli*.

25 Fig. 17 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 287 as cloned and expressed in *E. coli*.

Fig. 18 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 406 as cloned and expressed in *E. coli*.

## THE INVENTION

The invention is based on the 961 nucleotide sequences from the genome of *N. meningitidis* shown as SEQ ID NOs:1-961 of Appendix C, and the full length genome of *N. meningitidis* shown as SEQ ID NO. 1068 in Appendix D. The 961 sequences in Appendix C represent substantially the whole genome of serotype B of *N. meningitidis* (>99.98%). There is partial overlap between some of the 961 contiguous sequences ("contigs") shown in the sequences in Appendix C, which overlap was used to construct the single full length sequence shown in SEQ ID NO. 1068 in Appendix D, using the TIGR Assembler [G.S. Sutton et al., *TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects*, Genome Science and Technology, 1:9-19 (1995)]. Some of the nucleotides in the contigs had been previously released. (See [ftp://ftp.tigr.org/pub/data/n\\_meningitidis](ftp://ftp.tigr.org/pub/data/n_meningitidis) on the world-wide web or "WWW"). The coordinates of the 2508 released sequences in the present contigs are presented in Appendix A. These data include the contig number (or i.d.) as presented in the first column; the name of the sequence as found on WWW is in the second column; with the coordinates of the contigs in the third and fourth columns, respectively. The sequences of certain MenB ORFs presented in Appendix B feature in International Patent Application filed by Chiron SpA on October 9, 1998 (PCT/IB98/01665) and January 14, 1999 (PCT/IB99/00103) respectively.

In a first aspect, the invention provides nucleic acid including one or more of the *N. meningitidis* nucleotide sequences shown in SEQ ID NOs:1-961 and 1068 in Appendices C and E. It also provides nucleic acid comprising sequences having sequence identity to the nucleotide sequence disclosed herein. Depending on the particular sequence, the degree of sequence identity is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more). These sequences include, for instance, mutants and allelic variants. The degree of sequence identity cited herein is determined across the length of the sequence determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following parameters: gap open penalty 12, gap extension penalty 1.

The invention also provides nucleic acid including a fragment of one or more of the nucleotide sequences set out herein. The fragment should comprise at least  $n$  consecutive nucleotides from the sequences and, depending on the particular sequence,  $n$  is 10 or more

(e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 75, 100 or more). Preferably, the fragment is unique to the genome of *N. meningitidis*, that is to say it is not present in the genome of another organism. More preferably, the fragment is unique to the genome of strain B of *N. meningitidis*. The invention also provides nucleic acid that  
5 hybridizes to those provided herein. Conditions for hybridizing are disclosed herein.

The invention also provides nucleic acid including sequences complementary to those described above (e.g., for antisense, for probes, or for amplification primers).

Nucleic acid according to the invention can, of course, be prepared in many ways (e.g., by chemical synthesis, from DNA libraries, from the organism itself, etc.) and can take  
10 various forms (e.g., single-stranded, double-stranded, vectors, probes, primers, etc.). The term "nucleic acid" includes DNA and RNA, and also their analogs, such as those containing modified backbones, and also peptide nucleic acid (PNA) etc.

It will be appreciated that, as SEQ ID NOs:1-961 represent the substantially complete genome of the organism, with partial overlap, references to SEQ ID NOs:1-961 include  
15 within their scope references to the complete genomic sequence, e.g., where two SEQ ID NOs overlap, the invention encompasses the single sequence which is formed by assembling the two overlapping sequences. Thus, for instance, a nucleotide sequence which bridges two SEQ ID NOs but is not present in its entirety in either SEQ ID NO is still within the scope of the invention. Additionally, such a sequence will be present in its entirety in the single full  
20 length sequence of SEQ ID NO. 1068.

The invention also provides vectors including nucleotide sequences of the invention (e.g., expression vectors, sequencing vectors, cloning vectors, etc.) and host cells transformed with such vectors.

According to a further aspect, the invention provides a protein including an amino  
25 acid sequence encoded within a *N. meningitidis* nucleotide sequence set out herein. It also provides proteins comprising sequences having sequence identity to those proteins. Depending on the particular sequence, the degree of sequence identity is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more). Sequence identity is determined as above disclosed. These homologous proteins include mutants and allelic variants, encoded  
30 within the *N. meningitidis* nucleotide sequence set out herein.

- 7 -

The invention further provides proteins including fragments of an amino acid sequence encoded within a *N. meningitidis* nucleotide sequence set out in the sequence listing. The fragments should comprise at least *n* consecutive amino acids from the sequences and, depending on the particular sequence, *n* is 7 or more (e.g., 8, 10, 12, 14, 16, 18, 20 or more). Preferably the fragments comprise an epitope from the sequence.

The proteins of the invention can, of course, be prepared by various means (e.g., recombinant expression, purification from cell culture, chemical synthesis, etc.) and in various forms (e.g. native, fusions etc.). They are preferably prepared in substantially isolated form (i.e., substantially free from other *N. meningitidis* host cell proteins).

Various tests can be used to assess the *in vivo* immunogenicity of the proteins of the invention. For example, the proteins can be expressed recombinantly or chemically synthesized and used to screen patient sera by immunoblot. A positive reaction between the protein and patient serum indicates that the patient has previously mounted an immune response to the protein in question; i.e., the protein is an immunogen. This method can also be used to identify immunodominant proteins.

The invention also provides nucleic acid encoding a protein of the invention.

In a further aspect, the invention provides a computer, a computer memory, a computer storage medium (e.g., floppy disk, fixed disk, CD-ROM, etc.), and/or a computer database containing the nucleotide sequence of nucleic acid according to the invention.

Preferably, it contains one or more of the *N. meningitidis* nucleotide sequences set out herein.

This may be used in the analysis of the *N. meningitidis* nucleotide sequences set out herein. For instance, it may be used in a search to identify open reading frames (ORFs) or coding sequences within the sequences.

In a further aspect, the invention provides a method for identifying an amino acid sequence, comprising the step of searching for putative open reading frames or protein-coding sequences within a *N. meningitidis* nucleotide sequence set out herein. Similarly, the invention provides the use of a *N. meningitidis* nucleotide sequence set out herein in a search for putative open reading frames or protein-coding sequences.

Open-reading frame or protein-coding sequence analysis is generally performed on a computer using standard bioinformatic techniques. Typical algorithms or program used in the analysis include ORFFINDER (NCBI), GENMARK [Borodovsky & McIninch (1993)]

*Computers Chem* 17:122-133], and GLIMMER [Salzberg et al. (1998) *Nucl Acids Res* 26:544-548].

A search for an open reading frame or protein-coding sequence may comprise the steps of searching a *N. meningitidis* nucleotide sequence set out herein for an initiation codon and searching the upstream sequence for an in-frame termination codon. The intervening codons represent a putative protein-coding sequence. Typically, all six possible reading frames of a sequence will be searched.

An amino acid sequence identified in this way can be expressed using any suitable system to give a protein. This protein can be used to raise antibodies which recognize epitopes within the identified amino acid sequence. These antibodies can be used to screen *N. meningitidis* to detect the presence of a protein comprising the identified amino acid sequence.

Furthermore, once an ORF or protein-coding sequence is identified, the sequence can be compared with sequence databases. Sequence analysis tools can be found at NCBI (<http://www.ncbi.nlm.nih.gov>) e.g., the algorithms BLAST, BLAST2, BLASTn, BLASTp, tBLASTn, BLASTx, & tBLASTx [see also Altschul *et al.* (1997) Gapped BLAST and PSI-BLAST: new generation of protein database search programs. *Nucleic Acids Research* 25:2289-3402]. Suitable databases for comparison include the nonredundant GenBank, EMBL, DDBJ and PDB sequences, and the nonredundant GenBank CDS translations, PDB, SwissProt, Spupdate and PIR sequences. This comparison may give an indication of the function of a protein.

Hydrophobic domains in an amino acid sequence can be predicted using algorithms such as those based on the statistical studies of Esposti *et al.* [Critical evaluation of the hydropathy of membrane proteins (1990) *Eur J Biochem* 190:207-219]. Hydrophobic domains represent potential transmembrane regions or hydrophobic leader sequences, which suggest that the proteins may be secreted or be surface-located. These properties are typically representative of good immunogens.

Similarly, transmembrane domains or leader sequences can be predicted using the PSORT algorithm (<http://www.psort.nibb.ac.jp>), and functional domains can be predicted using the MOTIFS program (GCG Wisconsin & PROSITE).

The invention also provides nucleic acid including an open reading frame or protein-coding sequence present in a *N. meningitidis* nucleotide sequence set out herein. Furthermore, the invention provides a protein including the amino acid sequence encoded by this open reading frame or protein-coding sequence.

5       According to a further aspect, the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means known to those skilled in the art.

      The antibodies of the invention can be used in a variety of ways, e.g., for confirmation that a protein is expressed, or to confirm where a protein is expressed. Labeled antibody  
10   (e.g., fluorescent labeling for FACS) can be incubated with intact bacteria and the presence of label on the bacterial surface confirms the location of the protein, for instance.

      According to a further aspect, the invention provides compositions including protein, antibody, and/or nucleic acid according to the invention. These compositions may be suitable as vaccines, as immunogenic compositions, or as diagnostic reagents.

15       The invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (e.g., as vaccines) or as diagnostic reagents. It also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of (i) a medicament for treating or preventing infection due to Neisserial bacteria (ii) a diagnostic reagent for detecting the presence of Neisserial bacteria or of  
20   antibodies raised against Neisserial bacteria. Said Neisserial bacteria may be any species or strain (such as *N. gonorrhoeae*) but are preferably *N. meningitidis*, especially strain A, strain B or strain C.

      In still yet another aspect, the present invention provides for compositions including proteins, nucleic acid molecules, or antibodies. More preferable aspects of the present  
25   invention are drawn to immunogenic compositions of proteins. Further preferable aspects of the present invention contemplate pharmaceutical immunogenic compositions of proteins or vaccines and the use thereof in the manufacture of a medicament for the treatment or prevention of infection due to Neisserial bacteria, preferably infection of MenB.

      The invention also provides a method of treating a patient, comprising administering  
30   to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.

- 10 -

According to further aspects, the invention provides various processes.

A process for producing proteins of the invention is provided, comprising the step of culturing a host cell according to the invention under conditions which induce protein expression. A process which may further include chemical synthesis of proteins and/or  
5 chemical synthesis (at least in part) of nucleotides.

A process for detecting polynucleotides of the invention is provided, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting said duplexes.

A process for detecting proteins of the invention is provided, comprising the steps of:  
10 (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.

Another aspect of the present invention provides for a process for detecting antibodies that selectably bind to antigens or polypeptides or proteins specific to any species or strain of  
15 *Neisseria* bacteria and preferably to strains of *N. gonorrhoeae* but more preferably to strains of *N. meningitidis*, especially strain A, strain B or strain C, more preferably MenB, where the process comprises the steps of: (a) contacting antigen or polypeptide or protein according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.

20 Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

#### Methodology - Summary of standard procedures and techniques.

##### 25 General

This invention provides *Neisseria meningitidis* MenB nucleotide sequences, amino acid sequences encoded therein. With these disclosed sequences, nucleic acid probe assays and expression cassettes and vectors can be produced. The proteins can also be chemically synthesized. The expression vectors can be transformed into host cells to produce proteins.

30 The purified or isolated polypeptides can be used to produce antibodies to detect MenB proteins. Also, the host cells or extracts can be utilized for biological assays to isolate



- 11 -

agonists or antagonists. In addition, with these sequences one can search to identify open reading frames and identify amino acid sequences. The proteins may also be used in immunogenic compositions and as vaccine components.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature e.g., Sambrook *Molecular Cloning; A Laboratory Manual, Second Edition* (1989); *DNA Cloning, Volumes I and ii* (D.N Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed, 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Transcription and Translation* (B.D. Hames & S.J. Higgins eds. 1984); *Animal Cell Culture* (R.I. Freshney ed. 1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide to Molecular Cloning* (1984); the *Methods in Enzymology* series (Academic Press, Inc.), especially volumes 154 & 155; *Gene Transfer Vectors for Mammalian Cells* (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), *Immunochemical Methods in Cell and Molecular Biology* (Academic Press, London); Scopes, (1987) *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.), and *Handbook of Experimental Immunology, Volumes I-IV* (D.M. Weir and C.C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are used in this specification.

All publications, patents, and patent applications cited herein are incorporated in full by reference.

#### Expression systems

The *Neisseria* MenB nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, plant cells, baculoviruses, bacteria, and yeast.

##### i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g., structural gene) into mRNA. A

- 12 -

promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation (Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In *Molecular Cloning: A Laboratory Manual*, 2nd ed.).

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible). Depending on the promoter selected, many promoters may be inducible using known substrates, such as the use of the mouse mammary tumor virus (MMTV) promoter with the glucocorticoid responsive element (GRE) that is induced by glucocorticoid in hormone-responsive transformed cells (see for example, U.S. Patent 5,783,681).

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter (Maniatis et al. (1987) *Science* 236:1237; Alberts et al. (1989) *Molecular Biology of the Cell*, 2nd ed.). Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer (Dijkema et al (1985) *EMBO J.* 4:761) and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus (Gorman et al. (1982b) *Proc. Natl. Acad. Sci.* 79:6777) and from human cytomegalovirus (Boshart et al. (1985) *Cell* 41:521). Additionally, some enhancers are regulatable and

- 13 -

become active only in the presence of an inducer, such as a hormone or metal ion (Sassone-Corsi and Borelli (1986) *Trends Genet.* 2:215; Maniatis et al. (1987) *Science* 236:1237).

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation (Birnstiel et al. (1985) *Cell* 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) *Trends Biochem. Sci.* 14:105). These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40 (Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*).

Usually, the above-described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of

- 14 -

stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 (Gluzman (1981) *Cell* 23:175) or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 (Kaufman et al. (1989) *Mol. Cell. Biol.* 9:946) and pHEBO (Shimizu et al. (1986) *Mol. Cell. Biol.* 6:1074).

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

## ii. Plant Cellular Expression Systems

There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: U.S. 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to the references described above in Vaulcombe et al., *Mol. Gen. Genet.* 209:33-40 (1987); Chandler et al., *Plant Molecular Biology* 3:407-418 (1984); Rogers, *J. Biol. Chem.* 260:3731-3738 (1985); Rothstein et al., *Gene* 55:353-356 (1987); Whittier et al., *Nucleic Acids*

Research 15:2515-2535 (1987); Wirsal et al., *Molecular Microbiology* 3:3-14 (1989); Yu et al., *Gene* 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R.L. Jones and J. MacMillan, Gibberellins: in: *Advanced Plant Physiology*.

- 5 Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, *Plant Cell*, 2:1027-1038(1990); Maas et al., *EMBO J.* 9:3447-3452 (1990); Benkel and Hickey, *Proc. Natl. Acad. Sci.* 84:1337-1339 (1987)

- Typically, using techniques known in the art, a desired polynucleotide sequence is  
10 inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an  
15 original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker; and, for *Agrobacterium* transformations, T DNA sequences for *Agrobacterium*-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable marker  
20 gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, *Plant Mol. Biol. Repr.*, 11(2):165-185.

- Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like  
25 for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.

- 30 The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only

- 16 -

one expression cassette, although two or more are feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region, plant 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5' and 3' ends of the cassette allow for easy insertion into a pre-existing vector.

A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed. While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.

Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's spliceosome machinery. If so, site-directed mutagenesis of the "intron" region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, *Cell* 41:95-105, 1985.

The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, *Mol. Gen. Genet.*, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., *Nature*, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., *Nature*, 327, 70-73, 1987 and Knudsen and Muller, 1991, *Planta*, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley. Yet another method of

introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79, 1859-1863, 1982.

The vector may also be introduced into the plant cells by electroporation. (Fromm et al., *Proc. Natl. Acad. Sci. USA* 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersion*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Hererocallis*, *Nemesia*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Lolium*, *Zea*, *Triticum*, *Sorghum*, and *Datura*.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension.

These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

- 18 -

In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected.

Alternatively, the embryos and embryoless-half seeds or other plant tissue may be

- 5 mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.

10

### iii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains  
15 both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and  
20 appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for  
25 baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987) (hereinafter "Summers and Smith").

- 30 Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an



- 19 -

intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its own set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, *Virology* (1989) 17:31.

The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, 42:177) and a prokaryotic ampicillin-resistance (*amp*) gene and origin of replication for selection and propagation in *E. coli*.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g., structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlcek et al., (1988), *J. Gen. Virol.* 69:765.

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al.

- 20 -

(1988) *Gene*, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human ( $\alpha$ -interferon, Maeda et al., (1985), *Nature* 315:592; human gastrin-releasing peptide, Lebacqz-Verheyden et al., (1988), *Molec. Cell. Biol.* 8:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA*, 82:8404; mouse IL-3, (Miyajima et al., (1987) *Gene* 58:273; and human glucocerebrosidase, Martin et al. (1988) *DNA*, 7:99, can also be used to provide for secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.

Alternatively, recombinant polypeptides or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.* (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a

- 21 -

restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays* 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

5       The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing  
10 recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15  $\mu$ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells  
15 infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. *Current Protocols in Microbiology* Vol. 2 (Ausubel  
20 et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, *supra*; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and *Trichoplusia ni* (PCT Pub. No. WO 89/046699; Carbonell et al.,  
25 (1985) *J. Virol.* 56:153; Wright (1986) *Nature* 321:718; Smith et al., (1983) *Mol. Cell. Biol.* 3:2156; and see generally, Fraser, et al. (1989) *In Vitro Cell. Dev. Biol.* 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith  
30 *supra*.

- 22 -

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides;

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

#### iv. Bacterial Systems

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the

- 23 -

RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the *lac* operon in *Escherichia coli* (*E. coli*) (Raibaud *et al.* (1984) *Annu. Rev. Genet.* 18:173). Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) (Chang *et al.* (1977) *Nature* 198:1056), and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) (Goeddel *et al.* (1980) *Nuc. Acids Res.* 8:4057; Yelverton *et al.* (1981) *Nucl. Acids Res.* 9:731; U.S. Patent 4,738,921; EPO Publ. Nos. 036 776 and 121 775). The beta-lactamase (*bla*) promoter system (Weissmann (1981) "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I. Gresser)), bacteriophage lambda PL (Shimatake *et al.* (1981) *Nature* 292:128) and T5 (U.S. Patent 4,689,406) promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter (U.S. Patent 4,551,433). For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and *lac* operon sequences that is regulated by the *lac* repressor (Amann *et al.* (1983) *Gene* 25:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci.* 80:21). Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system (Studier *et al.* (1986) *J. Mol. Biol.* 189:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci.* 82:1074). In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO Publ. No. 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome

- 24 -

binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine *et al.* (1975) *Nature* 254:34). The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of *E. coli* 16S rRNA (Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberg)). To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site, it is often necessary to optimize the distance between the SD sequence and the ATG of the eukaryotic gene (Sambrook *et al.* (1989) "Expression of cloned genes in *Escherichia coli*." In *Molecular Cloning: A Laboratory Manual*).

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* or *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene (Nagai *et al.* (1984) *Nature* 309:810). Fusion proteins can also be made with sequences from the *lacZ* (Jia *et al.* (1987) *Gene* 60:197), *trpE* (Allen *et al.* (1987) *J. Biotechnol.* 5:93; Makoff *et al.* (1989) *J. Gen. Microbiol.* 135:11), and *Chey* (EPO Publ. No. 324 647) genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated (Miller *et al.* (1989) *Bio/Technology* 7:698).

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria (U.S. Patent 4,336,336). The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) (Masui *et al.* (1983), in: *Experimental Manipulation of Gene Expression*; Ghrayeb *et al.* (1984) *EMBO J.* 3:2437) and the *E. coli* alkaline phosphatase signal sequence (*phoA*) (Oka *et al.* (1985) *Proc. Natl. Acad. Sci.* 82:7212). As an additional example, the signal sequence of the alpha-amylase gene from various *Bacillus* strains can be used to secrete heterologous proteins from *B. subtilis* (Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. No. 244 042).

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will

- 26 -

generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline (Davies *et al.* (1978) *Annu. Rev. Microbiol.* 32:469). Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: *Bacillus subtilis* (Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541), *Escherichia coli* (Shimatake *et al.* (1981) *Nature* 292:128; Amann *et al.* (1985) *Gene* 40:183; Studier *et al.* (1986) *J. Mol. Biol.* 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907), *Streptococcus cremoris* (Powell *et al.* (1988)



*Appl. Environ. Microbiol.* 54:655); *Streptococcus lividans* (Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655), *Streptomyces lividans* (U.S. Patent 4,745,056).

- Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with  $\text{CaCl}_2$  or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. (See e.g., use of *Bacillus*: Masson *et al.* (1989) *FEMS Microbiol. Lett.* 60:273; Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; use of *Campylobacter*: Miller *et al.* (1988) *Proc. Natl. Acad. Sci.* 85:856; and Wang *et al.* (1990) *J. Bacteriol.* 172:949; use of *Escherichia coli*: Cohen *et al.* (1973) *Proc. Natl. Acad. Sci.* 69:2110; Dower *et al.* (1988) *Nucleic Acids Res.* 16:6127; Kushner (1978) "An improved method for transformation of *Escherichia coli* with ColE1-derived plasmids. In *Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering* (eds. H.W. Boyer and S. Nicosia); Mandel *et al.* (1970) *J. Mol. Biol.* 53:159; Taketo (1988) *Biochim. Biophys. Acta* 949:318; use of *Lactobacillus*: Chassy *et al.* (1987) *FEMS Microbiol. Lett.* 44:173; use of *Pseudomonas*: Fiedler *et al.* (1988) *Anal. Biochem.* 170:38; use of *Staphylococcus*: Augustin *et al.* (1990) *FEMS Microbiol. Lett.* 66:203; use of *Streptococcus*: Barany *et al.* (1980) *J. Bacteriol.* 144:698; Harlander (1987) "Transformation of *Streptococcus lactis* by electroporation, in: *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss III); Perry *et al.* (1981) *Infect. Immun.* 32:1295; Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655; Somkuti *et al.* (1987) *Proc. 4th Evr. Cong. Biotechnology* 1:412.

#### v. Yeast Expression

- Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS),

- 28 -

which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

5 Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and  
10 pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast *PHO5* gene, encoding acid phosphatase, also provides useful promoter sequences (Myanohara *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:1).

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the  
15 transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the *ADH2*, *GAL4*, *GAL10*, OR *PHO5* genes, combined with the transcriptional  
20 activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, *inter alia*, (Cohen *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:1078; Henikoff *et al.* (1981) *Nature* 283:835; Hollenberg *et al.* (1981) *Curr. Topics Microbiol.*  
25 *Immunol.* 96:119; Hollenberg *et al.* (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast *Saccharomyces cerevisiae*," in: *Plasmids of Medical, Environmental and Commercial Importance* (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon *et al.* (1980) *Gene* 11:163; Panthier *et al.* (1980) *Curr. Genet.* 2:109;).

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence  
30 may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the

- 29 -

ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, plant, baculovirus, and bacterial expression systems. Usually, a DNA sequence  
5 encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may  
10 or may not encode a cleavable site. See e.g., EPO Publ. No. 196056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (e.g., WO88/024066).

15 Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal  
20 peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62:096,086) and the A-factor gene (U.S. Patent 4,588,684). Alternatively, leaders of non-  
25 yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor  
30 leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; EPO Publ.

- 30 -

No. 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alpha factor. (See e.g., PCT Publ. No. WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 (Botstein *et al.* (1979) *Gene* 8:17-24), pCI/1 (Brake *et al.* (1984) *Proc. Natl. Acad. Sci USA* 81:4642-4646), and YRp17 (Stinchcomb *et al.* (1982) *J. Mol. Biol.* 158:157). In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake *et al.*, *supra*.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome (Orr-Weaver *et al.* (1983) *Methods in Enzymol.* 101:228-245). An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for

inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced (Rine *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:6750). The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or  
5 two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed.  
10 Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as *ADE2*, *HIS4*, *LEU2*, *TRP1*, and *ALG7*, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of *CUP1* allows yeast to grow in the  
15 presence of copper ions (Butt *et al.* (1987) *Microbiol. Rev.* 51:351).

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

20 Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors and methods of introducing exogenous DNA into yeast hosts have been developed for, *inter alia*, the following yeasts: *Candida albicans* (Kurtz, *et al.* (1986) *Mol. Cell. Biol.* 6:142); *Candida maltosa* (Kunze, *et al.* (1985) *J. Basic Microbiol.* 25:141);  
25 *Hansenula polymorpha* (Gleeson, *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302); *Kluyveromyces fragilis* (Das, *et al.* (1984) *J. Bacteriol.* 158:1165); *Kluyveromyces lactis* (De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:737; Van den Berg *et al.* (1990) *Bio/Technology* 8:135); *Pichia guilliermondii* (Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141); *Pichia pastoris* (Cregg, *et al.* (1985) *Mol. Cell. Biol.* 5:3376; U.S.  
30 Patent Nos. 4,837,148 and 4,929,555); *Saccharomyces cerevisiae* (Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163); *Schizosaccharomyces*

- 32 -

*pombe* (Beach and Nurse (1981) *Nature* 300:706); and *Yarrowia lipolytica* (Davidow, *et al.* (1985) *Curr. Genet.* 10:380471 Gaillardin, *et al.* (1985) *Curr. Genet.* 10:49).

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz *et al.* (1986) *Mol. Cell. Biol.* 6:142; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; Candida]; [Gleeson *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genei.* 202:302; Hansenula]; [Das *et al.* (1984) *J. Bacteriol.* 158:1165; De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:1165; Van den Berg *et al.* (1990) *Bio/Technology* 8:135; Kluyveromyces]; [Cregg *et al.* (1985) *Mol. Cell. Biol.* 5:3376; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555; Pichia]; [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163 *Saccharomyces*]; [Beach and Nurse (1981) *Nature* 300:706; *Schizosaccharomyces*]; [Davidow *et al.* (1985) *Curr. Genet.* 10:39; Gaillardin *et al.* (1985) *Curr. Genet.* 10:49; *Yarrowia*].

#### Definitions

A composition containing X is "substantially free of" Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.

The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell.

An "origin of replication" is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be

- 33 -

reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.

A "mutant" sequence is defined as a DNA, RNA or amino acid sequence differing  
5 from but having homology with the native or disclosed sequence. Depending on the particular sequence, the degree of homology between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more) which is calculated as described above. As used herein, an "allelic variant" of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a  
10 nucleic acid molecule, or region, that occurs at essentially the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic variant can also comprise an  
15 alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions. (see, for example, U.S. Patent 5,753,235).

#### Antibodies

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides  
20 composed of at least one antibody combining site. An "antibody combining site" is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. "Antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanized antibodies, altered antibodies, univalent  
25 antibodies, Fab proteins, and single domain antibodies.

Antibodies against the proteins of the invention are useful for affinity chromatography, immunoassays, and distinguishing/identifying *Neisseria* MenB proteins. Antibodies elicited against the proteins of the present invention bind to antigenic polypeptides or proteins or protein fragments that are present and specifically associated with  
30 strains of *Neisseria meningitidis* MenB. In some instances, these antigens may be associated with specific strains, such as those antigens specific for the MenB strains. The antibodies of

- 34 -

the invention may be immobilized to a matrix and utilized in an immunoassay or on an affinity chromatography column, to enable the detection and/or separation of polypeptides, proteins or protein fragments or cells comprising such polypeptides, proteins or protein fragments. Alternatively, such polypeptides, proteins or protein fragments may be  
5 immobilized so as to detect antibodies bindably specific thereto.

Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of  
10 labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 µg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline,  
15 preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by *in vitro* immunization using methods known in the art, which for the purposes of this invention is considered equivalent to *in vivo* immunization. Polyclonal antisera is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25°C for one hour, followed by incubating at 4°C for 2-18 hours. The serum is recovered by  
20 centrifugation (e.g., 1,000g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

Monoclonal antibodies are prepared using the standard method of Kohler & Milstein (*Nature* (1975) 256:495-96), or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum,  
25 the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells that express membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated  
30 spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (e.g., hypoxanthine, aminopterin, thymidine medium,



“HAT”). The resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either *in vitro* (e.g., in tissue culture bottles or hollow fiber reactors), or *in vivo* (as ascites in mice).

If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly  $^{32}\text{P}$  and  $^{125}\text{I}$ ), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3',5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. “Specific binding partner” refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example,  $^{125}\text{I}$  may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with  $^{125}\text{I}$ , or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

Antigens, immunogens, polypeptides, proteins or protein fragments of the present invention elicit formation of specific binding partner antibodies. These antigens, immunogens, polypeptides, proteins or protein fragments of the present invention comprise immunogenic compositions of the present invention. Such immunogenic compositions may further comprise or include adjuvants, carriers, or other compositions that promote or enhance or stabilize the antigens, polypeptides, proteins or protein fragments of the present

invention. Such adjuvants and carriers will be readily apparent to those of ordinary skill in the art.

#### Pharmaceutical Compositions

5        Pharmaceutical compositions can include either polypeptides, antibodies, or nucleic acid of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

10        The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature, when given to a patient that is febrile. The precise effective amount for a subject will depend upon the subject's size and health, the  
15        nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgment of the clinician.

20        For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

25        A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents.  
30        The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

- 37 -

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's

5 Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid

10 solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

#### Delivery Methods

15 Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the

20 interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal and transcutaneous applications, needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

#### 25 Vaccines

Vaccines according to the invention may either be prophylactic (i.e., to prevent infection) or therapeutic (i.e., to treat disease after infection).

Such vaccines comprise immunizing antigen(s) or immunogen(s), immunogenic polypeptide, protein(s) or protein fragments, or nucleic acids (e.g., ribonucleic acid or

30 deoxyribonucleic acid), usually in combination with "pharmaceutically acceptable carriers," which include any carrier that does not itself induce the production of antibodies harmful to

- 38 -

the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the immunogen or antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, etc. pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and th-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi<sup>TM</sup> adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox<sup>TM</sup>); (3) saponin adjuvants, such as Stimulon<sup>TM</sup> (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; (6) detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an E. coli heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., WO 93/13302 and WO 92/19265; and (7) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59 are preferred.

- 39 -

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), *etc.*

5       The vaccine compositions comprising immunogenic compositions (e.g., which may include the antigen, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Alternatively, vaccine compositions comprising immunogenic compositions  
10      may comprise an antigen, polypeptide, protein, protein fragment or nucleic acid in a pharmaceutically acceptable carrier.

More specifically, vaccines comprising immunogenic compositions comprise an immunologically effective amount of the immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is  
15      meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, primate, *etc.*), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the  
20      formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

Typically, the vaccine compositions or immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or  
25      suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

The immunogenic compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Additional formulations suitable for  
30      other modes of administration include oral and pulmonary formulations, suppositories, and transdermal and transcutaneous applications. Dosage treatment may be a single dose schedule

- 40 -

or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination may be employed (e.g., Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648).

#### Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs, including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence *in vivo* can be either constitutive or regulated.

The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) *Cancer Gene Therapy* 1:51-64; Kimura (1994) *Human Gene Therapy* 5:845-852; Connelly (1995) *Human Gene Therapy* 6:185-193; and Kaplitt (1994) *Nature Genetics* 6:148-153.

Retroviral vectors are well known in the art, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) *J. Virol.* 53:160) polytropic retroviruses e.g., MCF and MCF-MLV (see Kelly (1983) *J. Virol.* 45:291), spumaviruses and lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985.

Portions of the retroviral gene therapy vector may be derived from different retroviruses. For example, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

- 41 -

These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US patent 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see  
5 WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.

Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production  
10 of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (e.g., HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus, Mink-Cell  
15 Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) *J Virol* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC No. VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190).  
20 Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

Exemplary known retroviral gene therapy vectors employable in this invention include those described in patent applications GB2200651, EP0415731, EP0345242,  
25 EP0334301, WO89/02468; WO89/05349, WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698, WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825, WO95/07994, US 5,219,740, US 4,405,712, US 4,861,719, US 4,980,289, US 4,777,127, US 5,591,624. See also Vile (1993) *Cancer Res* 53:3860-3864; Vile (1993) *Cancer Res* 53:962-967; Ram (1993) *Cancer Res* 53 (1993) 83-88; Takamiya (1992) *J Neurosci Res* 33:493-503; Baba (1993) *J Neurosurg* 79:729-735; Mann (1983) *Cell* 33:153;  
30 Cane (1984) *Proc Natl Acad Sci* 81:6349; and Miller (1990) *Human Gene Therapy* 1.

- 42 -

Human adenoviral gene therapy vectors are also known in the art and employable in this invention. See, for example, Berkner (1988) *Biotechniques* 6:616 and Rosenfeld (1991) *Science* 252:431, and WO93/07283, WO93/06223, and WO93/07282. Exemplary known adenoviral gene therapy vectors employable in this invention include those described in the above referenced documents and in WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984, WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320, WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102, WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241, WO95/25807, WO95/05835, WO94/18922 and WO95/09654. Alternatively, administration of DNA linked to killed adenovirus as described in Curiel (1992) *Hum. Gene Ther.* 3:147-154 may be employed. The gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors. Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO93/09239. Most preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides. The native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive nucleotides in each AAV inverted terminal repeat (i.e., there is one sequence at each end) which are not involved in IIP formation. The non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position. Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini (1993) *Gene* 124:257-262. Another example of such an AAV vector is psub201 (see Samulski (1987) *J. Virol.* 61:3096). Another exemplary AAV vector is the Double-D ITR vector. Construction of the Double-D ITR vector is disclosed in US Patent 5,478,745. Still other vectors are those disclosed in Carter US Patent 4,797,368 and Muzyczka US Patent 5,139,941, Chartejee US Patent 5,474,935, and Kotin WO94/288157. Yet a further example of an AAV vector employable in this invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and construction are disclosed in Su (1996) *Human Gene Therapy* 7:463-470.



- 43 -

Additional AAV gene therapy vectors are described in US 5,354,678, US 5,173,414, US 5,139,941, and US 5,252,479.

The gene therapy vectors comprising sequences of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a  
5 sequence encoding a thymidine kinase polypeptide such as those disclosed in US 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar Institute), pHSVlac described in Geller (1988) *Science* 241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) *Human Gene Therapy* 3:11-19 and HSV 7134, 2 RH 105 and GAL4  
10 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross  
15 River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in US patents 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in U.S. Serial No. 08/405,627, filed March 15, 1995, WO94/21792, WO92/10578, WO95/07994, US 5,091,309 and US 5,217,879 are employable. Such alpha viruses may be  
20 obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see USSN 08/679640).

DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of  
25 eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.

Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, *Nature* 339 (1989) 385  
30 and Sabin (1973) *J. Biol. Standardization* 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) *J Cell Biochem* L401; pox viruses such as canary pox

- 44 -

- virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) *Proc Natl Acad Sci* 86:317; Flexner (1989) *Ann NY Acad Sci* 569:86, Flexner (1990) *Vaccine* 8:17; in US 4,603,112 and US 4,769,330 and WO89/01973; SV40 virus, for example ATCC VR-305 and those described in Mulligan (1979) *Nature* 277:108
- 5 and Madzak (1992) *J Gen Virol* 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in US 5,166,057 and in Enami (1990) *Proc Natl Acad Sci* 87:3802-3805; Enami & Palese (1991) *J Virol* 65:2711-2713 and Luytjes (1989) *Cell* 59:110, (see also McMichael (1983) *NEJ Med* 309:13, and Yap (1978) *Nature* 273:238 and *Nature* (1979) 277:108); human
- 10 immunodeficiency virus as described in EP-0386882 and in Buchschacher (1992) *J. Virol.* 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC
- 15 VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Trinitite virus, for example ATCC VR-469; Una virus, for example ATCC
- 20 VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) *Proc Soc Exp Biol Med* 121:190.
- 25       Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see US Serial No. 08/366,787, filed December 30, 1994 and Curiel (1992) *Hum Gene Ther* 3:147-154 ligand linked DNA, for example see Wu (1989)
- 30 *J Biol Chem* 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see US Serial No.08/240,030, filed May 9, 1994, and US Serial No. 08/404,796, deposition of

photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in US Patent 5,149,655, ionizing radiation as described in US5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) *Mol Cell Biol* 14:2411-2418 and in Woffendin (1994) *Proc Natl Acad Sci* 91:1581-1585.

Particle mediated gene transfer may be employed, for example see US Serial No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) *J. Biol. Chem.* 262:4429-4432, insulin as described in Hucked (1990) *Biochem Pharmacol* 40:253-263, galactose as described in Plank (1992) *Bioconjugate Chem* 3:533-539, lactose or transferrin.

Naked DNA may also be employed to transform a host cell. Exemplary naked DNA introduction methods are described in WO 90/11092 and US 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in U.S. 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in USSN. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of

photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. 5,206,152 and WO92/11033

5 Exemplary liposome and polycationic gene delivery vehicles are those described in US 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697; and WO91/14445; in EP-0524968; and in Stryer, *Biochemistry*, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) *Biochem Biophys Acta* 600:1; Bayer (1979) *Biochem Biophys Acta* 550:464; Rivnay (1987) *Meth Enzymol* 149:119; Wang (1987) *Proc Natl Acad Sci* 84:7851; Plant  
10 (1989) *Anal Biochem* 176:420.

A polynucleotide composition can comprise a therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

15

#### Delivery Methods

Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered ex vivo, to cells derived from the subject; or (3) in vitro for expression of recombinant proteins. The subjects to be treated can  
20 be mammals or birds. Also, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, transdermally or transcutaneously, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a tumor or lesion. Other modes of administration include oral and  
25 pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule. See WO98/20734.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., WO93/14778. Examples of cells useful in *ex vivo*  
30 applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells.

- 47 -

Generally, delivery of nucleic acids for both *ex vivo* and *in vitro* applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct  
5 microinjection of the DNA into nuclei, all well known in the art.

#### Polynucleotide and Polypeptide pharmaceutical compositions

In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide  
10 compositions.

#### A. Polypeptides

One example are polypeptides which include, without limitation: asialoorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin;  
15 interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.

#### B. Hormones, Vitamins, Etc.

Other groups that can be included in a pharmaceutical composition include, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.

#### C. Polyalkylenes, Polysaccharides, etc.

Also, polyalkylene glycol can be included in a pharmaceutical compositions with the desired polynucleotides and/or polypeptides. In a preferred embodiment, the polyalkylene glycol is polyethylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also,  
30 chitosan and poly(lactide-co-glycolide) may be included in a pharmaceutical composition.

- 48 -

## D. Lipids, and Liposomes

The desired polynucleotide or polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.

Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid or polypeptide. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) *Biochim. Biophys. Acta.* 1097:1-17; Straubinger (1983) *Meth. Enzymol.* 101:512-527.

Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7416); mRNA (Malone (1989) *Proc. Natl. Acad. Sci. USA* 86:6077-6081); and purified transcription factors (Debs (1990) *J. Biol. Chem.* 265:10189-10192), in functional form.

Cationic liposomes are readily available. For example, N(1-2,3-dioleoyloxy)propyl)-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY. (See, also, Felgner *supra*). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g., Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See e.g., Straubinger (1983) *Meth. Immunol.* 101:512-527; Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198;

- 5 Papahadjopoulos (1975) *Biochim. Biophys. Acta* 394:483; Wilson (1979) *Cell* 17:77); Deamer & Bangham (1976) *Biochim. Biophys. Acta* 443:629; Ostro (1977) *Biochem. Biophys. Res. Commun.* 76:836; Fraley (1979) *Proc. Natl. Acad. Sci. USA* 76:3348); Enoch & Strittmatter (1979) *Proc. Natl. Acad. Sci. USA* 76:145; Fraley (1980) *J. Biol. Chem.* (1980) 255:10431; Szoka & Papahadjopoulos (1978) *Proc. Natl. Acad. Sci. USA* 75:145; and  
10 Schaefer-Ridder (1982) *Science* 215:166.

#### E. Lipoproteins

In addition, lipoproteins can be included with the polynucleotide or polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, IDL, LDL,  
15 and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.

- 20 Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.

- A lipoprotein can comprise more than one apoprotein. For example, naturally  
25 occurring chylomicrons comprises of A, B, C, and E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, and E apoproteins, LDL comprises apoprotein B; and HDL comprises apoproteins A, C, and E.

- The amino acid sequences of these apoproteins are known and are described in, for example, Breslow (1985) *Annu Rev. Biochem* 54:699; Law (1986) *Adv. Exp Med. Biol.*  
30 151:162; Chen (1986) *J Biol Chem* 261:12918; Kane (1980) *Proc Natl Acad Sci USA* 77:2465; and Utermann (1984) *Hum Genet* 65:232.

Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in *Meth. Enzymol.* 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.

Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in *Meth. Enzymol.* (*supra*); Pitas (1980) *J. Biochem.* 255:5454-5460 and Mahey (1979) *J Clin. Invest* 64:743-750.

Lipoproteins can also be produced by *in vitro* or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) *Annu Rev Biophys Chem* 15:403 and Radding (1958) *Biochim Biophys Acta* 30: 443.

Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Technologies, Inc., Stoughton, Massachusetts, USA.

Further description of lipoproteins can be found in Zuckermann et al., PCT. Appln. No. US97/14465.

#### F. Polycationic Agents

Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide and/or polypeptide to be delivered.

Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both *in vitro*, *ex vivo*, and *in vivo* applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.

The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples of useful polypeptides include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as  $\Phi$ X174, transcriptional



factors also contain domains that bind DNA and therefore may be useful as nucleic acid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.

- 5           Organic polycationic agents include: spermine, spermidine, and putrescine.

The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.

10    G.     Synthetic Polycationic Agents

Synthetic polycationic agents which are useful in pharmaceutical compositions include, for example, DEAE-dextran, polybrene. Lipofectin™, and lipofectAMINE™ are monomers that form polycationic complexes when combined with polynucleotides or polypeptides.

15

Immunodiagnostic Assays

- Neisseria* MenB antigens, or antigenic fragments thereof, of the invention can be used in immunoassays to detect antibody levels (or, conversely, anti-*Neisseria* MenB antibodies can be used to detect antigen levels). Immunoassays based on well defined, recombinant
- 20   antigens can be developed to replace invasive diagnostics methods. Antibodies to *Neisseria* MenB proteins or fragments thereof within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols
- 25   may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

- 30    Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the

invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, *etc.*) required for the conduct of the assay, as well as suitable set of assay instructions.

## 5 Nucleic Acid Hybridization

"Hybridization" refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the  
10 type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook *et al.* (*supra*)  
15 Volume 2, chapter 9, pages 9.47 to 9.57.

"Stringency" refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200°C below the calculated  $T_m$  of the hybrid under study. The temperature and salt conditions can  
20 often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook *et al.* at page 9.50.

Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the  
25 sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1  $\mu\text{g}$  for a plasmid or phage digest to  $10^{-9}$  to  $10^{-8}$  g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides, substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a  
30 single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1  $\mu\text{g}$  of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of  $10^8$

- 53 -

cpm/ $\mu$ g. For a single-copy mammalian gene a conservative approach would start with 10  $\mu$ g of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than  $10^8$  cpm/ $\mu$ g, resulting in an exposure time of ~24 hours.

- Several factors can affect the melting temperature ( $T_m$ ) of a DNA-DNA hybrid
- 5 between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the hybridization buffer. The effects of all of these factors can be approximated by a single equation:
- 10  $T_m = 81 + 16.6(\log_{10}Ci) + 0.4\%(G + C)) - 0.6\%(\text{formamide}) - 600/n - 1.5\%(\text{mismatch})$
- where  $Ci$  is the salt concentration (monovalent ions) and  $n$  is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) *Anal. Biochem.* 138:267-284).

- In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes
- 15 and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (i.e., stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabeled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the
- 20 hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.

- In general, convenient hybridization temperatures in the presence of 50% formamide
- 25 are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If
- 30 non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this

approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

#### Nucleic Acid Probe Assays

5       Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA. A probe is said to "hybridize" with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.

10       The nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells. mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding  
15       sequence.

      The probe sequence need not be identical to the Neisserial sequence (or its complement) -- some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected. Also, the nucleic acid probe can include additional nucleotides to stabilize the  
20       formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex. For example, a non-complementary nucleotide sequence may be attached to the 5' end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity  
25       with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.

      The exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like. For example, for diagnostic applications, depending on the complexity of the analyte sequence, the nucleic acid probe  
30       typically contains at least 10-20 nucleotides, preferably 15-25, and more preferably at least

30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.

Probes may be produced by synthetic procedures, such as the triester method of Matteucci *et al.* (*J. Am. Chem. Soc.* (1981) 103:3185), or according to Urdea *et al.* (*Proc. Natl. Acad. Sci. USA* (1983) 80: 7461), or using commercially available automated oligonucleotide synthesizers.

The chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated e.g., backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase *in vivo* half-life, alter RNA affinity, increase nuclease resistance *etc.* (e.g., see Agrawal & Iyer (1995) *Curr Opin Biotechnol* 6:12-19; Agrawal (1996) *TIBTECH* 14:376-387); analogues such as peptide nucleic acids may also be used (e.g., see Corey (1997) *TIBTECH* 15:224-229; Buchardt *et al.* (1993) *TIBTECH* 11:384-386).

One example of a nucleotide hybridization assay is described by Urdea *et al.* in international patent application WO92/02526 (see also U.S. Patent 5,124,246).

Alternatively, the polymerase chain reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in: Mullis *et al.* (*Meth. Enzymol.* (1987) 155: 335-350); US patent 4,683,195; and US patent 4,683,202. Two "primer" nucleotides hybridize with the target nucleic acids and are used to prime the reaction. The primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.

A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase, they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labeled probe will hybridize to the Neisserial sequence (or its complement).

Also, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook *et al.* (*supra*). mRNA, or cDNA generated from mRNA using a polymerase

- 56 -

enzyme, can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labeled with a radioactive moiety.

## EXAMPLES

The invention is based on the 961 nucleotide sequences from the genome of *N. meningitidis* set out in Appendix C, SEQ ID NOs:1-961, which together represent substantially the complete genome of serotype B of *N. meningitidis*, as well as the full length genome sequence shown in Appendix D, SEQ ID NO 1068.

It will be self-evident to the skilled person how this sequence information can be utilized according to the invention, as above described.

The standard techniques and procedures which may be employed in order to perform the invention (e.g. to utilize the disclosed sequences to predict polypeptides useful for vaccination or diagnostic purposes) were summarized above. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.

These sequences are derived from contigs shown in Appendix C (SEQ ID NOs 1-961) and from the full length genome sequence shown in Appendix D (SEQ ID NO 1068), which were prepared during the sequencing of the genome of *N. meningitidis* (strain B). The full length sequence was assembled using the TIGR Assembler as described by G.S. Sutton et al., *TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects*, Genome Science and Technology, 1:9-19 (1995) [see also R. D. Fleischmann, et al., Science 269, 496-512 (1995); C. M. Fraser, et al., Science 270, 397-403 (1995); C. J. Bult, et al., Science 273, 1058-73 (1996); C. M. Fraser, et al., Nature 390, 580-586 (1997); J.-F. Tomb, et al., Nature 388, 539-547 (1997); H. P. Klenk, et al., Nature 390, 364-70 (1997); C. M. Fraser, et al., Science 281, 375-88 (1998); M. J. Gardner, et al., Science 282, 1126-1132 (1998); K. E. Nelson, et al., Nature 399, 323-9 (1999)]. Then, using the above-described methods, putative translation products of the sequences were determined. Computer analysis of the translation products were determined based on database comparisons. Corresponding gene and protein sequences, if any, were identified in *Neisseria meningitidis* (Strain A) and *Neisseria*

- 57 -

gonorrhoeae. Then the proteins were expressed, purified, and characterized to assess their antigenicity and immunogenicity.

In particular, the following methods were used to express, purify, and biochemically characterize the proteins of the invention.

5

#### Chromosomal DNA Preparation

*N. meningitidis* strain 2996 was grown to exponential phase in 100 ml of GC medium, harvested by centrifugation, and resuspended in 5 ml buffer (20% Sucrose, 50 mM Tris-HCl, 50 mM EDTA, adjusted to pH 8.0). After 10 minutes incubation on ice, the bacteria were  
 10 lysed by adding 10 ml lysis solution (50 mM NaCl, 1% Na-Sarkosyl, 50 µg/ml Proteinase K), and the suspension was incubated at 37°C for 2 hours. Two phenol extractions (equilibrated to pH 8) and one  $\text{CHCl}_3$ /isoamylalcohol (24:1) extraction were performed. DNA was precipitated by addition of 0.3M sodium acetate and 2 volumes ethanol, and was collected by centrifugation. The pellet was washed once with 70% ethanol and redissolved in 4 ml buffer  
 15 (10 mM Tris-HCl, 1mM EDTA, pH 8). The DNA concentration was measured by reading the OD at 260 nm.

#### **Oligonucleotide design**

Synthetic oligonucleotide primers were designed on the basis of the coding sequence of each ORF, using (a) the meningococcus B sequence when available, or (b) the  
 20 gonococcus/meningococcus A sequence, adapted to the codon preference usage of meningococcus. Any predicted signal peptides were omitted, by deducing the 5'-end amplification primer sequence immediately downstream from the predicted leader sequence.

For most ORFs, the 5' primers included two restriction enzyme recognition sites (*Bam*HI-*Nde*I, *Bam*HI-*Nhe*I, or *Eco*RI-*Nhe*I, depending on the gene's restriction pattern); the  
 25 3' primers included a *Xho*I restriction site. This procedure was established in order to direct the cloning of each amplification product (corresponding to each ORF) into two different expression systems: pGEX-KG (using either *Bam*HI-*Xho*I or *Eco*RI-*Xho*I), and pET21b+ (using either *Nde*I-*Xho*I or *Nhe*I-*Xho*I).

5'-end primer tail: CGCGGATCCCATATG (*Bam*HI-*Nde*I )  
 30 CGCGGATCCGCTAGC (*Bam*HI-*Nhe*I)

- 58 -

CCGGAATTCTAGCTAGC (*EcoRI-NheI*)3'-end primer tail: CCGGCTCGAG (*XhoI*)

For some ORFs, two different amplifications were performed to clone each ORF in the two expression systems. Two different 5' primers were used for each ORF; the same 3' *XhoI* primer was used as before:

5'-end primer tail: GGAATTCATATGGCCATGG (*NdeI*)5'-end primer tail: CGGGATCC (*BamHI*)

Other ORFs were cloned in the pTRC expression vector and expressed as an amino-terminus His-tag fusion. The predicted signal peptide may be included in the final product. *NheI-BamHI* restriction sites were incorporated using primers:

5'-end primer tail: GATCAGCTAGCCATATG (*NheI*)3'-end primer tail: CGGGATCC (*BamHI*)

As well as containing the restriction enzyme recognition sequences, the primers included nucleotides which hybridized to the sequence to be amplified. The number of hybridizing nucleotides depended on the melting temperature of the whole primer, and was determined for each primer using the formulae:

$$T_m = 4 (G+C) + 2 (A+T) \quad (\text{tail excluded})$$

$$T_m = 64.9 + 0.41 (\% \text{ GC}) - 600/N \quad (\text{whole primer})$$

The average melting temperature of the selected oligos were 65-70°C for the whole oligo and 50-55°C for the hybridising region alone.

Oligos were synthesized by a Perkin Elmer 394 DNA/RNA Synthesizer, eluted from the columns in 2 ml  $\text{NH}_4\text{-OH}$ , and deprotected by 5 hours incubation at 56 °C. The oligos were precipitated by addition of 0.3M Na-Acetate and 2 volumes ethanol. The samples were then centrifuged and the pellets resuspended in either 100  $\mu\text{l}$  or 1ml of water.  $\text{OD}_{260}$  was determined using a Perkin Elmer Lambda Bio spectrophotometer and the concentration was determined and adjusted to 2-10 pmol/ $\mu\text{l}$ .

Table 1 shows the forward and reverse primers used for each amplification. In certain cases, it might be noted that the sequence of the primer does not exactly match the sequence in the ORF. When initial amplifications are performed, the complete 5' and/or 3' sequence



- 59 -

may not be known for some meningococcal ORFs, although the corresponding sequences may have been identified in gonococcus. For amplification, the gonococcal sequences could thus be used as the basis for primer design, altered to take account of codon preference. In particular, the following codons may be changed: ATA→ATT; TCG→TCT; CAG→CAA;  
5 AAG→AAA; GAG→GAA; CGA and CGG→CGC; GGG→GGC.

### Amplification

The standard PCR protocol was as follows: 50-200 ng of genomic DNA were used as a template in the presence of 20-40 µM of each oligo, 400-800 µM dNTPs solution, 1x PCR buffer (including 1.5 mM MgCl<sub>2</sub>), 2.5 units *TaqI* DNA polymerase (using Perkin-Elmer  
10 AmpliTaq, GIBCO Platinum, Pwo DNA polymerase, or Tahara Shuzo Taq polymerase).

In some cases, PCR was optimised by the addition of 10µl DMSO or 50 µl 2M betaine.

After a hot start (adding the polymerase during a preliminary 3 minute incubation of the whole mix at 95°C), each sample underwent a double-step amplification: the first 5 cycles  
15 were performed using as the hybridization temperature the one of the oligos excluding the restriction enzymes tail, followed by 30 cycles performed according to the hybridization temperature of the whole length oligos. The cycles were followed by a final 10 minute extension step at 72°C.

The standard cycles were as follows:

	Denaturation	Hybridisation	Elongation
First 5 cycles	30 seconds 95°C	30 seconds 50-55°C	30-60 seconds 72°C
Last 30 cycles	30 seconds 95°C	30 seconds 65-70°C	30-60 seconds 72°C

20

The elongation time varied according to the length of the ORF to be amplified.

The amplifications were performed using either a 9600 or a 2400 Perkin Elmer GeneAmp PCR System. To check the results, 1/10 of the amplification volume was loaded onto a 1-1.5% agarose gel and the size of each amplified fragment compared with a DNA  
25 molecular weight marker.

The amplified DNA was either loaded directly on a 1% agarose gel or first precipitated with ethanol and resuspended in a suitable volume to be loaded on a 1% agarose

- 60 -

gel. The DNA fragment corresponding to the right size band was then eluted and purified from gel, using the Qiagen Gel Extraction Kit, following the instructions of the manufacturer. The final volume of the DNA fragment was 30µl or 50µl of either water or 10mM Tris, pH 8.5.

## 5 Digestion of PCR fragments

The purified DNA corresponding to the amplified fragment was split into 2 aliquots and double-digested with:

NdeI/XhoI or *NheI/XhoI* for cloning into pET-21b+ and further expression of the protein as a C-terminus His-tag fusion

- 10 BamHI/XhoI or *EcoRI/XhoI* for cloning into pGEX-KG and further expression of the protein as a GST N-terminus fusion.

For ORF 76, *NheI/BamHI* for cloning into pTRC-HisA vector and further expression of the protein as N-terminus His-tag fusion.

- Each purified DNA fragment was incubated (37°C for 3 hours to overnight) with 20  
15 units of each restriction enzyme (New England Biolabs ) in a either 30 or 40 µl final volume in the presence of the appropriate buffer. The digestion product was then purified using the QIAquick PCR purification kit, following the manufacturer's instructions, and eluted in a final volume of 30 (or 50) µl of either water or 10mM Tris-HCl, pH 8.5. The final DNA concentration was determined by 1% agarose gel electrophoresis in the presence of titrated  
20 molecular weight marker.

## Digestion of the cloning vectors (pET22B, pGEX-KG and pTRC-His A)

- 10 µg plasmid was double-digested with 50 units of each restriction enzyme in 200 µl reaction volume in the presence of appropriate buffer by overnight incubation at 37°C. After loading the whole digestion on a 1% agarose gel, the band corresponding to the digested  
25 vector was purified from the gel using the Qiagen QIAquick Gel Extraction Kit and the DNA was eluted in 50 µl of 10 mM Tris-HCl, pH 8.5. The DNA concentration was evaluated by measuring OD<sub>260</sub> of the sample, and adjusted to 50 µg/µl. 1 µl of plasmid was used for each cloning procedure.

## Cloning

The fragments corresponding to each ORF, previously digested and purified, were ligated in both pET22b and pGEX-KG. In a final volume of 20  $\mu$ l, a molar ratio of 3:1 fragment/vector was ligated using 0.5  $\mu$ l of NEB T4 DNA ligase (400 units/ $\mu$ l), in the presence of the buffer supplied by the manufacturer. The reaction was incubated at room temperature for 3 hours. In some experiments, ligation was performed using the Boehringer "Rapid Ligation Kit", following the manufacturer's instructions.

In order to introduce the recombinant plasmid in a suitable strain, 100  $\mu$ l *E. coli* DH5 competent cells were incubated with the ligase reaction solution for 40 minutes on ice, then at 37°C for 3 minutes, then, after adding 800  $\mu$ l LB broth, again at 37°C for 20 minutes. The cells were then centrifuged at maximum speed in an Eppendorf microfuge and resuspended in approximately 200  $\mu$ l of the supernatant. The suspension was then plated on LB ampicillin (100 mg/ml).

The screening of the recombinant clones was performed by growing 5 randomly-chosen colonies overnight at 37 °C in either 2 ml (pGEX or pTC clones) or 5ml (pET clones) LB broth + 100  $\mu$ g/ml ampicillin. The cells were then pelleted and the DNA extracted using the Qiagen QIAprep Spin Miniprep Kit, following the manufacturer's instructions, to a final volume of 30  $\mu$ l. 5  $\mu$ l of each individual miniprep (approximately 1g) were digested with either *NdeI/XhoI* or *BamHI/XhoI* and the whole digestion loaded onto a 1-20 1.5% agarose gel (depending on the expected insert size), in parallel with the molecular weight marker (1Kb DNA Ladder, GIBCO). The screening of the positive clones was made on the base of the correct insert size.

## Cloning

Certain ORFs may be cloned into the pGEX-HIS vector using *EcoRI-PstI*, *EcoRI-SalI*, or *SalI-PstI* cloning sites. After cloning, the recombinant plasmids may be introduced in the *E.coli* host W3110.

## Expression

Each ORF cloned into the expression vector may then be transformed into the strain suitable for expression of the recombinant protein product. 1  $\mu$ l of each construct was used to

- 62 -

transform 30 µl of *E.coli* BL21 (pGEX vector), *E.coli* TOP 10 (pTRC vector) or *E.coli* BL21-DE3 (pET vector), as described above. In the case of the pGEX-His vector, the same *E.coli* strain (W3110) was used for initial cloning and expression. Single recombinant colonies were inoculated into 2ml LB+Amp (100 µg/ml), incubated at 37°C overnight, then diluted 1:30 in 20 ml of LB+Amp (100 µg/ml) in 100 ml flasks, making sure that the OD<sub>600</sub> ranged between 0.1 and 0.15. The flasks were incubated at 30°C into gyratory water bath shakers until OD indicated exponential growth suitable for induction of expression (0.4-0.8 OD for pET and pTRC vectors; 0.8-1 OD for pGEX and pGEX-His vectors). For the pET, pTRC and pGEX-His vectors, the protein expression was induced by addition of 1mM IPTG, whereas in the case of pGEX system the final concentration of IPTG was 0.2 mM. After 3 hours incubation at 30°C, the final concentration of the sample was checked by OD. In order to check expression, 1ml of each sample was removed, centrifuged in a microfuge, the pellet resuspended in PBS, and analysed by 12% SDS-PAGE with Coomassie Blue staining. The whole sample was centrifuged at 6000g and the pellet resuspended in PBS for further use.

#### 15 **GST-fusion proteins large-scale purification.**

A single colony was grown overnight at 37°C on LB+Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight. Bacteria were diluted 1:30 into 600 ml of fresh medium and allowed to grow at the optimal temperature (20-37°C) to OD<sub>550</sub> 0.8-1. Protein expression was induced with 0.2mM IPTG followed by three hours incubation. The culture was centrifuged at 8000 rpm at 4°C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml cold PBS. The cells were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again. The supernatant was collected and mixed with 150µl Glutathione-Sepharose 4B resin (Pharmacia) (previously washed with PBS) and incubated at room temperature for 30 minutes. The sample was centrifuged at 700g for 5 minutes at 4C. The resin was washed twice with 10 ml cold PBS for 10 minutes, resuspended in 1ml cold PBS, and loaded on a disposable column. The resin was washed twice with 2ml cold PBS until the flow-through reached OD<sub>280</sub> of 0.02-0.06. The GST-fusion protein was eluted by addition of 700µl cold Glutathione elution buffer 10mM reduced glutathione, 50mM Tris-HCl) and fractions collected until the OD<sub>280</sub> was 0.1.

21µl of each fraction were loaded on a 12% SDS gel using either Biorad SDS-PAGE Molecular weight standard broad range (M1) (200, 116.25, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5 kDa) or Amersham Rainbow Marker (M<sup>+</sup>) (220, 66, 46, 30, 21.5, 14.3 kDa) as standards. As the MW of GST is 26kDa, this value must be added to the MW of each GST-fusion protein.

#### 5 His-fusion soluble proteins large-scale purification.

A single colony was grown overnight at 37°C on a LB + Amp agar plate. The bacteria were inoculated into 20ml of LB+Amp liquid culture and incubated overnight in a water bath shaker. Bacteria were diluted 1:30 into 600ml fresh medium and allowed to grow at the optimal temperature (20-37°C) to OD<sub>550</sub> 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours. The culture was centrifuged at 8000 rpm at 4°C, the supernatant was discarded and the bacterial pellet was resuspended in 7.5ml cold 10mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8). The cells were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again. The supernatant was collected and mixed with 150µl Ni<sup>2+</sup>-resin (Pharmacia) (previously washed with 10mM imidazole buffer) and incubated at room temperature with gentle agitation for 30 minutes. The sample was centrifuged at 700g for 5 minutes at 4°C. The resin was washed twice with 10 ml cold 10mM imidazole buffer for 10 minutes, resuspended in 1ml cold 10mM imidazole buffer and loaded on a disposable column. The resin was washed at 4°C with 2ml cold 10mM imidazole buffer until the flow-through reached the O.D<sub>280</sub> of 0.02-0.06. The resin was washed with 2ml cold 20mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 20 mM imidazole, pH 8) until the flow-through reached the O.D<sub>280</sub> of 0.02-0.06. The His-fusion protein was eluted by addition of 700µl cold 250mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8) and fractions collected until the O.D<sub>280</sub> was 0.1. 21µl of each fraction were loaded on a 12% SDS gel.

#### His-fusion insoluble proteins large-scale purification.

A single colony was grown overnight at 37 °C on a LB + Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight. Bacteria were diluted 1:30 into 600ml fresh medium and let to grow at the

- optimal temperature (37°C) to O.D<sub>550</sub> 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours. The culture was centrifuged at 8000rpm at 4°C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml buffer B (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 8.8). The cells
- 5 were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed twice and centrifuged again. The supernatant was stored at -20°C, while the pellets were resuspended in 2 ml guanidine buffer (6M guanidine hydrochloride, 100mM phosphate buffer, 10 mM Tris-HCl, pH 7.5) and treated in a homogenizer for 10 cycles. The product was centrifuged at 13000 rpm for 40 minutes. The supernatant was mixed with
- 10 150µl Ni<sup>2+</sup>-resin (Pharmacia) (previously washed with buffer B) and incubated at room temperature with gentle agitation for 30 minutes. The sample was centrifuged at 700 g for 5 minutes at 4°C. The resin was washed twice with 10 ml buffer B for 10 minutes, resuspended in 1ml buffer B, and loaded on a disposable column. The resin was washed at room temperature with 2ml buffer B until the flow-through reached the OD<sub>280</sub> of 0.02-0.06.
- 15 The resin was washed with 2ml buffer C (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 6.3) until the flow-through reached the O.D<sub>280</sub> of 0.02-0.06. The His-fusion protein was eluted by addition of 700µl elution buffer (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 4.5) and fractions collected until the OD<sub>280</sub> was 0.1. 21µl of each fraction were loaded on a 12% SDS gel.

## 20 His-fusion proteins renaturation

- 10% glycerol was added to the denatured proteins. The proteins were then diluted to 20µg/ml using dialysis buffer I (10% glycerol, 0.5M arginine, 50mM phosphate buffer, 5mM reduced glutathione, 0.5mM oxidised glutathione, 2M urea, pH 8.8) and dialysed against the same buffer at 4°C for 12-14 hours. The protein was further dialysed against dialysis buffer
- 25 II (10% glycerol, 0.5M arginine, 50mM phosphate buffer, 5mM reduced glutathione, 0.5mM oxidised glutathione, pH 8.8) for 12-14 hours at 4°C. Protein concentration was evaluated using the formula:

$$\text{Protein (mg/ml)} = (1.55 \times \text{OD}_{280}) - (0.76 \times \text{OD}_{260})$$

**Mice immunisations**

20µg of each purified protein were used to immunise mice intraperitoneally. In the case of some ORFs, Balb-C mice were immunised with Al(OH)<sub>3</sub> as adjuvant on days 1, 21 and 42, and immune response was monitored in samples taken on day 56. For other ORFs, CD1 mice could be immunised using the same protocol. For other ORFs, CD1 mice could be immunised using Freund's adjuvant, and the same immunisation protocol was used, except that the immune response was measured on day 42, rather than 56. Similarly, for still other ORFs, CD1 mice could be immunised with Freund's adjuvant, but the immune response was measured on day 49.

**10 ELISA assay (sera analysis)**

The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37°C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 7ml of Mueller-Hinton Broth (Difco) containing 0.25% Glucose. Bacterial growth was monitored every 30 minutes by following OD<sub>620</sub>. The bacteria were let to grow until the OD reached the value of 0.3-0.4. The culture was centrifuged for 10 minutes at 10000 rpm. The supernatant was discarded and bacteria were washed once with PBS, resuspended in PBS containing 0.025% formaldehyde, and incubated for 2 hours at room temperature and then overnight at 4°C with stirring. 100µl bacterial cells were added to each well of a 96 well Greiner plate and incubated overnight at 4°C. The wells were then washed three times with PBT washing buffer (0.1% Tween-20 in PBS). 200 µl of saturation buffer (2.7% Polyvinylpyrrolidone 10 in water) was added to each well and the plates incubated for 2 hours at 37°C. Wells were washed three times with PBT. 200 µl of diluted sera (Dilution buffer: 1% BSA, 0.1% Tween-20, 0.1% NaN<sub>3</sub> in PBS) were added to each well and the plates incubated for 90 minutes at 37°C. Wells were washed three times with PBT. 100 µl of HRP-conjugated rabbit anti-mouse (Dako) serum diluted 1:2000 in dilution buffer were added to each well and the plates were incubated for 90 minutes at 37°C. Wells were washed three times with PBT buffer. 100 µl of substrate buffer for HRP (25 ml of citrate buffer pH5, 10 mg of O-phenildiamine and 10 µl of H<sub>2</sub>O) were added to each well and the plates were left at room temperature for 20 minutes. 100 µl H<sub>2</sub>SO<sub>4</sub> was added to each

- 66 -

well and OD<sub>490</sub> was followed. The ELISA was considered positive when OD<sub>490</sub> was 2.5 times the respective pre-immune sera.

#### **FACScan bacteria Binding Assay procedure.**

The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37°C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 4 tubes containing 8ml each Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD<sub>620</sub>. The bacteria were let to grow until the OD reached the value of 0.35-0.5. The culture was centrifuged for 10 minutes at 4000 rpm. The supernatant was discarded and the pellet was resuspended in blocking buffer (1% BSA, 0.4% NaN<sub>3</sub>) and centrifuged for 5 minutes at 4000 rpm. Cells were resuspended in blocking buffer to reach OD<sub>620</sub> of 0.07. 100µl bacterial cells were added to each well of a Costar 96 well plate. 100µl of diluted (1:200) sera (in blocking buffer) were added to each well and plates incubated for 2 hours at 4°C. Cells were centrifuged for 5 minutes at 4000 rpm, the supernatant aspirated and cells washed by addition of 200µl/well of blocking buffer in each well. 100µl of R-Phicoerytrin conjugated F(ab)<sub>2</sub> goat anti-mouse, diluted 1:100, was added to each well and plates incubated for 1 hour at 4°C. Cells were spun down by centrifugation at 4000rpm for 5 minutes and washed by addition of 200µl/well of blocking buffer. The supernatant was aspirated and cells resuspended in 200µl/well of PBS, 0.25% formaldehyde. Samples were transferred to FACScan tubes and read. The condition for FACScan setting were: FL1 on, FL2 and FL3 off; FSC-H Threshold:92; FSC PMT Voltage: E 02; SSC PMT: 474; Amp. Gains 7.1; FL-2 PMT: 539. Compensation values: 0.

#### **OMV preparations**

Bacteria were grown overnight on 5 GC plates, harvested with a loop and resuspended in 10 ml 20mM Tris-HCl. Heat inactivation was performed at 56°C for 30 minutes and the bacteria disrupted by sonication for 10' on ice ( 50% duty cycle, 50% output ). Unbroken cells were removed by centrifugation at 5000g for 10 minutes and the total cell envelope fraction recovered by centrifugation at 50000g at 4°C for 75 minutes. To extract cytoplasmic membrane proteins from the crude outer membranes, the whole fraction was resuspended in



- 67 -

2% sarkosyl (Sigma) and incubated at room temperature for 20 minutes. The suspension was centrifuged at 10000g for 10 minutes to remove aggregates, and the supernatant further ultracentrifuged at 50000g for 75 minutes to pellet the outer membranes. The outer membranes were resuspended in 10mM Tris-HCl, pH8 and the protein concentration  
5 measured by the Bio-Rad Protein assay, using BSA as a standard.

### Whole Extracts preparation

Bacteria were grown overnight on a GC plate, harvested with a loop and resuspended in 1ml of 20mM Tris-HCl. Heat inactivation was performed at 56°C for 30' minutes.

### Western blotting

10 Purified proteins (500ng/lane), outer membrane vesicles (5 µg) and total cell extracts (25µg) derived from MenB strain 2996 were loaded on 15% SDS-PAGE and transferred to a nitrocellulose membrane. The transfer was performed for 2 hours at 150mA at 4°C, in transferring buffer (0.3 % Tris base, 1.44 % glycine, 20% methanol). The membrane was saturated by overnight incubation at 4°C in saturation buffer (10% skimmed milk, 0.1% Triton X100 in PBS). The membrane was washed twice with washing buffer (3% skimmed  
15 milk, 0.1% Triton X100 in PBS) and incubated for 2 hours at 37°C with 1:200 mice sera diluted in washing buffer. The membrane was washed twice and incubated for 90 minutes with a 1:2000 dilution of horseradish peroxidase labeled anti-mouse Ig. The membrane was washed twice with 0.1% Triton X100 in PBS and developed with the Opti-4CN Substrate Kit  
20 (Bio-Rad). The reaction was stopped by adding water.

### Bactericidal assay

MC58 strain was grown overnight at 37°C on chocolate agar plates. 5-7 colonies were collected and used to inoculate 7ml Mueller-Hinton broth. The suspension was incubated at 37°C on a nutator and let to grow until OD<sub>620</sub> was in between 0.5-0.8. The  
25 culture was aliquoted into sterile 1.5ml Eppendorf tubes and centrifuged for 20 minutes at maximum speed in a microfuge. The pellet was washed once in Gey's buffer (Gibco) and resuspended in the same buffer to an OD<sub>620</sub> of 0.5, diluted 1:20000 in Gey's buffer and stored at 25°C.

- 68 -

50 $\mu$ l of Gey's buffer/1% BSA was added to each well of a 96-well tissue culture plate. 25 $\mu$ l of diluted (1:100) mice sera (dilution buffer: Gey's buffer/0.2% BSA) were added to each well and the plate incubated at 4°C. 25 $\mu$ l of the previously described bacterial suspension were added to each well. 25 $\mu$ l of either heat-inactivated (56°C waterbath for 30 minutes) or normal baby rabbit complement were added to each well. Immediately after the addition of the baby rabbit complement, 22 $\mu$ l of each sample/well were plated on Mueller-Hinton agar plates (time 0). The 96-well plate was incubated for 1 hour at 37°C with rotation and then 22 $\mu$ l of each sample/well were plated on Mueller-Hinton agar plates (time 1). After overnight incubation the colonies corresponding to time 0 and time 1h were counted.

The following DNA and amino acid sequences are identified by titles of the following form: [g, m, or a] [#].[seq or pep], where "g" means a sequence from *N. gonorrhoeae*, "m" means a sequence from *N. meningitidis B*, and "a" means a sequence from *N. meningitidis A*; "#" means the number of the sequence; "seq" means a DNA sequence, and "pep" means an amino acid sequence. For example, "g001.seq" refers to an *N. gonorrhoeae* DNA sequence, number 1. The presence of the suffix "-1" or "-2" to these sequences indicates an additional sequence found for the same ORF. Further, open reading frames are identified as ORF #, where "#" means the number of the ORF, corresponding to the number of the sequence which encodes the ORF, and the ORF designations may be suffixed with ".ng" or ".a", indicating that the ORF corresponds to a *N. gonorrhoeae* sequence or a *N. meningitidis A* sequence, respectively. Computer analysis was performed for the comparisons that follow between "g", "m", and "a" peptide sequences; and therein the "pep" suffix is implied where not expressly stated.

#### EXAMPLE 1

The following ORFs were predicted from the contig sequences and/or the full length sequence using the methods herein described.

##### Localization of the ORFs

ORF: contig:  
279 gnm4.seq

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 962>:

- 69 -

## m279.seq

```

1  ATAAACGCGGA  TTTGCGGCTG  CTTGATTTC  ACGGTTTTC  GGGCTTCGGC
51 AAGTTTGTGCG  GCGGCGGGTT  TCATCAGGT  GCAATGGGA  GGTACGGACA
101 CGGCGACGCG  CAGGCGCGCT  TTGACACGG  CTTCTTTGG  GGCAGCCATG
151 GCGCGTCCGA  CGGCGCGGCG  GTTGCTGCA  ATCACGATT  GTCCGGGTGA
201 GTTGAAGTGT  ACGGCTTCGA  CCACCTGCT  TTGGGCGGCT  TCGGCACAAA
251 TGGCTTTAAC  CTGCTCATCT  TCCAAGCCG  GAATGCGCG  CATTGCGCCC
301 ACGCCTTGCG  GTACGGCGGA  CTGCATCAGT  TCGGCGCGCA  GCGCAGCAGG
351 TTTGACCGCG  TCGGCAAAAT  TCAATGCGC  CGCGGCAAC  AGTGCCTGT
101 401 ATTCGCGCAG  GCTGTGTCCG  GCAACGGCG  CAGGCGTTT  GCGCGCCGCT
451 TCTAAATAG

```

This corresponds to the amino acid sequence &lt;SEQ ID 963; ORF 279&gt;:

## m279.pep

```

15 1  ITRICGCLIS  TVFRASASIS  AAGFIRLOWE  GTDTGSGRAR  LAPASLAAM
51  ARPTAALPA  ITICPGELKL  TASTTSLWAA  SAQMALTCSS  SKPRIAIAIP
101 TPCGTADCIS  SARRRSLTA  SAKFNAPAA  SAVYSPRLCP  ATAAGVLPFA
151 SK*

```

20 The following partial DNA sequence was identified in *N.gonorrhoeae* <SEQ ID 964>:

## g279.seq

```

1  atgacgcgga  tttgcggctg  cttgattca  acggttttg  gtgtttcggc
51 aagtttgtcg  gggcggggtt  tcatcaggct  gcaatgggaa  ggaacggata
101 cggcgagcgg  cagggcggtt  ttggtcggg  cttctttgg  ggcagccatg
251 gtgcgtccga  cggcgcggtt  gttgcttga  atcacgactt  gtcgggcgga
201 gttgaagtgt  atggcttcga  ccacttgcc  ctgtcggtat  tcggcacaaa
251 tctgcctgac  ctgttcatct  tccaaccaca  aaatggcgc  cattgcgctt
301 acgccttgcg  gtacggcgga  ctgcacagt  tcggcgcgca  ggcggcagag
351 tttgacggca  tcggcaaaat  ccaatgcttc  ggcggcgaca  agcggtgtgt
301 401 attgcgcgag  gctgtgtcgg  gcaacggcgg  caggcggttt  gccgccactt
451 tccaaatag

```

This corresponds to the amino acid sequence &lt;SEQ ID 965; ORF 279.ng&gt;:

## g279.pep

```

35 1  MTRICGCLIS  TVLSVSASIS  AAGFIRLOWE  GTDTGSGRAR  LAPASLAAM
51  VRPTAALPA  ITICPGELKL  TASTTSPCAD  SAQICLTCS  SKPKMAIAIP
101 TPCGTADCIS  SARRRSLTA  SAKSNASAA  SAVYSPRLCP  ATAAGVLPPT
151 SK*

```

ORF 279 shows 89.5% identity over a 152 aa overlap with a predicted ORF (ORF 279.ng) from *N. gonorrhoeae*:

```

40 10      20      30      40      50      60
m279.pep  ITRICGCLIS TVFRASASIS AAGFIRLOWE GTDTGSGRAR LAPASLAAM ARPTAALPA
: ||||| : ||||| : ||||| : ||||| : ||||| : |||||
45 g279      MTRICGCLIS TVLSVSASIS AAGFIRLOWE GTDTGSGRAR LAPASLAAM VRPTAALPA
10      20      30      40      50      60

70      80      90      100     110     120
m279.pep  ITICPGELKL TASTTSLWAA SAQMALTCSS SKPRIAIAIP TPCGTADCIS SARRRSLTA
|| ||||| : ||| : ||||| : ||||| : ||||| : |||||
50 g279      ITICPGELKL TASTTSPCAD SAQICLTCS SKPKMAIAIP TPCGTADCIS SARRRSLTA
70      80      90      100     110     120

130     140     150
m279.pep  SAKFNAPAA SAVYSPRLCP ATAAGVLPASP SX
||| ||||| : ||||| : ||||| : ||||| : ||||| : |||||
55 g279      SAKSNASAA SAVYSPRLCP ATAAGVLPPT SX
130     140     150

```

- 70 -

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 966>:

```

a279.seq
1  ATGACNCGA TTTGCGGCTG CTTGATTCA ACGGTTTNA GGGCTTCGGC
5  51  GAGTTTGTG GCGGCGGGTT TCATGAGGCT GCAATGGGAA GGTACNGACA
    101  CNGGCAGCGG CAGGCGGCGT TTTGCGCGCG CTTCTTTGGC GGCAAGCATA
    151  GCGCGCTCGA CCGGCGGCGC ATTGCCTGCA ATCAGCACTT GTCCGGCGCA
    201  GTTGAAGTTG ACGGCTTCAA CCATCTCATC CTTGCGGGAT TCGGCGCAAA
10  251  TTTGTTTAC CTTGTCATCT TCACAAGCGA GAATCGCGCG CATTGCGCCC
    301  ACGCCTTGGC GTACGGCGGA CTGCATCAGT TCGGCGGCGA NGGCGCAGC
    351  TTTGACGCGG TCGGCAAAAT CCAATGGGCG GCGCGCAACN AGTGCGGTGT
    401  ATTGCGCGAN GCTGTGTCG GCAACGGGCG CAGGCGTTTT GCGCGCCGCT
    451  TCCGAATAG

```

15 This corresponds to the amino acid sequence <SEQ ID 967; ORF 279.a>:

```

a279.pep
1  MTXICGCLIS TVXRASASLS AAGFMRLQWE GTDTGSGRAR LAPASLAASI
5  51  ARSTAALPA ITTCPGELKL TASTTSSCAD SAQICFTCSS SKPRIAIAIP
    101  TPCGTADICIS SARXRTSLTA SAKSNAPRAAT SAVVSPXLCF ATAGVLPFA
20  151  SE*

```

m279/a279 ORFs 279 and 279.a showed a 88.2% identity in 152 aa overlap

```

25  m279.pep      10      20      30      40      50      60
      ITRICGCLISTVFRASASLSAAGFIRLQWEGTDTGSGRRARLAPASLAAMARPTAALPA
      :| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279      MTXICGCLISTVXRASASLSAAGFMRLQWEGTDTGSGRRARLAPASLAASIAARSTAALPA
      10      20      30      40      50      60

30  m279.pep      70      80      90      100     110     120
      ITTCPGELKLTA TSTSLWAASQMALTCSSSKPRIAIAIAPTTCGTADICISSARRRSTSLTA
      || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279      ITTCPGELKLTA TSTSSCADSAQICFTCSSSKPRIAIAIAPTTCGTADICISSARXRTSLTA
      70      80      90      100     110     120

35  m279.pep      130     140     150
      SAKFNAPAATS SAVVSPRLCPATAAGVLPASEX
      || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279      SAKSNAPAATS SAVVSPXLCPATAAGVLPASEX
      130     140     150
40

```

519 and 519-1 gnm7.seq

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 968>:

```

45  m519.seq (partial)
      1  ..TCGGTTATCG GCGGTATGGA GTTGGACAAA ACGTTTGAA GACGCGACGA
      51  AATCAACAGT ACTGTTGTTG CGGCTTTGGA CGAGGCGGCC GGGCTTgGG
      101  GTGTGAAGGT TTTGCTTAT GAGATTAAAG ACTTGGTTCC GCGCGAAGAA
      151  ATCCTTCGCT CAATGCAGGC GCAAATTACT GCGGAACGCG AAAAAACGCG
50  201  CCGTATCGCC GAATCCGAAG GTGTAATAAT CGAACAAATC AACCTTGCCA
      251  GTGGTCAGCG CGAAGCGGAA ATCCAACAAT CCGAAGGCGA GGCTCAGGCT
      301  GCGGTCAATG CGTCAATGCG CGAGAAAATC GCCCGCATCA ACCGCGCCAA
      351  AGGTGAAGCG GAATCCTTGC GCCTTGTGTC CGAAGCCAAT GCGGAAGCCA
      401  TCCGTCAAAAT TGCCGCGGCC CTTCAAACCC AAGGCGGTGC GGATGCGGTC
55  451  AATCTGAAGA TTGCGGAACA ATACGTGCTG GCGTCAACA ATCTTGCCAA
      501  AGAAAGCAAT ACGCTGATTA TGCCGCGCAA TGTTCGCGAC ATCGGCGAGC
      551  TGAATTTCTG CCGTATGAAA ATTATCGACA CGAGCAAAC CGCCAAATTA

```

- 71 -

This corresponds to the amino acid sequence <SEQ ID 969; ORF 519>:

```

m519.pep      (partial)
1      ..SVIGRMELDK TFEERDEINS TVVAALDEAA GAWGVKVLRY EIKDLVPPQE
51      ILRSMQAQIT AEREKRARIA ESEGRKIBQI NLASGQREAE IQQSEGEAAQ
101     AVNASNAEKI ARINRAKGEA ESLRLVAEAN AEAIQIAAA LQTQGGADAV
151     NLKIAEQYVA AFNNLAKESN TLIMPANVAD IGSILISGMK IIDSSTAK*
  
```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 970>:

```

g519.seq
10      1      atggaatttt tcattatctt gttggcagcc gtcgcggttt toggcttcaa
51      atcctttgtc gtcattcccc agcaggaagt ccacggtgtc gaaaggtctg
101     ggcgtttcca tcgcgcctcg acggcggttt tgaatatttt gattcccttt
151     atcgaccgcg tcgcctaccg ccattcgctg aaagaattcc ctttagactg
15      201     acccagccag gtcgtcatca cgcgcgataa tacgcaattg actgttgacy
251     gcattcatcta ttccaagta accgatccca aactcgcttc atacggttgc
301     agcaactaca ttatggcaat taccagcttt gcccaaacga cgtcgcttc
351     cgttatcggt cgtatggagt tggacaaaac gtttgaagaa cgcgacgaaa
401     tcaacagtac cgtgtctccc gccctcgatg aagcgcgcgg gcttgggggt
451     gtgaaagtcc tcgttaccga aatcaaggat ttggttcctc cgcacaaagt
20      501     ccttcgcgca atgcaggcac aaattaccgc cgaacgcgaa aaacgcgcc
551     gtattgcgca atccgaaggc cgtaaaatcg acaaatcaa ccttgcaggt
601     ggtcagcgctg aagccgaaat ccaacaatcc gaagcgaggt ctacggctgc
651     ggtcaatgctg tccaatgcgc agaaaatcgc cgcgatcaac cgcgcaaaag
701     gcgaagcgga atccctgcgc cttgttgctg aagccaatcg cgaagccaac
25      751     cgtcaaatgt cgcgcgccct tcaaacccaa acgccccgga atcggttcaa
801     tctgaagatt gggggacaat acgttaccgc gttccaaaat cttgcaaaag
851     aagacaatac ggggattaag cccgccaagg ttgcgcaat cgggaacctt
901     aattttcgcc ggcattgaaa attttgcga gaagcaaaaa cggcacaata
951     a
  
```

30 This corresponds to the amino acid sequence <SEQ ID 971; ORF 519.ng>:

```

g519.pep
1      MEFFIILLAA VAVFGFKSFV VIPQOEHVHV ERLGRFHRAL TAGLNILIPF
51      IDRVAYRHSI KEIPLDVPSQ VCITRDNTOI TVDGIIFYQV TDPKLSAYGS
101     SNYIMAITOL AQTTLRSVIG RMELDKTFEE RDEINSTVVS ALDEAAGAWG
35      151     VKVLYEIKD LVPPOEILRA MQAQITAEER KRARIAESG RKIEQINLAS
201     GOREAEIQQS EGEAQAANVA SNAEKIARIN RAKGEAESLR LVAEANAEN
251     RQIAAALQTO SGADAVNLKI AQQVTVAFKN LAKEDNTRIK PAKVAEIGNP
301     NFRHEKFPSP EAKTAK*
  
```

40 ORF 519 shows 87.5% identity over a 200 aa overlap with a predicted ORF (ORF 519.ng) from *N. gonorrhoeae*:

```

m519/g519
45      m519.pep      10      20      30
                        SVIGRMELDKTFEERDEINSTVVAALDEAA
g519      YFQVTDPKLASYGSSNYIMAITQLAQTTTLRSVIGRMELDKTFEERDEINSTVVSALDEAA
                        90      100      110      120      130      140

50      m519.pep      40      50      60      70      80      90
                        GAWGVKVLRYEIKDLVPPOEILRAMQAQITAEERKRARIAESEGRKIBQINLASGQREAE
g519      GAWGVKVLRYEIKDLVPPOEILRAMQAQITAEERKRARIAESEGRKIBQINLASGQREAE
                        150      160      170      180      190      200

55      m519.pep      100      110      120      130      140      150
                        IQQSEGEAAQAVNASNAEKIARINRAKGEAESLRVAEANAETQIAAALQTCGGADAV
  
```

- 72 -

```

|||||
g519      IQQSEGEAAVNASNAEKIARINRAKGEAFSLRLVAEANAFAIRQIAAALQTQGGADAV
          210      220      230      240      250      260

5
          160      170      180      190      200
m519.pep  NLKLAIEQYVAAPNNLAKESNTLIMPANVADIGSL- ISAGMKIIDSSKTKAK
          ||||| |||:|:|:|:|:| |||:|:|:|:| :|:|:|:|
g519      NLKLAIEQYVAFKNLAKEDNTRIKPAKVABIGNPNFRHRHEKFSPEAKTAK
          270      280      290      300      310

```

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 972>:

```

a519.seq
1      ATGGAATTTT TCATTATCTT GCTGGCAGCC GTGCTGTGTT TCGGCTTCAA
51     ATCCTTTGTT GTCATCCOCAG AGCAGGAAGT CCAAGTTGTC GAAAGGCTCG
15     GCGGTTTCCA TCGCGCCCTG ACGGCGGTTT TGAATATTTT GATTCCCTTT
151    ATCGACGCGG TCGCCTACGG CCATTGCTGT AAAGAAATCC CTTTAGAAGT
201    ACCACGCCAG GTCTGCATCA CGCGCGCAAA TACGAGCTGT ACTGTTGAAG
251    GTATCATCTA TTTCCAGTA ACCGACCCCA AACTCGCCTC ATACGGTTTG
301    AGCAACTACA TTATGCGCAT TACCCAGCTT GCCCAAACGA CGCTGGTTTC
351    CGTTATCGGG CGTATGGAAT TGGACAAAAC GTTTGAAGAA CGCGACGAAA
401    TCAACAGCAC CGTCTCTCC GCCTCGATG AAGCCGCGGG AGCTTGGGGT
451    GTGAAGGTTT TCGCTTATGA GATTAAAGAC TTGGTTCGCG CGCAAGAAAT
501    CCTTCGCTCA ATCGAGCGGC AAATTACTGC TGAACGCGAA AAACGCGCCC
551    GTATCGCCGA ATCCGAAGGT CGTAAATCGC AACCAATCAA CTTTGCCGAT
601    GGTGAGCGCG AAGCCGAAT CCAACAATCC GAAGGCGGAG CTCAGGCTGC
651    GGTCAATGCG TCAATGCGC AGAAATCGC CCGCATCAAC CGCGCCAAAG
701    GTGAAGCGGA ATCCTTGCGC CTTGTTGCGG AAGCCAAATC CGAAGCCATC
751    CGTCAAAATG CCGCGCGCCT TCAAAACCAA GGCGGTGGGG ATGCGGTCAA
801    TCTGAAGATT GCGGAACAAT ACGTCGCGCG GTTCAACAAT CTTGCAAAAT
851    AAAGCAATAC GCTGATTATG CCGGCCAATG TTGCGGACAT CGGCGAGCTG
901    ATTTCTGCGG GTATGAAAT TATGACAGC AGCAAAACCG CCAATAAT

```

This corresponds to the amino acid sequence <SEQ ID 973; ORF 519.a>:

```

a519.pep
1      MEFFIILLAA VVVEGFKSFV VIPQOEHVHV ERLGRFHRAL TAGLNILIPF
51     IDRVAHYRSL KEIFLDVPSQ VCITRNTQL TVDGIYFQV TDFKLASYGS
101    SNYIMAITOL AQTTLRISVG RMELDKTFEE RDEINSTVVS ALDEANGAWG
151    VKVLRYEIKD LVFPQELRS MQAQITAEERE KRARIAESEG RKIEQINLAS
201    GQREAFKIQS EGEAAAVNA SNAEKIARIN RAKGEAFSLR LVREANAEAI
251    RQIAAALQTQ GGADAVNLKI AEQYVAAPNN LAKESNTLIM PANVADIGSL
301    ISAGMKIIDS SKTKA*

m519/a519  ORFs 519 and 519.a showed a 99.5% identity in 199 aa overlap

a519      YFQVTDPKLASYGSSNYIMAITOLAQTTLRSVIGRMELDKTFEERDEINSTVVSALDEAA
          90      100      110      120      130      140

m519.pep  SVIGRMELDKTFEERDEINSTVVAALDEAA
          |||||
a519      YFQVTDPKLASYGSSNYIMAITOLAQTTLRSVIGRMELDKTFEERDEINSTVVSALDEAA
          90      100      110      120      130      140

m519.pep  GAWGVKVLRYEIKDLVPPQELRSMQAQITAEFEKRKRARIAESEGKRKIEQINLASGQREAE
          40      50      60      70      80      90

a519      GAWGVKVLRYEIKDLVPPQELRSMQAQITAEFEKRKRARIAESEGKRKIEQINLASGQREAE
          150      160      170      180      190      200

m519.pep  IQQSEGEAAVNASNAEKIARINRAKGEAFSLRLVAEANAFAIRQIAAALQTQGGADAV
          |||||
a519      IQQSEGEAAVNASNAEKIARINRAKGEAFSLRLVAEANAFAIRQIAAALQTQGGADAV
          210      220      230      240      250      260

```

- 73 -

```

                    160      170      180      190      200
m519.pep  NLKIAEQYVAAFNNLAKESNTLIMPANVADIGSLISAGMKIIDSSKTAKX
5          a519  |||||
                    270      280      290      300      310
                    NLKIAEQYVAAFNNLAKESNTLIMPANVADIGSLISAGMKIIDSSKTAKX

```

- 10 Further work revealed the following DNA sequence identified in *N. meningitidis* <SEQ ID 974>:

```

m519-1.seq
1  ATGGAATTTT TCATTATCTT GTTGGTAGCC GTCGCGGTTT TCGGTTTCAA
15 51 ATCCTTTGTT GTCATCCACC AACAGGAAGT CCACGTTGTC GAAAGGCTGG
101 GCGTTTCCA TCGCGCCCTG ACGGCGGTTT TGAATATTTT GATTCCCTTT
151 ATCGACCGCG TCGCTACCG CCATTGCTG AAAGAAATCC CTTTAGACGT
201 ACCGAGCCAG GTCTGCATCA CGCGGCACAA TACGCAGCTG ACTGTTGACG
251 GCATCATCTA TTTCCAAAGTA ACGAGCCCA AACTCGCCTC ATACGTTTCG
301 AGCAACTACA TTATGGCGAT TACCCAGCTT GCCCAACGA CGCTGCGTTC
20 351 CGTTATCGGG CGTATGGAGT TGGACAAAAC GTTTGAAGAA CGCGACGAAA
401 TCAACAGTAC GTTGTGTGCG GCTTTGGACG AGCGCGCGGG GCCTTGGGGT
451 GTGAAGGTTT TCGCTATGGA GATTAAAGAC TTGGTTCGCG CGCAAGAAAT
501 CCTTCGCTCA ATCGAGGCGC AAATTACTGC CGAACGCGAA AAACGCGCCC
25 551 GTATCGCGCA ATCCGAAGGT CGTAAATTCG AACAAATCAA CTTTGCCAGT
601 GGTCAAGCTG AAGCCGAAT CCAACAATCC GAAGGCGAGG CTCAGGCTGC
651 GGTCAATGCG TCAAAATGCC AGAAAATCGC CGCATCAAC CGCGCCAAAG
701 GTGAAGCGGA ATCCTTGGCG CTGTGTCGCG AAGCAATATG CGAAGCCATC
751 CTTCAAAATG CGCGCGCCTC TCAAAACCAA GCGCGTGGCG ATGCGGTCAA
801 TCTGAAGATT CGCGCAATAT ACGTGCCTGC GTTCAACAAT CTTGCCAAAG
30 851 AAAGCAATAC GCTGATTATG CGCGCAATG TTGCGACAT CGCGAGCCTG
901 ATTTCTGCGC GTATGAAATAT TATGACAGC AGCAAAACCG CCAATATA

```

This corresponds to the amino acid sequence <SEQ ID 975; ORF 519-1>:

```

m519-1.
35 1  MEFFIILLVA VAVFGKSFV VIPQVEHVHV ERLGRFHRAL TAGLNILIFP
51 IDRVAHYRESL KEIFLDVFSQ VCITRDNTQL TVDGIIFYQV TDFKLASYGS
101 SNYIMAITQL AQTTLSRVIG RMELDKTFEE RDEINSTVVA ALDEAAGAWG
151 VKVLYREIKD LVPPQEILRS MQAQITAEER KRARIAESEG RKIEQINLAS
201 GQREAEIQQS EGEAQAQAVNA SNAEKIARIN RAKGEAESLR LVAEANAELI
40 251 RQIAAALQTO GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL
301 ISAGMKIIDS SRTAK*

```

The following DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 976>:

```

g519-1.seq
45 1  ATGGAATTTT TCATTATCTT GTTGGCAGCC GTCGCGGTTT TCGGCTTCAA
51 ATCCTTTGTC GTCATCCACC AGCAGGAAGT CCACGTTGTC GAAAGGCTCG
101 GCGTTTCCA TCGCGCCCTG ACGGCGGTTT TGAATATTTT GATTCCCTTT
151 ATCGACCGCG TCGCTACCG CCATTGCTG AAAGAAATCC CTTTAGACGT
50 201 ACCGAGCCAG GTCTGCATCA CGCGGCATAA TACGCAATATG ACTGTTGACG
251 GCATCATCTA TTTCCAAAGTA ACGGATCCCA AACTCGCCTC ATACGTTTCG
301 AGCAACTACA TTATGGCAAT TACCCAGCTT GCCCAACGA CGCTGCGTTC
351 CGTTATCGGG CGTATGGAGT TGGACAAAAC GTTTGAAGAA CGCGACGAAA
401 TCAACAGTAC CGTGTCTCC GCCCTCGATG AAGCGCGCGG GCCTTGGGGT
451 GTGAAGGTCC TCGCTACGGA AATCAAGGAT TTGTTTCGCG CGCAAGAAAT
55 501 CCTTCGCGCA ATCGAGGCAC AAATTACCGC CGAACGCGAA AAACGCGCCC
551 GTATTTCGCGA ATCCGAAGGC CGTAAATTCG AACAAATCAA CTTTGCCAGT
601 GGTCAAGCTG AAGCCGAAT CCAACAATCC GAAGGCGAGG CTCAGGCTGC
651 GGTCAATGCG TCCAAATGCC AGAAAATCGC CGCATCAAC CGCGCCAAAG
701 CGGAAGCGGA ATCCCTGCGC CTGTGTCGCG AAGCAATATG CGAAGCCATC
751 CGTCAAAATG CGCGCGCCTC TCAAAACCAA GCGCGGCGCG ATGCGGTCAA
60 801 TCTGAAGATT GCGGAACAAAT ACGTAGCGCG GTTCAACAAT CTTGCCAAAG

```

- 74 -

851 AAAGCAATAC GCTGATTATG CCCGCCAATG TTGCCGACAT CGGCAGCGTG  
 901 ATTTCTGCGC GCATGAAAT TATCGACAGC AGCAAAACCG CCAATAA

This corresponds to the amino acid sequence <SEQ ID 977; ORF 519-1.ng>:

5 g519-1.pep  
 1 MEFFIIILAA VAVFGFKSFV VIPOQEVHVVERLGRFHRALTAGLINILIFFIDRVAYRHSL  
 51 IDRVAYRHSL KEIPLDVPSQ VCITRNTQL TVDGIIFYQV TDPKLASYGS  
 101 SNYIMAITQL AQTTLSRVIG RMELDKTFEE RDEINSTVVS ALDEAGAWG  
 151 VKVLRYEIKD LVPPQELIRA MQAQITAEER KRAIAESEG RKIEQINLAS  
 201 GOREAEIQOS EGEAQAQVNA SNAEKIARIN RAKEAEESLR LVAEANAEAI  
 251 RQIAAALQTO GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL  
 301 ISAGMKIIDS SKTAK\*

15 m519-1/g519-1 ORFs 519-1 and 519-1.ng showed a 99.0% identity in 315 aa overlap

20 g519-1.pep MEFFIIILAAVAVFGFKSFVVIPOQEVHVVERLGRFHRALTAGLINILIFFIDRVAYRHSL  
 m519-1 MEFFIIILVAVAVFGFKSFVVIPOQEVHVVERLGRFHRALTAGLINILIFFIDRVAYRHSL

25 g519-1.pep KEIPLDVPSQVCITRNTQLTVDGIIFYQVTDPKLASYGSSNYIMAITQLAQTTLSRVIG  
 m519-1 KEIPLDVPSQVCITRNTQLTVDGIIFYQVTDPKLASYGSSNYIMAITQLAQTTLSRVIG

30 g519-1.pep RMELDKTFEERDEINSTVVSALDEAGAWGVKVLRYEIKDLVPPQELIRAMQQAQITAEER  
 m519-1 RMELDKTFEERDEINSTVVAALDEAGAWGVKVLRYEIKDLVPPQELIRSMQQAQITAEER

35 g519-1.pep KRARIAESEGKIEQINLASGOREAEIQOSEGEAQAQVNASNAEKIARINRAKGEAESLR  
 m519-1 KRARIAESEGKIEQINLASGOREAEIQOSEGEAQAQVNASNAEKIARINRAKGEAESLR

40 g519-1.pep LVAEANAEAIHQIAAALQTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL  
 m519-1 LVAEANAEAIHQIAAALQTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL

45 g519-1.pep ISAGMKIIDS SKTAKX  
 m519-1 ISAGMKIIDS SKTAKX

50 The following DNA sequence was identified in *N. meningitidis* <SEQ ID 978>:

55 a519-1.seq  
 1 ATGGCAATTT TCATTATCIT GCTGGCAGCC GTCGTGTGTT TCGCGTTCRA  
 51 ATCCTTTGTT GTCATCCACC AGCAGGAAGT CCACGTGTGC GAAAGGCTCG  
 101 GCGCTTTCCA TCGCGCCCTG AGCGCGGTT TGAATATTTT GATTCCTTTT  
 151 ATCGACCGCG TCGCTACCGC CCATTGCGTG AAAGAATATC CTTTAGAGGT  
 201 ACCGACCCAG GTCGTGCATCA CGCGGACACA TACCGAGCTG ACTGTTGAGG  
 251 GTATCATCTA TTTCAGTA ACCGACCCCA AACTCGGCTC ATACGTTTCG  
 301 AGCAACTACA TTATGGCGAT TACCAGGCTT GCCCAACGA CGCTGCGGTT



- 75 -

```

351 CGTTATCGGG CGTATGGAAT TGGACAAAC GTTTGAAGAA CGCGACGAAA
401 TCAACAGCAC CGTGTCTCC GCCCTCGATG AAGCGCGGG AGCTTGGGGT
451 GTGAAGTTT TCGCTTATGA GATTAAAGAC TTGTTCCGCG CGCAAGAAT
501 CTTTCTGCTCA ATCGAGGCGC AAATTACTGC TGAACGCGAA AAACGCGCCC
551 GTATCGCCGA ATCCGAGGCT CGTAAATCG AACAAATCAA CCTTCCGAGT
601 GGTACAGCGG AAGCGGAAT CCAACATCC GAAGCGGAGG CTCAGGCTGC
651 GGTCAATGCG TCAATGCGC AGAAATCGC CCGCATCAAC CGCGCCAAAG
701 GTGAAGCGGA ATCTTGGCGC CTTTGGCGC AAGCCAATCG CGAAGCCATC
751 CGTCAAAATG CGCGCGCCCT TCAAAACCAA GCGGCTGGCG ATCGCGTCAA
801 TCTGAAGATP GCGGAACAA ATGTCGCGCG GTTCAACAA CTTCGCAAA
851 AAGCAATAC GCTGATTATG CCGGCCAATG TTGCGACAT CGCGAGCTG
901 ATTTCTGCCG GTATGAAAT TATCGACAGC AGCAAAACCG CCAAAATTA

```

This corresponds to the amino acid sequence <SEQ ID 979; ORF 519-1.a>:

```

15 a519-1.pep.
      1 MEFFIILLAA VVVFQKSFV VFPQEVHV V ERLGRFHRAL TAGLNILIPF
      51 IDRVAIRHSL KEIPLDVPSQ VCITRDNTQL TVDGIYFQV TDPKCLASYGS
      101 SNYIMAITQL AQTTLRSVIG RMELDKTFEE RDEINSTVVS ALDEAAGAWG
      151 VKVLYEIKD LVFPQELRS MQAQITARE KRARIAESG RKIEQINLAS
      201 GQREAEIQGS EGEQAQAVNA SNAEKIARIN RAKGEAESLR LVAEANAELI
      251 RQIAAALQTQ GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL
      301 ISAGMKIIDS SKTAK*

25 m519-1/a519-1 ORFs 519-1 and 519-1.a showed a 99.0% identity in 315 aa
    overlap

      10      20      30      40      50      60
a519-1.pep MEFFIILLAAVVVFQKSFVFPQEVHVVERLGRFHRALTAGLNILIPFIDRVAIRHSL
      101
m519-1 MEFFIILLVAVVVFQKSFVFPQEVHVVERLGRFHRALTAGLNILIPFIDRVAIRHSL
      101
      10      20      30      40      50      60
a519-1.pep KEIPLDVPSQVCITRDNTQLTVDGIYFQVTDPKCLASYGSSNYIMAITQLAQTTLRSVIG
      101
m519-1 KEIPLDVPSQVCITRDNTQLTVDGIYFQVTDPKCLASYGSSNYIMAITQLAQTTLRSVIG
      101
      70      80      90      100      110      120
a519-1.pep KEIPLDVPSQVCITRDNTQLTVDGIYFQVTDPKCLASYGSSNYIMAITQLAQTTLRSVIG
      101
m519-1 KEIPLDVPSQVCITRDNTQLTVDGIYFQVTDPKCLASYGSSNYIMAITQLAQTTLRSVIG
      101
      70      80      90      100      110      120
a519-1.pep RMELDKTFEERDEINSTVVSALDEAAGAWGVKVLRYEKDLVFPQELRSMQAQITARE
      101
m519-1 RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYEKDLVFPQELRSMQAQITARE
      101
      130      140      150      160      170      180
a519-1.pep RMELDKTFEERDEINSTVVSALDEAAGAWGVKVLRYEKDLVFPQELRSMQAQITARE
      101
m519-1 RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYEKDLVFPQELRSMQAQITARE
      101
      130      140      150      160      170      180
a519-1.pep KRARIAESG RKIEQINLASGQREAEIQSGEQAQAVNASNAEKIARINRAKGEAESLR
      101
m519-1 KRARIAESG RKIEQINLASGQREAEIQSGEQAQAVNASNAEKIARINRAKGEAESLR
      101
      190      200      210      220      230      240
a519-1.pep KRARIAESG RKIEQINLASGQREAEIQSGEQAQAVNASNAEKIARINRAKGEAESLR
      101
m519-1 KRARIAESG RKIEQINLASGQREAEIQSGEQAQAVNASNAEKIARINRAKGEAESLR
      101
      190      200      210      220      230      240
a519-1.pep LVAEANAELIRQIAAALTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL
      101
m519-1 LVAEANAELIRQIAAALTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL
      101
      250      260      270      280      290      300
a519-1.pep LVAEANAELIRQIAAALTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL
      101
m519-1 LVAEANAELIRQIAAALTOGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL
      101
      250      260      270      280      290      300
a519-1.pep ISAGMKIIDS SKTAKX
      101
m519-1 ISAGMKIIDS SKTAKX
      101
      310

```

576 and 576-1 gnm22.seq

5 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 980>:

```

m576.seq.. (partial)
1 ..ATGCAGCAGG CAAGCTATGC GATGGGCGTG GACATCGGAC GCTCCCTGAA
51 GCAAAATGAG GAAACAGGCG CGAAATCGA TTTGAAAGTC TTACCGAAG
101 CCATCGAGCG AGTGTATGAC GGCAAGAAA TCAAAATGAC CGAAGAGCAG
151 GCTCAGGAGG TCATGATGAA ATTCCTTCAG GAACAACAGG CTAAGACCGT
201 AGAATAACAC AAGGCGGAGC CGAAGGCCAA TAAAGAAAAA GGCGAAGCCT
251 TTCTGAAAGA AAATGCGGCC AAGACGCGCG TGAAGACCAC TGCTTCCGCT
301 CTGCAATACA AAATCACCAC ACAGGCGGAA GGCRAACAGC CGACCAAGA
351 CGACATCGTT ACCGTGGAAT ACGAAGCGCG CCTGATTGAC GGTACGGTAT
15 401 TCGACAGCAG CAAAGCCAAC GCGCGCCCGG TCACCTTCCC TTTGAGCCAA
451 GTGATTCCGG GTTGGACOGA AGGCGTACAG CTTCTGAAAG AAGCGCGGCA
501 AGCCACGTTT TACATCCCGT CCAACCTTGC CTAACCGGAA CAGGGTCGGG
551 GCGACAAAAT CGTCCGAAC GCCACTTTGG TATTTGATGT GAAACTGGTC
601 AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCCGG CTCAGTCGA
20 651 CATCAAAAAA GTAAATTAA

```

This corresponds to the amino acid sequence &lt;SEQ ID 981; ORF 576&gt;:

```

m576.pep.. (partial)
1 ..MQQASYAMGV DIGRSLKQMK EQGAIDLVK FTEAMQAVYD GKEIKMTEEQ
25 51 AQEVMKFLQ EQQAKAVEKH KADAKANKEK GEAPLEKNAE KDGKVTASG
101 LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
151 VIPGWTEGVQ LLKEGGGEATF YIPSNLAYRE QGAGDKIGPN ATLVDVVKLV
201 KIGAPENAPA KQPAQVDIKK VN*

```

30 The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 982>:

```

g576.seq.. (partial)
1 ..atgggcggtg acatcgagcg ctcctgaaa caaatgaag aacaggcgcg
51 ggaatcgat ttgaaagtct ttaccgatgc catgcaggca gtgtatgacg
101 gcaaaagaat caaatgacc gaagagcagg cccagggaat gatgatgaaa
35 151 ttctcgagg agcagcaggc taagaccgta gaaaaacaca aggcggatgc
201 gaaggccaac aaagaaaaag gcgaagcctt cctgaaggaa aatgcccgcg
251 aagacggcgt gaagaccact gcttcgggtc tgcagtacaa aatcaccaaa
301 caggggtgaag gcaaacagcc gacaaaaagc gacatcgtaa cgtgggaata
351 cgaaggcccg ctgattgacg gtaccgtatt cgacagcagc aagcacaacg
40 401 gcggcccgcc cacttccct ttgagccaa tgatccggg ttggaccgaa
451 ggcgtacggc ttctgaaaga aggcggcgaa gccactgtct acatccggtc
501 caactctgcc tcccggaac aggggtcggg cyaaaaaatc ggtccggaac
551 ccactttggt atttgacgtg aaactggtca aaatcgcgcg acccgaaac
601 gcgcccgcca agcagccgga tcaagtcgac atcaaaaaa taaattaa
45

```

This corresponds to the amino acid sequence &lt;SEQ ID 983; ORF 576.ng&gt;:

```

g576.pep.. (partial)
1 ..MGVDIGRSLK QMKEQGAID LKVFTDAMQA VYDGKEIKMT EEQAQEVMMK
51 FLOEQQAKAV EKHKADAKAN KEKGEAPLKE NAAEDGVKTT ASGLQYKITK
50 101 QGEGKQPTKD DIVTVEYER LIDGTVFDS KANGPATFP LSQVIPWTE
151 GVRLLKEGGE ATFYIPSNLA YREGAGEKEI GPNATLVFDV KLVKIGAPEN
201 APAKQPDQVD IKKV*

```

55 Computer analysis of this amino acid sequence gave the following results:  
Homology with a predicted ORF from *N. gonorrhoeae*

m576/g576 97.2% identity in 215 aa overlap

- 77 -

		10	20	30	40	50	60
	m576.pep	MQQASYAMGV DIGRSLKQMK EQGAEIDLKVFTEAMQAVYDGKEIKMTTEQAQEVMMKFLQ					
5	g576	MGVDIGRSLKQMK EQGAEIDLKVFTEAMQAVYDGKEIKMTTEQAQEVMMKFLQ					
		10	20	30	40	50	
		70	80	90	100	110	120
10	m576.pep	EQQAKAVEKHKADAKANKEGAEFLKENAAKDGVKTTASGLQYKIKTQEGEKQPTKDDIV					
	g576	EQQAKAVEKHKADAKANKEGAEFLKENAAEDGVKTTASGLQYKIKTQEGEKQPTKDDIV					
		60	70	80	90	100	110
		130	140	150	160	170	180
15	m576.pep	TVEYEGRLIDGT VFDSSKANGGPVTFPLSQVIPGWTEGVQLLKEGGEATFYIPSNLAYRE					
	g576	TVEYEGRLIDGT VFDSSKANGGPATFPLSQVIPGWTEGVRLLEKGEATFYIPSNLAYRE					
		120	130	140	150	160	170
20		190	200	210	220		
	m576.pep	QGAGDKIGPNATLVFDVKLVKIGAPENAPAKQPAQVDIKKVNK					
	g576	QGAGEKIGPNATLVFDVKLVKIGAPENAPAKQPDQVDIKKVNK					
		180	190	200	210		

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 984>:

	a576.seq	
	1	ATGAACACCA TTTTCAAAT CAGCGCACTG ACCCTTCCG CGCTTTGGC
	51	ACTTTCCGCG TCGGCGRAAA AAGAAGCCGC CCCCGATCT GCRTCCGAAC
30	101	CTGCGCGCGC TTCTTCCGCG CAGGCGACA CCTTCGAT CGCAGCAGG
	151	ATGCAGCAGG CAAGCTATGC GATGGCGGTG GACATCGAC GCTCCTGAA
	201	GCAATGAAG GAACAGGCG CGGAATCGA TTGAAAGTC TTACCGAAG
	251	CAATCGAGG AGTGTATGAC GGCAAGGAA TCAAAATGAC CGAAGAGCAG
	301	GCTCAGGAAG TCATGATGAA ATTCTTTCAG GAACACAGG CTAAGAGCGT
35	351	AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GGCGAGCCT
	401	TTTCAAAAGA AAGTCCGCGC AAAGACGCGC TGAAGACCAC TGCTTCGCGC
	451	CTGCAATACA AAATCACCAA ACAGGCGGAA GGCAACAGC GCACCAAGA
	501	CGACATCGTT ACCGTGGAAT ACGAAGCCGC CCGATTGAC GTTACGGTAT
	551	TCGACAGCAG CAAAGCCAA CAGGCGCCGG TCACCTTCCC TTTGAGCCAA
40	601	GTGATCTCGG GTTGGACCGA AGGCGTACAG CTTCGAAAG AAGCGCGCGA
	651	AGCCACGTTT TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGCTGCGG
	701	CGGACAAAAT CGGCGCGAAC GCCACTTTGG TATTGTATGT GAACTGCTC
	751	AAAATCGCGC CACCGGAAA CGCGCCCGCC AAGCAGCGG CTCAAGTCGA
45	801	CATCAAAAAA GTAAATTAA

This corresponds to the amino acid sequence <SEQ ID 985; ORF 576.a>:

	a576.pep	
	1	MNTIFKISAL TLSSAALALS
	51	MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ
50	101	AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLEKNAE KDGVKTTASG
	151	LQYKIKTQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
	201	VILGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVFDVKLV
	251	KIGAPENAPA KQPAQVDIKK VN*
55	m576/a576	ORFs 576 and 576.a showed a 99.5% identity in 222 aa overlap
	m576.pep	10 20 30
		MQQASYAMGV DIGRSLKQMK EQGAEIDLKV
60	a576	CGKKEAAPASAPAAASAGQDTSIGSTMQQQASYAMGV DIGRSLKQMK EQGAEIDLKV
		30 40 50 60 70 80

- 78 -

		40	50	60	70	80	90
	m576.pep	FTEAMQAVYDGKEIKMTEEQAEVMMKFLQEQQAKAVEKHKADAKANKEKGEAFLENAA					
5	a576	FTEAMQAVYDGKEIKMTEEQAEVMMKFLQEQQAKAVEKHKADAKANKEKGEAFLENAA					
		90	100	110	120	130	140
	m576.pep	KDGVKTTASGLQYKITKQEGKQPTKDDIVTVEYEGRLIDGTVFDDSSKANGGPVTFPLSQ					
10	a576	KDGVKTTASGLQYKITKQEGKQPTKDDIVTVEYEGRLIDGTVFDDSSKANGGPVTFPLSQ					
		150	160	170	180	190	200
	m576.pep	VIPGWTEGVOLLKEGGEATFYIPSNLAYREQGAGDKIGPNATLVFDVKLVKIGAPENAPA					
15	a576	VILGWTEGVOLLKEGGEATFYIPSNLAYREQGAGDKIGPNATLVFDVKLVKIGAPENAPA					
		210	220	230	240	250	260
	m576.pep	KQPAQVDIKKVN					
20	a576	KQPAQVDIKKVN					
		270					

25 Further work revealed the following DNA sequence identified in *N. meningitidis* <SEQ ID 986>:

	m576-1.seq	
30	1 ATGAACACCA TTTTCAAAAT CAGCGCACTG ACCCTTTCCG CGCTTTGGC	
	51 ACTTTCCGCG TGCGGCAAAA AAGAAGCGCG CCGCATCT GCATCCGAAC	
	101 CTGCGCGCGC TTCTTCGCGG CAGGGCGACA CCTCTCGAT CGGCAGCAG	
	151 ATGCAGCAGG CAAGCTATGC GATGGCGGTG GACATCGGAC GTCCTCGAA	
	201 GCAATGAAG GAACAGGGCG CGGAAATCGA TTTGAAAGTC TTTACCGAAG	
35	251 CCATGCAGGC AGTGTATGAC GGCRAAGAAA TCRAAATGAC CGAAGAGCAG	
	301 GCTCAGGAAG TCATGATGAA ATTCTTTCAG GAACAACAGG CTAAAGCGGT	
	351 AGAAAAACAC AAGGCGGAGC CGAAGGCCAA TAAAGAAAAA GCGCAAGCCT	
	401 TTCTGAAAGA AAATGCGCGC AAAGACGCGC TGAAGACCAC TGCTTCGGGC	
	451 CTGCAATACA AAATCACCAA ACAGGGCGAA GGCAACAGC CGACCAAGAA	
40	501 CGACATCGTT ACGGTGGAAT ACGAAGCGCG CTTGATTGAC GGTACGGTAT	
	551 TCGACAGCAG CAAAGCCAA C GGGCGCCCG TCACTTTCC TTTGAGCCAA	
	601 GTGATTCCGG GTTGACCGA AGGCGTACAG CTTCTGAAAG AAGCGGGGA	
	651 AGCCACGTTT TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGCTGGCG	
	701 GCGCAAAAT CGGTCCGAAC GCCACTTTGG TATTGTATG GAACTGGTC	
	751 AAAATCGGGC CACCCGAAAA CGCGCCGCC AAGCAGCGG CTCAAGTCGA	
45	801 CATCAAAAAA GTAAATTA	

This corresponds to the amino acid sequence <SEQ ID 987; ORF 576-1>:

	m576-1.pep	
50	1 MNTIFKISAL TISAALALSA CGKKEAPAS ASEPAASSA QGDTSIGST	
	51 MQQASYAMGV DIGSLKQMK EQGAIDLKV FTEAMQAVYD GKEIKMTEEQ	
	101 AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG	
	151 LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDDSSKAN GGPVTFPLSQ	
	201 VIPGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVFDVKLV	
55	251 KIGAPENAPA KQPAQVDIKK VN*	

The following DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 988>:

	g576-1.seq	
60	1 ATGAACACCA TTTTCAAAAT CAGCGCACTG ACCCTTTCCG CGCTTTGGC	
	51 ACTTTCCGCG TGCGGCAAAA AAGAAGCGCG CCGCATCT GCATCCGAAC	
	101 CTGCGCGCGC TTCTTCGCGG CAGGGCGACA CCTCTCAAT CGGCAGCAG	
	151 ATGCAGCAGG CAAGCTATGC AATGGCGGTG GACATCGGAC GTCCTCGAA	

- 79 -

201 ACAATGAAG GAACAGGGCG CGGAATCGA TTGAAATGC TTTACCGATG  
 251 CCATGCAGGC AGTGTATGAC GGCAAGAAA TCAATGAC CGAAGAGCAG  
 301 GCCAGGAGG TGATGATGAA ATTCTGCGAG GAGCAGCAGG CTAAGGCCGT  
 351 AGAAAAACAC AAGGCGGATG CGAAGGCCAA CAAAGAAAA GCGAAGCCT  
 401 TCCTGAAGGA AAATGCCGCG AAAGACGCGC TGAAGACAC TGCTTCCGCT  
 451 CTGCAGTACA AATCACCACA ACAGGTTGAA GGCAACAGC GCACAAAGA  
 501 CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACCGTAT  
 551 TCGACAGCAG CAAAGCCAA CAGGCGCCGG CCACCTTCC TTTGAGCCAA  
 601 GTGATTCCGG GTTGGACCGA AGGCGTACGG CTTCCTGAAG AAGGCGGCGA  
 651 AGCCACGTTT TACATCCCGT CCAACTTGG CTACCGCGAA CAGGCTGCGG  
 701 GCGAAAAAAT CGTCCGGAAC GCCACTTTGG TATTGACGT GAAATGCTC  
 751 AAAATCGGCG CACCCGAAA CGCGCCCGCC AAGCAGCCGG ATCAAGTGA  
 801 CATCAAAAAA GTAAATTAA

15 This corresponds to the amino acid sequence <SEQ ID 989; ORF 576-1.ng>:

g576-1.pep  
 1 MNTIFKISAL TLSAALALSA CGKKEAPAS ASEPAASAA QGDTSSIGST  
 51 MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTDAMQAVYD GKEIKNTBEQ  
 101 AQEVMMKFLQ EQQAKAVEKH KADAKANKKEK GEAFLEKENA KDGWKTASG  
 151 LQIKTKQGE GKQFTKDDIV TVEYEGRLID GTVFDSSKAN GGFATFPLSQ  
 201 VFWTEGTVR LLKEGGGATF YIPSNLAYRE QGAGEKIGPN ATLVFDVKLV  
 251 KIGAPENAPA KQPDQVDIKK VN\*

25 g576-1/m576-1 ORFs 576-1 and 576-1.ng showed a 97.8% identity in 272 aa overlap

		10	20	30	40	50	60
30	g576-1.pep	MNTIFKISAL	TLAALALSA	CGKKEAPAS	ASEPAASAA	QGDTSSIGST	MQQASYAMGV
	m576-1	MNTIFKISAL	TLAALALSA	CGKKEAPAS	ASEPAASAA	QGDTSSIGST	MQQASYAMGV
		10	20	30	40	50	60
		70	80	90	100	110	120
35	g576-1.pep	DIGRSLKQMK	EQGAEIDLKV	FTDAMQAVYD	GKEIKNTBEQ	AQEVMMKFLQ	EQQAKAVEKH
	m576-1	DIGRSLKQMK	EQGAEIDLKV	FTDAMQAVYD	GKEIKNTBEQ	AQEVMMKFLQ	EQQAKAVEKH
		70	80	90	100	110	120
40		130	140	150	160	170	180
	g576-1.pep	KADAKANKKEK	GEAFLEKENA	AKDGWKTASG	LQYIKTKQGE	GKQFTKDDIV	TVEYEGRLID
	m576-1	KADAKANKKEK	GEAFLEKENA	AKDGWKTASG	LQYIKTKQGE	GKQFTKDDIV	TVEYEGRLID
		130	140	150	160	170	180
45		190	200	210	220	230	240
	g576-1.pep	GTVFDSSKAN	GGFATFPLSQ	VFWTEGTVR	LLKEGGGATF	YIPSNLAYRE	QGAGEKIGPN
	m576-1	GTVFDSSKAN	GGFATFPLSQ	VFWTEGTVR	LLKEGGGATF	YIPSNLAYRE	QGAGEKIGPN
50		190	200	210	220	230	240
		250	260	270			
	g576-1.pep	ATLVFDVKLV	KIGAPENAPA	KQPDQVDIKK	VN		
55	m576-1	ATLVFDVKLV	KIGAPENAPA	KQPDQVDIKK	VN		
		250	260	270			

The following DNA sequence was identified in *N. meningitidis* <SEQ ID 990>:

a576-1.seq  
 60 1 ATGAACACCA TTTTCAAAAT CAGCGCACTG ACCCTTTCCG CCGCTTTGGC  
 51 ACTTTCCGCG TCGCGCAAAA AAGAAGCCGC CCCCGCATCT GCATCCGAAC  
 101 CTGCGCCGCG TTCTTCGCGG CAGGCGGACA CTTCTTCGAT CGGCAGCAGC

- 80 -

151 ATGCAGCAGG CAAGCTATGC GATGGCGGTG GACATCGGAC GCTCCCTGAA  
 201 GCAATGAAG GAACAGGGCG CGGAATTCGA TTGAAAGTC TTACCGAAG  
 251 CCATGCAGCG AGTGATGATG CGCAAGAGAA TCAAAATGAC CGAAGAGCAG  
 301 GCTCAGGAAG TCATGATGAA ATTCTTTT CAG GAACAACAGG CTAAGCCGT  
 351 AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GCGCAGCCCT  
 401 TTCTGAAGA AATGCGCGCC AAGAGCGCGC TGAAGACCAC TGCTTCCGGC  
 451 CTGCAATACA AAATCACCAG ACAGAGCGGAA GGAACACAGC GCACCAAGA  
 501 CGACATCGTT ACGGTGGAAT ACGAAGCGCG CCTGATTGAC GGTACGGTAT  
 551 TCGACAGCAG CAAAGCCCAAC GCGCGCCCGG TCACCTTCCC TTTGGGCCAA  
 601 GTGATTCTGG GTTGACCGGA AGGCGTACAG CTTCTGAAG AAGGCGGCGA  
 651 AGCCACGTTT TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGCGTGGG  
 701 GCGACAAAAT CGGCCGGAAC GGCACCTTGG TATTGTATGT GAAACTGCTC  
 751 AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCGCG CTCAAGTCGA  
 801 CATCAAAAAA GTAAATTTAA

This corresponds to the amino acid sequence <SEQ ID 991; ORF 576-1.a>:

a576-1.pep  
 1 MNTIFKISAL TLSAALALSA CGKKEAPAS ASEPAASSA QGDTSSIGST  
 51 MQQASYAMGV DIGRLKQKH EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ  
 201 101 AQEVNMFLEQ EQQAKAVEKH KADAKANKEK GEAFLEKNA KDGVTKTASG  
 151 LQYKTIKQGE GKOPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ  
 201 VILGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGFN ATLVFDVKLV  
 251 KIGAPENAPA KQPAQVDIKK VN\*  
 a576-1/m576-1 ORFs 576-1 and 576-1.a 99.6% identity in 272 aa overlap  
 10 20 30 40 50 60  
 a576-1.pep MNTIFKISALTLSAALALSACGKKEAPASASEPAASSAQGDTSSIGSTMQQASYAMGV  
 30 m576-1 MNTIFKISALTLSAALALSACGKKEAPASASEPAASSAQGDTSSIGSTMQQASYAMGV  
 10 20 30 40 50 60  
 70 80 90 100 110 120  
 a576-1.pep DIGRLSKMKKEQGAIEDLKVFTTEAMQAVYDQKEIKMTEEQAQEVNMFLEQEQQAKAVEKH  
 35 m576-1 DIGRLSKMKKEQGAIEDLKVFTTEAMQAVYDQKEIKMTEEQAQEVNMFLEQEQQAKAVEKH  
 70 80 90 100 110 120  
 130 140 150 160 170 180  
 a576-1.pep KADAKANKEKGEAFLEKNAADGVKTASGLQYKTIKQGEKQPTKDDIVTVEYEGRLID  
 40 m576-1 KADAKANKEKGEAFLEKNAADGVKTASGLQYKTIKQGEKQPTKDDIVTVEYEGRLID  
 130 140 150 160 170 180  
 190 200 210 220 230 240  
 a576-1.pep GTVFDSSKANGGPVTFPLSQVILGWTEGVQLLKEGGEATFYIPSNLAYREQAGDKIGFN  
 45 m576-1 GTVFDSSKANGGPVTFPLSQVILGWTEGVQLLKEGGEATFYIPSNLAYREQAGDKIGFN  
 190 200 210 220 230 240  
 250 260 270  
 a576-1.pep ATLVFDVKLVKIGAPENAPAKQPAQVDIKKVN\*  
 55 m576-1 ATLVFDVKLVKIGAPENAPAKQPAQVDIKKVN\*  
 250 260 270

919 and 919-2

gnum43.seq

60

The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 992>:

```

m919.seq
1  ATGAAAAAAT  ACCTATTCCG  CGCGGCCCTG  TACGGCATCG  CGCGGCCCAT
5  CCTCGCGGCC  TGCCAAAGCA  AGAGCATCCA  AACCTTTCCG  CAACCCGACA
101 CATCCGCTCAT  CAACGGCCCG  GACCGGCCGG  TCGGCATCCC  CGACCCCGCC
151 GGAACGACGG  TCGCGGGCGG  CGGGGCCGTC  TATACCGTTG  TACCGCACTT
201 GTCCCTGCCC  CACTGGGCGG  CGCAGGATTT  CGCCAAAAGC  CTGCATCTCT
251 TCCGCTCCGG  CTGCGCCAAT  TTGAAAAACC  GCCAAGGCTG  CGAGGATGTG
10  301 TCGGCCCAAG  CCTTTCAAAC  CCCGCTCCAT  TCCTTTT CAGG  CAAAACAGTT
351 TTTTGAACGC  TATTTCAAGC  CGTGGCAGGT  TGCAGGCAAC  GGAAGCCTTG
401 CCGGTACGGT  TACCGGCTAT  TACGAACCGG  TGCTGAAGGG  CGACGACAGG
451 CGGACGGCAC  AAGCCCGCTT  CCCGATTAC  GGTATTTCCG  ACGATTTTAT
501 CTCCGTCGCC  CTGCTGCCGG  GTTTGGCGAG  CGGAAAAGCC  CTGTCCGCA
15  551 TCAGCGAGAC  GGGAAAAAAC  AGCGGCACAA  TCGACAATAC  CGCGGCCACA
601 CATACGCGCG  ACCTCTCCCG  ATTCCCCTAT  ACCGCGCGCA  CAACGCAAT
651 CAAAGGCAGG  TTTGAAGGAA  CGCGCTTCTT  CCCCTACCA  ACGCGCAAC
701 AAATCAACGG  CGCGCGCGCT  GACGCGCAAG  CCCCGATACT  CGGTACCGCC
751 GAAGACCTTG  TCGAACTTTT  TTTTATGCAC  ATCCAAAGCT  CGGTACCGCT
20  801 GAAACACCCG  TCCGCGCAAT  ACATCCGCAT  CGGCTATGCC  GACAAAAAGC
851 AACATCCyTA  CGTTTCCATC  GGAAGCTATA  TGGCGGATA  GGGCTACCTC
901 AACATCGGAC  AACCTCCAT  CGAGGCGCAT  AAGTCTTATA  TGGCGAAAA
951 TCGCAACGCG  CTCGCCAAG  TTTTGGGTCA  AAACCCGAGC  TATATCTTTT
25  1001 TCGCGAGGCT  TCGCGGAAGC  AGCAATGAGC  GCCTCTCGCG  CGCATGGCG
1051 ACGCGCGTGA  TGGGGGAATA  TCGCGCGCG  GTCCAGCGCG  ACTACATTAC
1101 CTTGGGTGCG  CCTTATTATT  TCGCCACCGC  CCATCCGCTT  ACCCGCAAG
1151 CCTCAACCG  CCTGATTATG  CGCGAGGATA  CGGCGAGCG  GATTAAAGCG
1201 GCGGTGCGCG  TGGATTATTT  TTGGGGATAC  GCGCAAGAG  CGCGGAACT
30  1251 TGGCGGCAAA  CAGAAAAACA  CGGATATGT  TGGCAGCTC  CTACCGCAAC
1301 GTATGAAGCC  CGAATACCGC  CCGTAA

```

This corresponds to the amino acid sequence <SEQ ID 993; ORF 919>:

```

m919.pep
1  MKKYLFRAL  YGIAAAILAA  QSKSIQTFP  PQDTSVINGP  DRPVGIPDPA
5  GTTVGGGAV  YTVPHLSLP  HWAQDPFAS  LQSFRLGCAN  LKNRQWQDV
101 CAQAFQTPVH  SFQAKOFFER  YTFWQVAGN  GSLAGTVTGY  YEPVLKGDDR
151 RTAQARFPIY  GIPDDFISVP  LPAGLRSKA  LVRIRQTGKN  SGTIDNTGGY
201 HTADLSRFP  I  TARTTAIKGR  FRGSRFLPYH  TRNQINGAL  DGKAPILGYA
40  251 EDPVELPFMH  IQSGRLKTP  SGKYIRIGYA  DKNBHPVYS  GRYMADKGYL
301 KLGQTSMQGI  KSYMQRNPQR  LAEVLGNPS  YIFFRELAS  SNDGPVGLAG
351 TPLMGEYAGA  VDRHYITLGA  PLFVATAHPV  TRKALNRLIM  AQDTGSAIKG
401 AVRVDYFWGY  GDEAGELAGK  QKTTGYVWQL  LPNGMKPEYR  P*

```

The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 994>:

```

m919-2.seq
1  ATGAAAAAAT  ACCTATTCCG  CGCGGCCCTG  TACGGCATCG  CGCGGCCCAT
5  CCTCGCGGCC  TGCCAAAGCA  AGAGCATCCA  AACCTTTCCG  CAACCCGACA
50  101 CATCCGCTCAT  CAACGGCCCG  GACCGGCCGG  TCGGCATCCC  CGACCCCGCC
151 GGAACGACGG  TCGCGGGCGG  CGGGGCCGTC  TATACCGTTG  TACCGCACTT
201 GTCCCTGCCC  CACTGGGCGG  CGCAGGATTT  CGCCAAAAGC  CTGCATCTCT
251 TCCGCTCCGG  CTGCGCCAAT  TTGAAAAACC  GCCAAGGCTG  CGAGGATGTG
301 TCGGCCCAAG  CCTTTCAAAC  CCCGCTCCAT  TCCTTTT CAGG  CAAAACAGTT
55  351 TTTTGAACGC  TATTTCAAGC  CGTGGCAGGT  TGCAGGCAAC  GGAAGCCTTG
401 CCGGTACGGT  TACCGGCTAT  TACGAACCGG  TGCTGAAGGG  CGACGACAGG
451 CGGACGGCAC  AAGCCCGCTT  CCCGATTAC  GGTATTTCCG  ACGATTTTAT
501 CTCCGTCGCC  CTGCTGCCGG  GTTTGGCGAG  CGGAAAAGCC  CTGTCCGCA
551 TCAGCGAGAC  GGGAAAAAAC  AGCGGCACAA  TCGACAATAC  CGCGGCCACA

```

- 82 -

5  
10  
15

```

601 CATACGCGC ACCTCTCCG ATTCGCCATC ACCGGCGGCA CAACAGCAAT
651 CAAAGGCAGG TTGGAAGGAA GCGGCTTCCT CCCCTACCAC ACGGCAACCC
701 AAATCAACGG CGGCGCGCTT GACGGCAAGG CCCCGTACT CGGTACGCGC
751 GAAGACCCCTG TCGAACTTTT TTTTATGCAC ATCCAGGCTT CGGGCGCTCT
801 GAAACCCCGC TCCGGCAAA ATCATCGCAT CGGCTATGCC GACAAAAACG
851 AACATCCCTA CGTTTCCATC GCGAGCTATA TGGCGGATAA GGGCTACCTC
901 AAATCTGGAC AAACCTCCAT GCAGGGCATT AAGTCTTATA TGGCGCAAAA
951 TCCGCGACGC CTCGCCGAGG TTTTGGGTCA AAACCCAGC TATATCTTTT
1001 TCCGCGAGCT TCGCGGAAGC AGCAATGAGC GCGCTGTGGC GCACTGGGCG
1051 ACGCCGCTGA TGGGGGAATA TCCGCGCGCA GTCCAGCCGC ACTACATTAC
1101 CTTGGGTGCG CCCTTATTATG TCGCCACCGC CCATCCGGTT ACCGCGAAG
1151 CCCTCAACCG CCGTATTATG GCGCAGGATA CCGCGAGCGC GATTAAAGGC
1201 GCGGTGCGCG TGGATTATTT TTGGGGATAC GCGCGAGGAG CCGCGCAACT
1251 TGCCGCGCAA CAGAAAAACA CGGGATATGT CTGGCAGCTC CTACCCAAACG
1301 GTATGAAGCC CGAATACCGC CCGTAA

```

This corresponds to the amino acid sequence <SEQ ID 995; ORF 919-2>:

m919-2.pep

```

20 1 MKKYLFRAL YGIAAAILAA CQSKIQTFF QPDTSVINGP DRPVPIDPA
51 GTTVGGGGAV YTVVHLSLF HWAQDFAKS LQSFRLGCAN LKNRGWQDV
101 CAQAFOTFVH SFOAKOFFER YFTWQVAGN GSLAGTVTG YEPVLKGDNR
151 RTAQARFFIY GIPDDFISVF LPAGLRSGLK LVRIQTGKN SGTIDNTGCT
201 HTADLSRFFI TARTTAIKGR FEGSRFLPYH TRNININGAL DGKAPILGYA
25 251 EDVVELFFMH IQSGSRLKTF SGKYIRIGYA DKNEHPPYSI GRYMADKGYL
301 KLGQTSMQGI KSYMRONPOR LAEVLGNFYS YIFRELAGS SNDGPGVALG
351 TPLNGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG
401 AVRVDYFWYG GDEAGELAGK QKTTGYVWQL LFNMGKPEYR P*

```

The following partial DNA sequence was identified in *N.gonorrhoeae* <SEQ ID 996>:

g919.seq

```

35 1 ATGAAAAAAC ACCTGCTCCG CTCGCCCTGT TACGGcatCG CCGCGgeat
51 CctcgCGGCC TGCCAAAGca gGAGCATCCA AACCTTTCCG CAACCCGACA
101 CATCCGTCRT CAACGGCCCG GACCGGCCGG CCGGCATCCC CGACCCCGCC
151 GGAACGACGG TTCCCGCGGG CGGGGCCGTC TATACCGTTG TGCOCGACCT
201 GTCCATGCCC CACTGGCGGG CCGaggATTT TGCCAAAAGC CTGCAATCTT
25 251 TCCGCTCCGG CTGCGCCAAT TTGAAAAACC GCCAAGGCTG CAGAGATGCT
301 TCGGCCCAAG CTTTCAAAAC CCCCCTGCAT TCCTTTTCAGG CAAAGCGgTT
35 351 TTTTGAAACG TATTTCACGC cgtGGCaggt tgcaggcaAC GGAAGcCTTG
401 CaggtaaggT TACCGGCTAT TACGAACCGG TGCTGAAGGG CGACGCGAGG
45 451 CGGACGGAAc GGGCCCGCTT CCGGATTAC GGTATTCCCG ACGATTTTAT
501 CTCCTGCCCG CTGCTGCCCG GTTTGCGGGG CGGAAAAAAC CTTGTCCGCA
55 551 TCAGGCGAGc gggGAAAAAC AGCGGCACGA TCGCAATGCG CGGCGGCAGC
601 CATACGCGCG ACCTCTCCCG ATTCGCCATC ACCGCGCGCA CAACGCGaat
651 caaaGGCAGG TTGGAaggAA GCGGCTTCCT CCCTTACCAC ACGCGCAACC
701 AAATcaacGG CGGCGcgCTT GACGGCAaag cccCATCCT CggtatcgCG
75 751 GAgaccCcgT tcgaactTTT TTTCA TGCAc AtccaaggCT CGGCGCGCCT
80 801 GAAACCCCGc tcggcaaat acatCCGcAT cggATagcgc gacAAAAACG
85 851 AACATccgTa tgtttccatc ggAGCctaTA TGGCGAGCAA AGGCTACCTC
90 901 AAGctcgggc agACCTCGAT GCAGGgcatc aaagcTATA TGGCGCAAAA
95 951 TCCGCAACGC CTCGCCGAGG TTTTGGGTCA AAACCCAGC TATATCTTTT
100 1001 TCCGCGAGCT TCGCGGAAGC GGCAATGAGG QCCCGCTGCG GCACTGGGCG
105 1051 ACGCCACTGA TGGGGGAATA CCGCGCGCA ATCGAGCCGC ACTACATTAC
110 1101 CTTGGGCGCG CCCTTATTATG TCGCCACCGC CCATCCGGTT ACCGCGAAG
115 1151 CCCTCAACCG CCGTATTATG GCGCAGGATA CAGCGAGCGC GATCAAAGGC
120 1201 GCGGTGCGCG TGGATTATTT TTGGGTGTTAC GCGCAGGAG CCGCGCAACT
125 1251 TGCCGCGCAA CAGAAAAACA CGGGATACGT CTGGCAGCTC CTGCCCCAAGC
130 1301 GCATGAAGCC CGAATACCGC CCGTAA

```



- 83 -

This corresponds to the amino acid sequence &lt;SEQ ID 997; ORF 919.ng&gt;:

g919.pep  
 1 MKKHLRLSAL YGIAAAILAA CQSRSIQTFF QPDTSVINGP DRPAGIDPPA  
 5 51 GTTVAGGGAV YTVVPHLSMP HWAQDFAKS LQSFRLGCAN LKNRQGWQDV  
 101 CAQAPQTPVH SFQAKRFFER YFTPWQVAGN GSLAGVTGY YEPVLKGDGR  
 151 RTERARFPIY GIPDDFISVP LPAGLRGGKN LVRIQTGKN SGTIDNAGGT  
 201 HTADLSRFFI TARTTAIKGR FEGRFLPYH TRNQINGGAL DGKAPILGYA  
 251 EDPVLEPFMH IQGSGRLKTP SGKYIRIGYA DKNHEPYSI GRYMADKGYL  
 301 KLGQTSMQGI KAYMRQNPR LAEVLGQNPS YIFPRELAGS GNEGPVAGLG  
 10 351 TPLMGEYAGA IDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG  
 401 AVRVDYFWGY GDEAGELAGK QKTGTGVWQL LPNGMKPEYR P\*

ORF 919 shows 95.9 % identity over a 441 aa overlap with a predicted ORF (ORF 919.ng)  
 from *N. gonorrhoeae*:

m919/g919

20	m919.pep	10	20	30	40	50	60
		MKKYLFRAALYGIAAAILAACQSKSIQTFFQPDTSVINGPDRPVGIDPPAGTTVGGGGAV					
	g919	MKKHLLRSALYGIAAAILAACQSRSIQTFFQPDTSVINGPDRPAGIDPPAGTTVAGGGAV					
		10	20	30	40	50	60
25	m919.pep	70	80	90	100	110	120
		YTVVPHLSLPHWAAQDFAKSLQSFRLGCANLKNRQGWQDVCAQAPTPVHSFQAKQFFER					
	g919	YTVVPHLSMPHWAQDFAKSLQSFRLGCANLKNRQGWQDVCAQAPTPVHSFQAKRFFER					
		70	80	90	100	110	120
30	m919.pep	130	140	150	160	170	180
		YFTPWQVAGNGSLAGTVTGYEPLVKGDDRRTAQARFPIYIGIPDDFISVPLPAGLRSGKA					
	g919	YFTPWQVAGNGSLAGTVTGYEPLVKGDDRRTERARFPIYIGIPDDFISVPLPAGLRGGKN					
		130	140	150	160	170	180
35	m919.pep	190	200	210	220	230	240
		LVRIQTGKNSGTIDNAGGTHADLSRFFITARTTAIKGRFEGRFLPYHTRNQINGGAL					
	g919	LVRIQTGKNSGTIDNAGGTHADLSRFFITARTTAIKGRFEGRFLPYHTRNQINGGAL					
		190	200	210	220	230	240
40	m919.pep	250	260	270	280	290	300
		DGKAPILGYAEDPVLEPFMHIQGSGRLKTPSGKYIRIGYADKNEHPYISGRYMAKRGYL					
	g919	DGKAPILGYAEDPVLEPFMHIQGSGRLKTPSGKYIRIGYADKNEHPYISGRYMAKRGYL					
		250	260	270	280	290	300
50	m919.pep	310	320	330	340	350	360
		KLGGQTSMQGIKSYMQRNPRLAEVLGQNPSYIFPRELAGSSNDGPVAGLGTPLMGEYAGA					
	g919	KLGGQTSMQGIKAYMRQNPRLAEVLGQNPSYIFPRELAGSGNEGPVAGLGTPLMGEYAGA					
		310	320	330	340	350	360
55	m919.pep	370	380	390	400	410	420
		VDRHYITLGAFLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDYFWGYGDEAGELAGK					
	g919	IDRHYITLGAFLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDYFWGYGDEAGELAGK					
		370	380	390	400	410	420

- 84 -

430                      440  
 m919.pep      OKTTGVVWOLLPNGMKPEYRFX  
 5                      |||||  
 g919              OKTTGVVWOLLPNGMKPEYRFX  
                          430                      440

The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 998>:

10 a919.seq  
 1 ATGAAAAAAT ACCTATTCCG OGCGGCCCTG TCGCGCATCG COGCGCCCAT  
 51 CCTCGCGGCC TGCCAAAGCA AGAGCATCCA AACCTTTCCG CAAACCGACA  
 101 CATCGGTCAT CAACGCGCCG GACCGGCGCG TCGGCATCCC CGACCCCGCC  
 151 GGAACGACGG TCGGCGGCGG CGGGGCCGTT TATACCGTTG TCGCGCACCT  
 201 GTCCCTGCCG CACTGGGCGG OGCAAGATTG CGCCAAAGCG CTGCAATCCT  
 251 TCGCGCTCGG CTGGCCCAAT TTGAAAAACC GCCAAGGCTG GCAAGATGTG  
 301 TCGCGCCAGG CTTTTCAAAC CCCCCTCCAT TCGGTTCAAG CAAACAGTTG  
 351 TTTTGAACGC TATTTACAGC GTGGCAGGT TGCAGGCAAC GGAAGCCTTG  
 401 CGGTACGGT TACCGGCTAT TACGAGCCGG TGCTGAAGGG CGAAGACAGG  
 451 CGGACGGCAC AAGCCCGCTT CCGGATTAC GGTATTCCCG ACGATTTTAT  
 501 CTCCGTCGCC CTGCGTCGCG GTTTGCGGAG CGGAAAAGCC CTTGTCGCGA  
 551 TCGGCGAGAC GGGAAAAAAC AGCGGCACAA TCGACATAC CGGCGGCACA  
 601 CATACCGCG AGCTCTCCCA ATTCCCGCAT ACTGGGCGCA CAAAGCAGAT  
 651 CAAAGCGAGG TTTGAAAGGA GCGCGTTCT CCCCACCAAC ACGCGCAACC  
 701 AATCAACGG CGCGCGGCTT GACGCAAG CCGCATACT CGGTTACGCG  
 751 GAAGACCCCG TCGAACCTTT TTTTATGCAC ATCCAGGCTC CGGCGCGTCT  
 801 GAAAACCCCG TCCGCAAAAT ACATCGCAT CCGCATAGCC GACAAAAAGC  
 851 AACATCCCTA CSTTTCCATC GGAAGCTATA TGGCGGACAA AGGCTACCTC  
 901 AAGCTCGGCG AGAAGCTGAT GCAGGCGCAT AAAAGCTATA TGCAGCAAAA  
 951 CCGCAACGCG TCCGCGGAAG TTTTGGGCGA AAAACCCAGC TATATCTTTT  
 1001 TCGGAGAGCT TACGGGAGC AGCAATGACG GCCCTGTCGG CGCACTGGGC  
 1051 ACGCGGCTGA TGGGCGAGTA CGCGCGGCG GTGACCGGGC ACTACATTAC  
 1101 CTTGGGCGCG CCTTATTG TCGCCAGCG CCATCCGGTT ACCCGCAAGG  
 1151 CCTCAACCG CCTGATTATG GCGCAGATA CGCGCAGCG GATTAAAGCG  
 1201 CGGTGCGCG TGGATTATTT TTGGGATAC GCGGACGAG CCGGCGAGCT  
 1251 TCGCGGCAAA CAGAAACCA CGGGATATGT CTGGCAGCTT CTGCGCAACG  
 1301 GTATGAGGC CGAATACCG CCGTAA

This corresponds to the amino acid sequence <SEQ ID 999; ORF 919.a>:

40 a919.pep  
 1 MKKYLFRALAL CGIAAAILAA CQSKSIQTFF QPDTSVINGP DRPVGIDPEA  
 51 GTTVGGGGAV YTVVPHLSLF HWAADDFAKS LQSFRLGCAN LKNRQGWQDV  
 101 CAQAFQTPVH SVQAKQFFER YTPWQVAGN GSLAGTVGY YEPVLKGGDR  
 151 RTAQARFFIY GIPDFDISVP LPAGLRSGKA LVRIRGTGN SGTIDNNTGT  
 45 201 HTADLSQFPI TARTTAIKGR FEGRSLPYH TRNNGINGAL DKGAPILGYA  
 251 EDFVELFFMH IQSGRLKTF SGKYIRIGYA DRNEHYYSI GRYMADKGYL  
 301 KLQTSMQGI KAYMOQNFOR LAEVLQNPIS YIFRELTS SNGDPVAGLG  
 351 TPLMGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG  
 401 AVRVDYFWGY GDEAGELAGK QRTGVVWQL LFNMGPEYR P\*

m919/a919 ORFs 919 and 919.a showed a 98.6% identity in 441 aa overlap

55 m919.pep      10                      20                      30                      40                      50                      60  
                          MKKYLFRALALYGLIAAAILAACQSKSIOTFFQPDTSVINGPDRPVGIDPAGTTVGGGGAV  
                          |||||  
 a919              MKKYLFRALALYGLIAAAILAACQSKSIOTFFQPDTSVINGPDRPVGIDPAGTTVGGGGAV  
                          10                      20                      30                      40                      50                      60  
 60 m919.pep      70                      80                      90                      100                      110                      120  
                          YTVVPHLSLPHWAAADDFAKSLQSFRLGCANLKNRQGWQDVCAQAFQTPVHVSQAKQFFER  
                          |||||  
 a919              YTVVPHLSLPHWAAADDFAKSLQSFRLGCANLKNRQGWQDVCAQAFQTPVHVSQAKQFFER

- 85 -

		70	80	90	100	110	120
		130	140	150	160	170	180
5	m919.pep	YFTFWQVAGNSLACTVTGYEYEPVLKGD	DRRTAQAARFIYIGIPDDFTSVPLPAGLRSGKA				
	a919	YFTFWQVAGNSLACTVTGYEYEPVLKGD	DRRTAQAARFIYIGIPDDFTSVPLPAGLRSGKA				
		130	140	150	160	170	180
10	m919.pep	LVRIRQTGKNSGTIDNTGGTHTADLSRFPITARTTA	IKGRFEGSRFLPYHTRNQINGCAL				
	a919	LVRIRQTGKNSGTIDNTGGTHTADLSRFPITARTTA	IKGRFEGSRFLPYHTRNQINGCAL				
		190	200	210	220	230	240
15	m919.pep	DGKAPILGYAEDPVELFFMHIOGSGRLKTFSGKYIR	IGYADKNEHPYVSIGRYMA	DGKYL			
	a919	DGKAPILGYAEDPVELFFMHIOGSGRLKTFSGKYIR	IGYADKNEHPYVSIGRYMA	DGKYL			
		250	260	270	280	290	300
20	m919.pep	KLGGTSMOGIKSYMQRNQLAEVLGONPSYIFFREL	AGSSNDGPVGLGTPLMGEYAGA				
	a919	KLGGTSMOGIKSYMQRNQLAEVLGONPSYIFFREL	AGSSNDGPVGLGTPLMGEYAGA				
		310	320	330	340	350	360
25	m919.pep	VDRHYITLGAPLFAVATAHFVTRKALNRLIMAQDT	GSIAKGAVRVDFYFWGDEAGELAGK				
	a919	VDRHYITLGAPLFAVATAHFVTRKALNRLIMAQDT	GSIAKGAVRVDFYFWGDEAGELAGK				
		370	380	390	400	410	420
30	m919.pep	QKTGYVWQLLPNGMKFEYRFX					
	a919	QKTGYVWQLLPNGMKFEYRFX					
		430	440				
35	m919.pep	QKTGYVWQLLPNGMKFEYRFX					
	a919	QKTGYVWQLLPNGMKFEYRFX					
		430	440				

40 121 and 121-1

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1000>:

m121.seq

45	1	ATGGAACAC	AGCTTTACAT	CGGCATCATG	TCGGGAACCA	GCATGGACGG
	51	GGCGGATGCC	GTA	CTGATAC	GGATGGACGG	CGGCAATATGG
	101	AAGGCGACGC	CTTTACCCCC	TACCCCGGCA	GGTTAGCCCG	CCAATTGCTG
	151	GATTTGCGGG	ACACAGCGCG	AGACGAACTG	CACCGCAGCA	GGRTTTTGTG
	201	GCAAGAACCT	AGCCGCGTAT	ATGGCGAAAC	CGCCCGCGAA	CTGCTGTGCA
50	251	GTCAAACACT	CGCACCGTCC	GACATTACCG	CCCTCGGCTG	CCACGGGCAA
	301	ACCGTCCGAC	ACGCGCCGGA	ACACGGTTAC	AGCATACAGC	TTCGCGATT
	351	GC	CGCTGCTG	CGG	XXXXXXXXXX	XXXXXXXXXX
	401	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX
	451	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX
55	501	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX
	551	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX
	601	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX	XXXXXXXXXX
	651	CATATTGCCG	CAACTGCTCG	ACAGGCTGCT	GCAAGTCCG	CACAAAGGCA
	701	AACGCCACCC	TAAAGCACCG	GGCGCGAC	TGTTTGGCAT	AAATTGGCTC
60	751	GAAACCTACC	TTACGCGCGG	CGAAAACCGA	TACGAGCTAT	TGCGGACGCT
	801	TTCCCGTTTT	ACCGCGCAAA	CGGTTTGGGA	CGCGCTCTCA	CACGACGCGG

- 86 -

851 CAGATGCCCG TCAATGTAC ATTTGCGAGC GCGGCATCCG CAATCCTGTT  
 901 TTAATGGGGG ATTTGGCAGA ATGTTTGGCG ACACGCGTTT CCTGCACAG  
 951 CACGCGCCAG CTGAACCTCG ATCCGCAATG GGTGGAAGCC GCCGAATTTC  
 1001 CGTGGTTGGC GGGCTGTTGG ATTAATCGCA TTCCCGGTAG TCCGCACAAA  
 5 1051 GCAACCGGCG CATCCAAACC GTGTATTCTG AnCGCGGGAT ATTATTATTG  
 1101 A

This corresponds to the amino acid sequence <SEQ ID 1001; ORF 121>:

10 m121.pep  
 1 METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTP YPGLRRRLQL  
 51 DLQDTGADEL HRSRLSQEL SRLYAQTAAE LLCSONIAPS DITALGCHGQ  
 101 TVRHAFPEHY SIQLADLPLL AXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX  
 151 XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX XXXXXXXXXXXX  
 201 XXQLFYDKNG AKSAQGNILP QLLDRLLAHP YFAQRHPKST GRELFAINWL  
 15 251 ETYLDGGENR YDVLRLTSRF TAQTVCDAVS HAAADARQMY ICDGGIRNPV  
 301 LMADLAECFG TRVSLHSTAD LNLDPQWVEA AXFAWLAACW INRIPGSPHK  
 351 ATGASKPCIL XAGY\*\*\*

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1002>:

20 g121.seq  
 1 ATGGAACAC AGCTTTACAT CGGCATTATG TCGGGAACCA GTATGGACGG  
 51 GCGCGATGCC GTGCTGGTAC GGATGGAACG CGGCAATAGG CTGGCGCGGG  
 101 AAGGGCAGCG CTTTACCCCC TACCCTGACC GGTTCGCGCC CAATTTGCTG  
 151 GATTTCGAGG ACACAGGCAC AGACGAACCTG CACGCGCAGCA GGATGTTGTC  
 25 201 GCAAGAACTC AGCGCGCTGT ACGGCGCAAC CGCGCGCAGAA CTGCTGTGCA  
 251 GTCAAAACCT CGCTCCGTGC GACATTACCG CCTTCGGCTG CCACGGGCAC  
 301 ACCGTCCGAC ACGGCGCGGA ACACGGTtac AGCATAACAG TTGCGGATT  
 351 CGCGCTGCTG GCGGAACTGa cgcggatttT TACCGTCggc gacttcCGCA  
 401 GCGCGGACCT TGCTGCCGGC GgacaAGGTG CGCGCTCGT CCGCGCTTT  
 30 451 CACGAAGCCC TGTTCGCGGA TGACAGGGAA ACAACGCTGG TACTGAACAT  
 501 CGCGGGGATT GCCAACATCA GGTACTCCC CCGCGCGCA CCGCGCTTCG  
 551 GCTTCGACAC AGGCGCGGCG AATATGCTGA TGGAcgctg gacgcaggca  
 601 cactGGcagc TGCCTTACGA CAAAacggtt gcAAAGcgg cacaAGGCaa  
 35 651 catatTGcgc cAACTGCTCG gcaagctGCT CGCCcaacCG TATTTCCTAC  
 701 AACCcCaacc aaAAGCACG GgGcGCGaac Tgtttgccct AAattggctc  
 751 gaaacctAcc ttgacgcgcg cgaaaaccca tacgacgtat tgcgacgct  
 801 ttccccattc accgcgcaaa ccgTttggga cgccgtctca CACGCAAGCG  
 851 CAGATGCCCG TCNAATGTAC ATTTGCGGGC GCGGCATCCG CAATCCTGTT  
 901 TTAATGGCGG ATTTGCGAGA ATGTTTGGCG ACACGCGTTT CCTGCACAG  
 40 951 CACCGCCGAA CTGAACCTCG ATCTCAATG GGTGGAAGCC gccgCATTtg  
 1001 cgtggttgGc GGGCTGTTGG ATTAACCGCA TTCCCGGTAG TCCGCACAAA  
 1051 GCGACCGGCG CATCCAAACC GTGTATTCTG GCGCGGGAT ATTATTATTG  
 1101 A

This corresponds to the amino acid sequence <SEQ ID 1003; ORF 121.ng>:

45 g121.pep  
 1 METQLYIGIM SGTSMGDADA VLVRMDGGKW LGAEGHAFTP YPDLRRRLKL  
 51 DLQDTGTDEL HRSRLSQEL SRLYAQTAAE LLCSONIAPC DITALGCHGQ  
 101 TVRHAFPEHY SIQLADLPLL AELTRITVVG DFRSRDLAAG GQGAPLVPAF  
 50 151 HEALFRDDRE TRVVLNIGI ANISVLPPGA PAFGFDTPG NMLMDAWTQA  
 201 HWQLFYDKNG AKAAQGNILP QLLGRLLAHP YFSOPHPKST GRELFALNWL  
 251 ETYLDGGENR YDVLRLTSRF TAQTVWDVAVS HAAADARQMY ICGGGIRNPV  
 301 LMADLAECFG TRVSLHSTAE LNLDPQWVEA AAFWLAACW INRIPGSPHK  
 351 ATGASKPCIL GAGY\*\*\*

ORF 121 shows 73.5% identity over a 366 aa overlap with a predicted ORF (ORF121.ng) from *N. gonorrhoeae*:

60 m121/g121

- 87 -

		10	20	30	40	50	60
	m121.pep	METQLYIGIMSGTSMGDADAVLIRMDGGKWLGAEGHAFTYPYGRIRRLQLDLQDTGADEL					
5	g121	METQLYIGIMSGTSMGDADAVLVRMDGGKWLGAEGHAFTYPYDRLRRKLLDLQDTGTDDEL					
		10	20	30	40	50	60
		70	80	90	100	110	120
	m121.pep	HRSRILSQELSRLYAQTAARELLCSQNLAPSDITALGCHGQTVRHAPEHGYISIQDLADLP					
10	g121	HRSRILSQELSRLYAQTAARELLCSQNLAPCDITALGCHGQTVRHAPEHGYISIQDLADLP					
		70	80	90	100	110	120
		130	140	150	160	170	180
	m121.pep	XX					
		:	:	:	:	:	:
15	g121	AELTRIFTVGDFRSRLAAGGQGAFLVPAPHEALFRDDRETRVLNIGGIANISVLPPGA					
		130	140	150	160	170	180
		190	200	210	220	230	240
	m121.pep	XXXXXXXXXXXXXXXXXXXXXKQLPYDKNGAKSAQGNILPOLLDRLLAHPHYFAQRHPKST					
		:	:	:	:	:	:
20	g121	PAFGFDTGPGNMLMDAWTQAHWQLPYDKNGAKAAQGNILPOLLGRLLAHPHYFSQHPKST					
		190	200	210	220	230	240
		250	260	270	280	290	300
	m121.pep	GRELFAINWLEYTLVGGENRYDVLRTLSRFTAQTVCDASHAAADARQMYICDGGIRNPFV					
25	g121	GRELFAINWLEYTLVGGENRYDVLRTLSRFTAQTVCDASHAAADARQMYICGGGIRNPFV					
		250	260	270	280	290	300
		310	320	330	340	350	360
	m121.pep	LMADLAECFGTRVSLHSTADLNLDQWVEAAXFAWLAACWINRIFGSPHKATGASKPCIL					
30	g121	LMADLAECFGTRVSLHSTAEINLDQWVEAAAFWLAACWINRIFGSPHKATGASKPCIL					
		310	320	330	340	350	360
	m121.pep	XAGYYYY					
35	g121	GAGYYYY					

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1004>:

40	a121.seq	1	ATGGAACAC	AGCTTTACAT	CGGCATCATG	TCGGGAACCA	GCATGGAAGG
		51	GGCGGATGCC	TACTAGTAC	GGATGGACGG	CGGCAATGG	CTGGCGCGGG
		101	AAGGGACGCG	CTTTACCCCG	TACCCGCGCA	GGTTACGCGG	CAAAATGGCT
		151	GATTTCGAGG	ACACAGCGCG	GGACGAACTG	CACCGCAGCA	GGATGTTGTC
		201	GCAAGAACTC	AGCGCGCTGT	ACGCGCAAAC	CGCGCGCGAA	CTGCTGTGCA
45		251	GTCAAAACCT	CGCGCGCTGC	GACATTACCG	CCCTCGGCTG	CCACGGGCAA
		301	ACCGTCAGAC	ACGCGCGCGA	ACACAGTTAC	AGCGTACAGC	TTGCGGATTT
		351	CGCGCTGCTG	CGGGAACGGA	CTCAGATTTT	TACCGTCGCG	GACTTCCGCA
		401	CGCGCGACTT	TGCGGCGCGG	GGACAGGGCG	CGCGCTCGTT	CCCGCGCTTT
		451	CACGAAGCCC	TGTTCCGCGA	CGACAGGGAA	ACACGCGCGG	TACTGAACAT
50		501	CGCGGGGATT	GCCAAACATCA	CGGTACTCCC	CCCGACGCGA	CCCGCTTCG
		551	GCTTCGACAC	AGGAACGGGC	AATATGCTGA	TGGACGCTGT	GATGACGGCA
		601	CACCTGGCAG	TTCTTACGA	CAAAAACGGT	GCAAGGCGGG	CACAGGGCAA
		651	CATATTGCCG	CAACTGCTCG	ACAGGCTGCT	CGCCACCGCG	TAITTCGACG
		701	AACCCACACC	TAAAGACAGC	GGGCGCGAAC	TGTTTGCCTT	AAATTTGGCTC
55		751	GAAACCTACC	TTGACGCGGG	CGAAAACCGA	TACGACGTAT	TGCGGACGCT
		801	TTCCCGATTG	ACCGCGCAAA	CCGTTTTCGA	CGCGCTGTCA	CACGACAGCG
		851	CAGATGCCCG	TCAAATGTAC	ATTTCGGGCG	GCGGCATCGG	CAATCTCTGT
		901	TTAATGGGCG	ATTTCGCAGA	ATGTTTCGGC	ACAAGCGTTT	CCCTGCACAG
		951	CACCGCGGAA	CTGAACCTCG	ATCCGCAATG	GGTAGAAGCC	GCGCGGTTCG
60		1001	CATGGATGGC	GCGGTGTTGG	GTCACCCGCA	TTCCCGGTAG	TCGCGACAAA
		1051	GCAACGCGCG	CATCCAAACC	GTGTATTCTG	GCGCGGGGAT	ATTATTATTATG
		1101	A				

- 88 -

This corresponds to the amino acid sequence &lt;SEQ ID 1005; ORF 121.a&gt;:

a121.pep		1	METQLYIGIM	SGTSMGDADA	VLIRMDGGKW	LGAEGHAF	TP	YPGRLLRKL	L
5	51	DLODTGADEL	HRSRMLSQEL	SRLYAQTAAR	LLCSQNLAPS	DITALGCHGO			
	101	TVRHAPHEYSY	SVQLADLP	LLAERTQIF	FTVG	DFRSRLDAAG	QGQAPLVP	AF	
	151	HEALFRDDRE	TRAVLNIGGI	ANISVLP	FPDA	PAFGFDTGPG	NMLMDAWMQA		
	201	HWQLPYDKNG	AKAAQGNILP	QLDLRLLAHP	YFAQPHPKST	GRELFAINWL			
	251	ETYLDGGENR	YDVLRTLSRF	TAQTVDAVS	HAAADARQMY	ICGGGIRNPV			
10	301	LMADLAECFG	TRVSLHSTAE	LNLDPQWVEA	AAFAWMAACW	VNRIPGSPHK			
	351	ATGASKPCIL	GAGYYY*						
m121/a121		ORFs 121 and 121.a 74.0% identity in 366 aa overlap							
15	m121.pep	10	20	30	40	50	60		
	a121	10	20	30	40	50	60		
20	m121.pep	70	80	90	100	110	120		
	a121	70	80	90	100	110	120		
25	m121.pep	130	140	150	160	170	180		
	a121	130	140	150	160	170	180		
30	m121.pep	190	200	210	220	230	240		
	a121	190	200	210	220	230	240		
35	m121.pep	250	260	270	280	290	300		
	a121	250	260	270	280	290	300		
40	m121.pep	310	320	330	340	350	360		
	a121	310	320	330	340	350	360		
45	m121.pep	310	320	330	340	350	360		
	a121	310	320	330	340	350	360		
50	m121.pep	XAGYYYX							
	a121	GAGYYYX							

55 Further work revealed the DNA sequence identified in *N. meningitidis* <SEQ ID 1006>:

m121-1.seq		1	ATGGAACAC	AGCTTTACAT	CGGCATCATG	TCGGGAACCA	GCATGGACGG
60	51	GCGGATGCC	GTACTGATAC	GGATGGACGG	CGGCAATGG	CTGGGCGGG	
	101	AAGGGACGC	CTTTACCCCC	TACCCCGCA	GTTACGCGC	CCAATTGCTG	
	151	GATTTCAGG	ACACAGCGC	AGACGAAGT	CACCGACGA	GGATTTGTC	
	201	GCAAGAACTC	AGCGCCTAT	ATGCGCAAC	CGCCGCCGA	CTGCTGTCA	

- 89 -

251	GTCAAAACCT	CGCACCCTCC	GACATTACCG	CCCTCGGGTG	CCACGGGCAA
301	ACCGTCCGAC	ACGGCCCGGA	ACACGGTTAC	AGCATACAGC	TTGCCGATT
351	GCCGCTGCTG	GCGGAACGGA	CGCGGATTTT	TACCGTCGGC	GACTTCCGCA
401	GCCGCGACCT	TGCGGCCGGC	GGACAAGGCG	CGCCACTCGT	CCCCGCTTT
451	CACGAAGCCC	TGTTCCGCGA	CAACAGGGAA	ACACGGGGG	TACTGAACAT
501	CGGCGGGATT	GCCAAATCA	CGCTACTCCC	CCCCAGCGCA	CCCGCTTCG
551	GCTTCGACAC	AGGGCCGGGC	AATATGCTGA	TGGACGGGTG	GACGACGGCA
601	CACTGGCAGC	TTCTTACGCA	CAAAAACGGT	GCAAGGGGG	CACAAGGCAC
651	CATATTGCCG	CAACTGCTCG	ACAGGCTGCT	CGCCACCCCG	TATTTGCCAC
701	AACCCCAACC	TAAAGACACG	GGGCGCGAAC	TGTTTGCCCT	AAATTGGCTC
751	GAACCTTACC	TTGACGGCGG	CGAAAACCGA	TACGACGTAT	TGGCGACGCT
801	TTCCCGTTTT	ACCGCGCAAA	CCGTTTGCGA	CGCCGTCTCA	CACGACGGCG
851	CAGATGCCCG	TCAAATGTAC	ATTTCGGCGG	GCGGCATCCG	CAATCCTGTT
901	TTAATGGCGG	ATTTCGCAGA	ATGTTTCGGC	ACACGGCTTT	CCCTGCACAG
951	CACCGCCGAC	CTGAACCTCG	ATCCGCAATG	GGTGAAGGCC	GCCGNATTTG
1001	CGTGCTTGGC	GGCGTGTGG	ATTAATCGCA	TTCCCGGTAG	TCCGCACAAA
1051	GCAACCGGGC	CATCCAAACC	GTGTATTCTG	ANGCGGGGAT	ATTATTATTG
1101	A				
20	This corresponds to the amino acid sequence <SEQ ID 1007; ORF 121-1>:				
	m121-1.pep				
	1	METQLYIGIM	SGTSMGDGADA	VLIRMDGGKW	LGAEGHAFTP
	51	DLQDTGADEL	HSRRLSQEL	SRLYAQTAAE	LLCSQNLAPS
	101	TVRHAFPHGY	SIQLADLPLL	AERTRIFTVG	DFRSRLDLAG
	151	HEALFRDNRE	TRAVLNIGGI	ANISVLPDDA	PAFGFTDTPG
	201	HWQLPYDKNG	AKAAQGNILP	QLDLRLAHP	YFAQHPKST
	251	ETYLDGGENR	YDVLRLSRF	TAQTVCDAVS	HAAADARQMY
	301	LMADLAECFG	TRVSLHSTAD	LNLPQWVEA	AXFAPLAACW
	351	ATGASKPCIL	XAGYYY*		
30	m121-1/g121	ORFs 121-1 and 121-1.ng showed a 95.6% identity in 366 aa overlap			
35	m121-1.pep	10	20	30	40
	g121	10	20	30	40
40	m121-1.pep	70	80	90	100
	g121	70	80	90	100
45	m121-1.pep	130	140	150	160
	g121	130	140	150	160
50	m121-1.pep	190	200	210	220
	g121	190	200	210	220
55	m121-1.pep	250	260	270	280
	g121	250	260	270	280
60	m121-1.pep	290	300	310	320
	g121	290	300	310	320

- 90 -

		310	320	330	340	350	360
m121-1.pep		LMADLAEFCGTRVSLHSTADLNLDPMQVFAAXFAWLAACWINRIPSGPHKATGASKPCIL					
5	g121						
		310	320	330	340	350	360
		LMADLAEFCGTRVSLHSTAEINLDPMQVFAAFAWLAACWINRIPSGPHKATGASKPCIL					
10	m121-1.pep	XAGYXXX					
	g121	GAGYXXX					

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1008>:

	a121-1.seq	
15	1	ATGGAAACAC AGCTTTACAT CGGCATCATG TCGGGAACCA GCATGGACGG
	51	GGCGGATGCC GTACTGATAC GGATCGACGG CGGCAATATG CTGGGCGCGG
	101	AAGGCGACGG CTATTACCCC TACCCGGGCA GGTTACGCGG CAAATTGCTG
	151	GATTTCGAGG ACACAGCGCG GGACGAACTG CACCGCAGCA GGATGTTGTC
	201	GCAAGAACTC AGCGCGCTGT ACGCGCAAC CGCCGCGGAA CTGCTGTGCA
20	251	GTCAAAACCT CGCGCGCTCC GACATTACCG CCTCTGGCTG CACGCGGCA
	301	ACCGTCAAGC ACGCGCGGGA ACACACTTAC AGCGTACAGC TTGCGGATTT
	351	CGCGCTGCTG CGGGAACGGA CTCAGATTTT TACCGTCGGC GACTTCCGCA
	401	CGCGCACTCT TCGGCGCGCG GGACAAGCGG CGCGCTCGCT CCGCGCTTT
	451	CACGAAGCCC TTTTCCGCGA CGACAGGAA ACACGCGCGG TACTGACAT
25	501	CGGCGGGATT GCCACATCA CGTACTCCCC CCGCGACGCA CCGCGCTTGG
	551	GCTTCGACAC AGGACCGGCG AATATGCTGA TGGACGCGTG GATGACGCA
	601	CATGCGCAGC TTCTTACGGA CAARAACGGT GCAAGGCGCG CACAAGCA
	651	CATATTGCGC CAACTGCTCG ACAGGCTGCT CGCCCAACCG TATTTCGCAC
	701	AAACCCACCC TAAAGCACG GGGCGCGAAC TGTTTGCCCT AAATTGCTCT
30	751	GAACCTTACC TTGACGCGCG CGAARAACGA TACGACGTAT TCGGACGCT
	801	TTCCCGATTCT ACCGCGCAAA CCGTTTTCGA CGCGCTCTCA CACGACGCGT
	851	CAGATGCGCG TCAAAATGAT ATTTGCGCGG CGGCGATCCG CAATCTGTT
	901	TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCCTGCACAG
	951	CACCGCGGAA CTGAACCTCG ATCCGCAATG GGTAGAAGCG CGCGGTTGCG
35	1001	CTATGGATGGC GCGGTGTTGG GTCAACCGCA TTCCCGGTAG TCGGCACAAA
	1051	GCAACCGGCG CATCAAAACC GTGTATTCTG GCGCGGGAT ATTATTATTG
	1101	A

This corresponds to the amino acid sequence <SEQ ID 1009; ORF 121-1.a>:

40	a121-1.pep	
	1	METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTF YPGLRLRKL
	51	DLQDTGADEL HRSRLSQEL SRLYAQTAAE LLCSONLAPS DITALGCHGQ
	101	TVRHAPHEHY SVQLADLPLL AERTQIFTVG DFRSRDLAAG GGQAPLVFAP
45	151	HEALERDDRE TRAVLNIGGI ANISVLPPDA PAFGFDTPFG NMLMDAMWQA
	201	HWOLFYDKNG AKAAQGNILP QLLDRLLAHP YFAQHPFKST GRELFALNWL
	251	ETYLDCGEMR YDVLRTLSRF TAQTVFDAVS HAAADARQMY ICGGGIRNPF
	301	LMADLAEFCG TRVSLHSTAE LNLDPMQVFA AAFAMMAACW VNRI PGSPHK
	351	ATGASKPCIL GAGYXXX
50	m121-1/a121-1 ORFs 121-1 and 121-1.a showed a 96.4% identity in 366 aa overlap	
		10 20 30 40 50 60
	m121-1.pep	METQLYIGIMS GTSMGDADAVLIRMDGGKWLGAEGHAFTFYPGLRLRQLLDLQDTGADEL
55	a121-1	METQLYIGIMS GTSMGDADAVLIRMDGGKWLGAEGHAFTFYPGLRLRKLLDLQDTGADEL
		10 20 30 40 50 60
		70 80 90 100 110 120
	m121-1.pep	HRSRLSQELSRLYAQTAAELLCSONLAPSDITALGCHGQTVRHAPHEHYSIQLADLPLL
60	a121-1	HRSRLSQELSRLYAQTAAELLCSONLAPSDITALGCHGQTVRHAPHEHYSIQLADLPLL
		70 80 90 100 110 120



- 91 -

		130	140	150	160	170	180
	m121-1.pep	AERTRIFTVGDFRSRLAAGGGAPLVPAPFHEALFRDNRRETRAVLINIGGIANISVLPPDA					
5	a121-1	AERTQIFTVGDFRSRLAAGGGAPLVPAPFHEALFRDRETRAVLINIGGIANISVLPPDA					
		130	140	150	160	170	180
	m121-1.pep	PAFGFDTPGNMILMDAWTQAHWQLPYDKNGAKAAQGNILPOLLDRLLAHPYFAQPHPKST					
10	a121-1	PAFGFDTPGNMILMDAWMQAHWQLPYDKNGAKAAQGNILPOLLDRLLAHPYFAQPHPKST					
		190	200	210	220	230	240
	m121-1.pep	GRELFAFNWLETYLDGGENRYDVLRLTSRFTAQTVCDAVSHAAADARQMYICGGGIRNPV					
15	a121-1	GRELFAFNWLETYLDGGENRYDVLRLTSRFTAQTVCDAVSHAAADARQMYICGGGIRNPV					
		250	260	270	280	290	300
	m121-1.pep	LMADLAECFGRVSLHSTADLNLDQWVEAAAFWAAACWVNIRIPSGPHKATGASKPCTL					
20	a121	LMADLAECFGRVSLHSTAEINLDQWVEAAAFWAAACWVNIRIPSGPHKATGASKPCTL					
		310	320	330	340	350	360
	m121-1.pep	XAGYXXX					
25	a121	GAGYXXX					

128 and 128-1

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1010>:

35	m128.seq (partial)	
	1	ATGACTGACA ACGCACTGCT CCAITTTGGGC GAAGAAACCC GTTTTGATCA
	51	AATCAAAACC GAAGACATCA AACCGGCCCT GCAAAACGCC ATCGCGAAG
	101	CGCGCGAACA AATCGCGGCC ATCAAGAGCCC AAACGCGACG CGGCTGGGCA
	151	AACACTGTGC AACCCCTGAC CGGCATCACC GAACCGCTCG GCAGGATTGG
40	201	GGCGCTGTGT TCGCACTCTA ACTGCGTGGC CGACACGCC GAAGTGGCGG
	251	CCGTCTATAA CGAACTGATG CCGGAAATCA CGGTCTCTCT CACCGAAATC
	301	GGACAAGACA TCGAGCTGTA CAACCGCTTC AAAACCATCA AAAATTCCCC
	351	CGAATTGACG ACCCTCTCCC CGGCACAAAA AACCAAACTC AACCCAC
45	1	TACGCCAGCG AAAAAGTCGG CGAAGCCAAA TACGCTTCA GCGAAACCGA
	51	wGTCAAAAAA TATTTCCCGG TCGGCAAAAG ATTAAACGGA CTGTTCGCCG
	101	AAmTCAAAAA ACTmTACGGC ATCGGATTTA CGGAAAAAAC yGTCCCGCTC
	151	TGGCACAAGG ACGTGGCGTA TTKTGAATTG CAACAAAAAG GCGAAmCCAT
	201	AGGCGGCGTT TATATGGATT TGTACGCACG CGAAGGCAAA CGCGGCGGCG
	251	CGTGGATGAA GACTACAAA GGCAGCGGCC GTTTTTCAGA CGGCAAGCTG
50	301	CAAyTGCCCA CGCCTACCT CGTCTGCAAC TTCGCCCCAC CGGTGGCGGG
	351	CAGGGAAGCC CGCyTGAGCC ACGAGAAAT CCTCATCTCT TTCCAAGAAA
	401	CCGACACCGG GCTGCACCAC CTGCTTACCC AAGTGGACGA ACTGGGGGTA
	451	TCCGGCATCA ACGGCGTAKA ATGGAGACGG GTTCGAACTGC CCAGCCAGTT
55	501	TATGGAAAAA TTCTGTTGGG AATACAATGT CTGGGACAAA mTGTGAGGCT
	551	ACGAAGAAAC CGGCGTTCCC yTGGCGAAG AACCTCTTGA CAAATGCTCT
	601	CGCCGCAAAA ACTTCCAAGG CGGCATGTTT yTGGTCCGG AAATGGAATT
	651	GCCTCTCTTT GATATGATGA TTTCACGCGA AGACGACGAA GGCGCTCTGA
	701	AAAACGTGCA ACAGGTTTTA GACAGCGTGC GCAAAAAAGT CGCGCTCATC
	751	CAGCCGCGCG AATACAACCG CTTCCGCTTG AGCTTCGGCC ACATCTTCGC
60	801	AGGCGGCTAT TCCGAGCTm ATTACAGCTA CGCGTGGGCG GAAGATTATGA

- 92 -

851 GCGCGGACGC ATACGCCGCC TTTGAAGAAA GCGACGATGT CGCCGCCACA  
 901 GGCAAAAGCT TTTGGCAGGA AATCCTCGCC GTCCGGGnAT CGCGCAGCGG  
 951 nGCAGAAATCC TTCAAGACCTC TCCGCGCGCG CGAAGCGAGC ATAGACGCAC  
 1001 TCTTGGCGCA CAGCGTTTC GACAAACGCG TCTGA  
 5 This corresponds to the amino acid sequence <SEQ ID 1011; ORF 128>:  
 m128.pep (partial)  
 1 MTDNALHLHG EEPRFDQIKT EDIKPALQTA IAEAREQIAA IKAQTHITGWA  
 51 NTVEPLTGIT ERVGRIWGVV SHLNCVADTP ELRAVYNELM PEITVFEITEI  
 101 GQDIELYNRF KTIKNSPEFD TSLSPAQTKL NH  
 10 //  
 1 YASEKLREAK YAFSETXVKK YFPVGXVLNG LFAQXKKLYG IGFTEKTVPV  
 51 WHKDVRYXEL QONGEXIGGV YMDLYAREBK RGGAMWMDYK GRRRPSDGLT  
 101 QLEPTAYLVCN FAPVVGREA RLSHDEILIL PHETGHGLHH LLTQVDELGV  
 151 SGINGVXWDA VELPSQFMEN FWWEYNVLAQ XSAHEETGVP LPKELXDKXL  
 15 201 AAKNFOXGMF XVRQXEFALF DMIIYSEDD ERLKNWQVLV DSVRKKVAVI  
 251 QPPEYNRFAL SPGHIFAGGY SAAKXSYAWA EVLSADAYAA FEESDDVAAT  
 301 GKRFRQWELA VGXSRSGAES FKAFRGREPS IDALLRHSGF DNAV\*

20 The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1012>:

g128.seq  
 1 atgattgaca acgCactgct ccacttggggc gaagaacccc GTTTTaataca  
 51 aatccaaacc gaagACatca AACCOCGCGT CCAAAACGCC ATGCGCGAAG  
 101 CGCGCGGACA AATCGCGGCC GTCAAGCGCG AAGCGCACAC CGGCTGGGCG  
 151 AACACCGTGG AGCGTCTGAC CGGCATCACC GAAGCGGTGG CGAGGATTGT  
 201 GGGCGTGGTG TCCCATCTCA ACTCGTGGT CGACACCGCC GAATCGCGCG  
 251 CGCTATATAA CGAAGTGATG CCGTAAATCA CCGTCTCTCT CACCGAAATC  
 301 GGCACAGACA TCGAATCTGA CAACCGCTTC AAAACCATCA AAAATTCCCC  
 351 CGAATTGCA ACGCTTTCCC CGGCACAAA AACCAAGCTC GATCACAGAC  
 401 TGGCGGATT CTGATTGAGC GCGCGGAAAC TGCGCGCGGA ACGGCAGGCA  
 30 451 GAATCTGGCA AACTGCAAA CGAAGCGCG CAATCTTCCG CCAAAATTC  
 501 CCAAAACGTC CTAGACGCGA CGCAGCGGTT CGGCATTATC TTGACGATG  
 551 CGCACACGCT TGCGCGGATT CCGGAAGACG CGCTCGCCAT GTTTGCGCCG  
 601 GCGCGCGCAA GCGAAGGCAA AACAGGTTAC AAAATCGGCT TGCAGATTCC  
 651 GCACATACCT GCGCTTATCC AATACGCGCG CAACCGCGAA CTGCGCGAAC  
 35 701 AAATCTACCG CGCCTACGTT ACCCGTGCCA CGGAACCTTC AAACGACGCG  
 751 AAATTCGACA ACACCGCCAA CATCGACCGC ACGCTCGAAA ACGCATTGAA  
 801 AACCGccaaa cTGCTCGGCT TTAAMAAATTA CGCGGAATG TCGCTGGCAA  
 851 CCAAAATGGC GGACACGCCG GAACAGGTTT TAAACTTCTT GCACGACCTC  
 901 GCGCGCGCGG CCAAAACCTA CGCGGAAAAC GACTCTGCGG AAGTCAAAAG  
 40 951 CTTCGCGCGG GAACACTCGT GTCTCGCGGA CCGCGACCGG TGGGACTTGA  
 1001 GCTACGCGCG CGAAAACCTG CGCGAAGCCA AATACGCAAT CAGCGAAACC  
 1051 GAJGTCAAAA AATACTTCCC CGTGGCGAAA GTTCTGGCAG GCCTGTTCCG  
 1101 CCAAAATCAA AACTCTACCG CATCGGATT CGCGGAAAAA ACGCTTCCCG  
 1151 TCTGGCAAAA AGACGTGGCG TATTTTGAAT TGCACAAAAA CGCGAAAACC  
 45 1201 ATCGCGCGCG TTTATATGGA TTTGTACGCA CGCGAAGGCA AAGCGCGCGG  
 1251 CGCGTGGATG AACGACTaca AAGGCGCGCG CGCGTTTGGC GACGgcaCGC  
 1301 TGCAACTGCG CACGCGCTAC CTCGTCTGCA ACTTGGCGCC GCGCGTGGCG  
 1351 GGCAAGGAAG CGCGTTTAA GCGACGAGAA ATCCTCACC TCCTCCAGAC  
 50 1401 AaCGGCGCAC GGACTGCACC ACCTGCTTAC CCAAGTGGAC GAATCGGGCG  
 1451 TGTCGCGCAT CAAGggggtA GAATGGGACG CGGTGGAATC GCGCAGCCAG  
 1501 TTTATGGAAA ACTTGGTTTG GGAATACAAT GTATTGGCAC AAATGTCCCG  
 1551 CACGAAGAAA ACGGCGAGC CCCTGCGGAA AGAACTCTTC GACAAAATGC  
 1601 TCGCGCGCAA AACTTCCAG CGCGGTATGT TCCTGCTCCG GCAAAATGAG  
 1651 TTGCGCTCTC TCGATATGAT GATTACAGT GAAGAGCGAG AATGCGTCT  
 55 1701 GAAAAACTGG CAGCAGGTTT TAGACAGCGT GCGCAAGAAA GTcCGCGTCA  
 1751 TCCAAACGCC CGAATACAAC CGCTTCGCCA ACAGCTTCGG Ccaatcttc  
 1801 GCGggCGCT ATTTCGCGAG CTATTACAGC TACGCGATGG COGAAGTCTC  
 1851 cAGCACCGAT GCCTACGCGG CCTTTGAAGA AAGcGACGac gtcCGCGCA

- 93 -

1901 CAGGCAAACG CTTCGGCAA GAAAtccttg cegtcggcgg ctCCCGCAGC  
 1951 gcgGCGGAAT CCTTCAAAGC CTTCGCGGA CGCAACCGA GCATAGACGC  
 2001 ACTGCTGCGC CaaagcggtT TCGACAACGC gGcttga

5 This corresponds to the amino acid sequence <SEQ ID 1013; ORF 128.ng>:

g128.pep  
 1 MIDNALLHLG EEPFRNQIQT EDIKPAVQTA IAEARQIAA VKAQTHGTGWA  
 51 NTVERLTGIT ERVGRWGVV SHLNSVVDTP ELRAVYNELM PEITVFFTEI  
 101 GQDIELYNRF KTIKNSPEFA TLSPAQKTKL DHDRLDFVLS GAELPPERQA  
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA  
 201 AAQSEGKTGY KIGLQIPHYL AVIOYAGNRE LREQIYRAYV TRASELSNDG  
 251 KFDNTANIDR TLENALKTAK LLGFKNYAEL SLATKMADTP EQVNLFLHDL  
 301 ARRAKPYAEK DLAEVKAFAR EHLGLADPOP WDLKYAGEKL REAKYAFSET  
 351 EVKKYFPVGK VLAGLFAQIK KLYGIGFAEK TVPVVHKDVR YFRELQONGKT  
 15 401 IGGVYMDLYA REGKRGGAWM NDYKGRRRFA DDTLQLPTAY LVCNFAPPVG  
 451 GKEARLSHDE ILTLFHETGH GLHLLTQVD ELGVSGINGV ENDAVELPSQ  
 501 FMENFVWEYN VLAQMSAHEE TGEPLPKELF DKMLAAKHQF RGMFLVRQME  
 551 FALFDMMIYS ESDECKLKNW QQVLDVSRKE VAVIQPPEYN RFANSPGHIF  
 601 AGGYSAGIYS YAWAEVLSTD AYAAFEESDD VAATGKRFWQ EILAVGGSRs  
 20 651 AAESFKAFRG REPSIDALLR QSGFDNAA\*

ORF 128 shows 91.7% identity over a 475 aa overlap with a predicted ORF (ORF 128.ng) from *N. gonorrhoeae*:

25 m128/g128

	10	20	30	40	50	60
g128.pep	MIDNALLHLGEEPRFNQIQTEDIKPAVQTAIAEARQIAAVKAQTHGTGWANTVERLTGIT					
30 m128	MTDNALLHLGEEPRFDQIKTEDIKPAQTAIAEARQIAAIKAQTHGTGWANTVEPLTGIT					
	10	20	30	40	50	60
	70	80	90	100	110	120
35 g128.pep	ERVGRWGVVSHLNSVVDTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFA					
40 m128	ERVGRWGVVSHLNCVADTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD					
	70	80	90	100	110	120
	130	140	150	160	170	180
45 g128.pep	TLSPAQKTKLDHDLDFVLSGAELPPERQAEALAKLQTEGAQLSAKFSQNVLDATDAFGIY					
50 m128	TLSPAQKTKLNH					
	130					
	//					
			340	350	360	
55 g128.pep			YAGEKLREAKYAFSETEVKKYFPVGKVLG			
60 m128			YASEKLREAKYAFSETXVKKYFPVGKVLG			
			10	20	30	
	370	380	390	400	410	420
65 g128.pep	LFAQIKKLYGIGFAEKTVPVHKDVRYPFELQQNGKTIIGGVYMDLYAREGKRGGAWMNDYK					
70 m128	LFAQXKKLYGIGFTEKTVVHKDVRXELQQNGEXIGGVYMDLYAREGKRGGAWMNDYK					
	40	50	60	70	80	90
	430	440	450	460	470	480
75 g128.pep	GRRRFADGTLQLPTAYLVCNFAPPVGGKEARLSHDEILTLFHETGHGLHLLTQVDLGV					

[illegible]

The following partial DNA sequence was identified in *N. meningitidis* <SEO ID 1014>:

[illegible]

5

1556	CCGACGAAGAA	ACCCGGCTTC	CCCTCGCGTAA	AGAAATCTTC	GACAAATGAG
1601	TCGCGCCCAA	AAATCGTTCA	CGGGAAATGT	TCCTCGCTCG	CCAAATGGAG
1651	TTCCGCGCTCT	TTGATATGAT	GATTTACAGC	GANGCAGACG	AAGCGCGTGT
1701	GAAATCACTGG	CAACAGGTTT	TAGACAGGTT	CGCGCAAGAA	TGCGCGTGT
1751	TCGCACGGCC	CGAATCAACG	CTCTCGCCA	ACAGCTTCGG	CCAGATCTTC
1801	CAGCGGGGCT	ATTCCGCGAG	CTATTACAGC	TACCGGTGG	CGGAAGTATT
1851	GAGCGGGACG	GCATACGAGC	CTTTTGAAGA	AAGCGACGAT	TGCGCGGCA
1901	CAGGCAACCG	CTTTTGGCAG	GAAATCTCG	CCGTGCGGCG	ATCGCGGCGA
1951	CGCGCAGAAT	CTTCAAAAGC	CTTCGCGGCA	CGGCAACCGA	GCATAGACGG
2001	ACTCTTGGCG	CAGCAGCGCT	TGCAACAAGC	CGGTTGA	

10

This corresponds to the amino acid sequence <SEQ ID 1015; ORF 128.a>:

```

1      a128.pep    1      MTDNALHLHG EEPFRDQIKT EDIKPALQTA IABAREQIAA IKAQHTGTWA
15     51      NTVEFLTGIT ERVGRINGVV SHLNSVTDTP ELRAAYNELM FEITVFTEI
        101     QGDIELYNRF ETKINSPEFD TLSHAQTKTL NHDLRDFVL3 GADLPPEQQA
        151     ELAKLTQZEGA LQSARFSNFO LDSTAQFYIG FDDAPLAGI PADALAMFAA
        201     AAQSEKGTGY KIGLOQLPHY AVIQYANDRK LRQITYRAYV TRASELSDDG
        251     KFDNTANIDR TLBNALQTHL FGLFKPNYAL SLATKMADTP EQVLNLHLHLD
        301     ARRAKPYAEK DLNGVKAFAR ESGLIGDALQ WDLGYAGEKL REAKYAFSET
        351     EVKKYPYVGK VLAESFQAIR KLYVGJTFKE TVPVHHKDVR YFELOQNGET
        401     IGGVYMNDLYA REGKGARGWM NYDKGRRRFS DGTGLQPTAY LVNCNTPPVG
        451     KEARLSHDE IL'L'FHETHG GLHLLHQVD ELGVSGINVG EWDAVELPLSQ
        501     FMENFMWYFN VLQMSAAHE TQVLPKELEF DKMLAANKFQ RGMFLVRQME
25     551     FALFDMIMYS EDDGEGRKLNW GGDSLVKRK VAUVRPPEYN RFANSFGHIF
        601     AGGYSAGYYS YANAWEALLD AYAATESSDP VAATGKRFWO EILAVGGSRS
        651     AESFKAFERG REPSIDALLS HSGFNAAA*

```

m128/a128 ORFs 128 and 128.a showed a 66.0% identity in 677 aa overlap

30	m128.pep	10 20 30 40 50 60 MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIKAQTHTGWANTVEPLTGIT 
	a128	MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIKAQTHTGWANTVEPLTGIT 
35		10 20 30 40 50 60
m128.pep	70 80 90 100 110 120 ERVGRIGVGVSHLNCVADPELRAVYNELMPEITVFTEIGQDIELYNRFKTIKNSPEFD 	
a128	ERVGRIGVGVSHLNSVTDPELRAAYNELMPEITVFTEIGQDIELYNRFKTIKNSPEFD 	
40		70 80 90 100 110 120
m128.pep	130 TLSPAQKTKLNH----- 	
a128	TLSHAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY 	
45		130 140 150 160 170 180
m128.pep	----- -----	
a128	FDDAAPLAGIPEDALAMFAAAQSEKGTGYKIGLQIHYLAVIQYADNRKIREQIYRAYV -----	
50		190 200 210 220 230 240
m128.pep	----- -----	
a128	TRASELSDDGKFDNTANIORTLENALQTAKLLGPKNYAELSLATKMADTPEQVNLFLHDL -----	
55		250 260 270 280 290 300
m128.pep	----- -----	
a128	----- -----	
60		140 150 YASEKLRKAKYAFSETXVKKYFPVGX 
m128.pep	----- -----	

- 96 -

	a128	ARRAKPYAEKDLAEVKAFARESLGLADLPQWDLGYAGEKLREAKYAFSETEVKKYFPFVGK	310	320	330	340	350	360
5	m128.pep	VINGLFAQXKKLYGIGFTEKTVFVWHKDVRYKELQNGEXIGGVYMDLYAREGKRGGAAM	160	170	180	190	200	210
	a128	VINGLFAQIKKLYGIGFTEKTVFVWHKDVRYKELQNGEXIGGVYMDLYAREGKRGGAAM	370	380	390	400	410	420
10	m128.pep	NDYKGRRRFSDGTLQLPTAYLVCNFPVVGGRARLSHDEILILFHETGHLHLLTQVD	220	230	240	250	260	270
	a128	NDYKGRRRFSDGTLQLPTAYLVCNFTPPVVGGRARLSHDEILILFHETGHLHLLTQVD	430	440	450	460	470	480
15	m128.pep	ELGVSGINGVXWDAVELPSQFMENFVWEYNVLAQXSAHEETGVPLPKELXDKXLAANKFQ	280	290	300	310	320	330
	a128	ELGVSGINGVWDAVELPSQFMENFVWEYNVLAQXSAHEETGVPLPKELXDKMLAANKFQ	490	500	510	520	530	540
20	m128.pep	XGMFXVRQXEFALFDMMIYSEDDDEGR.LKNWQV.LDSVRKKVAVIOPPEYNRFALSPGHIF	340	350	360	370	380	390
25	a128	RGMLVRQMEFALFDMMIYSEDDDEGR.LKNWQV.LDSVRKKVAVRPPPEYNRFANSPGHIF	550	560	570	580	590	600
30	m128.pep	AGGYSAAKYSYAWAEVLSADAYAAFEESDDVAATGKRFWQELIILAVGSRSGAESFKAERG	400	410	420	430	440	450
	a128	AGGYSAGYYSYAWAEVLSADAYAAFEESDDVAATGKRFWQELIILAVGSRSGAESFKAERG	610	620	630	640	650	660
35	m128.pep	REPSIDALLRHSGFDNAVX	460	470				
	a128	REPSIDALLRHSGFDNAA	670					

Further work revealed the DNA sequence identified in *N. meningitidis* <SEQ ID 1016>:

	m128-1.seq							
45	1	ATGACTGACA	ACGCACGTCT	CCATTGGGCG	GAAGAACCCC	GTTTGTGATCA		
	51	AATCAAAACC	GAAGACATCA	AACCGCCCT	GCAACCCGCC	ATCGCCGAG		
	101	CGCGGACACA	AATCGCGGCC	ATCAAGCCCC	AAACGCACAC	CGGCTGGGCA		
	151	AACTACTGTC	AATCCCTGAC	CGGCATCACC	GACGCGTCG	CGAGGATTTG		
	201	GGGCTGTGT	TGCGACATCA	ACTCGTTCG	CGACAGCGCC	GAACGCGGCG		
50	251	CGCTCTATAA	CGAACTGATG	CCGAAATCA	CGGTCTTCT	CACGAAATTC		
	301	GGACAGACAC	TGCACTGTGA	CAACGCTTC	AAACCATCA	AAATTCGCC		
	351	CGAATTCGAC	ACCTCTCTCC	CGACACAAA	AAACCAATCT	AACCACTGCA		
	401	TGCGGATTT	CGTCTCTGCG	GGCGGGAAC	TGCGGCGGA	ACACGAGTCA		
	451	GAACGTGCAA	AACCTGAAAC	CGACGCGCG	CACTTTCCG	CCAAATTCCT		
	501	CCAAAACGCT	CTAGACGCGA	CGACCGCTT	CGCATGCTAC	TTTGAAGATG		
55	551	CCGACACGCT	TGCGGCGATT	CCGAGACAG	CGCTGCGCAT	GTTTGGCGCC		
	601	GCGCGGCAAA	GCGAAGACAA	AACAGGCTAC	AAATCGCTC	TGCAATTTCC		
	651	ACACTTACCT	CGGCTCATCC	AATACGCGA	CAACCGCGAA	CTGCGGAGAC		
	701	AAATCTACCG	CGCTCATGTT	ACCGCGGCA	GCGAATTTT	ACAGAGAGGC		
	751	AAATTCGACA	ACACGCGCAA	CATCGACGCG	ACGCTGCGAA	ACGCGCTGCA		
60	801	AACGCCCAA	CTGCTCGGCT	TCAAAAACCTA	CGCGGAATTG	TGCTGTGCAA		
	851	CCAAAATGCG	GGACACGCCC	GAACAAGTTT	TAACTTCTCT	GCAACGACCTC		

	901	GCCGCGCCGG	CCAAACCCTA	CGCGGAAAAA	GACCTGCGCG	AAGTCAAAGC
	951	CTTGCGCCGC	GAAAGCCTGA	ACCTGCGCGA	TTTTCGAACG	IGGGACTTGG
	1001	GCTACGCCAG	CGAAAAATCG	CGCGAAGCCA	AATACGCGTT	CAGCGAAACG
	1051	GAAGTCAARA	AATATTCTCC	CGTGGGCAAA	GTATTTAAAG	GACTGTTCGG
5	1101	CGAATCAAA	AAACTCTACG	GATCTGGATT	TACCGAAAAA	ACCGTCCCCG
	1151	TCGTGCACAA	AGACGTGGCG	TATTTTGAA	TGCAACAAAA	CGCGGAAACG
	1201	ATAGCGCGCG	TTTATATGGA	TTTGTACCGA	CGCGAAGCCA	AACGGCGCGG
	1251	CGCGTGGATG	AACGACTACA	AAGCGCGCGA	CCGTCTTTTCA	GACGGCAGCG
	1301	TGCAACTGCG	CACGCGCTAC	CTCGTCTGCA	ACTTTCGCGCC	ACCGTCCGCG
10	1351	GGCAGGGAG	CCGCGCTGAG	CCACGAGAA	ATCCTCATCC	TCTTTCAGCA
	1401	ACCGGAGAC	GCGCTGCACT	ACATGCTTAC	CCAGTGGGAC	GAACCTGGCG
	1451	TATCGCGCAT	CAACGGCGTA	GATGGGACG	CGGTGGAAGT	GCGCGGCGAG
	1501	TTTATGGAAR	ATTTCGTTTG	GAAATACAA	GTCTTGGCAG	AAATGTCCAG
	1551	CCACGAGAA	ACCGCGCTTC	CCCTGCGGAA	AGAATCTTTC	GACAAATGAG
15	1601	TGCGCGCCAA	AAACTTCCAA	CGCGCATCT	TCCTGCTCCG	GCAAAATGAG
	1651	TTGCGCCTCT	TTGATATGAT	GATTTCACGC	GAAAGCGAGC	AAGCGCTCT
	1701	GAAAACTGG	CAACAGGTTT	TAGACAGCT	GCGCAAAAAA	GTGCGCGTCA
	1751	TCCACGCGCC	CGAATACAAC	CGCTTCGCGT	TGAGCTTCGG	CCACATCTTC
	1801	CGAGCGCGCT	ATTCCGCGAG	CTATTACAGC	TACGGTGGGG	CGGAAGTATT
20	1851	GAGCGCGGAC	GCATACGCGC	CCTTTGAAGA	AAGCGACCAT	GTGCGCGCCA
	1901	CAGGCAAAAG	CTTTTGGCAG	GAAATCTCTG	CCGTGCGCGG	ATGCGCGAGC
	1951	GCGGCAGAAT	CCTTCAAAGC	CTTCGCGCGC	CGCGAACCGA	GCATAGACGC
	2001	ACTCTTGGCG	CACACGGGTT	TGCAACAACG	GCTCTGA	

25 This corresponds to the amino acid sequence <SEQ ID 1017; ORF 128-1>:

		m128-1.pep.	
	1	MDNALLHLG	EEPRFDQIKT
	51	NTVEPLTGIT	EVGRIGWV
30	101	GDIELYNRF	KTIKNSPEFD
	151	ELAKLTEGA	OLSAKFSQNV
	201	AAQSEKSTGY	KIGLQIHYL
	251	KFDWNTANIDR	TLANALQTA
	301	ARRAKPIYAEK	DLAEVKAFAR
35	351	EVKIFYPVKG	VINGLFAQIK
	401	LGGVMDLYA	REGKRGWMM
	451	GREARLSHDE	ILLIFHETGH
	501	FMENFVWEYN	VLAQMSAHEE
	551	FALFDMMIYS	EDDEGRILKNW
40	601	AGGYSAGYYS	YAAEVLSDAD
	651	AAESTKAFRG	REFSIDALLR

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1018>:

		g128-1.seq (partial)	
45	1	ATGATTGACA	ACGCACTGCT
	51	AATCAAACCC	GAAGACATCA
	101	CGCGCGGACA	AATCGCGCGC
	151	AACACCGTGG	AGCGTCTGAC
	201	GGGCGTCTGT	TCCATCTCTA
50	251	CGGTCTATAA	CGAACTGATG
	301	GGACAAGACA	TGCAACTGTA
	351	CGAATTGACA	ACGCTTTTCC
	401	TGCGCGATTT	CGTATTGAGC
	451	GAATCTGCAG	AACTGCAAAC
55	501	CCAAACAGCT	CTAGACGCGA
	551	CGCACCGCGT	TGCGCGGCAT
	601	GCGCGGCAAA	GCGAAGGCAA
	651	GCACTACCTT	CGCGTTATCC
	701	AAATCTACGC	GGCTACGTTT
60	751	AAATTCGACA	ACACGCGCAA
	801	AACCGCCAAA	CTGCTCGGCT
	851	CCAAATATGG	GAACACGCGC
	901	GCCGCGCGCG	CCAAACCCTA

- 98 -

951 CTTGCGCCCG GAACACCTCG GTCTCGCCGA CCGGCGCCG TGGGACTTGA  
 1001 GCTACGCGCG CGAAAACCTG CGGGAAGCCA AATACGATT CAGCGAAACC  
 1051 GAAGTCAAAA AATACTTCCC CGTCGGCAA GTTCTGGCAG GCCTGTTCGC  
 5 CCAATCAAAA AACTCTACG GCATCGGATT CGCGAAAAA ACCGTTCOCG  
 1151 TCTGGCACAA AGACGTGCGC TATTTTGAT TGCACAAAA CGCGAAAAAC  
 1201 ATCGCGCGCG TTTATATGGA TTTGTACGA CGCAAGGCA AAGCGCGCGG  
 1251 CGCGTGGAGG AACGACTTACA AAGCGCCCG CGCTTTGCC GACGCGCAGC  
 1301 TGCAACTGCC CACCGCCTAC CTGCTCTGCA ACTTCGCCCC GCGCGTGGC  
 1351 GGCAAGGAAG CGCGTTTAAG CCACGACGAA ATCTCCACCC TCTTCCACGA  
 10 AACCGGCCAC GGACTGCACC ACTGCTTAC CCAAGTGGAC GAATCGGGCG  
 1451 TGTCCGGCAT CAACGGCGTA AAA

This corresponds to the amino acid sequence <SEQ ID 1019; ORF 128-1.ng>:

g128-1.pep (partial)  
 1 MIDNALLHLG EEPFRIQIKT EDIKPAVQTA IAEARGQIAA VKAQTHGTGWA  
 51 NTVERLTGIT ERVGRINGVV SHLNSVVDTP ELRAVINELM PEITVFFTEI  
 101 QQDIELYNRF KTIKNSPEFA TISPAQKTKL DHDLRDFVLS GAELPFERQA  
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA  
 201 AAQSEKGTGY KIGLQIPHIL AVIQYAGNRE LREQIYRAYV TRASELSNDG  
 251 KFDNTANIDR TLENALKTKAK LLGFKNYAEL SLATKMDATP EQVINFLHDL  
 301 ARRAKPYAEK DLAEVKAFAR EHLGLADPQP WDLISYAGEKL REAKYAFSET  
 351 EVKKYFPVKG VLAGLFAQIK KLYGIGFAEK TVPVVHKDVR YFELQQNGKT  
 401 IGGVIMDLIA REGKRGGAWM NDYKRRRFA DGTLLQLPTAY LVCNFAFPVG  
 451 GKEARLSHDE IITLFHETGH GLHLLTQVD ELGVSGINGV K

m128-1/g128-1 ORFs 128-1 and 128-1.ng showed a 94.5% identity in 491 aa overlap

30		10	20	30	40	50	60
	g128-1.pep	MIDNALLHLG	EEPFRNQIKT	EDIKPAVQTA	IAEARGQIAA	VKAQTHGTGWA	NTVERLTGIT
	m128-1	MFNDALLHLG	EEPRFDQIKT	EDIKPALQTA	IAEAREQIAA	IKAQTHGTGWA	VEPLTGIT
35		10	20	30	40	50	60
	g128-1.pep	ERVGRINGVV	SHLNSVVDTP	ELRAVINELM	PEITVFFTEI	QQDIELYNRF	KTIKNSPEFA
	m128-1	ERVGRINGVV	SHLNSVADT	ELRAVINELM	PEITVFFTEI	QQDIELYNRF	KTIKNSPEF
40		70	80	90	100	110	120
	g128-1.pep	TISPAQKTKL	DHDLRDFVLS	GAELPFERQA	ELAKLQTEGA	QLSAKFSQNV	LDATDAFGIY
	m128-1	TISPAQKTKL	NHDLRDFVLS	GAELPFERQA	ELAKLQTEGA	QLSAKFSQNV	LDATDAFGIY
45		130	140	150	160	170	180
	g128-1.pep	FDDAAPLAGI	PEDALAMFAA	AAQSEKGTGY	KIGLQIPHIL	AVIQYAGNRE	LREQIYRAYV
	m128-1	FDDAAPLAGI	PEDALAMFAA	AAQSEKGTGY	KIGLQIPHIL	AVIQYADNRE	LREQIYRAYV
50		190	200	210	220	230	240
	g128-1.pep	TRASELSNDG	KFDNTANIDR	TLENALKTKAK	LLGFKNYAEL	SLATKMDATP	EQVINFLHDL
	m128-1	TRASELSNDG	KFDNTANIDR	TLENALKTKAK	LLGFKNYAEL	SLATKMDATP	EQVINFLHDL
55		250	260	270	280	290	300
	g128-1.pep	ARRAKPYAEK	DLAEVKAFAR	EHLGLADPQP	WDLISYAGEKL	REAKYAFSET	VEKKYFPVKG
	m128-1	ARRAKPYAEK	DLAEVKAFAR	EHLGLADPQP	WDLISYAGEKL	REAKYAFSET	VEKKYFPVKG
60		310	320	330	340	350	360
	g128-1.pep	YFELQQNGKT	IYGGVIMDLIA	REGKRGGAWM	NDYKRRRFA	DGTLLQLPTAY	LVCNFAFPVG
	m128-1	YFELQQNGKT	IYGGVIMDLIA	REGKRGGAWM	NDYKRRRFA	DGTLLQLPTAY	LVCNFAFPVG



- 99 -

m126-1		ARRAKPYAEKDIAEVKAFARESINLADLPWDLGYASEKLEAKYAFSETEVKYFPVCK					
		310	320	330	340	350	360
5	g126-1.pep	370	380	390	400	410	420
		VLAGLFAQIKKLYIGIFAEKTVPVVHKDVRVYFELQNGKTIIGGVYMDLYAREGKRGGANM					
	m126-1	VINGLFAQIKKLYIGIFTEKTVPVVHKDVRVYFELQNGETIIGGVYMDLYAREGKRGGANM					
		370	380	390	400	410	420
10	g126-1.pep	430	440	450	460	470	480
		NDYKGRRRFADGTLQLPTAYLVCNFAPPVGGKEARLSHDEILTLFHEHGHLLHLTQVD					
	m126-1	NDYKGRRRFSDGTLQLPTAYLVCNFAPPVGGREARLSHDEILTLFHEHGHLLHLTQVD					
		430	440	450	460	470	480
15	g126-1.pep	490					
		ELGVSGINGVK					
	m126-1	ELGVSGINGVENDAVELPSQFMENFVWEYNVLAQMSAHEETGVLPKELFDKMLAARNFQ					
		490	500	510	520	530	540

The following DNA sequence was identified in *N. meningitidis* <SEQ ID 1020>:

a126-1.seq		
25	1	ATGACTGACA ACGCACTGCT CCATTGGGCG GAAGAACCCC GTTTTGATCA
	51	AATCAAAACC GAAGACATCA AACCGCGCCT GCARACCCCG ATTGCGCGAG
	101	CGCGCGAACA AATCGCGCGC ATCAAGGCCG AAACGCGCAC CGGCTGGGCA
	151	AACACTGTGC AACCCCTGAC CGGCATCACC GAACGCGTGG CGAGGATTTG
	201	GGCGGTGGTG TCGCACCTCA ACTCGCTCAC CGACAGCGCCG GAACGCGCGG
	251	CGCGCTACAA TGAATTAAATG CCGGAAATTA CGGTCTTCTT CACCGAAATC
30	301	GGACAGACAT TCGAGCTGTA CAACGCGCTT CAACACATCA AAAACTCTCC
	351	CGAGTTGCGAC ACCCTCTCCG ACGCGCAAAA AAGCGAAATC AACCGAGCTC
	401	TGCGCGATTT CGTCTCGAGG GCGCGGAAAC TCGCGCGGCA ACAGCAGGCA
	451	GAATTCGCAA AACTGCAAAC CGAGGCGCGG CAACTTTCCG CCAATTTCTC
	501	CCAAAGCGTC CTAGACGCGA CCGACGCGTT CGGCATTATC TTGACGATG
	551	CGGACCGCTT TCGCGCGCAT CCGAGAGACG CGCTGGCATC GTTTGCGCGT
35	601	CGCGCGCAAA GCGAAGCGAA AACAGGCTAC AAAATCGGTT TGCAGATTCC
	651	GCATCTACCT GCGCTCATCC AATACGCGCA CAACGCGAAA CTGCGCGAAG
	701	AAATCTACCG CGCTTACGTT ACCCGCGCCA CGGAGCTTTC AGACGACGCG
	751	AAATTCGACA ACACCGCGAA CATCGACCGC ACGCTCGAAA ACGCCTCGAA
40	801	AACCGCGCAA CTGCTGGGCT TCMAAAACTA GCGCGAATTG TCGCTGGCAA
	851	CCAAATGGCG GGACACCGCC GAACAAGATT TAAACTTCTT GCACGACCTC
	901	GCGCGCGCGG CCAAAACCTA CGCGGAAAAA GACCTCGCGG AAGTCAAAAG
	951	CTTCGCGCGG GAAAGCGCTG CGCTCGCGCA TTGCAACCGG TGGGACTTGG
	1001	GTCACGCGCG GAAAAACTG CGGGAAGCCA AATACGATT CAGCGAAACC
45	1051	GAAGTCAAAA AATACTTCCG CGTGGCGAAA GTATTAAAGC GACTGTTTGC
	1101	CCAAATCAAA AACTCTACG CATCGGATT TACCGAAAAA ACGTCCCCCG
	1151	TCTGGCACAA AGACGTGGCG TATTTTGAAT TCGAACAAAA CGGCGAACC
	1201	ATAGCGCGGG TTTATATGGA TTTGTACGCA CGCGAAGGCA AACGCGCGCG
	1251	CGGCTGGATG AACGACTACA AAGGCGCGCG CGGTTTTTCA GACGCGCAGC
50	1301	TGCAACTGCC CACCGGCTAC CTCGTCTGCA ACTTCAACCC GCGCGTGGCG
	1351	GGCAAGAAGC CGCGCTTGAG CCATGACGAA ATCTCAACCC TCTTCCACGA
	1401	AACCGGACAC GGCCTGACCC ACCTGCTTAC CCAAGTCGAC GAATGGGCG
	1451	TATCGCGCAT CAACGCGGTA GAATGGGACG CAGTGGAACT CCCAGTCAG
55	1501	TTTATGGAAT ATTTGCTTTG GGAATACAA GTCTTGGCGG AAATGTCCCG
	1551	CCACGAAGAA ACGCGGCTTC CCCTGCGGAA AGAATCTTTC GACAATAATGC
	1601	TCGCGCGCAA AACTTCCCAA CGCGGAATGT TCTTGTCCG CCAATGGAG
	1651	TTCCGCTCTT TTGATATGAT GATTTCACGC GAAGACGACG AAGCGGCTCT
	1701	GAATAACTTG CAACAGGTTT TAGACAGCGT GCGCAAGAA GTCCGCTGCT
	1751	TCCGACCGCC GAAATCAAC CGCTTCGCCA ACAGCTTGGG CCACATCTTC
60	1801	GCAGCGGCGT ATTTCGCGAG CTATTGACG CATCGGTGGG CGGAAGTATT
	1851	GAGCGCGGAC GCATACGCGC CTTTGAAGA AAGCGACGAT GTCCGCGCA
	1901	CAGGCAACGC CTTTGGCAG GAAATCTCG CGTTCGCGG ATCCGCGACG

- 100 -

1951 GCGGCAGAACT CCTTCAAAGC CTTCGCGGGA CGCGAACCGA GCRTAGACGC  
 2001 ACTCTTGGCG CACAGCGGCT TOGACAAACGC GGCTTGA

This corresponds to the amino acid sequence <SEQ ID 1021; ORF 128-1.a>:

5 a128-1.pep  
 1 MTDNALLHLG EEPFRDQIKT EDIKPALQTA IAEAREQIAA IKAQTHGTWA  
 51 NTVEPTTGIT ERVGRWGVV SHLNSVTDTP ELRAAYNELM PEITVFTEI  
 101 GQDIELYNRF KTIKNSPEFD TLSHAQKTKL NHDLRDFVLS GAELPPEQQA  
 151 ELAKIQTEGA QLSAKFSQNV LQATDAFGIY FDDAALPLAGI PEDALAMFAA  
 201 AAQSEGRGTGY KIGLQIPHYL AVIQYADNRK LREQIYRAYV TRASELSDDG  
 251 KFDNTANIDR TIENALQTA LIGFKNYAEL SLATKMADTP EQVLNLFHDL  
 301 ARRAKPYAEK DLAEVKAFAR ESLGLADLQP WDLGYAGEKL REAKYAFSET  
 351 EVKYPFVGK VLNGLFAQIK KLYGIGTEK TVPVVHKDVR YFELQONGET  
 401 IGGVMDLYA REGKRGGAMW NDYKRRRFS DGLQLPLTAY LVCNFTFPVG  
 451 GKEARLSHDE ILTLFHETGH GLHLLTQVD ELGVSGINGV EWDDELPSQ  
 501 FMENFVWEYN VLAQMSAHEE TGVPLPKELF DKMLAANKFQ RGMFLVRQME  
 551 FALFDMMIYS EDDEGRKNW QOVLDSVRKE VAVVRPPEYN RFANSFGHIF  
 601 AGGYSAGYYS YAWAEVLSAD AYAAFEESDD VAATGKRFQW EILAVGGSR  
 651 AAESKAFPRG REPSIDALLR HSGFDNAA\*

m128-1/a128-1 ORFs 128-1 and 128-1.a showed a 97.8% identity in 677 aa overlap

25	a128-1.pep	10	20	30	40	50	60
		MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIIKAQTHGTWANTVEPLTGIT					
	m128-1	MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIIKAQTHGTWANTVEPLTGIT					
30	a128-1.pep	70	80	90	100	110	120
		ERVGRWGVVSHLNSVTDTPELRAAYNELMPEITVFTEIGQDIELYNRFKTIKNSPEFD					
	m128-1	ERVGRWGVVSHLNSVADTPELRAAYNELMPEITVFTEIGQDIELYNRFKTIKNSPEFD					
35	a128-1.pep	130	140	150	160	170	180
		TLSHAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY					
	m128-1	TLSHAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY					
40	a128-1.pep	190	200	210	220	230	240
		FDDAALPLAGIPEDALAMFAAAQSEGRGTGYKIGLQIPHYLAVIQYADNRKLEQIYRAYV					
	m128-1	FDDAALPLAGIPEDALAMFAAAQSEGRGTGYKIGLQIPHYLAVIQYADNRKLEQIYRAYV					
45	a128-1.pep	250	260	270	280	290	300
		TRASELSDDGKFDNTANIDRTIENALQTAKLIGFKNYAELSLATKMADTPPEQVLNLFHDL					
	m128-1	TRASELSDDGKFDNTANIDRTIENALQTAKLIGFKNYAELSLATKMADTPPEQVLNLFHDL					
50	a128-1.pep	310	320	330	340	350	360
		ARRAKPYAEKDLAEVKAFARESLGLADLQFPWDLGYAGEKLREAKYAFSETEVKKYFPVGK					
	m128-1	ARRAKPYAEKDLAEVKAFARESLGLADLQFPWDLGYAGEKLREAKYAFSETEVKKYFPVGK					
55	a128-1.pep	370	380	390	400	410	420
		VINGLFAQIKKLYGIGTEKTVPVVHKDVRVYFELQONGETIGGVMDLYAREGKRGGAMW					
	m128-1	VINGLFAQIKKLYGIGTEKTVPVVHKDVRVYFELQONGETIGGVMDLYAREGKRGGAMW					

## - 101 -

		370	380	390	400	410	420
		430	440	450	460	470	480
5	a128-1.pep	NDYKGRRRFSDGTLQLPTAYLVCNFTPPVGGKEARLSHDEILTLFHETGHGLHLLTQVD					
	m128-1	NDYKGRRRFSDGTLQLPTAYLVCNFAPVGGREARLSHDEILTLFHETGHGLHLLTQVD					
		430	440	450	460	470	480
10	a128-1.pep	ELGVSGINGVWDVAVELPSQFMENFVWEYNVLAQMSAHEETGVLPKELFDKMLAAKNFQ					
	m128-1	ELGVSGINGVWDVAVELPSQFMENFVWEYNVLAQMSAHEETGVLPKELFDKMLAAKNFQ					
		490	500	510	520	530	540
15	a128-1.pep	RGMFVLRQMEFALFDMMIYSEDDDEGRLLKNWQQVLDSVRKEVAVVRPPEYNRFANSFGHIF					
	m128-1	RGMFVLRQMEFALFDMMIYSEDDDEGRLLKNWQQVLDSVRKEVAVIQPPEYNRFANSFGHIF					
		550	560	570	580	590	600
20	a128-1.pep	AGGYSAGYYSYAWAEVLSDAYAAFEESDDVAATGKRFWQETLAVGGSSRAESFKAFRG					
	m128-1	AGGYSAGYYSYAWAEVLSDAYAAFEESDDVAATGKRFWQETLAVGGSSRAESFKAFRG					
		610	620	630	640	650	660
25	a128-1.pep	REPSIDALLRHSFGFDNAAX					
	m128-1	REPSIDALLRHSFGFDNAVX					
		670	679				
30	a128-1.pep	REPSIDALLRHSFGFDNAAX					
	m128-1	REPSIDALLRHSFGFDNAVX					
		670					

206

35

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1022>:

	m206.seq	
	1	ATGTTTCCCC CGACAAAAC CCTTTCTCTC TGTCTCAGCG CACTGCTCCT
	51	CGCTCATGCG GGCACGAAGT CCGGCAAAAC CCGCAACCG AAACCCAAAC
40	101	AGACAGTCCG GCAAATCCAA CGCGTCCGCA TCACCCACAT CGACCGCACA
	151	CAAGCGCTCGC AGGAAGTCAAT GCTCCACAGC CTCGGACTCA TCGGCACGCC
	201	CTACAAATGG GCGCGCAGCA GCACCGCAAC CGGCTTCGAT TGCAGCGGCA
	251	TGATTCGAAT CGTTTACAA AAGCCCTTCA ACGTCAAGCT GCGCGCAGCC
	301	GCCCGCAGCA TGGCGCGCGC AAGCCGGA AAA ATCCCGAGCA GCGCGCTCAA
45	351	GGCCGCGCAG CTCGTATTCT TCAACACCGG CCGCGCAGAC CGCTACTCAC
	401	ACGTGCGGACT CTACATCGGC AAGCGCGAAT TCATCCATGC CCCCAGCAGC
	451	GGCAAAACCA TCAAAACCGA AAAACTCTCC ACACCGTTTT ACGCCAAAAA
	501	CTACCTCGCG GCACATACTT TTTTACAGA ATGA

50

This corresponds to the amino acid sequence &lt;SEQ ID 1023; ORF 206&gt;:

	m206.pep..	
	1	MFPPDKTLFL CLSALLLASC GTTSGKHRQP KPKQTVROIQ AVRISHIDRT
	51	QGSQELMLHS LGLIGTFYWK GGSSTATGFD CSGMIQFYVK NALNVKLPRP
	101	ARDMAAASRK IPDSRKAGD LVFVFTGGAH RYSHVGLYIG NGEFIHAPSS
55	151	GKTIKTEKLS TPFYAKNYLG AHTEFTE*

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1024>:

	g206.seq	
	1	atgtttttccc ccgacaaaac ccttttctc tgtctcgcg cactgctect

- 102 -

51 cgcctcatgc ggcacgacct ccggcaaaaca ccgccaaacg aaacccaaac  
 101 agacagtcgc gcaaatccaa cgcgtccgca tcagccacat cggcgccaga  
 151 caaggtctgc aggaactcat gctccacagc ctcgactca tcggcacggc  
 201 ctacaaatgg ggccggcgaca gcaccgcac ccggttcgac tgcagcgga  
 251 tgattcaatt ggtttacaaa aacgccctca acgtcaagct gccgcgcacc  
 301 gcccgcgaca tggcggcgcc aacgcgcaaa atccccgaca gccgcctcaa  
 351 ggccggcgac atcgattctt tcaacacccg ccggcgacac cgctactcac  
 401 acgtcggaact ctacatcgcc aacggcgaa tcatccatgc ccccgcgacg  
 451 ggcaaaaacca tcaaaaccca aaaactctcc acacggtttt acgcaaaaaa  
 501 ctaccttgga ggcatacgt tttttacaga atga

This corresponds to the amino acid sequence <SEQ ID 1025; ORF 206.ng>:

g206.pep  
 1 MFSPDKTLFL CLGALLLASC GTTSGKHRQP KPKQTVRQIQ AVRISHIGRT  
 151 QGSQELMLHS LGLIGTPYKW GGSSTATGPD CSGMIQLVYK NALNVKLFRS  
 101 ARDMAASRK IPDSRLKAGD IVFFNTGCAH RYSHVGLYIG NGEFIHAPGS  
 151 GKTIKTEKLS TPFYAKNYLG AHTFFTE\*

20 ORF 206 shows 96.0% identity over a 177 aa overlap with a predicted ORF (ORF 206.ng) from *N. gonorrhoeae*:

m206/g206

25	m206.pep	10	20	30	40	50	60
		MFPPDKTLFLCLLSALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIDRTQGSQELMLHS					
	g206	MFSPDKTLFLCLGALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIGRTQGSQELMLHS					
		10	20	30	40	50	60
30	m206.pep	70	80	90	100	110	120
		LGLIGTPYKWGSSSTATGFDSCGMIQFVYKIALNVKLPRRTARDMAAASRKIPDSRLKAGD					
	g206	LGLIGTPYKWGSSSTATGFDSCGMIQLVYKIALNVKLPRRTARDMAAASRKIPDSRLKAGD					
		70	80	90	100	110	120
35	m206.pep	130	140	150	160	170	
		LVFFNTGGAHRYSHVGLYIGNGEFIHAPSSGKTIKTEKSTPFYAKNYLGAHTFFTE*					
	g206	IVFFNTGGAHRYSHVGLYIGNGEFIHAPSGKTIKTEKSTPFYAKNYLGAHTFFTE					
		130	140	150	160	170	

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1026>:

a206.seq  
 45 1 ATGTTTCCCC CCGACAAAAC CTTTTCCTC TGTCACGCG CACTGCTCT  
 51 CGCCTCATGC GGCACGACCT CCGGCAAAAC CGGCCAACCG AAACCCAAAC  
 101 AGACAGTCCG GCAAAATCCAA GCGCTCCGCA TCAGCCACAT CGACCGCACA  
 151 CAAGGCTCGC AGGAACCTCAT GCTCCACAGC CTCGGACTCA TCGCGACGCC  
 201 CTACAAATGG GGGCGGCAGCA GCACCGCAAC CGGCTTCGAT TGCAGCGGCA  
 251 TGATTCAATT GTTTTACAAA AAGCCCTCTA ACCTCAAGCT GCCGCGCACC  
 301 GCCCGCGACA TGGCGCGGGC AAGCGCAAAA ATCCCCGACA GCCGCTTAA  
 351 GGCGCGCGAC CTCGTATTCT TCAACACCGG CGGCGCACAC CGTACTCAC  
 401 ACGTCGGACT CTATATCGGC AAGCGGAAT TATCCATGC CCCCAGCAGC  
 451 GGCAAAACCA TCNAAACCGA AAAACTCTCC ACACGTTTT ACGCCAAAA  
 501 CTACCTCGGC GCACATACCT TCTTACAGA ATGA

This corresponds to the amino acid sequence <SEQ ID 1027; ORF 206.a>:

a206.pep

1 MFPPDKTLFL CLSALLLASC GTTSGKHROP KPKQTVRQIQ AVRISHIDRT  
 51 QGSQELMLHS LGLIGTPYKW GGSSTATGFD CSGMIOFVYK NALNVKLPRT  
 101 ARDMAAASRK IPDSRLKAGD LVFFNTGGAH RYSHVGLYTG NGEFIHAPSS  
 151 GKTIKTEKLS TPFYAKNYLG AHTFFTE\*

m206/a206 ORFs 206 and 206.a showed a 99.4% identity in 177 aa overlap

		10	20	30	40	50	60
m206.pep		MFPPDKTLFLCLSALLLASC	GTTSGKHROPKPKQT	VRQIQAVRISHIDRT	QGSQELMLHS		
a206		MFPPDKTLFLCLSALLLASC	GTTSGKHROPKPKQT	VRQIQAVRISHIDRT	QGSQELMLHS		
		10	20	30	40	50	60
		70	80	90	100	110	120
m206.pep		LGLIGTPYKWGGSSTATG	FDCSGMIOFYVYNALNV	KLPRTARDMAAASRK	IPDSRXKAGD		
a206		LGLIGTPYKWGGSSTATG	FDCSGMIOFYVYNALNV	KLPRTARDMAAASRK	IPDSRLKAGD		
		70	80	90	100	110	120
		130	140	150	160	170	
m206.pep		LVFFNTGGAHRYSHVGLY	TGNGEFIHAPSSGKT	IKTEKLS	TPFYAKNYLG	AHTFFTE	
a206		LVFFNTGGAHRYSHVGLY	TGNGEFIHAPSSGKT	IKTEKLS	TPFYAKNYLG	AHTFFTE	
		130	140	150	160	170	

30 The following partial DNA sequence was identified in *N. meningitidis* <SEO ID 1028>:

		m287.seq				
	1	ATGTTTAAAC	GCACGGTAAT	CGCAATGGCT	TGTAATTTTG	CCCTTTCAGC
	51	CTGGCGGGGC	GGCGGTCGGC	GATCGCCCGA	TGTCAAAGTG	CGGAGCAACG
35	101	TGTCAAAACG	TGCCGTCGGC	GTGTTTCTCG	AGAAAGAGAC	AGGAGCAACG
	151	AAGAATGCGC	CACAGCGGCG	TTTCTCAAGA	CAGGGCGCGC	CATCCGCACA
	201	AGGCATGCA	GATATGGCGG	CGGTTTCCGA	AGAAATATCA	GGCAATGGCG
	251	TGCGCGTAAC	ACGCAGTAAT	CCCAAAATAT	AGACAGAGGT	GGACCAAAAT
	301	GATATGCGCG	AAAATGCGCG	CGGTAACAGT	AGTTTGCAC	CGAATCACAC
40	351	CCCGGATCGC	AAATATGCTTG	CGCGAAATAT	GGAAATATCA	CGAACGGATG
	401	CGCGGGAATC	GTCTCAGCGC	GCACAAACAC	CGGATATGCG	CGAATCGGCG
	451	GACGGAATCG	AGGGGACGSA	TCGGTCGCGA	CGGCGGCAAA	ATGCGCGCAA
	501	TACGCTGCGC	CACAGGTGCAA	ATACAGCGG	AAACAATCAA	CGCGCGTGCT
	551	CTTCAGATAT	CATCCCGCGC	TCAAACCGTG	CACCTCGGAA	TGGCGGTCAG
45	601	AATTTTGGAA	GGGTTTGATT	GGCTATATGG	CTTTTGATTG	AGGGCGGCGC
	651	GCAGAAATATA	ACGTTGCACC	ACGTAAAGG	CGAATTCTTG	AGTGCCAAAT
	701	ATTTCTTGG	TGAAGAAGTA	CAGCTAATAG	CAGATTTTGA	AAAAATTAAGT
	751	GATGCAGACA	AAATAAGTAA	TTACAACAGAA	GATGGGAAGA	ATGATCAAAAT
	801	TGTGCGTTTG	TTTGCGCGTA	GTGTGCAGAT	GAGGGAAGTA	AATCAAAATAT
50	851	TTATCTTTTA	TAAACCTCAA	CCCACTCAT	TTCGCGGAT	TAGGCGCTTCT
	901	GACAGTCGGA	GGCGGTGCGC	TCGCGCCAG	TGCGCTGTA	TTCCGCTTAC
	951	TCAGCGGAT	ACGCTGATTG	TGCGTGGGA	ACGCGTCAG	CTGACGGGCG
1001	1001	ATTCGCGCAA	TATCTGCTG	CCCGGAAGGA	TATCCGCTGA	CTGACTTAC
	1051	GGGGCGGAAA	TGTTGCCGCG	CGGATCGTAT	GCCCTTGCTG	TTCAAGCGGA
55	1101	ACGCGCAAAA	GGCGAAATGC	TGGCGGCGCG	CGGCTGTGAC	AACGCGGAAG
	1151	TACCTGATTT	CATACAGGAA	AAOCCGCGCT	CGTACCGGAC	CAGGGGCGAC
	1201	TTTGCAGCAA	AGATCGAATT	GGGACGACGA	CTCTGTGAGC	GAAATTCAGA
	1251	CAGCGCGGAT	ATTATGCTATA	TGGGTACGCA	AAAAATTCAAA	CGCGGATCGT
	1301	TAGGAAGACG	CTTTAAGCGG	ACTTGAACGG	AAATATGCGAC	CGGGATGTGT
	1351	TCGCGAAGAT	TTTACGCCCC	GGCGCGCGAG	GAGTGTGCGG	GAAATACAG
60	1401	CAATCGCCG	ACAGATGCGG	AAAGGCGCG	ATTCGCGGCT	TTTCCGGGG

- 104 -

1451 AAAAAGAGCA GGATTGA

This corresponds to the amino acid sequence &lt;SEQ ID 1029; ORF 287&gt;:

```

5      m287.pep
      1 MFKRSVIAMA CTFALSACGG GGGGSPDVKs ADTLSKPAAP VVSEKKEKRAK
      51 EDAPQAGSQG QGAPSAQGSQ DMAAVSEENT GNGGAVTADN PKNEDEVAQN
101    DMPQNAAGTD SSTPNHTPDP NMLAGNMENQ ATDAGESSQP ANQPDMAANA
151    DGMQGDPSA GGQNAAGTAA QGANQAGNNQ AAGSSDPTPA SNPAPANGGS
201    NFRGVDLANG VLIDGPSQNI TITHCKGDSC SGNNFLDREV QLKSEFEKLS
10      251 DADKISNYKK DGKNDKFPVL VADSVQMRGI NOYIIFYKPK PTFARFRRS
301    ARSRRSLPAE MPLIPVQAD TLIVDGEAVS LTGHSNIFA PEGNYRYLTY
351    GAELKPGGSY ALRVQGEPAK GEMLAGNAVY NGEVLHFHTE NGRPYPTRRG
401    FFAKVDGFSK SVDGIDSGD DLHMGTKQFK AAIDGNGFGK TWTENGSGDV
451    SGKFGYPAGE EVAGKYSYR PDAEKGFGV FAGKKEQD*

```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1030>:

```

20      g287.seq
      1 atgtttaaac gcagtgatgat tgcaatggct tgtatttttc ccccttcagc
      51 ctgctggggcg ggcggtggcg gatcgcccgga tgtcaagtcg gcggacacgc
101    cgtcaaaaccc gcccgccccc gtgtgtgctg aatattgcgg ggaaggggtg
151    ctgcggaag aagaagaaga tgaggaggca gcggcgctg cgcccgcaag
201    cgatacgcag gacgcaacgc cgggagaaag cagccaagat atggcgccag
251    tttcggcaga aatacacggc aatggcgctg cgcccaaac gcgcaacccc
301    aaaaatgaag acgcgggggc gcaaaatgat atgcgcgcaa atgccgcgca
25      351 atcgcaaat caaacaggga acaaccaacc cgcggttctc tcagattccg
401    ccccgcgctc aaacccctgcc cctgcgaatg gcggtagcga ttttgaagag
451    acgaaacgtgg gcaattctgt tgtgattgac ggaccgtcgc aaaaataaac
501    gtgtgaccac tgtaaaaggcg attctgttaa tgggtgataa ttattggatg
551    aagaagcacc gtcaaaatca gaatttgaaa aattaaagtg tgaagaalaa
30      601 attaagcgat ataaaaaaga cgaagcaacgc gagaattttg tcggttttgtt
651    tgctgacagg gtaaaaaagg atggaaatca caaatataac atctctata
701    cggacaaaac acctactcgt tctgcacggt cgaggaggct gcttcgggac
751    gagattccgc tgattcccgat caatcaggcc gatcagctga ttgtggatg
801    ggaagcggtc agcctgacgg ggcattccgc caatatcttc gcgcccgaag
35      851 ggaattaccg gtatctgact tacggggcg gaaaaatgccc cgcgggatcg
901    tatgccctcc gtgtgcaagg cgaaccggca aaaggcgcaa tgctgtgttg
951    cagggcggtg tacaaaggcg aagtgtctga ttcccatatg gaaaacggcc
1001    gtccgtaccg gtccggaggc aggtttgcgg caaaagtcga tttcgcgacg
1051    aaatctgtgg acggcattat cgacagcgcc gatgatctgc atatgggtac
40      1101 gcaaaaattc aaagccgcga tcgatggaaa cggcttttaag gggacttgga
1151    cggaaaaatg cggcggggat gtcttcgcaa ggttttacgg cccggccggc
1201    gaggaagtgg cgggaaaaata cagctatcgc cgacagatg ctgaaaaagg
1251    cggattcgcc gtgtttgcgg gcaaaaaaga tcgggattga

```

This corresponds to the amino acid sequence &lt;SEQ ID 1031; ORF 287.ng&gt;:

```

45      g287.pep
      1 MFKRSVIAMA CTFPLSACGG GGGGSPDVKs ADTFSKPAAP VVAENAGEV
      51 LPKFKKDEFA AGGAPQADTQ DATAGEGSDQ MARVASENTG NGGAATDNP
101    KNEDAGAQND MPQNAAESAN QTGNQAPAGS SDSAPASNPA PANGGSDDFGR
50      151 TNVGNSSVID GPSONITLTH CKGDSCNGDN LLDEEAPSKS EFKLSDEEEK
1201    IKRYKKDEOR ENFVLVADR VKKDGNTKYI IFYTDKPPTR SARSRSLPA
251    EIPFLPVNQA DTLLVDEAV SLTGHSGNIF APEGNYRYLT YGAELKPGGS
301    YALRVQGEPA KGEMLVGTAV YNGEVLHFHM ENGRPYPSGG RFAAKVDGFS
351    KSVGDIIDSG DDLHMGTKQFK KAAIDGNGFK GTWTENGSGD VSGRFYGPAG
55      401 EVAGKYSYR PDAEKGFGF VFAGKKDRD*

```

m287/g287 ORFs 287 and 287.ng showed a 70.1% identity in 499 aa overlap

- 105 -

		10	20	30	40	49
	m287.pcp	MFKRSVIAHACIFALSACGGGGGGSDPKSADTLSPKPAFVSE-----KETE				
5	g287					
		10	20	30	40	50
		60	70	80	90	100
	m287.pcp	KEDAPQAGSQGQAPSAQSGQDMAAVSEENTGNGGAVTADNPKNEDEVAQNMPQNAAGT				
10	g287					
		70	80	90	100	110
		120	130	140	150	160
15	m287.pcp	DSSTPNHTPDPMNLAMNENQATDAGESSQFANQPDMAAADGMQGGDPAGGQNAAGNTA				
	g287	-----				
		170	180	190	200	210
	m287.pcp	AQGANQAGNNQAGSSDPIASNPAPANGSGNFGVLDLANGVLDPSPQNTITLTHCKGDS				
20	g287					
		120	130	140	150	160
		170	180	190	200	210
	m287.pcp	CSGNNFLDEEVOLKSEFEKLSDADKISNYKKDKGNKDFVGLVADSVQMGINQYIIFYKP				
25	g287					
		180	190	200	210	220
		230	240	250	260	270
	m287.pcp	KPTSFARFRSARSRRLPAEMPLIPVNOADTLIVDGEAVSLTGHSNIFAPEGNRYRLT				
30	g287					
		240	250	260	270	280
		290	300	310	320	330
	m287.pcp	YGAELPGGSYALRVOGEPAKGEMLAGAAVYNGEVLHFHTENGRPYPTGRGFAAKVD FGS				
35	g287					
		300	310	320	330	340
		350	360	370	380	390
	m287.pcp	YGAELPGGSYALRVOGEPAKGEMLVGTAVYNGEVLHFHMENGRPYPSGGRFAAKVD FGS				
40	g287					
		300	310	320	330	340
		350	360	370	380	390
	m287.pcp	KSVDDGIIDSGDDLHMGTOKFAAIDGNGFGKTWTENGSGDVSGRFYGPAGEEVAQKYSYR				
45	g287					
		360	370	380	390	400
		410	420	430	440	450
	m287.pcp	PTDAEKGFGVFAKGKQDX				
50	g287					
		420	430	440	450	460

55 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1032>:

	a287.seq	1	ATGTTTAAC	GCAATGTGAT	TGCNATGGCT	TGTATTGTG	CCCTTTCAGC
		51	CTGTGGGGGC	GGCGGTGGOG	GATGCGCCGA	TGTTAACTCG	GCGGACACGC
60		101	TGTCAAACCC	TGCCGCCCT	CTTGTACTAC	AAGATGTCGG	GGAAGAGGTG
		151	CTGCGGAAG	AAAGAAGA	TGAGGAGCG	CTCACTGGTG	CGCCGACAGC
		201	CGATACGCAG	GACGCACCG	CGGAAAGCG	CGTCAAGAT	ATGGCGGCGAG
		251	TTTGGCGAGA	AAATACAGGC	AATGCGCGTG	CGGCACACAC	GGATATTCCT

- 106 -

301	GAATAAAG	AGGAGGAC	GCAAAATGAT	ATGCGCGCAA	ATGCCGCGCA
351	TACAGATAGT	TGACACCGA	ATCACACCCC	TGCACCGAAT	ATGCCAACCA
401	GAGATATGGG	AAACCAAGCA	CGCGATCGCG	GGGAATCGGC	ACAAACCGCA
451	AACCAACGGG	ATATGGCAAA	TGCGGCGGAC	GGAAATCGAG	GGGACGATCC
501	GTGCGCAGGG	GAATAATGCG	GCAATACGGC	AGATCAAGCT	GCAAAATCAAG
551	CTGAAACAAA	TCAAGTCGGC	GGCTCTCAAA	ATCCTGCGTC	TTCAACCAAT
601	CTTACGCCCA	CGAATGGCGG	CAGCGATTTT	GGAAAGATAA	ATGTAGCTAA
651	TGGCATCAAG	CTTGACAGCG	GTTCGCAAAA	TGTAACGTTG	ACACATTGTA
701	AGGACAAAGT	ATGCGATAGA	GATTTCTTAG	ATGAAGAAAG	ACCAACAAAA
751	TGAGATTTTG	AAAATTTAAG	TGATGAAGAA	AAAATTAATA	AATATAAAAA
801	AGACGAGCAA	CGAGAGAATT	TTGTCTGTTT	GTTTCTGAC	AGGGTAGAAA
851	AGAATGGAAC	TAAACAATAT	GTCAATCATT	ATAAGACAA	GTCCGCTTCA
901	CTTCTATCTG	CGCGATTGAG	GCGTCTGCA	CGGTGAGGCG	GCTCGCTTCC
951	GGCCGACATG	CGCGTGAATC	CGGTCAATCA	GGCGGATACG	CTGATTGTGCG
1001	ATGCGGAAGC	GGTCAGCTGT	ACGGGCGATT	CGCGCAATAT	CTTCGCGGCC
1051	GAGGGAATTT	ACCGTATCTC	GACTTACGGG	CGGCAAAAT	TGTCGCGCGG
1101	ATCGTATGCC	CTCAGTGTGC	AAGCGAAGC	GGCAAAAGC	GAAATGCTTG
1151	CGGCGACGCG	CGTGTACAC	GGCGAATGCG	TGCAATTCCH	TATGGAAAAAC
1201	GGCGTCCGCT	CGCGTCCGCG	AGCGACGTTT	GCGCCAAAG	CGTATTTCGG
1251	CAGCAAACTC	GTGGACGGCA	TTATCGACAG	CGCGGATGAT	TTCGATATGG
1301	GTACGCAAAA	ATTCAAGCCG	GTATCGATGT	GACACGGCTT	TAGGGGGAAT
1351	TGGACGGAAA	ATGGCGCGCG	GGATGTTTTC	GGAAAGCTTT	ACGGCCGCGC
1401	CGGCGAAGAA	GTGGCGGGAA	AATACAGCTA	TGCGCCGACA	GATGCGGAAA
1451	AGCGCGGAT	CGGCGCTTTT	GCCGCAAAA	AAGACGAGA	TTGA

This corresponds to the amino acid sequence &lt;SEQ ID 1033; ORF 287.a&gt;:

a287.pep	1	MFKRSVIAMA	CIVALSACGG	GGGSPDVKS	ADTLKPAAP	VVTEDVGEEV
30	51	LPKEKKDEEA	VSGAPQADTQ	DATAGKGGQD	MAVSAENTG	NGGAATTDNF
	101	ENKDEGPQND	MPQNAADTDS	STPNHTPAPN	MPTRDMGNQA	PDAGESAQPA
	151	NQPDMAAAD	GMQGDPSAG	ENAGNTADQA	ANQANNQVG	GSONPASSTN
	201	PNATNGGSDG	GRINVANGIK	LDGSGENVTL	THCKDKVCDK	DFLDEEAPPK
	251	SEFEKLSDEE	KINKYKDEQ	RENFVLVAD	RVEKNGTNKY	VIIYDKDSAS
35	301	SSSARFRSRA	RSRRSLPARE	PLIPVNAQDT	LIVDGEAVSL	TGHSNIGFAP
	351	EGNYRYLYTG	AEKLSGGSYA	LSVQGEPAKG	EMLAGTAVYN	GEVLHFHME
	401	GRPSPSGGRF	AAKVDGSGS	VDGLIDSGDD	LHMGTQKFKA	VIDNGNFKGT
	451	WTENGGGDVS	GRFYGPAGEE	VAGKYSYRPT	DAEKGGEVGF	AGKKEQD*
40	m287/a287	ORFs 287 and 287.a showed a 77.2% identity in 501 aa overlap				
		10	20	30	40	49
	m287.pep	MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLKPAAPVVSE-----KETE				
	a287	MFKRSVIAMACIVALSACGGGGGGSPDVKSADTLKPAAPVVTEDEVGEEVLPEKKDEEA				
45		10	20	30	40	60
	m287.pep	50	60	70	80	109
	a287	KEDAPQAGSQGGAPSAQGSQDMAAVSEENTGNGGAVTADNPKNEDEVQNDMPQNAAGT				
50		70	80	90	100	110
	m287.pep	VSGAPQADTQ--DATAGKGGQDMAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAADT				
	a287	110	120	130	140	169
	m287.pep	DSSTPNHTPDPNMLAGNMENQATDAGESSQPANQPDMAANAAGGMQGDPSAGGQNAAGNTA				
	a287	120	130	140	150	170
	m287.pep	170	180	190	200	229
	a287	QAGANQAGNNQAGSSDPIPASNPAPANGGSGNFRVLDLANGVLIDGPSQNTLTTHCKGDS				
		180	190	200	210	220
	m287.pep	DQANQAGNNQAGSSDPIPASNPAPANGGSGNFRVLDLANGVLIDGPSQNTLTTHCKGDS				
	a287	190	200	210	220	229
		DQANQAGNNQAGSSDPIPASNPAPANGGSGNFRVLDLANGVLIDGPSQNTLTTHCKGDS				



- 107 -

		180	190	200	210	220	230
5	m287.pep	230	240	250	260	270	280
	a287	289					
		CSGNNFLDEEVQLKSEFEKLSADAKISNYKKDGKNDKFVGLVADSVQMKGINQYII FYKP					
		: :       :       :     : :       : : :       : :       :					
		CD-RDFLDEEAPPKSEFEKLSDEEKINKYKKDQRENFVGLVADRVERKNGTKNYVIYKD					
		240	250	260	270	280	290
10	m287.pep	290	300	310	320	330	340
	a287						
		KP--TSFARFRRSARSRRLSPAEMELIPVNOADTLIVDGEAVSLTGHSGNIFAPEGNRYR					
		: :       :       :       :       :       :       :       :					
		KSASSSARFRRSARSRRLSPAEMELIPVNOADTLIVDGEAVSLTGHSGNIFAPEGNRYR					
		300	310	320	330	340	350
15	m287.pep	350	360	370	380	390	400
	a287						
		LTYGAEKLPGGSYALRVQGEPAKGEMLAGAAVYNGEVLHFTHTENGRPYPTRGRFAAKVDF					
		:       :       :       :       :       :       :					
		LTYGAEKLSGGSYALSVQGEPAKGEMLAGTAVYNGEVLHFTHTENGRPSYGRFAAKVDF					
		360	370	380	390	400	410
20	m287.pep	410	420	430	440	450	460
	a287						
		GSKSVDSGIIISGDDLHMGTKFKAAIDGNGFKGTWTWNGSGDVSQKFGYFAGEEAVGKYS					
		:       :       :       :       :       :       :					
		GSKSVDSGIIISGDDLHMGTKFKAVIDGNGFKGTWTWNGSGDVSQKFGYFAGEEAVGKYS					
		420	430	440	450	460	470
25	m287.pep	470	480	489			
	a287						
		YRPTDAEKGFGVFAKGKEQDX					
		:       :       :       :       :       :       :					
		YRPTDAEKGFGVFAKGKEQDX					
		480	490				

406

35

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1034>:

m406.seq

40	1	ATGCAAGCAC	GGCTGCTGAT	ACCTATTCTT	TTTTCAGTTT	TTATTTTATC
	51	CGCTCGCGGG	ACACTGACAG	GTATTCCATC	GCATGGCGGA	GGTAAACGCT
	101	TGCGGTCGCA	ACAAGAACIT	GTGGCCGCTT	CTGCCAGAGC	TGCCGTTTAA
	151	GACATGGATT	TACAGGCATT	ACACGGAGCA	AAAGTTGCAT	TGTACATTGC
	201	CACATAGGCG	GACCAAGGTT	CAGGCGATTT	GACAGGGGGT	CGCTACTCCA
	251	TTGATGCACT	GATTCTGTGC	GAATACATPA	ACAGCCCTGC	CGTCCGTACC
45	301	GATTACACCT	ATCCACGTTA	CGAAACACC	GCTGAAACAA	CATCAGGCGG
	351	TTTGACAGGT	TTAAACCACT	CTTTATCTAC	ACTTAATGCC	CCTGCACTCT
	401	CTCGACCCA	ATCAGACGGT	AGCGGAAGTA	AAAGCAGTCT	GGGCTTAAAT
	451	ATTGCGGGA	TGGGGGATTA	TCGAAATGAA	ACCTTGACGA	CTAACCCGCG
	501	CGACACTGCC	TTTCTTTCCC	ACTTGGTACA	GACCGTATTT	TTCTGGCGCG
50	551	GCATAGACGT	TGTTTCTCTC	GCCAAATGCG	ATACAGATGT	GTTTATTAA
	601	ATCGACGTAT	TCGGAACGAT	AOCGAACAGA	ACCGAAATGC	ACCTATACAA
	651	TGCGGAAACA	CTGAAAGCCC	AAACAAACT	GGAAATATTC	GCAGTAGACA
	701	GAAACCAATA	AAATTTGCTC	ATCAAAACCA	AAACCAATGC	GTTTGAAGCT
	751	GCCTATAAAG	AAATTTACGC	ATTGTGGATG	GGGCCGTATA	AAGTAAGCAA
55	801	AGGAATTAAG	CCGACGGAAG	GATTAATGGT	CGATTTCTCC	GATATCCGAC
	851	CATACGCGAA	TCATACGGGT	AACTCCGCCC	CATCCGTAGA	GGCTGATTA
	901	AGTCATGAGG	GGTATGGATA	CAGCGATGAA	GTAGTCGCGC	AACATAGACA
	951	AGGACAACCT	TGA			

- 108 -

This corresponds to the amino acid sequence <SEQ ID 1035; ORF 406>:

```
m406.pep
1  MQARLLIPIL FSVFILSACG TLTGIPSHGG GKRFAVEQEL VAASARAARK
51 DMDLQALHGR KVALYIATMG DQSGSLTGG RYSIDALIRG EYINSPAVRT
101 DYTYPRYETT AETTSGLTGG LTTSLSTLNA PALSRQTSDG SGSSSSLGLN
151 IGGMGDYRNE TLTTNPRDTA FLSHLVQTVF FLRGIDVVSF ANADTDVFIN
201 IDVFGTIRNR TEMHLYNAET LKAQTKLEYF AVDRTNKKLL IKPKTNAFEA
251 AYKENYALWM GPYKVSIGIK PTEGLMVDPS DIRPYGNHTG NSAPSVADND
301 SHEGYGYSDE VVRQHRQGP *
```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1036>:

```
g406.seq
1  ATCGGGGCAC GGCCTGCTGAT ACCTATTCTT TTTTCAGTTT TTATTTTATC
51 CGCCTGCGGG ACACGTACAG GTATTCCATC GCATGGCGGA GGCAAAACGT
101 TCGCGGTACA ACAAGAACTT GTGGCCGCTT CTGCCAGAGC TGCCGTTAAA
151 GACATGGATT TACAGGCATT ACACGGACGA AAGTTGTCAT TGACATTGCT
201 AACTATGGGC GACCAAGGTT CAGGCAGTTT GACAGGGGGT CGCTACTCCA
251 TTGATGCACT GATTGCGGGC GAATACATAA ACAGCCCTGC GCTCCGCACC
301 GATTACACCT ATCCGCGTTA CGAAACACCC GCTGAAACAA CATCGGCGGG
201 TTTGACGGGT TTAAACCACT CTTTATCTAC ACTTAATGCC CCTGCACCTC
401 CGCGCACCCA ATCAGACGGT AGCGGAAGTA GGAGCAGTCT GGGCTTAAT
451 ATTGGCGGGA TGGGGGATTA TCGAAATGAA ACCTTGACGA CCAACCGCG
501 CGACACTGCC TTTCTTTCCC ACTTGGTGCA GACCGTATT TTCTGCGCG
551 GCATAGACGT TGTTTCTCCT GCCAATGCCG ATACAGATGT GTTTTAAAC
251 ATCGACGTAT TCGGAACGAT AGCAACAGA ACCGAAATGC ACCTATACAA
601 TGCCGAACAA CTGAAGGCC AAACAAACT GGAATATTTC GCCTAGACA
701 GAACCAATAA AAAATTGCTC ATCAACCCA ARACCAATGC GTTTGAAGCT
751 GCCTATAAAG AAAATTACGC ATTGTGATG GGGCGGTATA AAGTAAGCAA
801 AGGAATCAAA CGACGGAAG GATTGTGAT CGATTCTCC GATATCCAAC
301 CATACGGCAA TCATACGGGT AACTCCGCC CATCCGTAGA GCCTGATAAC
901 AGTCATGAGG GGTATGGATA CAGCGATGAA GCAGTGCAG AACATAGACA
951 AGGGCAACCT TGA
```

This corresponds to the amino acid sequence <SEQ ID 1037; ORF 406.ng>:

```
g406.pep
1  MRARLLIPIL FSVFILSACG TLTGIPSHGG GKRFAVEQEL VAASARAARK
51 DMDLQALHGR KVALYIATMG DQSGSLTGG RYSIDALIRG EYINSPAVRT
101 DYTYPRYETT AETTSGLTGG LTTSLSTLNA PALSRQTSDG SGSSSSLGLN
151 IGGMGDYRNE TLTTNPRDTA FLSHLVQTVF FLRGIDVVSF ANADTDVFIN
401 IDVFGTIRNR TEMHLYNAET LKAQTKLEYF AVDRTNKKLL IKPKTNAFEA
251 AYKENYALWM GPYKVSIGIK PTEGLMVDPS DIQPYGNHTG NSAPSVADND
301 SHEGYGYSDE AVRQHRQGP *
```

ORF 406.ng shows 98.8% identity over a 320 aa overlap with a predicted ORF (ORF406.a) from *N. gonorrhoeae*:

g406/m406

```

10      20      30      40      50      60
50  g406.pep  MRARLLIPILFSVFILSACGTLTGIPSHGGGKRFAVEQELVAASARAARKDMDLQALHGR
      |||||
m406      MQARLLIPILFSVFILSACGTLTGIPSHGGGKRFAVEQELVAASARAARKDMDLQALHGR
      10      20      30      40      50      60

70      80      90      100     110     120
55  g406.pep  KVALYIATMGDQSGSLTGGRYSIDALIRGEYINSPAVRTDYTYPRYETTAEETTSGLT
      |||||
```

- 109 -

m406	KVALYIATMGDQSGSGSLTGGRYSIDALIRGEYINSFAVTRDYTYPRYETTAETTSGLG
	70 80 90 100 110 120
5	g406.pep
	130 140 150 160 170 180
	LTTSLSTLNAPALSRTQSDGSGSSSLGNIIGMGDYRNETLTTPRDTAFLSHVQTVF
m406	LTTSLSTLNAPALSRTQSDGSGSSSLGNIIGMGDYRNETLTTPRDTAFLSHVQTVF
	130 140 150 160 170 180
10	g406.pep
	190 200 210 220 230 240
	FLRGIDVVSANADTVFINIDVFGTIRNRNTEMLYNAETLKAQTKLEYFAVDRTNKKLL
m406	FLRGIDVVSANADTVFINIDVFGTIRNRNTEMLYNAETLKAQTKLEYFAVDRTNKKLL
	190 200 210 220 230 240
15	g406.pep
	250 260 270 280 290 300
	IKPKTNAFEAAAYKENYALWMGPYKVSIGIKPTEGLMVDSDIQPYGNHMGNSAPSVADN
m406	IKPKTNAFEAAAYKENYALWMGPYKVSIGIKPTEGLMVDSDIRPYGNHMGNSAPSVADN
	250 260 270 280 290 300
20	g406.pep
	310 320
	SHEGYGYSDEAVRHRQGPX
25	m406
	SHEGYGYSDEVVRHRQGPX
	310 320

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1038>:

30	a406.seq
	1 ATGCAAGCAC GGCTGCTGAT ACCTATTCTT TTTTCAGTTT TTATTTTATC
	51 CGCCTGCGGG ACACTGACAG GTATTCCATC GCATGCGCGA GGTAAACGCT
	101 TCGCGGTGGA ACARGAACTT GTGCCGCGTT CTGCCAGAGC TGCCGTAAAT
	151 GACATGGATT TACAGGCATT ACACCGACGA AAGATTGCAT TGTCATCTGC
	201 AACTATGGGC GACCAAGGTT CAGGCAAGTT GACAGSGGGT CGCTACTCCA
35	251 TTGATGCACT GATTCTGGC GATATACATA ACAGCCCTGC CGTCCGTACC
	301 GATTACACCT ATCCACGTTA CGAAACACCC GCTGAACAA CATCAGCGCG
	351 TTTGACAGGT TTAACCACTT CTTTATCTAC ACTTAATGCC CCTGCACTCT
	401 CGCGCACCCA ATCAGACGGT AGCGGAAGTA AAGCAAGTCT GGGCTTAAAT
	451 ATTGCGGGGA TGGGGGATTA TCGAAATGAA ACCTTGACGA CTAACCCGCG
40	501 CGACACTGCC TTTCTTTCCC ACTTGSTACA GACCGTATT TTCTGCGCGG
	551 GCATAGACGT TGTTTCTCCT GCCAATGCCG ATACCGATGT GTTTATTAAC
	601 ATCGACGTAT TCGGAACGAT ACGCAACAGA ACCGAAATGC ACCTATACAA
	651 TGCCGAAACA CTGAAGCCCC AAACAAACT GGAATATTTC GCAGTAGACA
	701 GAACCAATAA AAAATTGCTC ATCAACCAA AAACCAATGC GTTTGAAGCT
45	751 GCCTATAAAG AAAATTACGC ATTGTGGATG GACCGGTATA AAGTAAGCAA
	801 AGGATTTAAA CCGACAGAAG GATTAAATGG CGATTTCTCC GATATCCAAC
	851 CATACGGCAA TCATATGGGT AACTCTGCCC CATCCGTAGA GGCTGATAC
	901 AGTCATGAGG GGTATCGATA CAGCGATGAA GCAGTGOGAC GACATAGACA
50	951 AGGGCAACCT TGA

This corresponds to the amino acid sequence <SEQ ID 1039; ORF 406.a>:

40	a406.pep
	1 MQARLLIPIL FSVFILSACG TLTGIPSHGG GKREAVEQEL VAASARAVRK
	51 DMUQLALHGR KVALYIATMG DQSGSGLTGG RYSIDALIRG EYINSFAVTR
55	101 DTYTYRYETT AETTSGLGTC LTTSLSTLNA PALSRTOSDG SSGSSSLGNI
	151 IGGMGDYRNE TLTTPRDTA FLSHLVQTVF FLRGIDVVSF ANADTVFIN
	201 IDVFGTIRNR TEMHLYNAET LKAQTKLEYF AVDRTNKKLL IKPKTNAFE
	251 AYKENYALWM GPYKVSIGIK PTEGLMVDSD IQPYGNHMG NSAPSVADN
60	301 SHEGYGYSDE AVRRHRQGPX *

- 110 -

m406/a406		ORFs 406 and 406.a showed a 98.8% identity in 320 aa overlap									
5	m406.pep	10	20	30	40	50	60				
	a406	10	20	30	40	50	60				
10	m406.pep	70	80	90	100	110	120				
	a406	70	80	90	100	110	120				
15	m406.pep	130	140	150	160	170	180				
	a406	130	140	150	160	170	180				
20	m406.pep	190	200	210	220	230	240				
	a406	190	200	210	220	230	240				
25	m406.pep	250	260	270	280	290	300				
	a406	250	260	270	280	290	300				
30	m406.pep	310	320								
	a406	310	320								
35	m406.pep	310	320								
	a406	310	320								

40 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1040>:

		m726.seq									
45	1	ATGACCATCT	ATTTCAAAA	CGGCTTTTAC	GACGACACAT	TGGCGCGCAT					
	51	CCCGGAAGGC	GCGGTTGCGG	TCCGCGCCGA	AGAATACGCC	GCCCTTTTGG					
	101	CAGGACAGCG	GCAGGGCGGG	CAGATTGCGG	CAGATTCCGA	CGGCGGCCCG					
	151	GTTTAAACCC	CGCCGCGGCC	GTCGATTACG	CACGAATGGG	ACGCGAAAAA					
	201	ATGAAAAATC	AGCAAGCGCG	CGCGCGCGCG	CCGTTTCGCC	AAACAAAAAA					
50	251	CGCCTTTGCG	ATTCGCGCTC	GCGGAAAAAG	CGGACGAACT	CAAAACACGC					
	301	CTCTTGCGCG	GCTATCCCCA	AGTGAANAATC	GACAGCTTTT	ACAGGCAGGA					
	351	AAAAGAAGCC	CTCGCGCGGC	AGGCGGACAA	CAACGCCCGG	ACCCCGATGC					
	401	TGGCGCAAT	CGCGCGCGCA	AGGGGCGTGG	AATTGGAAGT	TTTGATTGAA					
	451	AAAGTTATCG	AAAAATCCSC	CGCGCTGGCT	GTTGCGCGCG	GCGCGATTAT					
55	501	CGGAAAGCGT	CAGCAGCTCG	AGACAAATTT	GAACACCATC	GAAACCGCGC					
	551	CGGATTGGGA	CGCGCTGGAA	AAGGAAATCG	AAGAATTGAC	GCTAATACATC					
	601	GGCTGA									

This corresponds to the amino acid sequence <SEQ ID 1041; ORF 726>:

m726.pep											
60	1	MTIYFKNGFY	DTLTGGIPEG	AVAVRAEEYA	ALLAGQAQGG	QIAADSQGRF					
	51	VLTTPRPSPDY	HEWDGKKWKI	SKAAAAARFA	KORTALAFRL	AEKADELKNS					

- 111 -

```

101 LLAGYPOVEI DSFYRQEKEA IARQADNNAP TPMLAQIAAA RGVELDVLIE
151 KVIEKSARLA VAAGAITIGKR QLEEDKLIAT I ETAPGLDALE KEIEEWTLNI
201 G*

```

5

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1042>:

```

101 m907-2.seq
      1 ATGAGAAAC CGACCGATAC CCTACCCGTT AATCTGCAAC GCCGCCGCCCT
      51 GTTGTGTGCC GCCGGTGGCT TGTGTCTCAG TCCTCTGSGG CAOCCGCCGCCG
101 101 CGCAACGTGA GGAACCGCTT GCCGACGATG TGGCTTCCGT GATGAGGAGT
151 151 TCTGTCSGCA CGCTCAATCC GCCGAGGCTG GTGTTTGACA ATCCGAAAGA
201 201 GGGCGAGCGT TGGTTGTCTG CCATGTGGCC ACGTTTGCCA AGGTTCTGCTC
151 251 CCGAGGAGGA GGAGCGGCGC AGGCTGCTGG TCAATATCCA GTACGARAAC
301 301 AGCCGGGCGG GTTTGGATAC GCAGATTGTG TTGGGGCTGA TTGAGGTGGA
351 351 AAGCGCGTTC CGCCAGTATG CAATCAGCGG TGTCGCGCGC CGCGCCCTGA
401 401 TGCAGGTTAT GCCGTTTGG AAAAAGTACA TCGGCAAAAC GGCGCACAAC
451 451 CTGTTTCGACA TCGGCAACCA CTGCGTTTAC GGCTGTACCA TCCTCGGCCA
201 501 TTACCGGAAT CTTGAAAAAG GCAACATCGT CCGCGCGCTT GCCCGCTTTA
551 551 ACGCAGCTT GGGCAGCAAT AATATTCGAA ACGCGGTTT GGGCGCGTGG
601 601 CGCAACCGCT GGCAGTGGC TTGA

```

This corresponds to the amino acid sequence <SEQ ID 1043; ORF 907-2>:

```

251 m907-2.pep
      1 MRKPTDTLPV NLQRRRLCA AGALLSPLA HAGAQRETL ADDVASVMRS
      51 SVGSVNPRL VFDNPKGER WLSAMSARLA RFVPEEEERR RLLVNIQYES
301 101 SRAGLDTQIV LGLIEVESAF RQYAISGVA RGLMVVFVF KNYIGKPAIN
151 151 LFDIRTNLRY GCTILRHYRN LEKGNIVRAL ARFNSLGSIN KYPNAVLAGW
201 201 RNRWQWR*

```

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1044>:

```

351 m953.seq
      1 ATGAAAAAAA TCATCTTCGC CGCACTCGCA GCCGCCGCCA TCAGTACTGC
      51 CTCGCCGCCC ACCTACAAAG TGGAGCAATA TCACGCCAAC GCCCGTTTCG
401 101 CCATCGACCA TTTCAACACC AGCAACCAAC TCGCGGTTT TACGGTCTG
151 151 ACCGGTTCG TCGAGTTTGA CCAAGCAAAA CGCGACGTA AATCGACAT
201 201 CACCATCCCC ATTGCCAACC TGCAAGCGGG TTCCGCAACAC TTTACCGACC
251 251 ACCTGAAATC AGCCGACATC TTCGATGCGG CCCAATATCC GGACATCCGC
301 301 TTTGTTTCCA CCAAAATCAA CTTCAACGGC AAAAAGCTGG TTTCCGTTGA
351 351 CGGCAACCTG ACCATGCACG GCAAAACCGC CCCGTCAAA CTCAAAGCCG
451 401 AAAAATTCAA CTGCTACCAA AGCCCGATGG AGAAACCGGA AGTTGTGGC
451 451 GGCAGCTTCA GCACACCAT CGACCGCACC AATGGGGCA TGGACTACCT
501 501 CGTTAACGTT GGTATGACCA AAAGCGTCCG CATCGACATC CAAATCGAGG
551 551 CAGCAAAACA ATAA

```

This corresponds to the amino acid sequence <SEQ ID 1045; ORF 953>:

```

551 m953.pep
      1 MKKIIFAALA AAAISTASAA TYKVEYHAN ARFAIDHENT STNVGGFYGL
      51 TGSVEFDQAK RDGKIDITIP IANLQSGSQH ETDHLKSADI FDAAQYPDIR
101 101 FVSTKFNPNK KRLVSDVGNL TMHGKTAPVK LKAEEKNCYQ SPMEKTEVCG
151 151 GDFSTTIDRT KWGMDYLVNV GMTKSVRIDI QIEAAKQ*

```

60

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1046>:

orf1-1.seq

	1	ATGAAAAACAA	CGCAAAACG	GACAAACGAA	ACACACCGCA	AAGCCCCGAA
	51	AACCGCGCGC	ATCGCTTCT	CGCGTGTTA	CTTAGCATA	TGCGTGTCTG
	101	TCGGCATTTCT	TCCCAAGCC	TGGGGGGGAC	ACACTTATT	CGCGATCAAC
	151	TACCAATACT	ATCGGACTT	TGCCGAAAT	AAAGGCAAT	TTGCAGTCGG
5	201	GGCGAAGAT	ATTGAGGTTT	ACACAACAAA	AGGGGAGTTG	GTCGCAAAAT
	251	CAATGACAAA	AGCCCGATG	ATTGATTTT	CTGTGGTGT	GGGTAACGGC
	301	GTGGCGGCAT	TGCTGGGCGA	TCAATATATT	GTGAGCGTGG	CACATAACGG
	351	CGGTATTAAC	AACGTTGATT	TGTGGCGGA	AGGAAGAAAT	CCGATCAAC
	401	ATCGTTTTAC	TTATAAAAT	TGAAACCGA	ATAATATAA	AGCAGGGACT
10	451	AAAGGCCATC	CTTATGGCGG	CGATTATCAT	ATGCCGCGTT	TGCATAAATT
	501	TGTCACAGAT	GCAGAACCTG	TGAAATGAC	CAGTATATAG	GATGGCGGGA
	551	AATATATCGA	TCAAAATAAT	TACCCTGACC	GTGTTCTGAT	TGGGGCAGGC
	601	AGGCAATATT	GGCGATCTGA	TGAAGATGAG	CCCAATAACC	GCGAAAGTTC
	651	ATATCATATT	GCAAGTGCCT	ATTCTTGGCT	CGTTGGTGGC	AATACCTTTG
15	701	CACAAATAGG	ATCAGTGGT	GGCACAGTCA	ACTTAGGTAG	TGAAAAAAAT
	751	AAACATAGCC	CATATGGTTT	TTTACCAACA	GGAGGCTCAT	TTGGCGACAG
	801	TGGCTCACCA	ATGTTTATCT	ATGATGGCCA	AAAGCAAAAG	TGGTTAATTA
	851	ATGGGGTATT	GCAACCGGGC	AACCCCTATA	TAGGAAAAAG	CAATGGCTTC
20	901	CAGCTGGTTC	GTAAGAGATT	GTTCTATGAT	GAAATCTTTG	CTGGAGATAC
	951	CCATTTCAGTA	TCTACGAAAC	CAGCTCAAAA	TGGGAAATAC	TCTTTTAACG
	1001	ACGATATAAA	TGGCACAGGA	AAATCAATG	CCAAACATGA	ACACAATTTCT
	1051	CTCGCTAATA	GATTAAAAAC	ACGAACCGTT	CAATTGTTTA	ATGTTTCTTT
	1101	ATCCGAGACA	GCAAGAGAAC	CTGTTTATCA	TGCTGCAGGT	GGTGTCAACA
	1151	GTTATCGACC	CAGACTGAAT	ATTGAGAGAA	ATATTTCCTT	TATTCAGCAA
25	1201	GGAAAGGGCG	AATTGATACT	TACCAGCAAC	ATCATCAAG	GTGCTGGAGG
	1251	ATTATATTTT	CAAGGAGATT	TTACGGTCTC	GCTTGAATAT	AACGAAACTT
	1301	GGCAAGGGCG	GGCGTTCAT	ATCAGTGAAG	ACAGTACCGT	TACTTGGAAA
	1351	GTAACCGGCG	TGGCAACGGA	CCGCGTGTCC	AAATTCGGCA	AAGGCACGCT
30	1401	GCACGTTCAA	GCCAAAGGGG	AAAACCAAGG	CTCAGTCAGC	GTGGCGAGCG
	1451	GTACAGTCAT	TTTGGATCAG	CAGGCAGAGC	ATAAAGGCAA	AAAACAAGCC
	1501	TTTAGTGAAT	TGCGTTTGGT	CAGCGGCAGG	GGTACGGTGC	AACCTGAATG
	1551	CGATAATCAG	TTCAACCCCG	ACAAACTCTA	TTTCGGCTTT	CGCGCGGAGT
	1601	GTTTGGATTT	AAACGGGCGT	TGCGTTTCGT	TCCACCGTAT	TCAAAATACC
	1651	GATGAAGGGG	CGATGATTGT	CAACCACAAT	CAAGACAAGG	AATCCACCGT
35	1701	TACCATTACA	GGCAATAAAG	ATATTGTCTAC	AACCGGCAT	AACCAACAGT
	1751	TGGATAGCAA	AAAAGAAATT	GCTTACAACG	GTTGGTTTGG	CGAGAAAGAT
	1801	ACGACCAAAA	CGAACGGGCG	GCTCAACCTT	GTTTACCAGC	CCGCGCGAGA
	1851	AGACCGCAC	CTGCTGCTTT	CCGGCGGAAC	AAATTTAAAC	GGCAACATCA
	1901	CGCAACAAA	CGGCAAACTG	TTTTTCAGCG	GCAGACCAAC	ACCGCACGCG
40	1951	TACAAATCATT	TAAACGACCA	TTGGTCGCAA	AAAGAGGGCA	TTCTTCGCGG
	2001	GGAAATCGTG	TGGGACAACG	ACTGGATCAA	CCGCACATTT	AAAGCGGAAA
	2051	ACTTCCAAT	TAAAGGCGGA	CAGGCGGTGG	TTTCCGCAA	TGTTGCCAAA
	2101	GTGAAGGGCG	ATTGGCATTT	GAGCAATCAC	GCCCAAGCAG	TTTTTGGTGT
	2151	CGCACCGCAT	CAAGGCCACA	CAATCTGTAC	ACGTTCCGAC	TGGACGGGTC
45	2201	TGCAAAATTG	TGTCGAAAAA	ACCAATACCG	ACGATAAAGT	GATTGTCTCA
	2251	TTGACTAAGA	CGCACATCAG	CGGCAATGTC	GATCTTCCGG	ATCACGCTCA
	2301	TTTAATCTCT	ACAGGGCTTG	CCACACTCAA	CGGCAATCTT	AGTGCAAATG
	2351	CGCATACACG	TTATACAGTC	AGCCACAACG	CCACCCAAA	CGGCAACCTT
50	2401	AGCCTCGTGG	GCAATGCCCA	AGCAACATTT	AATCAAGCCA	CATTAAACCG
	2451	CAACACATCG	GCTTCGGGCA	ATGCTTCATT	TAATCTAAGC	GACCAACGCG
	2501	TACAAAACGG	CAGTCTGACG	CTTTCGGCAA	ACGCTAAGGC	AAACGTAAGC
	2551	CATTTCGCAC	TCAACGGTAA	TGCTCCCTTA	CGCGATAAGG	CAGTATTCCA
	2601	TTTTGAAGCG	AGCGCTTTTA	CCGGACAAAT	CAGCGGGCGG	AAGGATACGG
	2651	CATTACACTT	AAAGACAGCG	GAATGGAAGC	TGCCGTGAGG	CACGGAATTA
55	2701	GGCAATTTAA	ACCTTGACAA	CGCCACCAATT	ACACTCAATT	CCGCGTATCG
	2751	CCACGATGCG	CGAGGGGCGC	AAACCGGCGG	TGCGACAGAT	GCGCGCGCGC
	2801	GCGGTTCCGC	CCGTTCCGCG	CGTTCCCTAT	TATCCGTTAC	ACCGCCAATG
	2851	TCGGTGAAGT	CCCGTTTCAA	CAGCGTGACG	GTAACCGGCA	AATTGAACCG
	2901	TCAGGGAAACA	TTCCGCTTTA	TGTCGGAAC	CTTCGGCTAC	CGCAGCGACA
60	2951	AATTGAAGCT	GGCGGAAAGT	TCGGAAGGCA	CTTACACCTT	GCGCGTCAAC
	3001	AATACCGGCA	ACGAACTGCG	AAGCCTCGAA	CAATTGACGG	TAGTGGAAAG
	3051	AAAGACAAAC	AAACCGCTGT	CGAAAAACCT	TAATTTTCACT	CTGCAAAACG
	3101	AACACGTCGA	TGCGCGGCGG	TGCGCTTACC	AATCATATCG	CAGAAGCGCG

- 113 -

3151	GAGTTCGGCC	TGCATAATCC	GGTCAAAGAA	CAAGAGCTTT	CGCGAAACT
3201	CGGCAAGGCA	GAAAGCAAAA	AACAGCGGGA	AAAAGACAA	GGCGAAGGC
3251	TTGACCGGCT	GATTTCGGCC	GGCGCGGATG	CCGTGGAAGA	CACAGAAAGC
3301	GTTCGCGAAC	CGGCGCGGCA	GGCAGCGGG	GAAATGTGC	GCAATTATGCA
3351	GGCGGAGGAA	GAGAAAAAAC	GGGTGACGGC	GGATTAAGAC	ACCGCCTTGG
3401	CGAAACAGCG	CGAAGCGGAA	ACCAGCGCGG	CTACACAGC	CTTCCCGCC
3451	GGCCGCGCGC	CGCGCGGGGA	TTTGCGCCAA	CTGCAACCC	AACCGCAGCC
3501	CGAACGCGAG	CGGACCTGTA	TCAGCGCTTA	TGCCAATAGC	GGTTTGAAGT
3551	AATTTTCCGC	CACGCTCAAC	AGCGTTTTCG	CGGTACAGGA	CGAATTAGAC
3601	CGCGTATTTC	CGGAAGACCG	CGCAAGCGC	GTTTGGACAA	CGGCGATCOG
3651	GGACACCAAA	CACCTACGTT	CGCAAGATTT	CCGCGCCTAC	CGCCACAAA
3701	CGGACCTGCG	CGAATCGGT	ATGCAGAAA	ACCTCGCGAG	GGGCGCGCTC
3751	GGCATCTGTG	TTTCGCAAAA	CGGACCGGAA	AACAACCTTC	ACGACGGCAT
3801	CGGCAACTCG	CGACGGCTTG	CCCAAGCGCG	CGTTTTCGGG	CAATACGGCA
3851	TCGACAGGTT	CTACATCGGC	ATCAGCGCGG	GGCGGGGTTT	TAGCAGCGGC
3901	AGCCTTTTCAG	ACGGCATCGG	AGGCAAAATC	CGCGCGCGCG	TGCTGCATTA
3951	CGGCATTTCAG	GCACGATACC	GGCGCGGTTT	CGCGGGATTG	GGCATCGAAC
4001	CGCACATCGG	CGCAACGCGC	TATTTCTGTC	AAAAAGCGGA	TTACGCTAC
4051	GAAGAGGTCA	ATATCGCCAC	CCCCGGCCTT	GCATTCAACC	GCTACCGGCG
4101	GGGCATTAAAG	CGAGATTATT	CATTCAAACC	GGCGCAACAC	ATTTCATACA
4151	CGCCTTATTT	GAGCCTGTCC	TATACCGATG	CGCGTTGGGG	CAAGTCCGAA
4201	ACACGCGTCA	ATACCGCGCT	ATTGGCTCAG	GATTTGGGCA	AAACCGCGAG
4251	TGCGGAATGG	GGGCTAAAGC	CGGAATCAAA	AGGTTTCAGC	CTGTCCTCTC
4301	ACGCTGCGCG	CGCCAAAGGC	CGCAACTTGG	AAGCGCAACA	CAGCGCGGGC
4351	ATCAAAATTAG	GCTACGCGTG	GTAAT		

This corresponds to the amino acid sequence &lt;SEQ ID 1047; ORF orf1-1&gt;:

30	orf1-1.pep	
	1	MKTTDKRTTE
	51	YQYYRDAEN
	101	VAALVGDQYI
	151	KGHYPGGDYH
35	201	RQYWRSEDEE
	251	KHSPYGFLEP
	301	QLVRKDWFTD
	351	LPNRLKTRTV
	401	KGGLILTSN
40	451	VNGVANDRLS
	501	FSEIGLVSGR
	551	DEGAMIVNHN
	601	TTKTNGRLNL
45	651	YNHLNDHWSQ
	701	VKGDWHLNSH
	751	LTKTDISGNV
	801	SLVNGAQTAF
	851	HSALNGVSL
	901	GNLNLNDATT
50	951	SVESRENTLT
	1001	NTNGEPASLE
	1051	EFRLHNPVKE
	1101	VAEPARQAGG
	1151	ARRARRDLPO
55	1201	RVFAEDRRNA
	1251	GILFSHNRTF
	1301	SLSDIGGGKI
	1351	ENVNIATPGL
	1401	TRVNTAVLAQ
60	1451	IKLGYRW*

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1048>:

```

    orf46-2.seq
1      TTGGGCATT  CCGCAAAT  ATCCCTTATT  CTGTCCATAC  TGGCAGTGTG
5      1      CCTCCGATG  CATGCACAG  CCTCAGATTT  GGCACACGAT  TCCTTTATTC
      101    GGCAGGTTCT  CGACCGTCAG  CATTTGGAAC  CGCAGCGGAA  ATACCACCTA
      151    TTGGCGAGCA  GGGGGGAACT  TGGCGAGCGC  AGCGGCCATA  TGGGATTGGG
      201    AAAAATACAA  AGCCATCAGT  TGGCGAACCT  GATGATTCAA  CAGGCGGCCA
      251    TTAAGAGGAA  TATCGGCTAC  ATTGTCCGCT  TTTCCGATCA  CGGGCACGAA
10      301    GTCCATCCCT  CTTTGCACAA  CCAATGCCCT  CATTCGAGAT  CTGATGAAGC
      351    CGGTAGACCC  GTTGACGAGT  TTAGCCTTTA  CGCATCCAT  TGGACCGGAT
      401    AGCAACACCC  TCCGCGCGAG  GGCTATGACG  GGCACACGGG  CGCGGGCTAT
      451    CCGCTCCCA  AAGCGCGGAG  GGATATATAC  AGCTACGACA  TAAAAGGCGT
      501    TGGCCAAAT  ATCCGCTCA  ACCTGACGGA  CAACCGCAGC  ACCGGACAA
15      551    GGCCTGCGGA  CGCTTCCAC  AATGCGCGTA  GTATGCTGAG  GCAAGAGATA
      601    GGCACAGGAT  CAAAGCGGCG  CACCGCATAC  AGCCCGGAGC  TGACACAGATC
      651    GGCATATGCC  CGCGAAGCCT  TCAACGCGAC  CGAGATATC  GTTAAAAACA
      701    TCATCGGCGC  GGCAGAGAG  AATTGTCGCG  CAGCGGCTGG  GTCTGCTTTC
      751    ATAGCGGAG  GCTCAAACAT  TGCTGTCTAT  CAGCGGCTGG  GTCTGCTTTC
20      801    CACGAAAAC  AAGATGGGCG  GCATCAACGA  TTTGGCAGAT  ATGGCGCAAC
      851    TCAAGACTA  TGCCGACGCA  GCCATCCGCG  ATTGGGAGT  CCAAAACCCC
      901    AATGCGCAC  AAGCATAGA  AGCGCTCAGC  AATATCTTTA  TGGCAGCCAT
      951    CCCCATCAA  GGGATTGGAG  CTGTTCCGGG  AAATATCGGC  TTGGCGGCGA
100     1001   TCACGGCACA  TCCTATCAAG  CGGTGCGAGA  TGGGCGGAGT  CGCATTCGCG
25     1051   AAAGGGAAT  CGCGGCTCAG  CGCAATTTT  GCGGATGCGG  CATACGCCAA
      1101   ATACCGTCC  CCTTACCATT  CCGGAATAT  CGGTCAAC  TTGGAGCAGC
      1151   GTTACGGCAA  AGAAAACATC  ACCTCCTCAA  CGGTGCGGCG  GTCACACGCG
      1201   AAAAATGCA  AACTGGCAGA  CCAACGCCAC  CGAAGACAG  GCGTACGCTT
30     1251   TGACGGTAAA  GGGTTTCCGA  ATTTTAGGAA  GCACGTGAAA  TATGATACGA
      1301   AGCTCGATAT  TCAAGAAAT  TCGGGGGGCG  GTATACCTAA  GGCTAAGCCT
      1351   GTGTTTGATG  CGAAACCGAG  ATGGAGGATT  GATAGGAAGC  TTAATTAAT
      1401   GACAACTCGT  GAGCAGGTGG  AGAAAATGT  TCAGGAATA  AGGAACGGTA
      1451   ATATAAACAG  TAACCTTTAG  CAACATGCTC  AACTAGAGAG  GGAATTAAT
35     1501   AAACATAAAT  CTGCCGATGA  AATTAATTT  GCAGATGGAA  TGGGAAAT
      1551   TACCGATAGC  ATGAATGACA  AGGCTTTTAG  TAGGCTTTG  AAATCAGTTA
      1601   AAGAGAATGG  CTTCAAAAT  CCACTTTGAG  AGTACCTTGA  AATAAATGGA
      1651   AAAGCATATA  TCGTAAGAGG  AAATAATRGG  GTTTTGTGCT  CAGATACCTT
      1701   TGGCAGGATA  CATGAATTAA  AATTAAATA  AGTTGACTTT  CTTGTTCCTA
40     1751   ATACTAGTTG  GAAATATCCT  ACTGATGTCT  TGAATGAATC  AGGTAAATGT
      1801   AAGAGACCTC  GTTATAGGAG  TAAATAAA

```

This corresponds to the amino acid sequence <SEQ ID 1049; ORF orf46-2>:

```

45     orf46-2.pep
      1  LGISRKISLI  LSILAVCLPM  HAHASDLAND  SFTKQVLDRO  HFEPDGKYHL
      51  FGSRGELAER  SGHIGLGIQ  SHLGNLMIO  QAAIKNGIV  IVRFSDHGHE
101  VHSFPDNHAS  HSDSDEAGSP  VDFGSLYRIH  WDGVEHHPAD  GYDGPQGGVY
151  PAPKGARDIY  SYDIKGVQON  IRLNLTNRS  TQRLADRFH  NAGSMLTQGV
201  GDGFKRATRY  SPELDRSNGA  AEAFTGTADI  VKNIIGAAGE  TVGAGDAVQF
251  ISEGSNIAYM  HGLGLLSTEN  KMARINDLAD  MAQLKDYAAA  AIRDWAQVNP
301  NAAQIEAVS  NIFMAAIIPI  GIGAVRGKYG  LGGITAHPIK  RSCMGAIALP
351  KGKSAVDNPF  ADAAYAKYPS  PYHSRNIRSN  LEQYKGKNI  TSSTVPPSNG
55  401  KNVKLADORH  PKTGVPPFDG  GPFNFEKHVK  YDTKLDIQEL  SGGGIPKAKP
      451  VFDKPRWEV  DRKLNKLTTR  EQVEKNVQEI  RGNINHSFHS  QHAQLEREIN
      501  KLSADEINF  ADMGKFTDS  MNDKAFSLRV  KSVKENGFTN  PVVEYVEING
      551  KAYIVRGNR  VFAAEYLGRI  HELKFKKVDF  PVPNTSWRNP  TDVLNESGNV
      601  KRPRYRSK*

```



Using the above-described procedures, the following oligonucleotide primers were employed in the polymerase chain reaction (PCR) assay in order to clone the ORFs as indicated:

## 5 Oligonucleotides used for PCR

Table 1

ORF	Primer	Sequence	Restriction sites
279	Forward	CGCGGATCCCATATG-TTGCCTGCAATCACGATT <SEQ ID 1050>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTTAGAAGCGGGCGGCAA <SEQ ID 1051>	XhoI
519	Forward	CGCGGATCCCATATG-TTCAATCCTTTGTCGTCA <SEQ ID 1052>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTTGGCGGTTTGCTGC <SEQ ID 1053>	XhoI
576	Forward	CGCGGATCCCATATG-GCCGCCCCGCATCT <SEQ ID 1054>	BamHI-NdeI
	Reverse	CCCGCTCGAG-ATTTACTTTTTGATGTCGAC <SEQ ID 1055>	XhoI
919	Forward	CGCGGATCCCATATG-TGCCAAAGCAAGAGCATC <SEQ ID 1056>	BamHI-NdeI
	Reverse	CCCGCTCGAG-CGGGCGGTATTCGGG <SEQ ID 1057>	XhoI
121	Forward	CGCGGATCCCATATG-GAAACACAGCTTTACAT <SEQ ID 1058>	BamHI-NdeI
	Reverse	CCCGCTCGAG-ATAATAATATCCCGCGCCC <SEQ ID 1059>	XhoI
128	Forward	CGCGGATCCCATATG-ACTGACAACGCACT <SEQ ID 1060>	BamHI-NdeI
	Reverse	CCCGCTCGAG-GACCGGTTGTGCAAA <SEQ ID 1061>	XhoI
206	Forward	CGCGGATCCCATATG-AAACACCGCAACCGA <SEQ ID 1062>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTCTGTAAAAAAGTATGTGC <SEQ ID 1063>	XhoI
287	Forward	CCGGAATTCTAGCTAGC-CTTTCAGCCTGCGGG <SEQ ID 1064>	EcoRI-NheI
	Reverse	CCCGCTCGAG-ATCCTGCTCTTTTGGC <SEQ ID 1065>	XhoI
406	Forward	CGCGGATCCCATATG-TGCGGGACACTGACAG <SEQ ID 1066>	BamHI-NdeI

- 116 -

	Reverse	CCCGCTCGAG-AGGTTGTCCITGTCTATG <SEQ ID 1067>	XhoI
--	---------	---	------

## EXAMPLE 2

Expression of ORF 919

5           The primer described in Table 1 for ORF 919 was used to locate and clone ORF 919. The predicted gene 919 was cloned in pET vector and expressed in *E. coli*. The product of protein expression and purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 919-His fusion protein purification. Mice were immunized with the purified 919-His and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal

10 assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; PP, purified protein, TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 919 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity

15 plots, antigenic index, and amphipatic regions of ORF 919 are provided in Figure 10. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 919 and the amino acid sequence encoded thereby is provided in Example 1.

20

## EXAMPLE 3

Expression of ORF 279

          The primer described in Table 1 for ORF 279 was used to locate and clone ORF 279. The predicted gene 279 was cloned in pGex vector and expressed in *E. coli*. The product of protein expression and purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 279-GST purification. Mice were immunized with the purified 279-GST and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle

25 preparation. Arrows indicate the position of the main recombinant protein product (A) and

30

- 117 -

the *N. meningitidis* immunoreactive band (B). These experiments confirm that 279 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 279 are provided in Figure 11. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 279 and the amino acid sequence encoded thereby is provided in Example 1.

## EXAMPLE 4

Expression of ORF 576

The primer described in Table 1 for ORF 576 was used to locate and clone ORF 576. The predicted gene 576 was cloned in pGex vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 576-GST fusion protein purification. Mice were immunized with the purified 576-GST and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B).. These experiments confirm that ORF 576 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 576 are provided in Figure 12. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 576 and the amino acid sequence encoded thereby is provided in Example 1.

## EXAMPLE 5

Expression of ORF 519

The primer described in Table 1 for ORF 519 was used to locate and clone ORF 519. The predicted gene 519 was cloned in pET vector and expressed in *E. coli*. The product of

- 118 -

protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 519-His fusion protein purification. Mice were immunized with the purified 519-His and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 519 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 519 are provided in Figure 13. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 519 and the amino acid sequence encoded thereby is provided in Example 1.

## EXAMPLE 6

### Expression of ORF 121

The primer described in Table 1 for ORF 121 was used to locate and clone ORF 121. The predicted gene 121 was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 121-His fusion protein purification. Mice were immunized with the purified 121-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Results show that 121 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 121 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 121 are provided in Figure 14. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 121 and the amino acid sequence encoded thereby is provided in Example 1.

- 119 -

## EXAMPLE 7

Expression of ORF 128

The primer described in Table 1 for ORF 128 was used to locate and clone ORF 128.

5 The predicted gene 128 was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 128-His purification. Mice were immunized with the purified 128-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D) and ELISA assay (panel E). Results show that 128 is a surface-exposed protein. Symbols: M1, 10 molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 128 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipathic regions of ORF 128 are provided in 15 Figure 15. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 128 and the amino acid sequence encoded thereby is provided in Example 1.

## EXAMPLE 8

Expression of ORF 206

The primer described in Table 1 for ORF 206 was used to locate and clone ORF 206.

25 The predicted gene 206 was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 206-His purification. Mice were immunized with the purified 206-His and sera were used for Western blot analysis (panel B). It is worth noting that the immunoreactive band in protein extracts from meningococcus is 38 kDa instead of 17 kDa (panel A). To gain information on the nature of this antibody staining we expressed ORF 206 in *E. coli* without the His-tag and including the predicted leader peptide. Western blot analysis on total protein extracts from *E.* 30 *coli* expressing this native form of the 206 protein showed a reactive band at a position of 38 kDa, as observed in meningococcus. We conclude that the 38 kDa band in panel B) is

- 120 -

specific and that anti-206 antibodies, likely recognize a multimeric protein complex. In panel C is shown the FACS analysis, in panel D the bactericidal assay, and in panel E) the ELISA assay. Results show that 206 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 206 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 519 are provided in Figure 16. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 206 and the amino acid sequence encoded thereby is provided in Example 1.

#### EXAMPLE 9

##### Expression of ORF 287

The primer described in Table 1 for ORF 287 was used to locate and clone ORF 287. The predicted gene 287 was cloned in pGex vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 287-GST fusion protein purification. Mice were immunized with the purified 287-GST and sera were used for FACS analysis (panel B), bactericidal assay (panel C), and ELISA assay (panel D). Results show that 287 is a surface-exposed protein. Symbols: M1, molecular weight marker. Arrow indicates the position of the main recombinant protein product (A). These experiments confirm that 287 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 287 are provided in Figure 17. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 287 and the amino acid sequence encoded thereby is provided in Example 1.

- 121 -

## EXAMPLE 10

Expression of ORF 406

The primer described in Table 1 for ORF 406 was used to locate and clone ORF 406. The predicted gene *406* was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 406-His fusion protein purification. Mice were immunized with the purified 406-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Results show that 406 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 406 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipathic regions of ORF 406 are provided in Figure 18. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 406 and the amino acid sequence encoded thereby is provided in Example 1.

The foregoing examples are intended to illustrate but not to limit the invention.

- 122 -

Claims

1. A method for identifying an amino acid sequence, comprising the step of searching for putative open reading frames or protein-coding sequences within one or more of *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.
2. A method according to claim 1, comprising the steps of searching a *N. meningitidis* nucleotide sequence for an initiation codon and searching the upstream sequence for an in-frame termination codon.
3. A method for producing a protein, comprising the step of expressing a protein comprising an amino acid sequence identified according to any one of claims 1-2.
4. A method for identifying a protein in *N. meningitidis*, comprising the steps of producing a protein according to claim 3, producing an antibody which binds to the protein, and determining whether the antibody recognises a protein produced by *N. meningitidis*.
5. Nucleic acid comprising an open reading frame or protein-coding sequence identified by a method according to any one of claims 1-2.
6. A protein obtained by the method of claim 3.
7. Nucleic acid comprising one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID NO 962 to SEQ ID NO 1044.
8. Nucleic acid comprising a nucleotide sequence having greater than 50% sequence identity to a nucleotide sequence disclosed in the sequence listing SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.



- 123 -

9. Nucleic acid comprising a fragment of a nucleotide sequence disclosed in the sequence listing SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

5 10. Nucleic acid according to claim 9, wherein the fragment is unique to the genome of *N. meningitidis*.

11. Nucleic acid complementary to the nucleic acid of any one of claims 7-10.

10 12. A protein comprising an amino acid sequence encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

15 13. A protein comprising an amino acid sequences having greater than 50% sequence identity to an amino acid sequence encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

20 14. A protein comprising a fragment of an amino acid sequence selected from the group consisting of one or more odd-numbered SEQ ID NOs 963-1037, amino acid sequences having greater than 50% identity with one or more odd-numbered SEQ ID NOs 963-1045, amino acid sequences encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, and amino acid sequences encoded by one or more even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

25

15. Nucleic acid encoding a protein according to any one of claims 6-8.

30 16. A computer, a computer memory, a computer storage medium or a computer database containing the nucleotide sequence of a nucleic acid according to any one of claims 7-11.

- 124 -

17. A computer, a computer memory, a computer storage medium or a computer database containing one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961.

5 18. A polyclonal or monoclonal antibody which binds to a protein according to any one of claims 12-14 or 6.

19. A nucleic acid probe comprising nucleic acid according to any one of claims 5, 7-10, or 15.

10

20. An amplification primer comprising nucleic acid according to any one of claims 5, 7-10, or 15.

21. A composition comprising (a) nucleic acid according to any one of claims 5, 7-10, or 15; (b) protein according to any one of claims 12-14; and/or (c) an antibody according to claim 18.

15

22. The use of a composition according to claim 21 as a medicament or as a diagnostic reagent.

20

23. The use of a composition according to claim 21 in the manufacture of (a) a medicament for treating or preventing infection due to Neisserial bacteria and/or (b) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria.

25


24. A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 21.

*FIG. 1A*

919 (46 kDa)

PURIFICATION

M1 919

*FIG. 1B*

919 (46 kDa)


WESTERN BLOT

OMV TP PP

*FIG. 1C*


919 (46 kDa)

FACS

*FIG. 1D*

919 (46 kDa)

BACTERICIDAL ASSAY

*FIG. 1E*

919 (46 kDa)

ELISA assay: positive

*FIG. 2A*


279 (10.5 kDa)  
PURIFICATION  
M1 279

*FIG. 2B*


279 (10.5 kDa)  
WESTERN BLOT  
TP OMV

*FIG. 2C*

279 (10.5 kDa)  
FACS

*FIG. 2D*

279 (10.5 kDa)  
BACTERICIDAL ASSAY

*FIG. 2E*

279 (10.5 kDa)  
ELISA assay: positive

*FIG. 3A*

576 (27.8 kDa)

PURIFICATION


M1 576

*FIG. 3B*

576 (27.8 kDa)


WESTERN BLOT

TP OMV

*FIG. 3C*



576 (27.8 kDa)

FACS

*FIG. 3D*

576 (27.8 kDa)

BACTERICIDAL ASSAY

*FIG. 3E*

576 (27.8 kDa)


ELISA assay: positive

*FIG. 4A*


519 (33 kDa)  
PURIFICATION  
M1 519

*FIG. 4B*



519 (33 kDa)  
WESTERN BLOT  
TP OMV

*FIG. 4C*

519 (33 kDa)  
FACS

*FIG. 4D*

519 (33 kDa)  
BACTERICIDAL ASSAY

*FIG. 4E*

519 (33 kDa)  
ELISA assay: positive

*FIG. 5A*

121 (40 kDa)

PURIFICATION

M1 121

*FIG. 5B*

121 (40 kDa)


WESTERN BLOT

TP OMV

*FIG. 5C*


121 (40 kDa)

FACS

*FIG. 5D*

121 (40 kDa)

BACTERICIDAL ASSAY

*FIG. 5E*

121 (40 kDa)

ELISA assay: positive

*FIG. 6A*


128 (101 kDa)  
PURIFICATION  
M1 128

*FIG. 6B*


128 (101 kDa)  
WESTERN BLOT  
TP OMV

*FIG. 6C*

128 (101 kDa)  
FACS

*FIG. 6D*

128 (101 kDa)  
BACTERICIDAL ASSAY

*FIG. 6E*

128 (101 kDa)  
ELISA assay: positive



*FIG. 7A*

206 (17 kDa)

PURIFICATION


M1 206

*FIG. 7B*

206 (17 kDa)


WESTERN BLOT

TP OMV

*FIG. 7C*



206 (17 kDa)

FACS

*FIG. 7D*

206 (17 kDa)

BACTERICIDAL ASSAY

*FIG. 7E*

206 (17 kDa)

ELISA assay: positive

*FIG. 8A*

287 (78 kDa)


PURIFICATION

M1 287

*FIG. 8B*



287 (78 kDa)

FACS

*FIG. 8C*

287 (78 kDa)

BACTERICIDAL ASSAY

*FIG. 8D*

287 (78 kDa)

ELISA assay: positive

*FIG. 9A*


406 (33 kDa)  
PURIFICATION  
M1 406

*FIG. 9B*



406 (33 kDa)  
WESTERN BLOT  
TP OMV

*FIG. 9C*

406 (33 kDa)  
FACS

*FIG. 9D*

406 (33 kDa)  
BACTERICIDAL ASSAY

*FIG. 9E*

406 (33 kDa)

ELISA assay: positive


**919****Hydrophilicity Plot, Antigenic Index and AMPHI Regions**

Fig. 10


Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 11


576-1Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 12

519-1  
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 13

121-1  
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 14



128-1  
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 15

206


Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 16

287


Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 17


406Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 18

## APPENDIX A

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
1	GNMAA01R	9866	10311
1	GNMAA27F	10765	11284
1	GNMAA27R	11771	12130
1	GNMBA57F	5365	5930
1	GNMBA57R	6594	7118
1	GNMCD17F	9494	10035
1	GNMCD21F	14937	15512
1	GNMCD21R	16217	16700
1	GNMCD26F	27033	27561
1	GNMCD26R	25650	26101
1	GNMCD28F	27012	27561
1	GNMCD58F	27525	28047
1	GNMCD58R	26208	26582
1	GNMCF39F	25928	26411
1	GNMCF39R	24501	25188
1	GNMCK12F	18475	18966
1	GNMCK12R	16734	17175
1	GNMCL43F	31264	31793
1	GNMCL43R	32603	33038
1	GNMCL77F	7112	7681
1	GNMCL77R	8587	9143
1	GNMCO24R	8321	8920
1	GNMCP77F	24906	25412
1	GNMCP77R	26565	27107
1	GNMCQ74F	14937	15617
1	GNMCQ74R	13764	14477
1	GNMCS43F	3607	4278
1	GNMCS56F	21955	22578
1	GNMCS57F	7909	8608
1	GNMCV14F	5771	6272
1	GNMCV15R	7143	7800
1	GNMCV64F	23017	23484
1	GNMCV64R	21277	22018
1	GNMCV74F	16990	17305
1	GNMCV74R	18058	18796
1	GNMCV83F	4008	4503
1	GNMCV83R	2768	3286
1	GNMCY30F	7157	7897
1	GNMCY30R	8378	8912
1	GNMCZ78F	14192	14686
1	GNMCZ78R	15697	16234
1	GNMCZ93F	31337	31862
1	GNMCZ93R	30119	30639
2	GNMAA02F	27133	27648

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
2	GNMAA02R	26120	26546
2	GNMAA38F	16163	16379
2	GNMAA38R	14815	15335
2	GNMAA46F	2337	2704
2	GNMAA46R	3242	3746
2	GNMBA17F	15637	15798
2	GNMCD47F	11113	11453
2	GNMCD78F	13704	14196
2	GNMCD78R	15013	15380
2	GNMCK27F	4941	5490
2	GNMCK27R	3670	4086
2	GNMCL17F	23033	23527
2	GNMCL17R	21424	21995
2	GNMCL82F	24805	25200
2	GNMCL82R	26093	26659
2	GNMCN19F	5929	6601
2	GNMCP32F	18556	19103
2	GNMCP32R	19956	20403
2	GNMCQ84F	16351	17040
2	GNMCQ92F	3243	3692
2	GNMCQ92R	2022	2644
2	GNMCS51F	6645	7300
2	GNMCV24F	28139	28637
2	GNMCV25R	26839	27453
2	GNMCV77F	5149	5575
2	GNMCV77R	6008	6841
2	GNMCY52F	21892	22580
2	GNMCY52R	23157	23662
2	GNMCY74F	21900	22552
2	GNMCY74R	23519	24073
2	GNMCZ69F	1489	1999
2	GNMCZ70F	1489	1985
2	GNMCZ70R	2707	3232
3	GNMAA03F	16946	17459
3	GNMAA03R	18236	18447
3	GNMAA15F	3641	4156
3	GNMAA15R	4704	5176
3	GNMCA12F	8812	9427
3	GNMCB27F	19908	20403
3	GNMCB27R	21309	21630
3	GNMCB59F	22046	22554
3	GNMCB59R	20650	21230
3	GNMCD50F	8711	9229
3	GNMCF53F	15376	15861
3	GNMCF53R	16619	17312
3	GNMCF86F	22322	22760

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
3	GNMCL55F	12659	13194
3	GNMCL55R	13854	14380
3	GNMCM46R	11972	12662
3	GNMCM63F	7397	8071
3	GNMCM63R	8734	9381
3	GNMCP05F	2224	2964
3	GNMCV27F	10472	10969
3	GNMCV28R	11455	12172
4	GNMAA04R	21367	21727
4	GNMAA66F	9998	10514
4	GNMAA66R	9150	9669
4	GNMAA70F	19444	19961
4	GNMAA70R	20446	20841
4	GNMAB18F	34311	34576
4	GNMAB18R	32690	33102
4	GNMBA24F	21408	21950
4	GNMCA71F	35444	36106
4	GNMCA85F	14906	15535
4	GNMCB46F	27141	27652
4	GNMCB46R	28558	29138
4	GNMCD85F	25929	26447
4	GNMCF35F	37587	38065
4	GNMCF35R	36661	37327
4	GNMCK26F	23722	24268
4	GNMCK26R	25176	25751
4	GNMCK39F	26270	26836
4	GNMCK39R	27576	27934
4	GNMCK64F	37686	38053
4	GNMCK64R	36356	36915
4	GNMCL60F	2659	3206
4	GNMCL60R	4028	4520
4	GNMCM12F	21992	22465
4	GNMCM12R	23335	23919
4	GNMCM80F	15507	16171
4	GNMCM80R	16264	16990
4	GNMCN08R	33415	33739
4	GNMCO47F	23101	23700
4	GNMCO47R	24872	25344
4	GNMCP24F	34864	35552
4	GNMCP24R	33620	34225
4	GNMCP44F	24613	24976
4	GNMCP44R	25712	26279
4	GNMCQ80F	35274	35964
4	GNMCQ80R	34053	34632
4	GNMCS02F	37528	38035
4	GNMCV40F	33203	33632

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
4	GNMCX19F	37333	38076
4	GNMCX19R	36229	36871
4	GNMCX25F	28667	29362
4	GNMCX25R	27755	28398
4	GNMCX31F	1336	2085
4	GNMCX31R	1	640
4	GNMCX38F	15063	15774
4	GNMCX38R	14158	14836
4	GNMCY53F	8159	8846
4	GNMCY53R	6905	7405
4	GNMCZ25F	42411	42912
4	GNMCZ25R	40673	41229
4	GNMCZ27F	4786	5245
4	GNMCZ27R	3484	4030
5	GNMAA05F	5819	6334
5	GNMAA05R	6898	7190
5	GNMAA09F	15867	16369
5	GNMAA09R	15935	16368
5	GNMAA50R	17996	18383
5	GNMAA51F	44043	44409
5	GNMAA51R	43157	43679
5	GNMCA06F	43254	43764
5	GNMCA72F	7437	8102
5	GNMCA87F	36458	36899
5	GNMCB41F	44654	45224
5	GNMCB41R	45601	46039
5	GNMCD77F	46927	47437
5	GNMCD77R	48378	48761
5	GNMCF13F	18408	18911
5	GNMCF13R	16858	17553
5	GNMCF26F	44946	45450
5	GNMCF26R	46355	47018
5	GNMCF51F	31870	32355
5	GNMCK15F	34028	34591
5	GNMCK15R	33072	33560
5	GNMCK52F	13042	13587
5	GNMCK52R	11706	12267
5	GNMCK67F	16111	16399
5	GNMCK67R	14116	14459
5	GNMCL36F	26130	26644
5	GNMCL36R	24478	25038
5	GNMCL57F	46883	47459
5	GNMCL57R	48232	48759
5	GNMCL93F	6901	7404
5	GNMCL93R	5298	5897
5	GNMCN22F	4118	4792



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
5	GNMCN22R	5337	5969
5	GNMCN58F	17211	17798
5	GNMCN58R	15825	16436
5	GNMCN85F	38026	38698
5	GNMCN85R	39079	39669
5	GNMCP14F	47197	47893
5	GNMCP14R	47924	48597
5	GNMCP42F	23201	23701
5	GNMCP42R	24295	24875
5	GNMCP60F	31050	31537
5	GNMCP60R	29886	30442
5	GNMCQ39R	321	1003
5	GNMCS18F	39300	39713
5	GNMCS74F	41338	41970
5	GNMCS84F	47085	47801
5	GNMCS85R	48062	48687
5	GNMCV51F	33257	33720
5	GNMCV53F	35594	36106
5	GNMCV53R	36624	37232
5	GNMCV80F	3433	3924
5	GNMCV80R	2239	2949
5	GNMCX14F	15425	16088
5	GNMCX14R	14412	15041
5	GNMCY05F	26090	26786
5	GNMCY05R	25093	25665
5	GNMCY24F	45941	46684
5	GNMCY24R	47197	47748
5	GNMCY75F	9003	9618
5	GNMCY75R	9968	10503
5	GNMCZ74F	32693	33186
5	GNMCZ74R	31650	32179
6	GNMAA06F	43077	43280
6	GNMAA33F	21695	22061
6	GNMAA33R	22761	23120
6	GNMAA39F	11023	11390
6	GNMAA39R	12412	12870
6	GNMAB43F	13579	14098
6	GNMAB56F	20656	21079
6	GNMCA67F	37544	38219
6	GNMCB01F	34331	34902
6	GNMCB01R	35502	36050
6	GNMCD62F	6122	6648
6	GNMCD62R	4831	5183
6	GNMCD93F	1679	2157
6	GNMCD93R	3169	3495
6	GNMCK06F	20928	21478

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
6	GNMCK06R	19697	20289
6	GNMCL39F	24705	25251
6	GNMCL39R	23194	23548
6	GNMCM21F	32432	33056
6	GNMCM21R	33649	34334
6	GNMCN70R	14256	14926
6	GNMCO52F	13197	13922
6	GNMCO85F	26216	26827
6	GNMCO85R	25022	25686
6	GNMCS27F	16689	17300
6	GNMCS61F	3508	4184
6	GNMCS77F	40570	41276
6	GNMCS83F	32447	33093
6	GNMCS84R	30598	31235
6	GNMCV08F	42819	43260
6	GNMCV09R	44363	44932
6	GNMCV75F	14981	15479
6	GNMCX36F	38996	39738
6	GNMCX36R	39855	40528
6	GNMCX59F	39178	39574
6	GNMCX59R	40477	41178
6	GNMCY92F	24695	25185
6	GNMCZ42F	15656	16179
6	GNMCZ42R	17126	17641
6	GNMCZ59F	38912	39364
6	GNMCZ59R	37528	38062
7	GNMAA07F	8291	8808
7	GNMAA07R	9371	9793
7	GNMAA10F	39307	39822
7	GNMAA10R	37810	38060
7	GNMAA76F	289	796
7	GNMAA76R	1117	1517
7	GNMAB01F	33973	34541
7	GNMAB01R	34969	35306
7	GNMAB04F	53611	54157
7	GNMAB04R	52653	53059
7	GNMAB52F	37174	37740
7	GNMAB55F	52123	52618
7	GNMBA81F	28757	29327
7	GNMBA81R	27546	28097
7	GNMBB21F	40393	40959
7	GNMBB21R	39008	39449
7	GNMCA75F	31357	32032
7	GNMCB25F	33514	34085
7	GNMCB25R	34748	35431
7	GNMCB48F	14504	15191

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
7	GNMCB56F	36436	37114
7	GNMCB56R	35390	36079
7	GNMCB67F	42108	42771
7	GNMCB67R	41133	41740
7	GNMCB69F	27142	27807
7	GNMCB69R	25881	26530
7	GNMCD33R	50431	50757
7	GNMCD51F	6134	6629
7	GNMCF11F	35219	35727
7	GNMCF11R	36756	37229
7	GNMCF37F	51876	52358
7	GNMCF37R	49997	50607
7	GNMCF45F	40695	41177
7	GNMCF45R	41795	42403
7	GNMCF58F	6844	7311
7	GNMCF58R	5528	6208
7	GNMCF89F	52016	52469
7	GNMCF89R	53363	54002
7	GNMCH63F	39350	39770
7	GNMCH80F	20170	20607
7	GNMCK02F	43141	43483
7	GNMCK02R	41418	41852
7	GNMCK03F	41843	42407
7	GNMCK03R	40397	40952
7	GNMCK75F	29011	29346
7	GNMCK75R	27279	27840
7	GNMCL37F	37566	38097
7	GNMCL37R	38870	39442
7	GNMCL38F	38465	38990
7	GNMCL38R	37261	37843
7	GNMCL50F	52471	53006
7	GNMCL50R	51307	51879
7	GNMCM16R	43200	43943
7	GNMCM28F	31079	31677
7	GNMCM28R	29986	30699
7	GNMCM75F	29426	30002
7	GNMCM75R	28230	28947
7	GNMCM07R	31678	32296
7	GNMCM08F	30220	30908
7	GNMCM66F	49682	50383
7	GNMCM68R	48507	48702
7	GNMCP52F	53906	54238
7	GNMCP75F	3335	3631
7	GNMCP75R	2430	2916
7	GNMCP87F	19818	20336
7	GNMCP87R	21539	21853

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
7	GNMCQ05F	16992	17629
7	GNMCQ05R	15900	16596
7	GNMCQ06F	8173	8758
7	GNMCQ06R	6774	7461
7	GNMCQ11F	35268	35953
7	GNMCQ11R	36305	36981
7	GNMCQ13F	28320	29037
7	GNMCQ13R	29418	30079
7	GNMCQ24F	40176	40783
7	GNMCQ24R	40841	41510
7	GNMCQ37R	20188	20919
7	GNMCQ55F	40743	41309
7	GNMCQ55R	41980	42698
7	GNMCS30F	49344	49993
7	GNMCS53F	16879	17595
7	GNMCS95F	29469	29622
7	GNMCV01R	30937	31651
7	GNMCV17F	24334	24812
7	GNMCV18R	25368	26100
7	GNMCV28F	26427	26916
7	GNMCV29R	24847	25211
7	GNMCV69F	16647	17098
7	GNMCV91F	10009	10521
7	GNMCV91R	8630	9420
7	GNMCX23F	36634	37387
7	GNMCX23R	38318	38893
7	GNMCX24R	33857	34497
7	GNMCX67F	44537	45096
7	GNMCX67R	45763	46455
7	GNMCX77F	3423	4090
7	GNMCY56F	44117	44788
7	GNMCY56R	45883	46440
7	GNMCY79F	37394	38041
7	GNMCY79R	38954	39287
7	GNMCY84F	7387	8023
7	GNMCY84R	8749	9223
7	GNMCZ21F	28454	28986
7	GNMCZ21R	29774	30347
8	GNMAA08F	3883	4232
8	GNMAA08R	4930	5373
8	GNMAA17F	20102	20622
8	GNMAA17R	19135	19510
8	GNMAA18F	18255	18770
8	GNMAA69F	3985	4501
8	GNMAA69R	2840	3310
8	GNMBA02R	18827	19205

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
8	GNMBA38R	20196	20729
8	GNMBB17F	16245	16809
8	GNMBB17R	14789	15278
8	GNMCD01F	1726	2071
8	GNMCD01R	3032	3560
8	GNMCD57F	15533	16080
8	GNMCD57R	14017	14387
8	GNMCH21F	7735	8074
8	GNMCH58F	20193	20483
8	GNMCK17F	12025	12589
8	GNMCK17R	13519	14068
8	GNMCN37F	11716	12367
8	GNMCN37R	10459	10898
8	GNMCQ71F	15717	16394
8	GNMCQ71R	17082	17799
8	GNMCV56F	2818	3221
8	GNMCV56R	4184	4873
8	GNMCW18F	11443	12002
8	GNMCW19F	12243	12874
8	GNMCX44F	13230	13907
8	GNMCX44R	12093	12776
8	GNMCX81F	6904	7509
8	GNMCX81R	8613	9312
9	GNMAA11R	3820	4070
9	GNMCF10F	4237	4718
9	GNMCF10R	5381	6021
9	GNMCF16F	6231	6723
9	GNMCF16R	4976	5578
9	GNMCH10F	8003	8324
9	GNMCH10R	6412	6886
9	GNMCS36F	8057	8725
9	GNMCX89R	7787	8447
10	GNMAA12F	700	1214
11	GNMAA13F	48121	48639
11	GNMAA13R	49787	50045
11	GNMAA73F	9309	9827
11	GNMAA73R	10319	10725
11	GNMAA95F	5068	5583
11	GNMAA95R	4340	4731
11	GNMAB70F	44475	44906
11	GNMAB70R	45692	46213
11	GNMAB84F	34949	35517
11	GNMAB84R	35628	36115
11	GNMBA30F	35071	35637
11	GNMBA30R	34080	34618
11	GNMBA65F	46358	46779

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
11	GNMBA65R	48334	48629
11	GNMBA96F	25616	26168
11	GNMBA96R	27180	27576
11	GNMCA79F	12432	13093
11	GNMCA81F	64372	65033
11	GNMCB75F	12474	13003
11	GNMCB75R	11368	11898
11	GNMCB79F	12463	12998
11	GNMCB79R	11374	11879
11	GNMCB80F	12394	13044
11	GNMCB80R	11355	11761
11	GNMCB88F	26453	27107
11	GNMCB88R	25225	25878
11	GNMCD37R	1837	2210
11	GNMCD48F	36014	36541
11	GNMCD48R	37485	37833
11	GNMCD61F	33776	34331
11	GNMCD61R	32513	32886
11	GNMCF05F	61923	62430
11	GNMCF05R	63324	63994
11	GNMCF20F	64093	64548
11	GNMCF20R	62670	63312
11	GNMCF27F	7865	8322
11	GNMCF27R	6252	6941
11	GNMCF31F	2643	3144
11	GNMCF31R	3621	4255
11	GNMCF32F	34812	35310
11	GNMCF32R	33489	34167
11	GNMCF44F	7905	8323
11	GNMCF44R	6275	6806
11	GNMCF54F	4208	4682
11	GNMCF54R	5789	6419
11	GNMCH29F	4781	5137
11	GNMCH75F	60773	61203
11	GNMCH75R	62111	62403
11	GNMCK80F	40661	41202
11	GNMCK80R	39298	39847
11	GNMCL01F	59052	59569
11	GNMCL01R	57689	58283
11	GNMCL62F	36623	37174
11	GNMCL62R	38138	38721
11	GNMCL65F	11758	12282
11	GNMCL65R	13221	13807
11	GNMCM44R	3393	4077
11	GNMCM85R	60497	61118
11	GNMCN29F	75370	76048

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
11	GNMCN29R	76487	77001
11	GNMCN90F	53115	53836
11	GNMCN90R	51986	52525
11	GNMCP26F	38602	39106
11	GNMCP26R	37257	37549
11	GNMCQ58F	61396	62055
11	GNMCQ58R	62637	63355
11	GNMCS12F	7065	7598
11	GNMCV05F	4623	5085
11	GNMCV06R	3299	4083
11	GNMCV16F	51884	52341
11	GNMCV17R	53784	54354
11	GNMCV88F	70556	71043
11	GNMCV88R	69005	69740
11	GNMCW41F	39495	40133
11	GNMCX04F	26396	27141
11	GNMCX04R	25242	25882
11	GNMCX65F	43846	44360
11	GNMCX65R	45795	46258
11	GNMCY01F	42714	43318
11	GNMCY03F	16064	16747
11	GNMCY03R	17171	17665
11	GNMCY76F	36967	37624
11	GNMCY76R	38440	38999
11	GNMCZ26F	45695	46211
11	GNMCZ26R	46903	47445
11	GNMCZ30F	53419	53933
11	GNMCZ30R	54651	55202
11	GNMCZ86R	43568	43996
12	GNMAA14F	51035	51374
12	GNMAA62F	22307	22668
12	GNMAA62R	21211	21585
12	GNMAA84F	4132	4648
12	GNMAA84R	3028	3497
12	GNMAB19F	53197	53641
12	GNMAB19R	51715	51941
12	GNMAB34F	59820	60248
12	GNMAB75F	8230	8726
12	GNMAB75R	6772	7086
12	GNMBA16F	61880	62448
12	GNMBA16R	63397	63930
12	GNMBA55F	54894	55463
12	GNMBA55R	53249	53699
12	GNMBB07F	45401	45967
12	GNMBB07R	46474	46846
12	GNMBB23F	23330	23896

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
12	GNMBB23R	21762	22258
12	GNMBB28F	17524	18093
12	GNMBB28R	19255	19581
12	GNMCA08F	80267	80572
12	GNMCA26F	95492	95876
12	GNMCB71F	3761	4447
12	GNMCB71R	2760	3305
12	GNMCD40F	25822	26340
12	GNMCD40R	27392	27712
12	GNMCF14F	254	698
12	GNMCF23F	25032	25512
12	GNMCF23R	26296	26954
12	GNMCF59F	543	781
12	GNMCF59R	1909	2359
12	GNMCF75F	38537	38993
12	GNMCH09F	70027	70360
12	GNMCH09R	68764	69057
12	GNMCK63F	82010	82461
12	GNMCK63R	83284	83844
12	GNMCL27F	36594	37139
12	GNMCL27R	38339	38900
12	GNMCL83F	24969	25304
12	GNMCL83R	26594	27175
12	GNMCM24F	58035	58620
12	GNMCM24R	56788	57519
12	GNMCM26R	43862	44449
12	GNMCM33F	59354	60069
12	GNMCM33R	58194	58939
12	GNMCN23F	31658	32330
12	GNMCN23R	29999	30623
12	GNMCP07F	62762	63498
12	GNMCP07R	61716	62463
12	GNMCQ25F	29033	29713
12	GNMCQ25R	27952	28642
12	GNMCQ31F	33826	34489
12	GNMCQ31R	32628	33318
12	GNMCQ35F	99046	99645
12	GNMCQ35R	100151	100867
12	GNMCS06F	35210	35790
12	GNMCS07F	38327	38874
12	GNMCS37F	93209	93927
12	GNMCS45F	52207	52867
12	GNMCS59F	49955	50647
12	GNMCS63F	13556	14245
12	GNMCS75F	95191	95899
12	GNMCS94F	39007	39638



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
12	GNMCV02F	96642	97004
12	GNMCV03R	95290	96043
12	GNMCV19F	13169	13632
12	GNMCV20R	11334	12063
12	GNMCV67F	12472	12929
12	GNMCV67R	11158	11877
12	GNMCV95F	48011	48518
12	GNMCV95R	48842	49450
12	GNMCX03F	64105	64613
12	GNMCX03R	65502	66139
12	GNMCX62F	91416	91831
12	GNMCX68R	55716	56405
12	GNMCX82F	55372	56082
12	GNMCX82R	54147	54839
12	GNMCX90F	81959	82454
12	GNMCX90R	83099	83791
12	GNMCX91F	82087	82392
12	GNMCY47F	80254	80920
12	GNMCY47R	78886	79381
12	GNMCY81F	17736	18413
12	GNMCY81R	19180	19621
12	GNMCZ02F	24891	25412
12	GNMCZ02R	26406	26946
12	GNMCZ10F	34243	34706
12	GNMCZ10R	35555	36086
12	GNMCZ54F	59674	60174
12	GNMCZ54R	58180	58651
12	GNMCZ65F	70323	70828
12	GNMCZ65R	71871	72382
13	GNMAA19F	12931	13449
13	GNMAA19R	11822	12291
13	GNMAA55R	4581	5101
13	GNMAA63F	36862	37225
13	GNMAA63R	35706	36096
13	GNMAA77F	20561	20750
13	GNMAB20F	14416	14852
13	GNMBA41R	21126	21626
13	GNMCB15F	3423	3980
13	GNMCB15R	4343	4984
13	GNMCB38F	22717	23346
13	GNMCB38R	21451	22022
13	GNMCB57F	11695	12343
13	GNMCD23F	33967	34506
13	GNMCD23R	32498	32984
13	GNMCD27F	25756	26330
13	GNMCD27R	24266	24695

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
13	GNMCD30F	25823	26369
13	GNMCD30R	24703	25016
13	GNMCD91F	36457	36958
13	GNMCF77F	11321	11777
13	GNMCF77R	9878	10580
13	GNMCH04F	9222	9510
13	GNMCK07F	20658	21162
13	GNMCK07R	21983	22516
13	GNMCK24F	11029	11566
13	GNMCK24R	12531	12904
13	GNMCL26F	33412	33883
13	GNMCL26R	32004	32585
13	GNMCL42F	25017	25487
13	GNMCL42R	26410	26988
13	GNMCM18F	9081	9580
13	GNMCM18R	7774	8463
13	GNMCM79F	28296	28959
13	GNMCM79R	29623	30321
13	GNMCN57F	43959	44583
13	GNMCN57R	42560	43109
13	GNMCO81F	36053	36717
13	GNMCO81R	34853	35488
13	GNMCP18F	20932	21612
13	GNMCP18R	19724	20394
13	GNMCS73F	26639	27284
13	GNMCS76R	25539	26264
13	GNMCV09F	46801	47242
13	GNMCV10R	45342	46019
13	GNMCV48F	40436	40867
13	GNMCV81F	21352	21853
13	GNMCW37F	45183	45820
13	GNMCX11F	1628	2393
13	GNMCX11R	2983	3629
13	GNMCX76F	41236	41920
13	GNMCX76R	42308	42978
13	GNMCY20F	20524	21188
13	GNMCY20R	19350	19922
13	GNMCY46F	15097	15751
13	GNMCY46R	16501	17054
13	GNMCY87F	21699	22313
13	GNMCY87R	20274	20660
13	GNMCZ29F	46571	47106
14	GNMAA20F	2883	3399
15	GNMAA21F	12719	13236
15	GNMAA21R	11967	12439
15	GNMAA83F	2799	3318

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
15	GNMAA83R	3978	4448
15	GNMBA09F	4054	4621
15	GNMCB52F	15275	16007
15	GNMCB52R	16498	16827
15	GNMCB77F	18627	19229
15	GNMCB77R	20264	20766
15	GNMCB83F	18623	19271
15	GNMCB83R	20266	20777
15	GNMCL14F	3072	3593
15	GNMCL14R	1651	2228
15	GNMCL87R	9692	10245
15	GNMCN52F	5357	5991
15	GNMCN52R	6753	7339
15	GNMCP45F	11548	12079
15	GNMCP45R	13429	13801
15	GNMCQ09F	19788	20364
15	GNMCQ09R	18441	19134
15	GNMCQ40F	20922	21572
15	GNMCQ40R	22245	22939
15	GNMCV26F	13405	13894
15	GNMCV27R	12194	12828
15	GNMCW08F	23327	23910
15	GNMCX17F	4323	5048
15	GNMCX17R	3040	3690
16	GNMAA22F	54115	54632
16	GNMAA22R	55087	55557
16	GNMAA40R	44790	45219
16	GNMAA72F	58127	58639
16	GNMAA72R	57179	57650
16	GNMAB05F	47515	48081
16	GNMAB05R	46674	47004
16	GNMAB06F	65453	66020
16	GNMAB06R	66416	66833
16	GNMAB07F	65453	65772
16	GNMAB28F	70440	71008
16	GNMAB28R	71467	71806
16	GNMAB41F	21694	22260
16	GNMAB54F	45585	46150
16	GNMAB65F	18770	19084
16	GNMBA69F	9418	9986
16	GNMBA69R	8303	8848
16	GNMBA76F	39980	40549
16	GNMBA76R	41451	41944
16	GNMBA79R	1185	1359
16	GNMCA89F	63127	63781
16	GNMCB30F	5241	5748

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
16	GNMCD32R	3919	4495
16	GNMCD69F	20174	20609
16	GNMCD69R	21508	21899
16	GNMCD74F	20264	20751
16	GNMCF08F	25798	26287
16	GNMCF08R	24361	25036
16	GNMCF36R	42733	43371
16	GNMCF46R	4203	4663
16	GNMCF48F	40973	41398
16	GNMCF48R	39629	40232
16	GNMCF73F	27684	28143
16	GNMCF73R	26442	27127
16	GNMCF81F	67923	68332
16	GNMCH17F	68971	69291
16	GNMCH34R	22199	22496
16	GNMCK28F	17936	18486
16	GNMCK28R	16766	17104
16	GNMCK32F	20788	21317
16	GNMCK32R	21768	22345
16	GNMCK85F	4360	4910
16	GNMCK85R	5620	6191
16	GNMCL06F	5123	5624
16	GNMCL06R	3812	4383
16	GNMCL34F	28058	28532
16	GNMCL34R	26957	27535
16	GNMCL63F	31053	31621
16	GNMCL63R	32284	32700
16	GNMCL70F	26168	26684
16	GNMCM31F	50181	50817
16	GNMCM31R	48867	49582
16	GNMCN28F	69538	70215
16	GNMCN28R	68459	69068
16	GNMCN84F	68423	69040
16	GNMCN84R	66998	67589
16	GNMCO18F	2622	3166
16	GNMCO18R	1677	2332
16	GNMCO35F	70510	71084
16	GNMCO35R	69198	69780
16	GNMCP19F	46453	47147
16	GNMCP19R	48299	48962
16	GNMCP43F	14799	15124
16	GNMCQ02F	19223	19930
16	GNMCQ02R	20338	21001
16	GNMCQ22F	21355	22030
16	GNMCQ22R	19917	20600
16	GNMCQ53F	7175	7907

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
16	GNMCQ53R	8198	8928
16	GNMCQ96R	29546	30182
16	GNMCS41F	29075	29776
16	GNMCS68F	9040	9703
16	GNMCS75R	1277	1893
16	GNMCS76F	2498	3167
16	GNMCV38F	37452	37889
16	GNMCV55R	34048	34804
16	GNMCV60F	59043	59536
16	GNMCV60R	57614	58367
16	GNMCX12F	3746	4302
16	GNMCX12R	5111	5734
16	GNMCX21F	11333	11997
16	GNMCX21R	10200	10848
16	GNMCX63F	225	712
16	GNMCY14F	72030	72750
16	GNMCY14R	70731	71300
16	GNMCY23F	43229	43994
16	GNMCY23R	42083	42641
16	GNMCY41F	27768	28553
16	GNMCY41R	28801	29356
16	GNMCY50F	59253	60030
16	GNMCY50R	58094	58480
16	GNMCY59F	48831	49574
16	GNMCY59R	50018	50543
16	GNMCZ40F	12172	12645
16	GNMCZ40R	13578	14094
16	GNMCZ41F	60265	60795
16	GNMCZ41R	61535	62088
16	GNMCZ80F	29797	30278
16	GNMCZ80R	28542	29086
16	GNMCZ90R	34086	34573
17	GNMAA23F	31103	31553
17	GNMAA23R	32120	32558
17	GNMAA31F	20779	21295
17	GNMAA31R	21615	22086
17	GNMAA67F	32770	33282
17	GNMAA67R	33955	34310
17	GNMAB08F	35151	35717
17	GNMAB08R	33887	34310
17	GNMBA18F	51385	51952
17	GNMBA36F	8398	8967
17	GNMBA36R	9832	10331
17	GNMBA54F	57853	58426
17	GNMBA54R	56651	57182
17	GNMBA74F	22767	23336

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
17	GNMBA74R	21413	21911
17	GNMBA85F	33077	33648
17	GNMBA85R	31797	32251
17	GNMCA19F	36042	36621
17	GNMCB06F	26433	26953
17	GNMCB06R	28247	28714
17	GNMCB10F	38250	38813
17	GNMCB10R	36756	37384
17	GNMCB82F	31729	32377
17	GNMCB82R	32858	33235
17	GNMCF22F	37912	38405
17	GNMCF22R	36753	37421
17	GNMCK05F	7321	7797
17	GNMCK05R	5987	6514
17	GNMCK57F	39678	40046
17	GNMCK57R	40958	41325
17	GNMCM38F	10453	11189
17	GNMCM38R	11737	12393
17	GNMCM58F	22688	23288
17	GNMCM58R	23628	24315
17	GNMCN30F	55573	56235
17	GNMCN30R	56832	57420
17	GNMCO01F	27343	28038
17	GNMCO07F	12194	12723
17	GNMCO07R	13433	14166
17	GNMCO26R	5725	6371
17	GNMCO43F	35750	36434
17	GNMCO43R	37161	37681
17	GNMCO44F	32920	33658
17	GNMCO44R	31733	32327
17	GNMCO55F	10439	11147
17	GNMCO55R	12310	12961
17	GNMCO56F	54670	55322
17	GNMCO56R	55704	56309
17	GNMCP57F	10671	10932
17	GNMCP57R	8680	9034
17	GNMCP66F	57727	58211
17	GNMCP66R	58838	59416
17	GNMCQ42F	22050	22733
17	GNMCQ42R	23218	23942
17	GNMCQ81F	41410	42152
17	GNMCQ81R	42968	43610
17	GNMCS03F	707	1334
17	GNMCS35F	52431	53137
17	GNMCS44F	35071	35764
17	GNMCS70F	6806	7540

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
17	GNMCS89F	38449	39120
17	GNMCS90R	39272	39972
17	GNMCV42F	51980	52438
17	GNMCV92F	43715	44212
17	GNMCV92R	42381	43040
17	GNMCX53F	18076	18436
17	GNMCX53R	16632	17267
17	GNMCY21F	26276	26984
17	GNMCY21R	25220	25785
17	GNMCY43F	55511	56209
17	GNMCY58F	10946	11675
17	GNMCY58R	9574	10130
17	GNMCZ14F	4034	4557
17	GNMCZ14R	5449	5997
17	GNMCZ81F	12505	13016
17	GNMCZ81R	10929	11485
18	GNMAA24F	14784	15300
18	GNMAA24R	15822	16278
18	GNMAA91F	3107	3623
18	GNMAA93F	14115	14633
18	GNMAA93R	12779	13156
18	GNMAB47F	6436	7001
18	GNMCA24F	17599	18212
18	GNMCB51F	10483	11109
18	GNMCB51R	9080	9547
18	GNMCK79F	4421	4931
18	GNMCK79R	5949	6533
18	GNMCM27F	17624	18228
18	GNMCM27R	16432	17178
18	GNMCM56F	13615	14160
18	GNMCM56R	14770	15435
18	GNMCN40R	15893	16523
18	GNMCN44F	14468	15195
18	GNMCN44R	15922	16524
18	GNMCP83F	14201	14738
18	GNMCP83R	15673	16259
18	GNMCY13F	2490	3240
18	GNMCZ03F	14791	15109
18	GNMCZ03R	16087	16657
18	GNMCZ15F	6918	7405
18	GNMCZ15R	5483	6044
18	GNMCZ61F	15232	15736
18	GNMCZ61R	16804	17347
19	GNMAA25F	3689	4210
19	GNMAA25R	4679	5150
19	GNMAA53F	17218	17584

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
19	GNMAA53R	16131	16651
19	GNMAB22F	11317	11854
19	GNMBA56F	29237	29799
19	GNMBB20F	42956	43521
19	GNMBB20R	41743	42275
19	GNMCB08F	1626	2186
19	GNMCB08R	2749	3408
19	GNMCB49F	24542	25193
19	GNMCB49R	23154	23800
19	GNMCB50F	1442	2136
19	GNMCB50R	457	1122
19	GNMCB84F	25574	26173
19	GNMCB84R	24112	24577
19	GNMCD36F	32463	32986
19	GNMCF17F	11187	11695
19	GNMCF17R	9855	10520
19	GNMCF56F	43830	44301
19	GNMCF56R	42446	43137
19	GNMCF62F	46052	46506
19	GNMCH41R	48920	49204
19	GNMCK19F	5471	5977
19	GNMCK19R	6934	7451
19	GNMCK60F	19464	19828
19	GNMCK60R	20624	21189
19	GNMCL07F	29947	30379
19	GNMCL07R	31253	31828
19	GNMCL47F	13187	13681
19	GNMCL47R	11739	12309
19	GNMCL67R	10328	10861
19	GNMCM83F	7074	7667
19	GNMCM83R	5824	6505
19	GNMCM87R	6816	7475
19	GNMCM99F	21718	22367
19	GNMCM99R	23279	23896
19	GNMCO19F	7892	8641
19	GNMCO19R	6509	7230
19	GNMCQ23F	22847	23439
19	GNMCQ23R	24531	25070
19	GNMCQ63F	24578	25176
19	GNMCQ63R	23445	24129
19	GNMCS09F	31343	31944
19	GNMCS34F	32710	33397
19	GNMCV13F	11334	11854
19	GNMCV14R	10046	10690
19	GNMCX15F	8333	9060
19	GNMCX15R	10180	10827



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
19	GNMCX27F	8333	9060
19	GNMCX27R	10188	10827
19	GNMCX56F	40847	41206
19	GNMCX56R	41903	42589
19	GNMCX87F	33938	34084
19	GNMCX87R	31658	32349
19	GNMCY07F	37467	38035
19	GNMCZ04R	24360	24843
20	GNMAA26F	11314	11834
20	GNMAA34R	15825	16187
20	GNMBA46F	9402	9971
20	GNMBA83F	9481	10050
20	GNMBA83R	11039	11224
20	GNMBA92F	3716	4284
20	GNMBA92R	2437	2882
20	GNMCA93F	10570	11228
20	GNMCB42F	12316	12924
20	GNMCB42R	10720	11380
20	GNMCF68F	145	549
20	GNMCS13F	3147	3776
20	GNMCS19F	3135	3707
20	GNMCV43F	4932	5463
20	GNMCV43R	3493	4272
20	GNMCX01R	8929	9576
20	GNMCX32F	2827	3562
20	GNMCX32R	1753	2386
21	GNMAA29F	7970	8459
21	GNMAA29R	6973	7381
21	GNMAA79F	60518	61036
21	GNMAA79R	61382	61783
21	GNMAB13F	91199	91695
21	GNMAB13R	90065	90490
21	GNMAB15F	18098	18666
21	GNMAB15R	17086	17514
21	GNMAB38F	89228	89794
21	GNMAB49F	90018	90554
21	GNMAB53F	57858	58423
21	GNMAB76F	69791	70359
21	GNMAB76R	71099	71621
21	GNMBA08F	88398	88961
21	GNMBA08R	89946	90480
21	GNMBA62F	91149	91717
21	GNMBA62R	90149	90587
21	GNMBB08F	57329	57895
21	GNMBB08R	58629	59155
21	GNMCB36F	86172	86807

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCB36R	87700	88359
21	GNMCB40F	55242	55889
21	GNMCB40R	56581	57269
21	GNMCD13F	26267	26840
21	GNMCD13R	24739	25235
21	GNMCD14F	63282	63678
21	GNMCD22F	39214	39744
21	GNMCD89F	20621	21136
21	GNMCD89R	19243	19626
21	GNMCE04F	48264	48570
21	GNMCE16F	8955	9401
21	GNMCE16R	10419	10933
21	GNMCK72F	28120	28413
21	GNMCK72R	29725	30288
21	GNMCK82F	16224	16679
21	GNMCK82R	17910	18284
21	GNMCK92F	21493	21930
21	GNMCK92R	22899	23382
21	GNMCL15F	15475	16027
21	GNMCL15R	16323	16894
21	GNMCL18F	40761	41272
21	GNMCL18R	39414	39980
21	GNMCL35F	58131	58677
21	GNMCL35R	56683	57252
21	GNMCM02F	77632	78241
21	GNMCM02R	76049	76774
21	GNMCM42F	44749	45453
21	GNMCM51F	70991	71600
21	GNMCM51R	72059	72786
21	GNMCM59F	46177	46805
21	GNMCM59R	47628	48296
21	GNMCM67F	58893	59524
21	GNMCM67R	57080	57810
21	GNMCN01F	29541	30134
21	GNMCN03R	26156	26805
21	GNMCN04F	27776	28333
21	GNMCN07F	3923	4589
21	GNMCN20F	23898	24435
21	GNMCN20R	22616	23262
21	GNMCN38R	27178	27843
21	GNMCN42F	28721	29325
21	GNMCN42R	27182	27579
21	GNMCN48F	31545	32275
21	GNMCN48R	30254	30829
21	GNMCN56F	38871	39524
21	GNMCN56R	37891	38510

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCN74R	76122	76780
21	GNMCN76F	76705	77420
21	GNMCN87F	81602	82287
21	GNMCN87R	80523	81067
21	GNMCO27F	12120	12686
21	GNMCO27R	10881	11591
21	GNMCO37R	5718	6199
21	GNMCO40F	81181	81864
21	GNMCO40R	80087	80668
21	GNMCO41F	64583	65194
21	GNMCO41R	63303	63895
21	GNMCO62F	24786	25412
21	GNMCO62R	23316	23927
21	GNMCO69F	29872	30526
21	GNMCO69R	28732	29361
21	GNMCP53R	42566	43118
21	GNMCP68F	17274	17781
21	GNMCP68R	18590	19166
21	GNMCP78F	20880	21383
21	GNMCP78R	22662	23004
21	GNMCQ50F	52354	53060
21	GNMCQ50R	53094	53813
21	GNMCQ56F	24974	25298
21	GNMCQ56R	26318	26936
21	GNMCQ76F	26247	26921
21	GNMCQ76R	27401	28002
21	GNMCQ86F	45276	45978
21	GNMCQ86R	46636	47364
21	GNMCS08F	7772	7922
21	GNMCS22F	49814	50311
21	GNMCS62F	56147	56850
21	GNMCS82F	1052	1732
21	GNMCW22F	55865	56223
21	GNMCX02R	45344	45988
21	GNMCX09F	6251	6961
21	GNMCX09R	4718	5291
21	GNMCX16F	60624	61395
21	GNMCX16R	59855	60393
21	GNMCX60F	40043	40437
21	GNMCX60R	41031	41715
21	GNMCX74F	59663	60376
21	GNMCX74R	58460	59136
21	GNMCY45F	42419	43108
21	GNMCY45R	44124	44642
21	GNMCY64F	58336	59059
21	GNMCY64R	57045	57582

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCZ28F	82973	83440
21	GNMCZ28R	81697	82250
21	GNMCZ46F	28043	28521
21	GNMCZ46R	26632	27064
21	GNMCZ77F	22158	22671
21	GNMCZ77R	23472	24017
22	GNMAA30F	2165	2683
22	GNMAA30R	3510	3980
22	GNMBA03F	25307	25874
22	GNMCB39F	5720	6103
22	GNMCB39R	3638	3945
22	GNMCK48F	14049	14546
22	GNMCK48R	12667	13251
22	GNMCL28F	17498	18022
22	GNMCL28R	16124	16700
22	GNMCM15R	284	872
22	GNMCN47R	4247	4891
22	GNMCO22F	9932	10637
22	GNMCO22R	11087	11794
22	GNMCO23F	10489	11080
22	GNMCO23R	11662	12303
22	GNMCQ04F	25363	26023
22	GNMCQ04R	24009	24693
22	GNMCS17F	5636	6187
22	GNMCS20F	21715	22271
22	GNMCV45F	11101	11552
22	GNMCV45R	12185	12992
22	GNMCV65F	21938	22388
22	GNMCW11F	21268	21882
22	GNMCZ08F	9245	9752
22	GNMCZ56R	4001	4481
22	GNMCZ57F	92	610
22	GNMCZ57R	1391	1949
23	GNMAA32R	501	916
24	GNMAA32F	34126	34644
24	GNMAA78F	12905	13389
24	GNMAA78R	11993	12173
24	GNMAA92F	5430	5906
24	GNMAA92R	6781	6979
24	GNMBA28F	25580	26147
24	GNMBA28R	24581	24744
24	GNMBA64F	44750	45281
24	GNMBA64R	43715	43924
24	GNMCA03F	47978	48229
24	GNMCA11F	5227	5845
24	GNMCB53F	31273	31860

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
24	GNMCB53R	29940	30477
24	GNMCD60F	49318	49836
24	GNMCF28R	25897	26427
24	GNMCF33F	53794	54122
24	GNMCF33R	55250	55649
24	GNMCF55F	18332	18818
24	GNMCF55R	16670	17304
24	GNMCF88F	31085	31484
24	GNMCF88R	29803	30387
24	GNMCF94F	32330	32765
24	GNMCF94R	30474	31147
24	GNMCH39F	20653	21054
24	GNMCH71F	20501	20708
24	GNMCK74F	31152	31629
24	GNMCK74R	32456	33004
24	GNMCK94F	19578	20116
24	GNMCK94R	18366	18866
24	GNMCL74F	16135	16693
24	GNMCL74R	18346	18913
24	GNMCM07F	48543	49161
24	GNMCM07R	47427	48064
24	GNMCM72F	14897	15471
24	GNMCM72R	15789	16445
24	GNMCM86F	32288	32811
24	GNMCM86R	31171	31832
24	GNMCN14F	11430	12112
24	GNMCN14R	12286	12980
24	GNMCN59F	46864	47475
24	GNMCN59R	47935	48525
24	GNMCN60F	22771	23206
24	GNMCN60R	24286	24873
24	GNMCN91F	1694	2415
24	GNMCN91R	411	1022
24	GNMCO65F	4379	5044
24	GNMCO65R	5399	6070
24	GNMCO91F	54004	54574
24	GNMCO91R	55258	55836
24	GNMCP23F	21885	22586
24	GNMCP23R	20351	20912
24	GNMCP71F	53082	53612
24	GNMCP71R	54382	54958
24	GNMCQ33F	31360	32059
24	GNMCQ33R	30167	30816
24	GNMCS10F	52384	52999
24	GNMCS79R	9557	10245
24	GNMCV21F	13147	13602

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
24	GNMCV22R	14356	15028
24	GNMCV63F	11801	12250
24	GNMCV63R	12681	13494
24	GNMCV66F	53565	54040
24	GNMCV66R	52285	53073
24	GNMCV73R	42644	43443
24	GNMCV78F	23665	24161
24	GNMCV78R	24559	25362
24	GNMCX22F	8574	9293
24	GNMCX22R	9681	10320
24	GNMCX33F	23234	23994
24	GNMCX33R	21803	22176
24	GNMCX34F	23296	23994
24	GNMCX34R	21787	22355
24	GNMCX40F	28130	28866
24	GNMCX40R	29005	29697
24	GNMCX70F	10118	10635
24	GNMCX70R	11461	12043
24	GNMCX72F	27541	27741
24	GNMCY35F	32221	32765
24	GNMCY35R	31087	31546
24	GNMCY55F	45603	46359
24	GNMCY66R	2897	3449
24	GNMCY77F	29179	29866
24	GNMCY77R	27766	28254
24	GNMCY82F	9582	10184
24	GNMCY82R	11010	11421
24	GNMCY94F	6998	7520
24	GNMCY96F	22341	22994
24	GNMCY96R	23886	24294
24	GNMCZ37F	24346	24873
24	GNMCZ37R	23379	23953
25	GNMAA34F	450	701
25	GNMBA48F	4952	5519
25	GNMBA48R	4021	4222
25	GNMCA16F	14824	15438
25	GNMCB09F	22420	22990
25	GNMCB09R	23872	24453
25	GNMCD04F	2415	2961
25	GNMCD04R	1176	1633
25	GNMCK09F	3101	3667
25	GNMCK09R	4706	5009
25	GNMCK50F	8704	9235
25	GNMCK50R	10150	10511
25	GNMCM76R	3069	3807
25	GNMCM96F	13743	14447

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
25	GNMCM96R	12253	12967
25	GNMCN04R	15105	15705
25	GNMCN05F	13789	14465
25	GNMCP16F	9455	10151
25	GNMCP16R	8452	9076
25	GNMCP62R	9951	10498
25	GNMCX61F	2026	2420
25	GNMCX61R	3150	3850
25	GNMCY04F	10646	11249
25	GNMCY04R	12076	12645
25	GNMCZ20F	13438	13952
25	GNMCZ20R	12311	12861
26	GNMAA37F	45118	45485
26	GNMAA37R	46181	46702
26	GNMAA44F	38832	39198
26	GNMAA44R	37468	37990
26	GNMBB25F	2584	3149
26	GNMBB25R	4308	4852
26	GNMCA28F	34335	34909
26	GNMCB61F	37090	37496
26	GNMCE76F	146	542
26	GNMCE76R	1633	1980
26	GNMCF66F	27879	28279
26	GNMCF66R	29423	30059
26	GNMCL21F	39439	39981
26	GNMCL21R	37698	38064
26	GNMCL69F	3546	4121
26	GNMCL69R	4207	4797
26	GNMCM34R	3940	4653
26	GNMCM89F	5891	6343
26	GNMCM89R	7010	7718
26	GNMCM92R	30750	31399
26	GNMCN54F	28683	29364
26	GNMCN54R	27207	27807
26	GNMCN79F	51540	52223
26	GNMCN79R	50402	50941
26	GNMCO14F	33740	34469
26	GNMCO14R	35347	36067
26	GNMCQ26F	47379	47982
26	GNMCQ26R	48736	49406
26	GNMCS81F	36588	37281
26	GNMCS88F	19142	19409
26	GNMCS89R	17251	18014
26	GNMCV32F	18068	18514
26	GNMCV33F	30470	30781
26	GNMCV33R	28683	29309

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
26	GNMCV70F	41545	42025
26	GNMCV70R	42579	43282
26	GNMCV76F	30234	30720
26	GNMCV76R	31359	32063
26	GNMCV86R	42591	43300
26	GNMCV87F	41330	41805
26	GNMCV87R	42509	43300
26	GNMCX26R	42058	42510
26	GNMCY31R	1275	1860
26	GNMCY86F	27767	28402
26	GNMCY86R	26306	26736
26	GNMCZ13F	23798	24317
26	GNMCZ13R	24994	25572
26	GNMCZ64F	26763	27169
26	GNMCZ64R	27996	28534
26	GNMCZ71F	47451	47955
26	GNMCZ71R	46061	46606
26	GNMCZ95R	8013	8499
26	GNMCZ96R	8005	8483
27	GNMAA41F	3036	3402
27	GNMAA41R	2156	2677
27	GNMAA65F	58776	59296
27	GNMAA65R	60307	60457
27	GNMAB83F	38177	38746
27	GNMAB83R	36806	37326
27	GNMAB86F	20818	21390
27	GNMAB86R	21914	22429
27	GNMAB92F	21743	22226
27	GNMBA25F	28880	29408
27	GNMBA25R	27506	28043
27	GNMBA49F	40184	40752
27	GNMCB28F	15988	16497
27	GNMCB28R	14642	15180
27	GNMCB30R	14648	14996
27	GNMCB35F	33768	34099
27	GNMCB35R	32048	32548
27	GNMCB37F	31837	32567
27	GNMCB37R	30832	31421
27	GNMCB58F	30329	31041
27	GNMCB58R	31809	32460
27	GNMCD83F	15824	16290
27	GNMCD79F	63644	64156
27	GNMCD79R	62110	62364
27	GNMCF64F	41517	41871
27	GNMCF84F	518	956
27	GNMCF84R	1834	2533



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
27	GNMCF85F	6358	6815
27	GNMCF85R	7660	8383
27	GNMCH76F	22610	22966
27	GNMCH77F	22613	22953
27	GNMCK01F	62394	62733
27	GNMCK01R	60888	61415
27	GNMCK18F	66502	66997
27	GNMCK18R	65282	65724
27	GNMCK25F	27644	28213
27	GNMCK61F	32761	33107
27	GNMCK61R	30995	31329
27	GNMCK76F	19006	19542
27	GNMCK76R	17573	18122
27	GNMCK81F	61093	61511
27	GNMCK81R	59863	60445
27	GNMCK87F	36665	36996
27	GNMCK87R	34928	35498
27	GNMCL44F	38519	39001
27	GNMCL44R	37283	37863
27	GNMCL76F	49805	50300
27	GNMCL76R	48285	48854
27	GNMCM23F	27097	27789
27	GNMCM23R	25771	26483
27	GNMCN12F	8559	9239
27	GNMCN12R	7161	7752
27	GNMCN13F	68144	68833
27	GNMCN13R	66871	67394
27	GNMCN17F	36140	36815
27	GNMCN17R	35179	35753
27	GNMCN18F	55803	56468
27	GNMCN18R	54618	55229
27	GNMCN34F	59534	60268
27	GNMCN34R	19457	20056
27	GNMCN38F	17990	18719
27	GNMCN61F	18037	18594
27	GNMCN61R	19452	20056
27	GNMCN70F	32750	33421
27	GNMCN80R	37432	38115
27	GNMCN81F	38597	39329
27	GNMCN81R	37434	38096
27	GNMCO02R	59813	60549
27	GNMCO38F	51253	51930
27	GNMCO52R	33701	34400
27	GNMCO57F	37843	38469
27	GNMCO57R	36757	37320
27	GNMCP50F	7088	7522

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
27	GNMCP50R	5679	6058
27	GNMCO93R	2933	3510
27	GNMCS49F	11768	12343
27	GNMCV50F	28795	29193
27	GNMCV50R	27644	28413
27	GNMCV85F	21568	22089
27	GNMCV85R	22559	23351
27	GNMCW02F	47088	47658
27	GNMCW24F	56091	56713
27	GNMCY27R	5455	5536
27	GNMCY33F	37884	38598
27	GNMCY33R	39134	39678
27	GNMCY62F	39794	40529
27	GNMCY62R	41156	41683
27	GNMCY63F	39843	40316
27	GNMCY72F	15711	16330
27	GNMCY72R	14681	15239
28	GNMAA45F	4450	4816
28	GNMAA54R	4273	4733
28	GNMCD82F	1790	2266
28	GNMCD82R	3389	3826
28	GNMCO78F	6645	7293
28	GNMCO86F	6688	7310
28	GNMCO86R	8039	8651
28	GNMCW05F	6711	7331
28	GNMCZ09F	13148	13623
28	GNMCZ09R	11925	12279
29	GNMAA47F	27107	27473
29	GNMAA47R	25852	26322
29	GNMAA71F	19984	20503
29	GNMAA71R	21408	21826
29	GNMAA80R	20918	21282
29	GNMAB31F	32769	33333
29	GNMAB31R	31525	31942
29	GNMAB77F	21439	22007
29	GNMAB77R	22335	22857
29	GNMCA22F	9411	10028
29	GNMCB74F	26713	27450
29	GNMCB74R	25839	26476
29	GNMCD08F	17015	17514
29	GNMCD31F	19776	20146
29	GNMCF43F	26320	26631
29	GNMCF43R	27361	28023
29	GNMCF87F	30819	31269
29	GNMCF87R	32125	32845
29	GNMCH41F	30939	31379

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
29	GNMCK20F	2703	3104
29	GNMCK20R	4020	4346
29	GNMCL02F	32166	32619
29	GNMCL02R	33533	33884
29	GNMCL12F	360	831
29	GNMCL12R	1490	2039
29	GNMCL73R	32923	33504
29	GNMCL85R	10861	11425
29	GNMCM77F	17717	18313
29	GNMCM77R	16440	17172
29	GNMCN64F	6192	6750
29	GNMCN64R	7430	8018
29	GNMCN68F	30002	30712
29	GNMCN83F	34059	34776
29	GNMCN83R	32873	33458
29	GNMCO28F	7197	7872
29	GNMCO28R	8396	9089
29	GNMCO53F	20633	21342
29	GNMCO53R	22061	22663
29	GNMCO67F	1523	2102
29	GNMCO67R	2871	3524
29	GNMCP82F	30881	31419
29	GNMCP82R	29550	30117
29	GNMCS26F	30683	31168
29	GNMCS90F	16067	16703
29	GNMCS91R	16949	17757
29	GNMCW09F	3770	4381
29	GNMCY19F	14037	14742
29	GNMCY89F	7491	8173
30	GNMAA48R	1027	1347
30	GNMAB21R	3808	4233
30	GNMCC90F	7658	8102
30	GNMCL10F	2942	3470
30	GNMCL10R	4319	4883
30	GNMCM64R	7645	8319
30	GNMCO63F	12259	12933
30	GNMCO63R	11104	11789
30	GNMCP58F	8513	9047
30	GNMCP58R	10322	10707
30	GNMCV03F	10383	10724
30	GNMCV04R	8992	9749
30	GNMCX06F	11346	12072
30	GNMCX06R	12784	13418
30	GNMCX18F	11968	12726
30	GNMCX18R	13547	14189
30	GNMCX71F	9073	9653

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
30	GNMCX71R	7669	8353
30	GNMCY15F	3214	3933
30	GNMCY15R	1508	2079
31	GNMAA49F	7079	7444
31	GNMAA49R	5736	6260
31	GNMBA38F	692	1262
31	GNMBA79F	7797	8367
31	GNMCL32F	3721	4184
31	GNMCL32R	2230	2815
31	GNMCN88F	1761	2482
31	GNMCN88R	3292	3892
31	GNMCQ51F	3265	3909
31	GNMCQ51R	4295	5012
31	GNMCX63R	7311	8010
31	GNMCY61R	4386	4868
31	GNMCY91F	2862	3456
32	GNMAA52F	1739	2107
32	GNMAA52R	2617	3138
32	GNMAA89F	13148	13666
32	GNMAB90F	5624	6192
32	GNMAB90R	6600	7118
32	GNMCF38F	3403	3878
32	GNMCF38R	4584	5237
32	GNMCK38F	6598	7143
32	GNMCK38R	5207	5792
32	GNMCP85F	6949	7473
32	GNMCP85R	5282	5869
32	GNMCQ07F	10995	11623
32	GNMCQ07R	12678	13358
32	GNMCV23F	5455	5912
32	GNMCV24R	4006	4751
32	GNMCX13F	9897	10671
32	GNMCX13R	8710	9345
32	GNMCX45F	3857	4557
32	GNMCX45R	2724	3424
32	GNMCX57F	6426	6642
32	GNMCX57R	6424	6642
32	GNMCY06F	10183	10812
32	GNMCY06R	9259	9808
33	GNMAA57F	2954	3324
33	GNMAA57R	1924	2445
33	GNMAB30F	5838	6402
33	GNMAB30R	4864	5193
33	GNMAB48F	8816	9381
33	GNMBA50F	7809	8374
33	GNMBA50R	6161	6686

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
33	GNMCA25F	18305	18918
33	GNMCA80F	3189	3849
33	GNMCL88F	12941	13492
33	GNMCL88R	11494	12068
33	GNMCM57F	6934	7569
33	GNMCM57R	7814	8548
33	GNMCN49F	18067	18780
33	GNMCN49R	16729	17352
33	GNMCO54F	17815	18524
33	GNMCO54R	16974	17598
33	GNMCP59F	13173	13661
33	GNMCP59R	14688	15102
33	GNMCQ29F	13338	14036
33	GNMCQ29R	11998	12686
33	GNMCQ87F	5967	6647
33	GNMCQ87R	7354	7981
33	GNMCS47F	7736	8461
33	GNMCV30F	18040	18529
33	GNMCV31F	1808	2296
33	GNMCV31R	16473	17092
33	GNMCV32R	2897	3643
33	GNMCY12F	13632	14327
33	GNMCY12R	14891	15465
33	GNMCZ12F	14374	14860
33	GNMCZ12R	12879	13414
34	GNMAA59R	20271	20600
34	GNMAB63F	21594	22082
34	GNMAB87F	4234	4656
34	GNMAB93F	8137	8678
34	GNMAB93R	7021	7543
34	GNMBA26F	17728	18076
34	GNMBA31R	20426	20952
34	GNMBA60F	2998	3562
34	GNMBA60R	4887	5305
34	GNMBA89F	12688	13184
34	GNMBA89R	11336	11869
34	GNMBA90F	1963	2532
34	GNMBA90R	3410	3918
34	GNMBB10F	18931	19469
34	GNMBB10R	20494	20791
34	GNMCA73F	10776	11434
34	GNMCD09F	1576	2151
34	GNMCD09R	202	580
34	GNMCL40F	6504	7032
34	GNMCL40R	7906	8476
34	GNMCM41F	15257	15722

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
34	GNMCM41R	13646	14279
34	GNMCM84F	10143	10755
34	GNMCM84R	11418	12090
34	GNMCP65R	13124	13566
34	GNMCQ57F	1107	1637
34	GNMCQ57R	2550	3230
34	GNMCV15F	10810	11260
34	GNMCV16R	9522	10243
34	GNMCX35F	24683	25380
34	GNMCX35R	25964	26651
34	GNMCX48F	27078	27683
34	GNMCX48R	25636	26324
34	GNMCZ82R	4431	4970
35	GNMAA60R	9724	9928
35	GNMAA81R	42064	42495
35	GNMAB09F	29605	30171
35	GNMBA37F	1865	2426
35	GNMBA37R	755	1265
35	GNMCA66F	14095	14490
35	GNMCB95F	29548	30210
35	GNMCB95R	28364	28994
35	GNMCD41F	4298	4824
35	GNMCD41R	2960	3326
35	GNMCD49F	47011	47510
35	GNMCD49R	45671	46032
35	GNMCD52F	46968	47374
35	GNMCE13F	44763	45068
35	GNMCE13R	43656	44020
35	GNMCK86F	32959	33472
35	GNMCL94F	45671	46185
35	GNMCL94R	44388	44948
35	GNMCM08F	32206	32865
35	GNMCM08R	33769	34324
35	GNMCN16F	11716	12326
35	GNMCN16R	10117	10693
35	GNMCN33F	2863	3568
35	GNMCN33R	4337	4927
35	GNMCO11F	117	667
35	GNMCO11R	1479	2220
35	GNMCO20F	41254	41858
35	GNMCO20R	42840	43385
35	GNMCP03R	15135	15820
35	GNMCP33F	33871	34386
35	GNMCP33R	31902	32446
35	GNMCS31F	25024	25611
35	GNMCS80F	26013	26719

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
35	GNMCV20F	11142	11598
35	GNMCV21R	9547	10242
35	GNMCV41F	1508	1764
35	GNMCV41R	2993	3375
35	GNMCV46F	19148	19638
35	GNMCX37F	10287	10978
35	GNMCX75F	16758	17496
35	GNMCX75R	17915	18615
35	GNMCY38F	35286	36002
35	GNMCY38R	36447	37009
35	GNMCZ63F	17628	18139
35	GNMCZ63R	16308	16866
36	GNMAA61F	17639	18003
36	GNMAA61R	19148	19669
36	GNMAB14F	9325	9894
36	GNMAB14R	10480	10900
36	GNMAB23F	5098	5510
36	GNMAB23R	5999	6420
36	GNMBA04F	7545	8114
36	GNMBA04R	8552	9087
36	GNMCB81F	1908	2616
36	GNMCB81R	1189	1739
36	GNMCD86F	266	753
36	GNMCD86R	1917	2276
36	GNMCL29F	19188	19732
36	GNMCL46F	5977	6459
36	GNMCL46R	6855	7431
36	GNMCL71R	2286	2862
36	GNMCN74F	8750	9460
36	GNMCN76R	7557	8138
36	GNMCP37R	5055	5645
36	GNMCS39F	3380	4120
36	GNMCV57F	6730	7217
36	GNMCV57R	7760	8463
36	GNMCX54F	7658	7977
36	GNMCX54R	6197	6884
36	GNMCY85R	6699	7077
36	GNMCZ06F	17782	18302
36	GNMCZ73F	15242	15755
37	GNMAA64F	11674	12041
37	GNMAA64R	10619	11088
37	GNMAB25F	25946	26508
37	GNMAB25R	27013	27437
37	GNMAB32R	446	844
37	GNMAB89F	2515	3085
37	GNMAB89R	3403	3923

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
37	GNMAB91F	19524	19900
37	GNMAB91R	18389	18909
37	GNMCA84F	8986	9651
37	GNMCA92F	10174	10831
37	GNMCB13F	28388	28959
37	GNMCB44F	17203	17885
37	GNMCB44R	16050	16676
37	GNMCB72F	15012	15708
37	GNMCB72R	16365	16857
37	GNMCD32F	4633	5112
37	GNMCD32R	2775	3142
37	GNMCD34F	21613	22123
37	GNMCD34R	23152	23452
37	GNMCD43F	23745	24277
37	GNMCF03F	23267	23766
37	GNMCF03R	21815	22457
37	GNMCK16F	12575	13127
37	GNMCK69R	981	1281
37	GNMCL41F	4846	5357
37	GNMCL41R	6380	6932
37	GNMCM06R	17272	17986
37	GNMCM82F	14731	15358
37	GNMCM82R	15814	16507
37	GNMCQ08F	20211	20740
37	GNMCQ08R	18866	19521
37	GNMCQ59F	16099	16826
37	GNMCQ59R	15132	15853
37	GNMCSS58F	16358	17054
37	GNMCV94F	21841	22327
37	GNMCV94R	20477	21267
37	GNMCX07F	25522	26245
37	GNMCX07R	26310	26960
37	GNMCX69F	10320	10866
37	GNMCX69R	11842	12449
37	GNMCX93F	7947	8360
37	GNMCX93R	6445	6970
37	GNMCY18F	10778	11193
37	GNMCY18R	9630	10203
37	GNMCY67F	26216	26689
37	GNMCY67R	24586	24992
37	GNMCZ87F	28035	28543
37	GNMCZ87R	26386	26930
38	GNMAA74F	185	702
38	GNMAB59F	370	710
38	GNMCM68F	512	991
39	GNMBA35F	3187	3756



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
39	GNMCL49F	518	1006
39	GNMCM19F	3839	4413
39	GNMCM19R	2735	3480
39	GNMCM68R	3717	4374
39	GNMCN15F	11	695
39	GNMCN15R	1589	2036
39	GNMCS14F	2485	3018
39	GNMCV29F	4010	4481
39	GNMCV30R	2621	3321
39	GNMCZ91F	4347	4839
39	GNMCZ91R	3070	3594
40	GNMAA75F	1493	2009
40	GNMBA84F	14749	15315
40	GNMBA84R	13039	13401
40	GNMBB27F	7061	7629
40	GNMBB27R	5877	6280
40	GNMCA65F	10805	11468
40	GNMCF01F	9566	10068
40	GNMCF01R	7689	8249
40	GNMCF52F	13446	13800
40	GNMCF52R	14807	15448
40	GNMCK41F	1322	1894
40	GNMCK41R	1	549
40	GNMCN01R	8094	8669
40	GNMCN02F	6573	7152
40	GNMCY39F	12214	12932
40	GNMCY39R	11377	11773
40	GNMCZ75F	4573	5040
40	GNMCZ75R	3272	3824
41	GNMAA82F	1944	2123
41	GNMAA82R	540	848
41	GNMCA09F	4155	4769
41	GNMCL45F	5831	6382
41	GNMCL45R	7014	7592
41	GNMCX84F	6407	7029
41	GNMCX84R	4937	5630
41	GNMCZ07F	753	1256
41	GNMCZ07R	2139	2681
42	GNMAA85F	33488	34005
42	GNMAA85R	34461	34906
42	GNMAB11F	27021	27587
42	GNMAB16F	16195	16762
42	GNMAB16R	17262	17683
42	GNMAB51F	32336	32901
42	GNMAB64F	9048	9478
42	GNMBA52F	25714	26279

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
42	GNMBA52R	26930	27429
42	GNMBA63F	25856	26418
42	GNMCA10F	9199	9803
42	GNMCA90F	12306	12957
42	GNMCD76F	43170	43607
42	GNMCD80F	25485	25983
42	GNMCD80R	24100	24472
42	GNMCD81F	25467	25981
42	GNMCF21F	42792	43250
42	GNMCF21R	43820	44488
42	GNMCF79F	19953	20412
42	GNMCF79R	18429	19107
42	GNMCH08F	10638	10983
42	GNMCH61F	35608	36017
42	GNMCK58F	11541	12006
42	GNMCK58R	13419	13981
42	GNMCM03R	37448	38182
42	GNMCM48F	1	622
42	GNMCM48R	1215	1878
42	GNMCO34F	11655	12379
42	GNMCO34R	10537	11201
42	GNMCO70R	39192	39848
42	GNMCO84F	24768	25509
42	GNMCO84R	24098	24770
42	GNMCP29F	40509	41019
42	GNMCP29R	38958	39359
42	GNMCQ60F	38032	38565
42	GNMCQ69F	8563	9122
42	GNMCQ69R	6981	7666
42	GNMCS69F	3213	3921
42	GNMCV25F	17625	18095
42	GNMCV26R	16021	16633
42	GNMCX46F	4775	5450
42	GNMCX46R	3438	4125
42	GNMCX88R	17104	17778
42	GNMCY37F	7223	7838
42	GNMCY37R	5827	6323
42	GNMCY69F	22213	22853
42	GNMCY69R	21279	21796
42	GNMCZ85F	19300	19813
43	GNMAA86F	5244	5760
43	GNMAA86R	4311	4783
43	GNMCS54F	3163	3797
43	GNMCV84F	1109	1600
43	GNMCV84R	2002	2781
44	GNMAA87F	26931	27447

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
44	GNMAA87R	27952	28361
44	GNMAA90F	6714	7230
44	GNMAA90R	8124	8276
44	GNMAB27F	4036	4606
44	GNMAB27R	4904	5327
44	GNMCD11F	4246	4813
44	GNMCD11R	5623	6146
44	GNMCQ17F	6327	7009
44	GNMCQ17R	7631	8317
44	GNMCQ67F	1410	2013
44	GNMCQ67R	2571	3261
44	GNMCS92F	21392	22037
44	GNMCS94R	22779	23479
44	GNMCS96F	22613	22986
44	GNMCX79F	14815	15344
44	GNMCX79R	16086	16760
44	GNMCZ44F	19312	19820
44	GNMCZ44R	20486	21049
45	GNMAA88F	3827	4313
45	GNMBA05F	7835	8403
45	GNMBA05R	6395	6824
45	GNMCZ39F	143	619
45	GNMCZ39R	1545	2114
46	GNMAA94F	5740	6254
46	GNMAA94R	6575	7044
46	GNMAB29F	659	1225
46	GNMAB29R	1871	2298
46	GNMAB78F	16523	16951
46	GNMAB78R	15145	15666
46	GNMCA05F	4467	5137
46	GNMCD25F	11261	11830
46	GNMCD25R	10056	10529
46	GNMCD45F	4725	5273
46	GNMCD45R	3455	3826
46	GNMCD72F	12772	13251
46	GNMCD72R	14201	14542
46	GNMCK45F	6690	7258
46	GNMCK45R	5280	5857
46	GNMCK53F	9263	9636
46	GNMCK53R	10581	11122
46	GNMCN62R	20059	20606
46	GNMCO72F	11911	12654
46	GNMCO72R	10592	11291
46	GNMCS38F	8266	8953
46	GNMCS50F	9604	10313
46	GNMCY09F	18777	19443

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
46	GNMCY09R	20339	20885
46	GNMCY48F	13317	14054
46	GNMCY48R	12373	12900
47	GNMAB03F	39285	39849
47	GNMAB03R	40395	40825
47	GNMAB57F	8125	8631
47	GNMAB62F	5129	5697
47	GNMAB72F	25957	26522
47	GNMAB72R	26812	27332
47	GNMBA39F	10581	11112
47	GNMBA39R	9272	9805
47	GNMBA68F	33182	33747
47	GNMBA68R	32098	32634
47	GNMBB31F	46909	47485
47	GNMBB31R	45477	45996
47	GNMCB64F	8634	9225
47	GNMCB64R	9880	10466
47	GNMCD39F	26389	26882
47	GNMCF18F	42086	42592
47	GNMCF18R	40473	41111
47	GNMCF47F	46147	46634
47	GNMCF47R	44893	45560
47	GNMCK29F	14259	14820
47	GNMCK29R	12913	13476
47	GNMCK33F	11732	12246
47	GNMCK33R	10377	10759
47	GNMCK51F	19259	19619
47	GNMCK51R	17899	18248
47	GNMCL24F	21022	21491
47	GNMCL24R	19374	19922
47	GNMCL66F	34263	34768
47	GNMCL66R	35478	36049
47	GNMCM30R	35959	36642
47	GNMCM37R	18280	18787
47	GNMCM36F	28250	28958
47	GNMCM73F	29393	30074
47	GNMCM73R	28267	28921
47	GNMCM93F	1262	1971
47	GNMCM93R	2446	2878
47	GNMCO45F	14719	15397
47	GNMCO45R	15952	16635
47	GNMCO49F	38118	38828
47	GNMCO49R	39315	39845
47	GNMCO60F	21461	22152
47	GNMCO60R	19964	20648
47	GNMCO83R	16405	17063

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
47	GNMCP08F	4600	5318
47	GNMCP08R	5704	6436
47	GNMCP12F	44482	45180
47	GNMCP12R	43247	43929
47	GNMCQ70F	28264	28919
47	GNMCQ70R	27232	27902
47	GNMCS79F	28111	28860
47	GNMCX52F	44094	44441
47	GNMCX52R	45425	46100
47	GNMCX73F	8582	9157
47	GNMCX73R	7456	8141
47	GNMCY08F	22073	22785
47	GNMCY08R	20965	21539
47	GNMCY17F	13457	14071
47	GNMCY17R	12199	12710
47	GNMCY60F	4726	5396
47	GNMCY60R	3394	3937
47	GNMCZ72F	26112	26584
47	GNMCZ72R	27111	27642
48	GNMAB10F	45864	46429
48	GNMAB10R	46823	47246
48	GNMAB26F	18205	18771
48	GNMAB26R	17068	17496
48	GNMAB46F	39600	40166
48	GNMAB71F	36266	36835
48	GNMAB71R	35583	35981
48	GNMBA10F	24081	24641
48	GNMBA10R	25627	26158
48	GNMCA01F	2669	3310
48	GNMCA69F	24907	25573
48	GNMCA77F	44240	44904
48	GNMCB68F	48529	49183
48	GNMCB68R	49751	50229
48	GNMCD05F	61093	61524
48	GNMCD05R	47029	47548
48	GNMCD24F	41436	41982
48	GNMCD24R	42664	43161
48	GNMCD70F	43366	43798
48	GNMCE06F	45703	46081
48	GNMCE07R	46605	47129
48	GNMCE90F	6380	6925
48	GNMCE90R	5283	5799
48	GNMCF24F	56963	57448
48	GNMCF24R	55581	56243
48	GNMCF70R	50946	51263
48	GNMCF93F	46705	47157

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
48	GNMCF93R	48122	48692
48	GNMCH40F	24168	24458
48	GNMCH64F	60688	61022
48	GNMCK08F	12988	13530
48	GNMCK08R	11548	12144
48	GNMCK31F	48379	48939
48	GNMCK31R	47177	47731
48	GNMCK46F	13297	13814
48	GNMCK46R	12071	12654
48	GNMCK56F	29433	29963
48	GNMCK56R	27927	28487
48	GNMCK70F	41792	42156
48	GNMCK70R	43324	43888
48	GNMCL05F	22552	23041
48	GNMCL05R	21742	22293
48	GNMCL61F	15321	15724
48	GNMCL61R	14006	14449
48	GNMCL86F	23803	24358
48	GNMCL86R	22389	22965
48	GNMCM40F	60172	60784
48	GNMCM40R	43992	44623
48	GNMCM49R	63033	63741
48	GNMCM60F	28595	29249
48	GNMCM60R	27285	27929
48	GNMCM95F	21768	22424
48	GNMCM96F	52482	53159
48	GNMCO12F	49771	50550
48	GNMCO12R	49060	49698
48	GNMCO76F	26934	27624
48	GNMCO76R	25392	26062
48	GNMCO90F	10121	10652
48	GNMCO90R	8744	9318
48	GNMCP81F	26207	26575
48	GNMCP81R	27441	28017
48	GNMCQ16R	1	661
48	GNMCQ36R	13779	14476
48	GNMCQ48F	44157	44770
48	GNMCQ48R	43032	43754
48	GNMCQ64F	12475	13200
48	GNMCQ66F	12668	13370
48	GNMCQ66R	13747	14472
48	GNMCQ89F	16922	17619
48	GNMCV06F	48695	49152
48	GNMCV07R	47510	48231
48	GNMCV11F	26723	27238
48	GNMCV12R	27836	28452

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
48	GNMCV18F	35744	36244
48	GNMCV19R	34456	35205
48	GNMCV82F	8278	8644
48	GNMCV82R	8280	8645
48	GNMCV96F	45990	46492
48	GNMCV96R	44480	45162
48	GNMCX28F	42946	43632
48	GNMCX28R	44129	44767
48	GNMCX29F	59233	59998
48	GNMCX29R	58344	58984
48	GNMCX42F	22170	22862
48	GNMCX42R	23577	24264
48	GNMCX50F	29838	30232
48	GNMCX50R	30956	31633
48	GNMCX80F	30061	30735
48	GNMCX80R	31536	32224
48	GNMCY70F	13009	13629
48	GNMCY70R	11725	12281
48	GNMCZ84R	4001	4533
49	GNMAB32F	401	684
50	GNMAB35F	17857	18274
50	GNMBA70F	14615	15180
50	GNMBA70R	15849	16383
50	GNMCB20R	20852	21453
50	GNMCB89F	12569	13223
50	GNMCB89R	14045	14508
50	GNMCF67F	4524	4879
50	GNMCF67R	3257	3858
50	GNMCH89F	19690	20140
50	GNMCH89R	18248	18535
50	GNMCK49F	20201	20965
50	GNMCK49R	18771	19297
50	GNMCM01F	2158	2770
50	GNMCM01R	708	1314
50	GNMCN41F	21893	22570
50	GNMCN41R	23128	23476
50	GNMCO04F	2174	2638
50	GNMCO04R	837	1541
50	GNMCO82F	16481	17139
50	GNMCO82R	17538	18219
50	GNMCP61F	13046	13330
50	GNMCP61R	14605	15154
50	GNMCS33F	27679	28393
50	GNMVC22F	21920	22410
50	GNMVC23R	20644	21369
50	GNMVC47F	17147	17659

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
50	GNMCV47R	18206	18900
50	GNMCV58R	1132	1905
50	GNMCV59R	1242	1814
50	GNMCX41F	3977	4725
50	GNMCX41R	5212	5916
50	GNMCY22F	22454	23103
50	GNMCY29R	22461	23008
50	GNMCY71F	10076	10646
50	GNMCY71R	9041	9543
50	GNMCZ52F	20698	21140
50	GNMCZ52R	22156	22569
50	GNMCZ94F	3890	4317
50	GNMCZ94R	5230	5743
50	GNMCZ95F	3902	4346
50	GNMCZ96F	3902	4346
51	GNMAB39F	5946	6511
51	GNMBA51F	8613	9139
51	GNMBA51R	6844	7329
51	GNMCL84F	7136	7509
51	GNMCL84R	8501	9072
51	GNMCO08R	979	1711
51	GNMCY10F	1194	1921
51	GNMCY10R	50	610
51	GNMCZ33F	3405	3947
51	GNMCZ33R	4668	5244
52	GNMAB40F	15814	16385
52	GNMCB93F	7437	8109
52	GNMCB93R	8732	9304
52	GNMCF69F	9103	9470
52	GNMCF69R	7871	8573
52	GNMCF92F	2901	3235
52	GNMCF92R	1359	2018
52	GNMCL51F	16830	17360
52	GNMCL51R	18234	18580
52	GNMCM61R	12794	13378
52	GNMCN24F	1	676
52	GNMCN24R	1452	2016
52	GNMCO31F	17039	17664
52	GNMCO31R	18187	18861
52	GNMCS05F	11540	12169
52	GNMCX49F	10221	10402
52	GNMCX49R	8569	9260
52	GNMCX96R	4202	4835
52	GNMCZ83F	11839	12349
52	GNMCZ83R	13065	13609
53	GNMAB50F	81	306



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
54	GNMAB60F	4573	5141
54	GNMCD66F	258	750
55	GNMAB66F	1314	1623
55	GNMCB73F	3597	4316
55	GNMCB73R	5062	5644
55	GNMCM35F	3120	3883
55	GNMCM35R	2555	3288
55	GNMCX47F	5496	6201
55	GNMCX47R	4289	4982
55	GNMCM34F	5585	6305
56	GNMAB79R	1	246
57	GNMAB80F	19923	20432
57	GNMAB80R	21103	21624
57	GNMBA07F	14530	15093
57	GNMBA07R	15847	16378
57	GNMCB11R	30694	31243
57	GNMCB47F	29518	30234
57	GNMCB47R	28242	28881
57	GNMCD55F	32780	33171
57	GNMCE88F	13260	13679
57	GNMCE88R	14546	15067
57	GNMCF06F	16859	17358
57	GNMCF06R	15242	15921
57	GNMCF40F	18554	19027
57	GNMCF40R	19698	20365
57	GNMCF50F	20435	20910
57	GNMCF50R	21576	22262
57	GNMCF63F	30402	30884
57	GNMCF63R	28818	29412
57	GNMCF86R	32361	33020
57	GNMCK71F	8763	9100
57	GNMCK71R	10055	10613
57	GNMCL95F	3811	4223
57	GNMCL95R	2299	2901
57	GNMCM67F	20529	21206
57	GNMCM67R	19529	20102
57	GNMCP09F	2860	3520
57	GNMCP09R	1894	2615
57	GNMCP70F	17618	18104
57	GNMCP70R	18924	19511
57	GNMCP79F	8875	9372
57	GNMCP79R	10275	10855
57	GNMCQ41F	20359	21104
57	GNMCQ41R	19619	20345
57	GNMCQ44F	10270	10898
57	GNMCQ44R	11575	12244

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
57	GNMCS16F	20638	20868
57	GNMCS86F	30569	31246
57	GNMCV34F	21537	21988
57	GNMCY40F	20132	20855
57	GNMCY40R	19153	19716
57	GNMCY49R	26133	26607
57	GNMCY80F	8452	8787
57	GNMCY80R	6998	7416
57	GNMCY90F	19373	19946
57	GNMCZ43F	31206	31711
57	GNMCZ43R	32436	32921
58	GNMAB82F	9525	10095
58	GNMAB82R	8509	9029
58	GNMCO58R	15112	15768
58	GNMCY78R	3411	3857
58	GNMCY83F	11793	12472
58	GNMCY83R	10643	11053
59	GNMAB85F	2737	3302
59	GNMAB85R	1900	2305
59	GNMCO33F	2304	2941
59	GNMCO33R	1257	1881
59	GNMCX86F	2826	3461
59	GNMCX86R	1441	2128
59	GNMCZ32F	1619	2126
59	GNMCZ32R	2661	3195
60	GNMAB95F	13774	14279
60	GNMAB95R	15289	15810
60	GNMCA30F	937	1556
60	GNMCD44F	303	826
60	GNMCF04F	9775	10276
60	GNMCF04R	8305	8976
60	GNMCF90F	3862	4310
60	GNMCF90R	2510	3187
60	GNMCH28F	9435	9696
60	GNMCK30F	13554	14101
60	GNMCK30R	12158	12740
60	GNMCM05F	9295	9874
60	GNMCM05R	10879	11616
60	GNMCM55F	10074	10731
60	GNMCM55R	10796	11542
60	GNMCS87F	13103	13751
60	GNMCW39F	15206	15851
60	GNMCX55F	12701	12889
60	GNMCX55R	13822	14516
60	GNMCX62R	1554	2237
61	GNMBA06F	22890	23457

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
61	GNMBA06R	24229	24758
61	GNMCB04F	30158	30722
61	GNMCB04R	28612	29214
61	GNMCB21F	23862	24428
61	GNMCB21R	25186	25806
61	GNMCB63R	3796	4094
61	GNMCB86F	23284	23998
61	GNMCB86R	24021	24623
61	GNMCD18F	31187	31608
61	GNMCF95F	20692	21018
61	GNMCF95R	19232	19872
61	GNMCK40F	11307	11811
61	GNMCK65F	9007	9517
61	GNMCL04F	20077	20543
61	GNMCL04R	18687	19271
61	GNMCL20F	27968	28464
61	GNMCL20R	29257	29840
61	GNMCL22F	13417	13939
61	GNMCL22R	14872	15438
61	GNMCL29R	34192	34771
61	GNMCL53F	1518	2034
61	GNMCL53R	214	686
61	GNMCL90R	8315	8896
61	GNMCM65F	15441	16117
61	GNMCM65R	14289	14994
61	GNMCM71F	10516	11122
61	GNMCM71R	11703	12405
61	GNMCO61F	14512	15200
61	GNMCO61R	13255	13946
61	GNMCQ79F	15902	16644
61	GNMCQ79R	16726	17426
61	GNMCQ90F	2342	3073
61	GNMCQ90R	804	1426
61	GNMCQ95F	19198	19483
61	GNMCQ95R	20653	21277
61	GNMCS24F	19718	20379
61	GNMCS46F	18786	19366
61	GNMCV12F	30913	31415
61	GNMCV13R	31908	32632
61	GNMCY25F	25038	25729
61	GNMCY25R	26701	27270
62	GNMBA12F	7833	8334
62	GNMBA66F	8661	9232
62	GNMBA66R	9606	10138
62	GNMBB30F	3235	3799
62	GNMBB30R	4483	5016

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
62	GNMCB05F	4772	5096
62	GNMCB05R	6111	6717
62	GNMCD67F	7723	8233
62	GNMCF78F	3478	3931
62	GNMCM43F	12550	13285
62	GNMCM43R	11540	12127
62	GNMCP28F	3321	3756
62	GNMCP28R	1814	2235
62	GNMCP67F	2320	2824
62	GNMCP67R	3943	4497
62	GNMCV62F	8092	8582
62	GNMCV62R	9694	10487
62	GNMCX39F	7125	7796
62	GNMCX39R	5729	6265
62	GNMCZ55F	5209	5724
62	GNMCZ55R	3782	4320
62	GNMCZ76F	4455	4947
62	GNMCZ76R	3027	3553
63	GNMBA13F	14825	15391
63	GNMBA13R	13165	13703
63	GNMBA14F	12491	13059
63	GNMBA14R	13757	14281
63	GNMBA80F	12477	12855
63	GNMCB32F	472	756
63	GNMCD42F	20565	21089
63	GNMCF07F	13708	14215
63	GNMCF07R	12522	13201
63	GNMCK47F	10432	10931
63	GNMCK47R	9275	9813
63	GNMCK91R	9054	9617
63	GNMCN32F	16696	17346
63	GNMCN32R	17927	18521
63	GNMCS55F	1461	2208
63	GNMCX85R	14727	15427
63	GNMCZ11R	17115	17610
63	GNMCZ18F	1990	2479
63	GNMCZ18R	3109	3667
63	GNMCZ34F	13696	14216
63	GNMCZ34R	12451	13003
64	GNMBA27F	2420	2987
64	GNMBA27R	649	1182
64	GNMCK68F	8858	9142
64	GNMCN47F	8600	9323
64	GNMCQ47F	5300	5761
64	GNMCQ47R	3904	4632
64	GNMCZ45F	6005	6471

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
64	GNMCZ45R	7509	8073
64	GNMCZ89F	6722	7164
65	GNMBA40F	9256	9800
65	GNMBA40R	7884	8418
65	GNMCK42F	8125	8438
65	GNMCK42R	9146	9679
65	GNMCK43F	14839	15396
65	GNMCK43R	13196	13745
65	GNMCM11R	2515	3190
65	GNMCO03F	4056	4557
65	GNMCO03R	5332	6065
65	GNMCO32F	10209	10877
65	GNMCO32R	11348	11993
65	GNMCO78R	1107	1782
65	GNMCQ10F	9012	9752
65	GNMCQ10R	10149	10831
65	GNMCQ36F	19	522
65	GNMCZ17F	1839	2369
65	GNMCZ17R	3149	3711
65	GNMCZ24R	3485	4030
65	GNMCZ50R	2017	2356
65	GNMCZ51F	3684	4187
65	GNMCZ51R	5216	5657
66	GNMBA45F	5960	6527
66	GNMBA45R	4417	4948
66	GNMBB01F	3556	4094
66	GNMBB01R	2060	2598
66	GNMCA23F	4257	4873
66	GNMCN50F	6431	7098
66	GNMCN50R	5020	5625
66	GNMCO46F	1766	2443
66	GNMCO46R	706	1195
66	GNMCQ15F	1788	2506
66	GNMCQ15R	994	1686
66	GNMCZ67F	1099	1592
66	GNMCZ67R	2554	3093
66	GNMCZ68F	1130	1584
67	GNMBA56R	828	1363
67	GNMCZ01F	1176	1497
67	GNMCZ01R	2672	3147
68	GNMBA58F	11648	12214
68	GNMBA58R	10145	10680
68	GNMBB14F	7190	7758
68	GNMBB14R	8579	9037
68	GNMCD71F	502	959
68	GNMCL54F	10328	10882

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
68	GNMCL54R	11852	12293
68	GNMCN39F	13282	13967
68	GNMCN39R	11911	12477
68	GNMCP34F	12249	12751
68	GNMCP34R	10521	11087
68	GNMCP74F	9533	10032
68	GNMCP74R	8395	8982
68	GNMCV35F	11085	11475
68	GNMCV35R	12496	12972
69	GNMBA67F	10755	11332
69	GNMBA67R	9691	10167
69	GNMCA68F	138	798
69	GNMCA95F	7720	8389
69	GNMCB19F	7635	8181
69	GNMCB62F	4968	5465
69	GNMCB62R	6482	7170
69	GNMCD88F	6048	6546
69	GNMCD94F	10463	10960
69	GNMCD94R	12298	12546
70	GNMBA87F	8256	8675
70	GNMBA87R	6890	7385
70	GNMCA76F	9130	9792
70	GNMCB96F	10306	11006
70	GNMCB96R	11786	12359
70	GNMCD20F	2427	2973
70	GNMCD20R	3980	4417
70	GNMCE77F	10510	10866
70	GNMCF49F	13718	14204
70	GNMCF49R	11782	12414
70	GNMCF57F	24615	25081
70	GNMCF57R	23522	24203
70	GNMCF81R	14890	15469
70	GNMCK10F	32790	33342
70	GNMCL64F	2279	2735
70	GNMCL64R	1098	1594
70	GNMCM94F	15929	16589
70	GNMCM94R	16990	17708
70	GNMCO70F	6253	6962
70	GNMCP46F	28269	28572
70	GNMCP46R	29399	29799
70	GNMCP69R	14839	15383
70	GNMCQ60R	4262	4932
70	GNMCV71F	1570	2085
70	GNMCV71R	316	1151
70	GNMCV72F	29887	30336
70	GNMCV72R	28290	29022

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
70	GNMCV79F	9283	9798
70	GNMCV79R	8344	9079
70	GNMCV90F	15009	15476
70	GNMCV90R	16482	17299
70	GNMCX43F	15135	15898
70	GNMCX43R	14040	14726
70	GNMCY28F	27547	28277
70	GNMCY28R	26646	27207
70	GNMCZ35F	32742	33250
71	GNMBB05F	1960	2525
71	GNMBB05R	3344	3515
71	GNMCQ43F	7860	8357
71	GNMCQ43R	8617	9224
71	GNMCV39F	3444	3908
71	GNMCV39R	1967	2637
71	GNMCV40R	1959	2698
71	GNMCX05F	7245	7867
71	GNMCX05R	9020	9558
71	GNMCY02F	11233	11831
71	GNMCY02R	10519	11074
71	GNMCZ22F	12199	12719
71	GNMCZ22R	10978	11535
71	GNMCZ62F	5934	6428
71	GNMCZ62R	7330	7740
72	GNMBB26F	8760	9327
72	GNMBB26R	7556	8099
72	GNMCA20F	13469	14085
72	GNMCA70F	3932	4596
72	GNMCA83F	16236	16703
72	GNMCD73F	16569	17077
72	GNMCD73R	15204	15432
72	GNMCF25F	16016	16451
72	GNMCF25R	14647	15269
72	GNMCM14R	10622	11346
72	GNMCS42F	5706	6424
72	GNMCS67F	9325	10026
72	GNMCS91F	3912	4620
72	GNMCY88F	1473	2157
73	GNMCA21F	82	736
73	GNMCA82F	3679	3975
73	GNMCL92F	4664	5205
73	GNMCL92R	5485	5880
73	GNMCM22R	708	1428
73	GNMCM29R	1947	2683
73	GNMCO16R	1657	2311
73	GNMCV93F	347	830

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
73	GNMCV93R	1879	2561
74	GNMCA78F	5557	6224
74	GNMCB76F	5584	6225
74	GNMCB76R	4398	4946
74	GNMCF14R	1573	2079
74	GNMCF30F	9638	10051
74	GNMCF30R	8180	8703
74	GNMCL96F	16170	16676
74	GNMCL96R	14728	15294
74	GNMCN51F	7918	8654
74	GNMCN51R	6999	7601
74	GNMCN65F	14177	14895
74	GNMCN65R	12918	13517
74	GNMCN66R	12940	13557
74	GNMCO71F	2786	3525
74	GNMCO71R	3980	4683
74	GNMCP02F	9531	10254
74	GNMCP02R	10574	11268
74	GNMCQ12F	1447	2032
74	GNMCQ12R	416	1065
74	GNMCV61F	12114	12501
74	GNMCV61R	10643	11335
74	GNMCX30F	18292	19013
74	GNMCX30R	20178	20810
74	GNMCX94F	21616	22251
74	GNMCX94R	20632	21246
74	GNMCY73R	13205	13774
74	GNMCZ16F	14762	15283
74	GNMCZ16R	13378	13933
74	GNMCZ19F	23465	23941
75	GNMCA94F	3978	4349
75	GNMCB55F	2185	2819
75	GNMCB55R	3259	3917
75	GNMCL13F	4716	5241
75	GNMCL13R	2852	3443
75	GNMCL80F	4341	4845
75	GNMCL80R	2903	3473
75	GNMCM78R	2146	2889
75	GNMCV07F	1	479
75	GNMCV08R	1221	1918
75	GNMCV10F	5011	5503
75	GNMCV11R	3483	4212
75	GNMCV36F	4495	4971
75	GNMCV36R	3285	3527
75	GNMCV52F	3868	4351
75	GNMCV52R	2491	3098



Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
75	GNMCX78F	3135	3788
75	GNMCX78R	4397	5087
76	GNMCB02F	2416	2977
76	GNMCB02R	3352	3966
76	GNMCB07F	2416	2984
76	GNMCB07R	3352	3954
76	GNMCB12F	2416	2974
76	GNMCB12R	3314	3966
76	GNMCY54R	5129	5668
77	GNMCB54R	4435	4640
77	GNMCB85R	2747	3439
77	GNMCF72F	4490	4924
77	GNMCF72R	5936	6649
77	GNMCK68R	568	1128
77	GNMCM47F	3316	3922
77	GNMCM47R	4346	4995
77	GNMCX10F	6886	7627
77	GNMCX10R	5801	6436
77	GNMCZ08R	3508	3954
78	GNMCB60F	1387	2047
78	GNMCB60R	2757	3429
79	GNMCB65F	287	954
79	GNMCB65R	1598	2122
79	GNMCY11F	3301	4016
79	GNMCY11R	2339	2911
81	GNMCD15F	1	519
82	GNMCO75R	2040	2712
83	GNMCD53F	466	1013
84	GNMCF02F	1638	2132
85	GNMCF15F	3019	3523
85	GNMCF15R	1257	1932
85	GNMCY26F	1834	2612
85	GNMCY26R	555	1120
86	GNMCF34F	1890	2365
86	GNMCF34R	259	918
86	GNMCS21F	1678	2392
87	GNMCF36F	274	748
88	GNMCF71R	10636	11160
88	GNMCL78F	2657	3153
88	GNMCL78R	4106	4665
88	GNMCN10F	7355	8034
88	GNMCQ46F	10928	11579
88	GNMCQ46R	9882	10586
88	GNMCQ88F	574	1196
88	GNMCQ88R	2017	2549
89	GNMCF76F	1981	2406

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
89	GNMCF76R	1	500
89	GNMCF80F	920	1305
89	GNMCF80R	2032	2709
89	GNMCL16F	247	763
89	GNMCL16R	1226	1784
89	GNMCN80F	788	1493
89	GNMCQ82F	1969	2554
89	GNMCQ82R	401	1093
89	GNMCZ19R	2292	2850
123	GNMCH27F	119	501
145	GNMCP17R	991	1517
152	GNMCP17F	81	776
153	GNMCK10R	756	1346
153	GNMCS01F	823	1344
153	GNMCX08F	332	1001
153	GNMCX08R	1513	2144
153	GNMCZ35R	695	1204
154	GNMCK14R	1	352
155	GNMCK59R	1	445
156	GNMCK78F	8693	9133
156	GNMCM20F	2049	2694
156	GNMCM20R	632	1335
156	GNMCS15F	3468	4033
156	GNMCS66F	4788	5488
156	GNMCV01F	1890	2231
156	GNMCV02R	166	894
156	GNMCV68F	2538	3032
156	GNMCV68R	3475	4231
157	GNMCL11F	295	834
157	GNMCL11R	1294	1846
158	GNMCL30F	1756	2276
158	GNMCL30R	448	1028
158	GNMCV49R	4317	5164
159	GNMCL48F	5961	6264
159	GNMCL48R	4706	5280
159	GNMCQ61R	922	1535
159	GNMCS71F	314	1024
159	GNMCY32F	8722	9407
159	GNMCY32R	10063	10584
159	GNMCY51F	8917	9628
159	GNMCY51R	10406	10895
160	GNMCL58R	4560	5111
160	GNMCN05R	9955	10528
160	GNMCO37F	8602	9262
160	GNMCV04F	951	1370
160	GNMCV05R	1971	2742

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
161	GNMCN26F	4880	5549
161	GNMCN26R	3911	4533
161	GNMCQ77F	6238	6857
161	GNMCQ77R	5035	5760
161	GNMCZ58F	3859	4357
161	GNMCZ58R	2375	2916
162	GNMCN45F	1676	2346
162	GNMCN45R	400	977
163	GNMCN92F	507	1223
163	GNMCN92R	1454	2112
163	GNMCY42F	1142	1860
163	GNMCY42R	2736	3290
163	GNMCZ36F	4711	5225
163	GNMCZ36R	6070	6592
164	GNMCN94F	3000	3708
164	GNMCN94R	1705	2265
165	GNMCQ54F	51	677
165	GNMCQ54R	936	1639
166	GNMCS72F	19	432
166	GNMCS74R	1	181
167	GNMCV58F	314	808
167	GNMCZ38F	6858	7329
167	GNMCZ38R	5443	5996
168	GNMCX26F	1	660
169	GNMCX92F	341	587
170	GNMCY65R	195	567

## APPENDIX B

## MenB ORFs

## Number 1 ORF

```

1  ..TTTCGGCGA CATCGGGGT TTGAAGTCA ATGCCCCGT CAAATCGCA
51  GGCGTATTGG TCGGGCGGT CGGCGCTATC GGACTTGACC CGAAATCCTA
101 TCAGGCGAGG GTGCGCTCG ATTTGACGCG CAAGTATCAG TTCAGCAGGG
151 ACGTTTCGCG GCAAACTCTG ACTTCGGGCG TTTTGGGCGA GCGATCATCT
201 GGGCTGACAG AGGGGCGGCA CACGGAACAT CTGCTGCGG GCGACACCAT
251 CTCGTAACCG AGTTCTGCAA TGGTCTGGA AAACCTTATC GGCAAATCTA
301 TGACGAGTTT TCCGAGAAA AATGCCGACG GCGGCAATCG GGAAGAAAGC
351 GCCGAATAA

```

## Number 2 ORF

```

1  ..ATTTTGATAT ACCTCATCGG CAAGAATCTA GGTTGCGCGG TCTTCTTCTT
51  TCAGGAACGC CCGGAAAGG ACGGAAACCT TTTTAAATG GTCAAATCTC
101 GTTCCATGCG CGACGGCTTG TATTGACGCG GCATTCGCTC GCCGCGAGGA
151 GAACGCTGGA CACCGTTCGG CAAAAAAGT CGTGCGGCA GTGTGGACGA
201 ACTGCTGAA TTATGGAATA TCTTAAAGG CGAGATGAGC CTGGTCGGCC
251 CCGCGCGCTG GCTGATGCAA TATCTGCCCG GTGACGACA CTTCGAAAC
301 CGCGCGCACG AATGAAACCG CGCATTAACC GGCTGGGCG AGGTCAACGG
351 GCGCAACGCG CTCTGTTGGG ACGGAAATCT CGCTGCGAT GTTTGGTATA
401 TCGACCACTT CAGCTGTGCG CTGACATCA AAATCTACT GCTGACGTT
451 AAAAAAGTAT TAATCAAGGA AGGGATTTCG GCACAGGGCG AACA_aCAT
501 GCCCGCTTTC ACAGGAAACG GCAAACTCGG CGTGTGCGT GCGGGCGGAC
551 ACGGAAAGT CGTTCGCGAC CTTGCGCGCG CACTCGGCG GTACAGGGA
601 ATCGTTTTTC TGGACGACCG CGCAACAGCG AGCGTCAAG GCTTTTCCGT
651 CATCGGACG ACGCTGCTGC TTGAAACAG TTTATGCCCG GAACAATAGC
701 ACGTCGCGGT CGCGTGCAGG AACCAACGCA TCGCGCGCA AATCGCGAA
751 AAGCGCGCG CGCTCGGCTT CGCCCTGCC GTACTGGTTC ATCGGAGCG
801 GACCGTCTCG CCTTCTGCAA CAGTCGACA AGGCAGGCTC GTTATGCGCA
851 AAGCGGTCG..

```

## Number 3 ORF

```

1  ..AACCATATGG CGATTGTCAT CGACGAATAC GCGCGCACAT CCGGCTTGTT
51  CACCTTTGAA GACATCATCG AGCAAAATCG CGCGGAAATC GAAGACGAGT
101 TTGACGAAGA CGATAGCGCC GACAATATCC ATGCGCTTTC TTGACACAG
151 TGGCGCATCC ATGACGCTAC CGAAATCGAA GACATCAACA CCTTCTCGGG
201 CACGGAATAC AGCATCGAAG AAGCCGACAC CATT_GSGCG CTTGGTCATT
251 CAAGAGTTGG GACATCTGCC CGTGCAGCGG GAAAAAGTCC TTATCGCGGG
301 TTTGCACTTC ACCGTGCGAC GCGCGACAA CGCGCGCTG CATACGCTGA
351 TGGCGACCG CGTGAAGTAA GC..... ACCGCG GTTCTCTGCA
401 CAGTTTAG

```

## Number 4 ORF

```

1  ATGCGCGGCG GCAGGCGGGA TTCGTTACC GTGAGATTG TCGAAGGTTT
51  GCGTTTTCG CATATGAGGA AAGTCATCGA CGCAACGCCG GACATCGGAC
101 ACGACACCAA AGGCTGGAGC AATGAAAAAC TGATGGCGGA AGTTGCCGCC
151 GATGCTTCA CGGCGCAATC TGAAGGCCAG TTTTCCCCG ACAGCTACGA
201 AATCGATGCG GCGCGAGTGT ATTTGAGAT TTACCAAAAC GCCTACAAAG
251 GCGATGCAAC CGCGCTGAA TGAAGGATG GGAAGCAGG CAGGACGGGC
301 TGCTTTATAA AAACCTTATG GAAATGCTGA TTATGGCGAG CTGGTCTGAA
351 AAGGAAACAG GGCATGAAGC CGAaCGAC CATGTGCTT CGGTCTCGT
401 CAACGCGCTG AAAATCGGTA TCGCGCTGCA AACCGAssCG TCCGTGATTT

```

-2-

```

451  ACGGCATGGG  TCGGGCATAC  AAGGGCAAAA  TCGSTAAAGC  CGACCTGGCG
501  CGCGACACGC  CGTACAACAC  CTACACGGCG  GCGCGTCTGC  CGCCAACCCC
551  GATTGGCGTG  CCC..

```

**Number 5 ORF**

```

1  CGTTTCAAAA  TGTTAACTGT  GTTGACGGCA  ACCTTGATTG  CCGGACAGGT
51  ATCTGCGGCC  GGAGGCGGTG  CGGGGGATAT  GAAACAGCCG  AAGGAAGTGG
101  GAAAGGTTT  CAGAAAGCAG  CAGCGTTACA  GCGAGGAGAA  AATCAAAAAC
151  GAACGCGCAC  GGCTTGGGCG  AGTGGGCGAG  CGGGTTAATC  AGATATTATC
201  GTTGCTGGGA  GGGGAAACCG  CTTTCAAAA  GGGGCGAGCG  GGAACGGCTC
251  TGGCAACCTA  TATGCTGATG  TTGGAACGCA  CAAAATCCCC  CGAAGTCGGC
301  GAACGCGGCT  TGGAAATGGC  CGTGTCGCTG  AAGCGGTTTG  AACGACGGGA
351  AATGATTAT  CAGAAATGGC  GGCAGATTGA  GCCTATACGC  GGTAAAGGCG
401  AAAAACGCG  GGGGTGGCTG  CGGAACGTGC  TGAGGGAAAG  AGGAAATCAG
451  CATCTGACG  GACGGGARGA  AGTGTGGCT  CAGGCGGACG  AAGGACAG

```

**Number 6 ORF**

```

1  AACCTCTAG  CCGGCCGCA  GACCACATCC  GTCATCGCAA  ACATCGCCGA
51  CAACCTSCAA  CTGSCCAAG  ACTACGGCAA  AGTACACTGG  TTGCGCTCCC
101  CGCTCTCTG  GCTCTGAA  CAATCGACA  ACATCATCGG  CAACCTGGGG
151  TGGGGGATTA  TCGTTTAA  CATCATCGT  AARGCGTAG  TGATATCATT
201  GACCAACGCC  CTATCGGCT  CTATGGGCAA  AATGCGTGCC  GCGCGCCCA
251  AACTGCAAGC  CATCAAGAG  AAATACGGCG  ACGACCGTAT  GCGCGCAAC
301  CAGGCGATGA  TACGACTTTA  CACGACGAG  AAATCAACCC  CGGCTGGGGG
351  GCTCGCTGCG  TATGCTGTC  GCAATCCCG  CTCTCATCGG  ATTGATTATG
401  GCAATTCTCG  CTTCCGTAGA  ATTGCGGAG  GCACCTTGGC  TGGGTTGGAT
451  TACCGACTC  AGCCGCGCG  ACCCTACTA  CATCTGCGC  ATCATTTATG
501  CGGCAACGAT  GTTCCGCCAA  ACTTATCTGA  ACCCGCGCGC  GACCGACCG
551  ATGcagGGA  AATGATGAA  AATCATGCGC  TTGGTTTCT  CgSwCTGTG
601  CTTCTCTTC  CTTGCGCGk  TGGTATTGTA  CTGGGTASTC  AACAACTCC
651  TGACCATGC  CAGCAATGG  CACATCAACC  GCAGCATCGA  AAAACAACG
701  GCCCAGGCG  AAGTCGTTT  CTA

```

**Number 7 ORF**

```

1  . . GCGCTCTAA  TCATCGAATT  ATTGACGGGA  ACGGTTTATC  TTTTGGTTGT
51  NAGCGGSGCT  TTGGGSGGT  CGGGCATTCG  TTACGGGCTG  ACCGGAGTGA
101  CGCGCTCGCG  CGTCTTGACC  GNGCGTCTGC  TTTCCGGGCT  GGGATTATTG
151  TTCTTCAAG  CCAACACGC  CGTTAGRAAA  GTTGAAACSG  ATTCAATATCA
201  GGAATTGGAT  CGCGGACAT  ATCTCGAAAT  CTTCCGACAC  ACAGCGGCGA
251  ACGGTTACGA  AGTT  TTTAT  CGCGTAGC  ACTGCGAGCG  TCAAAATACG
301  GGGCAAGAG  AGCTTGAACC  AGGAACTCG  GCGCTCATTG  TCCGCAAGGA
351  AGGCAACCTT  CTTATTATCA  CACACCTTA  A

```

**Number 8 ORF**

```

1  ATGTWIGATT  TCGGTTTGG  CGArCTGGT  TTTGTGGCA  TTATCGCCCT
51  GATWGLCTC  GGCOCGGAAC  GCSTGCCGA  GCGCGCCGC  AYCSCGAGAC
101  GGCCTCATCG  CAGCTTGCA  CGCTTTGTG  GcAGCTCAA  ACAGAAATTT
151  GRACACTCAA  TCGAAGTGA  AGACTGAG  AAGGCAAGC  AGGAATTTGA
201  AGCTGCGCGC  GCTCAGGTC  GAGACGCT  CAAGAAACC  GGTACGGATA
251  TSGAAGGCA  TCTGCAAGC  ATTTCCGAG  GTCTCAAGC  TTGGGAAAA
301  CTGCGCAAG  AGCGGACAC  TGCGATTTC  GGTGTGATG  AAAAGGCAA
351  TCGGCT  TCG  CGATGCGGCA  AACACCTTAT  CAGACGGCAT  TTCCGACGTT
401  ATGCGCTC..

```

**Number 9 ORF**

```

1 ATGCAAGCAC GGCCTGCTGAT ACCTATTCTT TTTTCAGTTT TTATTTTATG
51 CGC.TGCGGG ACACCTGACAG GTATTCCATC GCATGGCGGgA GKTAACGcCT
101 TTgCGGTcGA ACAAGAActT GTGGCCGcTT CTGCCAGAGC TGCCGTtAAA
151 GACATGGATT TACAGGCATT ACACGGACGA AAgTTGCAT TGtACATTGC
201 CACTATGGGC GACCAGGTTT CAGGcAGTTT GACAGGGGGG TGcCTACTCC
251 ATTGATGCAC kGtTwCstGG CGAATACATA AACAGCCCTG CGGTCGGTAC
301 CGATTACACC TATCCACGTT ACgAAACCAc CGCTGAACA ACATCAGGGC
351 GTTTGACAGG TTTAACACTT TCTTTATCTA CACTTAATGC CCCTGCACCT
401 TCTCGCACCC AATCAGACGG TAGGGGAAGT AAgAGCAGTC TGgGCTtAAA
451 TATTGGCGGG ATGGGGGATT ATCGAAATGA AACCTTGACG ACTAACCCGC
501 GCGACACTGC CTTTCTTTCC CACTTGGTAC AGACCGTATT TTTCTGCGC
551 GGCATAGACG TTGTTTCTCC TGCCAATGCC GATACAGATG TGTTTATTAA
601 CATCGACGTA TTCGGAAcGA TACGCAACAG AACCgAAATG..

```

**Number 10 ORF**

```

1 ..GG.CAGCACA AAAACAGGC GGTtGAACGS AAAACCCGTA TTTACGAIGA
51 TGCCGGGTAT GATATTGGCG GTATTACAGS GCGCATTCTC CGCAAAATAT
101 ATCCCCCGGT TCGGGCTTCA AATTtTCTTC ATCCTGTTTT TtAACCGCGT
151 CGCATTCAAA ACACtCGATA CCGACCCtCA GACGGCATCC CGCCCGCTGC
201 CCGGACTGCC CgGACTGACT CGGgTTTCCA CACTGTTCCG CACAATGTGG
251 AGCTGGGTcG GcRTAGGCGG CGgTTCACTT TCCGTCCCTC TCTTAATCCA
301 CTGCGGGTTc CcCGCCcATA AAGCCATCGG CACATCATCC GGCCTTGcCT
351 GGCCGATTGC ACTCTCGCGG GCAATATCGT ATCTGCTCAA CGGCTGAAAT
401 ATTGcAGGAT TGCCCGAAGG GTCACTGGCG TtCTTTTACC TGCCCGCGCT
451 CGCCGTCTCT AGCGCGGcAA CcATTGcCTT TGCCCGGCTC GGTGTCAAAA
501 CCGCCCAcAA ACTTtCTCTT GCCAACTCA AAAAATC.TT CGGCATTATG
551 TTGCTTTTGA TTGCCGGAAt AATGCTGTAC AACCTGCTTT AA

```

**Number 11 ORF**

```

1 ..GGAAACGGAT GGCAGGCAGA CCCCgAACAT CCGCTGCTCG GcCTTTTTGC
51 CGTCAGTAAT GTATCGATGA CGCTTGCTTT TGTCGGAATA TGTCGGTTGG
101 TGcATTATtG CTTTTCGGGA ACgGTtCAAg TGtTTGTGTT TGCGGCACtG
151 CTCAAACTTT ATGCGCTGAA GCGGGTTtAT TGgTTGtGT TGcAGTTTGT
201 GCTGATGGCG GTTGcCTATG TCCACCGCTc CGGTATAGAC CGGcAGCCCG
251 CGTCAACGTT CGCGGGCTCG CAGCTGCGcT TGCGCGGGTT CAGGCAGGG
301 TTGATGCAGG TCTCGGTACT GGTGCTGCTc CTTTCAGAAA TTGGAAAGATA
351 A

```

**Number 12 ORF**

```

1 ATGAAAACCC CACTCCTCAA GCCTCTGCTN ATTACCTCGC TTCCCGTTTT
51 CGCCAGTGTt TTTACGCGCG CcTCATCGT CTGGCAGCTA GCGGAACCCA
101 AGCTCGCCAT GcCCTTCGTA CTGGCAtCA CTGCGCGGG CTTTGTGcAT
151 TTGGACAACc NcNTGACCGG ACgGCTNAAA AAcATcATCA CCACCGTCGC
201 CcTGTTCAcC CcTCTCCTCG TcACGGcCA ARGACCCCTC GGCACAGGGC
251 TGCCCTTCAT CcTCGcCATG ACCTGATGA CTt.CG.CTT CACCATTTTA
301 GGCGCGGTCG ...

```

**Number 13 ORF**

```

1 ATGAATATGC TGGGAGCTTT GGCAAAAGTC GcCAGCCTGA CGATGGTGTC
51 GCGCGTTTtG GgATTtGTGC GcGATACGGT CATTGGCGGG GCATTTCGGCG
101 CGGGTATGGC GACGAGTGCg TTTTtTGTCG CGTTCAAACT GcCCAACCTG
151 CTTCCGCCGC TGTtTGCGGA GGGGGGgTTT GCCCAAGCGT TTGTGCGCAT
201 TTTTGGCGGA TACAAGGAAA CcGCTTCAAA AGAGGCGG.C GAAcCTTTTA
251 TCCGCCATGT GCGCGGGATG CTGTCTtTG TACTGGTTAT CGTTACCGCG
301 CTGGGCATAC TTGCGCGGCC TTGGGTGATT TATGTtTCCG CACCcAGGTT

```

```

351 TTGCCCAAGA TGCCGACAAA TTTCAGCTCT CGATCGATT GCTGGGGATT
401 ACGTTTCCTT ATATATTATT GATTCCCTG TCTTCATTG TCGGCTCGGT
451 ACTCAATCTC TATCAATAAGT TCGCATGTC GCGGTTTAGC CCAC.GTTTC
501 TGAACGTGTC GTTTATCGTA TTGCGCTGT TTTGCTGCC GTATTTCGAT
551 CGCGCCGTTA CGCGCGYGGC GTGGCGGTC TTTGTGGGG GCATTTTGCA
601 ACTCGTTC CAATCGCCTT GCTGGCGAA ACTGGGCTT TTGAACCTGC
651 CCAAACTGAG TTTCARAAGT CGCGCGTCA ACOCGGTGT GAAACAGATT
701 CGCGCTGCGA TTTTgGGCGT GAgCTGGCG CAGGTTCTT TGGTGAICAA
751 CACGATTTTC CGCTCTATC TGCATCGGG CAGGTTCTT TGGATGATT
801 ACGCGACGCG CATGATGGAG CTGCGCAGG CGGTGCTGGG GCGCGCACTC
851 GGATGATT TTGCTGCGAG TTGTCTCAA CACTCGCAA ACCAGATAC
901 GGACAGTTT TCGCGCTGC TCGCATGGG TTTGCGCTG TGCATGCTgc
951 TGACGCTGCC GCGCGgGGT GGACTGGCG TGTGTGCTT cCGctGGTg
1001 GCGACGCTGT TTATGTACCG CGWATTTAGC CTGTTGAGC CGCAGATGAC
1051 GCAACACGCG CTGATTGCCT ATTCTTTCG TTTAATCGCG TTAATCATGA
1101 TTAAGTGTT GGCACCCGGC TTCTATGCG GGCAAAACAT CAWAmGCC
1151 GTCAAAATCG CATCTTCAC GTCATCTGC mCGCAGTTGA TGAACCTTgS
1201 CTTTAYCGCG CCACTrAAC tCaTTCGGAC TTTGCGTTG CATGCTGTG
1251 GCGCGGTGA TCAATGCGG ATTGTTGTT TACCTGTTC GCNACACGG
1301 TATTTACCAA CTGG. CAAG GGTGGGCGAG GTTCTT.AG CAAAAATGCT
1351 GCTCTGCTC GCGGTGA

```

**Number 14 ORF**

```

1 atGATTAAAA TCAAAAAAGG TCTAAACCTG CCATCGCGG GCAGACCGGA
51 GCAAGCCGTT LACGACGGCC CGGCCATTAC CGAAGTCGCG TTGCTGGCG
101 AAGAATATGC CGGTATCGCG CCTCGATGA AAGTCARAGA AGCGGATGCC
151 GTCAAAAAAG GCGAAGTGCT GTTTGAAGAC AAAAAGAATC CGGCGTGGT
201 GTTTACTGCG CGGCTTCAG GAAAAATGCG CGCGATTAC CGTGGCGAAA
251 AGCGCGTACT TCACTGACTC GTGATTGCGG TTGAAGCAA CGACGAATC
301 GAGTTTGAAC GCTACGCACC TGAAGCGCTG GCAAACTTAA CGCGCGAAGA
351 AGTGGCGCGC AACCTGATCC AATCGGTTT GTGGACTGCG CTGCGCACCC
401 GTCCGTTCAG CAAATTCCT GCGTCGATG CCGAGCGGTT GCCCATCTTC
451 GTCAATGCGA tGGACACCAA TCCG..

```

**Number 15 ORF**

```

1 ..GCnCGnAAA TCATCCATCC CC..nACGTC GTAGGCGCTG AAGCCAACTG
51 GTTTTTTATG GTAGCCAGTA CGTTTGATG TGCTTGAT TGGTATTTTG
101 TTAAGTAAA AATCGTGAAG CGGCAATTGG GCCTTATCA ATCAGATTTG
151 TCACAAGAAG AAAAAGACAT TCGGCATTCC AATGAATCA CGCCTTTGGA
201 ATATAAAGGA TTAATTGGG CTGGCGTGGT GTTGTGTGCC TTATCGCGCC
251 TATTGGCTTG GAGCATGCTC CCGCGCGAG GTATTTTGCG TCATCTGA
301 ACAGGATTGG TTTCGGGTC GCGGTTTTTA AAATCGATTG TGTGTTTTAT
351 TTTCTGTGTG TTGCACTGC CGGCGATTGT TTATGGCGCG GTAACCGGAA
401 GTTTGCGCGG CGAACAGGAA GTCGTTAATG CgmyGGCCGA ATCGATGAGT
451 ACTCTGGsGC TTThTTTgsw CAkATCTTT TTGCGCGCAC AGTTTGTGCG
501 ATTTTTTAAAT TGGACGAATA TTGGGCAATA TATTGCCGTT AAAGGGGCGCA
551 CGTCTCTAAA AGAAGTGGCG TTGGGCGGCA GCGTGTGTTT TATCGTTTTT
601 ATTTTAAATT GTGCTTTTAT CAATCTGATG ATAGGCTCCG CCTCCGCGCA
651 ATGGGGCGGTA ACTGCGCGGA TTTTCGTCCC TATGCTGATG TTGGCGGGCT
701 ACGGGCGCGA AGTCATTCAA GCGGCTTACC GCATCGGTGA TTGCTTACC
751 AATATTATTA CGCGGATGAT GAGTTATTTC GGCTGATTA TGCGACGGT
801 GrkCmmuTAC AAAAAAGATG CCGGCGTGGG TaCGcTGATT wCATGATGT
851 TGCGGTATTC CGCTTTCTTC TTGATTGCTT GGATGCTCTT ATTCTGCATT
901 TGGGTATTGT TTTTGGGCTT GCGGTGCTT CCGGCGGCGC CCACATTCTA
951 TCCCGCACCT TAA

```

**Number 16 ORF**

```

1 ..ACAGCGCGCG CAGCAGGTTn CnCGTCTTC GTTTTCGTAA CGGACAGTCA
51 GGTGGAGGTG TTGGGAACA TCCAGACCGC AGTGGAAACA GGTTTTTTTT

```

-5-

```

101 ATGGCATTTC GGTTCGTCT GTGTTTGGTG CGGCGGCACA AGACTCGGCA
151 ATgGCTTCGC GCAGTGCCTG TATACCGGTA TTTTCAGCAA CGGAAATGCG
201 GACGGcGgCA ATTTTCCCGC CAGCGTCGCG CCATATGCCC GTGTTTgTT
251 CTTCAgACGG CAGCAGCTCG GTTTTGTGT ACACCTTgAT GCACGGaTA
301 TCGCCGCGAT GGATTTCCTG CAGTACGTTT TCCAGCTCTT CAATCTGCTG
351 TCcGCTGTTC GGAGCGGCGG CATCGACGAC GTGCAGCAGC ACATCgGcTT
401 gCGCGGTTC TTCCAGCGTG GCgGAAAAGG CGGAAATCAG TTTgTGCGGC
451 agATyGCTnA CGAATCGCAC GGTATCGGTC AGGATAATGC TCCATTcGGG
501 ACT..

```

**Number 17 ORF**

```

1 ..GGCCATTACT COGACCCGAC TTGGAAGCCG CGTTTGNGCG GCCGCCGTCT
51 GCCGTATCTG CTTTATGGCA CGCTGATTGC GGTATTGTG ATGATTTTGA
101 TGCCGAATCT GGGCAGCTTC GGTTCGGCT ATGCGTCGCT GCCGCGTTTG
151 TCGTTCGCGC CGCTGATGAT TCGCTGTGTA GACGTGTCGT CAAATATGCG
201 GATGACGCGC TTTAAGATGA TGGTCGGCGA CATGGTCAAC GAGGAGCAGA
251 AAA.NTACGC CTAACGGATT CAAAGTTTCT TAGCAAAATAC GGGCGCGGTC
301 GTGGCGGCGA TTCTGCGGTT TGTGTTTGGC TATATCGGTT TGGCGAACAC
351 CGCCGANAAA GCGGTTGTGC CGCAGACCGT GGTGCTGGCG TTTTATGTGG
401 GTGCGCGGTT GCTGGTGATT ACCAGCGCGT TCACGATTTT CAAAGTGAAG
451 GAATACGANC CGGAACCTA GCGCGTTAC CACGGCATCG ATGTCGCGCG
501 GAATCAGGAA AAAGCCAAC TGGATCGCACT CTTAAAA.CC GCGC..

```

**Number 18 ORF**

```

1 ATGTTGTGCC GTAAAACGAC CGCGCGGCTT TTGGCGCATA COTTGATGCT
51 GAACGGCTGT ACGTTGATGT TGTGGGGAAT GAACAACCCG GTCAGCGAAA
101 CAATCAACCCG NARAACGTT GNCAAGAGCC AAATCGNGN CTTGCGTGTG
151 GTTGCCGAAG ACAATGCCCA ATTGGAAGAG GGCACGCTGG TGATGATGGG
201 CGGAAAATAC TGGTTCGTGC TCAATCCCGA AGATTGCGCG AA.NTGAAG
251 GNATTTTGAN GGCAGGGCTG GACARACCT TCCAAATAGT TNAGGATACC
301 CCGAGCTATG C.TGCCACCA AGCCTGCGC GTCAAACTCG GATCGNCTGG
351 CAGCCAGAAAT...

```

**Number 19 ORF**

```

1 ..GTCAGTCTG TACTGCCTAT TACACACGAA CGGACAGGGT TTGAAGGTGT
51 TATCGGTTAT GAAACCCATT TTTCAGGGCA CGGACATGAA GTACACAGTC
101 CGTTCGATCA TCAATATTCA AAAAGCACTT CTGATTTCAG CGGCGGTGTA
151 GACGGCGGTT TTAAGTTTGA CCAACTTCAT CGAACATGGT CGGAAATCCA
201 TCGGAGGAT GAATATGACG GGCCGCAAGC AGCG.ATTAT CGGCCCCCG
251 GAGGAGCAAG GGATATATAC AGCTATTATG TCARAGGAAC TTCACAAAA
301 ACAAGACTA GTATTGTCCC TCAAGCCCCA TTTTCAGACC GTTGCTAGA
351 AGAAAAATGCC GGTGCCGCT CTGGT..

```

**Number 20 ORF**

```

1 ATGAAAAAAC AAATCACGCG AGCCGTAATG ATGCTGTCTA TGATTGCCCC
51 CGCAATGCA AACGCTTGG ACAATCAGGC ATTTGAAGAC CAAATGTTCC
101 ACACGCGGGC AGATGCACG ATGCAG...

```

**Number 21 ORF**

```

1 ATGAATAAAA CTCTCTATCG TGTAATTTTC AACGCAAAAC GTGGGGCTGT
51 GcTAGCGGTT GCTGAAACTA CCAAGCGGA AGTAAAGC GTGCGGATA
101 GTGATTCAAG CAGCGCTCAT GTGAAATCTG TTCCTTTTGG TACTACTCAT
151 GCACCTGTTT Gtg.CGTtAc AAATATCTTT TCTTTTTCTT TATTGGGCTT
201 TTCTTTATGT TTGGCTGTAG GtAcGgYCAA TATTGCTTTT GCTGATGGCA

```



251 TT..

**Number 22 ORF**

```

1 ATGAATACTC CTCCTTTTGT CTGTTGGATT TTTTGAAGG TCATCGACAA
51 TTTCCGGCGAC ATCGGGCGTTT CGTGGCGGCT CGCCCGTGT TTGCACCGCG
101 AACTCGGTTG GCAGGTGCAT TTGTGGACGG ACGATGTGTC GCGCTTGCCT
151 GCGCTTTGCC CTGATTGGCC CGATGTTCCC TCGGTTATC AGGATATTCA
201 TGTCCGCACT TGGCATTCGG ATCGGCGAGA TATTGATACC GCG..

```

**Number 23 ORF**

```

1 ..TTGTTCTCCTG GTGTNAAAGT GGGGCGTTTT TTCAGCAGTC CGGCGACGTG
51 GTTTCCGGGNC AAGAGCCCTG TAAATCAGCG GGTGTTGCGG CTGATATNCGG
101 ACGAGTGGCG GCA..ACTTCG GTACGTTGGA AAATAGNCGC AAGTCGCAC
151 AGCCTGTGGC TCTGCACGCT GCTCGGAATG CTGGTGTGCG TATTGTTGCT
201 GCTTTTGGTG CGGCAATATA CGTTCAACTG GGAAGACAGC CTGTTGAGCA
251 ATGCGCGTTC GGTACGCGCG GTGGAAATGT TGGCATGCTC GCGCTCGAA
301 CTCGGTTTCC CTGTCCCGGA TCGCGCGTGC GTCATCGAAG GCGCTCTGAA
351 CGGCAATATT GCGGATGCGC GGGCTTGGTC GGGGCTGCTG GTCGNCAGTA
401 TCGCTGCTA NCGCATCCTG CGCGCGCTG..

```

**Number 24 ORF**

```

1 ..CAGAAGATT TGTGAGAAT TTCTTTATGG GGGTTGGGCG GCGTGTTTTT
51 CGGGGTGTCC GGTCTGOTAT GTTTTCTTT GGGCGTTTCT TT..GAGTGGC
101 CCTGTTTTTC GGGTGTTCCT TTTCGGGGTT CGGAGCAGGG GACGTTTGTG
151 GGCAGTACGG GGGTTTCTTT GAGTGTGTTT TCAGCTTTGT TTCC..GGGCT
201 CGTCCGGCTG CTTGTGGGTT TGAGCTGTGT CGGACAGTTG CG..GTTTGA
251 CCGCGTTTTT CTTGGGTGCG GCAGGGGAGC TCATTCTCTC GCGGCTTCTG
301 TCTGTGCCCT CCGGCTGTGC GGGTTCGGAT GAGGCGCGCT GGTGGTGTTC
351 GGGTTGGGCG GCATCTTGTI CCGACTACGC CGTTTGGCAG CCAGAATTCG
401 GTTTCGCGGG GGTGTGCGGT GTGTTGCGGT TCGGCTTGAA GGGTTTGTG
451 GTCC..

```

**Number 25 ORF**

```

1 ATGAAAACT TCTTCAAAAC CTTTCCGCC GCGCACTCG CGCTCATGCT
51 CGCGCGCTCG GGATT..CAA AAGACAGGCG GCGCGCGCA TCCGCTTCTG
101 CGCGCGCGCA CAACGGCGCG CGGTAAAAA GAAATCGTCT TCGGCACAGC
151 CGTCGGCGCA TTCGGCGATA TGCTCAAGA ACAATCCAA GCGGAGCTGG
201 AGAAAAAAGS CTACACCGCT AAATGCTCG AGTTTACCGA CTATGTACGC
251 CGGAATCTGG CATTGCTGA GGGCAGTTG

```

**Number 26 ORF**

```

1 CCTCGTCTC CTCGGCATGC TCCAGTTTCA AGGGCGGATT TACTCCAAGG
51 CGGTGGAAGC TATGCTCGGC ACGTTCATCG GGCTGGGCGC GGGTTTGGCG
101 GTTTTATGGC TGAACACGCA TTATTTCAC GGCAACCTCC TCTTCTACCT
151 CACCGTCTCG ACGGCAAGCG CACTGGCGGG CTGGGCGGGG GTCCGCAAAA
201 ACGGCTACGT CCGTGTGCTG GCAGGGCTGA CGATGTGTAT GCTCATCGCG
251 GACAACGGCA GCGAATGGCT CGACAGCGGA CTCATGCGCG CCATGAACGT
301 CCTCATCGCG GYGGCCATAT CCATCGCGCG CGCCAAACTG CTGCGGCTGA
351 AATCCACACT GATGTGGGCT TTATGCTTG CGACAACCT GGGCGACTGC
401 AGCAAAATGA TTGCCGAAAT CAGCAACGCG AGGCGCATGA CCGCGGAAGC
451 CCTCGAGGAG AACATGGCGA AATGCGGCA AATCAACGCA CGCATGGTCA
501 AAAGCCGCGC CCATCTCGCC GCCACATCGG GCGAAAGCTG CATCAGCCCC
551 GCCATGATGG AAGCCATGCA GCAGCGCCAC CGTAAATCG TCAACACCA
601 CGAGCTGCTC CTGACCACCG CCGCAAGCT GCAATCTCCC AAATCAACG

```

-7-

```

651 GCAGCGAAAT CGGGCTGCTT GACGCCACT TCACACTGCT CCAAAC....
701 ..... GC AGACACGCCCC GCGCATTCGG
751 CATCGACAACC GCCATCAACC CGGAATCGGA AGCCCTCGCC GAACACCTCC
801 ACTACCAATG CGAGGGCTTC CTCTGGCTCA GCACCGATAT GCGTCAGGAA
851 ATTTCCGCC TCCTCATCCT GCTGCAACGC ACCCGCCGA AATGCGTGA
901 TGCCCAAGAA CGCCAACACC TGCGCCAAAG CTTGCTTGA

```

**Number 27 ORF**

```

1 ..GAATCAGCC TGGGTCCGA CACAGGCCG GTTTCGCTN CGAAGCGGG
51 GGATTCGGAA CGTTTCTCGT TGTTCGACGG CGGCAACAGC CGGCTCAAGT
101 GGGCGTGGT GGAACACGGC ACCTTCGCAA CGCTCGGTAG CGCGCGGTAC
151 CGCATTTGT CGCTTTGGG CGCGGAGTGG GCGGAAAGGG CGGATGGAA
201 TGTCCGCATC GTCGTTTGGC CTGTGCGGG AGAATTCAA AAGGCACAG
251 TGCAAGACA GCTCGCCGCA AAAATCGAGT GGTGCGGCT TTCCGACAG
301 GCTTT GGCA TACGCAACCA CTACGCCAC CCGGAAGAAC ACGTTCCGA
351 CGGCTGTTT AACGCTTGG GCAGCCGCGC CTTACGCGC AAGCGCTGG
401 TCGTCGTGAG TTGCGGCAAG GCGGTAAAGG TTGACGCGCT CACGATGAC
451 GGACATTATC TCGAGA.GG AACCATCATG CCGGTTTCC ACCTGATGAA
501 AGAATCGCTC GCGTCCGAA CGCCCAACCT CAACCGGAC GCGGTAAAG
551 GTTATCCTTT CCGACCGG..

```

**Number 28 ORF**

```

1 ATGTTTTACC AAATCCTTGC CCTGATTATC TGGAGCAGCT CGTTTATTGC
51 CGCCAAATAT GTCTATGGCG GCATCGATCC CGCATTGATG GTCCGGGTGC
101 GCCTGCTAAT TGCGCGCTG CCGTCACTGC CGGCTCGCG CGGTATGTC
151 GGCAAGATTG CGCGTAGGGA ATGGAAGCGG TTGCTGATTG TGTGTTTGT
201 CAACATATGT CTGACCTTGC TGCTTCAGTT TGTCCGGTTG AAATACACTT
251 CGCGCGCCAG CGCATCGGTC ATTTCCGAC TCAGACCGCT GGTGATGGTG
301 TTTTTCGGAC ACTTTTTCTT CAACGACAAA GCGCGTGCT ACCATGCTG
351 ATGCGGCGCG CGCGCATTTG CCGGTGTGCG GCTGCTGATG GCGGCGGCTG
401 CGGAAGAGGG CGCGCAAGTC GGTGTTTCG GCTGCTGCT GTGTGTTTG
451 GCGGCGCGCG GCTTTTGTGC CGCTATGCGT CCGACGCAAA GGCTGATTGC
501 ACGCATCGGC GCACCGGCAT TCACATCTGT TTCCATTGCC GCGCATGCT
551 TGATGTGCTC GCGGTTTTCG CTGCTTTTGG CGCAAGTTA TACCGTGGAC
601 TGGAGCGTCG GGATGGTATT GTGCTGCTG TATTGGGTT TGGGTTGC..

```

**Number 29 ORF**

```

1 ATGCGCGGTT TTCTACGAT CGCAGCCATA TCGCGmGwms TCCTGkkGTA
51 sGGACTGAGC GGGGCAACCG GCAGCACGAG TTCGCTGGCG GATTATTCT
101 GGTGGATTGT TGCGTTTCAAG GCAATGCTGC TGCTGGTGT GTCCGCGGTT
151 TTGGCAGGTT ATGTCTATT TGTGTTGAAA GACAGCGCGC ACGCGGTATT
201 CGGTTCCGTA srTYGCCAAA gSGCCTgkks TGGG.ATGTT TACGCTGGTT
251 GCGGCACTGC CCGGGGTGTT TCTGTTCCGG TTTCGCGCAC AGTTTCATCA
301 CGGCAGGATT AATTCGTGGT TCGGCAACGA TACCCAGCAG GCGCTTGAAC
351 GCAGCGCTCAA TTTGAGCAAG TCGCATTTGA ATTTGGGCGC AGACAACGCC
401 CTCGGCAACG CCGTCCCGGT GCAGATAGAC CTCTCGGCG CCGCTTCCCT
451 GCGCGGGGAT ATGGGCAAGG TGCTGGAACA TTACGCGCGC AGCGGTTTG
501 CCGAGCTTGC CCGTGACAAY kSCGCAAGCG GCAAAATCGA AAAAGCATC
551 AACCCGACGA AGCTCGATCA CCGGTTTCCA GGTAAAGCGC GTTGGGAaAa
601 AATCCaACGG GCGGGTTTCG TCAGGGATTT GGAAGCATA GCGCGGTAT
651 TGTaCGCGCA GGGCTGGCTG TCGGCGGATA CGCAWACGG GCGGATTAC
701 GCCTTTGTTT TCCGTCAGCC GGTTCGCCAA GCGCTGGCAG AGGATGCCGT
751 yTTAATCGAA AAGGCAAGGG CGAAATATGC TTAGTTGAGT TACAGCAAAA
801 AAGGTTTGCA GACCTTTTTC CTGGCAACCC TGCTGATTGC CTGCTGCTG
851 TCGATTTTTC TTGCACTGGT CATGGCACTG TATTTTCGCC GCGGTTTCGT
901 CGAACCCGTC CTATCGCTTG CCGAGGGGGG GAAGGCGGTT GCGCAAGCG
951 ATTTTCAGCA GACGCGCCCC GTGTTGCGCA ACGACGAGTT CGGACGCTTG
1001 ACCaGTTGT TCAACCATAT GACCGAGCAG CTTTCCATCG CCAAGATGAT
1051 AGACGAGCGC AACCGCGCGC GCGAGGAAGC CGCAGGCAT TATCTTGAAT

```

1101 GCGTGTGGGA GGGGCTGACC ACGGGCGTGG TGGTGTTGA CGAACAGGC  
1151 TGCTGAAAA CCTTCAACAA AGCGGCGGGT ACC..

**Number 30 ORF**

1 ATGTACGCAT TTACCGCCGC ACAGCAACAG AAGGCACCTCT TCCGGCTGGT  
51 GCTTTTTCAT ATCCTCATCA TCGCCGCGAG CAACATATCTG GTGCGAGTCC  
101 CTTTCCAAAT TTTCGGCATC CACACCCTTT GGGGCGCATT TTCTTTCCOC  
151 TTCACTCTCC TTGCCACCGA CCGTACCGTC CGCATTTTCG GTTCTCACTT  
201 GGCAACGCGG ATTATCTTTT GGTGATGTT CCGCGCCTT TTGCTTCTCT  
251 ACGTCTTTTC CGTTTGTGTC CACAACGGCA GTTGACACAG CTTGGGCGCG  
301 CTGTCCGAAT TCACACCTTT TGTCCGACGC ATCGCCTTAG CCAGCTTTGC  
351 CGCCTACCGC ATCGGACAAA TCCTGATAT TTTTGTATT CACAAATTAC  
401 GCGGTCTGAA AGCGTGGTGG ATTGCACCGA ACGCATCAAC CGTCATCGG  
451 CACGCGTGG ATACG...

**Number 31 ORF**

1 ATGGTCATAA AATATACAAA TTGAATTTT GCGAAATGT CGATAATTGC  
51 AATTTTGATG ATGTATTCGT TTGAAGCGAA TGCAAAAGCA GTTAAATAT  
101 CTGAACTGT TTCACTTGTG ACGGACAAAG GTGCGAAAT TCATAAGTTT  
151 GTACCTAAAA ATAGTAAAC TTATTCTATCT GATTTAATAA AAACCGTAGA  
201 TTTAACACAC AyyCCTACGG GCGCAAAAGC CGAATCAAC GCCAAATAA  
251 CCGCCAGCGT ATCCCGCGCC GCGGTATTGG CCGGGGTCCG CAACTTGCC  
301 CGCTTAGGCG CGAAATTCAG CACAAGGGCG GTTCCCTATG TCGGAACAGC  
351 CcTTTAGGCC CACGACOTAT ACGAAAcTTT CAAAGAGAC ATACAGGCAC  
401 GAGGTACCA ATACGACCCC GAACCGACA AATTTGTAAA AGGCTACGAA  
451 TATAGTAATT GCCTTTGGTA CGAAGACAAA AGACGTATTA ATAGAACCTA  
501 TGGCTGCTAC GGCCTTGAT..

**Number 32 ORF**

1 ATGAGATTTT TCGGTATCGG TTTTGTGGT CTGCTGTTT TGGAGATTAT  
51 GTCGATTGTG TGGGTTGCCG ATTGGCTGG GCGCGGCTGG ACGTTGTTTT  
101 TGATGGCGGC AGGTTTGGC GCCGCGCTGC TGATGCTCAG GCAACCGGG  
151 GCTGACCGGT CTTTATTGG CGGCGCGGCG AATGAGRAG GCGGGGAGG  
201 TATCCGTTTA TCAGATGTTG TGGCCTATC..

**Number 33 ORF**

1 ATGTTTGTGTT TTCAGACGGC ATTCTT.ATG TTTCAGAAAC ATTTGCAGAA  
51 AGCCTCCGAC AGCGTCGTG GAGGGACATT ATACGTGGTT GCCACGCCA  
101 TCGGCAATTT GCGGACATT ACCCTGCGCG CTTTGGCGGT ATTGCAAAAG  
151 GCG..... GCGCA AGACACGCGC GTTACCGCAC AGCTTTTGG  
201 CGCGTACGGC ATTACGGCA AACTGTCAG TGTGCGGAA CACAACGAAC  
251 GGCAGATGGC GGACAAGATT GTCCGCTATC TTTCAGACGG CATGGTTGTG  
301 GCACAGGTTT CGGATCGGG TACGCGGCC GTGTGCGACC CCGGCGGAA  
351 ACTGCGCCGC CGCGTCCGTG AGGCCGGTT TAAAGTCGTT CCGCTCGTGG  
401 GCGCAAC.GC GGTGATGGCG GCTTTGAGCG TGCCCGGTGT GGAAGGATCC  
451 GATTTTATTT TCACAGGTTT TGTACCGCCG AAATCGGGAG AACCGAGGAA  
501 ACTGTTTGCC AATATGGTGC GGGGCGGCTT TCCTATCGTC ATGTTTGAAA  
551 CGCGCACCGC CATCGGTGCA GCGCTGCGG ATATGCGGGA ACTGTTCCCC  
601 GAACGCGCAT TAATGCTGCG GCGCGAAATT ACGAAAACGT TTGAAACGTT  
651 CTTAAGCGGC ACGGTTGGGG AAATTCAGAC GGCATTGTCT GCGGACGGC  
701 ACCAATCGCG CCGCGAGATG CTGTTGGTGC TTTATCCGCG GCAGGATGAA  
751 AAACAAGGAG GCTTGTCCGA CTCGCGCAA AACATCATGA AATCCTCAC  
801 AGCCGAGCTG CCGACCAAC AGGCGGCGGA GCTTGTGCCC AAAATCACGC  
851 GCGAGGGAAA GAAAGCTTTG TACGAT..

**Number 34 ORF**

```

1 ATGAAACAGA AAAAACCGC TGCGCAGTT ATTGCTGCAA TGTGTGGCAGG
51 TTTTGGCGCA GC.AAAGCAC CCGAAATCGA CCCGGCTTTG .....
//
651 ..... .GAGTTGG TCAGAAACCA GTTGAGCAG GGTGTGAGAC
701 AGGAAAAAGC CGCTTGAA ATCGATGCC TTTTGGAAAG AACGGTGTGC
751 AAACCGTAA

```

**Number 35 ORF**

```

1 ATGAAAAAAT CTTCCTTAC GCTTGTCTG TATTCGTCT TACTTACCGC
51 CAGCGAAATT GCCTTACCC TTGGAATTG GGATTGAAAC CTTACCGGCG
101 GCMAAAATTG CGGAAACGTT TGCGCTGACA TTTGTGATTG CTGCGCTGTA
151 TCTGTTTGGC CGTAATAAGG TGACGCGTTT GTTGATTGCG GTGTTTTTTG
201 CGTTCAGCAT TATTGCCAAC AATGTGCATT ACGCGGATTA TCAAAGCTGG
251 ATGACG.... .....
//
1201 ..... CAAACCGTAT TCGAGCAGCT GCAAAAGACT CTTGACGGCA
1251 ACTGGCTGTT TGCCTATACC TCGCATCATG GCCAGTATGT TCGCCAAGAT
1301 ATCTACAATC AAGGCAACGGT GCAGCCCGAC AGCTATCTCG TGCCCGTAGT
1351 GTTGATACGC CGGATAAAGC CCGTGCAACA GGCTGCCAAC CAGGCTTTTG
1401 CGCCTTGCGA GATTGCTTTC CATCAGCAGC TTTCACGTT CTTGATTAC
1451 ACGTTGGGCT ACGATATGCC GGTTTACGTT GTGCGGAAG GCTCGGTAA
1501 GGGCAACCTG ATTACGGGTG ATCAGGCGAG CTTGAACATT CGCGACGGCA
1551 AGGCGGAATA TGTTTATCCG CAATGA

```

**Number 36 ORF**

```

1 ...ACCCCTGCTCC TCTTCATCCC CCTCGTCCTC ACAC.GTGC GCACACTGAC
51 CGGCATACTC GCCACGGCG GCGGCAAAACG CTTTGCCTG GAACAAGAAC
101 TCGTGCCGCC ATCGTCCGCC GCGCCGCTCA AAGAAATGGA TTTGTCCGCC
151 yTAAAGGAC GCAAAGCCGC CyTTTACGTC TCCGTTATGG GCGACCAAGG
201 TCGGGCAAC ATAAGCGGCG GACGCTACTC TATCGACGCA CTGATACCGG
251 GCGGCTACCA CACCAACCCC GAAAGTGCCA CCAATACAG CTACCCCGCC
301 TAGCACTA CCGCCACCAC CAAATCGAC GCGCTCTCCA CGGTAAACCAC
351 TTCCACATCG CTTTGAACG CCCC CGCGC GcyCyTGAC AAAAAACGG
401 GACGCAAGG CGAACGCTCC CGCGGACTGT CCGTCAACGG CACGGCGCAG
451 TACCGCAAGC AAACCTGTCT CGCCAACCCC CGGACGCTTT CTTCTCTGAC
501 CAACCTCATC CAAACGGTCT TCTACCTGCG CGGCATCGAA GTGcTACCGC
551 CCGcATACGC CGACACCGAC GTATTCTGTA CCGCTGACGT A...

```

**Number 37 ORF**

```

1 ATGGCAGAGA TCTGTTTGT ATCCGGCAGC CCCGGTTCAG GGAACACATT
51 AAAAAATGGT TCCATGATGG CGAATGATGA AATGTTTAAG CCTGATGAAA
101 AAGCCATACG CCGTAAAGTA TTTACGAACA TAAAGGCTTT GAAATACCG
151 CACACCTACA TAGAAACGGA GCGAAAAAAG CTGCGGAAT CGACAGATGA
201 CGAGCTTTTC GCGCATGATA TGTAAGAATG GATAAAGAAG CCCGAAATA
251 TCGGGTCTAT TGTCATTGTA GATGAAGCTC AAGACGTATG GCGGCAACGC
301 TCGGCAGGTT CAAAAATCCC TGAAAATGTC CAATGGCTGA ATACGCACAG
351 ACATCAGGCG ATTGATATAT TTGTTTGTAC TCAAGTCTCT AAGCTTCTAG
401 ATCAAAATCT TAGAAGCTGT GTACGGAAC ATTAACCAAT CGCTTCAAC
451 AAGATGGGTA TGCGTACGCT TTTAGAATGG AAAATATGCG CGGACGATCC
501 CGTAAAAATG GCATCAAGCG CATCTCCAG TATCTATACA CTGGATAAAA
551 AAGTTTATGA CTTGTATyrr TmmGGGAAG TTATACGCT AAAATAGGTC
601 AAGCGGTCAA AGTGTTTFTA CACTCTGCCa GTAAATGAT TGTGATTCC
651 CGTGTGTTTC GGCCTGTCTT ATAAAATGTT GAgCaGTTAC GGAAJAAAC
701 AGGAAGAACC CGCAGCAACA GAATCGCGG CACCAAGACA CGAGGCAGTA
751 CTTCCGGATA AACCAGAGG CGAGCCGGTA AATAACGGCA ACCTTACCG
801 AGATATGTTT GTTCCGATAT TGTCGGAaAa ACCCGcAAGC AAGCGcagTT
851 ATACCGGTGT AAGGCAGGTA AGAACCTTTG AATATATAGC AGGCTGTATA

```

-10-

```

901 GAAGGCGGAA GAACCGGATG CGCCTGCTAT TCGCaTCAAG GGACGGCATT
951 gaAAGAAGTG ACGGaGTTGA TGTGgaAgG aCTaTGtaAa AAacGGCGTTG
1001 CCGGTTTACC CaTACAAAGA AGAAAGCCAA GGGCAGGAAG TTCAGCAAAAG
1051 CGCGCagCAA CATTGGACA GGGGgCaAG TTGCcACaTT GGGCGGAAaA
1101 CCGTAGCAGA ACCTaATGTA CGaTaATTGG GAAGAaCGCG GGAaACCGTT
1151 TGAAGGaATC GgCGGGGCG GTGGTCCGAT CGGCAaACTG A

```

**Number 38 ORF**

```

1 GTGGTTTCC TGAATGCCGA CAACGGGATA TTGGTTCAGG ACTTGCCTTT
51 TGAAGTCAAA CTGAAAAAAT TCCATATCGA TTTTTCaCAAT ACGGGTATCG
101 CGCGTGATTT CGCCAGOGAT ATTGAAGTGA CGGACAAGGC AACCGGTGAG
151 AAACTCGAGC GCACCATCCG CGTGAACCAT CTTTTCaCCT TGCACGGCAT
201 CACGATTAT CAGGCGAGTT TTGCGACGG CGGTTCCGAT TTGACaTTCA
251 AGGCGTGGAA TTTGGGTGAT GCTTGCGCG AGCCTGTCTGT GTTGaAGGCA
301 ACATCCATAC ACCAGTTTCC GTTGAAATT GGCaaaCACA AATATCGTCT
351 TGAGTTCGAT CAGTTCaCTT CTATGaATT GTGaAGACATG AGCGAGGGCG
401 CGGAACGGGA AAAAAGCCTG AATCCaCGC TGCCCGATGT CCGCGCGGTT
451 ACTCAGGAAG GTCaCAAAATa CACCAAT . . . . . TACCG
501 TATCCGTGAT GCGCCAGGCC AGCGGCTCGA ATATAAAaAC TATATGCTCG
551 CGGTTTTGCA GGAACAGGAT TaTTTTTGGa TTACCGGCAC GCGCAGCGC.
601 TTGcAGCAGC AATACCGCTG GCTGCGTaTC CCCTTGGAaC AGCaATTGAa
651 AGCGGACACC TTTATGGCAT TGCGTGaTT TTTGAAGAT GGGGaAGGGC
701 GCaaACGTCT .GTTGCCGAC GCAACCAaAG CGGCACCTGC CGAAATCCCG
751 GAACAATTCA TGCTGGCTGC GGAaaACaCG CTGAaCATCT TTGCaCAAAa
801 AGGCTATTGT GGATGGaCG AaTTTaTTAC GTCCaATATC CCGMaAGAGC
851 AGCaGGATAa GATGCaGGGC TaTTTCTaCG AaATGCTTTa CGCGGTGATG
901 AACGTGCTT TGaTGAAaAC CaT. ACCCGG TaCGGCTTGC CCGaATGGCa
951 GCAGGATGAa GCGCGGAaTC GTTTCGTCT GCACaGTATG GaTGCGTaCA
1001 CGGGTTGAC CGaATATCCG GCGCTATGC TGCTGCAaCT TGaTGGGTTT
1051 TCGAGGTGC GTTCGTGGG TTTGCAGATG ACCCGTTCC C.GGTCGCT
1101 TTTGGTCTAT CTC. . .

```

**Number 39 ORF**

```

1 ATGATGAGTA ATaMaATGGa ACAaaaAGGG TTTACaTTGA TTGmGmTGAT
51 GATAGTGTGC GCGTaACTCG GCATTATCAG CGTCATTGCC ATaCTTCTTT
101 ATCmaAGTTa TaTTGaaaaa GGCTATCaGT CCCaCTTTa TACGGAGATG
151 GyCGGTATCA ACAATaTTTC CAaACaGTTT ATTTTGaaaa ATCCCGTaTG
201 CGATaATCAG ACCaTCGaGA ACAaACTGGA AATaTTTGTG TCAGGCTATA
251 AGATGAATCC GAAaATTGCC AaaaAaTATA GTGTTCCGT AAaGTTTGTG
301 GATAAGGAAA AATCaAGGGC ATACAGTTGT GTGCGGCTTC CGaAGCGGG
351 GACGGGTTAT ACTTTGTGCG TaTGaTGAA CAGCGTGGG GACGaTACA
401 AATGCCGTGA TGCGCTCTCT GCCCaAGCC ATTTGGAaAC CTGTCTCTCa
451 GATGTGGGTG GTGaAGCGTT CTCTaATCGT AaaaAaTaA

```

**Number 40 ORF**

```

1 ATGAAAAAAT CCTCCCTCAT CAGCGGATTG GGCATCGGTA TTTTGAGCAT
51 CGGcATGGCA TTTGCCGCC CTGCGCaCGC GGTaAGCCAA ATCCGTCAAA
101 ACGCCaCTCa AGTaTTGaGC ATCTTAAaAA ACGCGaTGC CaACaCCGT
151 CGCCAAAaAG CCGaAGCCTa TGCGaTTCC TATTTCGaTT TCCaAGTaT
201 GACCcGATTG CGGCTCGCaA ACCTTGgaG CACCG. GTCC GACG. GCaaa
251 AACaAGCGTT GGCCn. AGAA TTTCAaCC. . .

```

**Number 41 ORF**

```

1 ATGAAACACA TACTCCCCTT GATTGCCGCA TCCGCaCTCT GCATTTCaAC
51 CGCTTCGGGA CaTCTCGCaA GCGaACCGTC CaCTCAaAAC GAAaCCGTaA
101 TGATCaCGCa TACCCTCaTC TCAaaATACA GTTTTGnnn nnnnnnnnn
151 nnnnnnnnn nnGCCATAAA AAGCAaAGGG ATGGaCaTTT TTGCCGTaCT

```

-11-

```

201 CGACCATCAG GAAGCGGCAC GCGAAACGG CTTAACGATG CAGCCGCCAA
251 AAGTCATCGT CTTCGGCAGC CCCAAGCCG CTCAGCCGCT GATGGTCAAA
301 GACCCCGCCT TCGCCCTGCA ACTGCCCTA CCGCTCCTG TTACCGAAAC
351 GGACGGCAAA GTACGCGCCG CTTATACCGA TACGCGCGCC CTCATCGCCG
401 GCAGCGCAT CCGTTTCGAC GAAGTGGCAA TACTTTGGC AAACGCCGAA
451 AACTGATAC AAAAAACCGT AGCGAATAA

```

**Number 42 ORF**

```

1 ATGGCTTTTA TTACGCGCTT ATTCAAAGC AGTAAATGGC TGATTGTGCC
51 GCTGATGCTC CCCGCTTTC AGAATGTGGC GCGGAGGGG ATAGATGTGA
101 GCGGTGCGGA AGCGAGGATA ACGACGGCG GCGAGCTTTC CATCAGCAGC
151 CGCTTCCAAA CCGAGCTGCC CGACAGCTC CACAGCGCTG TCGCGCGGGG
201 CGTGC CGCTC AACTTTACCT TAAGCTGGCA GTTTCCGCC CCGATAATCG
251 CTCTTATCG GTTTAAATG GGGCACTGA TTGGCGATGA CGACAATATT
301 GACTACAAAC TGAGTTTCCA TCGCTGACC AaACGCTACC GCGTTACCGT
351 CGCGCGCTT TCGACAGACT ACGACACCTT GATGCGCGA TTGCGCGCGA
401 CCGCGCGCTG TGCAACTGG AAGTCTCTGA ACAAAGCGCG GCTGTCGCTG
451 GCGGAGCGAG GGGAAACCAA GCGCGAAATC CCGCTGACGC TGCTCACTTC
501 AAAACTGCCC AAGCTTTTTC AAATCAATGC ATTGACTTCT CAAAACCTGC
551 ATTTGGATTC GGGTTGGAAT CCTCTAAACA TATCGGGAA CAAATAA

```

**Number 43 ORF**

```

1 ATGGACACAA AAGAAATCCT CGG.TACGCG GcAGGcTCGA TCGGCAGCGC
51 GGTTTTAGCC GTTCATATCC TGC CGCTGCT GTGCTGGTAT TTCCCGCGCC
101 ACGCATCGG GCGCATCTGT CTGATCGAGA CCGCGCGCGG GCTGACGGTG
151 TCGGTGTGT GCCTCGGGCT GGATCAGGCA TACGTCCGCG AATACTATGC
201 CACCGCGGAC AAGACACaCT TGTTCAAAAC CCGTGTCTGT CCGCGCTGCG
251 TGCTGCCGC CGCATAGGCC GCGCTGCTCG TTTCCCGCCC GTCCCTGCCG
301 TCTGAAATCC TGTTTTCACT CGACGATGCC gCGCGCGCa TCGGGCTGCT
351 GCTGTTTGA CtgAGCTTCC TGCCATCCG cTTTCTCTTA CTGTTTTCG
401 GTATGGAAGG ACGCGCCCTT GCCTTTTCGT CCGCGCAACT CGTGCcMAG
451 CTCGCCATCC TGCTGCTG.T GCGCGTGAAC GTCGGGCTGC TGCATTTCC
501 AGCGAACACC GCGCTCTGA CCGCGCTTGA CCGCTGGCA AACCTTGCG
551 CCGCCGCTT TTTGCTGTTT CAAACCCGAT CCGCTGTA GCGCGCTCGG
601 CACGCACCGT TTTCCCGCG CGTCTGCAC CCGGGG.TGC GCTACGGCAT
651 ACCGATCGCA CTGAGCAGCA TCGCTATTG GCGGCTGGCA TCCGCGACCC
701 GTTTGTCTT GAAAAATAT GCGCGCTGG AACAGCTCG CGTTATTTCG
751 ATGGGTATTT CGTTCGGCG GCGCGATTA TTTTCCGAG GCATCTTTTC
801 AACGGTCTGG ACACCGTATA TTTTCCGCG AATCGAAGAA AACGCGCGCG
851 CCGCTCGCT CTGCGAACG GCAAGATCCG CCGCGCGCTT GCTTGCCTCC
901 GCGCTCTG.T TGACCGCAT TTTCTCGGCC GTTGCCTCC TCTGCTGCC
951 GGAATACTAC GCGCCGCTCC GGTTTATCGT CGTATCGTGT ATG.TGCCCG
1001 CGCTGTTTTC CACGCTGGCG GAAATCAGCG GCATCGTGT GAACGTCTGT
1051 CGCAAAACGC GCCGATCGC GCTCGCCACC TTGGCGCGC TGGCGGCAAA
1101 CCGCTGCTG CTGGGCGTTG ACCGTGCGT ACCGCGGAG GCGCC.GGCG
1151 CCGCGGTGCT CTGTCGCCCT TCAATCTGGC GTTTTTTTC GTTCAAGACC
1201 GAAAGCTCT GCGCGCTGTG GACGCGGCTC AAGCGCTGCG CGCTTTATCT
1251 GCACACATTG TTTGCTCTGA CCTCTCGCG GCGCTACACC TGCTTGGCA
1301 GCGCGGCAAA CTATCCCTGT TTTGCGGCG TATGGCGGCG ATATCTGGCA
1351 GCGTGCATCC TCGCGCACCG GAAAGATTGT CACAAACTGT TTCATTATT
1401 GAAAAACAA GGTTCCTCAT TATGA

```

**Number 44 ORF**

```

1..ATCTGAAAC CGCATACCA GCTTAAGGAA GACATCCAAC CTGATCCGCG
51 CGATCAAAAC GCGTTTCCG AACCGGATGC TCGCACAGAG GCAGAGCAGT
101 CGGATCGGGA AAATGCTGCC GACAGACGAG CCGTTGCGGA TAAAGCCGAC
151 GAGGTTGAAG AAAAGCGGG CGAGCGGGAA CGGGAAGAGC CGGACGGACA
201 GGCAGTGCST AAGAAAGCGC TGACGGAAGA CGTGAACAA ACCGTGAGG
251 AAAAAACGCA GAAAGAAGAT GCCAAACCG TTAATATACA AGCGGTAAAC

```

-12-

```

301 CCGTCTAAAG AAACAGAGAA AAAAGCTTCA AAAGAAGAGA AAAAGGCGG
351 GAAGGAAAAA GTTGACCCCA AACCAACCCC GGAACAAATC CTCAACAGCG
401 GcAgCATCGA AAAMGCGCGC AgTGCGCGCG CCAAGAAGT GCAGAAATG
451 AA.AACGTCC GACAAGGCGG AAGC.AACGC ATTATCTGCA AATGGCGCG
501 TATGCGGACC GTCAAGGCGC GGAAGGCGAG CGTGCCAAAC TGCGAATCTT
551 GGGCATATCT TCCAAGTGG TCGGTTATCA GCGGGGACAT AAAACGCTTT
601 ACGGGGTGCA AAGCGGCAAT ATGCTGCGCG ATGCGGTGA

```

**Number 45 ORF**

```

1 ATGAACCACG ACATCACTTT CCTCACCCCTG TTCCTACTCG GTKCTCTGG
51 CGGAACGCAC TGCATCGGTA TGTGCGGCGG ATTAAGCAGC GcGTTTgs.s
101 TCCAACCTCC CCGCATATC AACCGCTTTT GGCTGATCCT GCTGCTTAAC
151 ACAGGAAGGG TAAGCAGCTA TACGGCAATC GGCGTGATC TCGGATTAA
201 CGGCAGGCTC GGGCTTTCAC TCGACCAaAC CCGCTGCTCG CAGATAATTT
251 TATACACGGC CGCCAACCTC CTGCTGCTCT TTTTAGGCTT ATACTTGAGC
301 GGTATTTCTT CTTTGGGGCG AAAAATCGAG AaATCGGCA AACCGATATG
351 GGGGAACCTG AACCGGATAC TCAACCGGCT GTTACCCATA AAATCCATAC
401 CGCGCTGCTC tCGGtTCGGA ATATTATGGG GCTGGCTGCC GTGCGGAGTG
451 GTTTACAGCG CGTGCCTTTA CGCGCTGGGA AgCGGTAGTG CGGCAACGCG
501 CGGGTTATAT ATGCTTGCTT TTGCACTGGG TACGCTGCCC AATCTTTTAG
551 CAATCGGCAT TTTTTCCTTG CAACTGAaAA AAATCATGCA AACCGATAT
601 ATCGCGCTGT GTAACGGATT ATCGGTATCA TTATGGGCAT TATGAAACT
651 TCGGCTCTCG TGGCTGTAA

```

**Number 46 ORF**

```

1 ATGGA AAAACC AAAGCCGCT OCTAGGCTTT CGCTTGGCAC TTTTGGCGG
51 GATGACGTGG GGAACGCTGC CGAT.TCCGT GCGGCGAGTA TTGAAGTTTG
101 TCGATGCGCC GACGCTGGTG TGGGTGCGTT TTACCGTGGC GGCGCGGGTA
151 TTGTTTGT TTGCTGGCAT GGGCGGGGCG CTGCCGAAGC GGGGgGATT
201 TTTCTTGGTG CTCACTCAGG CTGCTGCTGC TCGGCGTGGC GGGCATTTG
251 GCAAACTTTG TGCTGATTGC CCAAGGGCTG CATTATATT TCOCGACCA
301 GACGCAGGTT TTGTGGCAGA TTTGCGCGTT TACGATGATT GTwGTGGTG
351 TGTGTGTGTT TAAAGACCGG ATGACTGCGC CTCAGAAAAA CGGCTTGGTT
401 TTGCTGCTTG CCGGTTTGCT TATGTATTTT AACGATAAAT TCGGCGAGTT
451 GTCGGGTTTG GSGCGGTATG C.AAGGGCGT GTTGCTGTGT GCGGCGAGCA
501 GTATGGCATG GGTGTGTAAT GCGGTGGCGC AAAAGCTGCT GTGCGGCGAA
551 TTCGGGCGCG AACAGATTCT GCTGTGATT TATGCGGCAA GTGCGCGGT
601 GTTCTGCGCC TTTGCCGAAC CGGCACACAT CGGAAGTATG GACGGTAGT
651 TGCGCTGGGT ATGTATTGGG TATTGCTGT TGAATACGTT AATCGGTTAC
701 GGCTCGTTGC GCGAGGGGTT GAAACATTGG GAGGCTTCCA AAGTCAGCG
751 GGTAAACAAC TTGCTCCCGT TGTTTACCGT AATAAATACT TTGCTCGGGC
801 ATTATGTGAT GCGTGAACCT TTTGCCGCGC CGGA..

```

**Number 47 ORF**

```

1 ATGGTAGCTC GTGCGGCTCA TAACCGAAG GTCGTAGGTT GGAATCCTGT
51 .CCGCAACC TAATTTCAAA CCCCTCGGTT CAATGCCGAG GG.GTTTGTG
101 T.TTGCTGTG TTCTGTTTCT GTGTTTCTG CCGCGCTCGT TTTTGTGCGG
151 ATTTTCTTTC CGCGCGCAAT ATCGGAACGG CAGACGCGCG TCTGTTTGGC
201 GTTGCAAAAT CAGGCAGTTT GGCTACAATC TTCCGATTG TCTTCAAGAA
251 AGCCAAACCAT CGCGACCGTC CGTTTACCG AATCGGTGAG CAAACAAGAC
301 CTTGATGCTC TGTTCAGATG GGCAAAAGCA AGTTACGGTG CAGAAAGTTG
351 CTGGA AAACG CTGTATCTGA ACGGTCysCC TTTGGGCAAC CTGTCGCGG
401 AATGGGTGGA ACGCGTsmmA AAGACTGGG AGGCAGGCTG CyCGGAGTCT
451 TCAGACGGCA TTTTCTCGAA TGCGGACGCG GTGcctGATA TGgGCGGag
501 cTTACAGCAC CTGCGCCTCG GTTGGCACTG TGCGGGGCTG TTTGACCGsT
551 GGGCGAACGA GTGTTTGGAC CTGACCGAGG CGCGCGGCAA CCGCTTGTTC
601 ACGCTCGaAc CGCGCGyTT mCGCTCKtC GGAAGTCTCA GCGCGCGCGT
651 CCATCTCAAC GGTCTGACCG AATCGGACGG CCGATGGCAT TTCTGGATAG
701 GCAGGCGCAG TCGCACAAA GCAGTCGATC CAAACAACT CGACAATACT

```

-13-

```

751 rCGCCGCGCG GTGTTTCCGG CGCGAAATG CGGTCTGAAG CCGTGTGTGG
801 CGAAAGCAGC GAAGAAGCCG GTTTGGATAA AACGCTGcTT CCGCTCATCC
851 GCCCGGTATC GCAGCTGCAC AGCCTGCGCT CCGTCAGCCG GSGGTGTACAC
901 AATGAAATCC TGTATGTATT CGATGCCGTC CTGCCG...

```

**Number 48 ORF**

```

1 ATGAATAGAC CCAAGCAACC CTCTCTCCGT CCGAAGTCG CCGTGTGCCG
51 CCAAAACGAG CTGACGGGTA AAGTGATTCT GACACGACCG TTGTCATTTT
101 CCCTATGGAC GACATTTGCA TCGATATCTG CGTTATTGAT TATCTGTGTT
151 TTGATATTTG GTAACATATC GCGAAGACAC ACAGTGGAGG GACAAATTTT
201 ACCTGCATCG GCGCTAATCA GGGTGTATGC AC CGgATACG rKACAATTA
251 CAGCGAAATTT CGTGGAAAGT GgmsAAAAGG TTAAGGCTGG CGACAAGCTA
301 TTTGCGCTTT CGACCTCAGC TTTGCGGCA GGAGGTAGCG TGCAACGACA
351 GTTGA AAAAGC GAGGCGATTT TGAAGAAAAC GTTGGCAGAA CAGGAACCTGG
401 GTCGTCTGAA GCTGATACAC GSGAATGAAA CGCGCagCcT TAAAGCAACT
451 GTCGAAGCTT TGGAAAACCA GGAACCTCAT ATTTGCGAAC AGATAGACCG
501 TCAGAAAAGG CGCATTAGAC TTGCGGAAGA AATGTTGCAG AAATATCGTT
551 TCCTATCCGC .CAATGA

```

**Number 49 ORF**

```

1 ATGCTGAATA CTTTTTTTGC GGTATTGGGC GGCTGCGCTG TGCT.TTGGC
51 GTGCGGCCAAA TCCGTAATA CGCGGTACAC GCCGCAAAAC CGGTTACAAA
101 GCGCGCGCAA ACCGGTTTTT AAAGTCATAT ATATCGACAA TACGGCGATT
151 CCGCGTTTGG ATTTGGGACA AAGCAGCGAA GCGCAAAACCA ACGCAGGCAA
201 AAAACRAATC AGTTATCCGA TTAAGGGCTT GCGGAAACAA AATGTTATCC
251 GACTGATCGG CAAGCATCCC GCGGACTTGG AAGCGCTCAG CGGCAATATC
301 ATGGA AACCG ATGATAAGGA CAGTCCGCGA GGTGGGCGC AAAACGGCGT
351 GTGCCATACC TTGTTTGCCA AACTGGTGGG CAATATCGCC GAAGCGCGCG
401 GCAAACTGAC GGATTACCTA GTTTGCGATG CCGCGCTGCA ACCCTATCAC
451 GCAGGCAAAA GCGGCTATGC CGCGTGCAG AACCGACGCT ATGCTGTGGA
501 AATCGACAGC GAAGGGGCGT TTTATTTCCG CCGCGCCCAT TATTGA

```

**Number 50 ORF**

```

1 ATGGAAGATT TATATATAAT ACTCGCTTTG GSTTTGGTTG CGATGATTGC
51 CGgATTTATC GATgcatTg cGggCGGGGG TGSTTTGATT ACGCTGCCGG
101 CACTCTTTGT GGCAGGTATT CCTCCCGGTG CGGCAATTGC CACCAACAAG
151 CTGCAAgCAG CCGCTGCTAC GTTTTCAGCT ACGGTTTCTT TTGCAACGAA
201 AGGTTTGATT GATTGGAAGA AAGGTCTCCC GATTGCCGCA GCATCGTTTG
251 TAGGCGGCGT GgCGGTGCA TTATCGGTCA GCTTGGTTTC CAAAGATATT
301 CTgCTgCGG TCGTgCGGT TTTGTGATA TTTGTGCGAC TGTATTTTGT
351 GTTTTCGCCC AAGCTCGACG GCACTAAGGA AGGCAAGGCC AGAATGTCTT
401 TTTTCTGTT cGGGCTGACG GTGCG. ACG CTTTTGGGTT TTTACGACGG
451 TGTGTTGCGA CCGGGTGTG GCTCGTTTTT TCTGATTGCC TTTATTGTTT
501 TGCTCGGCTG CAAGCTGTTG AACGCGATGT CTTACACCAA ATTGGCGAAC
551 GTTGCCTGCA ATCTTGTTTC GCTATCGTA TTCTGCTGC ACGGTTCGAT
601 TATTTTCCCG ATTGCGGCAA CgATGGCGGT CGGTGCGTTT GTCGtgCGA
651 ATTTAgGTGC GAGATTTGCC GTaCgctTCG GTTCAAGCT GATTAA

```

**Number 51 ORF**

```

1 .CTGCTAGGGT ATTGCATCGG TTATCGGTAC GGCTGTTGCA GCAAAACCAG
51 CCGCAGACGG ATTATTGGT CAAATTCGGA TCGTTTTGGG CGAG.ATTTT
101 TGGTTTTCTG GGAAGCTATG ACGTCTATGC TTCGCGATGG TTTGTGTTTA
151 TCAATGATTT TTTGGTGGTT TCTACCAAGT TGTGCTGAT TCAGCAATGTG
201 CCGCCGTTCT GCGCGGAAAT GAAGCTTTT CCGGAAAAGG TTAAGAAAAA
251 ATCTCTGGCG CGATGCGGCC ATCTTCTGCT GTTGGATGTA AAAATTGCGG
301 CCGAGGTGTC CAAAGCTTAT CTGGAAGTAC AAGGTTTTCA GGGGAAACCC
351 ATTAACCGTG AAGACGGGTC GGTTCGTATT GCGCGCAAAA AAGGCACAAT

```



-14-

```

401  GAACAAATGG  GGCTATATCT  TTGCCCATGT  TGCTTTGATT  GTCATTGTGC
451  TGGGOGGGTT  GATAGACAGT  AACCTGTCTG  TGAACCTGGG  TATGCTGACC
501  GGTCGGGATTG  TTCCGGACAA  TCAGGCGGTT  TATGCCAAGG  ATTTC, AAGC
551  CCGAAAGTAT  ,TTTGGGTGC  gTCCAATCTC  TCATTTAGGG  GCAACGTCAA
601  TATTTTCG. A  GGGGCAGAgT  GCGGATGTGG  TTTTCTCTGA

```

**Number 52 ORF**

```

1  ATGCGGCTCG  AAACACGGCT  GCGGAACCTT  ATCCGGCTCT  TGATATTGCG
51  OCTGGGTTTC  ATCTTCTCTGA  ACGCCTGTTC  GGAACMAACC  GCGCAACCGG
101  TTACCTCTGCA  AGGGGAAACG  ATGGGCACGA  CCTATACCGT  CAAATACCTT
151  TCAAATATATC  GGGACAAACT  CCGCTCACTC  GCGCAATATC  AAAAAGCAT
201  CGATGACGCG  CTTAAGAAG  TCAACCGGCA  GATGTCCACC  TATCAGCCGG
251  ATCTCGGAAT  CAGCGGTTTC  AACCACACA  CAGCGCGCAA  GCCCTCCGCG
301  ATTTCAAGCG  ACTTGCACA  CGTTACTGCC  GAAGCCGTCC  GCGTGAACCG
351  CCTGACACAC  GCGCGCTGG  ACGTAACTGT  CGGCCCTTGG  GTCAAOCTTT
401  GGGGATTTCGG  CCGCGACAAA  TCGCTTACCC  GTGAACCGTC  GCGGGAACAA
451  ATCAACACAG  CGGCATCTTA  TACGGGCATA  GACAAAATCA  TTTTGAACAA
501  AGGCAAGAT  TACGCTTCCT  TGAGCAAAAC  CCACCCCAAG  GCCTATTGGG
551  ATTTATCTTC  GATTGCCAAA  GGCTTCGGCG  TTGATAAAGT  TCGGGGCGAA
601  CTGGAAAAAT  ACGGCATTCA  AAATATCTGT  GTGCAAAATC  GCGGCGAGTT
651  GCACGGCGAA  GGCACAAAAC  GCGCGCGGCA  ACCGTGGCGC  ATCGGTATCG
701  AGCAGCCCAA  TATCTGCCAA  GCGCGCAATA  CGCAGATTAT  CGTCCCGCTG
751  AACACCCGTT  CGCTTGCCAC  TTCGGGCGAT  TACGATATT  TCCACGTGCA
801  TAAAAACGGC  AAACGCTCT  CCGATATCAT  CAACCCGAAC  AACAAACGAC
851  CCATCAGCCA  CAACCTCGCC  TCCATCAGCG  TGGTCGCAGA  CAGTGCAGTG
901  ACGGCGGACG  GCTTGTCCAC  AGGATTATTC  GTATTGGGCG  AAACCGAAGC
951  CTTAAAGCTG  CGAGAGCGCG  AAAAACTGCG  TGTTCCTCTG  ATTTGTCAGG
1001  ATAAAGGCGG  CTACCGCACC  GCCATGTCTT  CCGAATTGTA  AAAATGCTCT
1051  CGCTAA

```

**Number 53 ORF**

```

1  . . CCGTGCOCGC  GACAGGGCGA  CGACGTGTAT  GCGGCGCACG  CGTCCCGTCA
51  AAAATTTGGG  CTGCGCTTCA  TCGGCGGCGG  GTCGCATCAA  AATATACGGG
101  GCGGCGCGCG  TCGCGACGGG  TGGCGCAAGG  GCGTGCAATG  CCGCGGCGAG
151  GTGTTTGATC  GGCACAAATGA  AGGCAGCCKA  YTGGCAATCG  GCGTGATGGG
201  CCGCAGGGCC  GGCAGCACG  CWTCACTCAA  CGSCAAAGGC  GGTGCGGCGG
251  gCAGTGATT  GTATGGTTAT  GgCGGGGgTG  TTTATGCTgC  GTGCGATCAG
301  TTGCGCGATA  AACAAACGGG  TgCGTATTGG  GACGGCTGGT  TGCAATACCA
351  ACGTTTCAAA  CACGCGATCA  ATGATGAAAA  CCGTGCGGAA  CgCTACAAAA
401  CCAAGGGTTG  GACGCTTCT  GTCGAAGGCG  GCTACAAACG  GCTTGTGGGG
451  GAAAGGCATTG  TCGGAAAAGG  CAATAATGTG  CGGTTTTACC  TACAAACCGCA
501  GgCGCAATTT  ACCTACTTGG  GCGTAAACGG  CGGCTTTACC  GACAGCGAGG
551  GGAAGCGGGT  CGGACTGCTC  GGCAGCGGCT  AGTGGCAAAG  CCGCGCCGGC
601  AtTCGGGCAA  AAACCGGTTT  TGCTTTGCGT  AACGGTGCTA  ATCTTCAGCC
651  TTTTTCGGCT  TTTAATGTTt  TGACAGGCTG  AAAATCTTTC  GGCGTGGAAA
701  TGGACGGCGA  AAAACAGAGC  CTGGCAGGCA  GGACGGCACT  CGAAGGGCGG
751  TTCGTTATTG  AAGCGGGTTG  GAAAGGCCAT  ATGTCCCGCA. .

```

**Number 54 ORF**

```

1  . . CGGAATATG  TTCAGTTCTC  TATAGATTTG  TTCAGTGTGG  GTAAATCGGG
51  GGGCGGTATA  CCTAAGGCTA  AGCCTGTGTT  TGATGCGAAA  CCGAGATGGG
101  AGGTGTGATG  GAAGCTTAAT  AATATTGACA  CTCGTGAGCA  GGTGGAGAAA
151  AATGTTTCAG  AAACGAGAAG  AAGGAGTCAG  AGTAGTCAGT  TTAAGGCCCA
201  TGCGCAACGA  GAATGGGAAA  ATAAACACAG  GTTAGATTTT  AATCATTTTA
251  TAGGTGGTGA  TATCAATAAA  AAAGGCACAG  TAACAGGAGG  GCATAGTCTA
301  ACCGTGGTGT  ATGTACGGGT  GATACACAAA  ACCTCGGCAC  CTGATAARCA
351  TGGGGT. TTA  TCAACGACGA  GTGGAAATTN  A

```

**Number 55 ORF**

```

1 ATGAATATTC ACACCCCTGCT CTCCAACAA TGGACGTGC CGCCATTCTCT
51 GCCGAAACGG CTGCTGCTGT CCTCTGTGAT ACTGCTTGCC CCCAATGCGG
101 TGTTTTGGGT TTTGGCACTG CTGACCGCCA CGGCCCGCCC GATTGTCAAT
151 TTGGACTATC TTCCGCGCGC GCTGCTGATC GCGCTGCCTT GCGGTTTCTG
201 CAAAATGGCC GGCGTATTGG CGTTTGGCT GCGGTTTGGT TTTGACGGGG
251 TGTATGATGGT GATCCAACTC TTCCCTTTTA TGGATCTCAT CGCGGCATTC
301 AACCTCGTCC CTTTCATCTT GACCGCCGCC SCCCTTATC AGATAATGAC
351 CGGGCTG...

```

**Number 56 ORF**

```

1 ..GTGAGCGGAC GTTACCOCGC TTTGGATCGC GTTTCAAAA TCATCATGTT
51 TACTTTGAGT ATGCCACAGC TTGCCGCCGC CGGCATCGCT ATGTGCGCGG
101 GTATGCAAGT GCAGTCCGAT TTTATCGAGC CGACACCGTG GACGCTTGCC
151 GGTTTGGGCT TCCTGATCGC GCTGATGGG TGGATGCCGC CGCCGATTGA
201 AATTTCGCCC ATCAATTCTT TGTGGGTAA CAAAAACAA CGCATCAATC
251 CTTCGGAATA CCGCGACGGG ATTTTGAAT TCAACGTCGG TTATATCGCC
301 AGTCCGGTTT TGGCTTTGGT TTTCTTGCA CTGGGCGC G TAGCGCGAA
351 CGGCAACGGC GAACAGTGC AGATGGCGGG CGGCAATAT AACGGGCAAT
401 TGATCAATAT GTACGCC..

```

**Number 57 ORF**

```

1 ..TTGCGGGAAA CGGCATATGT TTTGGATAGT TTTGATCGTT ATTTTGTGT
51 TGCCTTGCC GCCTTGTTTT TTGTCGCGC ACAATCCGAA CGCGAGTGGG
101 TGCAGGAGGT TTCTGCGTGG CAGGAAAAAG AAGGGGAAAA ACAGGCGGAG
151 CTGCTGAAA TCAAGACGGG TATGCCGAT TTTCCGAAAC TTGCCCTGAT
201 GCTTTTCCAC GCGCTCAAAA CGGCAGTGTA TTGGCTGTTT GTCCGTGTGC
251 TCCGTTTCTG CCGAAACTAT CTGGCGCAGC AATCCGAACC GGACAGGCC
301 GTTCGCGCT..

```

**Number 58 ORF**

```

1 ATGATTTATC AAAGAAACCT CATCAAAGAA CTCTCTTTTA CGCCGTCGG
51 CATTTTCTGC GTCTCTTTGG CGGTATTGCT CTCCAACGAG GCAATCAACC
101 TGCTCGGCGG TGCGCGCGAC GGGC..GTGA TCGCCATCGA TGCGGTGTTG
151 GCATTGGTCG GCTTCTGGGT C.....
//
901 .....A TTGCCATGGG TTTGTTTTTA ATTTACCAAA ACGGGCTGAC
951 CCTGCTTTT GAAGCGGTGG AAGACGGCAA AATCCATTTT TGCGTCGGAC
1001 TGCTGCTATG GCACATTATC ATGTTTGTC TTGCACTCAT CTGTGTTGGC
1051 GTCCGAGTA TGCCGAGCCA GCCCTTCTGG CAGGCGGTTG GCAAAAGTCT
1101 GACATTGAAA GCGGAAAAAT GA

```

**Number 59 ORF**

```

1 ..GGTGGTGGTT TTATCAATGC TTCTGTGTC ACTTTGACGA CAGCCAAACC
51 GCAATATCAA GCAGGAGACC TTAGCGCTTT TAAGATAAAG CAAGGCAATG
101 TTGTAATGCG CGGACAGGTT TTGGATGCAC GTGATACGGA TTACACAGTG
151 ATTCTCAGTT ATCATTCCAA AATCGATGCA CCGTATGGG GACAAGATGT
201 TCGTGTCTGC GCGGACAAAA ACGATGTGGC CGCAACAGGT GATGCACATT
251 CGCTATTCTT CAATAATGCT GCTGCCARTA CGTCAAAACA TACAGCCAA
301 AACGCGACAC ATATCCCTTT ATTTGCGATT GATACAGGCA AATTAGGAGG
351 TAT.GTATGC CAACAAAATC ACCTTGATCA GTACGGTCGA GCAAGCAGG
401 ATTCTGTA

```

**Number 60 ORF**

```

1  ..TCAACGGGAC ATAGCGGAACA AAATTACACT TTGCCGCGAG AAATCACACG
51  CAACATTATCA CTGGGTTTCAAT TTGCCTATGA ATCGCATCGC AAAGCATTAA
101 GCCATCATGC GCCAGGCCAA GGCACGTAGT TGCCGCAAGG CAACGGTATT
151 TCGCTACCCCT ATACGTCCAA TTCTTTTACC CCATTACCCTA GCAGCAGCCT
201 ATACATTATC AATCCTGTCA ATAAAGGCTA TCTTTGTGAA ACCGATCCAC
251 GCTTTGGCAA CTACCGTCAA TGGTTGGTGA GTGACTATAT GCTGGACAGC
301 CTCAAACCTAG ACCCAACAAA TTACATAAAA CGTTTGGGTG ATGGTTATTA
351 CGAGCAACGT TTAACTCAATG AACAAATCGC AGAGCTGACA GGGCATCGTC
401 GTTTAGACGG TTATCAAAAC GACGAAGAAC AATTTAAAGC CTTAATGGAT
451 AATGGCGGCA CTGGGCGACG TTGATGAAT CTACGCGTTG GCATTGCATT
501 AAGTGCCGAG CAAGTAGCGC AACTGACCAG CGATATTGTT TGGTTGTATC
551 AAAAAGAAAT TAAGCTTCTT GATGGCGGCA CACAAACCGT ATTGGTGCCA
601 CAGGTTTATG TACGCGTTAA AAATGGCGAC ATAGACGGTA AAGGTGCATT
651 GTTGTACGCG AGCAATACAC AAATCAATGT TTCAGGCAGC CTGAAAACCT
701 CAGGCACGAT TGCAGGyGCG AATGCGCTTA TTATCAATAC CGATACGCTA
751 GACAAATATCG GTGGGCGTAT TCATGCGCAA AAATCAGCGG TTACGGCCAC
801 ACAAGACATC AATAAATTGG GCGGCATGCT TTCTGCCGAA CAGACATTAT
851 TGCTCAACGC AGGCAACAC ATCAACAGCC AAAGCACCCG CGCCAGCAGT
901 CAAATAACAC AAGGCAGCAG CACCTACCTA GACCGAATGG CAGGTATTTA
951 TATCACAGGC AAGGAAAAAG GTGTTT..

```

**Number 61 ORF**

```

1  ..TCAGGGAATA ACCTCAATGC CAAAGCTGCC GAAGTCAGCA GCGCAACCGG
51  TACACTGCTCT GTGTCTGCCA ATAATGACAT CAACATCAGC GCAGGCATTCG
101 ACACGAGCCCA GTTGTATGAT GCGTCCAAAC ACACAGGCAG AAGCGTGTGT
151 GGCAATAAAT TAGTCATTAC CGATAAAGCC CAAAGTCATC ACGAAACCGC
201 CCAAGGACAG ACCTTTTGAAG GAAGAAGAT TGTATTGCAG GCAGGAAGAGC
251 ATGCCAATCAT CCTTTGGCAGC AATGTTATTT CGGATAATGG CACCCAGATT
301 CAAGCAGGCA ATCATGTTGC CATTTGGTACA ACCCAAACCT AAAGCCAAAG
351 CGAAACCTAT CATCAAAACC AGAAATCAGG ATTGATGAGT GCAGGTATCG
401 GCTTCACTAT TGGCAGCAAG ACAAAACAC AAGAAAAGCA ATCCCAAAGC
451 AAGCAACATA CAGGCAGTAC CGTAGGCAGC TTGAAAGGCG ATACCAACAT
501 TGTGTGACGC AAACACTACG AACAAATCGG CAGTACCGTT TCCAGCCCGG
551 AAGGCAACAA TACCATCTAT GCCCAAAGCA TAGACATTCA AGCGGCACAC
601 AACAAATTAA ACAGTAATAC CACCCAAACC TTATGACAAA AAGC.CTAA
651 GGTGGCATTG AGTTGCGCCG TTACCGATTG GGCACAAACA ...

```

**Number 62 ORF**

```

1  ATGATTTTACA TCGTACTGTT TCTAGCTGTC GTCTCGCCG TTGTGCGCTA
51  CAACATGTAT CAGGAAAACC AATACGCGAA AAAAGTGCGC GACCAGTTGC
101 GACACTCCGA CAAAGATGCC CTGCTCAACA GCAAACACAG CCATGTCGCG
151 GACGGCAAAC CGTCGCGCGG GTGACTCATG ATGCCGAAAC CCCAACCGGC
201 GGTCAAAAAA ACGGCAAAAC CCCAAGACCC CGCATGCGC AACCTGCAAG
251 AACGAGATGC CGTCTACATC GCGAAGCAGA AACAGGCAAA AGCCTCCCGC
301 TTCAAAACG AATCGCAAC ACCTTTGGAA GAAAGCGGCA TTATCGGCAA
351 CTCGCGCAGC ACGCTTTCCG AACCCCAAC CGGACATTCC GCAACGAAAC
401 CTGCGCAGC GTGCGTAAAA CTTGCACCGG TTCCGCAJAC ACCTGC AAAA
451 CCGCTGATTA CGCTCAAGA ACTGTCAAAA GTCAATATT CCTGGTTTGA
501 CGTGGCATC GACTTCATCT CTTAT...

```

**Number 63 ORF**

```

1  ..GCGCGGCAGC GCACGGGAAGA TTTCTTCATG AACAAACAGG ACAC.ATCAG
51  CGAGATAGTC GAAAGCACCA CGGTTAGCAT GAAGCTGCTG ATTTCTCTCA
101 TCGCCTCATG TTCAATTGGTA GTCGGCGGCA TCGGCTGAT GAACATCATG
151 CTGGTCTCGG TTACGAGGCG CACCAAGAAA ATCGGCATAC GATGTGCAAT
201 CGCGCGCGG CGCGGCAATA TTTyGCAACA GTTTTGATT GAGGCGGTGT
251 TAACTCTGCT CATCGGCGGT TTGTGCGGCG TGGTTTGTG CGCGCGCGTC

```

-17-

```

301 AGCCTCGTGT TCAATCATTT TGTAACCGAC TTCCGGATGG ACAITTCGGC
351 CATGTCGCTG ATCGGCGGGG TCGCTGTTC GACCGGAATC GGCATCGGT
401 TCGGCTTTAT GCTTGCCAAT AAAGCAGCCA AACTCAATCC GATAGACGCA
451 TTGGCAGAG ATTGA

```

**Number 64 ORF**

```

1 ..GGGACGGGAG CGATGCTGCT GCTGTTTAC GCGSTAACGA T.CTGCCTTT
51 GGCACATGGC GTTACCTGTA GTTACACCTC GTGCTTTTT TTGGCGGTAT
101 TTTCTCTCCT GATTTTGAAA GAACGGATTT CCGTTTACAC GCAGCGGTG
151 CTGCTCTCTG GTTTTGGCGG CGTGGTATTG CTGCTTAATC CCTGTTCCG
201 CAGCGGTGAG GAACGGCGG CACTGCGCGG GCTGGCGGGG GCGCGATGT
251 CCGGCTGGCG GTATTTGAAA GTGCGCGAAC TGTCTTTGGC GGGCGAACCC
301 GGTGCGCGCG TCGTGTTTTA CCTTTCCGTG ACAGGTGTGG CGATGTGCTC
351 GGTGCGCGCG ACGCTGACCG GCTGGCACAC CCGTCTCTTT CCATCGCGGT
401 TTTATCTGTC GTGCATCGGC GTGTGCGGCG TGATTGCCCA ACTGTGATG
451 ACGCGCGCCT ACAAGTCGG CGACAAATTC ACGGTTCGCT CGCTTTCCTA
501 TATGACCGTC GTTTTTTCG CTCTGTCTCG CGCATTTTTT CTGGGCGAAG
551 AGCTTTCTG GCAGGAAATA CTGGGTATGT GCATCATCAT CCTCAGCGGT
601 ATTTTGA

```

**Number 65 ORF**

```

1 ATGAAGCGGC GTATAGCCGT CTTCGTCCTG TTCCCGCAGA TAATCCAGT
51 TTTGGGACAA CTGTTGCCGA AATCGTCAA TACAGTTCOG GCACATCGGA
101 TGCTCTTCGA GATTTTCGGG ATGTTCTTTT TCTTATACAC CCAGCAATAT
151 CTCCCGGGA TCGCGAAAT CGATTCCCA TCGGCGATCG TGTTCGGTG
201 GCTCCTCTTC CGTCATCTGC CCGCGGATTG CCGTGTATGT AAAGCGCGCG
251 TAGGGGATCG CgTTGCACAC GAACATCCAG TCGCTGATGT GGTCAACCGG
301 AACGCAACG cTTTCGCGCT GTTCGACATT GGTCAAGTTC CGSGGTTTAT
351 TGTTCAGCAC ACGCTAAATA TAAAGACCGT CAAAATAAAT ATCGTCGATC
401 CACATATGTT CGCAAAATTC GCGCTCTTCG CCGTCTTGGG AAAAAGGGAC
451 TTTGACCATG CAAAATTCGA AGCGCGAAAT AATGCGCGCG CGTCCCAAA
501 AAAGTCGCG CAAAATATAT TTGAATGTTT TACGGCGCGG TTGTCGGCA
551 CGGTTTACCG GTTCGTCTGC CTGTTCTACA TAATAAATGA CGGAATCGCC
601 CATCATATCT GTCCTCAAC GTGTACGTA TCTGTTTGA CTTACTGCG
651 GCTTCTGcC kTCGGCATCC GATTCCGATT TGAAAAGTTC mmfwyATTGG
701 GAATAG

```

**Number 66 ORF**

```

1 ATGGAAAATA TGGTAACGTT TTCAAAAATC AGACCGCTTT TGCCAATCGC
51 CGCGCGCGCG TTGCTTGGCG CC.TGCGGAG GCGGGGAAAT AATGCTGCC
101 CGAAGCCGCT CAACACCGCC AAACCCGCGC CAGTGTTCGG TTTGGCACTC
151 GGTGGCGGGG CATCTAAGG ATTTGCCCAT GTAGGTATTA TTAAGGTTT
201 GAAAGAAAAC GGTATTCCTG TGAAGTGTGT TACGCGCACC TCGCGAGTT
251 CGATTGTGCG CAACCTTTT GCATCGGGTA TGTGCGCCGA CCGCTCGAA
301 TTGGAAGCGG AATTTTLAG CAAAACCGAT TTGTCGATT TAACCTTGT
351 CACCAATGGG TTTATCAAG CGCAGAACT GCAAAATTAC ATCACCGAA
401 AACTCGCGG CATGCAGATT CAGCAGTTT CCATCAAAAT TGCGCGC...

```

**Number 67 ORF**

```

1 ATGTTTCGTT TACAATTGAG GCTGTTTCCC CCTTTGCGAA CCGCATGCA
51 CATCCTGTGT ACCGCGCTTG TCAAAAGCCT CTCCTGcTG CCGCTTTCCT
101 GTCTGCACAC GCTGGGAAC CGGCTCGGAC ATCTGGCGTT TTACTTTTAA
151 AAGGAAGACC GCGCGCGCAT CGTGCGcMAT ATGCGGCGAG CGGTTTGAA
201 CCGGACCCC AAAACGGTCA AAGCGGTTTT TGCGGAAACG GCAAAAGGG
251 GTTTGGAACT TGCCCCCGCG TTTTTCAGAA AACCGGAAGA CATAGAACAA
301 ATGTTCAAAG CGGTACACGG CTGGGAACAT GTGCAGCAGG CTTTGACAAA
351 ACACGAGGG CTGCTATTCC..

```

**Number 68 ORF**

```

1  ..GCCTGGTCGG CCGGCGAATC GTGGCGTGTG TTAATGGAAA GTGAACGCTG
51  GCATGCGGTG TGAATACTT TGCCTTCTC GCGCGCGGCG GTGTATGCGG
101 CAGCGGTTTT GGTGTGSGT TATCGGCGCG CCGCGCGGCG GTGCGGCTGG
151 ATGCGCGGGC TGATGTTTA GCGGTTTATG GTGTGCGGCG TTTGTGTTTC
201 GGCGGCGCTG CTGCTGCTTT ATCCGCGATG GACGCGTTCC TTGCCGTTGC
251 TGCTGGCGAT GTATGCGCTG CTGGCGTATC CGTTTGTGG AAAAGATGTT
301 TTATCAGCCT GGGATGCACT GCGCGCGGAT TACGCGAGGG CCGCGCGGCG
351 TTTGGGTGCA AACGGCTTC AGACGCGATG CCGCATCACG TTCCTCTCT
401 TGAACCGGCG GTTGGCGGCG GGTCTGACTT TGGCGGCGCG AACCTGCGTG
451 GCGGAATTGG CGGCGACATT GTTCTGTGCG CGTCCGGAAT GGCAGAGGCT
501 GACGACTTGG ATTTATGCCT ATTTGGGACG CCGGGGTGAG GATATTTAGC
551 CCGGCGCAT GGTGCTG..

```

**Number 69 ORF**

```

1  ATGGACGGCT GGACACAGAC GGTGTCCGCG CAAACCTGT TGGGCATTTT
51  GCGGCGGCGCA ATCATCTCA TTCTGATTTT AATGCTCAGA TTCGCGATCC
101 ACGCGCTGCT GACACTGGTC ATCTCAGGCC TCTCAGGCGG TTGGCAGCC
151 GGTTTGCCCA CAGGCGACAT TGTCAAAGAC ATACTGGTCA AAACTTCCG
201 CCGCACGCTC GCGGCGGTGG CGCTCTGTGT CCGCTCGGGC GCGATGCTCG
251 AACGTTTGGT C...

```

**Number 70 ORF**

```

1  ..GATTCGGCA TATCGCCGCT GTATCTTTGG GTTCCGCGCG CGTTCAAACA
51  TTGTGCTGCG CCGTGGGCTG CGACTCATA CGATGTGCGA CGCTTTCGAG
101 GCGTATTTT TGCCTGTATC GGACTGACTT CCTGCGGCTT TGGCGGTTTC
151 AACTTTTTGG GCGACACACA CCGGCGCACG GTGCTCTGTA TTCTCATCGG
201 CTGTATCGGG CTGATTCGAG TTGCCCATTT CTTCAACCCC GCTGCGCGCG
251 CCTTGGCGCG CGCGGAGCTG GTGCTGCGCG GTTATCTTTT GGCTCGCGCG
301 CGGCTGATGG CCGCTCTTT TCTGCTGGT ACGGCTGGA CGCTGATGTC
351 GTTGGCAGCA GCTTATCCGG CAGCAATTGC CCTGATGCTG CCTTTCGCGG
401 TACTGATGTT TTTCGCTCCG ..

```

**Number 71 ORF**

```

1  ..CRATCCGCA AATGTTTATC GGGCCAAACT CTAGTCGGCA CAGCAATTGG
51  GATACGCGGG CAGATAAAGC TTGGCGGCAA CCGTCAATAC GATATATTTA
101 CCGGCGCGCG ATTGAAAAG CCGCAATTTT TCCAAATCAG GAAATGGGCA
151 AGCGGTTTTT AGGTAGGCTA TACGTTTTTA

```

**Number 72 ORF**

```

1  ATGCGGACGA AATGTCAGC AGTGAGAAGC TGCTTACTTG GgCGGACACC
51  GCGGACATCG ATACCGCTTT GAACTGTGTT TACCGTTTGC AAAAATCGGA
101 ATTCTCTCTAT GCGCATGAAA ACGTCAATTC AGACGGCATC AATTTCGCGG
151 ACGAGCAATT CCGCTTGTGT ATGGAACAT TTCCCGGCGAG CCGTAAGGCG
201 TTATTGTGTG ATCGGAACGG TCTGTATCTT GCGAAGCGCA ATTTCCATCA
251 TGAGGCGGCG GAAGAGTTGG GCTTGTGTCG GCGAGAGTGC GCACAGATGG
301 AAAAGAAATA CCGGCTGCTG ATTAAGAAAC AC..

```

**Number 73 ORF**

```

1  ATGACCTTTT TACAAGGTTT GCAAGGTTTG GCAGACMATA AAATCTGTGG
51  GTTTGCATGG TCTGCTGCTC GCGCTTTTGA TGAAGAACGC GTACCGGAGT

```

-19-

```

101 CGGCGGCAAG CATGACGTTT ACGACGCTGC TGGCACTCGT CCGCGTGTG
151 ACCGTGATGG TGGCGGTGCG TTGACTTTTC CCGGTGTTTG ACCGTGTTG
201 GGATTCGTTT GTCTCTTCG TCAACCAAC CATCTGCGG CA.GGGCGGG
251 ACATGGTGTG CGACTATATC AATGGTTCG GCGGACAGCG GAACCGGTG
301 ACGGCAATCG CGAGCGTGAT GCTGGTCTGT ACCTCGCTGA TGCTGATTG
351 GACGATAGAC AATACGTTCA ACCGCTATCG GCGGCTCAA WTCCAGCGT
401 CCGTGGATG..

```

**Number 74 ORF**

```

1 ..AGACACGCCC GCGCATCCG CATGACACCG GCCATCAACC CGGAACCTGA
51 AGCCCTCGCC GAACACCTCC ACTACCAATG GCAGGCTTC CTCTGGCTCA
101 GCACCGTATG GCGTCAGGAA ATTTCCGCC TCCTCATCTT CTGCAACCG
151 ACCGCGCGCA AATGCGTGA TGCCACAGAA CGCCAACACC TCGGCGAAG
201 CCTGCTTGA ACACGGGAAC ACGGCTGA

```

**Number 75 ORF**

```

1 ..GCGAAGACA CGCGGTTAC CGCACAGCTT TTGAGCGGT ACGGCATTCA
51 GGGCAAACTC GTCACTGTGC GCGAACACAA CGAACGGCG ATGGCGGACA
101 AGATTGTCGG CTATCTTTCA GACGCGATGG TTGTGGGACA GGTTCGGAT
151 CGGGTACCG CGCGCGTGTG CGACCCGGCG CGCAAACTCG CCGCGCGGT
201 CGGTGAGGCC GGGTTTAAAG TGCTCCCGT CTGGGCGGA AC.GCGGTGA
251 TGGGCGCTTT GAGGTTGCCG GGTGTGGAAG GATCCGATT TTATTCCAC
301 GGTTTTGTAC CGCGAAATC GGGAGAACCG AGGAACTCT TTGCCAAATG
351 GGTGCGGCGG CGGTTTCTTA TGCTCATGTT TGAACCGCG CACGCGATCG
401 GTGCGCGCT TGCGGATATG CGGAACTGT TCOCGCAAG CCGATTAAATG
451 CTGGCGCGCG AAATTACGAA AACGTTTGA ACCTTCTTAA CGGCGACGT
501 TGGGGAATTT CAGACGCGAT TGCTGCGCA CGGCGACCAA TCGCGCGGG
551 AGATGCTGT GGTGCTTTAT CCGGCGCAGG ATGAAAACAA CGAAGCGCTG
601 TCCGAGTCCG CGCAAAACT CATGAAATC CTCACCGCG AGCTGCCAG
651 CAACAGCGCG GCGGAGCTTG CTGCCAAAT CACGCGCGAG GGAAGAAAG
701 CTTTGTACGA T..

```

**Number 76 ORF**

```

1 ATGAAACAA CGACAAACG GACAAACGAA ACACACCGCA AAGCCCCGRA
51 AACCGGTGCG ATCCGTTCT C.GCTGCTTA CTAGCCATA TGCGTGTGT
101 TCGGCATTCT TCCCAACGCC TGGCGGGGAC ACATTTATTT CGGCATCAAC
151 TACCAATACT ATCGGCACTT TGCGAAAAAT AAAGGCAAGT TTGAGTGGG
201 GCGGAAGAT ATTGAGGTTT ACAACAAAA AGGGAGTTGG GTGCGMAAT
251 CAATGACAAA AGCCCGATG ATTGATTTT CTGGGTGTC GGTAAACGGC
301 GTGGCGGAT TGCTGGGCG ATCAATATAT TGTGAGCGTG GCACATAACG
351 CGGCTATATA CAACGTTGAT TTTGTGCGG AAGGAAC.AA TATCCC.GAT
401 CAACAGGCTT TACTATATAA AATTGTGAAA CGGAATAATT ATAAAGCAGG
451 GACTAAAGGC CATCCTTATG GCGGCGATTA TCATATGCCG COTTTCGATA
501 AATWTGTCAC AGATGCAGAA CCTGTTGAAA TGACAGGTTA TATGATGGG
551 CGGAAATATA TCGATCAAAA TAATTACCT GACCGTGTTC GTATTGGGCG
601 AGGACGGCAA TATTGGCGAT CTGATGAAGA TGAGCCCAAT AACCGGAAA
651 GTTCATATCA TATTGCAAGT .....
701 ..... GGTCT ACCAATGTTT ATCTATGRTG CCAAAAGCAA
751 AAAGTGGTTA ATTAATGGG TATTGCAAA GGGCAACCCC TATATAGGAA
801 AAAGCAATGG CTTCGAGCTG GTTCGTAAG ATTGTTCTTA TGATGAATC
851 TTTGCTGGAG ATACCAATTC AGTATTCTAC GAACCAAGTC AAAATGGGAA
901 ATACTCTTTT AACGACGATA ATAATGGCAC AGGAAAAATC AATGCCAAAC
951 ATGAACACAA TTCTCTGCTT AATAGATTAA AAACACGAA CATTCAATTG
1001 TTTAATGTTT CTTTATCGGA GACAGCAAGA GAACCTGTTT ATCATGCTCG
1051 AGGTGGTGTG AACAGTTATC GACCCAGACT GAATAATGGA GAAATATATT
1101 CTTTATTGTA CGAAGGAAAA GCGGAATTGA TACTTACCAG CAACATCAAT
1151 CAAGTGCTG GAGGATTATA TTTCRAAGGA GATTTACGG TCTCGCTGTA
1201 AAATAACGAA ACTTGCAGAG GCGGCGGCTT TCATATCAGT GAAGACAGTA
1251 CCGTACTTGT GAAAGTAAAC GCGCTGGCAA ACGACCGCTT GTCCAAATCT

```

-20-

```

1301 GGCAAGGCA CGCTG.....
2101 .....//
2151 TGACTGCTTC ATTGACTAAG ACGACATCA GCGGCAATGT CGATCTTGCC
2201 GATCACGCTC ATTTAAATCT CACAGGGCTT GCCACACTCA ACGGCAATCT
2251 TAGTGCAAAAT GGCATACAC GTTATACAGT CAGCCACAAC GCCACCCAAA
2301 ACGGCAACCK TAqCctCgtG G..sAATGcCC AAGCAACATT TAATCAAGCC
2351 ACATTAAACG GCACACATC GGGCTCgGGC AATGCTTCAT TTAATCTAAG
2401 CGACCACGCC GTACAAAACG GCAGTCTGAC GCTTCCGGC AACGCTAAGG
2451 CAACCGTAAG CCATTCCGCA CTCAACGGTA ATGCTCCCT AGCCGATAAG
2501 GCAGTATCC ATTTTGAAG CAGCCGCTTT ACGGGACAAA TCAGCGGCGG
2551 CaagGATACG GCATTACACT TAAAAGACAG CGAATGGACG CTCGCGCTCaq
2601 GarCGGAATT AGGCAATTTA AACCTTGACA ACGCCACCAT TACACTCAAT
2651 TCCGCGCTATC GCCACGATGC GGCAGGGGCG CAAACCGGCA GTGCGACAGA
2701 TGCGCCGCGC CGCGCTTCGC GCCGTTCCGC CGGTTCCCTA TTATmCGTTA
2751 CACGCCCAAC TTCGGTAGAA TCCCGTTTCA ACACGCTGAC GGTAAACGGC
2801 AAATTGAACG GTCAGGGAAC ATTCGCGTTT ATGTCGGAAC TCTTCGGCTA
2851 CGCAGCGCAG AAATTGAAGC TGGCGGAAG TCCGGAAGGC ACTTACACCT
2901 TGGCGGTCAA CAATACCGGC AACGAACCTG CAAGCTCGA ACAATTGACG
2951 TAGTGGAAAG GAAAGACAA CAAACCGCTG TCCGAAAACC TTAATTTCACT
3001 CCGTCAAAC GAACACGTCG ATGACGGCGT GTGG.....
//
3551 .....//
3601 CCGCAACGCC GTTTGGACAA GCGGCATCCG GGACACACAA CACTACCGTT
3651 CGCAAGATT TT CGCGCCTAC CGCCACACAA CGACCTGCG CCAATCGGT
3701 ATGACAGAAA ACCTCGGCAG CGGCGCGCTC GGCATCTCTG TTTGCGACAA
3751 CGGACCGGAA AACACCTTCG ACGACGGCAT CGGCACTCG GCACGGCTTG
3801 CCGACGCGCG CGTTTTCCGG CAATACGGCA TCGACAGGTT CTACATCGCG
3851 ATCAGGCGCG GCGCGGGGTT TTAGCAGCGG CAGCCTTTaA GACGGCATCG
3901 GAGsmAAwT CGCGCCGCGC GTGCTGCATT ACGGCATTCA GGCACGATcG
3951 CGCGCGGgtt tcggyCGgAtt CGGCATCGAA CGGCACATCG GCGCAACGcg
4001 ctATTTCGTC CAAAAGCGGG ATTACCGCTA CGAAACGTC AATATCGCCA
4051 CCGCGGCGCT TGCATTCAAC CGcTACGCG CGGGCATTaA GGCAGATTAT
4101 TCATTCAAAC CGCGCGCAAC CATTTCATC ACGCCTTATT TGAGCTGTCT
4151 CTATACCGAT CGCGCTTCGG GAAAGTCG AGCAACGCTC AATACCGCGC
4201 TATTGGCTCA GGATTTCCGG AAAACCGGCA GTGCGGAATG GGgCGTAAAC
4251 CGCGAATCA AAGTTTTCAC GGTGTCCCTC CACGCTGCGC CGGCCAAAGG
4301 CCGCAACTG GAAGCGCAAC ACAGCGCGGG CATCAAAATTA GGCATCCGCT
4351 GGTAA...

```

**Number 77 ORF**

```

1 ..AAGGTGTGTC AATTGTGCGA AGA.CCGCTG CGTGCCGTGC TGCTGCGCA
51 CAGTTTTGAA CGACCGCGC AAAAATTGAA CCGTTTAAAG CGGGGTGCGG
101 CAACCATTTT GTTTTATGAA GATCAAAATG TCGTCAAAAG TTTGCAAGAG
151 CAGTTCCTGT CTTATGCGCG TAACCTCCCG GTTTGGGCGy ATCAGGCAAA
201 CGCGATGGTG CAGTATGCCG TTTGAGCAGC ACTTGCCCGC GTCGCGTAG
251 GTGCAAACTC GCAACATTAC AATCCCTTGC CCGATGCGCG GATTGCGAAA
301 GCGTGGAAAT TCCCGGAAAA CTGGTTGTG CCGGACACAA TGGTTATCGG
351 CGGTATTGAA GGGGCGGCAG GTGAAAGAC CTTTGAACCC GTTGCAAGAC
401 GTTTGAAGT GTTCGCGCA TAA

```

**Number 78 ORF**

```

1 ..GGCTACAAC ACCTGTTCCG GCGCGGCAG CGCATCGCA ACTACCAAT
51 CAACGGCATC CCGGTTGCCG ACGCGCTGCG CGATACGGGT CAATGCCAAC
101 ACGCGCGCCT ATGAGCGCGT AGAAGTCGTG CGCGCGTGG CGGGGCTGCT
151 GGACGGCAGC GCGCAGCGCT CGGCCACCGT CAATCTGGTG CGCAAGCGCC
201 TGACCGCGAA GCATTGT TTGAGTCCGCG CGGAAGCGGG CAACCGcAPA
251 CATTTCCGGC TGGACCGGGA CGTATCGGCG AGCCTGAACA CCGAAG.ctc
301 rCTGCGGcGCG CGCTGGTTT CCAcCTTCGG ACGCGGCGAC TCGTGGCGCG
351 GCGCGGAACG CAGCGGskAT GCCGAACCTC AGGCATTTT GGAATACGAC
401 ATGCAACCGC AAACCCGGGT CCACGACrCG ATGACTATCC AGCAGGCCAA

```

-21-

```

451  AGAAACCGCC GACGCGCGC TCAGTACGC CGTGTACGAC AGCCAAGTT
501  ATGCCACCGC CTTGCGCCGC AAAGACAAC CCGCCACAA TTGGGCGAAC
551  AGCCACCACC GTGCGCTCAA CTGTTCGCC GGCATCGAAC ACCGCTTCAA
601  CCAAGACTGG AACTCAAAG CCGAATACG CTAC..

```

**Number 79 ORF**

```

1  ATGGCGACGG CAGTGGTTTT GCTGTTGATC ATGCCGATGG CCGCTTCGTC
51  GGCAATGATG CCGGAAATGG TGTGCGCGGG CTGTGCGCGG GGAACGGCAA
101 TCATATCCAA GCCGACCGAA CAACGCGCGG TCATGGCTTC GAGTTTGTCC
151 AGCGTCAGcA GCCTGCTTTC GGGGgGgCa ATCATACCTT GCTCTTGGCA
201 AACGGGGATA AACGCGCCAC TCMAACCCCC GACCGCGCTG GAGCCATCA
251 TGCCGCTTTT TTTCAGCGCA TCGTTAGCA ATGCCAAAGC TGCTGTTGTG
301 CCGTGGGTAC CGCAGCGCT CAAGCCCAT TTTTCAAGAA TGCGTGGCAC
351 TnAGTCGCGC ACGGGG..

```

**Number 80 ORF**

```

1  .ACCGAGTGC AAAAAGAGTT GTCGCGGAA CAACGCAAGT GGGCGCAGGA
51  AAAATCAGC AACTGCGCAG AAGCCGCGCG GCAGCGCAGC CGGCGGGAAT
101 ACGCCGAATA CCTCAAGCTG CAATGCGACA CGCGGATGAC GCGCGAAGCG
151 ATACAGTATC TTGCGGCTA TTCCATCGAT TAG

```

**Number 81 ORF**

```

1  ATGCAGCTGA TCGACTATTC ACAATTCATT TCTCGGTTG TGCCACCCCTT
51  TTTGGCACTG GCATTTGCCG TCATTACCGG CCGCGTACTG CTGTCTTTAG
101 GCATCGGTAT TCTGwysGC GTTGCTTTT TGTCGCGCGG CAACCCGCTC
151 GACGGTCTGA CACACTGAA AGACATGGTC TTGCGCTTGG CTGTGTGAGA
201 CGsyGATTGG TGCTGGGCA AACCAAAAT CTGTGTTTC CMGATACTTT
251 TGGTATTTTT TACTTCCCTG CTGACTACT CCGGCAGCAA T.....
//
851  .....AC TTGCTGGTA
901  TTGCGCGGCA CTTGCGGCGT CTTTGCCTG TTTCTCTGCA CGCTCGGCAC
951  GATTAAACCC GCGACTATC CCAAGCCGT TTGGCAGGAT GCGAATCTTA
1001 TGTTCGGGCG AATCGCCATT TTAATCTCG CTTGGCTCAT CAGTACGGT
1051 TGCGGCGAAA TGACACCGG CGATTACCTC TCCACACTGG TTGCGGGCAA
1101 CATCCATCCC GGCTTCTCG CCGTCATCCT CTTCCTGCTC GCGAGCTGA
1151 TGCGGTTTGC CACAGGCACA AGCTGGGGGA CTTTGGCGAT TATGCTGCGC
1201 ATTGCGGCGC CCAATGGCGT CAAAGTCGAA CCGCGCTGA TTATCCGCTG
1251 TATGTCGCGA GTAAATGGCG GGGCGGTATG CCGCGACCAC TGCTGCGCCA
1301 TTTCGCGAC GACCATCCTG TCGTCCACGG CGCGCGCTG CAACCATATC
1351 GACCAAGTTA CTTGCAACT GCCTTACGCC TTAACCGTTG CCGCGCGCGC
1401 CGCATCGGGC TACCTCGCAT TGGGTCTGAC AAAATCCGCG CTGTTGGGCT
1451 TTGCGACGAC AGGCATTGTA TTGGCGGTGC TGAATTTTCT GTTGAAGAT
1501 AAAAAA..

```

**Number 82 ORF**

```

1  .AAGCAATGST ATGCCGACGN .AGTATCAAG ACGGAAATGG TTATGGTCAA
51  CGATGAGCCT GCCAAATTC TGACTTGGGA TGAAAGCGCG CGATTACTCT
101 CGGAATGTTC TATCGGCCAC CATCAACGCA ACGGGGTGCT TTTGAGTGG
151 TATGAGATG GTTCTAAAAA GAGCGAAGT. GTTTATCAGG ATGACAAGTT
201 GGTGAGGAAA ACCCAATGGG ATAAGGATGG TTTATTAATC GAACCTTGA

```

**Number 83 ORF**

```

1  ATGAAACAGA CAGTCAA.AT GCTTGCCGCC GCGCTGATTG CTTGGGCTT
51  GAACCGACCG GTGTGNGCG ATGACGTATC GSAATTTCCG GAAAACTTGC

```



-22-

```

101 A. GCGGCAGC ACAGGGAAT GCAGCAGCCC AATACAATTT GGGCGCAATG
151 TAT. TACAAA GGAAGCGGCT GCGCCGGGAT GATGCTGAAG CGGTGAGATG
201 GTATCGGCAG CGCGCGGAAC AGGGTTAGC CCAAGCCCAA TACAATTTGG
251 GCTGGATGTA TGCACAACGGC CGCG. GTGC GCCAAGATGA TACCGAAGCG
301 GTCAGATGGT ATCGGCAGCG GCGAGCGCAG GGGTTGTCC AAGCCCAATA
351 CAATTTGGCG GTGATATATG CCGAAGGACG TCGAGTGCGC CAAGCAGATG
401 TCGAAGCGGT CAGATGGTTT CGCGAGCGCG CAGCGCAGGG GGTAGCCCAA
451 GCCCAARACA ATTTGGGCGT GATGTATGCC GGAAGANCGC GCGTGGCCCA
501 AGACCG...

```

**Number 84 ORF**

```

1 ATGAAATTTA CCAAGCAGCC CGTCTGGGCA ATGGCGTTCC GCCCATTTTA
51 TTCGCTGGCG GCTCTGTACG GCGCATTGTC GGTATTGCTG TGGGTTTCAG
101 GCTACACGGG AACGCCACAG CTGTCCGGTT TCTATTGGCA CGCGGATGAG
151 ATGATTTGGG GTTATGCCGG ACTGGTCGTC ATCGCGTTCC TCGTAGCGCG
201 CGTCGCCACT TGGACGGGCG AGCGGCCACG CGCGGGCGCG GTATCTGCTC
251 GGCTTGACTA TCTTTTGCTT GGTGCGCGGG ATTGCGCCTT TTATCCGGGG
301 TTGGGGTGCG TCGGCAAGCG GCATCTCGG TACGCTGTTT TTCTGGTACG
351 GCGCGGTGTG CATGGCTTTG CCGGTTATCC GTTCGCAGAA TCACGCAAC
401 TATGTTgCGC GTTTCGCGCT GTTCTCTTTG GCGCGCAGCG ATCGCGGTTT
451 CCACGTCAG CTGCACAACG GCAACCTAGG GCGACTCTTG AGCGGATTCG
501 AGTCGGGCTT GGTGATG

```

**Number 85 ORF**

```

1 ..ATGCCGCTCT AAGGTTGAGA CGGmTCGGT GyCGGGGAAY CAGAAGyGGT
51 AGCGCATGCC CAATGAGACT TCGTGGGTTT TGAAGCGGGT GTTTTCCAGT
101 CGTCCCGAGT TGTGTTAAGC GTATCCGGTG TCyAArGTCA GCTTGGGyGT
151 GATGTGCAAA CGCAGCCCGG CGATGACACC AAGACCYAmg CTGCTGATrC
201 TGTkGCTTTT GTGATAGGsA GGTTTGyTGG kmsAsyTTG TayrATwKk
251 CCTssCwsTG kAGmGCCkTt CkyTGGTkkA swGrwArTAG TCGTGGTTyT
301 TKTtyyCACC GAATGAACyT GATGTTTAAC GTGTCCGTAG GCGAGCGGOG
351 CGCCGATATA GGGTTTGAAT TTATCGTTGA GTTTGAAATC GTAAATGGCG
401 GACCAAGCGA GAGAAGAAAC GGCGTGGAAG GTGCGGTTTC CCGTATGTTT
451 TGTTTGGGTT TCTTTGTAGT TGTGTTTAT CTCTTCAGTA ACTTTTTCAT
501 TAGAAGAAAT ACTTTCTTTC CATTTTCTGT AACTGGCATA ATCTGCGGCT
551 ATTCTCCAGC CGCGGAAATC ..

```

**Number 86 ORF**

```

1 ATGTTTGCTT TTTTAGAAGC CTTTTTGTG GAATACGGTT ATGCGCGTGT
51 TTTTTTGTGA TTGTCATCT GCGGTTTCGG CSTGCCGATT CCCGAGGATT
101 TGACCTTTGT AACAGCGGCG GTGATTTCCG GTATGGGTTA TACCAATCCG
151 CATATTATGT TTGCAGTCGG TATGCTCGCG GTATTGTCG GGGAGCGCAT
201 CATGTTTCGCC GCGGACGAA TTTGGGGGCA GArArTCTTA rGGTTCArAC
251 CTATTGCGSg CATCATGACG CGrAACGTT ATGAGCAGGT TCAGGAAAAA
301 TTGCAAAAT ACGGTAACTG GGTCTTATTT GTGCGCGGTT TCTGCGCGGG
351 TTTGAGAACG GCGGTATTGT TTACAGCGCG TATCAGCGCG AAGGTTTCAT
401 ACTTGCGTTT TATCATTATG GATGACTGCG CCGCA...

```

**Number 87 ORF**

```

1 ATGAAAAAAT TATTGGCGCG CGTGATGATG SCAGGTTTGG CAGGCGCGGT
51 TTCGCGCGCC GAGGTCACAG TTGAGGACGG CTGGGCGCGC ACCACCGTGG
101 AAGGTATGAA AATAGGCGCG GCGTTCATGA AATCCACAA CGACGAAGCC
151 AAACAAGACT TTTTGCTCGG CGGAAGCAGC CCGGTTGCGG ACCGOSTCGA
201 AGTGCAATCC CACATCAACG ACAACGGCGT SATGCGGATG CGCGAAGTCG
251 AAGGCGCGGT GCCTTTGGAA GCGAAATCCG TTACCGAACT CAAACCGCGG
301 AGCTATCATG TGATGTTTAT GGGTTTGAAG AAACAATTA AAGAGGGCGA
351 TAAAAATCCC GTTACCCTGA AATTTAAAAA GCCTAAAGCG CAAACCGTCC

```

401 AACTGGAAGT CAAAATCGCG CGATGCCGG CAATGAACCA C...

### Number 88 ORF

1 ATGACGTAA CTGCGGCCGA AGCGGCCAAA GCTGCCAAGG CGTTAAAAA  
 51 ATATCTGATT ACGGGCATTT TGCTCTGGCT GCCGATTGGG GTAAACGGTTT  
 101 GGGTGGTTTC CTATATCGTT TCGGCTCCG ATCAGCTCGT CAACCTGGTA  
 151 CGGAAGCAAT GCGCGCGCA ATATGTTTGG GGGTTTAATA TCCCGGGGCT  
 201 GGGCTTATC GTTSCCATTT CGGTATTTGT TGTAAACCGA TGTGTTGGCG  
 251 CCAAGCTATT GGGTCGCGAG ATCTCGCCG CGTGGGACAG CCGTGTGGGG  
 301 CGGATTCGGG TTGTGAATC CATCTATTCT AGGTGSAAA AAGTATCCGA  
 351 ATAcgTGCTG TCCGACAGCA GCCCTTCGTT TAARAACGCC GTACTCGTGC  
 401 CGTTTCCCCA GCCCGGTATT TGGACGATyG CTTTCTGTGC AGGGCAGGTG  
 451 TCGAATCGGG TTAAGGCCGC ATTCCGGAAs GACGGCGATT ATCTTTCGTT  
 501 GTATGTTCCG ACCACGCCGA ATCCGACCGG CGGTACTAT ATATGCTGTA  
 551 AGAAAGCGA TGTGCGCGAA CTCGATATGA CGTGGACGA AsCATTAATA  
 601 TATGTGATT CGCTGGGTAT GGTCACTCCT GACGACCTGC CCGTCAAAAC  
 651 ATTGCAAsGA CCTATGCCGT CTGAAAAGGC GGATTTGCCG GAACAACAAAT  
 701 AA

### Number 89 ORF

1 ATgAAAACGG TAGTCTGGAT TGTGTCCTG TTTGCCGCCG CCGTCGGACT  
 51 GCGCGTGGCT TCGGGCATT ACACCGGCCA CGTGTATATC GTACTCGSAC  
 101 AGACCATGCT CAGAAACAAC CTCGACGCCCT TTGTGTATAG TTCCGTGTA  
 151 GCGCTCGTGG TGTGTTATTT CTGTTTAAAT TTCAATTATCG GGTGACTCA  
 201 ATATCCCCGA AAGATGACAG CGTTTCTGTT CGGChCTAA AGGCKCKAAG  
 251 sCGsCGCTTG CTTTGAACAA GCGGGGTTTG GCGTATTTTG AAGGCGGTTT  
 301 TGAAAGGGG GAACTAGAAG CCTCAOCSGT GTTGCTCAAC AAAGtAGGCC  
 351 GaGAGACAAC CGGACTTTGG CATTGATGCT GtCGCGCAC GCCCGCGGAC  
 401 AGATGGAATA CATCGAsTG CGGACCGTT ATCTTGCSGA AATGCCCAAA  
 451 CTGCGCGAAA AACAGCAGCT TTCCCGTTAT CTTTGTGTGG CGGAATCGCG  
 501 GTTGAACCGG CGCGATTACG AAGCGCGGGA AGCCAATCTT CATGCGCGCG  
 551 CGAAGATGAA TGCCACACCTT ACGCGCTCGT TGCGTCTGCA .ATTCTGTAC  
 601 GCTTTGACGA GGGCGGACGC GTTGACGTT TTGGCAAAAA CCGAAAAACT  
 651 TTCCAGGGCG GCGCGGTTGG GCAATCGGA AATGGAACGG TATCAAAATT  
 701 GGGCATATCC GTGCGCAGCT GCGCGATGCT GCCGATGCCG CCGCTTTGAA  
 751 AACCTGCCTG AAGCGGATTC CCGACAGCCT CAAAACCGGG GAATTGAGCG  
 801 TATCGGTTGC GGAAAGTAC GAACGTTTGG GACTGTATGC CGATGCGGTC  
 851 AAATGGGTCA AACAGCATT TCGCAsAAC CGCGGCCCGG AGCTTTTGGTA  
 901 AGCCTTTTGC GAAAGCGTGC GCTTTTGGG CGAGCGCGAA CAGCAGAAAG  
 951 CCATCGATT TGCAGATGCT TGGCTGAAAG AACAGCCCGA TAAACGCGCT  
 1001 CTCTGATGAT ATCTCGGTGC GTCTCGCTTC GCGCGCAAA TTTGGGGCAA  
 1051 GGCAAAAGGC TACCTTAAG CGAGCAATTG ATTAAGCGG AGTATTTCCG  
 1101 CGCGTTTGGT TCTAACAAAG GTTTTCGACG AAATCGGAGA ACCGCAAGAG  
 1151 GCGGAGGCGC AC...

### Number 90 ORF

1 ATGATGTTTT CTGGTTCAA GCTGTTTCA TGTGTTTTTG TCATTTCTGT  
 51 GTTTGACGGG CTGTTTACC TGCCGAGGAT TTTCTGCAAT ATGGCGATAG  
 101 TTGATGTGCC GCGCGGCAAT CCGAGTATG TGCGTCTGTC GGGCATGGG  
 151 GTGCGGCTGT ACCGTTTTAT GTGCGCGTTC GGCTTCGGCG CGGTGCTGTT  
 201 GCGCGCGCGC ATACCGTTTG CCGCGCGCTG GTGGGGCAGC GGCTGGGTATC  
 251 ACGTCAAACT GTGTTTGGGC TTGATGCTCT TGCGTTACCA GTTGATTTCG  
 301 GCGCTGCTGC TGCGCGCTTT TCAGGATTAC AGCAATGCTT TTTCACACCG  
 351 CTGTTACCGC GTGTTCAACG AAATCCCGGT GCTGCTGATG GTTGCCGCGC  
 401 TGTATsTGGT CGTGTTCAAA CCGTTTTGA

**Number 91 ORF**

```

1  ATGGCAAAA  TGATGAATG  GCGCGTGTT  GCGGCGGTCG  CGGCGGCAGC
51  GGTTTGGGGC  GGATGGTCTT  AACTGAAGCC  CGAGCCGCAC  GTGCTTGATA
101  TTACGGAAAC  GGTCAAGCGC  GGC // ....
///  ATTTCTGTTA  CGATTTTGTC  CGAACCGGAT  ACGCGGATTA  AGGCGAAGCT
51  CGACAGCCTC  GACCCCGGGC  TGACCACGAT  GTCGTCGGGC  GGTTCACACA
101  GCAGTACGGA  TACGGCTTCC  AATGCGGTCT  ACTATTATGC  CCGTTCGGTT
151  GTGCGCAATC  CGGACGGCAA  ACTCGCCACG  GGGATGACGA  CGCAGAATAC
201  GGTGAAATC  GACGGCGTGA  AAAATGTGCT  GATTATTCCG  TCGGTGACCG
251  TGA AAAATC  GCGCGCGAAG  CGCTTTGTGC  CGGTGTTGG  TCGCGACGGC
301  AAGGCGGCGG  AAGCGGAAT  CCGGACCGGT  ATGAGAGACA  GTATGAATAC
351  CGAAGTAAAA  AGCGGGTTGA  AAGAGGGGGA  CAAAGTGGTC  ATCTCCGAAA
401  TAACCGCCGC  CGAGCAACAG  GAAAGCGGCG  AACGCGCCCT  AGGCGGCCGC
451  CCGCGCCGAT  AA

```

**Number 92 ORF**

```

1  ..ATTCGCCCA  CGATGACATT  TGAACGCAGC  GGCARTGCTT  ACAAATCGT
51  TTCGACGATT  AAAGTGGCGC  TATACAATAT  CCGTTTCGAG  TCCGGCGGTA
101  CGGTTGTCGG  CAATACCCCT  CACCCTACCT  ACTATAGAGA  CATACGCAGG
151  GCGAACTGTT  ATGCGGAAGC  CAAATTGCGC  GAGCGAGCG  TAACCTACGG
201  CAAAGCGGGC  GAGAGCAAAA  CCGAGCAAAG  CCCCAAGGCT  ATGGATTTGT
251  TCACGCTTGC  CTGGCAGTTG  CGGCGAAATG  ACGCGAAACT  CCCCOCGGGG
301  CTGAAATACA  CCAACGGCAA  AAACTTTAT  TCCGTCGGCG  GTTTGAATAA
351  GCGCGGTACA  GGA AAATACA  GCATAGGCGG  CGTGGAAACC  GAAGTCGTCA
401  AATATCGGTT  GCGGCGCGGC  GACGATCGGG  TAATGTATT  CTTCGACCGC
451  TCCTGAACA  ATATTCCGGC  ACAANTCGGC  TATACCGACG  ACGGCAAAAC
501  CTATAGCTG  AAATCTAAAT  CGGTGCAGAT  CAACGCCACG  GCAGCCAAAC
551  CGTAA

```

**Number 93 ORF**

```

1  ATGTATCGGA  GGAAAGGGCG  GGGCATCAAG  CCGTGGATGG  GTGCCGCTGC
51  .GCGTTTGCC  GCCTTGGTCT  GGCTGGTTTT  CGCGCTCGGC  GATACTTTGA
101  CTCGTTTGC  GGTTCGCGCG  GTGCTGGCGT  ATGATTGGA  CCCTTTGGTC
151  GAATGGTTGC  AGAAAAAGGG  TTTGAACCGT  GCATCCGCTT  CGATGCTCTG
201  GATGSGTGT  TCCTTGATTT  TGTGTTGGC  ATTATTGTTG  ATTATGCTCC
251  CTATGCTGGT  CGGGCAGTTC  AACAAATTGG  CATCGCGCCT  GCCCAATTA
301  ATCGGTTTGA  TGCAGAACAC  GCTGCTGCCG  TGGTTGAAAA  ATACAATCGG
351  CGGATATGTG  GAAATCGATC  AGGCATCTAT  TATTGCGTGG  CTTGAGGCGC
401  ATACGGGAGA  GTTGAGCAAC  GCGCTTAAGG  CGTGGTTTCC  CGTTTGTATG
451  AGGCAAGGCG  GCAATATT..

```

**Number 94 ORF**

```

1  ..ACTGCTTTT  CGGCGGCGCT  GCGCTTGAGT  CCATCATGAC  TCGTCATATT
51  TTTGCTCTTT  GGGAAACCGT  ATCAACAAAC  AGCGGCCATC  TTAACATTTT
101  TTTGCAAGCT  CTGCCCCGCG  CGTTCAAATG  CGTACCAGCA  ATACGCGCGC
151  CTGCGCCTCT  ATGCGCTTCA  TCGCGCCGAG  ATAGCCGAGT  TTTTCGTGG
201  TTTTGCTTT  GATGTTGACG  CACGAAATGT  CTATGCCCAA  ATCGGCGGCG
251  ATGTTGGCAC  GCATTTGCGG  AATGTGCGGC  GCGAGTGTGG  GTTCTGTGTC
301  AATCAGGTC  GTATCGACAT  TGACCGCGCT  CCAACCTCTG  GCCTGAACGC
351  TTTGATACGC  CGCAGCAAAA  AGGACGCGGC  TGTCCGATC  TTTGAATCTT
401  GCGGCGGTGT  CGGGGAAATG  GCTGCGGATA  TCGCCCAAAAC  CTGCGCCACC
451  GAGCAGCGCG  TCGGTAAACG  CGTGACAGAG  CGCATCGGCA  TCGGAGTGTG
501  CGAGCAGCCC  TTTTCAAAT  GGGATTTCAA  CTCGCGCAAG  TATCAG..

```

**Number 95 ORF**

```

1  ..GCCGCGCGGA  GTGCGAACAA  CATTTCGCGG  CGTTTTCGCG  AAACACCCGT

```

-25-

51 CGCTGTGAGC GTTACCGTGA TCGGCACGGT ACTTGCCGTC ATGCTGCCCG  
 101 TTACCGAATA TGAAACATTC CTGCTGCTTA TCGGCTCGGT ATTTGCCGCC  
 151 ATGGGGCGGA TTTTGATTGC CGACTTTTTC GTCTTGAAC GGCCTGA

**Number 96 ORF**

1 ATGACCCGTA TCGCCATCCT CGGCGGCGC CTCTCGGGAA GGCTGACCGC  
 51 GTTGACAGCTT GCAGAACAGG GTTATCAGAT TGCACCTTTT GATAAAAGCT  
 101 GCGCGCGGGG CGAACACGCC GCCGCCTATG TAGCGCGCGC CATGCTCGCG  
 151 CCTGCAGCGG A.ACAGTCTGA AGCCACGCC GAAGTGGTCA GGCTGGGCGAG  
 201 GCAGAGCATC CGCCTTTGGC GCGGCATCG ATGCCGCTG AACACGCCACA  
 251 CGATGATGCA GGAACACGCC AGCCTGATTG TATGGCACGG GCAGGACAAG  
 301 CCATTATCCA GCGAGTTCGT CGGCCATCTC AAACGCGCGC GCGT.ACGGA  
 351 TGACGAATC GTCCGTTGGC GCGCCGACGA CATCGCCGAA CGCGAACCGC  
 401 AACTCGGCGG ACGTTTTTAA GACGCATCT ACCTGCCGAC CGAAGC.CAG  
 451 CTCGACGGG GCGAATTATA GTCTGCACCT GCCGACGCTT TGGACGAAC  
 501 GAACGTCCCC TGCCATTGGG AACACGAATG CGTCCCCGAA GCGTCAAG..

**Number 97 ORF**

1 ATGACTGATA ATCGGGGTT TACGCTGGTT GAATTAATAT CAGTGGTCTT  
 51 GATATTGTCT GTACTTGCTT TAATTGTTTA TCCGAGCTAT CGCAATTATG  
 101 TTGAGAAAGC AAGATATAT GCAGTGCAGG CAGCCTTGTT AGAATATGCA  
 151 CATTTATGAG AAAAGTTTAA TCTGCAGATG GGGAGTTTAA ACAAACATC  
 201 TACCAAGTGG CCAAGTTTGC CGATTAAAGA GGCAGAAGC TTTGTATCC  
 251 GTTTGAATGG AATCGTCGCG CGGG..GCTT TAGACAGTAA ATTCATGTTG  
 301 AAGCGGCTAG CCATAGATAA AGATAAAAT CCTTTTATTA TTAAGATGAA  
 351 TGAAATCTA GTAACCTTTA gTTTGCAAGA AGTCCGCCAG TTCGTGTAGT  
 401 GACGGGCTGG ATTATTTTAA AGGAATGAT AAGGACTGCA AGTTACTTAA  
 451 GTAG

**Number 98 ORF**

1 ..GTGTCGCTG CTTCGGTGAT TGCCTCTCAA ATCTTCCTTT ACGAAGATTT  
 51 CAACCAATG CGGAAACCG GTGGAGCTAT CTGCGGTTTT CTGTCCCAAT  
 101 ATTTATCTGG GGTTCAGCA GGGGTATTTT GATTTGAGTG CCGACGAGAA  
 151 CCCGCTACTG CATATCTGGT CTTTGGCAGT AGAGGAACAG TATTACCTCC  
 201 TGTATCCOCT TTTGCTGATA TTTTGTGCA AAAAAACCAA ATCGCTACGG  
 251 GTGCTGCGTA ACATCAGCAT CATCCTGTTT TTGATTTTGA CTGCTCATC  
 301 GTTTTTGCGA AGCGGGTTTT ATACCGACAT CCTCAACCAA CCAATACTT  
 351 ATTACCTTTC GACACTGAGG TTTCCGAGC GTTTGGCAGG TTGCTGCTG  
 401 GCGGTTTACG GGCACACGCA AAACGGCAGA CGGCAACAG CAATGGAANA  
 451 ACGGCAATTG CTTCATCAC TCTGCTCGG CGCATTGCTT GCCTGCCTGT  
 501 TCGTGATTGA CAACACAAT CGTATTATCC CGGGAATGAC CCTGCTCCTT  
 551 CCTGCCTCG TGACGGCACT GCTTATCCGG AGTATGCAAT ACGGGACACT  
 601 TCCGACCCCG ATCCTGTGCG CAAGCCCAT CGTATTGTGC GGCRAAATCT  
 651 CTATTCCCTT ATACCTGTAC CATTGGATTT TTATTGCTTT GCCTCCGCTC  
 701 ATTAGAGGCG GGAACAGCT CGGACTGCCT GCCG..

**Number 99 ORF**

1 ..ATTATTACG AATACCGCTG GATGTTTCTT TACGGCGCAC TGACGACCTT  
 51 GGGGCTGACG CTCGTGGCAA C.GCGGGCGG TTGCGTATTG GGTCTGTGT  
 101 TGGCGTTGGC GCGCCTGATT CACTTGGAAA AAGCCGCTGC GCGCATGCGC  
 151 GTGCTGGCGT GGGCGTTGCG TAAAGTTTCG CTGCTGTATG TTACGCTGTT  
 201 CCGGGGTACG CCCTGTTTGG TGCAGATTGT GATTTGGGCG TATGCTGGT  
 251 TCCGTTTTT CGTC..

**Number 100 ORF**

```

1      ..CTGAAAGAAT GCCGCTCTGAA AGACCCTGTT TTTATTCCAA ATATCGTTTA
51     TAAGAACATC GCCATTACTT TCCTGCTCTT GCACGCCGCC GCCGAACTT
101    GGCTGCCCGC GCAAAACGCC GGTTTTACCG CGCTCGCGGT CGGCTTCATC
151    CTGCTGGCCA AGCTGCGTGA gCTTCACCAT CAGGAACACT TACGTAAGCA
201    cTAGCTCCGC ACTATTACy TGCTCCAACCT CTTTGCCGCC GAGAgcTAGT
251    TTGTGGACAG GCGCGCGwA ATTACAAAC ATCGCCGCyT CCGCGCCCTT
301    GCACCTGATT ACCCTCGCGC GCATGATGGG CGCGCTGATG ATGSGTGGGc
351    TGACCGCGCG ACTGTGGCAC AGCGGCTTTA CCAAACTCGA CTACCCCAAA
401    CTCTGCCGCA TTGCGGTGCC CATCCTTTTC GCGCGCGCGG TCTCGCGCGC
451    TTTCTTGrTG AACGTGAACC GStATTTTTt CATTACCGTT CTTGCGATTc
501    TGACCGCGCG CGTATTCTGA CTGATCTTT TCicGTTTAT ACCGATATTT
551    CGGGCGAAATG CGTTTACAGA CGATCCGGAT TAr

```

**Number 101 ORF**

```

1      ATGGAATTC GGGCAATAAA ATATACGGCA ATGGCTGCGT TGCTTGCAAT
51     TACGGTTGCA GGCTGCCCGC TGGCGGGGTG GTATGAGTGT TCGTCCCTCA
101    CCGGCTGTGT TAAGCCGAGA AAACCGGCTG CCATCGATT TTTGGGATAT
151    GGCGGCGSAGA GTCCGCGCTC TTTAGGGGAC TACGAGATAC CGCTTTCAGA
201    CGGCAATAGT TCGCTCAGGG CAACGGAATA TGAATCCGCA CACAACTCTT
251    ACTTTTACAG GAAATAGGG AAGTTTGAAG C.TGCGGGCT GGATTGCGGT
301    ACGCGTACG GCAAACTTTT GATTGAGACG TCAACACAGG GAGGATTTGA
351    CTGCTTGGAa AAG..

```

**Number 102 ORF**

```

1      ATGAAACACA TCCATATTAT CGGTATCGGC GGCACGTTTA TGCGGGGGCT
51     TGCGGCCATT GCGAAAGAAG CGGGGTTTGA AGTCAGCGGT TCGGACGCCA
101    AGATGTATCC GCGCATGAGC ACCAGCTCG AAGCCTTGGG TATAGACGTG
151    TATGAAGGCT TCGATGCCGC TCAGTTGGAC GAATTTAAAG CCGACGTTTA
201    CGTTATCGGC AATGTGCCA AGCGCGGGAT GGATGTGGT GAAGCGATT
251    TGAACCTCGG CTGCTCTTAT ATTeCGGCC CGCAATGGCT GTCGGAAAC
301    GTGCTGACCC ATCATTGGGT ACTGGTGTG GCGGGGACgC ACGGCAAAAC
351    GACCACCGCC TCCATGCTCG CATGGTCTT GGAATATgCC GGCCTCGCGC
401    CGGGCTTCTT TATTeGGCGC GTACC.GGAA AATtCGGCC TTTCGCCCG
451    CTTGCGCAA ACGCGCGGCC AAGACCCGAA CAGCCAATCG CGStTTTTcG
501    TcCTCGAAGC CGACGAATAC GACACCGCTT TTeCGACAA ACgtTCTAAA
551    TcCTCGAATt ACCGTCCGCG TACCGCCGTG TTAACAATc TTGAATTGGA
601    CCAAGCGGAC ATCTTTGGCG ACTTGGGCGC GATACAGAc CAGTTCCACT
651    ACCTCTGCGG TACCGTGGCG TCTGAAGGCT TAATCGTCTG CAACGAGCGG
701    CAGCAAGCC TGCAAGTAC TTTGACAAA GGCTGCTGGA CGCGGTGGA
751    AAAATTGCGC ACGGAACAGG GCTGGCA..

```

**Number 103 ORF**

```

1      ..CCGGGCTATT ACGGCTCGGA TGACGAATTT AAGCGGGCAT TCGGAGAAAA
51     CTCGCCACAA TmCAAGAATC ATTGCAACCG GAGCTCGGGG ATTTATGAAC
101    CGGATTGTAA AAAAAACGGC AAAAAAGCGC CCAACAACCA TTCGTCAGC
151    ATTAGTCGGG ACTTCGGCGA TTAATTGATG CCGTTCGCCA GCTATTGCGG
201    CACACACCGT ATGCCCAACA TCCAAGAAAT GTATTTTTCC CAAATCGGG
251    ACTCCGCGT CTACACCGCC TTAACAACAG AGGGGGGAAA CACTTTGCAT
301    TTTCGCTTc ATACCTATAA AAAGGATTG TTAAACAAG ATGATACAA
351    AGGATTAAAA CTGGTGGCT ACCGACGCC CATCGACAAC TACATCCACA
401    ACTTTTACGG GAATGCGGG GATTGAAAG GGSATATTTCC GAGCTGGGT
451    ACGACACCG GCTTTCCTA CACCATCCAA CATCGCATTT TCAWAGACAA
501    AGTGCATCAA nnnnnnnnnn nnnnnnnnnn nnnntTACGAT TATGGGCTTT
551    TTTTACCAA CTTTCTTAC GCCTATCAA AAGACGCGA ACCGACCAAC
601    TTCAGCGATG CGAGCGAATC GCCCAACAA GCCTCCAAG AAGACCACT
651    CAACAACAGT TATSGTTGA CAGGGTTTC CGCCTCGCG CGAGATTACG
701    GACGTTTGA AGTCGGTACG CGCTGGTTGG GCAACAACAT GACTTTGGG

```

-27-

```

751 GCGCGGATGC GCTATTTCGG CAAGAGCATC CGCGCGACGG CTGAAGAACC
801 CTATATCGAC GGCACCAACG GGGGAAATAC CAGCRAATTTC CGGCAACTGGS
851 CCAAGCGTTC CATCAAAACAA ACGGAAACTC TTGCCCGCCA GCCTTTGATT
901 TTWGATTTTt ACGCGCGTTA CGAGCGGAAG AAAAACCTTA TTTTCGCGC
951 CGAAGTCAAA AATCTGTTGG ACAGCGGTTA TATCGATCG CTGATGCGG
1001 GCAATGATGC GGCAC. GAG CGTTATTACA GCTCGTTTGA CCGCAAGAGC
1051 AAGGACrAG ACGTAACGTG TAATGCTGAT AAAACGTTGT GCAACGGCAA
1101 ATACGGCGGC ACAAGCAAAA GCGTATTGAC CAATTTTGCA CGCGACGCA
1151 CCTTTTTgAT GACGATGAGC TACAAGTTTT AA

```

**Number 104 ORF**

```

1 ATGAACCTGA TTTCAAGTTA CATCATCGT CAAATGGCGG TTATGGCGGT
51 TTACGGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT
101 ACGAAACCGG CAACCTCGGC AAAGGCGAGT ACGGCATATG GGAATGCTG
151 GGCTACACGG CCCTCAAAAT GCCCGCCCGC GCCTACGAAC TGATTCCCTGT
201 CGCGCTCCTT ATCGGCGGAC TGGTCTCCTC CAGCGACGTT GCCGCGGCA
251 GCGAACTGAC GGTCAACAA GCCACGGCCA TGAGACCAA AAAGCTGCTG
301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGGCTG
351 CGCGCAATGG GTTGCGCCCA CACTGAGCCA AAAAGCGCAA AACATCAAG
401 CGCGCGCCAT CAACGGCAAA ATCAGCACCG GCAATACGG CTTTGGCTG
451 AAAGAAAAAA ACAGCGTGAT CAATGTGCGC GAAATGTTGC CCGACCAT . .

```

**Number 105 ORF**

```

1 ATGAAACTTC TGACCAACCG AATCCTGTCT TCCGCAATCG CGCTCAGCAG
51 TATGGCTGCC GCGCTGGCA CGGACAAACC CACTGTTGCA AAAAARACCG
101 TCAGCTACGT CTGCGAGCAA GGTAAAAAAG TCAAGATTAAC CTACGGCTTC
151 AACCAACAGG GTCTGACCAC ATACGCTTCC GCCGTCACTA ACGGCAACCG
201 CGTGCAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT
251 ACGGCAAGA AGGCGGTTAT GTTTGGTGA CCGCGGTGAT GGATGGCAA
301 TCCTACGCA AACAGCCCAT TATGATTACC GCACTTGACA ACCAATCTGT
351 CTTCAAGAGC TGTGCCAC GTTAA

```

**Number 106 ORF**

```

1 .ACACTGTTGT TTGCAACGGT TCAGGCAAGT GCTAACCTAT GAAGAGCAAG
51 AAGAAGATTT ATATTAGAC CCGTACAAC GCACTGTTGC CGTGTGATA
101 GTCAATTCCG ATAAGAAGG CACGGGAGAA AAAGAAAAAG TAGAAGAAAA
151 TTCAGATTGG GCAGTATATT TCAACGAGAA AGGAGTACTA ACAGCCAGAG
201 AAATCACCTT CAAGGCCGCG GACAACCTGA AAATCAACAA AAACGGCACA
251 AACTTCACCT ACTCGCTGAA AAAAGACCTC ACAGATCTGA CCAGTGTGG
301 AACTGAAAAA TTATGTTTA GCGCAACCG CAATAAAGTC AACATACAA
351 GCGACACCAA AGGCTTGAAT TTTGCGAAG AAACGGCTGG sACGAACGCGC
401 GACACCCAGG TTCATCTGAA CGGTATTGGT TCGACTTTGA CCGATACGCT
451 GCTGAATACC GAGGCGACCA CAACGTTAAC CAACGACAA GTTACCGATG
501 ACGAGAAAAA ACGTGGCGCA AGCGTTAAAG ACGTATTAAA CGCTGGCTGG
551 AACATTAAAG GGGTTAAACC CGGTACAACA GCTTCCGATA ACGTTGATT
601 CGTCGCACT TACGACACAG TCGAGTTCTT GAGCGCAGAT ACGAAACAA
651 CGACTGTTAA TGTGGAAAGC AAAGACAACG GCAAGAAAAA CGAAGTTAAA
701 ATCGTGCGCA AGACTTCTGT TATTAAGAA AAAGAC . .

```

**Number 107 ORF**

```

1 .GGCACCGAAT TCAAAACCAC CCTTTCGGGA GCCGACATAC AGGCAAGGOT
51 GGGTGAAAAA GCCCGAGCCG ATCGGAAAT TATCCTAAAA GGCATCGTTA
101 ACGCATCCA AACCGAAGAA AAGCTGGAAT CCAACTCGAC CGTATGGCA
151 AAGCAGGCGG GAAGCGGAG CACGGTTGAA ACGCTGAAGC TACCGAGCTT
201 TGAAGGCGCG GCACTGCCTA AGCTGACCGC TCCTCGCGCG TATATCGCGC
251 ACATCCCAAA AGGCAACCTC AAAACCGAAA TCGAAAAAGT GGCCAAACAG
301 CCGAATATG CCTATCTGAA ACAGCTTACG ACGGTCAAG ACCTGAACTG

```

-28-

```

351  GAACCAAGTA CAGCTCGCTT ACGACAAATG GGAATAAAA CAGGAAGGCC
401  TAACCGGAGC CGGAGCGGCA ATTANCGCAC TGGCCGTTAC CGTGGTCAAC
451  TCAGGCGCAG GAACCGGAGC CGTATTGGGA TTAANACGNG TGGCCGCGGC
501  CGCAACCGAT GCAGCATT...

```

**Number 108 ORF**

```

1  ..CGGATCGTGT TAGGTTTGGC GATTCTTGC GCCGTAGTCA CCGTAGTCCC
51  AAGTATAAAC CAAGGCTTTG TCTTCGCCTT TCATTCCGAT AAGGGATATG
101 ACGCTTTGGT CGGTATAGCC GTCTTGGGAA CTTTGTCCA CCCAACGCAT
151 ATCTGCGTCG GGATTCATCAT TGCCGCTTCT TGGCTGCTGA TTTTCTGCC
201 TTCGGGTTTT TCAACTTCGC GCTTGAGGGC TTCGGCATAT TTGTCGCCCA
251 ACGCCATTTC TTTCGGATGC AGCTGCCTAT TGTTCCAATC TACATTGCGA
301 CCCACCACAG CACCACCACT ACCACCAGTT GCATAG

```

**Number 109 ORF**

```

1  ..AGTTTGACT TTACCTGGTT TATTCCGGCG GTAATCAAAT ACCGCCGGTT
51  GTTTTTTGAA GTATTGGTGG TGTCCGTTGG GTTCAGCTG TTTGCGCTGA
101 TTACGCCCTCT GTTTTCCAA GTGGTATGAG ACAAGTGCTC GGTACATCGG
151 GGATTCTCTA CTTTGGATGT GTGTGCGGTG GCTTTGTTGG TGGTGTGCGT
201 GTTTGAGATT GTGTGGGCGC GTTTGCGGAG GTATCTGTTT GCACATACGA
251 CTTCAAGTAT TGATGTGGAA TTGGGCGCGC GTTTGTTCCG GCATCTGCTT
301 TCCCTGCCCT TATCCTATTT CGAGCACAGA CGAGTGGGTG ATACGGTGGC
351 TCGGGTGCAG GAATTGGAGC AGATTTCGCA TTTCTTGACC GGTACAGGCG
401 TGACTTCGGT GTTGGATTG CGGTTTTCTG TTATCTTTCT GGCGGTGATG
451 TGGTATTACA GCTCCACTCT GACTTGGGTG GTATTGGCTT CGTTG....

//

1451 .....
1501 ..... ..ATTGCGCG
1551 CAACCGGACG GTGCTGATTA TCGCCACAGC TCTGTCCACT GTTAAACAGG
1601 CACACCGGAT CATTGCCATG GATAAAGCCA GGATTGTGGA AGCGGGGAAC
1651 CAGCAGGAAT TGCTGGCGAA CG..AACGGA TATTACCGCT ATCTGTATGA
1701 TTTACAGAAC GGGTAG

```

**Number 110 ORF**

```

1  ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT
51  CTACGCCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA
101 ACAGCCCTGAC CGCTATCGGC TTAGCCGTCG CGCAGAAACA GGCAGAGATT
151 GACGGGTGTA ACGCCCAAAC sGACCGCGAA ATCAGA...

```

**Number 111 ORF**

```

1  ATGGTTATCG GAATATTACT CGCATCAAGC AAGCATGCTC TTGTCAATTAC
51  TCTATTGTGA AATCCCGTCT TCCATGCATC CAGTTCGCTA TCGCGTTsGG
101 CAATACGGAA TAAATCTGCG TGTTCTGCTT TGGCTAAATT TGCCAAATTG
151 TTTATTGTTT CTTTAGGAGC AGCTTGCTTA GCCGCCCTCG CTTTCGACAA
201 CGCCCCCAAC GGCCTTCCC AAGCGTTGCC TACCGTTACC GCACCGGTGG
251 CGATTCCCGC GCCCGCTTCG GCAGCCTGA

```

**Number 112 ORF**

```

1  ATGTTTCAGTA TTTTAAATGT GTTCTTCATC TGTATTCTGG CTTGTGTAGT
51  CTCCTGGTGAG ACGCGCTACTA TATTTGGTAT CCTTGCTCTT TTTTACTTAT
101 TGTATCTTTC TTATCTTGCT GTTTTAAAGA TTTTCTTTTC TTTTTCCTTA
151 GACAGAGTTT CACTCGCGTG TCCAGGCTG GAGTGCAAAT GGCATGACCC
201 TTTGGCTCAC TGGCTCACGG CCACTTCTGC TATTTCGCCG CCTCAGCCTCT
251 CAGGG...

```

**Number 113 ORF**

```

1  ..GTGGCGACGT GGTGTGTTTT TTGGTTGCAG CGTTTGAAT ACCCGTTGTT
51  GCTTTGGATT GCGGATATGT TGCTGTACCG GTTGTGGGC GCGCGGGAAA
101  TCGAATGCGG CCGTTGCCCT GTGCCCGCGA TGACGGATTG GCAGCATTTT
151  TTGCCGCGGA TGGGAACCGT GTCCGGCTGG GTGGCGGTGA TTTGGGCATA
201  CCTGATGATT GAAAGTGAAA AAAACGGGAAG ATATTGA

```

**Number 114 ORF**

```

1  ATGTTTCAAA ATTTTGATT GGGCGTGTTC CTGCTTGCGG TCCTCCCGGT
51  GCTGCCCTCC ATTACCGTCT CGCACGTGGC GCGCGGCTAT ACGGCGCGCT
101  ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAAACCC
151  CTGCCCCATA TCGATTTGGT CGGCACAATC ATCgTACCGC TGCTTACTTT
201  GATGTTTCAG CCCTTCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT
251  CGCGCAACTT CGCAACCCG cGCCTTGCT GCGTTGCGT TGCOCGCTCC
301  GGCCCGCTGT CGAATCTAGC GATGGCTGTW CTGTGGGGCG TGGTTTTGGT
351  GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAATGG
401  CAAACTAAGG TATCTGTATC AATGCGATTG TTTCCGCGCT CAACATCATC
451  CCCATCTCTG CTTGGGACGG CGGCATTTTC ATCGACACTT TCTGTGCGC
501  GAAATATTCT CAGCGTTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA
551  TCCTACTGCT GATGCTGACC sGGGTTTTGG GTGCGTTTAT wGCACCGATT
601  sTGCgGmTgc GTGATTGCTT TTGTGCAGAT GTwCGTCTGA CTGGCTTTCA
651  GACGGCATAA

```

**Number 115 ORF**

```

1  ATGAACCTGA TTTCAGTTA CATCATCGT CAAATGGCGG TTATGGCGGT
51  TTACGCGCTC CTTGCCCTCC TCGCTTTGTA CAGCTTTTTT GAAATCTGT
101  ACGAAACCGG CAACCTCGGC AAGGCGAGTT ACGGCATATG GGAATGCTG
151  GGCTACACCG CCCTCAAAAT GCGCGCCCGC GCCTACGAAC TGATTCCTCT
201  CGCCGCTCCT ATCGGGCGAC TGGTCTCCCT CAGCCAGCTT GCGCGCGGCA
251  GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG
301  TTGATTCTGT CGCAGTCTGG TTTTATTTTT GCTATTGCCA CGCTCGCGCT
351  CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAGAGCGGAA AACATCAAG
401  CGCGCGCCAT CAACGGCAAA ATCAGCACCG GCAATACCGG CCTTTGGCTG
451  AAGAAAAAAA ACAGCGTGAT CAATGTGCGC GAAATGTTGC CGAACCAT..

```

**Number 116 ORF**

```

1  ..GCAGTAGCCG AAACCTGCCA CAGCCAGGGC AAAGGTAAC AGGCAGGCAG
51  TTGCGTTTCT GTTCACTGA AAACCTCAGG CGACCTTTGC GGCRAACTCA
101  AAACCAACCT TAAACCTTTG GTCTGCTCTT TGGTTTCCCT GAGTATGGTA
151  TTGCGTGCCG ATGCCCAAAAT TACCACCGAC AAATCAGCAC CTA AAAACCA
201  GCAGGTGCTT ATCCTTAAAA CCAACACTGG TGCCCCCTTG GTGAATATCC
251  AAACCTCGAA TGGACGCGGA TTGAGCCACA ACCGCTA.TA CGCATTGTAT
301  GTTGACAACA AAGGGGCACT GTTAAACAAC GACCGTAACA ATAACTCGTT
351  TGTGGTCAAA GCGAGTGCAG AATTGATTTT GAACGAGGTA CCGGCTACGG
401  CTAGCAAACT CAACGGCATC GTTACCGTAG CGGCTCAAAA GGCOCAGCTG
451  ATATTGTCCA ACCCCAACGG CATTACCGTT AATGGCGGCG GCTTTAAAAA
501  TGTCGGTCGG GGCATCTTAA CTACCGGTGC GCCCCAAATC GGCRAAGGAG
551  GTGCACTGAC AGGATTGTAT GTGGGTCAAG GCACATTGgA CCGTAGAGC
601  AGCAGGTGG AATGATAAAG GCGGAGCmrm yTACACCGG GTACTTGCTC
651  GTGCAGTTGC TTTGACGGGG AAATTwmnmg GTAAA.AACT GCGCGTTTCT
701  ACGGTCCTC AGAAGTAGA TTACGCCAGC GCGCAAAATCA GTGCAGGTAC
751  GGCAGCGGGT AGCAACCGA CTAATGCCCT TGATACTGCC GCACGTGGCG
801  GTATGTACGC CGACGATC ACACGTATTG CCAATGAAA AGCGTAGGCG
851  GTCTAA

```



**Number 117 ORF**

```

1      ..CGCTTCATTTC ATGATGAAGC AGTGGGCAGC AACATCGGGC GCGGCAAAAT
51     GATTGTTGCA GCGGGGCAGG ATATCAATGT ACGGGGCAnA AGCCTTATT
101    CTGATAAGGG CATTGTTTTA AAAGCAGGAC AGCAGATCGA TATTTCATC
151    GCCATAATCT GCTATACGGC CAATGAATAC CACGAGAGCA WAAAwTCAGG
201    CGTCATGGGT ACTGGCGGAT TGGGCTTTAC TATCGGTAAC CGGAaAACTA
251    CGATGACAC TGATCGTACC AATATTGTsC ATACAGGCAG CATTATAGGC
301    AGCCTGaaTG GAGACACCGT TACAGTTGCR GGAAaCCGCT ACCGCAAAAC
351    CGGCAGTACG GTCTCCAGCG CCGAGGGGCGC CAATACCGCT ACAGCCAAAw
401    GCATAGATGT AGAGTTCGCA AACAAcCGGT GTGCCACTGA CTACGCCTAA
451    ACCCaGGAA CAAAAGGCGC TTACCGTCGC CCTCAATGTC CCGGTTGTGC
501    AAGCTGCACA AAACCTCATA CAAGCAGCCC AAAATGTGGG CAAAGATAAA
551    AATAAAcGGC TTAATGCCAT GGCTGCAGCC AATGCTGCAT GGCAGAGTTA
601    TCAAGCAACC CAACAATGCG AACAAATTGG TCCAAGCAGC AGTGCGGGTA
651    AAGGTCNAaA CTACAATCAA AGCCCCAGTA TCAGTGTGTC CATTAC .TAC
701    GGCGAACAGA AAAGTCGTAA CGAGCAaAAA AGACATTACA CCGAAcGGC
751    AgCAAGTCaA ATTATCGCA AAGSGCAaAC CACACTTGCG GCaACAGGAA
801    GTGGGAGCA GTCCAATATC AATATTACAG GTTCCGATGT CATCGGCCAT
851    GCAGGTACTC C .CTCAATTGC CGACAACCA- ATCAGACTCC AATCTGCCCA
901    ACAGACCGGC AGCGAGCAAA GCaAAaACAA AAGCASTGGT TGGaATGCAG
951    CCTACCTm CAaATAGTGC AACCGCATCG GGTTTGAAAT TACCGCCGGA
1001   GAAATATCG GTAAAGGTAA AGACAGAGG GGAATACTA CCACCCGCCA
1051   CACCCATGTC GCGAGCAAA CCGCAaAAC TACCATTGCA AGCGCGGG
1101   GATACCACCC TCaAGGTGT CGAGCTCATC GCGAAAGCA TACAGCGAGA
1151   TACCGCAAC CTGCATATAG AAAGTCTTCA ACATCTAGAA ACCTATCAGA
1201   GCaAACAGCA AAACGGCAAT GTCCAAAGTt ACTGTCCGTT ACGGATTCAG
1251   TGCAAGCGGC AGTTACCGCC AAACCAAGT CAaAGCAGAC CATGCCTCGC
1301   TAAcCGGGCA AagCGGTATT TATGCGGAG AAGACGGCTA TCaAAATyAA
1351   GTyAGAGACA ACACAGACCT yAAGGGGGT ATCATCAGT CTAGCCAAAG
1401   CGCAGAAGAT AAGGGCAAA ACCTTTTTCA GACGGCCACC CTTACTGCCA
1451   GCGCATTTCA AAACCAACAGC CGCTACGAAG CGAGAAGCTT CGGCATAGGC
1501   GGCAGTTTCG ACCTGAACGG CGGCTGGGAG GGCACGGTTA CCGCAAAACA
1551   AGGCAGCGCT ACCyACAGGA TGAGCCCGGC AGCCGGCTAC GGCAGCGAGC
1601   GAGACAGCAa AAACAGCACC ACCCGCAGCG GCGTCAACAC CCaCAACATA
1651   CACATCACCG AOGAAGCGGG ACaACTTGC CGAAACAGCA GGACTGCAAA
1701   AGAAACCGAA GCGGTATCT ACACCGGCAT CGACACGGAA ACTGCGGATC
1751   AACACTCAGG CCATCTGAaA RACAGTTCG AC...

```

**Number 118 ORF**

```

1      ..ACGACCcGGCA GCCTCGGCGG CATACTTGCC GCGGGCGGCA CTTCCTTTGC
51     GCGACCGTAT TTGACAaAAG CGCGGGAaA CCTCGGTCG GCGGGCAaAG
101    CGGCGGTCAa CGCACTGGGC GGTGCGGCCA TCGGCTATGC AACTGGTGT
151    AGTGGTGTGT CTGTGGTGGG TGGGAATGTa GATTGGAACA ATAGGCACT
201    GCATCCGAAA GAATGGCCTT TGGCGCAaA ATATGCCGAa GGCCTCAAGC
251    GCGAAGTTGA AAAACCGGAA CGCAGAAaAA TCAGCAGCCA AGAAGCGGCA
301    ATGAGATTCG CGAGGCAGAT ATGCGTTGGG TGGCAAAAG TTTCCACAGC
351    GGCTATACCG ACCAAAGCGT CATATCCCTT ATCGGAATGA

```

**Number 119 ORF**

```

1      ..CAATGCCGTC TGAAAGCTC ACAATTTTAC AGACGGCAAT TGTATGCAa
51     GTACATATAC AGATTCCCTA TATACTGCCG AGrkCGTGC GTGGCTGAAG
101    ACACCCcCTTA CGCTTGCTAT TTGcAACAGC TCCAAGTCAC CAaAGCGTC
151    AACTGGAACC AGGTACwACT GCGGTACGAC AARTGGGACT ATAAACAGGA
201    AGGCTTAACC GGAGCCGGAG CAGCGATTAT TGGCTGGCT GTTACCGTGG
251    TTACTGGGGG CCGGGAaCG CCAGCCGACG TGGGcTTAAa CGGCGGGGc
301    GCAGCGGCAa CCGATCCCGC ATTGCCCTCG CTGGCCAGCG AGGcTTCCGT
351    ATCGCTCATC AaCAACAaAG GCAATATCGG TaaCACCTGT AAAGAGCTGG
401    GCAGAAGCAG CACGGTGAaA AATCTGATGS TTGCGCTCGc tACCGCAgGC
451    GTaGCGaCa AAATCGGTGC TTCGCAGCT AACAAATGTA CGGATAAGCA
501    GTGGATCAAC AACCTGACCG TCAACTCGGC CAATGCGGGC AGTGCcGCAC

```

-31-

```

551 TGATTAATAC CGCTGTCAAC GCGGCAGCC tGAAGACAA TCTGGAOCCG
601 AATATCCTGT CGGCTTTGGT GAATACTGCG CATGGAGAAG CAGCCACTTA
651 AATCAAAACAG TTGGATCAGC ACTACATTAC CCACAGATT GCCCATGCCA
701 TAGCGGGCTG TCGGCGTCCG GCGGCGAATA AGGCAAGTG TCAGGATGGT
751 GCGATAGGTG CGGCTGTGGG CGAGATAGTC GGGGAgGCTT TGACAAACGG
801 CAAAAATCTC GACACTTTGA CAGCTAAAGa ACCGCaACAG ATTTTGGCAT
851 ACAGCAAACT GGTTCGCGT ACGGTAAGCG GTGTGCTCG CGGCGATGTA
901 AATGCGGCGG CGAATCGCGC TGAGGTAGCG GTGAAAAATA ATCAGCTTAG
951 CGACAAATGA

```

**Number 120 ORF**

```

1 ATGGCAATCA TTACATTGTA TTATTCTGTC AATGGTATTT TAAATGTATG
51 TGC AAAAGCA AAAAATTATC AAGTAGTTCG CAATAATAAG AATATGGTGT
101 TTTTGGGTTT TTGGsmrGC ATCATCGCGG GTTCAACCAA TGCCATGTCT
151 CCCATATTGT TAATATTTTT GCTTAGCGAA ACAGAAAATA AAAATcGTAT
201 CGTAAATCA AGCAATCTAT GCTATCTTTT GCGGAAAATT GTTCAAAATAT
251 ATATGCTAAG AGACCAAGTAT TGGTTATTAA ATAAGAGTGA ATACGdTITA
301 ATATTTTTAC TGTCGGTATT GTCTGTTATT GGATTGTATG TTGGAATTGG
351 GTTAAGGACT AAGATTAGCC CaaATTTTTT TAAATGTGTA ATTTTATTG
401 tTTATTGGT ATTGGctCTG AAAATCGGG ATtcGGGTTT AtCAAACTT
451 TAA

```

**Number 121 ORF**

```

1 ATGTTACGTT TGACTGCTTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC
51 GTGTTGCGCG CAAAATTCGG ACTCTGCCCG ACAAGCCAAA GaACAGGCGG
101 TTTCCGCCCG ACAAAACGAA GgCGCGTCGG TTACCGTCAA AACCGCGCGC
151 GCGCAGCTTC AATAACGCA AAAACCCGAA CGCATCGCGG TTTACGATTT
201 GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGA AAACC GGTTTCTCGC
251 TCGATAAAAA CGCGCTGCCG TATTTAGAGG AATATTTCAA AACGACAAA
301 CCTGCCGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGTTACAA
351 ACCGCAAGCT ATCATCATCG GCAGCCGCGC GgCAAAGCGG TTTGACAAAT
401 TGAACGAAT CGCGCCGACC ATCGrmvTGA CGCCGATAC CGCAACCTC
451 AAAGAAAAGT CCAArGAGC ATCGACCTG GCGCAATCT TC..

```

**Number 122 ORF**

```

1 ATGAGACATA TGAAATACA AAAATTATTTA CTAGTATTTA TAGTITTACA
51 TATAGCCTTG ATAGTAATTA ATATAGTGT TTGTTATTTT GTTTTCTAT
101 TTGATTTTTT TCGGTTTTTG TTTTTGCAA ACGCTTTCT TCGCTAAAT
151 TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC
201 GATTTCATTT ATTATATGGA TGGTAATTC AATTAGTATG ATAAATATA
251 AATTTTATAA ATTTGAGCAT CAAATAAAGC AACAAAATAT ATCCGAGATT
301 ACTGGGGTGA TAAACCACA TGATAGTTAT AATTATGTT ATGACTCAA
351 TCGATATGCT AAATTAAGAG ATAATCATAG ATATGGTAGG GTAATTAGAG
401 AAACACCTTA TATTGATGTA GTTCATCTG ATGTTAAAAA TAAATCCATA
451 AGATTAAAGT TGGTTGTGG TATTATTC AATGCTCCAT GTGCAATTT
501 TATAAAATTT GTCAGG..

```

**Number 123 ORF**

```

1 ..ACCCCAACA GCGTGACCGT CTTGCCGTCT TTGCGGGAT TCGGCGCTAC
51 CGGCGCGACC ATCAATGCAG CAGGCGGGGT CGGCATGACT GCCTTTTCGA
101 CAACCTTAAAT TTCGTAGCC GAGGCGCGG TTGTAGAGCT GCAGGCGGTG
151 AGAGCCAAAG CCGTCAATGC AACCGCCGCT TGCATTTTTA CGGTCTTGAG
201 TAAGGACATT TTCGATTTCC TTTTTATTTT CCGTTTTAG ACGGCTGACT
251 TCCGCCTGTA TTTTCGCAA AGCCATGCGC ACAGCGTCG CTTGACTTC
301 ATATTTTAAA GdTTCGCGC GTGCCAGTTC CAGTTGCGC GCATAGTTTT
351 GAGCCGACAA CAGCAGGCGT TCGCCTTGT CGCGCTCCAT CTGTGCAATG
401 ACCGCTCGCA GCTTCGAAA TGCCGACTTG TAGCCTTGAT GGTGCGACAC

```

-32-

```
451 AGCCAAGCCC GTGCCGACAA GCGCGATAAT GGCAATCGGT TGCCAGTAAT
501 TCGCCAGCAG TTTCACGAGA TTCATTCTCG ACCTCCTGAC GCTTCACGCT
551 GA
```

## APPENDIX C

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1>:

**gnm\_1**

```

5  GAAATTTCAGCAGCAGCAGGAAGATTGCCAGCATTTCGCGCGCGGTTTTAAACTTACCGA
   CGGTGGCGACGGCAACGCTGTTCCTTTTGCCCATTTGCGCCATCCATTCGGCAATGCGGG
   AATGGTAAATTCCTTCGCGATGATGATCATGGCAACAAAACATAGGTCCCGGTGAGATT
   TGAACGAGTAAAGCAAAAGACAGCGGACCATCAGCTTGTGCGCAACGGGATCAGGAAGG
   CGCGAAATCCGAGGTCTGTTTCCACAACTTGCCAAAAATCCGTCAAACCACTCGGTCA
10  AGGCGGCAACGGCAAAATGACGGCGGCGGTGAGATTATCGTTTCTCCCGCAACCCAG
   GAAAPAGGCAGGTAAAAAAGGGCTGTACGAGCAGGAATGAGCAAGACCCCTCAACCATGTGA
   GGAAAGTGGGAGATTCCAAGGCATCGGTTTTCTGTGTGACAGCTGTAAAGTTGTGATTA
   TAAACGGTTATCCTCATAAACCAAAACGTAATAATGCTGCATGGGCATTCCCCGCCCGCGC
   CAATCTGTTTTACATCTTTTCAAACGCAAGGAAATGGCGGGCAATAAAAGCAAAATAC
15  CCAGTTTTCAGGCTGAAAACGGCAGGTTGTGCCAACACTTCGACAAAGGCGGTCTTCGTTGC
   GGGCAAAATCTTTATTGCTTATAGACACTGCCACTGTTGCGGTATTCCAAACAGACCGCG
   TTTAAAAAACCTTTTGGCAGCGGTTTCGCTTAAAAACGGCTCTAACCTGCTCCGCCCTGATG
   GTTCTGCCGATATTGCCGCTGTGCACAACTGTCAACCCATAGACAGGAAAGCCGGTAA
   TGTGCCCGTCTGCATCCAGTTTGATTGCCCTCCGCTGCGGTTGAGGGCGGTACCGTCT
20  AATTCCGCATATTGCAATGTTTTTTCTGTTGTTTCGTTGAAATGCCGTGAGGTGAAGTGAATA
   AAAACCGCGGACAACAGCAGCAGCTTATGCGCGGCAAAACATACCAGCGATATATATAGT
   GGATTAAATTTAAACCACTACAGCTTGGCTCGCTTAGCTCAAAGAGAACGATTGCTCTTA
   AGGTGCTGAAGCAACCAAGTGAATCGGTTCCGTTACTATTTGTACTGTCTGCGGCTTGCTG
   CCTTGCTCGTATTAAATTTAATCCACTATATTTACGCTTACCCTTGTTTTCTCAAATG
25  CCGTCTGAAATAAGCGGCTTAATATATTGTTTACAGTATTGGGAAGCATAAACAGACAAA
   TGGCGTCTGAAATATTTTACAGCGCATTTCTATCCGAACCGGATTATTTTTCGTTTTC
   AACCGCTTCCAATGCACGCAAGGCATTAAGTGAAGCGGCACCGCATTCAGGGCAATGGC
   GGTTCGCAATGCACCTGCGATTTCGCTGTCGTCGACCCGCTTGGTGGCGGCGGCGG
   GTGAACACTGATGCAGTCTCAACAAGTGTAGTAATGGCAACGGCGATGGCAATCAGTTT
30  CGGTGTTTTAGCATCAAGTGCCCTTCGAGCTGCCGCTTGTTCCAATGCCGCGTAGGCTCG
   CAGCATTTTAGGATGCGCCTTACCAGCTCGCGCAACGATTTTAAACCAATGCGGTATG
   TTCTTCCAATCTTTAAACATTTCTTTTCTTCTTCTGCGTTTAAACCTGATACGCGC
   TTGGGTATCTGTTTTCGATGTGCGTATTATTGCAATTAATCAGTTGTGTTTCTCGTTTAA
   TCATCTCATTTTATGGTTCAAAAAGATTTATGGACATTCGGACAACTGGTCGATTTCG
35  CCCAATTGACGGCAGTGTGGATGTGCACTGCCTTTTGGGCGGCAACTGGTCGGTACGGC
   ATGAACCTTGCACCGCGAAGGATTGGTACACATTGTTACATCGGGCAGCGGCTATCTCT
   GCATCGACGGCGAAACTTCCCGCGCTCCGGTCAGTACAGGGGATATTGATTTTCCCGC
   CGGGCTTGGGTATGTGTTGAGCCAGCAGGAAATGCGGAGAAAGTTTCAACACGGATA
   TGGCGGACAGCGTGCCTTACGTTCAAGCAGTGGCGCAACGACAGGATAGAGCCTGT
40  TTTGCGCCGCTTCCGCTACGACACCCACGCGATTGATGAACGGGCTGCCTGAACCG
   TTTTTCTGAACATTGCGCATCCGAGTTTACAGTATGTGGTTTTCAATGCTGCACTGGAAA
   GCAAAAAACCTTTGACGGGACGGTTTCATGGTCAACGCAATGTCGTCGCTCCGTGG
   TGCTTATCTGCGCGCCTATCTCGAACAGGATAAGGATGTGCAACTCTCGGGCGTATTGA
   AAGGTTAGCAGGACAAACGTTTGGGACATTTAATCCAAAGGTGATAGACAAACCGGA
45  ACGAATGGAATGTCGACAAAATGTTGGCGGCTGCCAATATGTGCGCGCGCAACTGATGC
   GCCGTTTTCAAAGCGGGCTCGGACTCAGCCGCAACGCTTTGTGAACCATATCCGCGCTG
   AAAAGAGCGCGTGTGCTGCTGAAAAAAACCCGGAATTCGTTTTGTCGGTGCACGTGCGG
   TAGGCTTTCAGTCGGAACGCACTTCGGCAAGCGCTTCAAACGGCAATACAGTTTCGCG
   CGGCTCAATACCGGAAAGAGCGGGCAAAAAATAATCGGGGCTTCAAACGCAATGCGCT
50  CTGAAGAGGCTTTCATACAGCATTTGCTACCGGCTCATTTCAAGGGCTGCATCTTCATC
   ACTTCCATCAAAAAGTTGTTAAATGCGGGGTTGTTGGGTTGACATCCATATTTTCCAA
   CGCTGCTGCCAGCCGCGCAAGGCATCTGGATATACAGCTTGGACTGTTCCGATTTGATT
   GCGCCCGCTGGCTGTCTATCGCGCAACGAGGTAGATTTCATACATAGTGTATCAGCG
   GCATTCGGTCCGACAGGCGTTTTCTGAAGTTGTTGAGATATGCGCGCCTGAACCTTG

```

5 GTCATTTTACCGATACCCACCTGATAGCCCAAGCGCTCGCTTCATCGTGATTTTGGCA  
 ACATCCGTCCAATGCGAAGAGGCAAGCGGAAACCTTTTCGAGGTGCTTCGGTTTTCGAGG  
 GTATTGATAGGATTCACGGGGATTTTCGTCATGTGGGCACATAAAATAGACTGGCAGCCG  
 GAAAGAACATGCCGCAATGGAAAGAGGGATAAGGTATTTTTCATGCCCCCATTAATATCA  
 10 AGTTTGCCTTGAGAAAACAAATTTGTCGGCAAGAAAATAAAATTTTCGGCATCAGAAAGCA  
 GGCAAAACACATITCCACAAGCCTTGCOCGCAAGGTTTACAATCCGACCGCTCTTATCGCA  
 ACGACCGCTTTATGGATACCGCAAAAAGACATTTAGGATCGGGCTGGATGCTGGTGGC  
 GCGCGCTCGCTTTACCATTAAGACGTATTGATTAAAGAGGCATCGGCAAAATTTGCCCT  
 CGGCACGGCGCAATTTGGTCTTTTGGCGCATGCTGTTTTCACCGCTGGCGCTCGGGCTGC  
 15 CGCCGTATTGCTCGGGACAmCTTCGCGACGCCCATTTGAAAAACCACTTAACACGCGAG  
 TATGGTGGGACGGGGCGATGCTGCTGCTGTTTACGCGGTAAACGATCTGCCCTTGGC  
 CACTGGCGTTACCTGAGTTACACCTCGTCGATTTTTCGCGGTATTTCTCTTCCTGAT  
 TTTGAAAGAACGGATTTCCGTTTACACGCAAGCGGTGCTGCTCTTGGTTTTCGCCGGCT  
 GGTATTCTGCTTAATCCCTCGTTCCGCGAGCGGTAGGAAACGGCGGCACTGCCCGGGCT  
 20 GCGCGGCGCGCGATGTCGGCTGGCGCTATTTGAAAGTGCAGCACTGCTTTTGGCGGG  
 CGAAACCCGGCTGGCGCTCGTGTTTTACCTTTCGTCGACAGGTGTGGCGATGTCGTCGGT  
 TTGGCGGACGCTGACCGGCTGGCACACCTGTCCTTTCATCGGCAGTTTATCTGTCGTG  
 CATCGGGCTGTCCGCGCTGATTGCCCACTGTCGATGACGCGCGCTACAAAGTCGGGCA  
 CAAATTCACGGTTGCTCGCTTTCCTATATGACCGCTGTTTTCGCGCTCTGCTCGCGC  
 25 ATTTTTCCTGGCGAAGAGCTTTCTGGCAGAAATACTCGGTATGTGCATCATCACTGCT  
 CAGCGGTATTTTGAGCAGCATCCGCCCACTGCCCTTCARACAGCGGCTGCAATCCCTGTT  
 CGCCCAAAGATAAAAAATGCCGTCCGAACATCTTCAGACGGCATATCGGGCTTTATTTTC  
 CCGCGCTTCACATCTGCCACTGGCGCACCAATAAATTCATGCCCGCGGTGATAGCG  
 ACCATGATAAAGCTGTTTTCATAATCTCTCGGTTGGGAAATTCGTTATGTCGTTTTCAT  
 30 TATCTGCTGTTCCATCAGCTCAGCGCAGGCTTAATCGAAGCGCGTAAGTAACGAAATTC  
 CGGTTTTTCGCGCACATTCGCGGTTCGAGGAAGTCGTTGATGATTTGTGCGGCTTGGCG  
 ACGTTTTTCGCATCTTTCGGAATCAGCAAGAATCCACCCAAATCCCAACGCCCTCTTTG  
 GGCATCATCAGCGGATTTTTCCTTGGCGCGCGCTCTTCGCGCAGCGCTTTGGCGATG  
 TTCAAATCGCCGCCGAAACCGATTGTTACGCAAGTATCGCGCGCGCCAAATCATCGATA  
 35 AAGCCGAGCAAGTAAGACGTTTGATATTGGGGCGGTTTTCTTGAGTAGGGCGGTGGCC  
 TCCCTGATGCTCTTCGCTATTGCTGCTGTTTCGGGTTTTTACCAAATAGTTCACACCATA  
 GGAATAGATTTCGCGCGCGCTGTCCAAATAGCTGATGCGCATTTGCTTGAGTTTGAACGTG  
 TATTCGGGGTCGAACACCAAAATCCCACTGGTTGTCCGGCAGCTTGTCGATACCCAAAGCG  
 40 TTTTTCACGCGTTCCGTATTGATGGCGAAGGTATTTGTCCCAATAAAGCGGCACGGCG  
 TATTCGTGGCGGGATCGACCCGCTCCATCAGCCTCATCATTTCCGGGTTGAGGTGTTTCA  
 TAATTGGGAATCAGCGACTTATCGATTTTCGATACGCACTGCTTAATCTGCTCGCCGCC  
 ACAACCGCATTTGGACGGCGGACAAATGTCGTAAACGGACTTGCTGTGACGACCTTGCTT  
 TCCAGGTTTCATCGCTGTGCTACACATCATAGTAACCTTGATGCGCTTTTCTTTTCA  
 45 AAATCGGCAACGGTTTCGGGATCGACATATTCGACCAAGTTGTAATTTCAATACGTTT  
 TGGTTTTTCGCGCGGTGCCGGTTTTTCGGCAGCGGTTTGTCCGAACCGCGCACGCTGCA  
 AGCAGCAAGCAGTCAGGACGGCCAGGGCGAGATGTTTGGTCAATTATCATTTCTTGCTATA  
 TCCGGTTGGAGAAAGCGGCCATTATAGCCGATTTGGCAACAGGGCTTCAGACGGCATTC  
 50 AAAATCCCGCCACACTCTTCGAAAAACCGCGCTTCCATAGCTAGAAAAAGGGATTTGGG  
 GTAAGATACGCCGCTCGTTTTCCTGCTTTTACATGACAAGACATTTGAGAGACATTG  
 AAAAAATTTATGAAAACCTCCGAACCTGCCGCAAAATTTCTAAAAATTTTGAAGACCAAG  
 GCCACACCGTCGTCGCTCTCCAGCCTCGTCCGCGACGACGACCCGACCTCTGCTGTTTA  
 CCAACCGCGGATGAACCAAGTTTAAAGACGTTATCTTAGGTTTCGACAAACGCCGTACA  
 55 GCGCGCCACACCGCGCAAAATGCTACGCGCAGGCGGCAACACACAGCACTTGGAA  
 ACGTCGGCTACACCGCGCGCCACCACTCTTTGAAATGATGGCGAATCTCTCCTTCG  
 GCGCACTACTTCAAACGCGACGCCATCCACTTCGCTGGGAAATTTCTGACTTCCCCCGAAT  
 GGCTTAACATCCCTAAGACAAACTTGGCGCACGCTTACCGGAAGACGACGCACT  
 ACAACACTCTGTTTGAACGAAATCGGTATGCCGTCCGAGCGCATCTGCCATCGCGACA  
 ACAAGGCGCGAAATACGCATCCGACAACTTCTGGCAATGGGCGACACCGCCCTTGGC  
 GCGCTGCTCCGAAATTTTTCACGACCGCGCAAGAAATCTGGGCGGATTTCCCGGCA  
 GTCGCCGAGAGACGCGCAGCGCTGGATCGAAATTTGGAACCTGCGTATTTATGCGATTCA  
 ACCGCGACGAACAGGCAATATGAACCGCTTCCCAACCTTCCGTGATACCGGATAGG  
 GCTTGGACGCGATAGCCCGCTCATGACGATGTTACAGCAACTACGAAATCGACTGTG

TCCAAGACCTGCTCAAAGCCGTTGCCGCGGAAACGGCGCGCGGTTTCAGAAATGGAAGAAC  
 CCAGCGCTGAAAGTCATCGCGACACATCCGCTCCTGCTCGTTCTGATTGCAGACGGCGG  
 TCTTGCCCTTCCAACGAAGCGCGGCTACGTATTGCGCGCATATTCCGCGCGCGCTGC  
 5 GCCACGGTTACAACCTGGGTCAAAGCAAACCGTTCTTCCACAAATCTCGTTGCGCGATTGGG  
 TCAAAGAGATGGGCGGTGCTTACCTGAAATGGAAGAAAAACAGCCAAATCGAAGAAG  
 CATTTGAAAAACGAAGAAAGCCGTTTGGCCAAACGCTGGAACCCGGTATGGCTTTGTTGG  
 AAAACCGCTGGTGTAAAGCGGCAAAACATCGCGGCGGAAATCATCTTCAACTCTACG  
 ATACCTACGGTTTCCATACGACTTGACTGCCGACATCTGCCGCAACGCAATATCGAAC  
 CGGACGAAGCAGGCTTCGAGCGCGAAATGGAAGCCCAACGCGCAGCGCACGCGCGCC  
 10 AAAGCTTCAAAGCCAAACGCCCACTGCCCTTATGACGGTCAAGACACCGAGTTTAAAGGTT  
 ATAGCGAACGCCAAACCGAATCCAAAGTCTCGCCCTCTACAAAGACGGCGAGCAAGTCA  
 ACGAATTGAACGAAGGCGACAGCGGCGAGTCGTATCGACTTTACCCGCTTCTATGCGA  
 AATCCGCGGCGCAAGTCGGCGATGTCGGCTATATCTTCTCAGGCGAAAAACCGCTTTGAAG  
 TACGCGATACCCAAAAAATCAAAGCGCGGTATTGCGTCAATTCGGCGTACAAATCTCAG  
 15 GCGCTCTGAAAGTCGCGCAGACGCTTACGCCAAAGTGGACGACGAAATCCGCAATGCCA  
 ATATGCGCAACCAACAGCGCAACCCACTTGATGCACAAAGCCCTGCGCGATGTATTGGCA  
 GACACGTCGAACAAAAAGGCTCTTTGGTTACCGCGCAATCCACCGGTTTCGACATTTCCC  
 ATCCCGAAGCGGTAACTGCCGAAGAAATTCGCGAGTAGAAGCGCGCTCACGAAGCA  
 TTTTGGCGAAGCTTTGCCGTCAATGCAGCCATTTATGACATGGAAGACGCGCAAAAAACCG  
 20 GCGCGATGATGCTCTTCGCGCAAAAAACGCGCGAAGTGGCGGTACTGCAATGGGCG  
 GTTCTCTACCGAATTGTGCGGCGGCAACACGTTTACGCGACCGGCGACATCGGCGCT  
 TCAAAATCATCAGCGAAGCGGTATTGCGCGAGGCGTGGCGGTATGCAAGCGATCACC  
 GCGTGAACGCACTCAAAATGGGCGCAAGAGCAAGAGCGTTTGGTGAAGACATTTATTGCG  
 25 AAACCAAAGCCCAACCGAAAAAGACGTACTGGCAAAATCAAAGCAGCGCGGCAACG  
 CCAAAGCATTTGAAAAAGAAATTTGGCAGCGCGCAAGCGCAACTCGCGCTCCAGCAGCG  
 CCAACTCTTTGGACGATGCAAAAGACTTTGGGCGCAGCCAAATCGTTGCGCGCCAAATCG  
 AAGCGCAGCGAGCCGCCCTGCGCGAAATCGTTACCGATTAAACCGGTAATTCGACAAACG  
 CCGTATTTCTTTAGCGGCGATTAACGACGCGCAAAAGTCTCCCTGTGCGCGGCGTATCCA  
 AACCCTTGACCGGCAAGTGAAGCAGGCGATCTGGTTAAATTCGACGCGCAACGATCG  
 30 GCGCAAAAGGCGCGCGCAGACGAGATTGGCGCAAGCGCGCGCACGGATGCCGACAAAT  
 TGCCCGCCGTGTTGGATAGCGTGAAGACTGGGTGCGGCGGARGCTGTTTGAATGGGGA  
 AAGCGAGCTGAAAGGTTTACGGCTGCCCTTTGTGCAAAAGAGCCGCTGAAAGGCTCTG  
 TTTGCCGTAGGTTGGTTCGCGACCCAAACAAATTTGTGAAGTATAAAATGTTGGTCAATG  
 ACCCAACCTACCTGCCCTTTTGTACAAAGAGGCTATCTGAAAGGCCCTGTTTGGCGTATG  
 35 GTGGGTGCGGACCCAGCAGATTTTATTAGGGTATGACCCAAAGCTACTTGCTACGATAAA  
 AAAGGATTTTAAATGAGCATTAGCCTTATTGGACTACACATTACCATAGCAATCATTTT  
 GTTTTTTACTACAAATTTTATGGGAAAAAATCATCTATATTATTGGCTATTACCAACTGTC  
 TTTTAGCGAAGAAAACTCACTCTCGGCAATTTAATATTTTACAGAGCATTTACCCCTAT  
 ATTATTATCGTTATTTTTCTGGGTGTTTACTAGTCTTGAAATTTCCCATTTCTCTGTA  
 40 AAGAGTAAACTATGTAGTAATTTATTATTTATAATATAGATTGTTATCTGTATTTGTTT  
 TGAGAAACACACATAGTTAACTGGTTTAACTCACTAAACAATACCCATACTTCCATAAC  
 ATTAATCATTTATAGTATATAACAAATGATTTTGCCCAAAAGTTTCTACTTCCATCCCT  
 ACAAGAGTAGCTACTACTTTTGAATAGCGCTTGGTGTACATATATAATATATAA  
 45 TAATGAATCAGGCACTTTAAATCTTTAAGAAGAAAGAGTAAATATGTAACACACAT  
 GCACAAAAAATTTGAAAGTTATTTTGGTAAATTTATAGTAAATAATCAAAGAGGATAG  
 TTATATATATGATGATTTTTTAACCGATAGAAAAAAGCACTAATATATTACAGTTTAAAT  
 TTATGAGAAATTTTAAAGGGGACTAGTTTATAGATATTTTGAAGAAATTTATTGTTGAT  
 GGTAGAAATAAAAACATTTGGAATAATGCAAGTAACCTCAGCAGAGTACCTTCCAAATGAG  
 50 GAAAGTATAAAAAAGGCGGAAATTTCTTATGGAATAATACAATGAAATAATATGATGAA  
 TCTATTGATGCAATAAACTCTCTATAAATCATATTAATGAATCAAGAGAGAGATATT  
 AAAAATCAACCCAGATGCAAAATACATTAATGAAATGAATCAATTTACATGATGCTT  
 GGAGAAATCTATCCAAATGCACAGACTTCATGTCACCAATTTTGGGGGAGCTGCTCT  
 GAGGGGGAAATAAATCATTTATTCTTTATTAGTTATTAGCAGGATTTTGTGCGGCATA  
 55 AATGGCCGACCTACAAATTCAAATTTTTTCAACCTCTGCGCAAAATTTTCACTTTGCAA  
 GGCTGTCTGAAACCCCAACCCCATTTTCAGACGGCTTTTTTCGCTAAAAATCCCATCAT  
 CGTTCAATCGGAAACACAGGAGAAATCATGGAAGTTACCATCTCGGCATCATCAAT  
 GCGCAATTTGCGACCAATACGCGAAGCGCGTAGTCAGTTTAAATGAAACGGGATGCTG

ATTTAATTCATTTTCTTTGAAACTACCAATAAAGCTGCCTCCATCATAAACTTAAAGCA  
 AGCCGTAGCTGCATTCCCACAAACCGCGTGCCTTGCCATGTCACACACCCCTACCTGGGG  
 GCGACGCAAACTTAAGAGACCTTTGCAAAATCCCCAAAATCCCTAAATTTCCACCAA  
 GACATTTAGGGGATTTCTCATGAGCACCTTCTTTCAACAAACCGCCCAAGCCATGATTGC  
 5 CAACACATCGACCGCTTCCCGCTATTGAAGTTGGACCGGGTGATTGATTGGCAGCTGT  
 CGAACCAATACCTGAAACCGTCAAAAACCCGCTTACCTTAGAGACCCAGCGGCGCTCTGC  
 CTATCCCTGCTGCTCATGTTCAAAGCGTCTGCTCGCAATGGCACGCTCTCCGA  
 TCCGAACTCGAACACAGCTCATTACCGGCATCGATTTCAACTGTTTTGCGGTTTTGA  
 CGAATCGAGCATCCCCGATTACAGCACCTTATGCGCGTACCGCAACCGGCTGGCGAAGA  
 10 CAATACCTGTCTGAATGTTGGAAGTATTAAACGCCAACTGACCGAAAAGGTTTAAA  
 AATAGAGAAAGCATCCGCTGCGCTGTTGACGCCACCATTTATTCAGACCGCGCGCAGCAA  
 ACAGCGTCAGGCCATAGAAGTTGACGAAGAAGGACAAATCAGCGGTCAAACCAACCGGAG  
 TAAGGACAGCGATGCCGTTGGATAAGAAAAACCGCCTCTACAAACTCGGTTACAAACG  
 ACATACCCGTACCGATCGAGAAGGCTATATCGAGAACTGCACATTACCCCGCGCAATGC  
 15 CCATGAGTGCAAAACCTGTGCGCGTTGTTGAAGGTTCTGCCAAAGGTACGACCGTCTA  
 TGCCGCAAAAGGCTATGACAGTGGGAAAAACCGCAACATCTGGAAGAACATCAGTTGCA  
 GGACGGCATTTGCGCAAGGCTGCCGCAACCGCGCTGTGGAAGTGCAAAACGAAGCG  
 TAAACGATATTGTCGAAGACCGGTTATGTGCTGAACAAGCTTCGGTACGCTGACCGG  
 TAAATTCGCGTATGCCGGCGAGCTATTTCGGAATGATTAAGTGAGTGGCAAGCCCA  
 20 TCTGAAGCGGATGTGTTTGAACTGTGTAAGGCGCGCAACAGGCTAAGTGGCGCGCGGT  
 CGCCTAAAAGGCGAGCCGGATGCTGATTATCGGGTGTCCGGGAGGATTAAAGGGGGTGT  
 TTGGGTAATAATTAGCGGTTATTGGGCGCAAAACAGCGCAAAACCTGTGTTGGGATTTTCG  
 GTTCTGCTGAGGAAAGGAATTTGCAAAAGTCTCCAGCAGTTTGCGCATACATCCCGTA  
 ACGCCAACTTATACGGCTTACCTCGGACAGCGGGCGTTGGTGGAAATCCCGAATAAGC  
 25 GGTTCAAAACGTGTGCTGCCAGGTAGCCATATACAGTGCTTAAAGCACCGCAGACCTGT  
 CGGCCAAAGCAGCGGCTTTGAAATTTGGCTTCCCGCTCTTCTCGGGTGGCGGGCAGT  
 CGGACCAACTCGCTATCCGTTTGTGCGACAGCGGCCCAATTACAGTAGCATCGGCATC  
 AGCCTAGCGCTGTTATCGAACCGATGCTCTTGATTGCTCCGCACTTGGGCTTTGCCG  
 TCAAAATCGGCTGGGTGTGCTGCTGATTGTTTGTGCGGATTCGTCAATCAGCGGCTCA  
 30 AAATGGGCAATCAGTTGTTGACGCTTCGCACTTCGCTTTCGTGAACCTGATGCAGAGCG  
 TTTTCTCGGCAGTCCGCATATCCGCGGATTTGTTGCGGCGGTTAAACAAAGGCTTCCAA  
 ACTTCTTCGCTTCTGTGGCGGGTGGTAGGGCATGTTTGCAATCTTCTTTCTGCTGCC  
 TTCATCTGTGCGAAGAAGGCAAGCATTTTGGCATCTTTGGCGTGGGTTTGGTCAAGGAC  
 TGGGATTGGGCAACTGATGCTCTGACGCGGGTTGGCGATAATCAGCGCTATGCGCTGT  
 35 CGGTGGATGGCTTTGGCGCGGGGATTTCGAGACCTCCGGTACTTTCCGTCAAGCAGAGG  
 GCGACCTTGTGTTTTTAAGGTATTCGATAGTATGGGCGATACCTTTGGGGTGTGTTGGTT  
 TCGGTTTGGTTTTAGCAAAAGCAGAAACGGCGATGACGAAGTTTCGTTTGGCGATGTGCG  
 ATATAGTTGAATTAACAAAAATCAGACAAAGGCGGCGAGCCGACACTACCGATAGTAG  
 40 GGAACCGATTCACTTGGTGCTTCAGCACTTAGAGAACTGTTCTCTTCGAGCTAAGGCGA  
 GGCAACCGCTACTGGTTTTTGTAAATCAGTATATCTGTGGTACGACGGCATGCGGT  
 CTGAAGGGTGTATATGCTGCATCAAGAAATTTCCGATTCCCTTTAGAGCTATTTCAGCAT  
 CGGCTGGGCTTGTGTTGCTTGGGGCTGTGCTGGGCTTACGGCGCGCTCTGTGGGCTGCT  
 CGCGGCTTGGCGCGCAATCGCTGCTTGGCGGCGCTTCGGTCTGCTGGCTCTTCTGCTG  
 45 GCGGCAATACCTGATCAAAATGTTTGGTACCGAAACGATTTTGTGCTGATTACCGCA  
 CTTGGTGCAATGCTGCTTCAACAGCGCATTCGATTACCGCTATGCTGGAGGACTCGC  
 GCTGAAGCCCTATCAGGACGGCGCGGCGGAGTCTGATTATGTCGGCGTTGCGGAGCA  
 GTTGGCTTTTTCGATGTATCGGCGGCGGCTGTGTCGGCGGCGCTGCAATCTCTGGAGG  
 GACGACGCGCATTTATCTGCTACGGTTGCGCAAACTTTGTACGCGGCTGATCTCT  
 50 GCGGCGGTTGGGCACTCATGATTATGACGCTTTGTTTTTTCGCGCGGCTATGTTTTCTG  
 GCTGAGCTTGAAGCCTCCATCTTGGCGAGCTGCGCACGGCGGACCGGTGCGGACGGC  
 CGCGCGCGGCTGGTGGCATCCAGCTTGCSCCGGCTTTTGTGCGGTGCGGCGGCTATT  
 TGCGCTCGGCGGTAAGTCGACGGTTTTGCGTTGGCATTAATCGGCTACGCGCTGCA  
 55 GCTTTGTTCTTGTGCGGCTGACCGCTGGTTTGGGAAGGTGGTTTTACGATGAGCTTT  
 TTGGGATTTTCATTTCGTTTTCGCGGCAATGGCAGGATGCGGTCTGCACTGGCGGCTTC  
 CGGCTATTGTCGGGCTTGGGGCTGACGCTTGCCACCGCGGATCGCAGGCGTGGGCGT  
 GCTGCTGTGCGTACGCTGCAACCGGATAGCAGCGGGCGTTTTCTGGTACGAGCTGATG  
 CGTTTTCGCGGCTTGTCAAAATGCGCTGTGAAACGCTGGGATTACAGCGGCAATTTTTTA

TTTACACCCTTACAGGTAGAAATTTTCGATGACTTCAAATGTGCTCCAATTTGTACA  
 CCAACGGCTGACCGGTGCGGATTTCCAAGCCCAATATGCTTCGTCGGAAATGCCCTCGA  
 TGTGTTTTTGGCAGCGCGCGCAGGGAGTTGCGTGCCTCCCGCCACCAAGACGCGTTTGGCCG  
 TCAAGTAAATCGCGGGGCGATTTGGTCTTCCCAAACCGCAATACGCGCTCCAGCGTTACTT  
 5 TCAAGTTTTCGCGGTGCGGTACGACATCGCAGGCAGATGGGCATAGCGGCGGCTTTGTG  
 GTGCGGAAACTCATGCTCTTGTCCAAAAGCGCGCGCAGGGTGTCTAGCTTCGCGCGCG  
 AGATCCCGGACTTGCTCGTCGCCCTATTGTTTCGCGGGTTTGTGTTTTTTCGACGGCCTTGCA  
 TTGCGCGGTGATGGCGTTTCGTTACGCCGCCACAGTTTGTATTTCGGGTACGAACGATTGCT  
 CGGATTCTTCCAAAACGATGTTGACGGTCTTAATCGCGCGGGTCAGGACGGATGTGAAGG  
 10 CGATGTCCAACTCATAGCCGTTTCTTTACGTTTCTTGCGCGCGCGCGCAGCCTCGGCA  
 GCGCCTGTCTCGCTCAGCTTCACGTGCGGCCAGCCTGTAAACAGGTTTTTCGCGTTCCATT  
 CGCTTGTGTCGTTGCGGATATAAATACCAAGTTCCATATCGTCTCCAATGTGTAAAGTGGGA  
 AAGCCTTATTATAACATATTTTACATTTCCCGTATTGATTAGATTACAGACACGCGC  
 CCACATTAGGTTTGGCGTTTTGATTTACAATAATGTCCTTTGCTTTACATTCCGATACAC  
 15 AATGAATACGCAAGCGCACGCCCAATACCGATTCCAATACGCTGATGCTCGGCCGATA  
 CGCGCAACGCGCCTATCTCGAATACGCCATGAGCGTGGTCAAAGCGCGCGCTGCCTGA  
 AGTTTCAGACGGCCAGAAAGCGGTGACGCGCGCGCAATTTTGTTTGCCATCGCGATATGGG  
 TTTGACCGCGGGGCGAAGCCGCTGAAATCGCGCGCGGTGGTGGCGGAGATTTGGGTAA  
 ATACCAACCGCACGCGGACAGTTTCGCGCTATGAGCGATGGTGGGATGGCGAGGATT  
 20 TACCTTGGCGTATCCCTTAAATCGACGGCATCGGCACTTCGGCTCGCGCGACGCGGACGG  
 GCGCGCGCGCATGCGTTACACGGAAGCGCGGTGACGCGGATTGCGGAATTGCTGTTGTC  
 CGAAATCAATCAGGGGACGTTGGATTTTGTGCCGAATACGACGGCGCGTTTGACGAACC  
 GCTGCACTGCCCGCCGCGCTGCTATGTTGTTGCTCAACGGCGCGTCAGGACTTCGCGT  
 GGGCATGGCGACCGAGATTCCGCGCCACAATTTGAACGAAGTAGCGACGGCGGGATTGC  
 25 TGTGTTGAAAAAGCCGACGCTGSAACCGCGGACCTGATGCAATATATTCTCGCCCCGA  
 TTTTGGCGCGCGGTCAAATCATCAGCGCGCGGACGAATTCGCGCGGATTATGAAC  
 CGCGAAGCGCAGCTGCGCGTGCCTGCGCGTTATGAATCGAAAAATTTGGCGCGGACA  
 GTGGCGCTCATCGTAACCGAGCTGCGCGCGAAGCCAAATCCGCGCAAAATCCTTGGCGA  
 AATCGAAGAGCAAAACCAACCGGAACCGAAGCGGGTAAGAAACAGCTCAACCAAGACCA  
 30 GCTCAATACCAAAAGCTGATGCTGGATTTAATCGAACCGGTGCGCGACGAGTCCGACGG  
 CGAACATCCCGTGGCATGTTATCGAGCGCAAAATCCAGCGCATCGATACCGATACCTT  
 CATCAACACGCTGATGGCGCAAACTTCGCTGGAAGGCAATGTGTCATGAATCTTGTGAT  
 GATGGGTTTGGACAACCGCGCGCGCAGAAAAAATCTGAAACGATTTTGACGAGTAATGGCT  
 GGATTTCCGCACCGTAACCGTAACACGCGCTCTGAAATTCGTTTGAACCAAGTGGAAAA  
 35 ACGGCTGCACATCTCGAAGGCGCTCTGAAGTCTTCTGCACATCGACGAGTGATTTAA  
 AGTCATCCGCGAATCAGACGACCGCGAAGCGGATTGATGGCGCGCTTCGGGCTGACGCA  
 AATCCAAGCGGAAGACATTTTGGAAATCGCGCTGCGCCAGTTGGCGCGTTTGGAGGGTTT  
 CAACCTCGAAAAAGAAATGAAACGAGTTGCGCGAGGAACAAGCGCGCTGAACATCTTTT  
 GAGCGACGAAAAACGAAAAACGCAAGCTGATTGTCAAGAGATGACGCGGATTTGAACAA  
 40 ATACGCGGACGCGCGACGCGACGCTGTTGGAAGAGGCGCGGACGCGCGTGTGACGCGAGAC  
 CACGCGCGACGAAACCATACGCTGATCTGTGCGAAAAAGGCTGGATACCGACGCGCGC  
 CGGACACAATCTCGATTGAGGCAAAACCGCGTTCAAAGAAGGCGACTGCTCAAAACAAAC  
 CTTCGAAGGCGAGAACGTTTTTACCGCTGCTCATCTCGATTCACTCGGGCAGCACTACAC  
 GCTCGATTGCCCGCAAAATCCCGGAGGGCGCGCGCAGCGGCTACCGGTTTCTCCTTAAAT  
 45 CGAGCTGCAAAACGCGCGCAAAACCGTTGCGATTGTGACAGGATTGCCGGAACACATTA  
 TTTATTATCAAGCAGCAGCGGCTATGGCTTCATCACCAGCTGGGCGATATGTTGCGGCG  
 CTTGAAAGCGGGCAAAAGTGGTGATGACCGCGACAGCAGCGCGAACCCTTTTGGCGCGGT  
 TGCCGCTATGCTCTCTGTTTCATCAACCCGCACTGCAAAATCATTTGCCGCCACAGTCA  
 ARAACGGCGCGCTCGCTTCCCATCGCGCGAATGAAATTTATGGCGAAGGCAAGGCGGT  
 50 GCAAAATCATCGGATTAAACGCGCGGCAATCGATGACGATACCGCGGTTTCTTCGAGGT  
 GGAAATCGTGATTGAAGCGGAAGGCGGCGCGCGCGCGCACAAAGACCGCATCCCAT  
 TCTCCCTGCTTGAGCGCAAAACGCGGCAAAAAAGGCAGACTATTGCCATATCGGCGAGCCT  
 GAAACAGCTTCTTCTCCCTAAATAAACCCGGTTCCGCGACATATTATGGTGATTTCACAAAC  
 CCGCGCAACTTGAAAAACTCAAGACCGGATTCCCAATCTGATCAACATCATCCGCGGTG  
 55 CCATCGTTTTTCCGCTGATGATTATGCACATCTCGGCTGGAACCGCGCAGCGGTGCGA  
 ACCTCCACGCTTCGTGGACGCGGTGGCGTTTTATGTTTGGCTCGCAATGCTGCTGGC  
 TGATTTTCTTTTCCATTATCCATCGCATTGGCAATGGGACTCGCTGAAATGCCCGTT



TCGAGCGGGTAGCGGACATCACGATGATCGGCGTGTGACCTACCTCTTCGGCGGCATCG  
 ATTCGGGCTTCGGGATCCTGATCCTGCCCTTCGTGCTGTGCTCTGCTGCTAGCTACG  
 GCGGCTACCCCTGCTCTATTCCAGCTACGCCGCACTCTGCTGATATTCAACGCCCAATTG  
 CGAGCGGGATATCGGCAAAATACCGCTCATATCGATGCCGGAACCCCTCGGCAACCT  
 5 TCACTCCTGTGCGCCGCTCCTATCTTTCGGCCATCTTCACTCACTGTTCGGTCAAAATACA  
 TCGACCGTTCGGGAAAACTCGCCCTACGACGCCATATCGCCTACCAACCGCATCAAGGCT  
 TGAAGCAAAACCGTACTCGAAGCGGTTCAGGAAGCTGTGCTGTCATCATGCGGCAAGGCG  
 TGGCGGCTGCTGTTCAACCGGAAGCGAAGACCTTTCCCGCGGCTCAAAATCGAAGCGG  
 10 GCGCGGCTGTGTCGATTCTGCGCGCGAATCTGGGATCAAGCCTCTCGCACACTTTCG  
 AATACGCTCTCGGCACACCGGCGCTGAACGCCGCGCATCGCGCGGCTTCGGTCAACAAAG  
 GGTTCGGAAGCTGTCTATCTCTACATCCGCCCGCAAGCGAAATTCAGGCAGAAAGCCC  
 TGTGCTCAAACTTGC CGCGCTCGGACAACTGACGCCCAACCTCGCCACGAAATCGCA  
 ACCCGATGTCGCGCATCCGCCAGCGCAACGACTGCTGCGCGAAAAATGGAAGCGGGGG  
 CGGCAGATTCGTTCAACGCCAAATTTGTCAAAATCATCGACGGCAACATCTCGCGCATCG  
 15 ACAAATCTCTGAAAGACTTTCTCGCTCAACACCGCAACAAACCGAACGCGAAACCA  
 TCGGCGTGATACCGTTTTCGGGAAGAAATCAAAACAGAGTTCTCTGCTCGGCATCCGGATG  
 CGCGAGCTGCATCGTCCGGACATTCAAGCGCGGACGCCGACCGCTATTTCGATCCGG  
 CCCACTTCGCGCAAAATATGTGGAACCTCGCCCAACACCGGTGGCGGCACAGCGCGAAAC  
 AGCCCGGCTCGATTTCCGTCACCATCGCCCGCGCAAAAAACACCTCTGTGATCTCTCT  
 20 TTGCGCACCGGCCGAAGTGCAGGAACACCTGTTGAAACCTTTTACACCAAGCGGGAAAA  
 CGGCACCGGCTTCGGGCTGTATGTGCGCCCGGCACTGGCGCACGCCAATTCGGCGATT  
 GACCTACTACTCGGAAGCCAAATGTTTCGAACTCACATTACCGGAAAAACCAATGACTG  
 AACTGCAACACCCGCTCTGCTGCTGATGACGAAACCGACATTCGACCTGATGGAAA  
 TGAACCTGATGAAAAATGGGCTTGGCGCTCCATACCGCTCAGGCGTTGCCGAAGCCAAA  
 25 ACAAGCTCGACAGCCAAAGCTATTGCTGCTCGCTCGACGATATGCGTATGCGGACGCGT  
 CGGGGCTGGAAGTCTGCAACACATCAACAGCGCGCTGCTCGATACGCGGTTGCGGTCA  
 TCACGCGCTTCGGCAAGCGCGATCAGGCAACGGAAGCGTTGCGTTGCGGCGGTTTCGACC  
 CGGATACCTTCAGATACAGGACTATCTCGACCAATCGAACGCGACATCATCGAACAAA  
 30 CCTCAACAAACCGAAGGCCACCGCACGCGCGCGCAACCGCTTGGGCATCAGCTTCC  
 GTTCCATGCGCTACCGTATGAAACGCGCTCAACATCGGCTGACGACAAAAACGGCATCCGCA  
 CCATCTCCGCCCAACCGAAAAAATGCCGCTCTGAAACGGCACGGGAAGCGGGTTTCGCCCC  
 ACGCCCGAACCGGACAAAAACCATGACCGACATCCTTATTGACAAACCGCCGCAACGAA  
 ACCGTCCGCAACCTGATACGGGCACTTCCCGCTTGTGCCGTTTCCCAACCGCCCGAACAA  
 GGCAGTTACTCTTTCGCGAACAGGATACCGTCAAGCTCAGGCTTTCGGGAAAAAAGC  
 35 AGCGTCATCTGATTTTGCTCTCGGCGCGGCACAATACCGGCGCAAAAAAGCGGGGGC  
 GAACTCATCGCAAAGCGCTCAACCAACCGCGCACCCGCCCTTTGAGACCAACCGCA  
 GGAATTGGGCGGACAGCTTCTGCTCTCGCTCGCTCGGCTGGCGCTTACCGCTTCGAG  
 CACATCCCGCGTCTGCTGCTGCTTCAGACGGCATCCGCGCGGCTCTCTCAATCCC  
 40 GAAACGCAAAAACCGCGCGCGACATCAACCTCATTTCGGCAACCGCGCGGACAAAAATG  
 CCGGCACTTGTCCAAAAACAAGGCAACCGGACATCGTCTATCTCGACCCGATGATCCC  
 GAACCGCGCAAAAGTGCCGCGTTAAAAAAGAAATGACCTACTTCAACCGGCTCTGCGG  
 GAAGCGCAAGTGAAGCGGCACTCTGATACCGCACGCGCAACAGCAAAAAACCGGCT  
 GTGCTCAACCGCGCGCGCTCGGCGAACACTTGC CGGCAAGAACCTGCTGCTACCAATC  
 ACAGGCAAAAGCACCGCTTCGACGTTTACCTGCGCTACGGGACGGAACAGGGATGAAGC  
 45 CCATAAAAACAAGACACGAAAAAATTTGCGGTTCTTATGCAACAGGAAACCGGTTTTCG  
 GTTTCGACTGTTTGGATTAAGTATCACACCTTAAAGTTTGTCACTCCACAGAAAGTGGG  
 AATCCGATTCATTCACTTTATAGTGGTTTAAATTTAAACCACTATAGTTGTTTCGAGT  
 TTTACGCAACTTCCAAACCGCTATTCCACGGAAGTGGGAATCTAGAAATGAAAGCAAC  
 AGGAATTTATCGTAAATGACTGAAACCGAAGCGGACTAGATTCCCGGCTACGCGGGAATGA  
 50 CGGGCGGCGGCGATGCGGCTGGAATTCGCTCATTCGCTGAAACCGGAACTAGAACT  
 TCTGATTTTTCAGACGACTTTTGAACATTGCCGCCACCAATGATCTGGATCCCACTG  
 CGCGGGAATGACGAGGTTTTCAGGTTGCTGTTTAAAGTTGCTGTTTCGGGTTCGCTTTT  
 TTATGGAATGACAGGTTTTCAGATTGCGAGAAATTTATCGGCTCTCGCTCATCTCCACG  
 GAACTGGGAATCCAGAAATGAAAGCAACAGGAATTTATCATAAATGACCGAAACCGCAAC  
 55 GGACTAGATTTCCGACTGCGCGGGAATGACGGGCGGGAGGATGCCGCTGTAATTCGCT  
 CATTCGCGTGAACCGGGAATCTAGAACTCTGATTTTCAGACGACTTTTGAACCTGCG  
 CGCTACCCAATGATTTGGATTCCGCGCTGCGCGGGAATGACGATGTAAATTTTCGGGA

T T C A A A A G A C A G G C T T T C A C A T C C G T G G G A A T G A C T G C G G A A A G A T G A T T T T A T A G T G  
 G A T T A C A A A A A A T C A G G A C A A G G C G A G C C G C A G A C A C T A C A A A T A G T A C G G C A A G G  
 C G A G G C A A C G C G T A C T G G T T T T G T T A A T C C A C T A T A T T T G T C A T A A A A A T C G C C A C C  
 T T A A T C A G T T G G C G G T T A A A T C A A A C T T T A G G G T G C A G A T T A C T T T T A T G A T T T C A G A  
 C A G C A T T T T G A C A G C G G C A G C T A T T T C G G C A A T A C C A A A A A C T T A A T C A C A G T T C T T  
 T G A A T A C A A A A C C G A A C A C G C C A A G C C C A A A A C C A A A A A A A A T G G C G A T G C C G A A T  
 T G C T G C T T T T G G A C T C C T T G C C A A A T T C A A A C G A T A A A A C C A A A A A A A A T A A T C A A G C  
 G C G T C A G G C A G A T T T C A A C G C C A A T C G G A A A A A C C G C T T C A T C C A T A T T T T T T C C T  
 A T T G T T G A T G T A T G C C A T A T A A G A T A A G G G T T C A G A C G G C A T C T G C T G C C A A T G C C  
 G T C T G A A A C A C G C A A T C A G C G T G C G A G T G C C T G T T C A A A T C G T C A A T C A A A T C G C C A C  
 A T A T T C C A A A C C G A C C G A C A G G C C A C A A T C C G G G G C G G A T G T T G G C G G C G A G T T T T C  
 T T C G G G C T G C A T C C T G C C G T G C G T G G T T G T C C A G G G T G G G T A A T G G T C G A G C G C A C G T C  
 A C C A G G T T G G C G G T G C G G A A A A G A T T C C A C G C G T C C A C A A C T T C C A C G C G C T T C  
 T T G A T C G G C A A C T T C A A A G C G A T G A C A T G C C G C C G C G T T T G C T G T T T G C G G A T A A G  
 C G C C G C T G A G G A T G G T C G G A C A A T C C G T G T A G T A C A C G C T T G A A C C T G C G G C T C G C  
 T T G C A C C A T T G T G C A T T T T C A G G C G T T G C A A C T G T T T T C C A T A C G C A G C A G  
 G G T T T C C A C G C C G C T C A A C A A C T G C C A C G C A T T A A C C G G A C A T C C C A G C C G C A A G A  
 G T T G C A A T C A T G G C G A C C T G C G C C A A C A C T C T T C G A A C C C G C A A C A C G C C G C C A T  
 C A C A C G C C G T G T C G C T A T A G G C T T T G G T C G G A G A A A C G G A A A T T C C G A C C G T G  
 T T T C A A A G G C T G C A G C C G A C G G G C A C A C A G G C T G T T G T C C A C C A C C A A G A G C G C C  
 A A T G C G G T G C G C C A A T T C G C C A A G G C T T C C A A G T C G G C A C T T C G C C T A A G G G T T G G A  
 C G G C T T T C C A A A A C A G C A G T T T G G T A T T G G C T T T G A C G C G G C T T C C A T T C G T T A A  
 A T C A G T C G G C A C A C G T G G C T C A C T T C G A T G C G A A T T T G G C A A C A T G T T A T T G A T A A  
 G C C A C G G T C G T G C G A A C A G G C T G C G G T G G A A A T C A C A T G T G C C C G C C T G C A A A A A  
 G T G A A A A C C C G C C T G A A T C G C A G A C A T A C C G C C G A A G T G G C A C C G C G C T T C G C  
 A C C T T C A A A G C G G C G A T G C G T T T T C A A A G C G G C T T G G T C G G G T T G G C G T A C G G G T  
 A T A A G T A A C C C T T T G A T T T T T T G A A A C A A A T C G C A G C G T T T G G G C G T T G T C C C A  
 C A T G A A G C T G C G G T C A G A A A C A A T G C C T G A T T G T G T T C G C G G A T T C G G T T T G T C T T T  
 G C C C C C G T A T G G C A G C G G T T T G C G A T G G A G T T T T T G C T C A T C G G T G A T T C C T C G G T  
 T T T T C G G T T C G G C A A C G G A G C G T G C G C C G T T G T T A A T T T G T A A T A T T T T G C G C C T G  
 T T C A T A T G A T G C T T C A A G T C G G A T G A G A A T G C A A A T G C C G T C T G A A A C G G C T T C A G A C  
 G C A T G G C A A T C A G C G T T T G A T T T T A A C T C G T A C T T G A T G T C G T T G A G G A T T T T G C G A C  
 A T C G T G T T C C A A C A C G T C T T C G A T A C C G C C C C G C T G C T C G T G C A G C A T C T G C T G G A G  
 C T G A T A G G T G A A A A C C G C A T C T G C T T T T G C A C C G C G T T C G A T G A T G C G G T T G A C G G T  
 A T C G G T C A G A T G C G G G C G A G C G G T T T G A T C A G C G G T T C G G T C A G C T C C T G T T C G A C A G  
 G C A G A A C A C T T C G C G C G G T T G A C G C G C T T C G G G T T C A G G A T A T T G A T T G G A C G G C A T  
 C A A G C T T C T T C C G C A T C G T T T C C C G C T T T C G A A A C C G C G G C T A T T C G T G C C G G A  
 T T T C G C C T C G C G G C G T T T C C C G C G T T C A A T C T G C G G T T T C A A T T C G A C A C T G T C  
 T T T T T G G A T C A A A C C G G A T T C C G C C G C A T T C G A T G T G T T T T C G A A A C C G A C A T  
 T T G C A G G A A G C C T G C G C G T T G A G C C A G T T T C C T G A A G A C A C A T C A T C G G G T C G G T T T C  
 G A C T C C T C G C G C A A T C G G A A C C G C G C A T T G T G T T C C T C G C A T T T T C C G A T A T T T C A G A T A  
 G C C C T T C A A C A C A C G G C T C G G C T C T C A T C G T C C A G T T T C G G C A C A G G C G C G T C G G T T C  
 G G T T T C A G A G G G C G G G A C A G C G G C G C T A A G T C G G C A C T G C C T C A T A C G G C G C G T C G  
 A C G C A G G T T T C C A A A C G T T T T C C A A T T C G G C T C T T A T T C G C A T C C A T T T T T G C G G T T  
 C G G T T C T T A A T C T T T G C A A G C A G A C A A C C C G C C C A A A G C G C G G T T T G A T A T A A T G G  
 C G C A T T T A A C A G A T T C G C G A G A T A C A T C A T G G G C A G C A T G A A C A C G G T T T G G A A T A T  
 C G A A A G A G C G A A C G A C G T G C T C G G T A T G C A G A A C C A C G T C C T G T C C A C C G C A T T C A A A  
 G C C T T A A T C C G C G C C T T C C C G C G A A A C C C G A A A T C G G G T C G A G T C G A T T C A G C T T  
 G C T T T T G A G A C G C C T T C G C A G A A T G A G C A T A G A G A C A G C C C G A T A C G A A T T A T T C  
 C A C A G C G T A C T T A T G C G T T T T C G G T G A A A A A G A A G T T A A T T T A T G T T A A A C T G C T  
 T T T A G G C T T T T G A T T A C C G A A A G G A A T T T G A T G A A T T A A A A A A T G G A T T G C C G C C  
 G C C C T T G C C T G T T C C G C G T C G C G C T G C T G C C T G C G C G C G T C A G G C A A A G A T A C G C C  
 C G C C T C C G C C A A C C C G A C A A A G T T A C C G C G T G G C T T C C A A C G C C A G T T T G C C C C  
 T T T A A T C T T A G A C T C G A A A G G C A A T T C G A A G G T T C G A T G T G G A T T T G A T G A A C G G  
 A T G C G A A G G C G G G C A A T T T A A A A T C G A A T T A A A C A C C A G C G T G G G A C A G C T T T T C  
 C C C C C T T A A A C A A C G G C G A T G C G G A C G T T G T A G T T C G G G C G T A A C C A T T A C C A G A C  
 C G C A A A C A G T C T A T G G A C T T C A G C A C C G G T A T T T G A A A T C A C C A A G T C G T C C T C G T

CCGAAAGGCCAAAAGATATCTTCTCCGAAGATTGAAAAACATGAACAAAGTCGGCGTG  
 GTAACCGGCTACACGGGCGATTCTCCGTATCCAACTCTTGGGCAACGACAAATCCGAAA  
 ATCGCGCGCTTTGAAAACGTTCCCTGATTATCAAAAGAACTGGAAAACGGCGGCTTGGAT  
 TCGGTGGTCAGCGACAGCGCGGTCATGCCAATTATGTGAAAAACAATCGCGCCAAAAGG  
 5 ATGGACTTCGTACCTTCCCGACTTACCACCGAACACTACGGCATCGCGGTATCGCAAA  
 GGGACGAAAGCAACCGTCAAAATGCTGAACGATGCGTTGGAAAAAGTACGCGAAAGCGCG  
 GAATACGACAAGATTACGCCAAATATTTTGCAAAAGAGACGACGAGGCCGCAAAATAA  
 GCCCGCGCTCCGAACAATGCGCTGTGAAGCCCTTCAGACGGCATGTTCATCAATC  
 GGCTCAATGAATGCTGCTGATTCTCCCTACCGCAAGCAACAGGCAAGGATTACAA  
 10 AATATCAAAATCCGATAAAACAGTATTTTATTAACAAATTTGATAATCAAGAGATTAG  
 AATTATGTAATTGCTTTACCGTACAAACGCTGGCACTATTCAACCTGATAAAAAACAGC  
 CTTCAAAAAGGTTGTTTAAACAGCAGCAGACACTTACCGCCACAACTTGAAGAGAAC  
 ACAATCATGACCGTCATCAACAGGAAGACTTTATCCAAAGCAATTGCGATGCCTCCAA  
 TTCAATCAGCTACTATCATCCCAAGACTACATCGACGCGCTTTATAAGGCGTGGCAGAAG  
 15 GAAGAAAATCTCGCGCAAGACGCGATGACGAGATTTTGGTCAACAGCGGTATGTGT  
 CGGGAACCAACCGCCCATCTGCCAAGACACAGGTATCGCAACCGTCTTCTCAAAGTC  
 GGTATGAACGTCCTAAATGGGATGCGGACATGAGCGTGAAGAGATGGTTAACGAAGCGCG  
 CGCGCGGCTCACTTGGGAAGGCAATACGCTGCGCGCTTCCGCTCGCGCATCGCGCG  
 GGCACAAAGCCCAACCAAGACCAACACCCCGCGCTCATCCATATGAGCATCGTGGCG  
 20 CGCGCTAAAGTCGAAGTAACTCGCGCGCAAAAGGCGGCGGCTCGAAAAACAAATCCCAA  
 CTCGCCATGCTCAATCTTCCGACCAACATCGCTGGGTATGGGATTTGAAAACCATCCGACC  
 ATGGCGCGGCGCTGGTTCCTCCCGGCATCTTGGGTATCGGCATCGGCGGCAACGCCGAA  
 AAGCCGCTGCTGATGGCAAAAGATTCCTGATGAGCCACATCGACATCAAGAAATTCGAG  
 25 GAAAAGGCGCGCTCGCGCGCGGAATTGTCCACCAACCGAAGCCCTCGCGCTCGAACTCTT  
 GAAAAGTCAACGCGCTGGGCATCGGCGCACAAAGGCTTGGCGGACTGACCAACGCTGTG  
 GACGTGAAATCTCGATTACCGACCCACGCGCGCTTCAAACCGATTTGCCATGATTCG  
 AACTCGCGCGCACCGCGCCACGTCGAATTTGAATTTGAGCGCTCAGGCGCTCGAACTC  
 ACGCGCGCGCGCTCGAAGACTGCGCGGATTTGACTTACAGCCCGACAAACGCAAAACG  
 GTCGATGTCGACAAGCTGACCAAGAAGAAGTGGCAAGCTGGAACACCGCGCGACTTTG  
 30 CTGTTGAACGGCAAAATCTCACCGCGCGCATGCGCGACCAAAACGCTCGTCGATATG  
 CTCACAAAGGCCAAGAATTGCCCTCGATTTCACCAACCGCGCTGATTACTAGCTCGCG  
 CCGCTCGATCCGCTCGCGATGAGTCTGCTCGGTCGCGAGGTCGAGCACAGCGACCCG  
 ATGGACAAATTCACCGGCCAAATGCTCGAACAAACGACCTCTTGGGATGATCGGCAAA  
 35 TCCGAGCGCGGCTGGCCACTCGCGAAGCCATCGCGGACAAACAAAGCCGTGACCTCATG  
 CGAGTCGCGCGCGCGGCTATCTCGTGGCAAAAGCCATCAATCTTCAAAGCTCTTGGCG  
 TTCCCGCAATTGGGCATGGAAGCCATTACGAATTTGAAGTCAAAGACATGCCCGTAACC  
 GTCCGCTCGATAGCAAAAGCGAATCCATCCAGGCCACCGCGCGCAAAATGGCAGGCG  
 AAAATTCGCGATCATCCCGTCGAATCTTGAGCGGCCATGCGCTCTGAACACAAATCTGCG  
 40 TCTCAGACGGCATTTCCGCGCCCGGTTGCGGTACAATCCACCATTTCATCACTCGCGGAC  
 CCACCGCTGAAAAATCTCATTTTAGGCAACGGACAGGTAGCTTCTACCGCTCGCAAAAA  
 CCTTGCCGCCATACCAACAAACGAGCTTAACCGTTATCGCATCGAGCAAAAAGCATTTGCA  
 GAAACAGGCGAGCGGCTCGATGTCCAACCGGTTTTCGGCAACGCGCATCCCCCTTACG  
 45 ATTGAAGATCGCGCGCGGGAAGATGCGCACTTGCTGCTCGCGCTCTCCGCGACCGGACA  
 AACCACATCGTCGCTGCAAAAGTTGCCGCGACCTGTTCAACATCCCCGCGCGCATCGC  
 CGCGCTCCGTTCCAGCGAATACCTCGAATACCTCAGCCCCAAGCTCGAAAACACGAAAA  
 CGGACGCTTTCCATATTCGGCATAAACGAAACCATCAGCCCCGAACAGCTCGTTACGGA  
 ACAGGTTTCGCGGCTGATAGACTGCCGCGGCGCATTCGAGGTTTACGTTTTCGACAGCA  
 CGCGCTCGGATGGTCAATACAGGCGCGGCGCGCGGCGGACTGCTTTCGCGACGACGAT  
 50 TCGCGCATCGCCCAAGATTTCGCGGACGGGCGGACTGCCAAATCTGCGCGGTTTACCG  
 CAACAAACCGCTCATCTGTCGCGCGCGCAACCGCTCATCTCGAAGCGACGAATCTCT  
 ATTTGCGCGCGCGCGGAAAAACATCGGCGGCTCATACCCGAATTCGCGCCAAAGAAAC  
 CAGCAACCCGCGCATCATGATTGCGCGCGCGGCAACATCGGCTACCGTCTCGCCAAAGCA  
 GCTCGAACACGCATACAACGCTCAAAATCATCGAATCGCGCGCGCGGCTCGCGAATGCT  
 55 AGCGGAAAACCTCGACAAACCTCTGCTTGCAGGTTTCGCAACCGACGACAAACCTGAT  
 CGACAAAGAAATACATCGACGAAATGACGATTTCTGCGCGCTGACCAACGACGACGAAG  
 CAACATTATGTCGCGCTTTTGGCGAAAACTCTCGGCGGACGAGCGGCTCATCGCATCGT  
 CAACCGCTCAAGTACGTCGATTGCTCGAAGGCAACAAATCGACATCGTCGCTCTCCCC

CCACCTCATCACCATCGGCTCGATCTCGCCACATCCGGCGCGGCACATCGTTGCCGT  
 CCACCCCATCCGGCGCGGCACGCGGGAAGCCATCGAAGTCGTGCGACACGGCGCAAAAAA  
 AACTTCGCCCATCATCGCGAGGCSATCAGCGGCATCAATGGCCGAAGGCTGCCACAT  
 TGC CGCGCTCGTCCGCGCGGAACCGGCGAAACCATATGGGACACCATACCGGAACCGT  
 5 CATTCAAGACGGCGACACACATCATCTTTTCTGCTCGCGCGCGCATCCTGGAACGAAC  
 GGAAAACTCATCCAGGTCAAATGGGCTTTTCGGATAAACCGCCCATTCGGGCATATA  
 TTGCGCCCAAGCGGTATGGAAGCGGAAATAATGTAGTGGCTTCAGACGGCATCCGCG  
 CTCGCCGTCACTCCCGCGTAAGCGGCATCCAGACCTTGGGATAGCGGCAATATTCAAAG  
 GTTATAAAGACCGTCACTCCGCGCAGCGCGGAATCCAGACCTTGGGATAGCGGCAAT  
 10 ATTTCAAAGGTTATCTGAAATTTAGAGGTTCTAGATTCCCGCTTCGCGGGAATGACGAA  
 AAGTTGCGGGAATCCAGAACGTGCGGCAACGCAATATTTCAAAGCCGCTCTGAAATTTA  
 AAGGTTCTAGATTCCCGCTTCGCGGGAATGACGAAGTTTCAGACGGCATCGCCCGCTAT  
 TTTTGATATAGCGGCACCCCGGACAAAAAACAATCCGGAACGCATCTGACCGTTCCG  
 GCTTGTTTTTCAGGCAATCCGCGCATCAGAACATACTGCGCACGCCATATTGACCTGC  
 15 CAAGTCTAGCGCATCTGTGTCATCGAAGACCTTTCGCGCTCAAAATAAAGCTGCCTTCG  
 TTGTCGCGATTACACGCAAAAAAATGAATTGCTTGATATTTCAATGTTTTATATGTT  
 TTTATATTGTGATGCGATCAGACAAACGCCCGCTGACATTTGTTAGACGGCATCGTAT  
 TGCTAAATTTCTATAAGTATGTATAATGTCCGTTTCAGCGGCCATCGCTAGAGGCT  
 AGGACATGCGCTTTCAGCGCGCAACCGGGTTTCAATCCCGTGGCGTGCCAATTCA  
 20 AAAACCTGCTTGTTCAGCAGSTTTTTTATTATGAGTCGTCATTCCGCAATTTTGTG  
 CATTCGCGCAAAAGCGGGAATCTAGAGCGTAGGGTTGAAGAACCGTTTTATCCGATAAG  
 TTTCCGTGCGCAGGTTCTGGATTTCGCGCTGCGCGGGAAGGACGCGAGAGGTTGGACGA  
 TGCGCTCTGAAGCTGACAAAGCATTTGATGCGCTCGAAACTTCGTCATTCCGCAAAA  
 CGCGGAATCTAGAGCGTAGGGTTGAAGAAACCGTTTTATCCGATAAGTTTCGTCGCCAG  
 25 AGGCTCGGATTCGCGCTTCGTAAGGAATGACGGAATTTTAGGTTTCTGTTTTGTGGAAA  
 TGACGAATAAAGCGTGCCTGTTTATGCTCGCGCAACACGCGGTTTCAGAGGGCATTGCTC  
 TCTTTTTCATTATCAGTGGGTGTAGCAACTGTATTTTACC CGCTCGGCGAAATAAC  
 AGTTGCTACGATGCACCCCGCGCGCTGCGCTGTGCTTGTCTGCAATACGCAATATAA  
 TGACACCAAAACCCCGCGCTGCGSTTTTCAGACGCGATCGCGTGTCTTTTACAGGCA  
 30 TTAGCCTCTTTTTCGCGACGCAATATTAGGAGGAACAATAAAGCTCTTTTGTGCGCA  
 ACGCTTACCATCGCGGTTTCGATTTCGGCGCGGTTGCGGGCATTCAGGCGGATTTGAAA  
 ACATTTTCAGATGCGCGGCTGTTTCGGAACGTGCGTCATCACCGCGTTTACCGCGCAATAA  
 ACCTTGGGCGTGTGCGCGGTTTCATCTCGTCCCGACGGAACCATCACCGCAAAATCCAA  
 GCAATCAGGGAAGACTTCGACATCCGCGCTCAAAAATCGGTATGCTCGGCAACGCGAA  
 35 ATCATCGAATCGGTTGCGGACAAGCTGAAACACTGCAGCTTTGGCAGGCGGCTACTCGAC  
 CCTGTGATGATTGCCAAGGCGGTGCGCGCTGTTGAGGATTCCGCGTTGCGGCACTG  
 ACGCGCTGCTGCTTCCGATACGGATGATTGACCCCAACCTGCCCGAAGCGGAAGCT  
 CTGACCGCGGTGCATATTGAAAACCTGAAGATGCGGAAGCTGCGGCAAAATCTCGTCT  
 GATTACGGGTGCAAAATGTCGTTATCAAAGCGGACATTTGAACGCGCAGCACAAGCGGA  
 40 CGCTGACGGAATTTGGCTGTTTACACAAATGAACCGCTGGAATTCGACAGCCCGCGTTT  
 CCGACCGCCACACGACGGCAGGGCTGCACGTTTTTCGCGCTGCATCACCGCGGATTG  
 GCAAAAGCTCGGACGTTTTCGGAAGCGGTACAGACTGCCAAGGCTACATCACGCGGCGCA  
 ATCTCAAACCTTTGGAATCGCGCGAGGACACGCGCGCTCAATATTGGCGGTATCGG  
 GACTAACGTAATAATGCGCTGTGAAACAAATGTTTACAGCGGCAATTTTGGAGGATTAT  
 45 CAGGCTTTTTGCGCAGCATGTTTACAAATTTAAACCGTATCGGATTGCGGTTTTGCTCT  
 TGCGATGATAGAACCAATTTCTTTTATATTCGACAGTTTCCCAATCCGATATAAAT  
 CCTCAGCTCGCCCTCTTAAATTTAAAGGGAACGCGCATCGGACAGGGAATCCGCG  
 TATCCATTGCGGATCAATCAAGTTGATCCCGCGCGCGCTGATGCGCTGCATATCGG  
 CAATCAGCTCGGGTACGCGCTGCGGCTCAGGAACATCAGCACCTGTTGCCAATAT  
 50 AATCAAACTCGCCTGCAAGCGCGCGGCTTCAAATCATATTCCAGCGTGGCGAGCTTCA  
 AACCTTCGCGCTGCGCAGCTCGCGCAGTTTTGCCAAGCGCGCGGATTGTGATCGACTG  
 CAGTAACCTCAAACCTTCAAACCGAGAAACAGCGGTTTGGCGCCCTGTGCGCAGCCCA  
 TATCCAAAGCCCTGCCCGCGGTCAGGTTTCCCGTCCGCGCGACCGAGAAATGCGTGG  
 CACTCATCCGCTATTTTTTGTGAAATAAGTCTGCGCGCGCAATACAGCGACAAACGGA  
 55 TTTGCGGATCGTCCGTTTTGCGTTTGACAGAAACACCTGCTGCGCGGCAACACCAAT  
 CGCGCGCTGCTGCCGACCAAACTTCTGCCGACCGCTCCGCTGCACGAACTTCGATCTGC  
 CTTGCAACACATTCAGGCGAGCCACTCCCTTCTCAGACGAATAGCCGACACAAAAA

CTTCCGGCAGGTTTTCACATTTCCATACAGGCATCTGTCCGAAACAAACAACTCGCCAC  
 TTTGACCCACTATCCGCTCCTTCAWATTCAAAAATAAAGTTGCACATTATATGCGCTATT  
 TAATCCGGCCGAATCTTTCAGACGGCAGCGCGCGCAACCGCTTATAATCAGCCGGGACA  
 CCACACAAAGGCACAAATAATGAACCAAACCGTTTACCTTTACACCGGACGGCGGTGCAAA  
 5 GGCAAATCCCGGCGCGGGCGGTGGGGCGTGTAAATGCGCTACGGTAGCCACGAAAAAGAA  
 CTTTTCGGCGGCGAAGCGCAACCAACCAACCGCATGGAAGTACTGCGGTATCATGAA  
 GGAATCGAAATCGCTCAAACGCGCTGACCGCTCATCTGCAACCGACTCGCAATACAGTC  
 AAAAATGGCATGAAAACCTGGATACACGGTTGGAAGCGCAACGGCTGAAAACCGCTCC  
 AACAAGCCCGTCAAACACGACGACTTGTGGAAGAACTCGACGCTCTAGTCGGACGGCAT  
 10 CAAAGTCAGTTGGACTTTGGGTGAAAGGACACGGGACACGGCGAAAACGAAACGGCGCGAC  
 GATTTGGCAAAACCGTGGCGCAGCGCAGTTTTCCTGACTGCCGCTCCGGCAAAAATGCGGT  
 CTGAACCCCGCTAATGGGCTTCAGACGGCATCTCTCCACCGCTATTCCCGCGCAAGCG  
 GAATCCAAACCGTTCGGGCAACGGCAATATTCAAAGATTATCTGAAGTTTGAAGTTCTAG  
 ATTCGCTTTTACGGGAATGACGAAAAGTTGCAAGAATGACGGAGTTTCAGGGCGGCATC  
 15 CGACCGCCCCGTATTCCCGCAAAAGCGGGAATCAAAAACCCCAACGCTGCAAGATTAT  
 CAGAAACAACTGAAACCGAACGGACTGGATTCCCGCTCGCGGGAAATGACGGGATTTTA  
 GTGCGCTAGCAACCGCTCGCGACGGCTTAAGGGGCTTCAGCAACCGTAGCAACTGCGCT  
 GTAGGGGAATGACGGCAAAATGGGCTTCAGACGGCATCTCTTGCCTGCGCTAAACGAAAT  
 TGCOCGCAAACTGTTCAAACGCGCTCCGATATGTTTCAACACACAGGACGACACATAAAGC  
 20 AACTCCCTATGTGTCGCTCTGATTGGAAGGGGTTACACCCCTCCCAAATAAAGTCTGTA  
 CCTCGCGCTCAAAGGGCGGGTTTCAACCGAAAAGGAATAAGATTGAAGTGGTACAAT  
 TAGCGGCAATGCGGACAGACAATAAATACTATAGTGGATTAAATTTAAACCAAGTAGCGCG  
 TTGCTCGCGCTTAGCTCAAAGAGAACGATTCTTAAGTGTCTGAAGCACCAAGTGAATCG  
 GTTCTGTACTATTGTACTGCTCGCGCTTCGTGCTTGTCTGATTTTTGTTAATCGC  
 25 CTATATCAGAAATTAACCTACCGTTTAAACACTTTCAGGAATAAGGAAAAATGACCG  
 CCAACCCCTGCCCATCTGACGGCGCAAAATGAAGACGTTTGTGCAAAACCCCAACCG  
 TCCGCTCATCGCGTCCATAACGACAGCGGTTGCGCTGCATTCTGCGCGCTCATTTGGC  
 GTAAGCATATTGCCGAAATGACCGACCTTCGCGCAGCGGAACGGCGCAATTTGATGGAAA  
 TGGTGTACAAAGTCGAAGCCGCTATGCGCAAGTGTTCGCGCGCAAAATCAACCTG  
 30 CCAGCTTGGCGAATGTCGTGCGCACCTGCATTGGCATATTATCGCCCGCTTTGAAACG  
 ATGCGCTTTTCCCGCGCGGATTTGGGCAAAACCCGTCGCGAAACACGGATGACCCCTGC  
 CGCAAGATTGGACGGAACAGCTTAAAAAGCTGCTTTAAGCCCGCGATGCGCTCGGAAC  
 CGTATGAAAGGGAAATATGACCGAACCGACCTCCCGCGCGCTTTCTGAACCACTGCA  
 35 CCGCGCTGCGCGCGGGGCTGCTTCAGGCTTGGCGCACATCCGCCACATCCGCTTCCGC  
 CCGCTTCCTCTTCCCATTCGCTTGTGAAGCCGGAACGTCGCTCTCCAACCGCAACGCC  
 GTCAAAGTTGCGACGGCAACCTTCTGCGCGTTGTCGCTTCGTGAGGATTGCGCGACGACA  
 CCAACCGCGTCAACACAGCTTTAACC CGCTTTACAATGTCGGTTTACGCTAACCAAC  
 AACAGCGGGGCGACCGCGCTTTCACAGCTTTGCGCGCACGGACACGCACTGCGCGCG  
 40 ATTTCCAGAGGTCGCTTCGCGCGCGTCCGCCGCTAAAGTGTGATGGGTTTGGCGCG  
 GCGGTTACGGTGGCGCGGGAATTGCGCGCATATCGATTTTGCTGCTGGGCAACAGGA  
 TGGCGAACACGGCACGCTCTTTTTCGGATTACGCGACGATATGCGCGCTCCAGCTGGCAT  
 TGTGGGCAAAAGGCAATATGATGAGTTTTCGCGCGGATGGCTATAGCGGATTTTGGCA  
 AACCCCGCCCGGTGGCTTACGATGATGCTTTTATCAAGGGTGCAACCCAAACCGGAC  
 45 TGACCGTGTATGTTCTTATATCCAACCGCGCATGTGAAACCGGAAGGCAATTGTCGG  
 GCGCGCACTTAAGCGTCTCGCGCTCGCTCGCGGCGACGCTTATATGCGCGACATCGAG  
 CGGCGATTTTGTTCCTCGAAGATGTGCGCGAACACGCCCTAACGATCGAAGCTATGCTCA  
 ATACGCTGTATCTTTCGGGTTTGTGAAGAAACAGCGCGCATCGTGTTCGCGCAATTTC  
 GTATGAAAAAATTCGAGATGTCTATGATCCGCTTATGATTTTCTGCGCTTGCACCAAC  
 50 ATGTTTCGCGCACGGCGAAAAATCCCGCTGCTGACGGGCTTCCGCTTCGGACATATCGCG  
 ACAAAATCACTTTCCTCTAGCGCGCGACGCCGCAATCCGTATGAACGGGAACACGGGT  
 ATTGCTGCGGTTGAAGCTACCCACACTCGATCGTCGCGCTGACTTTGGATACCC  
 TGCTCCACCGCGGATTGCCCCATTTCCCGGAAAGCGGTGTCGGGATTTTGGAAAT  
 AAACCCGCAACCGGCAAAATGCGCTCTGAAGCCTTCAGACGGCATTTCCCAAGACGCGCG  
 55 CAGATTACAGCAATGCCCGAATATCGGCTTCGATTTCTCGGGCGTAACACTAGGCGCAA  
 AACGCTCGACCACTTCGCGCTCGCGGTTGACGAGGAATTTGGTAAAGTTCCATTGATGT  
 CGCTCTGTCGCGCTTCTCTCCAAAGCTGCGAGCTTCAACACGAAATCTTAAACAGAT  
 GATTGCTTTATCTTGGGTTTGAACGATTTTCAGGTAGGCATACAAGGGCGCGGATTTG

CTCCTTGAAGTCTGATTTTGTGCAAAATCTTAACTTCGTGCCAACTTCATCATACACA  
 CTTGGGCAATTTCCGCTGCTTTCGGGAGCCTGTCGGCGAAGCTGGTTGCACGGAAAT  
 CCAAAATCTCCAAGCCTTCTCGGGTATATTGTGCATACAGCTTCTGCAAGCCTTCGTATT  
 CGCGGGTCAGACCGCAACGCGTTCGCGTGTGACAATCAGCAGAACCTTGC CGCGATAGC  
 5 TGCACAAATCAACCGCATTCGCTTCTGCATCTTTCATTGAAAAATCGTAAATACCCATT  
 TTATCCTTATCTGATGTAAACCGATGCCATCTGAAACGTGCTTCAGACGGCATGAAAGCA  
 GCRAATTGTATAGCCGATTAAAAATAAAAAATCCACATCCTTTCCATTCCCGTCCCAATCC  
 GCAATAAAAACTGCACCCGAAAAACGGGTGCAGTTGCTCATTTCATACCGGCAAACTTAT  
 TTGTCGGCGCGCAATACGATTTTAGTGGCTTGGATGGCGACACAGATTGCACGCGCGATA  
 10 AAGACCAAGTCAGCTGCGTACGTACGCCAACGCAAGGTATCGAGGATTTCCATTTCGAGG  
 AACCTTTCGCTGCGGGCATACCAACAGCCGTCGCTGATGGAGGCGTATGCCGTAATCGCG  
 CGCAGCGAGCAGCGCTGATGGCAATCATACGGGCCAAGCCGCGTTGAGCAGCCAGAAG  
 CCCCAGTCATCAGTTTTCGCTCAAACTGCGCGTTCGGTTTCAAATAACGGGCAACCCAGC  
 AATACGAAGCCCAATGCCAAGAAACCGTACACACAAACGAAGCGCGCGTGGCGGTGAACG  
 15 GCAGAAGTGTTCAAACCTTGGATATAGAACAGGGAATCGCGGATTTGATCAGGAAGCCG  
 AATACGCGCGGCACCGATCATATTCCAAAAGGCGACTGCCACGAAGCAGCATCAGCGCCAA  
 CGCAGGCGTTTCGCCACGTCGACAGGTGTTGTAAGACAGTGTTCGTATGCTTCACGG  
 CCCAGCAACACCAGCGGACGACTTCCAAAGCGGAGAAGCAGGCACCGATTGCCATAGAG  
 GCGGAGGTAGAGCCGGAGAGTACAGTGGTGCAGCGTCCCGGAAACGCCGCCCAACATA  
 20 AAGATGGCGGAGCGGCCAAAGTGGAGGCGAGTGGCGGTACTGCGGCGGACAAACGCCGATA  
 TTGTAGAAAGACAAAGGCCAAGGCGGCGAGTGGCAAACTACTTCAAGAAAGCCTTCTACCCAC  
 AGGTGAACCAACCCCAACGCGAGTATTCATAACGGCAATCGGGGATTTTTCGCCATAG  
 AACAGGCTGTGCGTAGAATACGCCACACCGACCATAGAAGCTACGAAGATAGCCAAAC  
 AGGTTTTTGTCCAGCCTTTTCTTTAAAGCGGAAACCGTGCACGCAACATCAGGAAT  
 25 AGCCATAACAGCAGACCGACCATCAAAAGGAGTTGCCAGAAACGTCCTCAAAATCGAGGAT  
 TCGTAACCTTGTGTCCGAACAGGAAGTTAAATTCGGGGGAAGGATGTGCGTCAACGCG  
 AAGAAGTTGCCCGCTAAGAACCOCGACACGATGAAGAGGCGATATAGAGGAAGTT  
 ACGCGCGCAGCTTGGAACTTGGGATCTTTACCGCGGTGCAATTCGGCGGAGGAACAAA  
 CCTGCGGTCAAAAAGC CGTTGCCAATCCAGAAGATGGCGGATTTGATGTGCCAAGTACGG  
 30 GTCAGGGCGTAGGGGAACCGAGTCGGACATTCAAAAGCCCAACGCGCTCGTCAATGCCGTAG  
 AAACCCCTGGCCTTCGACGGTGTAGTGGCGGGTCAGTCGCCCCAGCAATACTTGTACCCACA  
 AACAGGGCGACCGTCAGGAAGACGTATTTCGCCAATGCTTTTTCGAAGGGGTCACTTGG  
 ATTTTGGAAATCGGGTCTTCAGACGGCACTTCCACTTCTCGTGTTTGGTCAGGAAGGAA  
 TAACCCACATCAGCAAAACCGATGCCCATCAGCAGAAGAACAAACGCTGGTGAATGACCCAC  
 35 ATATAGTTTTTCAGTGTGCGGTACGTTGTGATCAAGGTTCTGTCGGCGCGAGTTGTGTTG  
 TAAGTAAAAATCTCGTCAGGACGGTTGGTTCGAAGCAGACCAAGAAGTCCAGAAAGAAAG  
 TTGAACAGTTTTTCAACGCCCTTCTTGGCTTGGCAATGTATTGTTTTTCATTGCAAAAGTGT  
 TCGCGAGTGGTTTGGAACTTAGGATCGTCGCTGTACACACCGTGGTGAAGCAGGATG  
 CTTTCGATGGCTTTCACGCGCGATCGCTGATGACGACGCTGCCGCTTCTCTTCACGCGG  
 40 CTTTGTATGCGGTATTTCGTCGGCCAGGCGTGTTCCTCAAGACGCGTGTTCCTCGGGGGAA  
 ACCTTCGTGCAATTTTTCGCGTAAAGTCTGTTGCGGGGTCAAAATCCAACGAGGCAACCAAC  
 TCACGATGCGAGCAGTCGCGCGTCCAGTCCGGAGCCTGATATGCACCGTGACCCAAAACT  
 GAACCGCACTTCCATACCGCCGCTAGTCTGCCATGACAGCTGACCTGCCAAAAATCTGCTC  
 TTCGTCAATCAAGACCTTGC CGGATGCGGAAACGACCTGTCGGGGTAAGCGCGGGCTTTT  
 45 TGTAAACCTCGCTGCCCATATAGCCAAGAATGTAAGACATAcGGGTAC

The following partial DNA sequence was identified in *N. meningitidis* >SEQ ID 2>:

# 50 gum\_2

CGAGGCGCAGATACAGGTTTGGAAAGATGTGCAGCTCAAGCGCAAGCGCGTACCGAAAGA  
 CAAAAAAGTGTTTACCGATGCGGCGTCCGATCGACCCGTCAGGATATATTCATAATCCAG  
 CGAAAACCTCGACAACATCGTACGCGCATCCCCGGTGCCTTTACACAGCAAGATAAAAG

CTCGGGCATTGTGTCITTTGAAIATTCGCGGCACAGCGGGTTCGGGCGGGTCAATACGAT  
 GGTGGACGGCATCAGCGAGACCTTTATTCGACTCTACCGATCGCGGCAGGGCAGGCGG  
 TTCATCTCAATTCCGGTGCATCTGTGACAGCAATTTATTGCGGACTGGATGTCTGTCAA  
 AGGACGCTTCAGCGGCTCGGAGGCATCAACAGCCTTGC CGGTTCGGCGAATCTCGCGGAC  
 5 TTTAGGCGTGGATGACGTGCTTCAGGGCAATAATACCTACGGCTGTCTGCTAAAGAGTCT  
 GACCGGCACCAATCAACCAAGGTAATGCGATGGCGCGATAGGTGCGCGCAATGGCT  
 GGAAGCGGGAGCATCTGTGCGTGTGCTTTACGGGCACAGCAAGCGCAGCGTGGCGCAAAA  
 TTACCGCGTGGCGGGCGGGCGGGCAGCAGCATCGGAAATTTGGCGCGGAATTTGGAAGC  
 GCGCAGCAGCGATATTTGTACAAGAGGCTGCTTTGAAATTCATTTCCGACAGCGGGA  
 10 ATGGGAGCGGGATTACAAAGGCAACAGTGGAAATCAAGCCGATATAAAATTAACAACA  
 CCAAGAACTACAAAATACATCGAAGAGCATGACAAAAGCTGCGGGAAAACCTGGCAAC  
 CGCAATACGACATTACCCCATCGATCCGTCCAGCTGAAGCAGCAGTCCGACGGCAATC  
 TGTTTAAATTCGAATACGACGGCGTATTCAATAATACAGCGCGAATTCGCGATTAA  
 15 ACACCAAAATCGCGAGCGCAAAATCATCAACCGCAATTATCAGTTCAATTACGGTTTGT  
 CTTTGAAACCGTATACCAACCTCAATCTGACCGAGCCTCAATTCGGGACGCGAATA  
 ATCCGAAAGGGTCGAAGTTTACAGGCTGGGGCTTTTAAAGGATTTTGAACCTTACAACA  
 ACAGCAAAATCCTCGACCTCAACACACCGGCACCTTCGGCTGCCCGCGAAACGAGT  
 TGCAACCCACTTTGGGCTTCAATTTTCCACACGAATACGGCAAAACCGCTTTCCTG  
 20 AAGAATTTGGGGCTGTITTTGACGGCTCCTGATCAGGACACGGGCTTTATTCCTATTGG  
 GCGGTTTAAAGGCGATAAAGGCTGCTGCCCAAAATCAACCATTTGTCCAACCGGCGG  
 CGAGCCATATTTCAACAGCTTCTACTTCGATGCGCGCTCAAAAAGACATTTACCGCT  
 TAAACTACAGCAACCAATACCTCGGCTACCGCTTCGCGGCGAATATACGGGCTATTACG  
 GCTCGGATGACGAATTTAAGCGGCGATTTCGGAGAAAATCGCGCATACRAGAAACATT  
 25 GCAACCGGAGCTCGGGATTTATGAACCGGATTGAAAAATACGGCAAAAGCGCGCA  
 ACAACCATTCGGTCAGCATTAGTCGGGACTTCGGCGCTTCGGCAGCTTCGGCAGCT  
 ATTCGCGCACACCGTATGCCCAACATCCAAGAATGTATTTTCCCAAAATCGGCGACT  
 TCGGCTTTCACACCGCTTAAAAACAGAGCGCGCAACACTTGGCAATTTGGGCTTCAATA  
 CTTATAAAAAAGGATTTGTAACAAGATGATACATTAGGATTAACCTTGGTCGGCTACG  
 30 CGAGCCGATCGACAACACTACATCCACAACGTTTACGGGAATGTTGGGATTTGAACGGGG  
 ATATTCGAGCTGGGTGACGACACCGGGCTTGCTTACACCATCAACATCGCAATTTTCA  
 AAGACAAGGTGCAACAACCGSTTTTGAGTTGGAGCTGAATTACGATTATGGGCTTTTC  
 TCACCAACCTTTCTTACGCTATCAAAAAGACGCAACCGACCAACTTCAGCGATGCGA  
 GCGAATCGCCCAACAATGCGTCCAAGAAGACCAACTCAACAAGSTTATGGGTGAGCA  
 35 GGGTTTCGCGCTCGCGGAGATTACGGACGTTTGGAGTGGTACGCGCTGTTTGGGCA  
 ACAAACTGACTTTGGGCGCGCGATGCGCTATTTTCGGCAAGAGCATTCGCGCGAGCGGCT  
 AAGAACGCTATATCGACGGCACCAACGGGGGAATACGCAATTTCCGCGAATCGGGCA  
 AGCGTTCCATCAACAAACCGAAACTCTTGC CGCCGACGCTTTGATTTTGATTTTATACG  
 CGGCTTACGAGCGGAAGAAAACCTTATTTTCGCGCGCAAGTCAAAAATCTGCTGCACA  
 40 GCGCTATATCGATCCGCTCGATGCGGGCAATGATGCGGCAACGCGAGCTTATTACAGCT  
 GCTTCGACCGGAAGACAAAGGACGAAGACGTAACTGTGATGCTGATAAAACGTTGTGCA  
 ACGGCAAAATACGGCGCACAGCAAAAGCGTATTGACCAATTTGACGCGGACGCACT  
 TTTTGATGACGATGAGCTACRAGTTTAAAGGACGCGCATTTGTAGAAAACGCAAT  
 GCGCTCTGAAGCGCTTACAGCGGCAATTTTTCGCCAAACGCAATCATCTGCCGCAAGC  
 45 CTAIGCCAATCCGTTTTATCGCATCGGCACTCAAGAAAAATCCATTTATTCCCGACG  
 AGGGAAGCGGTTTTTGATTTTCGGTATTTTGGTGTGTTTCGGGTAATTTATGATGCTG  
 ATTTCCGCAAAAGCGGAATCAGTTTTTAAAGTTTACGACCTTTCCGATAAATTCCTGT  
 GCGTTTACGTTTCGGGATTCCTCAATTCGTGAGAATGACGTGGTGCAGTTTCCGACGG  
 ATGATTCGTTCCTCCGCGCAGCGGGGAATCTAGACCGTTTCGGTTTCGGTTTTTTCGGT  
 50 TAGTGGCGCAACATTAATTTCTAGATTCCCACTTTTCGTGGGAATGACGGCGAGCGGTT  
 TCTGCTTTTCCAATAAATGCCCAACCTAAAATCGTCATTCCCGCGCAGCGGGAAT  
 CTAGACATCAATGCTAAGGCAATTTATCGGAATGACTGAAACTCAAAAACCTAGATT  
 CCACCTTCGTGGGAATGACGTGGTGCAGGTTTCGTATGATGGATTCTGCTATCCCGG  
 CAGGCGGGAATCTAGTCCGTTTCGGTTTCGGTTTTTTTGGCTAATGCCGCAACATTAAT  
 55 TCTAGATTCCCACTTTTCGTGGGAATGACGCGGAGCGSTTGTGTTTTTCCAATAAATG  
 CCCCACCACTAAAATCCGTCATTCCCGCGCAGCGGGAATCTAGTCCGTTTCGGTTTCGG  
 TTTTTTGGCTAGTGCCGCAACATTAATTTCTAGATTCCCACTTTTCGGGAATGACGG  
 CGGAGCGGTTTCTGCTTTTCCCAATAAATGCCCAACCTAAAATTCGTCATTTCGCCG

AGGCGGGAATTTAGACATTCAACGCTAAGGCAATTTATCGGAAATGACTGAAACTCAAAA  
 AACTGGATTCCCTCTTTTCGTGGGAATGACGTAGTGCAGGTTTCCSTACGGATGGATTTCGT  
 CATTCGCCGCGCAGGCGGGAATCTAGACATTCAATGCTAAGGCAATTTATCGGAAATGACT  
 5 GAACTCAAAAACTGGATTCCCGCTTTTCGTGGGAATGACGCGATTAGAGTTTCAAAAT  
 TTTCTAAATAGCTGAAACTCAACGCATCGATTCCCGCTGAGCGGGAATGACGGAATG  
 GAGTTTACCCGAACTTAAACAAGCGAAACGGAACGAACTGGATTCCCACTTTTCGTGGG  
 AATGACGGAATGTAGGTTTCGTGGGAATGACGGGATGCAAGTTTCGATGGATGGATTTCGT  
 CATTCGCCGCGCAGGCGGGAATCTAGACATTCAACGCTAAGGCAATTTATCGGAATGACT  
 GAAACTCAAAAACTGGATTCCCACTTTTCGTGGGAATGACGCGATTAGAGTTTCAAAAT  
 10 TATTCTAAATAGCTGAACTCAACGCATCGATTCCCGCTGAGCGGGAATGACGAATTT  
 CAGSTTGCCTGTTTTTGGTTTTCTGTTTTTGTGAAATAATGGGATTTTAGCTTGGGGTA  
 TTTACCGGAAAAACAGAAACCGCTCCGCGCTCATCCCGCAGGCGGGAATCTAGTCC  
 GTTCGGTTTCGGTTTTTTTGGCTAGTCCGCAACATTAATTTCTAGATTCCCACTTTTCG  
 TGGGAATGACGGGATGTATAGTGGAATTAACAAAAACGATACGGCTTGCCTCGCCTTAG  
 15 CTCAAGAGAACGATTGTCTAAGGTGCTGAAGCACCAGTGAATCGGTTCCGTAATAATTT  
 GTACTGCTCGCGCTTCGTGCTTGTCTGATTTTTTGTAAATCCACTATAAATTTAATC  
 CACTATATTTTTTGTTCAAAGTCAAAATATGCCGTCCGAACATCTGGGCGGCAGACAAA  
 ACGGCATCGCCGATAAAGGCGAGTCCGCTTTCGGTTTCAAAACGTAACATCAACCA  
 AATTAAGGCTTTATGCAATACCTGGTTGCCAGTTCATGTATTTTTTCATCAATCAATA  
 20 CGGAACATTTGATTTCGGAGGTGGAAATCATTTGGATGTGATACCCCTTCGCGGAGCG  
 TGCAGAGATTTTGGCGGCTACACCGACGTCGGAACGCATACCCAAACCGACTCGGGAGA  
 TTTTGCATACGCTGCTGCTGCCATCAATAGAAGCCGCGCGCATACTGCTTCGGCGTTCCG  
 ACAGGATTTTCCAAAGCTGCTGTGTAATCGCGCGCGGATACGGTAAGGGAATAATCGGTTG  
 TGCTTCGCTCGCCGACATTTTGGATAATCATATCGACTTCGATTTGGCATCGGCAACCG  
 25 CGCTCAAAATCTGATAGCGGACGCGCAGGTTTTCGGGTACGCGCGCATGTTGATGCGGG  
 CTTGGTTTTTATCGAATGCGATACCGGTTACGCGCAGCTCTTCCATGTTGTGCTCTCTT  
 CAAAGGTAATTAAGGTGCCATTGCCGCGCTTTCGAGGCTGCTCAGTACGCGCAGGCGCA  
 CTTTGTATTTTCGCGGAATTTCTACTGAACGGATTTCGAAAATTTTCGAACCGAGGCTCG  
 CAGTTTCGATCATTTCTTCAAATGTAAACGATATCCATGCGCGCGCTTCGGGTACGAGCG  
 30 GGGGTCGGTTGTGTAAACGCGCTCTACGTCGGTATAGATTGGCACTCGTCGGCTTTGA  
 GCGCGCGCGCAAGCGCGACGCGGGAAGTGTGGAACCGCGCGCTCCGAGCGTGAATAAT  
 GCCTTCACTGCTGATGCCTTGAAGCCGCGCAACGATGACGACTTTGCGCGCGGTAAAGT  
 CGGCACGCATTTTTTCGTCAATATGCTTTTCGATGCGGGCTTTGGTGTGGCGGTATCGG  
 TTTTGAAGCGGACCTCGCAGGCTGTGTAGCTTTTGGCATCCACGCGGATGCTTTTCAAATG  
 35 CCATCGCCAAAAGCGCGATGGTTACTTGTTCGCGCGTAGCTAAGACGACGCTCCAGCTCGC  
 GCGGATCGGGATGCTCTTGCAATTCGTGCGCCAGTGCAGAACGTCGGTTGGTTTCGCGCG  
 CTATGCGGATACGACGACTACGATGTGCTGTCTTCGCGCGGGCTTTGGCGACAGCTT  
 TGCTACGTTTTTGTATGCGTTTCGCGCGAGCTTACTGATGTGCGCGGATTTAGTACGA  
 TTAACGCCATGTTTCGTGCTTTCTTGTGGGGTTGTGCGGCGAGCTTGGTTTTCGTGAAAA  
 40 AGGGTTATTATTACTATTTTTCATGGAATTCAGAACGCGACTGCGCTTTCCGCGCTGC  
 CGTTTTCAGCGGCTCAGCGAAAACTGTTCTTTCAGATTGTTGCAGAAATGCCGCTCTGA  
 ACGGTTTTTCAGACGCAATCCGACGACANTCAGCGCGCGGACACGCAATTTTGTGGTGT  
 TGCAGCAGTTTCGCTATGCCTTTTTTGCGCCAGTGCACACGTTTGCCTCAATTCGTCCTAAA  
 45 CTGAACGCGCGCTCTTCGCGGTCCTGATTTTCGATGATTTTTCCGATGCGGCTAGG  
 ACGATATTCACATCAGTTCGCAACCGGAGTCTTCGGGATAATCCAAATCCCAAAGCGGCG  
 ACGCGCTTCACATACGCTACTGACACAGCGGCAACGGCTTCGCGGATGGGTTTTTCACCT  
 AAAATGCCGCTCTGAAACAGTTTTCGCGACGCGATTTCGACGCGCAACGACCGCGTA  
 ATCAGGCGCGTGCAGTACCGCGCTCTGCTGAATCACATCGCAGTCAATCAAGATTGTG  
 50 CGTTTCACCGAGTTTTTCCATATCCACGACCGCGCGGAGGAAACCGCGATCAAGGTTGG  
 ATTTCTTGTGTGCGCCGCGATGTTTGCCTCGCGAAGCTTCGCGGAGCATCCGGGAAGCA  
 GTTAGGCGAGGCGAGATCCCGTATTCCGCGTTTACCGAGCTTGGTTTTCACGCGCGA  
 AACCGCGGAGCTTTTCATCTATGGAAGCGGTACAATACCTTTTGTATTTCGCGCATTTCA  
 ATAAGCGACGAACCGTCCGATGCGCGAGGAAATGAGGGGTGATTTTGCATATGCGCGAG  
 55 CTGTCGCGCGCGCGAGATGCGGATGTAATCAAGCATACTGCCCTCCGTTAAAAACAG  
 ATAAATTTAAAGGCTTTAAATATGAAAAATCACATTAAGGCTTCAAACTGAAATTTTC  
 TACGCTCTTCGGCTTTCGTGCGGATAATCAAAAGCGGAGGTGGCTTTGGCGGATTAAC  
 GTTTCGCGAAAACGCCATTAAAGGTTGCAATCAGCCGCTACGTCGTCGCTACCCAAAC



ACCAGCAGGTGGCACCGGTTTTTCATCGGCATATCAACCAAACTCCTGGCGCATTTTCACGC  
 GCACCGCTTATTGGCAACAGCAGGTGTTTGACGGTATTTTCCACACCGAGTTCCTGGGGC  
 GTGCGCTCGGCGGCATCCAAAACCTCGTTGCCTTGGCGACGGCGGCGSCTTCGTAGCTT  
 TCGTGTTCGAAAAATTCGGGGGCGAGTGCCATATATTCGGCAGGATTCGCAACGTCGCAC  
 5 AAAGTCAGGCGCGCACCGCTTGACCCCGGCAAGCTCGGCGGCATGTTTCAGGGCATTTGATG  
 GAGCTTTCACTGCGCTCAACGGCAACAACCAATGTTTGACATATCSTATTCTCCCTTT  
 GCACCGCCTCGGGTGCCTCTTGTGGATGGGCGCAGGGACAGTTTCGCGTGTTCATT  
 ATAGACCGCGCTCGGGCTTTATACAACAGCGCAACAGCCGACCGCTTTCAGTATTAAT  
 ATCGCGCTTCGTGAGTCAGGCAGGATTTTTCGCGGCTTTCGTCACTTTTGATTGAGC  
 10 CAATCTTGACAGATTCAGCATGTCCGACAACGCTTTGACCTTTCGCGACGCTTCGCGC  
 GACTCGCCGACACTCTACGGAGACTCTGCCTTGGCGCACTTTTCACAGGCACACGCTCTGGC  
 TGTCGGCGTGGGCGGTGTGCGCTCGTGGGCGGTGAGGCTTTGGCGCGACGGGCATCG  
 GAGCTTTGACTTTGATTGATTGGACAACGTTGGCGAATCGAATGTCAACCGCAGCTGC  
 ACGCCCTGACCGCGACTTCGGCAAGCAAAAGTTACCGCTTGCSCGAACGCATTACAC  
 15 AAATTAACTCCGAATGCGAAGTGTTGAAATTGAAGATTTCGTTACCGAAGACAATTTCG  
 CGGAATACTTCGGAAGAAGGTTTGTATTCGTATCGACACGGATCGACCAAGTCGCGCTCA  
 AAGCAGCAATGGCGGCTTATTTTGTGAACGCAACAAACCGCTTTGCTCTCAGCGCGCGCG  
 CGGCGGACAAAAAATCCGCGCTTAATCCAAACCGCGGCTTTGAGCGCGTACCCACA  
 ACCCGCTGCTTGCCAACCTGCGCTACACCTTGGCGAAACGCTACGGAATCAGCGCGGATA  
 20 CGAAAGCAAAATATGCGCGCTGCTTGCCTGTAATCGACGAAAAATATCGTGGCGCGCGAGT  
 CTAGGCGAGCTTCTTCGCGAGATGCGCTCCGCAAGGCTTGTGTCGCGCGGCTACGGTG  
 CAAGCATGCTCGTTACCGCTTCGTTCCGGCTATATTGCGCAGCGGCGCGGTGGAAACACA  
 TCGCAGACAAAAAATAGCAATGCGCGCTGGAACAGGATTCAGACGGCATTTGAACAAAC  
 TATGTTATGATTAAAGCAACAAAGGATACGGATAAAAAATAACATAAAATATATGATT  
 25 CCTAATAATACCAAGTATCGGAGAGCTATTTAATGGAAATTCGTTAATAATTTAGTTAT  
 TTTTTCATTTTATTACTAATGCTTATTCGATATTTTGTAGTATATGGTATATACCA  
 TAAGATACGTTATCGAAAAATATGTATCCTAAGACAGTTTATATATTATGGTGAAT  
 ACTTTGAGTATGTATTACATATATTCGCGCTATCTTGACCAACAAAAAGTAGCTATTAT  
 TTGCATAGTGAACAATGTATTTCTATTGTTTCATCTATACAAAGATTATGGTATAAACTC  
 30 TCCACATATCGGAGAAATTTACGCAAGAAAAATATTGTTAGATTCAAGTAAGAGCTAA  
 AAATTAGCTGAATTACTTATGGAAGATGATATCAATTAGTAAAAAATTTTGGGGA  
 TAAATTTATCATTTATGGTGCTACCTGTAATATACGTAATGTAGATAATATTGAAGT  
 AAAAGAAGCTACTGGTTATATAGTAGATCCAGTACTGATTATATTGCTCAAGAAACTT  
 35 AAAATTGACACTTTATATTAAATTAAGAGGTTTTAGCAAGAGTGCGCTCAAAATATAGG  
 CGCATCATCGAATTCGCGAAAGACAAACGCTACGATGAACGTTTCAGAGGATTTGAAAAA  
 GAATCTATAGGCTATCTGAACCGGCATCCCGGTTTGGTGCCGACTACTCGAAGCGGCA  
 ATCAAGCTGTCGGTTAGAAAAACCAACATCAGCACGCTCAAAACCGTATTCAACAACCTG  
 CTCCTTTCAAAACATTTGCATTTAAAGCGCTTATAATGCGCTCTGACACTCTCGGCGA  
 40 CCACATATACGTGAATGTGCGGAGATTGTTTCTTTGTAAACTATATATAAAATCCAC  
 TTACCGATTTCAGCGCATGCGCGCATCCCTCGCCCATCTGCACCATCCGACGACACTGTC  
 GCATGGGTATTGCGCAACCGCTTACCGATTGCGCCAGGATTGTTTATTTCGCGCGGAT  
 GCATTGAAAGCTGATTGGCGAGCTTCCAGGCGCTTTSATCTACTGCTGATCTGATC  
 CGCAACAGAAATATCGACGCTACGATATCCGATGGTAAGATTACCGACGAGTATCTG  
 45 CACTACATCGCCAAATAGAAACCTATCAGTTTGATTGCGCGCGGAATATCTTTTGATG  
 GCAGCAATGCTGATTGAAATCAATCGCGCGCTGCTGCGCGCTACCGAAACCGTCGAA  
 AGCAAGAAGCGACCCGCGTCCGAGTTTGGTGCAGCGCTGCTGGCTTACGAACAGATG  
 AAGCTGGCGGCGAGGGTTTGGAGCGCTGCCCGAGCGGACGGGATTTCGCTGGGCT  
 TACTCTGCCGCTGAAATTTGCCGTGAAGCAAGCTGCCCGAAGTCTATATTACCGACTTG  
 50 ACGCAAGCGTGGCTGGGTATTTTGTCTCGGCAAAACACAGCGCAGCCAGCAAGATTATC  
 AAAGAAACCATCTCCGTGCGCGCAAAATGACGGCAATCTGCGCGCTTTGAAACGGACAC  
 GGAATATCTCAGGTTTCAGGACCTGTTCAATCCCAACAGGGCGCGCTTACGCTGGTCTC  
 AACTTCATCGCACTGTTGGAGCTTGCCAAAGAAGGATTGGTCAGAAATCTGTGCAAGGAAC  
 55 GGTTTGGAGAAATCCGAATCAGCCTCAATCATGAGGGGGCGCATTCAGACGGCATTTCC  
 GGCACAGCGGCGGCGGATGTGTTTCTAATACGCCCAAGCGCGCAACAAAAATCGGGA  
 GACACGCCATATGACCGGCATCATATTGCTGCTTGACACCGACCTTCACAAATTCAC  
 TATGCTGCAAGTGGTTCTGCACAGTTTCGCGACGACGACGCTTTACGAATTCGCGTG  
 CGGCAACGCCCTGACGCTATATCGCTTGGCGCATCAGGGAAGACTTGAAGCGCAACT

CGACGCGCTCTGCCAACTACGCTTCAACCACGACGAACTCGGCTATCTGCGCTCCCTGCG  
TTTCATTAAAGGCGACTTTGTCGATTATCTCGAACTCTTCCAGCTCCAACGCCGCTTTGT  
CGAAATCGGCACAGACGATAAAGACCGCTGGAACATCCGCATCGAAGTCCGATGATACA  
GGCGATGTTTTTGAAATCTTCATCTCGCCATTGTCAACGAACCTTACTTCCGCGCGCT  
5 GGAACCCCTCGAGTCATAGAAAGAGGCGAACGCCGCTTCAAGCCAAAGCGCGCGCT  
CAAGAAATCGCCGCCGACAAAACCCGACGAACGCCCTTCTGATTTCGCATCTCGG  
CACGCCGCCGCTACAAGCTCGCTGGCAGGAACAAGCTCATCCGACCTGCTTGAAGC  
CGCCCCGGCATCGTACGCCGACAGCAATGTCTTTCTCGCCAAAAAATCGGCATCAC  
CCCCATCGGCACCATGGCGCACGAGTTCTGACAGGCATTCCAGGCCCTCGACGTACGCT  
10 GCGGAATTTCCAAAAGGCCGCGCTCGAAAGCTGGGTGCAGAAATACCGGGCGATTGGG  
CGTTGCCCTGACCGAGCTGGTCCGTATGGATGCCTTCTCGCGGATTTCGACCTCTATT  
CGCCAAATTTTCGACGGCTGCGCCACGACAGCGGCACCTTACGTTTGGGCGACAA  
AGCTTACGCCCATATCAAAAGCTCAAAATCGACAGCGGCACCAAAATGCTGACCTTCT  
CGACGGCTGGACATCGAACGCTCTTGGGCATTGACCAATATTTCAAGACCGCTTCAA  
15 AACCGGCTTCGSCATCGGCACCACTCACCACGATATGGGCGATACGCCCTTGAATAT  
CGCTTTGAACTGGTCGAATGCAACGGGCGAGTCCGTGCGCAAGCTGCCGACTCTCCGG  
CAAAACCATGACCAACAACGACCTTCTCGCTTACTCGCCCAAGTGTTCGACGTACC  
CGAACCCGAAACGCCGTAACCCGCGAGAAAAGCGCAATCTCTGTTCTCGCGCATAA  
AACTTTTTAAATACCGCTGATTGTAATTTAACCGAAAGCCGAACCTCATGAACCTAC  
20 ATCAACCGTCGAAACACGAAGCGCGCGCGCTTTGCGCGCGCAGGATCGCGGACAGCC  
CTATTGTTTGCAGCGGACCAAAAACGCCGAACAGCGGATTTCCAAATCAACGGCGTGA  
TGGGTGCGCGGCAAAAAAGCCAAACAAAACCCGCGCGAGTTGGCGCAAAAGGTCTGCCGAAG  
CATTGGCGGACACCGCTGATTGAAAGCGCGGAAGTCCGCGGTCCGGCTTCATCAAC  
TGGCTCGCGCCCGAATTTCTCGCGCAAAACATTGACAGCGCTTGAACAGCGCTCGTT  
25 TCGGCGTGGCAAAAACCGCAAAACCGCAAAACCGCTGTTATCGACTATTCTTCGCGCAATC  
TGGCGAAGGAAATGACAGTCCGCCACTGCTGCTTCCAGCATCATCGCGACAGCATTTCCG  
CGGTGTTGGCATTTATGGGCAATACCGTTATCCGTCAAAACACAGTCCGCGACTTGGGTA  
CGCAGTTCCGTATGTTGGTCGCTTATTTGGTCGAGCAGCAAAAAGCAATTCGCCGTTTCG  
AGCTGGCGGATTTGGAGCAGTTTACC CGCGCGCAAAAGTCGCTTTGACGAAGACCTTG  
30 CCTTTGCGCACCCGACCGAATACGTTGTGAAGCTGCAAGCGCGCGATGAACCGTTT  
TGGCATTTGTGAAACAGTTTGTGATATTTGCTCTCGCACGCCCAAGCCGTTTACGACA  
CGCTGGGCTTGAAGCTGCGTCTGGAAGAGCTGGCAGGCGAATCGAAATACAAACGAGCTT  
TGCAACCCGCTGGTCGATGATTGGTTCAAAAAGGTCTGGCGGTTGAGGACGACGGCGGA  
AAGTCGTTCTTGGACGAATTTAAAACAAAGAAGCGCAACCCGCGCATTTATCTGTC  
35 AAAAAACAAGCGCGCGCTTCTCTACGCTTCCACCGATTGGGCTGCTGCGCTACCGCA  
TAGGCCGCTGAAAGCCGACCGCTGCTGTACGTGTCGACACCGCCAGCGCTGCGACT  
TCGAACAACTTTACCACTTCCGCGAAAGCAGGCTATCTGCGGAAAACGTCCGCGCGG  
CATTATTCGGCTTCGGCACCATGATGGGCAAAAGACGGCAAGCGTTCAAAACGCGCAGC  
GCGACACCGTGAAACTGGTCGATCTGCTGACCGAAGCCGCTGAGCGCGCCACCGCTTTGG  
40 TGAAGAAAAAATCCGAATTTGGTGGCGGAAGCCGCTAAAATCGGTAAAACCGTGC  
GCATCGGCGAGTCAAAATACGCGACTTGAGCAAAAACCGCACGCGACTATGTTGTTG  
ACTGGATGCCATGCTCTGCTTTGAAGGCAACCCGCCCTATCTGCAATACGCCGTACA  
CCCGCTGCAAAAGCGTGTTCGCGAAAGCAGGCGAATGGGATGCAATCGCGCAACCGTT  
TGACGAACCGCTGGA AAAACAGCTTCCCGCGAGCTGCTGAAATTTGAAGACGCTACTGC  
45 AAAGCGTGGCGGACAGCGGTATCCGCACTACTCGCGCTACCTCTATCAAAATGCGGA  
CCCTGTTACGCGCTTCTACGAAGCTGTCGGAATACTCAAGCGCAAGGCGCAAGCGCGCA  
ACAGCCGCTGCAACTGGCAAACTACCGCGGACAGCTGAACAAAGGCTTGGATTGCT  
TGGGATCGATGTGTTGGACGTAATGTAACCCGACGCCCGATTCGCGGACAAACAGCT  
CGCATCCTTATCCGAATCTGAAAAAGCGCGCGATACACCGTATCCCGCGCCCTCCC  
50 AAAATGCGAAACAAACAACGCCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA  
AGCAAGCAAAAAATATAACCCCTTCTGCGCGACGCGACCTTTCGCGCGCGCGATT  
CCCTTTTCCCGCCCTCAAATCCGCTTTTCTTCAGCGAGGTTTCAGCGCGCTCTTT  
TCCTTGTTTCTCTTCCCGCAGCGGCTGCGCTCCCTCTGCGCAGCTGTGCTGCACTTTC  
GCGCGCGGACGGCATGTTCCGCGCATCCGTTTCTGTTTACATACCCCTGTTTCAGAA  
55 AGAAATCGAGATGTTTCAACACACAGGACGACATAAAGACCGCCCTATGTGTTGCC  
TGATTTGGAGGGGTTACGCTTCCAAAATAAGATCTGATCTGCGCGCCCGAAGGACAGA  
TGTCGAGTGGGAAGTTTCAACCGAAAAGAAATACGATGAATATTACACCTCTGCTCT

CCAACAATGGACGCTGCGGCCATTCCTGCCGAAACGGCTGCTGCTGTCCTGCTGATAC  
 TGTCTGCCCCCAATGCGGTGTTTTGGGTTTGGCACTGCTGACCGCCACCGCCGCCCGGA  
 TTGTCAATTTGGACTATCTTCCGCGCGCTGCTGATCGCCCTGCCTTGGCGTTTGGTCA  
 AATATCGCGCGTATTGGCGTTTGGCTGGCGGTTTGTGTTGACGGGCTGATGATGGTGA  
 5 TCCAACCTTTCCTTTTATGGATCTCATCGCGCCATCAACCTCGTCCCTTCATCTCTGA  
 CCGCCCGCGCCCTTATCAGATATGACCGGGCTGTTGCTGCTGTATATGCTGGCGATCG  
 CGTTTGTGTTGCAGAAAGCGCCGCCAAACCGCATTCGCGCACATTGCGCTTCGCGCG  
 CGGTTGTGGCGGCGAGCGGCTATTTCACCGGCCATTGGATTACTACGACCGGGGTGGA  
 TGGCCAATATCTTCGCGCAAAACACTTCTACTACGCCAAAAGTCAGGCGATGCTCTACA  
 10 CCGTCAGCCAGAATGCCGACTTTATTACCGCGCGCTGGTCGATCCCGTCTTCCTCCCT  
 TGGGCAATCAACAGCGTGCAGCGCGCATCTGAACGAGCCGAAATCTCAAAAAATCCTCT  
 TTATCGTGCAGCAATCTTGGGGGTGCGCGCCAATCCGAACTTCAAAACGCCACTTTTG  
 CCAAACTGCTGGCGCAAAAGACCGTTTTTCGGTTTGGGAAAGCGGCGATTTCCTCTCA  
 TCGCGCGACGCTCGAAGCGCAAAATGCGCGAACTGTGTGCTACGGCGGTTTTCGCGGGT  
 15 TCGCACTGCGCGCGCGCGCGGACGAAAAATTTGCCGCTGCTCCCAACCGTTTGAAC  
 AAGAAGGTTACGCCACCTTTGCGATGCAACGCGCGGGCAGTTGCTTTACGACCGCTTCA  
 CGTGGTATCCGAGGGCGGGCTTTCAAGAAATCAAAACCGCGAAAACTGATCGGTAAAA  
 AAACCTGCGCCATTTCGCGCGCTGTGCGACAGCGAGCTGTTTCGCGAAGTGTTCGCGAT  
 TTTTCAAAAAACGACAGAGGAGCTGTTTTACTGGATGACGCTGACGACCCAGCGGACT  
 20 ATCCGAATCCGACATTTTCAACCCAGGCTCAATGCACCGAATATGGCTCGCCGCGG  
 AAACCGCACTTCGCGCAATTTCAAGCTGCACGCCAATTTCTGCACCACTGCGGCAAT  
 TGATCCAACGCCCGAAATGAAGAGCAGCGAGTCAATATGCTGGCGACCATCCGCGCA  
 CGCTCGCGAACCTCAATGAACTTCGCGTACCTCAAAACAGGGGACGTCGCGCTGCTCA  
 ACTTCAAAATCAAAATAACAATGCGCTCGAACGCAACAACGCTTCAGACGGCATTT  
 25 TTGCAGACAGACGACCTTCAAGCCCACTTTTTTCATCATCTCCGATAAATTCGTTGT  
 ATAGTGGATTAACAAAACAGTACGCGTTGCTCGCTTAGCTCAAGAGAACGATTCT  
 TCTAAGGTACTGAAGCACCAGTGAATCGTTTCGCTACTATTGTACTGTCGCGGCTCT  
 GTCCCTTGCTGATTTTTGTATATCCGCCATAAAGACCGTGGCGCTCTGACGCGCT  
 ATTCCGCGCAGCGGGAATCGAAGCTGGAATCAAGAAACCGTTTACCCGATAG  
 30 TTTCCGACCGACAGACTAGATTCCGCGCTGCGCGGAATGACGGGATTTAGGTTTCT  
 GATTTGGTTTCTGCTCTGTGGGAATGACGGGATGAGGTTATAGGAATGACGTGGT  
 GCAGGTTTCGATGATGATGATTGCTGTTCCCGCGAAAGCGGAATCCGAAACCCAAA  
 GCCACGGGAATTTATCGGAAAAACCGAACCGCTCCGCGCTCATTCCGCGCAGCGGGA  
 ATCATGGTCTGCGGTGCGGAACTTATCGGATAAAACGTTTCTTCAGATTTTACGTTT  
 35 TGGATTCCCACTTTCGTGGGAATGACGGGATGAGGTTTCGTAGGAATGACGTGGTGCAGG  
 TTTCCGATGGATGGGATTCCTCTTGGGTGAGGCTGACAGATGCGCTCTGAAAGACTTT  
 CAGACGGCATAGCTTTTCTCTTTGAATTTATAGTGGATTAAACAAAATCAGGACAAAGC  
 GGCAGCCCGCAGACAGTACAGATAGTACGGAACCGATTCACTCGGTCTTCAGCACTTA  
 GAGAATCGTTCTCTTTGAGCTAAGCGGAGGCAACGCGTACTGGTTTGTGTTAATCCACG  
 40 ATAAATTTGCCAAAAAAGCTGCCTCAATGAATACCCGGCGAGCTTTTGTGATATG  
 ACTCCAATCAGCGGTGTTGCGGATGTAACGTTTTTCCAAACGCAAGAAATATCCAGCCTA  
 AGAAAGTCGTCATCAACAGATAAATCAGGGCGACGGTGTAAAGCGGTTCTTCATAAACCG  
 AATACCGGCCCGTAATCGTATCTGAACATACGCCAACTCCGCCACAGCAATGACCGACA  
 CGAGCGAGTGCTTTCAAGAGCGTGATGAACCTGCTGCCAAAGGCGGCGAGCATGCGGC  
 45 GCAATGCTCGCGGAGAAATCAGATACGCGCATCGCTCGGATAGGTACGCCCAAGAAC  
 CGCGCGCTCCATCTGCTCTTTGCTATAGACTGGATGCCGCGCGGAAAAATCTCACAGA  
 TATACGCCGCCGAGTTGGCGATCAGTGCCAAAGAACCGCGCAATCAGCGGCCGATATCCG  
 CAGCGACGCGGATGCGCGCTGCGCGCTGACCAAAATGCGCTGTGAAGGATGGACGAAAA  
 AGCGAAACCCACATACGCCCAATCACAATCTGCACAAACAGCGGCGTACCGCGGACCA  
 50 CGCTAAATACAGCAGCGAACTTTACGCAACGCCACGCGCAGCAGCGCGCATCGCGGCAC  
 CGCTTTTCCAAAGTGAATCAGCGCGCCAAACGCCAACACAGACCAATACCGAACCGC  
 CCGCGTTGCCACGACCGCTCAGCGCCAGGTCGTGCTGCGCGTAAAGAAACATCCAG  
 GGTATTCGTAAATGATGCAAAACGAAAAATCCATAACCGTCGATATCAAAACCGGGCGG  
 AACTCGCGCGCTTGCAAAATAATCCGCACTTTTACGTAATAACCGCGGCTGAACCTTT  
 55 TTATCGCGGCACAGCGCGGTTGCCGCTTCCGCAAAAATGACGGCGCGCGGTTTCTCAGA  
 CGGCAATTTGCCCTTCAAGCGCTGCGGTGCTTTTACCAAAATGCCCAACTTCGCCACAG  
 GCATCCATCCAATCCTATTGCGCCGCGCGCTCTGCTGCTGCTGCGGCTAGCGCCACGGC

5 GCTTGC GGATTTT TAGCTTCCACAATCCTTTGCGTTCCCTTTCCGCGTGAATTTGAGGCG  
 TCGGCATATACGGCAAAATCCGCTTATCCTGCTGTTCTTTAGCATACCTTTTATAATGC  
 CAGCGCCCGCGCTCTGCACCTGCATCAGGTTCAAATCGGTTTGGCGACAGAAACCTGC  
 GGCATCTCGCGCTGGTAGCGGTGCGTATCGAAGACGGGCAGCTGACTTCTCGCTCTCC  
 10 CGCGCGCGCGCAGGTTGTGCGCGGAACGCTGCCGTAAAGCTGTTTATCTCGCGCGCG  
 TCGATATACGCCATCCGGATTTTGTGTTTCGCGCGCTCGCGCTCGATAACGTCGAAGGGTG  
 TCGCGCTCATAGACTTTGGACACCGTGCCTGTGTAGCGGTGGCGGATTTCCGCGCATGCT  
 CGCGCGCGCGCGCGCGTGGAAACCGCGTCCCTCGCGCGCGAGTAGCTCCGAGTAGC  
 GCAACCGCGTCCGACCGCTCGTGCCTACCCGCTATAACCAACGACCCCAAAGTGC  
 15 GACAGGGCGACGGGAAGCAATTTCAATGATTTTTTAATCTGCATATTTTCAATGCGGA  
 TGCCCTCTGAACATATCGGAATCGGATTTTCAGACGGCATCTTAACTCGAGATTACCCCT  
 GCGAGGGATAGATGACTTTTGCACCCCTCTTCGCTCCCAAAATCAACATCGCGGCGAT  
 CGCGCGCGGAATATGCCGTTTTCGAGCACGCGGTGATTTTGTGATTTCGCTTCCATCG  
 20 TCAGCGCTGATCGATATTCAGCGCTGGACATCGACGATTTGGTTCGCGTAAACGCTGG  
 TTAGCCGATACGAGTTTCGGGCTGCCGCCATAGCAGGACGTTTCGCGCAAAACGAG  
 AGCGCGCGCTTTCGACGACTTCCACAGGCAAGGGAATTTGCCAAACGTGAACATATTT  
 TGCTTTTCATCCGCAATCGAGATGAATTTTTCGGACGCGCTGGCGAGCATTTTTCGTTGA  
 GGTGGCGCGCGCACCGCTTTAATCATTTTCAGGCGGTGGTTCACTTCATCCGACCGT  
 25 CGATATAGACCGCAACCCGATACTTCGTTCAAGAAACGACGGGAATATCGTACTGGG  
 CAAGCAGTTCGCGGATTTTTCGAAGTAGATACCGCGCTTTGATTTTTTCGCGCTCT  
 TACCAAGGCTTCGATGAAGTGTGATGCTCGAGCGGTACCGATGCCGATATATTTCAT  
 TTTCCGGTACGAATTCGACTGCTTTTTTCGCGCGCGATGCGCTTGAGTTGCTCTTGTCG  
 TCATATTTTTCCTTTGGGAACCGTATCAACAAACGCGCATCTTAACATTTTTCG  
 30 GCAGTCCCTGCCCGCGCTTCAAATGCGTACAGCAATACCGCGCTGCGCTCTATG  
 CTTCTCATCGCGCGAGATAGCCGAGTTTTCGTTGGTTTTCGCTTTGATGTTTCGACGCA  
 GAAATGTCTATGCCAAATCGCGCGCATGTTGGCAGCATTTGCGGAATGTGCGCGCGG  
 AGTTTGGGTTTCTGTCAATACCGTGCATCGCATTCGACGCTTGCCACCTCCGCGCT  
 35 TGAACGCTTTGATACGCGCACGCAAAAGGACGCGCTGTCGCGCATCTTGAACCTCGCG  
 GCGGTGTCGGGGAATGGCTGCGGATATCGCCAAACCTGCGCGACGAGCGCGCTGC  
 GTAACGCGCTGCGACGAGCATCGGCATCGGAGTGTCCGAGCAGCCTTTTCAAATGGG  
 40 ATTTCAACTCCGCAAGTATCAGCTTTCGCTTCGGTCAGTGTGGTGAACATCGTAGGCC  
 TGTCCGATACGGATGTTCTGTCATCGTTTGTTCTCTGATGTTTGAATGAAGTTCAGAC  
 GGCATCGAGCAGCAGCTGACGATGTATGCTCCTCGCGCTGCGTCAGTTCAAATTTGCG  
 45 CACGTCGCCCTGTATCAGTAGCGGACGCACACCAATTTTCCACGGCGGACGCTTCATC  
 GGTAAATGCCGTCGAATTTTCGCGACCAATGCGCGGTGACAGACCCCGCGCGCAAGAA  
 CTGCGCGCTTTCGCGCTGCCAAAGGCTCGTCCGCTCGACGCTTGACATGATGTTCCACG  
 50 GTCCGCGCACTTGACGATATCGGCAATGGGAATTTGCCAAATCCCGCTTCGCGCGCGT  
 GCCCGCTGTTCTATCAACCGCGTCAAAGCTTCAGACGGCAGGACGACGCGCGCATC  
 GTGTACGAGAATATTGTCGTTTCCGCGCGCAACCGGTTTCCAAACGTTTTCGCGACAC  
 55 GTTGGCGAGGTTTTCGCGCGCGGTGTCGCGCTTTTCCACACCGCAACCTGTGGAAA  
 TGCGCTCTGAACCTTATCGGCAACGCTGCTTCGCGCGAGACGACACGACGCTGCAATC  
 GACGCGCTCATGCGTTCAAATCCCAATCGTATGTTCTAAACGCTTTGCTTCGGAT  
 TTCGACATATTGCTTGGGTTTGTGCGCACCGAAACGCGCCCGATGCGCGCGCGGAAT  
 CAGCGCGATATTTTTCGCTTCATGCGTCGCTCCCGCGTTTTCAGACGGCAGCGGTTC  
 60 TTGCGCGAGATACAGGCTTCGCCAAGCGCTGCAATATTGCGCGTCCGCGCGCTTTCG  
 TTTTCGTCGCGCTGATGACTTTTCAAGTTTCGCGCTGCGTTTGGTTTCGCGATGACACG  
 GGTTCGTTTCATTTTTCCTTCGCGCGCGCAACCATCAGTTCGAACTGCGCGCGGCTC  
 ATAGCAAGATAGACTTCGCCAAAAGTTCGAGTCGATCAATGCGCGCTGCAGGACGCGC  
 65 TTGCTCGCGTGCAGCGAAAACGCTTGACAAAGCATCCAGCTGCGTTTCTGCGCGGGG  
 AACATTTTCGCGCGCATGCCAGGATATCGTAACGATACAGCGAGTTTCAACAGCTG  
 70 GGCACCAACCATCCGCGGAACTCCATATTGAGGAAGCCACGCTGCAATTTGGCATTTG  
 ATAATCACTTCGACCGCGCAGGAATTCGCAATCTGCTTCGCGACCTCTGCAACAGGCG  
 GCGCGTTTTTCCCTTCCAAAACCTGTATGCTCAAGCGTGGACGCTGCGCGCTCTTC  
 75 GGCATATCGCGCTCGGGTGGACATAGAGGTGCGAGGTTTTCGCTTTCGCGCTTTCG  
 ACCATTTCAAACCGCAACTCGACCAAGCGGTTCGCGCGCTCGGCATACAGACCGGTG  
 GTTTCGGTATCGAGGATGATTTGGCGTGTGCTATATCGGTGCTTTCTCTATCTTCGT  
 AATTTGCTTATTTTAAAGCAATGATTTTTCTGTTTTTCATTTCAATGCACAAACCCACT

TATTACAGTGTGTTACAAACATTGGGCGAGCGGATTGTGATTTTGGGGACAATTTTT  
 CAGACGGCATTCAAGGTTTTTCTCGATTGCGCGCGCGCTAAAACCGCTTTTCGGGCT  
 TAATCAAAAATACCGACACGGAATATTGCCAAAGCGACAATCAGATACAAACAGGAA  
 TGTGTCAAAACAAAACAGCAACACCGCGCTCAAAACGCGAGCGGAAACATAAAAATAC  
 5 CGTTAACGATATTGTTGGCGGCAACGGCGCGGGCGCGGAAGTCTCGTACTGGCGGTTT  
 GCAGCCAGGATATAGAGCGGGAACGGAGAAAAATCCGCGGAAAAAGCCGATCAGCGTCATCA  
 CGGCCATCCGGGATATGCCATCTTGCATAAAAACCAAAAAATGCGTTGAGCCCTT  
 CAAAACGGTGTCCGTGCGTCAGCCACACCAAAACCAAGCCGCAACCGTCAAAACCAAGC  
 CACCAACCGTTACCCAAGCCAAACATCAGGCGTTCCCTGTAACTTGGCAACATCCG  
 10 AACCGCGGCAATACCGATGAAAAACAGAGCAAGCATCAGGTTGAAAAACATTGCGTTGC  
 CGCCAGATGGATTTGGTAAAGGTCGGCAGTTGCGTGGTATAAAACGCGCCGACAAAAC  
 AAAACCAACCAAAATACCGATAATGGCGGTA AAAACGCGCTTGTGCGCACCGTTTCAAGCA  
 GCAGGGATTTTGTGCCACGGACAATATCCACTCAATTTGTGTATCGGCAGCCTTGGCGG  
 GTACGGACGGCATAAACAGGCTGCCGACCGTGCCTCGACGCGACACGAAAAACAGTA  
 15 TCCCGCAATATAGCGGGTACACCTGCCACGCGCTTCCCAAAATCTGACCGAACAGGA  
 TGGCGACAAACGTAACCGATTCAATCAGGCTGTGGCCATCATCACTCTTTGTGCTCGA  
 GATAATCGGGCAGGATGGCGTATTTCAGCGCCGGAACAGCGTCGATTGCGCGCCCATCG  
 AAAAAAGCAGCAGCAAAAGCAGCGGGCGAGACGGATATAAAACCGGTATGCGCGCACCG  
 CCATAATGATCATTTCCAGCACCTTGACCCACGCGCCAAAACGCGCTTGTGGAATTTGT  
 20 TACCAACTGCGCCGACAGCGAGGAAAAACAGGAATAACGCAAAATAAACAGCAACGCGC  
 CCAAGTTCACATCTGTCCGCGAGGCAAGCGCTTTTGGCCCAACCGTAAAAACCCAA  
 TCATCAACAAACGCGCGGTTTTGAACACATTGTGTTGAACGCGCGGAGAAAGCTGCGTAG  
 CGAAAGAGGTTGCAAAACGCGCGCTTTTAAACAGTCCAAACCGCTTTTTAGCGCTTGA  
 TCGTTTTCCTCTCTTTTTCAATCAGTTTACTTGTGCAATCATCATCCATCAGGATCGGG  
 25 TGGCGCGCGCCTTCCAAGTCTGTCAACTGCGCGTTTTTGGCCGACCAACAAAAACCGAG  
 CCGATGACAAACGCCAAAAATAAGTGTGATGGGCAACATATAAACATGCTTTCCATCACA  
 TTTCCCTGTCAAATCGTTCAAAACAAAAAGTCTGCGCCGACACGCGTCAAGATTTGTTGA  
 GCAAGTTCCGACGGGAGCTTCGTCAAAACAGCTCGATCAGGTCCTTTGACCAACGCGCC  
 AATATTGGGGGATTTCCGTCTGACCGAACGGCGCAGGACATGATTTCCATTCGCGCTT  
 30 CAAGTTTGACGGCAAAACGCGCGCTTGGCGCGCTGCTCCGATTCTGCTGCGCGCAAGCA  
 GGTGAAAAAGCCTATATGCGCTCCCGATTGTCATGAATCTGAATAATGCATAAAT  
 TCCACCCGCGCTTTTTTCAGACGACCAACTAAAAACAGGGCGAATGTACCAAGTTTGA  
 CGGGAAAGATGCAAAAGAAATTCCTCCCTCCCGAGCGAAAAACCGGCAACCCGATATC  
 35 CCGCTTTTTCCGTCAAATGCCCTGACTTCCGCAATTTTCAAGCAACGCGCGATTAAAGC  
 CAAGCAATTGCAAAAGATTTTTGCTAGAAATAGCCTGCTCTTTTATCAACCTTTTCAGAC  
 GCGCCCTACTCTTCCGCGCCAGGAAGGCAAAACGGATTGCGCACGAATCCGGTTAGTAT  
 CCGTGTCCGATTTCCAATGCCGTCTGAACTTTCCGGAGTAAGAAAAATGTCCTCAAAATTTG  
 ACTTTGGTTTTGAACTGCGCGAGCTCGTCCCTCAAAGGCGCGGTCCTGGATACCGCGAGC  
 40 GCGGAGTCTGCTGCTGAGTGCCTTGGCGAAAAATCAACTGCCCGATGCCATCAGCA  
 TTTCAAAGTAAACGGCGAAAAACAAAGTCGATCTGTGCGCACTCCCGACCAACCGCGC  
 GCGGTGAAAGCCTGATGGAAGAACTCAAAGCCACGSGCTCGACAGCGCATCGGCGCC  
 ATCGGCCACCGCGTGTGACGGCGCGGAAGTGTACAGCGAATCCATCTCTGTTGAGCAG  
 GAAGTCATTGCGGCGATCGAAAAATGCATCCGCTGCGCCCTGCAACACCGCGCCAC  
 45 CTCTTGGGCTGCGTGGCGCGCAAGCAATTTCAAAGGCTGCGCCAAACGTCGTCGATATG  
 GATACCTCTTCCACAAACCATGCCGAAGTCGCTCAAAATACGCGCTTCCGAGGAG  
 TTGTATGAAAAATACGCGCTGCGCGTTACGCGCGCACGATACAGCATACCGCTTCTGCT  
 GCGCGACAAAACCGCGCGCTTCTCGGCAAGACAAAAAGACCTGCGTATGGTCAATGGC  
 CACTTGGGCAACGGCGCGTCCATTACCGCGCTGCGCAACGGCGAATCGCGCGACACAGT  
 50 ATGSGCCTGACCCGCTGGAAGGGCTGTGTAATGGGTACGCGCAGCGCGCATCATGATCT  
 TCGGTATTCGGCTTCTCGCGGAAAAACGCGCAATGACCATCGCCCAATCACTGAAATG  
 CTGCAACAAAAATCCGGTCTGCTCGGCATTTCGGGCTGTCACGACATGCGCGACCAT  
 GAAGAAAGCGCGCAAGGGCATAAAGGCGCGAAATGGCCTTGGATATGTTTATCTAC  
 55 CCGCTTGCCAAATACATCGGCGATATGGCGGTTGCCGAGGCGGTTTGGACGCACTGGT  
 TTTACCGCGGGCATCGCGAAAACTCCGACATCATCGCGAACCGTGATCGGCTACTGTT  
 GGCTTCTCGGTCTGAACATCGACCAAGAAGGCAACCTGAAAGCGCGCTTGGCAACGCG  
 CGCGGTATTACCACTGCGCGACGCAAGCGCTTGGCGGTCTTCCGACCAACGAAGAG  
 CTGATGATTTGCCACGACACTGCCCGTTTGGCGGTCTGTAAGTTTTATCCGACACGA

ACTGCCTCCGGAATGGAGGCAGTTTTTTATCCGGCTTTCCATGCTTAAACGACACTGC  
 CTCTTTT CAGACATTGACGGTTGCAGCGCTTACCTGAACCTTATAGTGGATTAAATTTA  
 AATCAGTAGCGCGTTGCTCGCCTTCCGCTACTCTGTACTGTCTGGGCTTCGTCCGC  
 TTTGCTGATTAAATTTAATCCACTATAATGATTAACCTATTTTAAATCATGTATTAT  
 5 TTTCCATAAAATACATGACATTAAAGATGTTTTCCACAAAAGATACACACCGCCAAAC  
 ACCGGCTGTGTTTATCTTTTCTTATGCCTATTTTTAATCATCGTATTTTATCTTTTAA  
 TTTCAATACGCAAACTAACTTATACACACGGTTTTACATCTTTAGACTGCTCCGTGTTG  
 TATAGTGGATATTGCCGTTTTCTTTCTGACAAAAATGCCGCTGAGAACTTCAGACGGC  
 ATTGAAACATCGGAATCAGCGGTTTTGTTCATACCCTCGATAAACTTGCTGCTTTGA  
 10 CAAAACCCAGCAGCGGCTCGCTGCGGCTGCCGTGCGAGCGGACGACAAAACCGCCGGG  
 GCCCGAACAGACCGTATTCTTTCAACAACGCTGATGTTCCGGGGTGTGGCGGTTACGT  
 CGATTTGAAAAAGCGTTCCATATCGACTGCCGTGATGCACTTCCGGCTGATTGAGCGGT  
 AAGCCGCCATTTCTTTCAGGAAATGCACGAGTCGGCATAAAAATCCAAAACGACGGGTT  
 TGTCCGGATGTTCTTTCAACGCGGTATCCATCGCTGCCCTCAGCGCGGCAGTATCGGCCA  
 15 ACATTTGCCGTTGTCCGAAGATTGCTGCTTCCGCTGTTGGATTGAGGGTCAGGAAAT  
 GGTGCAGCGCGTTCGTTTGGCGTTTGGCGCCTGCCAGCCGAACACGCGCCGCTATCA  
 GCAATATAACGCCCAATGCGAATGCCAGCTTTCGGACGGCGTTTCTGCTGCGTCGCT  
 TGACACGCAGCATAAAGCGAGAACCGATCAGCAGCGTGTACAGCGCAGCAGAT  
 AATAGGGCAAGTGCAGCGCTGGCGAGGTAAACGGCGACGCTAGCAGGATGAAGCCGAATG  
 20 CGTATTTGACGGCATTCATCCATCGCTGCCCTTAGGCAGGATATGCCCGCCGAACGCTG  
 CAGTGGCAATCAGCGGAACGCGGTGCCAAGCGCAAAAGTGTAAGTGCCAAACCGCTCA  
 AAACGCGATCGCCGCTCTGACCGATGTAGCCCAAAGCAATGCCAGCGCGGGGCGAGCG  
 ACGGCGCGACAATCAGCGCGACAATATGCCCATATAAAGACGAAACGATTTTACCGC  
 CTGAAAGCCTGCTGCTTTGATTCTGAAATACGACTGCACGGCGTTGGGAAGCTGGATGT  
 25 TGAACGCGCGAATACATAGACAGTGCCAAAGCAGCACTTAAAGCCGATGCCGCCAATACCA  
 CCCAAGCTGCTGCAACCATACGTTAGCGAGTGCAGCGCTGAGTCCGGCAACATGCCGA  
 CACGCGTATAAGTCAGAGCCAAACCTGAACATAAACGACGAGCAGCAACAAACGCCGCG  
 CTTGCCCGCCTTTTCTGCGCGACCAATACTGGAAACATCGGCAACAGGGGATACA  
 TACAGCGGTGTAAGCTCAGCGCCAAACCGAGCGAATAAACGCCAAAGATTGCCGTTGA  
 30 GCGTATCCCAAGACAGCTTGAAAGCGCTGTCGCGGCCCTCATCCCGCTTCCGGGGCGGCA  
 GCGCGCCGCTGCCGTTTTAGAGGAAGGCTGCAAAAAGCGGTTCTTTGGCGGATGCCGGTT  
 CGTCCGTTTTGCGGATGTAAGTCCGTTGCCGAAAAATCAAACTCGGTATCCACGGGCG  
 GATAGCACACGCGCGCTTCGGCACAGCCCTGATAGGTCAAAACCAATTTATACGGTTCCG  
 CGACAGCCCTTGCTAAGGAAGGCAACCTGCGCCTCGTGATGGTAACCGCTGCTGCCG  
 35 CGAAAACTCGTCTCTTCTCTTTCGCCCTTGCTGAAAGAAAGGCTGTCCTCAACAAATCCG  
 CGGATCGGTCTTGCCGACGATTTTCCGCTGATACATATAGTATCCGTCGGCAACTCTGA  
 AACGGACGTTTACACCGCTCGTCGGCAACGGCAAGCTCGCGCAGCAATGCTTTTCCGGCG  
 GCAGCAGATCGTTGCGATCCAGCGCGAAAGCTCGTCCGCAACATCAAAATCCGCGCA  
 ACAGGCAAAATCAGTTTTTTCATAATCGAATCCGTTTCAGACAAATAAATGCTCGCATTA  
 40 TAAATGTAAGGTGACGCTGGGATTTAATTTATGTAACCCGCCATATCCGAACCTA  
 TTTCCATAAACATCTTATCGAACCCGCCATGACGATGTCAATACCCAGATGTCGCGCG  
 CTTTTTCCGCCGCGTGTGGCAGCAGCGGCTCAATCGCTGCAACTGAGCGCATCGGAACA  
 GAAAGCGCTCCGCAATTTGTCGAAGCCATCCGGAATACACCGTTTATCTGCAACGCAATCGA  
 AGACCATCTGGACACCGACTGCTGCCCGAAAAACGGCGAAAGCAACCCCTTCTCGCATAT  
 45 GTCCGTCATCTGTCGCTCAAGAACAGCGGGCATAGACAGCGCGCAGCGCATACGCGC  
 AATCCAGACACCCCTGTGCGCCAAACGCGGCTGGCTGGAAGCGGAACACGAAATGATGGA  
 GGCATCGCGGAACACTGTGGAACGCGCAACGCTACGCGCACCGGTTTGGATGTCAATTT  
 CTACATGACCGCATGCGCAACTCATCGGCTTGGTGAGAAATCAAGCAGATGTAA  
 CCGCATGAAATCGCTGACCATCAACCCGCTGCAAAATGCCGCTGGAAGCGGAACAA  
 50 CCCCTTTACAGCGCATTCATTTTCCCCCAATCATTTCCACACCGCCTTTTTCAGCATAA  
 TCAACCAATCTTATTCAAAACGGGGCGTTGTGCAACACATCGTATCGGCACGATG  
 CCAGTTTCTGCAAAATCAACTGCGCCCAACCAATCATACGAGTTTCAAAACCGGATC  
 GCGCATTCAGTTCCCTTGCCAAAGCGGAACCCGCTTCAGCATACGGAACGCACGCGGAC  
 ACTCATACGCCATCAGCGCTGAAACGCGCATCCGCGCGCTGCTGCGCGATCTGTCTCT  
 55 CAGAAACCCGAAATTTCAACAAATCGTCTGCGGAATATAAACCCCTGCTTTTGGCAAT  
 CCACGCCACATCTGCAAAAAATTCACAGTTGCAAAAGCGTCAGATGCGTGCCTGTT  
 GCGCCAGCGACACCGCATCCGTTTTCCCGTACAAAGCGACATAATGGGTCCGACAGGGT

TGGCGGAACGCCGACAATAATCGGCCAGCTCGCCGAAATTTCCATACCTTGTTTTAAACCA  
 CATCTCTGAGAAAAATGCAGAAAGCAATCATAAACCGCTGCAAAATCCAAACCGAAGCGGCA  
 CAACCGCTCGGCATCCAATCGTGCAATCAAGGATGCGCCGACCGCGCCGATGCCA  
 ACACGCTCAACTCGCGCTGCAAAACCTCCAACCCCGCAACCTGGCTTCAGACGGGCATAC  
 5 TGCCCTCGTCCGCGCATATCGTCCGCGTCCGTGCAAAACGGGTACACCGCGTGAACCGGCT  
 TCCTCAACCTGCGCGGCAAAATCAGCGAACCGGACGGGAAAATTTCTCATATGCCCAACCG  
 ACATACCTTCTCCATCCATCAACAAAAATGCGCTCGAAACGGAAACAAACCTTTTCAGA  
 CGGCATCAGATACCTCCAAGCTGCGCGCAATCAGTGTGGTGATGACCGTGGGGCGCGTG  
 GACATGACCGTGTGGGATTCTCATCGGATGCATCGCGACGCTTCAACTGTAGCCTT  
 10 AAAGCGGATTTTCATGCTGCCAAAGGATGGTGGCGTCCACCACCGCCTTGCCGTGGC  
 AACATCGGTTACAGATAGCGCAACATCGCCGTTTCAGGATCGTCCGCTTCAAAACAT  
 CATCGGACTTCGACTTCAACAGGGAACAGCCCGCATCTTCGATACGGACCACTCCG  
 ATCCTGCTCGCGGAACGCATCGTGGCGGACAGCGCCACATCGACCGTATCGCCGGCATC  
 CTTACCGTGCAACGCTCTTCCACCAAGGAAAAATGCGCTCGTAACCGCGTGCAGATA  
 15 CGCAATCGGTTCTCGGTTTGTGCAAAAGCTGATTGTTGGCATCATACATCTCATAATG  
 CAGCGAAACACAGGAATTTTACGATAGCCATATTTGTCTTTCAGGAACAGCAGATTA  
 ATTACAGGCGCATTTAACAACAACCGCGCGCGCGCGGATACCCTTAACCTGTTTCATA  
 ACTGACACATATTTCAATGTAATCTTTGTTATTTTATGGCGGTGAACCTTTTTTA  
 CAACATTTCTAAACCATTCGACCTGTCTGCCGACTTCCCAATCGCCTTAATAAATC  
 20 ATACAAGATACGAAATTAATTAATCTCTATAATTTATCCCTATCGAATTTTAAACA  
 GCAAAACCGTTTTACAGGATTTATCAATCGCGCCGAGAAAACTTTTATCAAAACCTT  
 TTTCCCATCTGTAGACATTTGCAATCCCTTATTCATAGTGCATAATACGCAATTCAG  
 CGATGAATTTCCAAACCGGTTTGTAGTATGGTCGATAAAGACCTATTTGTTTCAATAAT  
 TAAATTTGGTTCTAAAGGTTACTAAATGAAAAAATCCCTGTTTGGCGCTGCTTTGTTGTC  
 25 TTTGTTCTGCGAGCTCGCGCGGTGAAAAAGCGCTGAAGCTCCGCTGCTGAAGCACCC  
 TGCCGCGGAAGCTCCGCTACTGAAGCACTGCCGCGGAAGCTCCGCTGCTGAAGCACCC  
 TGCCGCGGAAGCTCCTGCTGCTGAAGCTGCCGCTACCGAAGCACTCCGCTGAAGCTGC  
 CGCTACCGAAGCACTGCCGCTGAAGCTGCCGCTACCGAAGCACTCCGCTGAAGCTGC  
 TGCTGCCGAAGCTGCAAAATAAGCATTTTCCGCTTGCAAAAAAGCAGGATACGTTTCAGTA  
 30 TCCCTGCTTTTTGATTTTCAGACGGCATCAGATTCCTTCTCAATCTTCTCCTTACCC  
 TTCGCAAAACATGCTTGACCTTCATACCGAATTTTCCGACTCCTACCGGCAGATGAAA  
 TTGCGGAACCTTCTCCGACGCTTTTAAAGACCGCGCAACCGCTTACGCTCGACCAAG  
 ACATCATTTTTCAGCCGCTCAGCGTTTAAAGCGTGCAAAACCATATGCGGTTTCTGCCACC  
 35 AACACCGTATTCCGGTTACGCCGCAAGCGGCAATACTGTTTTCGCGCGCGCGAGTAT  
 CGGAAAAACGGCGTATTGCTGAACCTTTCCAAACTCAACCGCATCCGCGCATCAATTTGT  
 CAGACAACCTGCATAACCGTGAAGCAGGTTCCGTACTCCAAACCGTCCAACAGGCAAGCG  
 AAGCTCAAAACAGGCTGTTCCCACTCAGTCTGCCGAGCGAAGGCTCGTGCCAAATCGGG  
 GCAACATCTCCGTCGAATGCCGAGGTTTGAACGTAATGCGTTACGGCAGCATGCCGCACT  
 TGGTTATCGGTTTGAAGTCGTCTCTCCCAACGGCGAATGGTTTCCCATCTCCATCCCC  
 40 TGCATAAAAAACACCCAGGCTACGACCTGCGCCATCTGTTTATCGGTACGGAAGTACAT  
 TGGGCAATATCACTGCCGCCAGCTCAAGCTGTTTGCCAAACCCCTTAGACAAGCAACCG  
 CATGGTTCGCGCATACCGACATCGAATCCGCGCTCGGCTGCTGACCGAAACCAAGCAGC  
 ACTTTGCGCAACGCTATGCACTTTTGAGCTGATGGCGGCTTTGCGCGCGAATTTGTCTT  
 CGGAATTCAGCAAACTCCCTCGCGACACATTCAGAATGGCATATTTTACTTGAGTGA  
 45 CCGACTATTACCGCAGCAGCAATCTTGATGATCGGCTTGTCGAATTTCTTTATAAAAAAG  
 GCTTTACCGCAGCGGTGTTGGCGCAAGCGAACAAGACGATATCCATATGTGGCGGCTGCG  
 GCGAAAAACATCTCCGCTTCGCAACGCAAACTGGGCAACCGCATCAAACACGATTTGCGG  
 TTCCTATCGGGCGGCTTGCCGACTTTGTCGCGCGGTGCGCAAGATTTGGAACAGAAAT  
 TCAAAAGCATACAAATCGTCTGCTTGGACATCTGGGCGACGGCAGCTGCACATCAATA  
 50 CTTTCTGCGCGAAATCCTCAGCAATGAAGTCTATCGTTACGAAAACGACATCAACAGCA  
 CAGTCTATCGCAACGCTCTTCTGCTGCAACGCGCAGATTCGCGCGAACACGGCATAGGTA  
 TCATCAAAAAACAGTGGCTGGACAAGTACGCACGCTGCGGAAATCGCCCTGATGAAAA  
 GCATCAAAACACACCTTGATCCATATAACATTTAGATCCGGGCAACACTGCTTCGGAAC  
 CGGCAATTTTGATTTGCATACACAACAAAAAGGAGCAATAGATCCGATTTGCGGTTTA  
 55 CGCGGAGCTCGTGAGTGGGTTTAAAAATTTGGTGGAAATTACACGAAAAATGACCGCACTT  
 TTAATAATAAAAAATCGGCAGTGAATTTCCCTGCCGATTTTATTTGTTTCAACATTAAT  
 TAAACGCTCACTGTAATTCACAGCACCTTGTTTAGCTTGATGATGTTTGCTGTTGG

CGGTGAATGTGGCTTGTAAAGTTAAGTGAGATTTGATTTTCTACGTACACCTAATTGG  
 CTCTCAATTCCGGTCTTATTGTTTATCAC'TCGACGCTCTCCGTCCATT'TCCACACCGAAA  
 GGT'TGTTGTGGTAAAGCGGTTTACAGCGGCGAAAGGTT'CAATAGCGATATTTT'TATAG  
 AGTGAATAATAGAGCTTTAGCTTGAACGCGCAACCCGAGTTTGTAA'TGCGGGAGCCAAAGT  
 5 AATTCACGTTGGGCATTTTCGCTATCGCTGAATTTTCCGTTTACCCCCAAATAGCTCAAT  
 TGTGCTCTGGTTGTAGGTAACACGAAGGCTGT'TGCCCTTTT'TAGTGAAGTGT'TCCGCC  
 AATAACGCAATGTAACTGCTTCAATTGAGGCAGTAATACCTTTTGAAGTAAACGCTTCT  
 GTACCATTCTCAGTGT'GTATACGGTGGCGGAAGCGT'GTATATTGCATCCAGCTATCCGCA  
 TAGGCACCTGTCTGTTTGTCTGAAGTTGGTGCCAAAGTGGCGTAAACGCGCTGCACCAAG  
 10 CTTTTCACATTTCCCGTTGTAAAGATTGTCTGTATCTGGGTTGTGGAAGTGGCTACGTTGT  
 TCTGCTTGTCCGCCCAATTAGGCCAATAGAAAGTGTATTACTTTCGTTTGGCCATGTGAAT  
 ACTTCCGCCCGCAGATTGCACACCTTTACGATAGCCTCTACAGGTGCTGTTT'TGCTTGC  
 ACCCATTTGGTTGGAATGTCCGTCAATCACACGCAACCAAGCCTT'TGCGTGGTAAAGTG  
 CGGTGCAAAAATATCGCTGTTTTTGTGTTCAAACGCAAGGCGAATAAGGTATTGGCGGCT  
 15 TGAGCCTGTTGTGCATAAATCGCCATATCATCGGTTCTTGCACCTT'TGGTAAAAAGGCC  
 TCTGGCGTTGTTGTAAAGAAAGCGTATAAAATCCCTTTTGGTGT'TGCCAGAAAGACGG  
 AATGCGTGTTTATCTGCTGTGCCATT'TACTTTGATAATTTGATGCCCATCGAGGCTTTT  
 AAATCGCTATTGGATTTT'CGAAGATGATGTCGGAAGTGCCAGTAACATTTTCTCAA  
 ATTAATGCAGTATTTT'TCGCTTCTT'AGGATCGTAAGCAAAACGAAACGAGCTTCCGCCA  
 20 GCATAACTCTCTTTACGAGTAACTTTCATTTTAGTATTAAACGGATGTCTGCATTGT  
 GTTGT'TTTTAAATTTCCCAACATTAGAATCCCAACGGGGCTCCAGAGAGAA'TTCTTAAG  
 CGGAATTCATCCAAACTAATCGTTTGGCCGATACGCTGCGAGTGTCTGTAACTCAATA  
 TAGTGGAAATGGATCTAAACCAGAAATATAGATGTGCTGCAAAAGAAACATAA'TTTCAAT  
 25 TGATGAATTA'CTTGATAGCCACTCTGTATATTTCCGACAGATAAAATTT'CGCTGTG  
 ATATGACTATTTTATTTT'TGGACCTAAGGAGATAATATGACTTTTACTATTAAGAGGA  
 TGGGATCCAAATTTT'CAGCTTGGCAAGTACTATAATCAGTATCTT'AGTGTAGAA'TTA  
 AAACATTTCTTAAATATTTCCGTATT'TTGTCTCTGTGCCCATTTCTT'TTGTCAACC  
 CCTAAACCTCGGGGGAAGCCAACTAGGTAACCTTCGSTATATCTTGTATCAATAAAAGAA  
 30 ATCTTTT'TGAGTTATCTATGTTTTCGAATTTGGTATGTTCTTAGGTAATAGTCGGGAAG  
 GGTGGAAC'TTTGGATTATCCTCGGTTATAAGATAAGTTTCTTTT'TCCAAATATCTACTC  
 GTTTTATCGCGGAGTTT'TTAAAGCGGTAATTT'CATCATTAGTGAGCTTGGTTTGTGCG  
 TAAACGTATTCAACAGCCAAAGCGGAGAGGTATAAAGAA'TAGAAAAAATAGACTTACA  
 ATAAATGATTTTTTAACTTCTGCTTGTCTGCTTGTCTCGAGTTTCAATAATAAAT  
 35 TTCTTTT'GCAAGTAAAAATAAATGGGCGTGGATTTAGCATAAAACTGAACAAAAAT  
 GTCATTATCTCACATTTTCTCTATTATTTCTTGT'TATTAAGTAAACGTTTGCTT  
 TTTGCTATTTTGTCAAGCCAGTTTGAATAATGTGATAA'TTGCCCTCGTTATTTACAAAAA  
 TTTCAAGAAAAATGACCGCACTTTACCCTTGGCTAATGCCAATTTATCATCAAA'TTGCTC  
 40 AAACTTTTGACGAAAGCTTGGGCGATCATGCGGTGCTGATTAAGCGGATGCTGGTTTGT  
 GTGTAGAAGCTTTACACATCAGGCGGAGCCTTGCCCATACCGTCTGAAGCACTGT'TTCC  
 ACAATCAGCGCGTATGCTTAATCAACCGCTGTTTCTCGCGTTTCCAA'TCCGCCCTGATT  
 TACTCTGGCGTTTGTGCTGCTGTTTCTTACTTTTGCRAACCGATTTCATCTTGTAT  
 T'TCCGGGTGAAAAATGCAAAATCCAGCGGCACGATGGTGTAGCCGGCAGCTGTCCGTTTGC  
 45 CGATTAA'TTTGTTGATTTCGCACTGGT'TCAACAAGAGCTTGCGCGGACGTACGGCATCTG  
 GTTTAATGTGTGTCGAGGCTGTGGGCAAAAGCCGTAATATGGCAGCGACAGATATAAACG  
 CGTCTTTTTC'CAATAGATAATACTCTCTTAAAGTGTACGCGCGCGGCGCGGATTGCTT  
 TGACTTCCAGCCTTCCAAGACCAACCGGCTTCAATCCGGTCTTCAATGAAAAATTCGT  
 50 GAAATTTCTTTTATTTGTTT'CGAATAGCCATAAACATCCTATCAATCCGCGGTGAGAC  
 GGCATTAACCCGAAAAAGAACCCATCATACCGCCTCTTCAACCGCTGCACAA'TCTCT  
 CGGGATACAGCCTGTTGAGGCAGTCGGTATGCCCCAGCGGACATTCGCGTTTAAACACG  
 GCGAACATCCAAGTGCAGGCTGACGATTTTCCGCTATCGCTCAAGCGCGGCTATGCG  
 TCGGCTTGGAAAGCCGTTAAACCGCCACCACTTCTTCCCAAAGCTGCGCGCAATGCA  
 55 TCAATCCGCTGCTGTTACACAGCAAGCGTGTCCGCCAAGCAGCAAAATCAATGCTCGG  
 ACAAAATCGGTTTTCGCGCACAAATGACACACATACCGCTGTGAAGGCGGTTGATTTCTC  
 CGGCAATTTTCATCATCTTTT'TGGAACCGAACAGCCAAACCTGCCAACCGCGCGAGAT  
 AATGTTTGGCCAACTCGGCAAAATGCCTTGTGCGGCAACGCTTTCGCGGCGCAAGTTCCG  
 CACCCGACAAAAAGCCAGAACAGGCTTTTCAATATCCAAGCCAAAGGTTTGCAGAGAAA  
 TTTCCGCGCGCGTTTCAATCAATGAAACCTCGGGGAATCCGGAATGCCCGTCAAAATCTT



CCTGACTCGGATGCGCGAGAGCGGTATATCGATCCACCATTCAAAGGCAGACGTTCTCTTAT  
 CCAGCCTGCGTATATCGTTCAACAGAAAAATAACGGCTTTACCGACATAACCCGTCCTTT  
 TACCGATACCTGTGCGCGAGCGGATGATTGCCGATTTCAAAAGAACGGGCAACACGATAA  
 5 CTTGATCGTATCCGCGCCGCCCAAAATCCCTACCGACCCGCCCAACGGCGTTTCAACTCCA  
 ACGCACCATTGCCGAACGAATTCTCAAGAATTTCACTTCCGGCATACGCTCGCAACA  
 CCGCCATCGACCACTTCGGTGCGAACATCAATCGTGCAACCGGGGTGAAGTTCCTTCA  
 AACGGCGGAACAAGGGCTGGTCAATACGCGAGTCGCCATTCACACTGGGCGAAATATCA  
 GGATTTTGTATGGACATAACAAGAAACCGAAATCAGACAGGCAGAAATTTACCGCGAAACC  
 GTTGGAAACCTACTTTGCCGCAATCCGAACGCGGACGTGCAAAATATGAAGAAGCCGA  
 10 ACATTCAAGTTCGGGCTTCAAAATCTGGCTCCCGACCTGGGCTCGAACCGGGAACCTG  
 CGGATTAACAGTCGCTCGCTCTACCGACTGAGCTATCGGGGAATGGGCGGTATTATAGCG  
 TC

15 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 3>:

**gnm<sub>3</sub>**

GCGGGGGCTCCATCGAGTCATGCACAACATCTGCATCAAATGGTTTGCACCATATCG  
 CGCAACGCGCCGGTAAATGTCGTAAAACTCACCGCGCTTTCCACACCGAGCTGTTCGGGG  
 ATGGTCAACTGCACGCTTTCGATATATTTATGTTCCACAGCGGCTCGAACATTACATTG  
 20 TCGAAGCCAGCGCAAGCAGGTTTTCAGGCTTTCTTTGCCAAGTAGTGGTCGATCGG  
 TAAATTTGCCCTTCTTTGAAATAACGCGCAACATCGGTATTGATTGTCGGGAAGAAGCC  
 AAATCGTACCCAAACGGTTTTCAAAACTACGCGCACATTTGTCGCATTCAAACCGATC  
 GCAGCAAGTTTTCACAGGCTTCGCGCAAGAAATTTGGGCGCGTGGACAGATAGATGAGC  
 ACGTTGTGCGTTTCTTTGCGCGCTTTGACCAAAATCGGCCAAAGCGGCAAAATCGTCCGG  
 25 TCGCTAACATCGACTTTGAGATATCGGAACGTTGCAGAACGATGCCCAAGCGCTCATCG  
 GAAAAATTTCTTTACATGGATTTTGGAACTGGTTTCCACCTTCGCCAGAAAAACCTTCG  
 GTATCCAACCTCGCTGCGGCTGACCCCAAAAATACGCCCTTCGGGATGAAGCAGACCGGCA  
 ACATGCGCCTGGTACAGACAGGGCAACAGCTTGCATCGCCAAATCGCCGGTTCGACCG  
 AACAAACGCAAAATCAAATTTGTTGTGTACTCATCGTATTATCTCGTCAGGAAGAAGTT  
 30 TTTTCGATGCCCTCGAAACCTGTTTCCCCATCAGCTGCATCGCAATATCGGAACAACAA  
 GGCAGGCGGCATAATGAGTAGTAATACTACACACCGCTACACTTTTGTCTATTCCCAAT  
 TTTACAAATTTATTTGACCTAGTCCAAAAATCGGGCAGGTTTCCCTTATTCGTTACAACA  
 ATCGAAAGATTCTGCGATTTTAAATCAAATTTCTTTCAATGCCTGATTTTGTGTAACA  
 AATTACAATTTTGTACTATAATAACACCCGCTTCCCACTTTCAGACGGCATACCTTTTA  
 35 AATATAGTGGATTACAAAAATCAGGACAAGGCGAGAAAGCCGACAGACAGTACAGATAAG  
 TACGGAACCGATTCACTTTGGTGCTTCAGCACCTTAGAATCGTTCTCTTTGAGCTAAGG  
 CGAGGCAACCGCGTACTGGTTTTGTTAATCCATATACCTTACCCTCTGAATACCCGATA  
 CAAAAATCAGAAACGCACAAACAAATCCCCAATACCCCCCGCTTCGACAGGAGACGGA  
 CGGTGAACACTACTCCTATCCAATCCAAATCGCCGAAATCACCAGGCGCATATTGAAC  
 40 GCAGCCGTCGACGCGTGAAAAATATCTGGCGAAGTTCGCAAGTGCACAAACAAATGGGAC  
 GGTTAGAGCGCAACAGCTCGGCTGCAGCAACTTGGCACACGGCTATGCTGCCATGCCTA  
 AGAATGATGAAATCGAAATGCTTCAGGAACCGTCCCAACTTAGGCATCATACCGGCT  
 ACAACGACATGGTTTCGCGACACAGCGGTTTAAAGACTTCCCTGACCAATCAAGACG  
 AAGCGAGAAAAACGCGCGACCGCCCAAGTCCGCGCGGACGCGCCCGCATGTGCGACG  
 45 GCATCACGCAAGGTACGCGCGCATGGAATGTGCGCTGTCTCCCGCAGCTGATTGCCA  
 TGAGTACCGCCATCGGGCTGTGCATCAAATGTTGACGCGAGCCTGTTATGCGGGGTAT  
 GCGCAAAATCGTTCAGGTTTGTATGATAGGCGCGCTTTCGTTTCGCTCATATTCGGGGTA  
 TCTTCGTCGCCGAGGCGCGATGTCACAGCGGTATCGGCAACAAAGAAAAAGCCCGCACCC  
 GCCAGCTTTTCGCGAAGGCAAGTTCGACGCAACGAATTTTGAAGAAGCGAAATGGGTT  
 50 CTTACACAGCCCGGGCACCCTGCATTTCTACGGCAGCGCAAACTCCAACCAATGATGA  
 TGGAAATGATGGGCTGCACCTGCCTGCCGCGCGCTTCGTCACCTTACACCGAGCTGC  
 GCGAAGCGCTGACCGCTACGCCGCGGACACCTCGCGCGCGGCATCAAAACGGGACGGA  
 TTAACCTTTGGGCGAAATGTTGACCGAAAAATCCTTTATCAACGCTTGAATGGCGCTGA

TGGCAACCGGCGGTTGACCAACACACCATGCACCTCGTCGCTATGGCGGTGCGGCGG  
 GCGTGATTTTGAAGTGGGACGACTTCGACGAAATTTCTCCATCATCCGCTGCTCATCC  
 GCGTTTATCCGAACGGCAAGGCGGACGTGAATCACTTTACCGCAGCGGCGGATGCGCTT  
 TCGTATTCCGCGAATTGCTGAATGCGAGGCTGTTGCACGACGATGTCGATACCGTCTGCG  
 5 GACAGGTTATGCGCACTACACCAAGAGCGCTTTCCTTATCGACGGCAAACTCGAATGGC  
 CGCAAGCCCCGAAAACGAGCGGCAACGACGACATCCTGGCGAAAGCTGACAAACCGCTTCT  
 CCGCGAGCGGCGGTCTGCGCTGATGAAGGCAACATCGGACGCGCGTGATTAAAGTGT  
 CCGCGGTGCGCGAAGGCTGCCGATTATTGAAGCGCTGCCATCGTGTTCAACGACCAAC  
 CGGAAGTGTGGCTGCGTTTGAACGCGGCGAGTTGGAACGCGATTTTGTGTGCGTCGTCG  
 10 GCTACCAAGCGCGCGTGCCACCGTATGCCCGAATTGCACAACTGACCCCGCTTTGG  
 GCATCTGCAAGACCGCGGCTTCAAAGTGGCGTGCTGACCGCAGCGCGGTATGTCCGGCG  
 CGTCCGGCAAGTTCCAGCGCTCCATCCACATGACACCCGAAGCGCTGATGGCGGCAACA  
 TCGCCAAATCCGTACGCGGCGACTGATCCGCTCGACTCCGTTAGCGGCGAATCAACG  
 TCCTGATTAAACGAACCGAATGGAATGCCGCGAAGTCGAAGCATCGACTTGGGCGGA  
 15 ACCAACAAGGCTGCGGCGCGAATCTTCCGCAACTTCCGACGATGACCAGCAGCGCGG  
 AAACCGGTGCCATGAGTTTCGGCGCGAATTTGCCGTGATGCGGTTTCAGACGCGCTTTT  
 CAGACCGAAGCGCTCGTGAATAATTTCAAGCGTTTAAAGATAGACGTAGGTTGGAATTC  
 TCGAATTCGACACACCGCTCCAGATGTGCGTTTCTTGAATCCGACTACAACCTGTCC  
 ATCTTAATAAAATACCCATTCCACCGGAGAACGAAATGTTCCAACTGACCCCGCGG  
 20 AATTTTGAACCGCGGCGCAGTTGTGCGGTAATGGCGATTGACGACTTAAGCACCAGCA  
 TGATTGTTGCCACGCGCTTTCGAAGCGGCGATCCCTACCTCGAAATCACCTCGCA  
 CCGCTGTGCGGCTCGATGCCATCCGCGCTGATTGCCAAAGAAGTGCCCAACGCCATCGTG  
 CGGCGAGGTACGGTAACCAATCCGAACAGCTCAAGCGCTCGAAGACGCAAGCGCGGTTT  
 TCGCCATCAGCCCGGGGCTGATGAATCCCTCGCCAAAGCGGCGCAACAGCGGATCC  
 25 CCTGATTCCCGGTGTTGCCACCCCGGCGCAATCCAACTGGCTTTGGAAACAGCGCATCG  
 ACACCTCAAACTCTTCCCGCGCAAGTCGTGCGGCGCAAGCGCATGCTCAAGCCGTG  
 AGCGCCCTTACCGCGATGTTGCGTTCTGCCCGACAGCGGCGATCAGCTCGCCACGCGCG  
 CCGAGTACTTGGCACTGCCAACGCTCTGTGCGTCCGCGGCTCTTGCTGACACCGAAG  
 AAGCGTGAAAACAAAGACTGGGACCATCACCCGCTCGCCAAAGAGCGGCGGCT  
 30 TGAACCCAAAGCGTGATTGCGATCGTAAAAATGCGCTCGAAAACCTTTCCGTTTCA  
 GACGCGATTTTGCCTGATTAGGGCACAGTCGCGCATACACGCGCAGCACTGATCAGACATAC  
 CGCCCTAAAAATGCCCATCGCGCTTCGCGATAATAAAAAATACGTTTCAGTTTATTCGAC  
 CAGCCGGACAGCGCCATACTAAGCGGCTGAAAAATGCCGCTCTGAAACGCATTACAGCG  
 CATCGACTTAAAAAAAACAACTGATTCACGCGCGATTAAATCCGCTTCAAAACCATCTTC  
 35 ATCACTTGGTTTTGCGCGCGGTGTTGAACACGTCGTAGGCTTTTCCAAATCACTGAAT  
 TTGAATGATGGGTCAGCATTTTGGTGAATCGACGGAGCTGCTGGAATCGCCTTCATC  
 AGCATTTCCGTTGGTATTGGCGTTTACGACAGCGGTAGTGATGGCAAGCTTTTAACTAGC  
 AGTTTTTCCAGTTTGAATCAACGATTGACCATGTACCAACCAACAGCGGATTCGCG  
 CCGGGTTTCAATATGCTTGGCACATATTCCATGTAGCAGGGATACCGACGCGTTCGATG  
 40 GCGCAATCCACGCGCTCTTCGCGCAGGATGGCAAGACTTGTGTGGTACTTCGCGGAA  
 GCAGGGTTAATGGTATGGGTGCGCCCAATCTTTCGCGAGTTTCAACCGGTTTTCGTTCC  
 ATATCGCAACGATGATGCGCGCGGCACTGTACAGTTGGGCGGTCAACAGGCGCGACAT  
 CGACAGGCGCTGCCACGCGATGAATACGGTTCGCGGGTTTGACATCGCGGATTTCG  
 ACGCGGATTTCTGTTGGCGGTTCGCGAAGCGTCGCTCAACACAGGGCGGATTTCTTCGTTG  
 45 ACATATTTCGGGACGCGAAGCAGGCTGTTGTCGCGATAAGGCGTACGCAAGTATTCGCGC  
 TGAGTACCGTCAATCATGTAACCAAAATCCAAACCGCGTTACGCGAGTGTGAATAGAGT  
 TGGGTTTGCAGTTGTGCAAGTGCAACATTTGCTGACGATGAATATGACTTTATTCG  
 CCGGATTTGATGTTTTTACAGCTCGCGGACTTCTTACAATACCGATGCCCTCATGA  
 CGAGAAATACGCGCGTCGCAACTTCGGGTTTTTGCCTTCAAAATACCAATCCGTA  
 50 CCGCAAAATCGTGGTTTTCAGGATTTTACCACCGCATCGGTCGGATCGATAATCTCGGGA  
 CGGGGTTTTCTTCAAACGGATGTCGTTTGGCGCGTGAATAACCATTTGCTTATCATGCTG  
 ATACTCTTGTGTTTGAATAAATTTCAATACCGCAATAAAGTTTCTTATATGAGTT  
 ATATGCCCTTACAAAAATAAGTCAATAAGAATTTATTTTCAAAATGTATACAAATAACAT  
 ACCGTTTTAAATAAATAAACAACCGGATTGATATTAAATGAACACACCCATCCCTTCT  
 55 CGCAAGGCTCATCCGTGGCAAAACAACCGGTGCGCCACCACTCCCTTGGGAGTTC  
 AAAACCTCTATTGCGTCTGGCTTTCGAAATCATGCTCCAGCAACCGAAGTCGCCACG  
 GTTGGACTACTATCCGCGCTTCTTAGAAAAATTCGCGACGTTTCAGACGCTTGC CGCGG

CGCCGCAAGACGAAGTGTGTGCGTTGTGGGCGGGCTTGGGCTATTACAGCCGCGCGCGCA  
 ACCTGCACAAAGCCGCGCAACAATCGTCAGGCAATTCGGCGGCACGTTTCCGCTCGGAGC  
 GCAAGAGACTTGGAAACCCCTCTGCGCGGTAGGCAGAACGACCCGCGCCCAATTTGGCGCT  
 TCTCTCTCAACCGCCGCGAAACCACTTTTGGACGGCAACGCTCAACACGCGTACTCTGCCGCG  
 5 TGTTCGCCCGCGACGGCAATCCGAGGACAAAAAATTTGAAACTCGCTCTGGACACTTG  
 CCGAAAGCGTGTGCGGCTGTGAATACGCCGATATGCTCGCTATACACAAGGTTTGAATGG  
 ATTGGGCGCGACCGTGTGCAACCGGACGAAACCCCTTGTGCCACCAATGCCGATGGCGG  
 ACATCTCGAAGCGAAAGACAAACCGCCACCGCGAGCTGCCGCGCAAAAACCGCGCG  
 CGGAAGTACCGACCTCGCGCTTACTGGCTGATTGTCCGCAACCGGACGCGCGCATTT  
 10 TGCTGGAAAAACGCCCGCCAAAGGCATTGTGGGCGGGCTGTATTGCGTGGCGTTTGTG  
 AAAGTTTGAAACGGGCTTTCGACTTTGCCGCCAAATTTCTCCCTGACCATGGCAGATATGG  
 ACGAACAAACCGCCCTGACCCACCGCTGACGACCCGGCTGCTATTGATTACGCCCTTTG  
 AAGCACAAATGCGCTGTGAAGGCCCTTACAGCGGCATTGTGATAAAGCGCGCGCATTTGA  
 AAGATTACGGTTTGCCCAAGCCTTTGGAAATTTATTAAACGGTAATAGGTTAGAATAAA  
 15 CAAATTAACCCATTGAACGTGTTTGTGACGATATGCGACGAAACCAACCGATGAATTT  
 GGGTCGTATTTTAGGCGCGGGGATAAGTTTCAAATGGGACATTTGGAACCGGAAGAGTCG  
 GCAATTTAAAAAGGATTTAAAGCAAAGAGGTCAAAACATGAACCAAACTTAAATG  
 CAAAGACAAAGCCATGGATACCGCAATCAGGTTTCAGAAAGGATGAGGATTCCGAAT  
 TTTTCTTTTAATTTCTGGAAATCAATAGGTTTGGCGATTATCAAGACCGTGAATACCG  
 20 GTTCTAATTTTCTGCAAAATAACAATTAAATGTAATAATTTTCGTAATAATTTATCGGCTTT  
 AAAACAAAATGACTAAAAATGTCGCGAGTTTTTACTGCAATAAAGGAGATTGCAATGAA  
 TATGAAACCTTATTAGCACTAGCGGTAGTGCAGTATGTCAGTTGGTGTTCGCGAAGC  
 ACACGAGCATAATACGATACTTAAGTGCTTCTATTGAAGTGAAGTGCAACAACTTGA  
 TCCACTAAACGGTAACAAAGATGCGGTACAGTGACTATTACTGAATCTAATCTAGTCT  
 25 TGTGTTTACCCCTGATTTACAAGGATTAAAGCGAAGCTTACATGTTTCCACATCATGA  
 AAACCCAGCTGTGAGCAAAAGAAAAAGAGGTAATTTGACAGCTGGTTTAGCGCGAGG  
 CGGTCTGGGATCCTAAAGGTGCAAAACAACATGGTTACCCATGGCAAGATGATGCACA  
 CTTAGGTGTTTACCTGCATTAATGTATTGTCATGATGGCAGCAGCAACAACTCTGTTTT  
 AGCACCGACTTTAAACATTAGTGTGTTCCGGTCACTCTATTATGATCCACAGCGG  
 30 TGGTGATATCACTCCGATCATCCAGCTCCACTTGGCGGTGGCGGCCACGATATGCAATG  
 TGCGCTGATTAAATAATTCGATTGTCGAACGAAAGTGGGTGAATTTGACCGCACT  
 TTTTGTGATGATATTAGCATTGAGACCTTGCATAAACATAGGTTACTAAAAATTTTATG  
 CTCATCTCATTTTCAAAATGCAAACTTTTCTGATTTTCTCTACTTTTGTCTCAATAT  
 AGGAAGGTTTTAGGCAATTGAAATTTTTTGGCGCATTTTATGCGTCAAAATTTGCTTTAA  
 35 CAGACTATTTTGCAAAGGTTTCATTTCAATAGTTTCCGGAATTTCCAACATAACCGAAA  
 CCTGACATAAACCGTAGCACTGACCGCTCATCCCGGAAAGCGGGAATCTAGACCTTA  
 GAACAACAGCAATATTCAAAGATATCTGAAAGTCCGAGATTCTAGATTCCCGCTTTCCG  
 GGGAAATGACGAAAAAGAGACCTTTSCAAATTCCTTTTCCCGACAGCCGAAACCCCAACA  
 CAGGTTTTCGCGCTGTTTTCGCCCAATACCGCTTAATCTACCAAAATATCCCTTAAAT  
 40 CTTCCCGGATACCGGATAATCAAGCATCCGTGCTCGCTTTAGCGCGCACGGCGCAC  
 TTAGCTGTGTGGCGGCTTCAACAGGTTCAAACACATCGCCTTCAAGTGGCTTTGCGCAC  
 TCACTTTAAACAGTCCGAATAGSGTGCGCCGGCGTAGCGGAATTTACGGTGCAGCGTAC  
 CGAAGCTGTGTTCAACACATAACGGGCTTCGACAAATATCGGTTGCGTTTGGTTTGA  
 CTTCCGTCAGCGGACGGTTGCGGTGGGCTTTGCGCATTAATGCCGTCAGCACTGATGTT  
 45 CTTCCGATGTTTGGCGGTTTTCCGCACTGCTGAGCTTTGTGGCATAGAGGCTGATC  
 CTTTGGGCGAGTCTTCCAACAACGGCGACAGGTGTTTGACATCATGGGCATTGGCGGGG  
 TAATGTGCAAGTTTCATGATATAGCTTCTGCACTCGGTACGGGATGTTGTTTGTAAACGA  
 GTTTGTAGAGCCGTTTTTCTTTATCAACAGGGCATCGCTGCTTACTCGGTGCGGTTT  
 GACCGCTGATTTGTCTTCTCTGCTCAACTTCTATGGCTGACGCTGTTTGTGCGCGCGG  
 50 TCTGAATATGTTGGGCTCAACGACGGCAGCGGATGCTTCTCTATTTTTAAACCTTTT  
 CGGTCAAGTGGCGGTTAATCACTTCAACAGTTGACAGAGGATTTGTTCTTCCGCGACG  
 GGTTCGGGTAGCGGCATAAGGTGCTGTAATCGGGATGCTCAGTTGCTCAAAACGGCAAA  
 ACAGGTTGAAATCGATGCGGTTAATGAGGCTGTGTTGAGTTCCGGATCCGGAGAGGCTGT  
 GCAATGTCCGAGCAGGACGGCTTTGAACATGACAGCAGGGGATAGGCAGGACGGCGC  
 55 GGTGGTCTCTAAGGTAAACGGGTTTTTGTACGGTTCAAGTATTGTCGATCAGCTGCCAAT  
 CAATCACCCGCTCCAACCTCAATACGGGAAGCGGTGATGTTTGGCAATCAAGGCTT  
 GGGCGGTTTGTGGAAGAGGTGCTCTTGAGAAATCCCTAATATGCTTGGTGGGAATTT

AGGGGATTTTGGGGAATTTTGCAAAGGTTCTCTAGATGAGTGA AAAAGAAGTGCAGGCTGC  
 CTA AAAAGACAGAAAAAGTCTTTCCGGCAGCCTGCACTTTGGTTTCATTTTCAGTCAGTAA  
 ACCCATTAACACGAGGCTGTGAAACGCGAAGCGTTACGAAAAAGCAGCGCTACACGCCCCA  
 TCCCGCCGCTTCTACCCGTTCTGTAATCATACAGATAGCGGTAATATCCGTTCCGGCTC  
 5 GCGAGCAATCTCTGCTGTGTTCCGCTTCCACAATCTCTGCTTTATCCATGGCAATGATC  
 CGGTGTGCGGTTTAAACAGTGGACAGACGGTGGGCGATAATCAGCACCGCTCCGGTTGGCG  
 CAAATGGCCTGCATGTTCTGCATAATCGCTCGCTTCACTTTTCATAATCCAGCGCGTGGTG  
 GCTTCATCAAAAATCAGAATCGCGGATTGGTGATTAAACGCGCGGGCAATCGCAATACGC  
 TGGCCGCTGTCCGCCGACAAAGCGCGCCCTTGTTCGCCACACAGGTCGCGTAGCGCTTCC  
 10 GGCAGCTCCATAATAAACTCGTGTGCGCCGCCAGTTTGGTGCTTCGATAATCGGTTCC  
 AGCGCGATACCCGATATCCGTCAGCGCGATATTGTCGCGTATGCTCGGTTGAGCAGACATA  
 TTCTCTCGAAGACCAACGCGGACCTGCCGCCGACGCGAGGAGCGGCCAAAGCGCAA  
 TCGTGGCGCTCCACCAACCCGCTCCCTGCTCCGTCATACAGACGCTGCACCAATTTG  
 GTGAGTGTGGATTGCGCGACCCGGAACGTCGCCAATCCCGAGCCTTCCCGCCGCCGA  
 15 ATCCGCGAGTTCAAACTCTGCAAAATCAGCGTCCGCTCCGCTTATAGCGGAAATCGACA  
 TGTTCGAACGTAATCTCCCCCGGATATCGGGCAAGGCAAAATCGGAAGACGATTTCTCG  
 TCGCGCGATTCAAGATATCCCCCAACGCGCCACCGAAATCCCGACCTGCTGGAATCC  
 TGCCACAACCTGGCGCAACGAGTAAACGCGCCGCCACCTGTCCCGAGGATATTAAC  
 GCAATCAGCTGCCCCACCGTCAGCTTGTCTCAATTACGAGCGTGCGCCAATCCACAAC  
 20 GTCCGCCGCTCACCGAGTTCTGAAATCAGCTGCACCCCTGCTGGCGACACCGCGCAAC  
 TTGTTATCCGGAATCCCGAAGCACATAGCGCGCAACTGATTGTCCCAACGCTGGCTTC  
 ATCTCGCGCTCCACCGCCATCGCTTTACCGTACCCACGCGAGTGATGCTTTCTACTAAA  
 AACGACTGGTTGTCTGATTGCGCGCACTTATCGTTGAGACGCTCCGCGATTCGGA  
 CTGATAAATGCCGACCAAAACGATAGCGAGGCAACGAGGCCAATACCAACCAAGTCAGA  
 25 TGGAGCTGTAATACACATCAGCGCGAGAAAGATAAAGCAAAACGCAAAATCGCAACACC  
 GAAGTCAGCGCTGACCGGTCAAGAAATGCGAATCTGCTCCAATTCGCGCACCGGAGT  
 ACCGATACACCACTCGTCTGTGCTCGAAATAGGATAAAGCGAGGGAAGCAGATGCGCG  
 AACAAACGCGGCCCAATTCACATCAATACGTGAATCGTATGTCMAACAGATACGTC  
 CGCAACCGCCCAACACAATCTCAACAGCGACACCCCAACAAAGCCACGACACACACA  
 30 TCCAAAGTAGAGAATCCCCGATGTACCAGCACTTGTCCATCACCACTTGAAAAACAGA  
 GCGGTAATCAGCGCAACAGCTGCAACACCAACCGACACCAATACTTCAAAAACACAGA  
 CGCGGTATTTGATTACCGCGGAATAAACAGGTAAGTCAAACTTTGCCAACTGCGCC  
 AATACCGAAGCGCGGGAAGCAACCAATATCAGTTTCCCGCAATATCTGTAGAAATTCG  
 GCAAAAGCAATACCGCAGACTTATTCGTAACCAATCTGTATCAAAAATTTGGGCAATG  
 35 TCACCTCACCGTCTGTTTGGCCAAAATGAAATGGTTGCCGTCATCACCACTACCAAT  
 GCGGGTAAAGTCGCATAGCCAAACGTTTAATAGCTGGCGGACTACTTTTGCTCTCAAT  
 CCCAAAGATTGGCGGCTAACAGCCATTGCGTTTCAATTAATCGCTCTGTGCGGAGATGA  
 CAAAATTCATGCTGTATATCGGCAGGATTGGCGCAATCGCGTGGTAATGGGCGAGGATG  
 ATGAGGGCGGAAAGGCGGGGACGCGTGGCGATACGATAGACATAAAATAAATATAGTTA  
 40 GATTGGATGCGATAACGGCTGGCTGGGAARAGGAATATTAAGTAGAAAGAAATATATA  
 AATAAAACAGCAGAACGATTGAAGGATATATATGGGAATTTGAAGAGAAAGATATGGA  
 AAGTCTCTGTTTCAGGAAGGTAACCGGCTAGGAATCGAGTTAGATGAGGATGCTCCGTC  
 CACCTCTCGTGCTCTCGCATACCGTTAAGGCACAGGGTTAAGGTGCAGGCTGCTCCGAA  
 CTCTGTTGCGGTGCGGTAATGTTATTTTGTGTTTCAGGCGAGCTGAAATATCTGTATTA  
 45 TTTTGTTTTAAATAGATTTTAAAGATTGATACTGTTCTGACGATTTTCAAGAAAGG  
 AGTAATTTCAAGAAAGGAGTAAAGTGACTTATATCAATGACAAGCAACGCGCGAAGTG  
 ACAAGGAAAATCTACTTTAAATTCGAAGAGGTTTCAAGATATCATAAACCAATCAGAA  
 ACATAGAGATAAAAAATATGTAACAAATAAATCTCTTATACAAATTTATTCACAGTTGA  
 TTATGCTCTTTCAGAGCAAGCGTAGGGTGGGCACTTGTGCCCCACGCGTTTCATATTTCA  
 50 AGCGAGCTGAAACCGTGTGGCGATAAATGCCCTACCTACATCCCAAAAAACAGCGCAG  
 CCTCGCTGTGTAGGTCGCAACTTTCCGGCAGGTAGACAGCGAGTTTATATTTTCAAGCT  
 GAGGAGTCTTGAAGAAAGTACAAAACATTA AAAAATTAAGGGGCTGACTAGATTAGCCC  
 TAAATCCACACCAATCCCGCAAGATTTTTCAGCTGTGGGAGCGGTGTGCGCAAGTTTAAATC  
 GAAATTCGATCTTTCAAGAAACAGCGGGAAGAGATTGCGATCAATTCGCTTCTATTGCG  
 55 GCAAGACGCGTTTGGCTGATTCCAAAAGTTCTCAATCGCGTTTATGTGGTTCTGACGGT  
 CAGCAAAATCTTTGGAATGGTTGATGCGGTAATGGATAAAACCGCTTACGTCACCACTGT  
 CGTAACGTCTCAGGCTGTGCTGATAAACAATGCTGTCCGGCATGATTTTCTGTTTGATAA

CAGGCATTAAAGTATCGGACTTGGCATTATCTACGACAACGGTATAGACCCGTCGGTTAC  
 GTTTTCAGAAATGCCGAAGACAACCACTTTCTCTGCGCCAGCCGCGACCACTGTTGCTTTAC  
 GCGCTGCCGCGGAAATAGCTTTTCTGCTCACTCGACAGAGCCCTCGAAAACCTCATTTGGCAG  
 CCAAGGCCAGATAATGGCTGATGACCACTACGGATTTTGGCGTAGAACAGGACTGCCGGAAT  
 5 TCGGGTGGATACCCAAATATCGGCAGCAGACGGGCGGTAACTTCGAGTACAAAAAAC  
 GGGAGCAGCTCTTCTGTACTTTTTCTTTAATTTGCAGTGTGTATCTTCATATTTCCGG  
 GGTAAACATATCTGCTAATCTAGTACAGCCTCAACAAAAAAGAGAAATTTAAATTTCCGCT  
 AAATCGCATAAAGATTAATCAAGAGTATCATTAATGATATGAGTGAGCATCTAATATGC  
 CAAGAGAGTTGTTAAGACATAACGATTATTGAAATAGATTGTAATATAGATACCTTAGAT  
 10 AGTCTGAAAAACGGATTTTGTAACCTTTTATTACGGCCCATCATTTGAAATGAAACTT  
 AAAAAACACTTATCATATAAATATTTTCTTTACGTTGTTTGTCAATAAACCTCAGTGCA  
 TATCAGCGCAATATTTTATGGAAATTTTATGGATAACAAAAAAGATTTTATAATATTT  
 AACAAATAGGTATATGTGGATCTATCCATTGGTCTTAATATTTCTATTTCTACCTTTT  
 CCAGTCCCTACCAATCTTTTTTATTGCGCTTGGTTGTTGTTGCACTGGTTAGAAAAAT  
 15 GCAAGCTTAGATTTTAAATACAAATCATATTGTATTGTTAAATATAAAAGTGCCTG  
 GCGCATAAAAAAGTATTTTATTAGGATAGTAGTGTATGGTTGCGAGTAATGGAAT  
 ATGGATGTGTTTATTTCGGAATCATCAACGTGGGTATGCGGTGCTTTTGTTTAAATAG  
 TGAATATTGGAAAAATTTTTCGTGGCTTTGGTTATTCTGGTAGTTTATATTTTATTT  
 20 TATATTGATGATTGATCTCAATAAGTTAAGAGAGATTTTGAATTTTCAATTTTGTGTTG  
 ACTTAACTCAAGGAGAGTAAACATGATTGGTAGGGTGATCTAAACATAGAAAAAT  
 TTTCTCGGTGTGATGAAAAATACCAGCTCACAGTCCCTGCCCTAGACTTGGACGCGC  
 ACGGCTAGAAAAAGTCAACGCCAAAGGCTTTTCAGGCAGCTGAAGACTGAGAGAGTGA  
 ATCAGTAGGATATACACTCTATGCCACTAAATGATATTCTCAATATCATACAGCTATA  
 25 TTTTATTAAATGAGACATATGAAAAATAAAATATTACTAGTATTTATAGTTTACAT  
 ATAGCCTTGATAGTAAATAATATAGTTGTTGTTTATTGTTTCTATTTGATTTGTTT  
 CGGTTTTGTTTTTGCAGAGCTCTTCTTGCTGTAATTTATTTTATGAAAAAAG  
 ATAAAAACAAATATTTGTTTTTATGCGGATTCTATTATATATGGATGGTAAATCAT  
 ATTAGTATGATAAATAAATTTTATAAATTTGAGCATCAATAAGGAACAAAAATATA  
 30 TCCTCGATTACTGGGGTGATAAAACCATGATAGTTATAAATATGTTTATGACTCAAA  
 GGATATGCTAAATTAAGATATAATCATAGATATGGTAGGGTAATTAGAGAAACACTTAT  
 ATTGATGTAGTTGCATCTGATGTTAAAAATAAATCCATAAGATTAAAGCTTGGTTTGTGGT  
 ATTCATTCATATGCTCCATGTGCCAAATTTATAAAATTTGCAAAAAAACCTGTTAAATTT  
 TATTTTATAATCAACCTCAAGGAGATTTTATAGATAATGTAATTTTGAATTAATGAT  
 35 GGAAACAAAAAGTTGTACTGTTAGATAAGTATAAAACATTTTCTTATTGAAATGAT  
 GTTTGTATCGTATTAATTTTATTTAATTTAAATTTAATTTGCTTTTATAGGACTTAC  
 TTCAATGAGTTGGAATAGTTTGGTAATTTTATGAGCGCAGCTCATCCGCGTTAGCAGA  
 ATTTGGAATATGGTTGCTAATTTAGTTTCTGCAAAAAATGAGAAGATATCTCGAAACG  
 TAATGAATATTACAAACAGCTGGTTATAGTGCATTATTAGCATTTGGTAAATTGCTGTAG  
 40 TAAATTTGCACCAAGTAGTACGTATCGCATATTTGTAACGGGAACAAATGCCTCTGTGAT  
 TGCAGCCGCTCTCTCGGAAATATATCTTCAGCTATTTCAGGAGCATAAAGATGGTAAAGT  
 TAATATCAACCGTTTCAAATATTTTACGGGATTTATATTCATTGGGAGGTTAGGAAAG  
 TACATTAAATAGAGAAGATGGAATATGTCAGAGTTGGGGGATTCATATGACATTTGCTGG  
 AGATATAATTTGCAGCAACGGCTATTGCCACAGGAGATCTGGTACGATATCTACAGAGGA  
 45 ATTTTATAATTTGACAACGTGGAAGGTTTGGGTATGAGCTATTTGAAGACTGGTCTCG  
 TTGGGTATACGACTGGCTGCCCGACGGCTGGAATCTGTGGAAAGAAATGGACAGAAACCG  
 TTCAGGCCAATACCACATCTACGACCCCTCGCCCTAGACCTAGACGGCGCAGCGCATAGA  
 AACAGTCGCCGCCAAAGGCTTTTCAGCAGCCTTTCGACCATAACGGCAACGGCATCCG  
 CACCGCACTGGCTGGGTTCTGCGCATGACGGTTTACTCGTCCGCGATTGAAACGGCAA  
 CGGCATCATCGACAACGGCGCGAATCTTCGGCGCAACCAAACTGGCAGACGGTTC  
 50 TTTGCCAAACACGGCTATGACAGCTTTGGTCCGAATTTGGAATCAACGGCAACACATCT  
 CAACGGCGCAGACGCCGATTTCCATCCCTGCGGTGATGGCAGGATCTCAACAGGAGCGG  
 CATTTCCCAAGCTAATGAATTTGCTACCCCTGAAGAAATTTGGGTATCCAACTTTGGATCT  
 CGCCTATAAAGATGTAATAAATCTCGGTAACGGTAACACTTTGGCTCAGCAGGAGGAC  
 CTATACCAAAACAGACGGTACAAACCGCAAAATGGGGGATTTACTTTTACGACGGCGACA  
 55 TCTGCGCAGCGGCTTACGAACAAATGCTATCCATTAGCCATGTTCCGGGAAAAACAGAT  
 TTTCCCGGTTGTTTATAGGCTGTCTAAACAAATAACCATAAATGTATATCATTTTAA  
 TAAATAAAGATTTTAACTATTATTGACGAAATTTTAGAGAAGAGTAGACTGTCGATTAA

AATGACAAACAATAGTGAGAAAGGAAATATTTACTATCCGAGCACAGAGCATATTTTAGG  
 TAGCCTGTAACTGTTTCTGCTGGCGGAAGAGGATGAAGTTGACTTACCCGAGAATAAAT  
 TFCCTGTTGTGATATGGATGCCATGCGCGGAAGCAATTGATGCAATCACGCCAGTGCTCT  
 5 ACTTGAATGAAACCTGTCGTTGCGAATTTGAAACCGCTATTTTAAAGAAAGGATAAAGG  
 GAGAAAGAAATTTTGGTTTTTAAGTCGCATGAAACCGTGTGGAATAAATGCACACCTAC  
 GATAATTAATAATTTTCGTTTTTATCTACAAGCTATTTATATATGATGTCAAAAGTT  
 TATTTTTTAGATGCCAAAATATATTTTATATACTTCATATGTTTATATGCTTTATTT  
 TGAATATATCTTACGATGGGGAATATTTATATATTTTATAATAAATTTTACTCATTTCG  
 TAATATGTCATGGAATATTACTTGATTTTGTAGAATTTTCCATATGAAAATATTCAT  
 10 TTACTATTTTTCTGAACCTTATTAGTITATTTTTTAATATTTTACCTCTTATATTTACCA  
 TAAGAGAGCTAATTGATTCATATTTATGAGTCGATAAATAATTTATTTCTTAATTTTTAA  
 TTCTCAGCTTATTTTTTAATTTACTTGAAGGAAAGCAGATATGACATCTGCAAAATT  
 TAATATTAACGGTTTTGGAGATGGAATTAACACCCATTACCACCTCTTGGGATATAA  
 AGCTTGGGATTCATTTATTTGGTCTATTCAATCCTTATCTGATTTAATCTATAATGTGGA  
 15 TAACAAATAGAAAATAAATGGAATTAAGTCTTAATAATGCTATTCAAGCTGCAGATAGCTT  
 TTTAAGCAGTAATTGGAAGAGATAACAAAATAACAAAATAACAAAATAACAAAATAACAAAT  
 TCTTTACTTGCATCCTTCGATAACATTTTTTAAATTAAGAAATGTATCTCGAGATATAC  
 GAGAACAAGGAAAATTTAAACCTATGATATTCAACAAGCAATTTGCTGATATTTCAATG  
 CTGCTGGTGATGGATTACAATATATAAAACAACAAACAGAGCGGATGGCTCAAAGCAAT  
 20 TCTTACCACTAAATTAAGAACTGGTTAAATGATGCTCTTAATCTAGAATGCTAAAT  
 CCTGACTGTTTTACAGCATGAATGAATTAATAAGGATTATGGAAACGAGGATCTTGG  
 CGAATCTATAATGAATATAGATGATTTTACACCAAGTAAGATAGCAAACTTTTTTGGCGA  
 TCCGTGATACATACAGCAATGTATTAGAAGAAGTATCTAGGTTATATATTTCTTAGTTCC  
 25 TGTAGATGCACACCTTGAAGGGGGCGAAGATTATTTGAGCAGAGGATAGTGAATG  
 GGGAGGCTTACTGGAAAAATGGTATAAACAAGATTTTCTCCCTTATCTTGAAGAAGATGG  
 GACCAATTTCCGAAATTTGAAGATGGCTGCCTGAATTTCCCTGAATGGGCAAGAGAGTGG  
 TTGAAATTAGCTCTCAACGCTTCAGGCAAAATATAACGTTTACGATCCCTCGCCCTAGAT  
 TTGGAGCGGCGGATAGAAACCGTTGCCACAAAGGCTTTTCAGGCAGCTTATTTGAT  
 30 CACACCAACACGGCATCCGACCGCCACGGGCTGGATTGCTGCATATGACGCTTTTCTT  
 GTGCGCAAAATTAACAGTAACGGGGCATTATTAGCACGACAGATACCATTATCCAATCT  
 TTGCATACATGGCTTGATCATCAACCAAGATGATATTTCCCAAGCACAGCATGATGCATG  
 CCATTGAAAAATATAGAAAATTAATTGAAAGCTTAAATGGATTTGAAATGAATGATCAC  
 ATAGTACAAATATAAGAAGGTCGGGCTAGGTAGGATATTTTTTATTCGTATAGCAAA  
 35 TCATCTATAATAATTTTTCTTCGTATGTTGTTTATATATAATTTACAATATCAATTT  
 AATTACCTTTTCGCTTTAATTTATTTATTAACCAATTTGTGCAATATATATATGTTTATA  
 TTTTTTTAGGAAAACTAAGGATACATTAAACGACAGAGCGAAGAAAAAATTTTTTAAT  
 TCTATTTTTCCACTTAGAATTTCTAATGATAATAGGTTCTGAGAAAAAGAGGTTAGGCAT  
 40 GGTAGTTTTTATTTGCTAAACCTACTATGGATTATTTGGTGCTTATGATTATAGAGAA  
 CAGTCCCATTAAATAACTTAACCCCTCATTATCCTTCATATTTTCATTTATTTTTTA  
 TTATGTAATTTGTTTTATTAATGAATGTTATGTTTATTTTTTAAATTAAGAGAGGCT  
 TAATATGGTTTAATCAAAATCAATCTGATAATAATTCAGTTCTATGAAATTTATATAAGA  
 45 TTTTATACTCGAAGTACGGATGAATTAATCTGAGTTACGAAAAATTTTCGTAATAAATTT  
 TTATACAAAAATGTCAACTGATTTACCAATTTATGACGCAACCATGAAAGTTTAGGAAA  
 ATCGGTACAACTGTAATACAAAAAACCAAGTCAGTTGAGACAGTTCTTAGAAAAAT  
 50 CGAGATAAAATAATAATAATAATAAGCACGAGTAGCAGAAATATCTTTGTAAAGGCA  
 AATGCAAGGCAATTTTCGAAAAATATGAACAAAAATCTTGGTACAGCAACACTTT  
 GGCTCAACAGGCAGCTACACCAAAAAAGCGGCACAAACGCGCAGCAGCGGATTTGCT  
 GTTGGCTGCTGACAACTGCACAGCGCCTCACGGACAAATGCTATCCATTAGCCATG  
 55 TCGGGAAAAACAGATTTCGCCGTTGGTTTAGGCTGCTCAAAACAAATAACCAATATGC  
 ATATCATATTTTAAATAAATAAAGATTTAACATTTTTGACAAAAATTTAGAAATAG  
 AGCTAGAGTTTTAGTTAAGTAGAAATGATAGTGCCTCAAGGGAAGTATTCCTATGTTT  
 GCATTAAGGGGGCTGATAAAGCTATTATTCATTACTATGGACTTTTATTCATTATTT  
 TCAGGCGGAAATCTCATAGCCGTTTGAATTTTTCTCTCTCTTATTAATATACAAAAATA  
 TTAGTATATCTGATATGGATTTTTTGGAAATTTTTATATGTCTGCAATTAGAAAAATA  
 TTAATTAATAATCTTGCTTATGATGTAGTACGCTGAGTTTGTGAACTATTTTTTAT  
 ATGGCTATTAGCCCGAAGCTGTGTTGGTAGACTTTCTCTGGTAAAAAACAAAAAGA  
 TCTATTGAACTCAACAGAAATTTGTAACCTTATGCAATATCGTTAGGAATTAATTTT

ATACATTATGATCCAAAACAGGGGGAGAGGTTGGATTGATGATAACTTAAACTATCCATAT  
 AATATATCGGTAAATATTTAAAGTGAAGAAGATGGTAAAAAACTTATTATAGATGAG  
 TTGCTTACAGAGAGAAGTAGAAAATTAGGAGGCGGAGTATTTGGAGCTGGGGGAAATAC  
 AGTATGCAATATTTATGATTTTATTTGCGGGAAGGGGAATATTATTGAGATTTCTGAT  
 AATAGTGAATATATTCACCTTTACGATGAAATAAATAATTCTATAAGAATAGTAGTTAAT  
 5 GCACGAATTCAGTAAATTTTTCTAGAATGTGGGGTACTTATGGCTGATTATATCCGGA  
 TAACTGTAAAAATTGCGAAGCAGGCTACGCCACTGAAAACAGAGGGGGGTATCCAGAC  
 GGGTACGTTTGGGTGAACTGTATTCGGCTAGAGATAAAAAATCGGGCGCTGTACTAGCT  
 TAGCCCTAAATTCACACCAACTCCGCGAGGATTTTAAAGCTGTGGAGACGGTGTCCGGAAG  
 10 TTAATTCGAAATTCGCTATCTTCAAGAACAGCGGGAAGATTACGATCGATTCCGGTTG  
 TATTTCCGAAGACGCGTTTTGCCTGATTCCAAAAATTCTCAATGCCGTTAATGTGGTCT  
 TGACGGCTCGCAAAATTCCTTGGAAATGGTTGATCGCGTAAATGGATAAAACCGCTCACGTCC  
 AACTTGTGCGAGCTGCTCAGACTATCGGTATAAACAATACTGTCCGGCATGATTTCTTT  
 15 TTGATGACAGGGAGTAACGTTTACAGACTTGGCATTATCTACGACAACGGTATAGCCCGGT  
 CCGTTGCGTTTCAGAAATGCCGAAGACAACCACTTTCTCGCCGACACCGGACACGCTCTG  
 CTTTACGCGCTCCGCGAATTCGCTTTCTGCTCGGCTCGACAGGGCCCTCAAAAACCTCA  
 TCGGCGACCAAGGCCAAATGATGTTGATAACCGTGCAGGATTTTACGGTAGAACGACTAT  
 GCCGAATTTGGATGGATACCCAAAATATCGGCGCGAGAACGGGCGGTAACTTCAGCACA  
 20 AAAAAACGGGAGCAGTTCTTTCTGTACTTTTTCTTTAAATTTGCAGTGCCTATCTTCATA  
 TTTTCAGGGTAAACATATCTGCTAATCTAGTACAGCCCCAAAAATATACCAAAAACAGCAA  
 AACAAATTTGAAGGATAGGTATAGGCTTTGTAAGGTAAATTTGTAAAAAACAGTTTTT  
 TAAACGAATGAAACGGCTTCGGGCTGAAATATATGCTGATGCCCTGTCTTCCCGTATAT  
 CTTGTGTTTATTTTCAGCGGGCTTGAGATGTGTATAAGAAATATTGTTTGAATAAATTTAA  
 25 AAAAAATGATAATCGTTATTGACGATTTTAAAGGAAGCGTAGAGTGCCAAATCTATGAA  
 CGAATACGGTAAAGTAAACATGAAATATCTACTGCTTGGGTATAGAGCATATTTTACAAC  
 CCGTAACATATTCTTCGGGAAAACAGAGAAAAAAGTTTCTCTATCTTGGATAATATAT  
 TTACCTTCAGTTTAGTTAAGTATTGGAATTTATACCTAAGTAGTAAAAGTTAGTAATTTA  
 30 TTTTACTAAAGAGTTAGTATCTACCAATAATATTTCTTAACTAATTTCTAGGCTTGA  
 AATTATGAGACCATATGCTACTACTATTTATCACTTTTATTTGTTTATTGGGAGTGT  
 TTTTACTATGACCTCATGTGAACCTGTGAATGAAAAGACAGATCAAAAAGCAGTAAAGTGC  
 GCAACAGGCTTAAAGAACAAACAGTTTCAACAATCCGAGCCAATGACAGGATTTGAACA  
 TACGGTTACATTTGATTTTCAGGCAACCAAAATGGTTATCCCTATGCGCTATCTTGCACG  
 35 GTATACGCAAGCAATGCCACAAATGGCTTCCGACAGCCAGGCGAGATGCTTACTC  
 CATTAATTTGATAGAGATTAGCGTATTTACAAAAAACCGACCAAGGCTGGGTGCTCGA  
 ACATATCAACCAGCAAAACAAAGCGCACTTTATCCAATTTCTACGCGACGGTTTGGATAG  
 CGTGGACGATATTTGTTATCCGAAAAGATGCGTGTAGTTTAAAGCAGCACTATAGGGAAGA  
 ATTGCTTACTTACGGGGTTAAAAAAATGGCATTCGCTATCTGGAATACGAGGCTTATGA  
 40 AGATAAAGACATATTCCTGAAAATCCATATTTTCATGAATTTACTATATTAAGAAAGG  
 AGAAAAATCCGGCGATTATTACTCTCGGAACATATCAGGTATGAGAGAACGATTACAG  
 CACTAGCGTAGGTTCTGTATTAACGCTTTCACGGTACGGTATTACCGGTTTATTCGGGA  
 AAGCAGCAGCTCACACAGCAGGAGTTGGTAGGTTATCAACAACAGTAGACCAATGGT  
 ACAGAGTTTGTAAACAATCCAGTAAAAAATAATGGGCTGTCTAGATAACTAGGATA  
 45 AACTCGATTTTACTAATTTGTTTTAAAAAGGAACAGAACTTTTATCTCACTGTTTGTAAA  
 AGCCCATTCGCACTCCTTTAAATACAGCTCAAAATGGCTTTGGGAATGGCGTTAAACCT  
 GCGTAAATGACGTTTGGCTGTTTCCAAAAGTCTCAATTCATTAATATGTTTGTGTC  
 TTCAGCAAAATGTGTCTGTGATTGATACGAAAAACGAAGTTTCAGCGAAGCTAAACATGGC  
 TAAATTCGCGCACATCTAATACATCATAGCTACGATAACAATCCGTATAAATAATGCTGT  
 50 CAGGTTTCACTTGTTCACGGATAATAGGAATAAAGTAGCGGTTTGAGTATTCGGTACTG  
 TAACCGTATAAACCTTACCATTTCGCTTCAAAAGACCGAATACGGCGACTTTACCGGGAC  
 TCCAGGACCGCGTTTGGCTTTGGCTGTGTCGCGCAAAATAAATTTCTATCTGCTTCTACTT  
 CGCCATCAACATTTCCAAATCGGACTGTTTGATAAATAAGTAATCGTAACACGATGAA  
 AATAAGGCTGGGTTATTTTAAACCGCTACTAACTCTGCTGCGCTTGTTCAGATTA  
 55 CACCTGTGACAAATAGCTCAATGAGTTTATTTGTTTATACCTGGCTTAGACGACTTTTTC  
 TCAIAGGGATAATTTCAACTTAAATTTGAATTTCCCTAGTTATCTAGGACAGCCCTATTC  
 TTTAACTAATTTCTAAGCTTGAATATGAGACCAATGTCTACTACCATTTATCAACTTT  
 TTATTTGTTTATTTGGAGTGTTTACTATGACCTCATGTGAACCTGTAAATGAACAAA

CCAGTTTCAACAATCCCGAGCCAATGACAGGATTGAACATACGGTTACATTTGATTTTC  
 AGGGCACCAAAATGGTTATCCCTATGGCTATCTTGCACGGTATACGCAAGACAATGCCA  
 CAAAATGGCTTCCGACACCGCGAGGGCAGGATGCTTACTCCATTAATTTGATAGAGATTA  
 GCGTCTATTACAAAAAACCGCAAGGCTGGGTGCTCGAACCATACAACAGCAGAGAACA  
 5 AAGCACACTTTATTCAATTTCTACGCGATGGTTGGATAGCGTGGACGATATTGTTATCC  
 GAAAAGATGCGGTAGTTTAAGCAGGACTATGGGAGAAAGATTGCTTACTTACGGGGTTA  
 AAAAAATGCCATCTGCCTATCCTGAATACGAGGCTTATGAAGATAAAAGACATATTCTCG  
 AATATCCATATTTTCAATGAATTTTACTATATTAATAAAGAGAAAAATCCGGCGATTATTA  
 10 CTATTGGAAATAATCGAGTAACACGGCTGAAGAAGATAATTATAGCACTACGCTAGGTGT  
 CCTGTATTACCGGTTTCACGGTACAGTATTACCCGTTTATTTCGGGAAAGCAGCAGCTCA  
 CACAGCAGGAGTTGGTAGSTTATCACCACAAGTAGAGCAATTGGTACAGAGTTTGTGTA  
 ACAATTCAGTAAAAAATAATTTAAAGGATCTTATTATGAATGAGGGTGAAGTTGTTTAA  
 ACACAGACAATAATCCAAACCTTGCCTGGTTATGCTTCCCGTgCGATACCTATGGCGGT  
 TGGTATCCGAGCT

15

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 4>:

#### gnm\_4

CGGGGCTTACAACATCGGCGCAATCGACAAAAAGACCATGCGCGACTTTGACAAGTCCTG  
 20 CTTGACCGAAATCAACCGTTGAGCGGCGGAGACATCAAGGCAATCAGGGAAGAGGAGCG  
 ACTATCGCAAGCGCTTTCGCCATCTATCTCAACGTGGGAAAAAATCAGGTTTCGGCTTG  
 GGAGCGGGGCGTTAAAAAGCCGACGCGCGCGGCTTGAAGCTGCTGACCATCGTCAAAAA  
 CAAGGGCATCGAAGCCATTGCGTAGCGGACTTGGCAACGCGCAAAATCAGCAAGTTTACA  
 ATGACGCGCTGCTGAATATGCTGCCAAGACAGGCAAGACGCGCAACTGAATATCAGG  
 25 CTAGTCGCGCATAAATGCCGACGCGCATCAAAACGCGAAACGCGCGCGGTGCGAGCG  
 ACATAGCCCGACAGCAAGGCAAGGCGAGCGCGGCGAAACCGAAACATCACCAGCCG  
 CGAGGTACGGGGATTTTTTGCGCCGTTGACGGGGGGGATTGGATTTAAGCGGCGCGGG  
 TTGAAGGCAAAACGGGTGGGGCACAGAACTGTTAAATGCAGTCTGAATCTCAAAAGATT  
 TCAGCGCGCATTTTGAACAATGGCTCAAATCTCGATCCCCCTCCCTTAAACCGCGAGCT  
 30 TTTTTATTAACGCGCCCTTATTCTGACACTTTGCTCATAAACGCGCATACGGTTCGGC  
 AACCAACGTTTATAGATTTCTATACGGGCAATGTTTGTGCGATGAGTAGAGGTAATAGCA  
 TAAATAAAGCCGTTTGGTCGTTTTCCTGATTCATTTTTTCCAAACCTGACAGCGGGC  
 GCGGATGATAGCTGCCCTGCGGCATCAACATCATTCCCCCTCATCGGTTCTTCTTCC  
 AAGCTGCGGCTATAAGGCAAGGTAAGACGCTACGTCGCCAAATATCCATACCAATCCG  
 35 ACCAATTCGGGATTAGTATCCGCTTTTGTCTAATATAATCTGCGTGCTATCTCGCGC  
 CGCGTATGGTCAAGATTTGCTGCCGACCTTATTTTACCCTGTTATGTCAGGCGGCTGC  
 GTCATTTTCATGCCCATAAATGCGGCAATTTGCTCATCGTCAAGTTGAGTTTGTGCGAT  
 ATCCCCGTATAAAACGCCATTTTCCACCGGGCATTGCCACGCGTTTACGTCATCGTTT  
 TTAGAAACCGTCATTTTCCAGTCAAACTATGGCTGGTATTATTGCGCGATCGGCATAA  
 40 GSCAGCATACSTCGAAATACTGCCTGCACCTGCGGGCTGTTCTGGATGTGGTATCGACA  
 TTGCGCGCAGACTTGTTTAACTCAACGCTTTTCATATAATCTTTGGCAGCCGACGCTTC  
 ATTGTGGCGGAATCATGACCGTAAACATCAGCAACGACCGCACAGCCCCCAATACCGAG  
 ATTACTGCGGACAGGACAGTATCCGTTTAAAGGAAGGAAGGAAGGAATTTCTATATTAT  
 GGTTTACTCTTAAAAAATAAATTTCAAAAAATGCGCTCTGAATCCAAACCGGATTTA  
 45 GACGGCAGCTCTAACATTGTTTAATGTTTTAAAAAGATTTACACCACGATGTTCTCCAG  
 TCTGCCCGGTACGCGCATGATTTTCTTGGCAGGCTTGCTTCTATGAATTTACCCGCGCC  
 TTCAGCGCGCTATTCGGCAGCTTCTTCAGCCGGTTTGTGCAAAATCAGCATAAATTGCCA  
 ATAATTTCCCAACTTTTTTACGGCTGCTGCTGCCTTTTCGGCGCAATTGCGCTGAACTT  
 CAACTGTTTTCAAAATGGCAGAAGAAATAATATCCCTTGTGAATTCAGTATCATGATTG  
 50 AAATCAAAATACCTTTGGGAGTTGGGCGCAATTTATGATTTTTTGAAGTCGCGGACCA  
 ATGAATTCGATCGTATTTGGTCCGCGCAGAAATTTGCAACTGTTGGCGGATTTGTGCTCTG  
 ATATGGTTGGTTTGGGGAATTTGGATGGATGTTGTTTTCAAAATCATACAATTTGCGAGC



AATGTGAATTCTTCGGGGAGTTGGTCGATACATTTTCATAACAGCCAGAAGCCAGCCTTTG  
 CGCTCCGCATTTTGGTTGCGTAAAAACAAATTGGATTGCCATTTTTCAGAACGGTTTCG  
 GGTTCGATAATGCGGGAATTGTCTATTAAAGAATATTTTGCCGCTTCAGGCAAAAGGGCGG  
 AGATTGATGAACACATTAATGTGGTTGCGGCCGTTTTTAATGCCTTTATTCTCGGGAATA  
 5 ATCATATCCGCGCTGATGAAATGTTTGGGTACAGCACCAATTGCCGTATGGAGTAATCC  
 GCTTTTTTATATGCAAGAAAGAAAAAGTTGGGGTTGGTATCTGACCGGATGCCTCCAAC  
 ATGGTGTGATATGCAACCGTCAGGCACGCTGTTGCCATGCTTTTTTGATTCTTTACTCTTT  
 AATTCATATTGCTCGTGCAATTTGGGCAAAAGAGGTCGCAACAGGTTTGTTATTGGCA  
 10 AATCTCGCATCGGCTTGCTTCGCAACAGGGCGAGTAGCCGTTTTTTCCAACCAAGCC  
 TCGCTCATTTACAGGATTTTATGGGTGCTTTATTTTTGTGCTTCCCAATTTCGGTATCG  
 AAAATAAATTCATGTTTTGGGATTTTGAGATTTTCAGTTATTCGGGGTTCGTCATGCAGAC  
 AACACAATCCACCTTAAAAAGGCGCTCTGAACCCCTGTTTCCAAGTTTCAGACGGCCCTTT  
 ATCCGTGTGGCTAAACCTTAAAAAGCGGTTAGACACGATGTTCCACGAGCTGCCCGGTAC  
 GACGATGATTTTCTTCGCGGCTTGCTTCCATGAATTTACGCGCCTTCGGTGCGCAG  
 15 TCGCGCGGCTTCGAGGTGCGCTTTGATGCGTCGCGCGCAACAGTGAATTTGCCGCGCAG  
 TTTGCGCTTGACTTGAACCATCACTTCGATTTTCGGATTTGACCAAGGCGGCTTCGTCGAC  
 TGTGCGCGCAGCTGCTTCCACAGTTTTCGCGCGCTTCAATTTCGCTCCACAGGGTTTCGCA  
 GATGTGCGCGCAGTATGGGCGCAACAGCGCTACGGCGGTTTCCAATCTCTTGGGCGAC  
 GGGCGGCTCTTGTTCGCGCGGCTGTCGGTTTTGTCGATTGGTTGAGCAATTCATCACC  
 20 TCGCGCGATGCGGCTGTGAACTGCTGCGCGCGCGGCTAGTCGTCGCTGACTTTGGCAGT  
 GGTGCGGTGACGTTTGTGGCGCAGGTCCTTTGGGTTCTTAGACAAACCGCTTTGAGCTGCC  
 TCGCAACGCTTTCGACGCTTCGCGCTTGCTTCAAGTATTCGTAACCGGTACGCCACAGGGC  
 GCGCAGGAAGCGGTGTGCGCCTTCGACGCGCGCTGCTGCCATTCGAGGGACCTGTCGGG  
 CGGTGCGCGCAACATCATAACAGGCGCGCGGTGTCGCGCGCTGAGGCGTTAATCAGTTC  
 25 TTTGCGGATGACGCGCTGTTTTTGGACTTGGACATTTTTCGCTGCGCGTGTGATGACGAC  
 GGGCAGCCGCTCGGCTTTGAGGACGCGCGGAAATGGGCGGCGCTTTGTCGTCGAACGTCAG  
 CTGCACATCGCGCGGTTGATCCAATCTTTGCGCGCTTTGCTGTTTTGCGGCTAGTAGTT  
 TTCGCAACGACCATGCTTTCGCTCAGCAGGCGGTTCAAACGGTTTCGTCACCATTTGACTAG  
 ACCCTGCTGCGCATCAGTTTGGTGAAGAAACGCGCGGTACAAAGGTTGCAAAATCCGCGTG  
 30 TTCGATGCCCGCATGATTGGTCGACCGCGCCCGATTTTCGCGCGCGCAGGATCGAC  
 CATGCCGCTGAAAAATTTGGGCACATGTAGCGGAAGAAATACCAGCTCGATTCCATGAA  
 GGTGTCATGGTGTGCTTTCGCGTTTCGCGCGCGCGCGCAGCATGGGCGAGGAGCTTTC  
 GTAAAACTCGGGCATTTTTCCAGCGCGCAACCATGCCCTCGGGTACGACGCTTTTCAGG  
 35 CAAAACGACCGGCAATTGGTCGCGAGGGACGGTACGTCGCGCATTTGTCGCAATGGAC  
 CATGGGAATCGGCGAGCCCATGAGCTTGGCGCGAAATGCCCGAGTCGCGACGGCGGTA  
 TTTGGGTTTTTCGGTTTCGCGCGCGCTTTGGCTTTGACGCTTGCGCGCGACGGCGTCGAAATGC  
 CGCTGAAAAATCCAAAGCCGTCGAAGTCGCGCGCTGTTGACCAATACGCGCTTTCTTTGTC  
 GCGCTACCAATCTTGCCATTGGTTTTGCTCAAATGCTGTGTCGCGCGACGCAATGACTGT  
 40 TTTTTTCGCGAGATTGTATTGGTGGCGAATCAAAATCGCGTTTCGTCGTCGCGCGGCAAC  
 CGCCATCACGCGCGCTGCGCTAGCCGCCACATACATAGTTGGCAATCCACATCTCCAG  
 CTGTGTCGCGCTTGAGCGGTTGACGAGTGTAGCGCGCGGTCGCGACGCTTTTCTCCAT  
 CGTGCCCATATCGGCTTCGCGCAACCGAACCGGCTTGCATTCGCGCAATAAATGCGTGC  
 45 TTCGGTTTTGCGCGCGCTGCGCGGCTGCCAGCGGATTCGCGCGCAACGGCAACATA  
 AGTCGCAACCATCAGCGTGTGCGGGCGGGTGGTATAAATTCGAGGAATTTTCGCGTAAATC  
 GCTCTCCAGCGCTTGTGCTGTGCTCTGAACGGCGAAGCGCAGCTGATACGCGCGGA  
 TTTGCCGATCCAGTTGCGCTGCATGTTTTGACTTGTTCGCGCGAGTGTTCAGGCTTGTTC  
 CAAAGTCGTTGAGCAGCTCTTCGCGGCTAATCGGTCGATTTGAAGTAATACATCGGGATTT  
 CGGTTTTTCGATCAATGCGCGGACGCCAGCGCGCTTCGCTCGATGACTTGCTCGTTGGC  
 50 AAGACGGGTTTTGGCTGACAGGCTCCAGTTTACCCTGCGGTTTTTTCGCAATAACGATGCC  
 TTTTTCACACGCTTGGTAAACAGCCATTGTTCCACGCGGTAGTATTCGGGTTTTCAGGAT  
 TCGGTTTTCGCGCGCGCAGTCAATCGCAAAACCTTAGGCTTTTGAAGCTGGGTTTTCATGT  
 TTCGATGTTATCGTACGTCCAAGCGCAGGGGCGACGTTGTTTTTCATCGCGCGGTTTTTC  
 CCGCGGATCGCAACGCGTCCCAACCCATAGGCTGCATGACGTTGAAGCGGTTTTAAAG  
 55 TTTGAAGCGGCTCAATACATCGCGATGGTGTAGTTGCGCACATGCCCATTTGTGACGCTT  
 CGCGCTGGGATAGGGGAACATGGAGAGCAATAATTTTGGGTTTGAAGCGCTCTTCGGA  
 GACGTTCAAAATACGGGCGCTGCTCCCATTTTTTTCGCGCGCGAGGCTCAATGCGCGCGG  
 CGGATTTGTTCTGCTATAGTCATTCTGTTTTTCGCTTAAAAACGTTGGAATAAAGTC

GGCATCAATTATAACAGGTTGCCGGAAGCGGGGAATCGGCAGATTGCCGCGCAGGATGCGT  
 AAATTCCGACGCGCATTATTCGGTATGCCGTACAAATACACC CGCTTTATGATACGCAC  
 GTTTTTATGCTAAATTATACAACCAAAATCAAATGTTTAAACTCTCCTGATCGGCGCT  
 5 TCCGGAACAAAGGCGAGCGGGCATCGGGTAAAGAGGATTCTGCATATGAAATCAAAC  
 AAATCGTCAAACCGGGCTTGGCAGTATTGGCGGGGCGCTTCTGTCTGCCTCGCAACCA  
 AAGCAACGTCAAAGCCGACGGCAGCAGCAATCCGGTTTTCCGAAACCTTATTCGG  
 TAAAGCTGCACAACAAGCGGGCATTCCGACTTATGACAACTGGATCAGATCGCGC  
 CGGGCTGACCAAGACACATCACAATACTCGGCGCGCCGATTACGACGAAAGTA  
 TGTACGGCGTGGCGGAATGGGATTACCTGTTCCACTTCCATACCCGGGCGTAGGTATCG  
 10 ACCGTGAAACACTTCGGCGTAGAAGATGTTACTACCTGCCAATACAAAGTATTTCG  
 ATAAAGACAAATTTGCCCGACGTTCTACTGGAACCCGCTCTTCCGAAAGATGCCCGCT  
 GTCCGCGCGCCGACCCAAAGCGAGCGCAAGTCATCATCCGCGAAATCGTGGCGGAA  
 AACCGAAACGTATCCGCCAATATCCGACATGCCGTTCCGCTGTTTATAGGATATAT  
 GCGGCTGTCAATGGTTGCCCGGTATATGCAAGGGGCGCGGATACGGTGGCGACT  
 15 TTATCCAAAGAAAAAGTCATCGTGATACATCAAAGCGGAAGTCTGTTTCGTGACG  
 ACCGTGAGTGCCACCCGCTCTCATCGGTGTTGCCAGCCCAAGGGGACGTTCCGGCTGA  
 CGCTGAACAGTACCGACAAGCCGGATACGGCGCGGAAGTCATCGTTTCAAGCAGGAGG  
 GTGATTTCTTTTCCGCTGCACCGGTTTGGAAATCAGATACCTCGGAAAGCGGAAGC  
 AACGCATCGCTCCCGTCCGTGTCGACAGGATTATGACCAACGGCTGCATCAAGCTCA  
 20 CGGATCGGGTGACGAAAACTCGCTCATTATTTGTGTTGGAAGTGATTGTAAACAGAC  
 GGATACCGCACGCGCGGTATCTGTTTCAATTGCCCGATGCCTGAAACAGACTGTCC  
 GCCACGTCACTGCCCTGTGAAACCGGCGCAGATGCCGCCAAGCCTTCAGACGGCATTGCT  
 GCCCGCTCCGACCGAACAACAACCATCTTGGGAGAAGCTATGCCCGAACAATAACCGCA  
 TCCCTCGCGCGAAGTGAAGTCTGCTGGCATCAACCGCGCGTGTGGCGCAGCGGGAAG  
 25 ACCAAAGCTCCCGTTTGGAACGCGCTGCGCTTCTGTGCACTGTTTCAACAACTG  
 CAGAGTTTTGCAAGTCCGTATGGCGTGGCTGAAGCGCGAACAACACGCTGCCCGCAGC  
 CGAGCTGGACAAACGGCAAAATGCGCTTGAACCACTCCGCGAGTTACCGAAGCGCGG  
 GCTCCCTGATACGGCACCAAGTACGACCTGTCAACAACGCTCTTACGCCGAGCTGGAC  
 AAGAAGGCATCCATTTTACCGCGCGCAAAATGGACAGACACAGAAAAATGGATTG  
 30 AAGATATTTGACCGCGAATTGCTGCCGATCCTGACCCCATCGGACTCGACCTTCCC  
 ACCCTTCCCGCGCGCTGTAACAAATCGCTCAACTTCGCGCTCGAATCGACGGCAGAG  
 ACGGTTTCGCGAGGCTTCGGGGATGGCGATTGTGACGGCACACGCATCTCGCGCGG  
 TGTGTTCCCTCGCGCTCGAAGTGTGTGGCGCGGACAGGCTTCGTCTTCTCTCTCCA  
 TCCTGCACGCCACGTGCGAAACATCTTCCGGGCGATGAAGTCAAAGGCTGCCACCTG  
 35 TCCGCTGACGCGCGACAGCGACTTGACCGTTGACGAAGAAGACTGCAAAACCTCCGCG  
 CGCGCTTCAAACAGAGTTGCAACGACCGGAATACGGGACGGCGTGGCGCTCGAAGTCG  
 CGGACCGCTTCCGCGCTACATCCGCGACTTTCGTGTCGCAATTCAACTGACCGCGCG  
 CGGAAGTCTATCAGGTCAAAGGCGCGGTCAACCTGTCGCGCTCAACGCGTCCCCAGC  
 TAGTCAACCGCGCGGATTGGAATTTCCACACACACGCGGGCAGACTGAAAGCCTTGG  
 40 GCAAAACCGCGTCCAATTTCGATTGTTGGTGGCGCAATCGCCATCTCTGTGCAACCCCT  
 ACCAATCGTTGACCCCGTTGTCGAAATGATCGCGAAGCGCGCGGACCGCGCGGTG  
 TTGCGCTCAAAATGACGATTACCGCACCGGACGCGTTCCGAAACTGTCGCGCGCGCTGA  
 TGAAGGCGGCACTCGCGCGCAACAGTAACTCGTCTGTCGAAGTATGGCGCGCTTTG  
 ACGAAGCCACAACTGCAACTGGGCGAAGCAGCTCGAAGAGGCGGCGCGCAGCTGCTGT  
 45 ACGCGCTGTTGCGTCAAAAGTCCACGCGCAAAATGGCACTGTCATCCGCGCGAAGAC  
 CGGCTGTCAAACGTACGCCATCTCGGCGCGGCAACTACCAACAGGCACATCGCGCA  
 TCTACCCGACTTCGCGCTCATACCGCGCAGCAACAAATCACCGCGATGCAACTAT  
 TGTTTATGGAATCACAGTTTGGGCAACCCGGGCGGCTGAACAACTCTACCAAACTC  
 GCTTACCTGCAACAAATGGTATCGACCGCATCGACGAAACCGAACAACGCAAAAG  
 50 CCGGCAACCGCGCGGATTACCGCAAGATGAATTCGCTCATCGAACCGACGCTCATCG  
 AAGCCCTGTATCGGCGAAGCGCGGACGGCGTACAAATCGATTTGATTGTGCGGGGTATG  
 TCACTTGGCGCGGGTGTAAAGCTTGTGCGAAACATCCGCGTCCGCTCATCGCTCG  
 CGACGCGAGCTCGAACACGCGCGCTGTATTACTTCCATAACACGGCAGCGGACGATACCT  
 TTATCTCCAGCGCGGATTGGATGGGCGCAACTTCTCCGCGCATCGAAACCGCGACG  
 55 CGATTACCGCGCGCAACTCAAAGAGCGGTTATACATGAAGAGTACCATGGCACTGG  
 ACGAACAACCCACGCGTGGCTGATGACGCGCGGCGGCTATATCCGCGCGCACCTG  
 CCGAGGCGGAATCCGAAGCGGACTGCAAAACGATTGTGGACATGCTCGGAGGCTGAC

CCGCACCGCCCAATCAAAACCATGCGGCTGAAACCTTTCCGTTTCAGACGGCATGGT  
TTTACAGCAATCTAAACAGGSCGGACCGGAGTCAAAACACACCTTCGCCATTCTCGCAC  
AAGCACTTCCCTTATACGCTCCCAACCCCAAGCCGCGCATTCAGACGGCATTATAGTG  
GATTAAATTTTAGGGGCTGTACTAGATTAGCAGATATGTTACCTCTGAAATATGAAGATA  
5 AGCCTGCAAAATTAAGAAAAAAGTACAGAAAGAACTGCTCCGTTTTTTGTGCTGGAAG  
TTACGCCCGGTTCTGCCGCCGATATTTGGGTATCCATCCCAATTCGGCAGCACTGTTCT  
ACCGTAAAAATCCGACGGTTATCAACCATCATTTAGCCTTGGCTGCCGATGAGGTTTTG  
AGGGCGTCTCGAGCCGACGAAAGCGATTTCGGCGGACGGCTAAAGGCACAGCTGGTC  
CGCGTCGGCAGGAAAGTGGTTGCTCTGCGCATTCGAAACGCAACGACGGGCTATA  
10 CCGTTGTCGTAGATAATGCCAAGTCTGAAACGTTACTCCCTGTCTATCAAGAAGAAATCA  
TGCCGGACAGCATTGTTTTATACGATAGTCTGACGAGCTGCACAAAGTTGGACGTGAGGG  
GTTTTATCCATTACCGCATCAACCATCCAAAGGAGTTTGACAGCCGTAGAACCCACATTA  
ACGGCATTGAGAAATTTTGAATCAGGCAAAACCGCTCTTGCGAAAATATATGTGGATT  
ACAAAAATCAGGACAAGGCGACGAAGCCGACAGCAGTACAAATAGTACGAAACCGATTCA  
15 CTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTGAGCTAAGGCGAGGCAACGCCGTA  
CTGGTTTTTTGTTCACTCACTATACCTTTCGACAGCGCAACAAAACCCCGAATCCGCTG  
CAGGTTTCGGGTATATCTCCAATACGGGCATCGTGTTCGGAAAACCGTCAAAATCCGCA  
TCGGTATCACAATATATTTGAATTCGGATTGTTGCGCAGGTAAACAGCTCGCAGCGGCT  
TGATGTCGCGAAGGCAAGCTGCATATCGTCGAATGGATGTTGCGCAACAGCTGCATCA  
20 TAGAGCCGATATTTGAACCGACTTCGAGTTGCGCGCTTGATAGCGATTTCGATTTCCT  
CGCGCGCTTCTTCTGCTCGTTGTGCTGCACACACGCTCAACAGGCGGGTTGCAAAA  
ACAATCGCGCACCGGGAATTTTTCTTTGGCAGAAATCGATGACGTTTCCACCGGCCCA  
ACAATTTCTGCCCTGCACAACACGAAATCTTGTGCTTCCAAAGGAATCAGCGGGTTGA  
AATCGGGGAATTTGCCGTCGATGACCTTGTCTGACGATGGTGTGCGCTTGCATTTGAAAC  
25 GCACTGCTTTTGTCCAGCAGCTCGATTGAAATCGGATCGTCGGGGTTGTTCAACAGTTTGA  
ACAGTTTCAGCACCGTTTTGCGCGGCAAAATCACTTCGGCGCGCGGCAAAATCCGATCA  
TCGGCAGGCTGCATAGGCAAGCGGTTGCTCGTCCGCAAGCGCAACTGCGCTG  
CCTCAACCTGCATCAGCAGCGGTTGAGATAATAGCGGATGCTCTGCACCGCATGCTGT  
ACTGCATTCGACAGCATGGTTTTGAAACGCTCTCTGCTCCAGCGAGAAAGTCGCGCTGA  
30 TGTCTTCGCCGACATTATCATCTGAAAAATCGGCGCAGGCGAGGCTCGCAGGCAAAAC  
GCGATTTGCCGCTTCAGCGTCACAGCGCTGTCTCCCAATCCAGCGCACACGCGCAC  
CGCGAGGCGAGCGCGCAAAATATCTGAAATTTCTTGGCATTGGTGATGCGGAAAT  
CGCCCGCGCGCCCTCGGGACCGCGATGTGATTTGGATTTCCAAATCGGTGCCCAAGA  
35 GTTTGGTCTGACCGCTTTCCCTCAATCAGGAGCTTGGACAGGATGGGCGAGGTTGTGC  
GGCGTTCGACGATGCGGTAACGGCTTGCAACGGCTTGAGCAGGCTGTCGCGCTCGGCTT  
GTAARAATCAACATGTTGCTCCTTTAAATCGGTTGTATAGTGGATTAAATTTAAATCAG  
GACAAGCGCAGGAAGCCGACAGCGGTACAAATAGTACGGAACCGATTCACTTTGGTGCTTC  
AGCACTTTAGAGAATCGTTCTCTTTGAGCTAAGCGAGGCAACCGCTACTGTTTAAAG  
TTAATCGCTATATCTTTACCTCTCGGACGGCATGGGCAATATCATGTGCTGTGAAACG  
40 TTTTCCATCAGTTTTGAATCAGAATCAGCAGCTTTTATAATCCTGAGCAAATCGCAT  
CTTCTTCGCGAGTTTCGCCACTGCCCTGATGCCGTGCATAACGGTCGTATGTTGCGCGC  
CACCAACCGAATCGCCGATAGACGGCAGGCTCAAAGTAGTCAGTTCTTTGGTCAGGCTCA  
TCGCCACCTGGCGCGGACGGCAATGTTTCGTGTCGTTTCTTACCGACATCGCTGA  
45 TTTTGATGCGGTAATATTTGCCACCGCATCGATGATGATGTCGGCGGTGATGACTTTGT  
GCTTCTCGGCAATAATGCTCTGAAAGCGGTACGCGCAAAATCGATGTCGATGACGGGAC  
GGTTCATAAAGCGGCTGCTGCTCCGACACGATTAAACGCGCCTTCAAGCTCGCGCAGCT  
TGGAACGGATCAGATTGGCAATGAACAGCGCGGCTTCGCTTCGATACTGATGCCCGCG  
CTTCGCGCTTTTCTGCAAAATGGCGATGCGCATTTCCAATTCGGGCGGCTCGAGTTCCA  
AAGTCAGTCCCCATGAAAAACGGGATTTGAGCGGTCGTCATGCTTCGATTTTCGAG  
50 GCAACACATCGCAAGTGAGGATGAGCTGTTTTTCTCGTTGTGGAATGGTTGTACAGAT  
AGAAAACTCTTCCATCGTACGGTCTTGCTTTGATGAACGGATGGTCTGATAAATCA  
CGAGTCGTATTGCTTGATGCTGCTTGAACAGCTCGTAAGTGTGTTGCGAACCGCT  
TCATAAGCTCGGGATATAGTCATCCGAATCGATAGCGCACTTTGGCAATCGGACGAGT  
55 TTTTCAGAGCTCGTTGCCGACCGCTGCACAAAGTGGGTTTTGCCAAACCGCTGCTGC  
CATAGAGGAAGAACGGGTTGTAATCTGCCCGGGCTTTCCGCAATCGCTCGCGCGCAG  
CGCGCGACAGGCGGTTGCCCTTACCTTACCAACGTATCAACGCTGTAATCGCGAGACA  
GGTTGGTCTGCTGTAAACGCGCTCTTCGCGATCGGCTGCAGCTCCGTCGCTGTTGG

CAACTGCCACCGATTCCGGCCGGGAAGCAGACCCGGCAGCGTACGCGGGCTCGTGCGGCA  
 GGTTTTTTCATAGTTCCGCCAAAATATCCGCGCCGTTTTTCGAGCGAGCGGGTTTGACAG  
 GCTCTTCAGACGGCAGCTCGTCCAAACAGAACTCTCGACGGGCATTCCCTCGACCAACCG  
 CATGCAAGGACGGCTCGGCCAGGTTCCAGAGCACCTTCAACGCCGCCATCTCATTAACGCA  
 5 CGCGCTCTCCCGGTTGAATACGAAGGCGGAACGGCCGCGCAGCCAACTCTCCCTCAACCG  
 CTCTATTATTTCCGGCAAATCGGCTCTTGAGCATATTGCAGGCAAATCGTTTCTGCGCGT  
 ACACCAACCCATACGCCACCCCTCCTCACCACGCTAAGGGGCGCAATCCATTGCGCAAACT  
 GCCCTTGAGGCAACATATCGTGAAGACGGCGGAGGCACAGCGGCCAAAATCTGCTATTG  
 TCATGGATTGGCTCGAATCGGTAATAATGAAATCGAATAACAGAAATATAATATTATTC  
 10 AAAAGGAAAAAAATCTGTTGAACGCACATCGGTTCAAACCGGACTGCCCGATTATACC  
 GACTCAGGAATATTTATCCCAACCCGTGCAAAAATTTATCCACAGAAAGCGCGCGGAA  
 ATCCGAGGCAATCGGCAATCTCCCTGCAAAGTTCTATATTGATTGACAAAAGCGGCA  
 AATTGGAGTGTAATTACCGGTTTAATTATCTACCCATTCTATTTAGGAAACATCATGAA  
 ACGCACTTATCAACCTTCGGTTACCAACGCAAAACGCAACGCGCTTCCCTGGTGGCGCT  
 15 CCAAAACGCGCGCGCGCGCGAGTATTGGCCGACGCGCTGCCAAAGGCGCGCAACGCGC  
 TGGCGGTATAATTTGGACTACCGCTTCGGAAGCGAGTACCGCTTGTGAAAACGAGTGA  
 TTTTTCATCCGTTTTCGATTCAGAAACCGCGCAGCGCGCACTGCTGCAAGTTTCCGGC  
 CTTAACCCCAACGGGCTGGGCCATCCCGCATCGGTCTGGTGGTCGGCAAAAACCGCG  
 CAAACGCGCCCAACGAACGAATATATGAAGCGGTTATCCGCGACTGGTTAGATTGAA  
 20 CAAAAACCGGCTGCCCGCCAGGATTTCGTCGTGGCGCTCCACCGTAAATTCGACAGGCG  
 TACCGCAAAACAGGCAAGGCGGAATCGGCAACACTCATGTTCGGAACCCCGCAACCGG  
 ATGCAGGAACAGGCATGATCAGACCGTACTCTCGAGGCAAGGTTGAGAGCGCAACGGG  
 TTTCCCATACAAGGAACATCCCGATGAATCTCCTATTGTCAAAACCTCTGCTGGGACTGA  
 TACGGTCTTACCAATATTGCATCAGCCCGCTGATTCCGCGCGCTGCCGTTATACGCCGA  
 25 CCTGTTTCGCAATACGCGGTCGAAGCGGTCAAAAATACGCGCATTCRAAGGCGGCCGCG  
 TCGCATCAAGGCGATTGCAAGCTGCCACCCCTTTCCGGCGACAGGCAACGACCCCGTTT  
 CCGTACCCGACGCAATATCAAAATGACGCTTTTCCTTTATTTCCCATCGGTTTCTATA  
 TAATGCGCTCTGAAGCTTCGGGACGCGCGCAGCACCGCGGTTATGAAGCCCGCCCTAT  
 TCCCGCTCTATCGGAACAGCAACCTGCGGCATTTCGACCATTCakGAACCTCTATTG  
 30 ATTTTAAAGACTCACGCGGTTTTTTCGCATCGCGCTGGTGATTATGATCGGCTGGGAAA  
 AGATTGTTCCCACTCCGAAGCCCGTCCCGCGGCCCAACAGGCGACACAACACAGGCGC  
 TAACCGCTTCCGCGAAGCGCGCTCGGCGCGCAACGCGGATTACCGTAAACGACGACA  
 CGGTTCAAGCGTCATTGATGAAAAAGCGGCGACCTGCGCGCGCTGACCTTGCTCAAT  
 35 ACAAGAACACCGCGCAGCAAAATAAACCGTTTCATCTGTTTGGCGACGGCAAGAATAACA  
 CCTACGTCGCCCAATCCGAACCTTTTGGACGCGCAGGCGCAACCAATTCTAAAAGGCATCG  
 GCTTTAGCGCACCGAAAAACAGTACAGCTTGGAAAGCGCAAAAGTTGAAGTCGCCCTGA  
 CGCGCGCTGAAACAGCGGTCGAAAAATCGACAAAGTTTATACCTTCAACAAAGCGAGCT  
 ATCTGTGTCACGCTCCGCTTCGACATCGCAACGCGCAGCGGTCAAAACCGCAACCTGAGG  
 40 CGGACTACCGCATCGTCCGCGACCAAGCGAACCAGGCGTCAAGGTACTTTTACCACCT  
 CTTACGTCGGCCGTGTTGTTTATACCCCTGAAGGCAACTTCCAAAACGTACGTTTTCG  
 ACTTGACAGCGATGCCAAATCCGGCAATCCGAGCGGAATACATCGGCAAAACCCGGA  
 CGCGCTGGCTCGGCATGATTGAACACACTTCATGTCCACCTGGATTCTCCTCAACTAAAG  
 GCAGCAAAAGCGTTTTCGCGCGCAGCGAGTGCAACATCGACATCAAAACCGCGCAACGACA  
 45 AGCTGTACAGCACCAGCGTCAGCGTGCCCTTAGCGCCATCCAAAACGCGCGCAAGCCG  
 AAGCCCTCATCAACCTTACGCGCGCGCGACGACCATCTCGCTCATCGAAACATCTCGCC  
 ACAACCTCGAACTGGCCAAAGACTACGCGCAAGTACACTGGTTCGCCCTCCCGCTCTCTT  
 GGCTCTGAACCAACTGCACACATCATCGGCACTGGGGCTGGGCGATTATCGTTTAA  
 CCATCATCTGTCAAAGCGCTACTGTATCCATTGACCAACGCGCTTACCCTCTATGGGGA  
 50 AAATGGGTGCGCGCGCACCAAACTGCAAGCCATCAAAAGAAAAATACGGCGACGACGTA  
 TGGCGCAACACAGGCGATGATGACGCTTTACACAGACGAAAAATCAACCCGCTGGGCG  
 GCTGCTCGCTATGCTGTTGCAAAATCCCGCTCTTCACTGAGTGTATTGGGCACTGTTTCG  
 CCTCCGTAGAATTGCGCCAGGCACTTGGCTGGGTTGGATTACCAGACTCAGCGCGCGCG  
 ACCCTCTACTCATCTTGCCATCATATTGGCGGCAACAGTGTTCGCCCAAACTTATCTGA  
 55 ACCGCGCGCGACCGACCGGATGCAAGCGCAAAATGATGAAAAATCATGCGGTGGTTTGTG  
 CGGTCATGTTCTTCTTCTCCCTCGCGGTCTGGTATTGTACTGGGTAGTCAACCACTCTC  
 TGACCGCTCGCCAGCAATGGCACATCAACCGAGCATCGAAAAACAACGCGCCAGGCG  
 AAGTCGTTTCTAAATGCCGAGCATGAAAAATGCCGTCTGAACCTGTTTCAGACGGCAT

TTTTATTGCCACCCCTATCGGGGCGGAAATCTTCAACCCGCATACATCAGAAAAATCG  
 TCGGGCGTTTTTCAGATTGGCATTTCCTTTCTTTTCGCCACTGCACGATTGTTTGAAC  
 TGAATGATTTCTCTGTGTGGCAAGGTCAAATTCGTAGCCGTGCATAAACCGGTTTCAGGAT  
 CGACGGTTTTCCACCGCATCGGCAGCAGCGCATCATTCGGGTAAAGCGGTTTCAATAAAAA  
 5 TCTGGCTCTCGCCGCACTGGCGCGAAACGCTGTTCCAAAGCCGAAAGCGTTGAATCCGCT  
 CGTTTTTTTCAGACGGCAGATAGCCTTTAAACGCCAAACTCTGCCGTTTCGCACCCGGAAG  
 CATCAAAGCCAGCAGCAGGCTGGAAAGCCGACCGACGGACGCATTCAAAACCGCTGTT  
 TAGCGCCAAATGCCACAAATTCGCACCCGCGATCGGCCACAGCCGGGCAACCCGCTCAC  
 TGACAAATGCCATACTGCGCCCTTCTTGCAAAGGTTTCAGCAATTCCGCAAACTTCTCA  
 10 AATCCGTATGTTCAATCAACGTTTGCAGATTACGCTCGCGGATAGGCGTAGTCACGCCCA  
 AATGTTTCAAATGCGCACCGGCGGTTTTTTCGCGCTCCACGACAAAAATCCGTAGGCCGGA  
 CAATCGCCCTGTTGTTTCATGCGGCACAGGCACGGCGTGTACGGCGTACCCAAAGCGGTAG  
 GAATCAAATACAAAACAGGAGACATCATTCCTCACTCATCGGTTAAAAATGCCGCTCTGA  
 GCCTTTCAGACGGCATAAACGGGCACTTACAGAACCTCCACGCCCTCATTTTTCAAGAAA  
 15 TCGACGAGACGGAAAAACGGCAACCGATTAAAGCATTCGGATCGGTACTCTCAATCCTT  
 TCAATCAGCAATGCACCCAAATCCTCACTCTTCAGCGCACACGAAACAATAAACCCGATCA  
 GGCTCGCGCTCCAAATAGCGAGGATATGCAACTCGTCCAACTGCCATCACGACGCCCTG  
 CTCCTTCGATATGCCGCGCATCCTCGCCGTAACCGTATTCAACAGCATCATCGCGCTG  
 TAAAACTCAATCTCCTTGGCCGCTCAAGTGCATCAGCATCTTTGCGCATTGGCAAGGTTT  
 20 ATCGSCTTGCCCCACTGCTGCCCTGCGACCCAGCCACCTGGTCCGACCCGACATCAAC  
 GCCTCTGGGAAACGCGCGGTCAAGACCGCGCTTACCTCGGCAAGGGCGAATGCCGTC  
 TGAGGGGCGGATTCCCGACACATCGGCGTTTCGTCAAAATCGGGGACGCCGCTGAAAG  
 GCAATTCGGAGCCTTCCATCTGTTTCGGCGGCAAAACCGAACTCGTACCCAAATCAAA  
 GGCAGTTCAAAACCCATCCCATCTCTTACCGTTGAAACACGCCCGGAGGGGCGATCTTA  
 25 AATCAGCCGATGCGCGGAAACACGGATACCGGCTTCGGCGTACCGCAACATTTTTCTA  
 AAAATATTGACGTAGAACATCTAAATATATCATATCCGTTTATGTGACAGCCTTAATT  
 TGATTGACTTGAATTTTTGCCGCGAAGGCGAGAACTGCAAGGCAGTTTTCGTCTGG  
 AGAATTTGATGAACGCGCTCAGTTCGCACGATTATCCGCGCAGCAGGCAGACCAAAAT  
 CGTTTACACTGACCGGGCGTGCAGACCGGCTGCAACGCTGTTCTCGACTCGAACCTCA  
 30 AAGCCGATATGCCCTGATTGCGCAGAGATGTATCAAAACCATGCCGTTTATGCTTGAATG  
 AAAGCAGCGTATCGTCTGTTTTCCACGAAAGAGTCTTGAGCGAATCCATGCTTGGCG  
 ACGAAGAACTCGAAGGCATACGATTGAAAAAGAACTCGACGTGCGCACATTGTTAGAAG  
 ACCAAATCCTGATGTCCCTGCCCTTTTCGCCGCGACACGAAAGCTGCGGCGACAAATGGGA  
 35 CACTGGAAGAAGTCAATCGGACAAACCCCAACCCCTTTGCTGTTTTGGCAGGTTTAAAA  
 GCAATTGATTAGGACACAGTTTATTTATCTAGGAGCTTGAATGGCCGTTTCAACAAAAAC  
 AAAAAATCCCTTCCAAACGCGGTATGCACCGTTTCGCACGACGCGCTGACCGCGCTGAC  
 TGTCTGTGCACAGCACAAACGCGGAGGTACACGCGCCGACACATCTCCCCAACAGTGA  
 TGTACCGCGCGCGCAAAAGTGGTCAAAGCCAAAGGCGAATAATCCCTATTTCGACTGACGTGA  
 40 AAAAGCCAGAACATTGCCATGCAATTACTGGCTTTTTTGCATTGGACGCAACATCCGTC  
 CAACTTTTCGCCATACGTCAACACACAGGGGCAAGCGCTTCGTATAATACCCGCTGAA  
 ATATTCCAAAGCCCCAACCCAAAGAAATTCGATGAACAGAAAAATCTGGTACACCT  
 ACGATGACATCCACCGCGTCATCAAGCATTGGCAGAAAAAATCCGGAAACGCGACATCA  
 AATACGATGCCATGATTGCCATCGCGCGGCGGCTTTATTCGGCAGTATGCTGGGCT  
 45 GTTTTCTGAAATTCGATTTATGCCGTAAACCCGCTTATTACGACAGCGCAACGAAG  
 GACAGGTTACCGAAGAAGTCAAAAAAGTCCATGGCTCGACCCCGTTCCGGAAGCGCTGC  
 GGGGCAAAACGTAATCGTCTCGATGAAGTGACACAGCCGCGTAACCATGGAGTTCT  
 GCCTGAAAGAACTGCTCAGGAAGACTTCGTACGATCGGAGTCGCGTACTGCACGAA  
 AAATCAAAGCCAAAGCAGGCAAAATCCCGAAGGCATTCCTATTTTCAGCGGATCACCG  
 TAGAAGACTGGTGGATCAACTATCCGTGGGACGCACTGCACATCGACGAAACACACCGCT  
 50 TCGCCACAGCCGCGCGAGGCTGACCTTTTCAGACGCAATTTTCGCAACCGATCGGCTC  
 TGAAGCCCGCACAGCCCTTCGCGCAGACCGAAACCTCGGAGAAACCTATGATTACA  
 TTGGCCGTAGATGCCATGGGCGGCGACCAAGGATTGCGGTTACCGTACCCGCGGCAAC  
 GCATTTCTCCAGCACACCCCGATGTCCGCGCTGATTGACCGGCGAGCAAGCAAGCTC  
 55 CGCCACGCGCTGACCGCGGAGGCGACCGATGGAAGCATGACATCTGCCATACCAAC  
 CAGCTCGTCGGCATGGACGAAGCCCGCAATCCGCGCTGAAAAACAAAAAGACTCTCTC  
 ATGCGGCTCGCCATCAACAGGTTTAAAGAGGCAAGCCCAAGCCGCGTATCCGCGAGC  
 AACACGGGTGCGCTCATGGCAACCGCACGTTTCGTCTCAAAACCATTCGCGCATCGAA

CGCCCCGCCATCGCCAAATTCCTTCTTCGGACACCGACCAGTTTACCTTGCACCTCGAC  
 CTTCGCGCGGAACGCTGACTGCACGTCCGAAGACGCTCGCCCAATTTGCCGTATTCGGCAGC  
 GAACTCGTCTCAGCACTCCATCTCTCAAAAAGGACAGCCGCGCTCGGCTGGTCAACAGCT  
 5 GGCACGGAGACATCAAAGGTACGGACACCGTCAAAACAAACCTACAAACTGCTGCAAAAC  
 AGCAAACTCAACTTTATCGGCAACATCGAAAGCAACGGCATCTCTACGGCGAAGCAGAT  
 TCGTCTGCTCGCGACGGCTTTGTGCGCAACGTCACTGCTCAAAACCTCGAAGGCGCGGT  
 AAATTCATGAGCGGAGCATCCGCGCAATTCCAAAGCAACCTGTTCAACAACTTGCC  
 GCGCTTGCCGCCCTACCGCCCTCAAAGGGCTGAAAAACAAACTCGACCCGCGCAAAATC  
 AAGCGGCGCATCTCTGCTCGGCTCGCGGCATCTGATTAAAGCCACGGCGGCACAGAC  
 10 CAACCCGTTTCGGCTATGCCCTCGAAGAAGCTACCAAGCAAGCAAAGTCGCGCGGCTT  
 TCCAAAATCGAACGGGCGTAGCGCAAACTCGCCGCACTCGAAATGCCAAGCGCGT  
 CAACACCGAAAATGTCGGCGGTCTGTAACACACACAGATGCCGTCTGAACGCCCGCGCCCT  
 TTCAGACGGCATCCGCGCGCAACAACTCGCGGCGCGGACGGCGATGCGCCTGTCGCGC  
 ACTTCCCAAATATCGCCTTGTAAATTAAGGAGTATTTGAAAAATGAAGACATTAGAAAAA  
 15 CGGATGAAAGCTCTAGACAAACGGATATGAAGTTGGAATAATCCCTTGAAGCGAGGCT  
 GATGCCCGCTGATTGAATCCGCACTTGGATTATATTCATTATTCGGAACGTTTTTGGCT  
 TTTGAAATCTGTGTAATATATCGAAGATTTGATCTCGGCTGACGGAACAAGACTCA  
 CGGGAATTTTCTTTATCAACAGGAATTTGAGATGAAAGCAGCTCCGATTACCAATTA  
 CAGCCAATGGGTTGATAAACATGAAACATCGACGGTCTTTTTTGGCGGATTTTTATG  
 20 CAGCAACCGGAGAGCGAATCCAAATCCCGCTTTTGGAAAAATCTGACATTAGGGAATCA  
 ATCACTTTTTTCCGTATCAAATTTTGAGAAAAAACCGGCGCTCTTGTTTTCAGAAATCA  
 TCCCGAGCGCGGAATTTGGCAATACCGAATTAACGTCTATTATTAAGGATGATTTATA  
 GTGGATTAAACAAAACCAAGTACGGCGTTGCCCTGCCCTTACGCTACTGGTTTTTGTAACT  
 25 CACTATATCAGACGAAAAACAACACCGCGCCCAATAGGCTGACGCGCAACCGGCAATCAA  
 AATGCGCTCTGAAGCAGCTTGGGCTTTCAGAACGCAATTTCCCTTCGCTTAAACACGGCTAT  
 CGGCAACCCCGCCCTGCGCTGCTCCACGGCAATCTGCATCTGAAAACCATCTGTATCCCAA  
 CACACCCCTCATCCCTGTTTCCATCATGTGCACCTCTGCGCTATTGGGCAATCATCTGTT  
 TTTGCTTACAATAGCGGAATCTGAACCAATCTCTAAAAAGGCGCTTCCATCGAGTAT  
 GCAAAAATTTCCGGCACAGGCACTATCTTCCCGCAACCGCTCAGCAATGACGACCTT  
 30 GCCCAAAAGTAGATACCTCTGACGAGTGGATTACCGCGCGCACGGGCAATCAAATCCGC  
 CATATTGACGCGGAAAAACGAAAAACACGAGCATCTTGCGCCGAAGCGGCGACCCGCGC  
 CTGGATGCAGCCGGAATAGACAGCGGCGAAATCGATTGATTATCTGGCAACCGGCAACG  
 CCGGATATGACGTTTCCGTCTACTGCGACCATCTGTGCAACAAAATTTGGGCATCAACCA  
 GGCCTGCCCGCGCTTTGAGCTACAGCGGTGTGCGCCGCGCTTATGTAACGCGCTGACACG  
 35 GCAAAACGCTACATTAAAGCGGATGGCGAAAAACGCGCTGCTCATCGCGCGGAAACCT  
 TTCACGCGCATTGTAAGTCTGGAACGACCGCAACCTGCGTATTGTTGCGGACGCGCGCG  
 GCGCGCGTGGTTTTAAGCGCTGCGGACGCGCGGCAATCCACAGCAAACTCAAGCG  
 GACCGCAATTATCTGAAACTCTTAAACGCTCCCGGGCAATTCGCTGCGGCGAAAGTTTCC  
 GGTTCGCGCTACATTTCGATGGACGGTCCCGCGGTGTCAAAGTTGCGCTCAAATGCTGT  
 40 TCCAAAATCCCGCATGACGTTATCGAAGAAGCAGGTTACACCGCGCTCAAATGCACTGG  
 ATTGTTCCCATCAGGCAAAACCGCGCATTTATCGAATCGACCGGAAACATTAGGTTTG  
 AGTATGCAACAAGTCGCTCTGACCGTCCAGACACCGGCAACATCCGCGCATCGATT  
 CGCTGGCTTTGGATACGGGATCCGCAAGCAGCAAAATCAACCGGGTCAAACCTGCTG  
 CTCGAAGGCATCGCGCGGCTTTCGCTGGGCGCGGCTGCTGTGCAATATTGAACCCGA  
 45 TGCGCTCTGAAACAGGCTTTCAGACGGCATTTCCCATATCATGAAGCGGAGGCTTTCT  
 CAACTGATGGCGGTGTCGCGCATTTCTGTCTGCGCTTTCGCTGCGCTCCCGCTATTGGG  
 CGCGTGTACGCAATATTGTCCCTCTATGCGTTTGACTTTACGGCATCGCAAAACGGT  
 CGCCATACGCGGGCAACGCGCATTTCCCAAGACCGCTGCTGCTGCTGATGATGTCGG  
 CGCTGGGTGGGCGGTATTTCCGACGATGACATTCAAAACATAAGACAGCAAAAGCTG  
 50 TTTGTTCTGCTGTTCGCTGCTGCTGTTTCAGGTAATGTTCTGGCGACCTCATCTCGAT  
 TTATAGTGGATTAAATTAACACAGTACGGCGTTCCTCGCTTTCGCGTACTATTGTGAT  
 TGTCTGCGGCTTCGTGCGCTTGTCTGATTTTTGTAACTCACTATATTATTTTTCGCG  
 CCTGAATTTTTCGTAACCTCGGGCAGATACCTGATTATCAACCAACAAAGGAATAC  
 55 TATGCTTTTTCGCTTCTTTTTCGCGCAAGGTTCCCAAGCTCTGGTATGATGAACGG  
 CTTTGGCGAACACCGCATCGTCAAAACACCTTTGCGCAAGCTTCGCGCATATTGGGGA  
 GCACTTGTGGCGATGATAAACCGGACGCGATGCGCAAAATCATCGTCAACCGCTCAAC  
 CACGCCCATATGCTCGCGCGCGCGTTCGCTTACCGCGCTATTTAGAAGCGGGCGG

CAAAACGCGTCCGCCGTTGCCGGACACAGCCTCGGCGAATACACCCGACTCGTTGCCGC  
 CGCGCGATTTGAATTTGCCGACGCGGTCAAACCTCGTGCGCCCTGCGCGCCGAACATGATGCA  
 GTTCGCGCGTACCGCAGGCGTGGCGCAATGGCGGCGATTCTCGGCTTGGAGAGTAGGCA  
 GTCTTAAGCATTGTGCGCGAAGCGGCCAAAGCGAAGTGGTCGAAGCGCTCAACTTCAA  
 5 GTTACCCCGGACAAATCGTGATTGCAAGCAACGCGCGCGCTCGGACGCGCCATGGCTGC  
 CGCCAAAGAACGCGGTGCCAAACGCGCCTGCCGCTGCGCGTGTCCGTACCTTCCATTG  
 CAGCCTGATGAAPCCGCCGCGCAAACTTSCGAAGCCCTGAAAACGTTGAATCAA  
 SCAGCCGCAATCCGCCGTTATCCAAACGCCGACGTTGCCGCCCTACGATGATGCCAGCAA  
 AATCAAAGACGCGCTCGTCCGCCAGCTTTACAGCCCGTAGCTGGACGGAAACCGTCAA  
 10 CGCCCTCGTTTCAGACGGCATTGCCGAATCCGCGAATGCGGCCCGGGCAAGTGTGGC  
 GGGCTTGGCAAAACGCATCAACAAGCGCCGCGTGCAGCGCATGACCGATGCCGGACA  
 GGTTCGCCGCTTTATCGAAGCGCACTGACTTCGTTCTGCAAAAAGCAGCTGCCCTCTTC  
 AGGCTGCTTTTATGTCGAAGCAGCGGACGCCCATATTTACGCTATAATCCATCCCGAC  
 CAAACCCAGCAGCGGCTGCCGTTGCAAGTTCGCCGCCCTACCGATATGATAGAAAACTG  
 15 ACTTTCCGACTGTTTAAAAAAGAGACGCGCGCAGCTTTATGCGCCTGATGGCGTACGTC  
 CGGCCCTACAAAATCCGCATCGTTGCCGCCCTGATTGCCATTTTCGGCGTTGCCGCCAC  
 GAAAGCTACCTTGGCGCTTCATCGCCGCCCTGATTACACCGGCTTTTCGCGACCTGCC  
 CGCCGCCCGAGCTGTCTGCCGCCCGGCATCTTTCCACCCTGCAAACTGGCGCGAA  
 CACTTTACCTATATGGTTTGGGGGCGGAAAACAAAATCTGGACCGTCCCGCTCTTCCT  
 20 ATCATCTCGTCTGCATCGTGGCATCTCGCGCTTTACCAGCACCTATCTGATGACTTGG  
 GTCTCCGTGATGACCATCAGCAAAATCCGAAAGATATGTTTGCAAAATGCTGACCTTT  
 TCCCTCCGCTACCATCAGGAAACCGCGTCCGCCGCTACCTGATGAATATGCTCAACCTG  
 ACCGAAACAGTCGGTCAGCAACGCCAGCGACATCTCACCGCTCCTCAGCGCGACAGATG  
 ATCGTTACCGGCTGACCATCGTCTGCTTTAOCCTCACTGGCAGCTCAGCCTCATCTGTC  
 25 GTCTGATGTTCCCTGCTCTCCTGCTCTCGCGCTACTACCGCGACCGCTCTGAAACAC  
 GTCTATTCGACTCGCAAAAAGCATAGGCAGATGAACAACGTGATTGCGGAAACCCAT  
 CAGGACACCGCGTCTCAAGCTGTTCAACGGCGAGGCGAGCGGCAACCGGTTGAC  
 GCGGTCAACCGCACCATCTGTCGCTCAGCAAAAATCAGCGAGGCAACGGCGCACAT  
 TCCCGTTTCAGCGAAGTATGCTGCTCGATCGCTCGCCCTCGCGCTCATCTTCATCGCTG  
 30 TGGCAAGGCCAAACCGGCTACACCACCATCGCGAATTTATGGCATTTCATGTCGCGATG  
 CTGCAPATGTACGCCCCCATCAAAGCCTTGCCAACTCAGCATCCCTATGCGAGCGATG  
 TTCTTCGCCGCGACGGTGTATGTGCATTTCTGCACACCCCGCCGAAACAGGACAAAGGC  
 ACGCTCGCACCGCAGCGTGTGCAAGGGCGCATCAGCTTCCGCAACGTCGATGTCGAATAC  
 CGTTCAGACGGCATCAAAGCCCTCGACAACTTCAACCTCGACATCAGACAAGGCGACGCG  
 35 TCGCCCTGGTCGGACGTTCCGGCAGCGGCAATCCACCGTCTCAACCTGCTGCCCGCG  
 TTTGTGAAACCGTCTGCCGCAACATCTGCATAGACGGTATCGACATCGCGGACATCAA  
 CTCGACTGCTCGCGGCCCAATTGCCCTCGTCTCCCAAGACGTATTCCTGTTTGACGAC  
 ACCCTGTTTGAAGAGTCGATACAGCGCTCCGACGCGGGCGAAGCGGAAGCTCTGTTC  
 GCGCTCGMAACCGCAACCTGCAAGCGCTGATTGACAGCTCCCGCTCGGACTGCACAG  
 40 CCCATCGGATGAACGGCAGCACTTATCCGGCGGACAGCGGCAACGCGTCCGCTATGCC  
 CGCGCATTTTGAAGACGCGCGATATATTATTGAGCGAAGGCCACGAGCGATTAGAC  
 AACCAATCCGAACGCTCGTCCACAGGGCGTCGAACGCGTGTGAGAAACCCGACCGGC  
 ATCATCGTCGCCACCGCGCTGACCAACATCGAAGGGCGGACCGCATCATGTGATGAC  
 GACGGCAAAATCATCGAAACAGGCACACAGCAACACTGTTCGCCAAACCGTTTACTAC  
 45 ACGATGTTACGCAATATCTCAAACAGAGATGCGCGCGTCGGACCGCATAAACAAATGCG  
 CGTCGCAAAATGGTACAATCGCCCGACCCCTTTACAGCGGCATCATATCCGCGACCCATC  
 CGATTATCTTCAATCACTGAAAACCCATTATGACCCAGACAAAATCTCATCTCTTGAC  
 TCGGTTGCAAGTTACCCAGCTCATCGCCGCCGCGGTGCGCGAAGCCACGTTTATGTCG  
 GAGCTGCATTCTTTCGATATGCTTTTGCAGCAAAATCAAGCCTTCAACCCAAAGCAT  
 50 ATCTCTCTCGGCGGCCCAATTCCGTTTACGAATCCGACTATCAAGCCGATACCGGTATT  
 TTTGATTTGGGCATTCGCGTTTGGGCATCTGTACCGCATCGAGTTTATGGCGACACAC  
 TTTGGCGCGAAGTGCAGCCCGCAACAGCGCGAATTCGTTTATGGCAAGTAAACAC  
 ATAGACAGCGAGCTGACACGCGGCATTCAGATGGTGAGGCCAACACACTCGACGTATGG  
 ATGAGCCACGCGCACAAAGTGTCCAACCTGCCCGCGTTTCCGCGCATCTCGGCAACAC  
 55 CCGCTCTGCCGATTGCCATGATGAAAACCGCGAAAACAAATCTACGCGCATCGAGTT  
 CACCCGGAAGTTACCCACACCAACAGGCGCGCGCTGTTGAACCGCTTTGTCTTGAT  
 ATTTGCGGCGCACAAACGGGCTGACGATGCGGAATCATCTGAAGAACGCGTTGCCAAA

ATCCGCGCAACAGGTGCGGCAGCGACGAAGTGATTTTAGGTCTGTCCGCGCGCGTGGACTCT  
 TCCGTAGCCGCGCGCGTGTATCACCAGCGCATCGGCGACCAACTGACCTGCGTGTTCGCT  
 GATCACGGTTTGTGTGCGCTGAACGAAAGCAAAATGGTGATGGATATGTTCCGCCGCAAC  
 TTGGTGTGAAAGTGATACACGTCGATGCCCAAGGGCAGTTTATGGCGAAACTCGCCGCG  
 5 TACACCGACCCCGAGAAAAACGCAAAATCATCGTGGCGGAATTTATCGAAGTATTGAT  
 GCGGAAGAAAAAACTTACCAACGCGAAATGGTTGGCACAAGGCAGATTATACCTCTGAC  
 GTATTCGAATCCGAGGTGCAAAAACCAAAAAGCCACGCCATCAAAATCGCACCAACAC  
 GTCGCGCGGCTGCCTGAAAAACATGAAGCTCAAAATGCTTGAGCCTTTGCGCGATTGTTTC  
 AAGAAGCAAGTACGCGAATTTGGGTGTGGCTTTGGGCTGCCGCGGAAATGGTGACCGT  
 10 CATCGCTTCCCGGGTCCGGGTTTGGGCGTGCGTATTTTGGCGCAAGTGAAAAAAGAAATAT  
 CGCGACCTGCTTCGTACGGCAGACGATATTTTCATTCAAGAATTGCGCAATACTACCGGAT  
 GAAAAACGGTACATCTTGGTACGACCTGACCAGCCAGGCATTTCGCGTGTTCCTGCCCGTC  
 AAATCTGTGCGCGTAATGGGCGACGGCCGCACATACGATTACGCTATTGCTTGCCTGCC  
 15 AAGTGTCCAACCGCATCATCAACGAAGTCAAAGGCATCAACCGCGTGGTTATGATGTG  
 AGCGCAACACCGCTGCCACCATCGAGTGGGAATAAACAGCAAAACATGGCTGCCCGCTCC  
 GCGCGAGTCCCTCGATTATCGGAAAAAGGAAAAAATATGAGCACACAAGATTTTAAACGG  
 CAAATCGCTTTGGTAAACGGCGCATCGCGCGTATCGTGACGCAATTCGCGACACGCT  
 20 GCGCGCAGCGGTGCCAAAGTCATCGTACGGCGACCGTAGAGCGGTGCGCGCGCAT  
 TAGCGAGCGGTGGCGCAATGGGGCGCGGAAGGCCGCTATTAAATTCGCGCGAACCTGGA  
 AACCATCGAAAGCTGATTGCCGACATCGAAAAAGCGTTTCGCGCAACTCGATATTCGTTG  
 CAACACCGCGCGCATCACCGCGCAACACTCCTGATGCGCATGAAAGAGAAGAGTGGGA  
 CGACATCATGCAAGTCAACTCAAAATCGGTTCGCGCGTCTTAAAGCCGTTTTCGCGCG  
 25 TATGATGAAACACGTTTCGCGCGCATCATCAACATCAGTTCGCTGCGCGGTGATGGG  
 CAATGCGCGTCAACCAACTATGCGCGCGCAAAAGCAGGCTTAATCGTTTCTCCAAATC  
 CATGGCGCGCGAAGTCGCGAGCCGGGCGATTACGCTCAACTGCGCTCGCCCTCGCTTTAT  
 CGATACCGCATGACACGCGCCCTGCCGGAAGAAACCGCAAACTTTACCGCCCAACAT  
 CGCCTTGGGCAGATTGCGGACGCGCAAGACATCGCCGATGCGGTTCTGTTCTCTCGCTTC  
 CGACCAAGCAAAATACATCACCGGCCAAACGCTGCACGTCACCGCGGTATGCTGATGCC  
 30 TTAACAGACAACCTTTTCAACCATGCCGTCTGAAGCCCTTTCAGACGGCATTTGCAATTC  
 CAGGCAAAATGAACACACACACACCCCGCCTGCCATCGCGCTCAGGCACAAGCTGAG  
 ACCTTTGCAAAATTCCTTTCCCTCCCGCAGCGCGAAACCCCAACACAGGTTTTCAGTGT  
 TTTGAGCTGTTTTCGCCCCAAATACCGCCTAATTCATACCAAAATACCCCTTAATCCTCC  
 CGGCAACCTGATAATCAGGCATCCGGGTACCTTTTAGGCGCGCAGCGCGGCATCTT  
 35 CTGTTGGCGGCTTTCAAAGGTTCAAACACATCGCCTTCAGATGGCTTTCGCGCATCTACT  
 TTAATCAGTCCGAAATAGGCTGCCGCGGTAGCGGAATTTATGGTGCAGCGTACCGAAG  
 CTCTGTTGCACCATATAGTGGATTAAACAAAACAGTACGCGGTTGCCTCGCCTTAGG  
 TCBAAGAGAACGATTCTCTAAGGTGCTGAAGCACCGGAGTGAATCGGTTCGCTACTTTG  
 TACTGCTCTCGGCTTCGTCGCTTGCTGATTTTGTGTAATCCACTATACATCATCGCT  
 40 ACTACGTTCCGGCGCAACAGGCATCTTCGATCGCGCGCAACTGATGCAATGGAGTATA  
 GAAACCGAAGGGTGGGCTGAAGCTCATCTCGCAAGATACTCGGCAAGACACCGCC  
 CAAGTCGAATTTGAAGCCTACTTCGAGACGGCAACACCGATCCGCGCATACGAAGCTG  
 TCCGGCTTCGTCAACATCGCGGACAAATGGTATTTATCGATCCCAACCGTTCGCGATCCT  
 CGGATGAACACACCTGCATTTCGCGATCAGGCAAAAAATTCAAAGCCTGCTCGCGCAAA  
 45 TATCTGAAACCTGTGCAATAAAAAATGCGGTCTGAACGTTTCAGACGCGATTTCACGCTG  
 AAAAAAACCATTCATACCAAGGGTAAATGATGAATGGTCAATACATTGCGGGAACACGTC  
 TTACTGCTGCACTGCCGAAAGGGAGAAACGGCAGCGGTAATCAGCGGAAGGATTGTA  
 CCGGAATTAATATTAAGAAACGTTAATCGGAAAATATATTAACAAACCTGTTGAACCT  
 50 ATTGGTTTTCCGATATCACCCGACCCAGCGTTCAACAGCTTCGCTTCGAGCGCGGCA  
 CGACCGAGCGTTTGAACACGTTTACCACCTCCAAACCCGTGGCTTCCAAAGTCTGCA  
 GCTTCCGCGCCGCTCCTCGAAAAATCAAGCGCGCGCGGCATTAATCCACAGCTTCTGCC  
 CGCGTGGCAACATAAACATATAACGCGCGCAAGCATTAACCAATCCAAAGTCTGCTG  
 TGCCCATATCTCGTATCGTTCCAAAGGCGCGAGCGTACTCATACGGCTGGAAAGTTTTCG  
 55 CCGAAGCAGATATTTGATTTTCAACGCCCGCAATCGCCTCATTGAGTTTTTTATCCAGCA  
 GCGCGAGGGCGAGACGCTCCCGTTAAAAACGCCCTTCCCGCGTTCGCGATAAAAAC  
 ATTCCGCGCTGACTGGGTTGTAGATTACGCCCAATCGGCGCGCGCTTGGCGCAACACG  
 CCACCGATACCGCAAAATCGGCGACCGGTTGACAAAATTTGCTGTCGCTCTATCGGAT



CGACAATCCACAGCCCTTTTCCCGCGAATATTGTTCCCAACAAAGCCGACTGTTCTGCC  
GCGACATTTCTCACCACACATCGGACTGTGATTAAGAGCGGCAACGCGCGGCAAAAG  
CCGTCTGCGCGGAATGTCCGCTCGCTCAACATCGAACCGTCTTCTTGCGGTGAGACG  
GCGTATTCAAAAACGCGGCATTAATTCGGTTTGCGGATATGGCGCAGCACTTCTGCA  
5 AACGGTGTAAACACTTCTACTGTCTCATATTTGAACTTTCGGCGCGGCAACGTATAAT  
GTCCGCTTCATCAAGCGCTGCGACGGATTATAACCGTCCGAACGCCAAAACTATGC  
CCGATTTCCACCTGCCGAAACCTTTCCGTCCGACAAACCGTCCGCTGCCCCAGACA  
TCTGCCGACCTCAACGTCTCGCGCTCCGCCCCAACGAAACATCACCTCTTGACG  
10 GCAAGGCAAGGCACACGCCGACGGTGACCGTTTGGAAAAACGCCGCCGGAAGCG  
AAATCTCGACGAAGACACACACCGACACGAGTCCCGCTCAACATCACTGATACAAT  
CCATCTCTCCGCGCATCGCATGGATTTCACCTGCAAAAAGCGTCACTCGGCGTAA  
CGCGCATACAGCCCGTCATCAGCGAACGCTGCATCGTCCGCTCGATGGGAAACGCCCG  
CCAAACGCGCTCGCAGCTGCGAGGAATCGTCATCTCCGCTGCGAACAAAGCGCAGGA  
ACACCGTTCCCGCTACTGCCATCATCGCTACCGTGAAGCACTCGACAAATGCCGT  
15 CTGAAGACCAAGCTGATTATGAGCATCAACCGCGCCGCAAACTCGGCACATACGCC  
AACCTCCGCGCAATCGCTTTATGTCTCGGCCGGAAGCGGCTGGACAGAACGAAG  
AACACAGGCATTTGAAGCTGCGTTTCAGCGGTTTACACTCGGCAACAGGATTTACGCA  
CAGAACCGCCCACTCGCGCCCTCGCGCCATGACAGCGCTTGGGGCGATTTCGCAT  
20 AAACAGAAATGCGCTGAAACCGCTTCAGACGGCATTTTCAGCGGATTAAAGATAGTAG  
GTTCAATTAAGATTTCCCGTGTCTGCTATCCCGCGAAAGCGGGAATCTAGAAACGAAAA  
CTACAGAGATTTATCCGAAACACACCCCTCTCCGCGCAAAAGCGGGAAT  
CTAGAAACGAAAACTACAGGGATTATCCGAAACACAAACCTCTCCGCGCTCATCC  
CGCGCAGCGGGGAATCTAGAAACGAAAACTACAGGGATTATCCGAAACACAAACCTC  
25 CTCCGCGCTCATTCGCGCGAGCGGGGAATCTAGAAATTAACGTGCGGTGATTATCG  
GAAATCTGAAACTCAACGGAATGGATTCCCGCTCGCGGGGAATGACGAGATTTTAG  
TTCTGTTTTGGTTTTCTGTTCTCGCGGGAATTAACGGAATTTAAGTTTATAGGAATTTG  
TCGGAACACAGAAATCCCGCGCGCTCATTCGCGCAAAAGCGGGAATCTAGAAACGAA  
AACTACAGGGATTATCCGAAACACAAACCTCTCCGCGCTCATTCGCGGAAAGCGGG  
AATCTAGAAATTAACGTTGCGGTGATTATCGGAAATGACTGAAACTCAACGGACTGG  
30 TTCCGCTCGCGGGGAATGACGAATTTAGGTTTCTGTTTTGTTTTCTGTTCTCGCG  
GGAATACCGGAATTTAAGTTTATAGGAATTTATCGGAAACAGAAATCCCCCGCGCTC  
ATTCGCGCAAGCGGGGAATCTAGAAATTAACGTTGCGGTGATTATCGGAAATGACTG  
AACTCAACGGACTGGATTCCGCGCTCGCGGGGAATGACGAATTTAGGTTGCTGTTTT  
TGGTTTCTGTTTTTTCGGGAATGACGAATTTAGGTTTCTGTTTTGTTTTCTGTTCT  
35 CGCGGGAATACCGGAATTTAAGTTTATAGGAATTTGTCGGAACACAGAAATCCCCC  
CGCTCATTCGCGCAAAAGCGGGGAATCTAGAAATTTAAGCTTTCGGGTGATTATCG  
GAAATGACTCAACGGACTGGATTCCGCGCTCGCGGGGAATGACGAGTGAAGTTACCG  
AACTTTAAACAGCGAAACCGAACGGAATGACTAGTTCCGCTCGCGGGGAATGACAGT  
40 ATCCATTTCTAATTTTAACTCCGCTATATTTTACACAACTATTTGAACGATGACCG  
CTCGCGTAAGCTTTCTCAAGCTCGCGCTGCTTTGACGCTCCATCTTTCTCTTTCTC  
CTACCGAATTTACCAAGCAGCTTCAAGTCAAACTACCTTCAACGACGCGGGTGT  
CTTCTTCTGTTCCTATCTTTTCCAAATCGCTACCAACATCTGTTTTTACTGAGG  
AACTTGCAATAATGCAATCTTGGGTACATAAGCGGGAATTAACCTGATAAATGATATG  
45 CCCTCCTTATCAAGAAATAAGTAACATCATCAATCTACCGCTTAACTCACTCGCC  
GGCAAAACGGCAACCTTTCCAAAGAAACCGCATCGCTCAGCGGAATGATATAGCA  
CGCGTCCCCCAATGTTGCTCTCCAGCAAGGAATGACCGATTCTCATATCTCAGGAT  
TTATCCGCTGACATAACTTTCCGCAACATCGTTTCCAAACGACGATAAAGCGCAAA  
TCCTTATCAAAACGCTCTCCAAACCAAGTATCTTCGCAAGGAATTTTCTGCGTCTTG  
CCAAGCAGGACATCATCTCAAAATACGGCAACATAGGGCAGACCTTCATCCCAATGCGT  
50 TTCCACAAACGCGGTGGCTCATAAGCAGGCTTTTCCACTTCGCTCAACAGGTGCTGT  
TTTGCAATCCCGGCAACCAATTCGCGCATATCCGATTCAGTTCTTCAGACGGCATCAT  
GCGTCGAAAAACTGAAACGGGATCGCGCGCACGCCGAAGTTGCGGCAATGATGCGCCT  
CGTTCTCGCGCGGAAGCTAAGCTGATAACATGGTTTTGCAATAATTTATCCTGTTTTT  
55 CTGTTGATAAAGCGCGTTTTTCAACGGTTTTTTCAGCAATCGCGCAAAATGCGGAAGT  
ATTGCGCTCAAGGTAACAGCCGCCGATCCTGCGCTGCTGCAAAATACGATGCTCATCT  
CTCTCCTTTTATTTGAAAGGCACAATGAAGTGTTCGCGCTTTGCCGCGTTTTTCCCT  
TTCCTGCTGATTTTGGTCAAGCGCGGATCAGCGGTGTTTGAATGTGTGCGGGGA

ATCGCGCCTTTGCTGTTTGCGGTTCAGGAGGCGGTCGTGTCGATCAGGCTGCCAATGC  
 GCTGTTTTGGTTCGTGAAACTTGGCATAATGCAGCTCTTGGGCGCACAGGCGGGATGTAG  
 CTGGCAAAACCGGCATTCTTCCCTGTCGAAAAAATCGTGAACATCATCAGATCGACGGG  
 5 GTGACGCGCTTCGGGCGGCGAGGGCGCAAACCTGTCCAGGAAAAACCGCATCGCTTTTGG  
 GGAATGATATAGCCCGCGTCCCCAGTGTTCGCTTCCACAGCGGAAAGGCGGCGCC  
 CGAGTAATCCGCGCACGCGCGGAGGCGAGGTACAGGACGTGCATAAACATCGTTTCCAAAGC  
 GACGATAAAGCGGTATCCGGTCAAAGCGTCTTGCAGCCAAAGCGTCTTCGGCAAGGAA  
 TTTTCCGCGACCTTCGCGGAGTAAACGCTGCTCCATAACGGTGATATACGCGAGCC  
 10 TTGCTCAAATGCGCTGCTCCACAATACGGCGTGGCTCATAAAGCAGGCTTTTTCACATCC  
 GCTCAAATAGGGGTGCGCCGACAAAGCGGGGACGAGTCCGCCATTGCGCTTCCAGGCT  
 TTCAGACGGCATCAGTGCCTGAAAAACTGAAACGGGATGCGGTGCTGCCGAAGGTATC  
 GGCATGTGCGCCCTGCGTTCTGCGCGGAAAGTAAAGTGATAACGTGGTTTTTGCATAAT  
 TATCCTGTTTTTGTCTGTGGATAAAGCGGCTTTTCAACGGTTTTTCAGCAATCGG  
 TGCAAAATGCCGAAGTATTGCTCAAGGTAAACAGCGCGCATCCTCGCGTCTCGCGCA  
 15 AAATCCAGCCAGCGCGCGGCGGCGAGCGTTCGCTCGGTTGAAGCATTTGTACAAAAC  
 CGCGGGGCGGTTCAAATCTTCTTCGCGCAATGTTTCTCGACAATTACATCGCTACT  
 GCTTTTATTTGGCGGTATTCAAGGCTGCGAACCGGGTTTTAAACCCATGACATCGCAA  
 AATCGTTCTGGCGGTTTTTTGGATGCTTCGCGGATTCGTTGGCGGATGCTGAT  
 20 TTGGAAGAACCTGATTGGCGTGAAGCGGTATTTCGAACAGGCTTCGGGATATAAGCC  
 AGCCTGCCAATTTGCTGACATCCTACAAAATTTGTAATCTTCGCCAATCCCGCTCG  
 GTGTTGTAACGCAAAACCGCGTCAATGACGCTGCGCTCATATCATCTGTGTTGTTG  
 ATGGGTTGCCGAAGGAAAAAGTCGSCAATGCTTCGTGTGCGGTCGGTTTTTCCAA  
 ATTTTGGCGTGTTCGTGTCGCGCGCACGCGGTTGCGCTCTTTCTTCGCAAAACT  
 25 TCCAGCCAGCACCCCATCGCGATGATGCTGCGGTCTTTTCCATCTCACCCACGATTTTC  
 TCAATCCAGTCGGGGGCGGCAATATGCTGTGATCGGTGCGCGCAATATATCCGCCCC  
 CCCCCGACTTTGCCAATTCAATCAGCCGATGTTTAAAGAGGGAATCAGACGGGAATTG  
 CGCGCTGCGCGAGGATCGGATCGGCGCTCTGTTCTTGAAACGCTGGGCAATGGCA  
 AGCGTACCGTCCGTGAGCGCTCATCGCAATCAAATATCCAAGTTGGCGCAAGTTTGA  
 30 TTCAGCGCGCGCTAATGATTGGGCGAAATATTTTCTACGTTGTAGGCGCAATCAAT  
 ACGCTGACTAAAGGCTGCAATTTATCTCCGATAGGCAGATGCCGTCTGAAGGCTTCA  
 GACGGCATTTGAGCTGTACAACGGTTACTCGCCCAAAAGCGCATATCGCTACCGCGTT  
 CATTTGTTCTGCCAAGCGGTTACGAGGTTACGGCGTTTTGTTTCACGGCGGATCTTC  
 CGCCATCACCATCAGCGCGTGAAGAAAGGATCGACTTGGGTTTGAAGCAAGCGAGTT  
 35 GGCAAGGCGGCTTGGAATTTGCTTCGGCAACGGCGCGGCAATTTGCGCTGCAAGCC  
 TTGTGCGCGGCAAGAGGGCTTTTCTCGTCTGTGACAGCAAGCTTTCGTTAAGCGC  
 GCCCAACTCGGCATCGGCTTTTTCAGCAGGTTTTGACGCGTTTTGTTGGCAGCGCGAG  
 CGCGCGGCTTCGGGCAAGTTTGTGAACGCGCGGACAGCCTGCAAGTTTGGCGGTCAAATC  
 40 GTCCAAACGGCGCGCTGCTTGGCAAGTACGGCGCAACGATGTCTTGGGATAAATCGTT  
 TTGCAGCAATACGGCAAGGCGCGCTGCATGAAGTCGGCGTTTCAGACGGCGTTTTTTC  
 GTTAGCAAACTTGGCGGAAGCTGTTGAAGCGCGTCTGAATCAGTTTCGTTACGTCCAA  
 ACGCTATGCTCAGCATACGCAAAATACCAATGCGGCGGCGCGAGCGGTATGGGTCT  
 TTTGTGCGCGGTCCGAATCAGCGCGATACCCAAATGCCGACCAAGGTTTCCAGTTTTC  
 45 GGCAAGCGCAACGGCGCGGCAATTTGCCCTCAGGCAAGTTTGTGCGCGCAAAAGCGG  
 TTGTTAGTGTGCTCGACGGCTTCGGTAATTTCTCGGTTTCGCGCTGCAAGCGGGGTA  
 GTATTTGCCCATCGTGCTTCAGTTTCGGGAACTCGCGCACTTCGGTTACTAAGTC  
 GGGTTTTGCCAAACGCGCGCGGCTTCGGTTCGCGCGGATCCGCGCCCAAGCTTTGGC  
 CATATGGGCGGCGATGCTTTGCAGGCGTTCGATGCGTTTCGGTTGCAACCGATTTGTT  
 50 GTGATAAACCGTTCGTGAGTTTGGCGAGCGGCTTCCAAAGTCGCTTTTGGTCTTG  
 TTTGTAGAACACTCGGCATCAGCAGGCGCGCGCGCAAGACAGCTTCAATGCTTCGAT  
 GATGTTGACGGATCTTCGGTTTCAGATTGGACACGAGCAGGAGCGGTTTCATCGACT  
 CGCGTTTTTGGTGCAGCAGCGGGAAGTATTTTGGTTTGTGTCATCGTCAGATCAGGCA  
 55 TTTTGGGTAACGCGGAGGAGTGTCTTCAAACCGGCTTCAATACCAAGCGCATTC  
 GACCAAGCGCGTTACTTCGTTCAACAAGGCTTCATCGCGCGCGCGGCTCGCTTCAGACG  
 CGGTGCTGCCCTTCCAATACGCTGTAATCGCGGCTTTGCGCTCGGCAAAAGCAAGCAG  
 GACTTTGCTTGTCTCGCGATTTGTGCGCGTAGCTGTGCGGTTTTCAATGGTAATTTCT  
 GCGGTGGAGAGGAAGCGGTGTTCCAAAGTTTTTGGCGCTTTCGACCCCAAACTCGC  
 GACGTTCAATGTCGCGCGCTGCACTACAACTAGCCGTGAACGGGCGCACAAAGGT

AAACGTGCTGCTGCCCAACGCATTACTTTGGGAATCGGCAGCTTCTTAAACCGCTTGATT  
 GATAATGTCTTCCAAAAGTCCGCCCAACGGTTTGGCGATTGGACGTATTCTGATGGCGTA  
 CACGTCCTGTCTGCCGTGCTGGACGATGGTCAAAGTCTTCGATTTTCGCGCCCGCAACCGG  
 TCGGAAACCTTCCAAAGCCTTGGTTGGCGCACCGCTTTCATGGCATTCGCTACGGCAGG  
 5 CCTTTTTCACAAATTTTTTGATCAGCCTGAACGGCTTTGACGTTTTTGACTGAACCGG  
 CAAACGGCGCGCGAGGCATAAAGCGTAAATTCGGCTGCGCCGTCAACAGTTTGCCTTT  
 TTCAAAGCCTTCGGCAACGGAAGCGCGCAATGGTTGCCAGATTATTACGGGCTTTGGG  
 CGGGAGTCTTCGGTAAGGAGTTTCGATTAAAGGGTTTGGGTCAATCATTCGCTCTCTTT  
 GAATTTGGTTAACTCTGCTGTTTATAGGTTTCGCTGTAATTTCCAGCCGTCATCCCCA  
 10 TAAAAACCGTCAACAGCGGGGTGGCGTACAAAGTGGCAACATCTTCGCGGTCTGCCAGC  
 CAAGAGATAATGGCTTTTTCTCGGTTTCTCCCAAGCTTCGGGCACCGGATTTTGAAC  
 AGGCACGAAAAATCGCCCAATCGCCCCCGGCCATTTCAAAGCCGTTTGCOCGCAAGATA  
 CGCAATCAGCTCGTCCATAAGCGGTTCGAACGCTTCGGCATCGTCTCAGCTTGGTGCAA  
 15 ACTGCTTGAACGCCGAAAAATCAATGTTTGAACCTGCCCAATGACAGCTTTTATGCTG  
 CGCGCGGTCATTTTTGTGACAGCGTTTCTCGCTTGGGGTGGGAAATAGACAGGCATGAT  
 TTTCTCAAAAAATATAATGGCTTCGGGACGGCTGCCTTATCGTGCGGCCCGAAGCTAAAA  
 AATCGTGCCCGCTTAGCGCGGCTTTCGCTTCATTAAAGGGAAGCCAGTTTTCGCGGG  
 TTTCAACATATTTTTTGGCCACGGCGCGGCTCAATGCAAGATACGTTCCAATATAAGATTG  
 CCGGCTCAGTTACGGAATCGCGCGCGTGGCTTAAAGGTTGAACGTATGCCCGCGTT  
 20 TGAGCAACAGCTCGTAGGCAGGCAGGCGAGGCGCGGCTTTCTTCGCGAAGCAGGCGCT  
 TGCGTTGCGCTTCGTAGTCTTGAACCTGGCGCAGCAGCCAGTCGGCATCGCTGTATTGCA  
 AGTTGTAGGTCGATTGCTCGACTTCGTTTTTGGTGGTACAGTCGCCGTAGGTGACGGGT  
 TCGCGTCGAGCGTTTTTGGCCAAACAGAGGTCGTAGACGTTTTTCTACACTTGCACGTACA  
 25 TCGCCAGCGTTGCGATGCCGTAGGTGATTTTCGCGGATACGGGCGTGACGTGATGCCGCG  
 CGACTTTGTGAAATAGGTAACCTGGGTACTTCCATGCGGTTGAGCCAGACTTCCGAGC  
 CCAAAACCCACGCGCGAGGGTGGGTTTTTCCAGTCGCTCTTCGACAAGCGGATGTGCT  
 GGACTTTGGGATCGATGCCAATTTCGCGCAGAGATCGAGATAGAGTCTTGACATATGCT  
 CGGGAGCGGGCTTAGGGCGGACTTGAATTTGTAATAGTTTGCAGCGGTTGGGCTTGT  
 CGCGTAGCGGCGCTTTTGGGGCGCGGCTGGTTGGACGTAGGCGGAACCAACAGCT  
 30 CGGGCGGATGCGCGCAGGCGAGGTGGCGGATGGATGTGCGGCAACCGACTTCCATGT  
 CGAAGGTTGGATGACGGTGCAGCTTGTCTGCCAAGATGTTGCACTTTGAAGATGA  
 TTTGTTGGAAGTAAGCATGGCTTATGATTGATAAAAAAAGGGTTTTATTTACTGTTT  
 CCATTGCTGTTTGGATAGGTTTATCTCAAAGACAGACTGATTTGAAACACCGGCATACAT  
 GATATAGTGGATTAATTTAAACAGTACAGCGTTGCCTCGCCTTAGCTCAAAGAGAACG  
 35 ATTTCTTAAGGTGCTCAAGCACCAAGTGAATCGGTTCCGTACTATTGTTACTGTCTGGGG  
 CTTCTGTCGCTTGTCTGATTTTTGTTAATCGCTATATGTTTCGGTTAGGCGGAGGCT  
 GCGCTTATTAATACCTTAAAGCAGGCTATGCTGCCAACCGCATATCCAAACACAGTCTT  
 TAAATTTAAATCCGGAATAAAGAGCACGACCAACGCGTCGTGCTTTTCCAAAGCAACA  
 AGTTTATTCTTTGTGCGAAGCGGATATAGTCCAAAGTTTGAAGCTTGCAATTCGACGACG  
 40 CAATACTTTTATCGGCTTCGCGCAAGGCTTATCGTCTTTAGCTTTGGGAATGCCCGCTT  
 TGGCGGTTTTTTCGCTCTTCGCGACGTCGCCGATCCATCTCCGCACTCGGACGCGCAAC  
 ATCCGCAAGACAGTTACTTTATCAGGCTGTACTTCCAAACACCGCGGAAACGCAAC  
 CAAAACCTCTTTATCTCTCCCGGAACGCGTCAAACGAAAGCCCGCGCGCAACACT  
 CATATCGGCTCGTGTGCGGATATAATACCGAGTTCCGCCGTGACAGTCGGAACACAGAT  
 45 AATGTTGCTCGCTCGCTGAATAGATTTTCTGCTGCTACTTACCACTCAACTGCGATGAT  
 GCTCATGCCGACCTCCTTAGTTTAAAGGTTTTCGCTTCTCTACTGCTTCTCAATGCTGC  
 CGACCATATAGAATGCTGCTCGGCGAGATGATCGTATTCGCGCTTCAAGATGGCTTTGA  
 AGCGCGCAATGTTATCGCGCAGGGCGACATATTTACCGGAGAACCTGTAAACACTTCGG  
 CAACGTGGAACGGTTGGGACGGAAGCGTTGGATTTTACGCGCACGCATTACCGTCAGTT  
 50 TGCTCTCATCAGCAATTCGTCCATACCCAAAGTGGCGATGATGTCGCGCAATTCCTTTG  
 ATTTTTCGAGGTTGACTGCACACCGCGCGCCACGTCGTAGTGCTCTTGACCCAACTACA  
 TCGGATCAGTTTGGCGCAAGTAGAATCAAGCGATCGACTCGCGGGTAAATACCCAAG  
 AGGCAATATCGCGCTCAATACGACGGTTGGTCCAAGTGGCGAAGCTTGTGGCGGAG  
 55 ACGGGTCGCTCAAGTCTCGCGCAGGTACATACCGGCTTGGATGGAAAGTAATAGAACGG  
 TTTGGGTAGAGTAATACGCTCCTGCAACGACCATTTCTTCTGCCAATGTCGGTGGT  
 AGCCCATCGACGCGCATACGACCCAACTCGGATACCTTCGTCACGAGGCGGT  
 AACGCTAGATGTTTCCACGAAGAACATACGTCGCGGCTTTGCGCTTTTCTCTTTTT

CGTCACGGAAGTATTCGCGCATGGTCAAAACCGGTCAATGCGACGCGCAAAACGGTTGCCCCG  
 GAGGTTCTTTATCTGACCGCTAAACCAATTGCCACTTTATCCAATACGTTGGAAATCTTTCA  
 TCTCGTGGTAGAAGTCGTACCTTCGCGGGTAGCGTCACCCACGCGCTGCGAAGACGGACA  
 AGCCCGCTGTGCGCTTTGGCGATGTTGTTGATCAATTCATCATGTTACGCGTTTATACCCA  
 5 CACCGGCACCGCGCAACAGACCTACTTTACCGCCTTTGGCAACCGGACACAGCAAGTCAAT  
 TCACTTTAATGCCGTTTTCGAGCAATTCGGTTTGGGAAGACAGTTTCGTCAAACATTAGGGG  
 CAGCTTTGGTGGATGGCAGCGCTCTTTGTCGGTATCGATCGGACCTGCTTCGTCAACAGGGG  
 TTTCCCAATACATCGACAATGCGTCCCAACCTACCTTTTACCTACCGGCACAGTAATAGGGG  
 CACCGGATTTGCTCAGAGTCAATGCGCGGTTTCAAAACGCTCCGAGCTGCCCATGCAATGG  
 10 CACGGAATACGCGCTGCGCCAAAAGCTGTTGGACTTCCAAAGTCAGACCGTTCCTCGTCTA  
 ATTTCAAGCGCTGTAAGCGCGCGGAATCATGTGCGGTGGAAATTCACCGTCAACAAACCG  
 CACCGATAATTTGTACGATTTTGCTTTGGCTCATTATCGTATCCTAATTTCCGTACAGGA  
 TTCAGACGGCATCAGACAGCGCGCGACCTGCTCAAAATTTCTGACAATTCGGTGGTAATC  
 15 GCAGCTTGACGCGATTTGTTATATACCAAACGCAACTCTTTGATGGCATTGCCGTGCATTG  
 TCTGTTGACGCTTTTATGGCAACCATGCGGGCTGCCCTGTTGCGGATGCCATATTTCGCTC  
 AACGCTGATAAACACAGACTCTAATAAGCGGCAACAGATATTCACAACATGCAAGT  
 CGAGTCGGTTTCGTAGCGGATTTCCAGCTGAACGGTGATTGGGAGCTGAATGCCCAATTC  
 ACGTTCTCACCAGTAGGACAGCAATACTTCCATTTCTCGGTTCTTGACGATGGTATTGACA  
 20 AAACCGGAATACACAGATGGATTCTGTCAATTTTCATGTTTCTCATACCGTTGGAAGAT  
 TCTGTCAAAAGGTCGAGCAGCATTTCATTTTGGGGTATCGCCAAATTTACGGCACTG  
 GCAACCAATTCAGACCAATGCTCTGACACGCCATCAGACCTTTACTGCCAAAGCATACG  
 ATTTCTCTTCAATACCTTGATTCGGAATCTTGAACCTTGTCGCAAAACCTTTTTCAGC  
 ACGTTGGCGGTTCAAAACGCCACACAACCTTTATCAGACGTAATCAAAATAAACACCGGCA  
 25 CGTCTGATTTCCCGATGAGATTCCAGTAACGGAATACCATGATCGGTATTTGGTTTCGCGA  
 AGATGGCTCATCACCATACGCACCTTTTTCGGCATACGGACGCGCAACGCGATCCGTTCC  
 TGAGTCTTCGCGATTCTAGAGGTTGACACCATCTGCAATCGCTTTAGTGATCTTTTGGGTA  
 TTTCTGAACACTGCGGATTTTGGTGAGAACTCTTTTCTTACTGCAATTTTCAAGCTCCTTT  
 CACTTCAAGCCTTATGCTGATGAGCGTAAGAAGATTGGAAGGATTTCTAGGCTGCTTCA  
 AGCGTTTCTTCGCTCTGCTGGGACATTGCACTGAAGCATTGACGGCTTCCAAACCTTCC  
 30 GGATGTTGGGTACGGACAAGCTCAAAAATTCAGATTCAAAAGCCAGAGCTTTGGCAACG  
 GGAACATCAGAATACGAACCGTTGTTGATTGCCAAAGGTCAAAGCCATTTTCAGCGGTA  
 TTCAACGTAAGTCACTGTTCTGTTTCACTCAGTTCCGTTTACGACTTCGCGATGCTCAAT  
 TGTTTGCGCTAGCTTCATCAAAATCGGATGCAAAATTCGAGAAACGCCGCAATTCACGA  
 35 TATTGTGCCAACGCCAAACGGATACCGCCACCCAGCTTTTAAATCACTTTGGTTTGTGCA  
 GCACCGCTACCGCGGATACGGAAATACCGGCATTGATTGCAAGGACGGATACCGCGGTTG  
 AAGAGGTCGCTTTCCAAGAAAATCTGACCGTCGGTAAATCGAAATGACGTTAGTTCGAAGC  
 AAAGCAGATACGTGCCCGCTTTGGGTTTCGATAATCGGCAACGCGGTCAGAGAACCGGTT  
 TTGCTTTTACTTCGCGCTTGGTCAATTTCTCCACTTCGTGTTTATTGACAGCTGCGCGCA  
 40 CGTTCCAAACAGCGGGAGTCAGGTAGAACACATCGCGCGGATAGGCTTCGCGCGCGGGC  
 GGACGCGCGCAAAAGCAGGGAATTTGACGGTAAGCCACAGCTGTTTGGACAATCGTCA  
 TAAACAAATCAAGGCATCTTCGCCAGATCGCGGAAGAAATCACCCTATCGTCAACACGGAG  
 TAAGTTCGATATATTGCAATGCCCGCTTCAGATGCAAGTTGACGAACACGATGTTA  
 TGCTCCATCGCGCATGCTCTTCCAATTTGCGGAACACGTTGGCAATAGAAGATGCTTTT  
 TGACCAGTAGCGCATAGATACAGATAAACCCCGTACCTTTTGGTTGACAGATGGATCCG  
 45 AATGCTACGGCGGTTTACCTGTCTGACGGTCAAGATAAATCAACTACGCTGACGCTGACGCGCA  
 CCGACGGAACCATAGAGTCAATCGCTTCAGACCGGTTTGCATCGGCTGGTCAACCGAT  
 TTGCGCGCAATCAGCGCGGTCGATTTTTCGATAGGGGCGGTCAAAGTTGTATTAAATC  
 GGGCTTTGCCGTCGATAGGCGGACCAATGCAATCAACGACGCGTCCGACCAAGTTCGCGT  
 CCGACCGGCTCTTCAAGATACGACGGTACAGGTAACCGTGTGCGCTTCTTAAATGTGT  
 50 TCGTACTCGCCCAACTACGGCGCGCAGGAGTTCGCGCTCCAGGTTTCATGCGCAACGCGC  
 AAAGTGTATACCGGGAATTCGAGCATCTCACTTGCATTGCATTCGACAACCATGGATG  
 CGAACGATACCGTCAGTTACCGAAATACCGTACCACAGGTACGCACTTCGGCATTTACA  
 GACAGATTTTCGATCTTGGCTTTAATCAAAATCGCTAATTTGACGAGGATTAAGTCGATG  
 AAAACTCTCTAATTCGTATAGTCGTGTACAGGAACCTCAATTTGCTGTGACAGACAA  
 55 ATCCAAACCTGATCAACCACTTCACTTTTATGCCGCAACTCAGCTCCGTTTCGATTTT  
 GACAGAGATTTTCAGTTCGCTGTGAAACGCTTATTCAGCATTTGCACCACTGCGCCGAC  
 CTGTTTGTGCGGTCAACGGATAGGCATGTAATACGCGCAGATTGATATGGTTGAATGA

TAAGGTCAGTCTTGATATTGAGCATATACCTCCGGCAATATCGACAAACGTTTCTGCC  
GGCCACAGCATAACAAAGTTTTCAACTCCTTGCTCTTCAAACCGACCAATCTGATGAG  
GATATCTGCTTTTCTGAAGCATTGTTTCAAGACGGTCAATCAATGAAGCCAACTCTCC  
5 TTTCTGAACCAACCGCCGCAAGTTTTCAGATCCGCCCAACCAAGACTCAATTTGGT  
TTCTCGAGCAGACCGGAACATGCCTTTGCAATAGGCTCGGCAATCGTTGCGAATCTGC  
CATAGAATTACAGCTCCTGTTTCAGGGTATCGAGCAGTTTTCGCTGTTTGGAAAGCATCGA  
CTTCGCTGCGCAAAATAGATTGCGCACCTTTGACAGCCAAACCGGCAACCTGCTCGCGCA  
GGGATTTCGCTGCGCGGAACAATTCCTGCTCCACATCGGCTTTGCCTGAGCTGCATGCG  
CGCGCGCTCGGAAGAAGCCTGTTCTTGGCTTCTTCGACAAATTTGGCGGCACGTTTTT  
10 CGCGCTGGCAACCATTTTCGGAACCTGATTACGCCCTTCTGCCAAGAGTCTGCAACCT  
TTTTTTCAGCTGCTCAAAATCGCTTTTACACGCTCGGCGGCACCAAGCTCTGGCGA  
CTTTTTCGGCAGCTCATCCAAAGCTTTTGCATCGGCGGCACACGAATTCATGGTAA  
ACCATACCAAAACGAAAGACGATGATTGAGCGAATAATGTGCATTGATATTACAGT  
TACTTAACTTCGTACTGGGTTAATCAACAGGCTGCGCTGTACGGAACGGACGAATC  
15 CGTCCTGATTATGCACCTGCAACGGGTAAACGAAGGCGAAGCAGTGCATTTGGCGACA  
CCAATCAAGAAATCGGCATCAATCAACCGGCAATCAGGAACAGTTTGGTTTCAGCGGA  
CCGATCAGTTTCGGGCTGACGGGCGAAGACTCCAAATATTAGAACCGCACATTTGGGATA  
CGATAGAGGCCCCCAATGCACCAATGCAACGATCAAAACCATGCGATAGCAATCAAA  
CCCATTTTAACTCCTTAAAGAAACAAAGTTAACTACAAAAAATACTACTTAGGAAA  
20 ATCAGTGGGCATCATGTGCTGTGCGATATAGACGAACCGCAACGCATGAAATAAAGC  
CTCGAGGTTAATCAACAAATATGAAAAATCGCCATGCCAAACCGGCAATTTGCTGGGA  
ATACAAACGAAATCGGATCCATGACTTCGACGCTGCCGAAGCGCCCAAGCACCGCCAA  
GCAAGGCTATCAACAGAATACCAATTCGCCCGCATACATATTGCCGAACCGCATAC  
CGTGGGATCAGGTTTATAGAAAGAACTCGACCAATTCACAGAAAGTTTCGAGGTGCGA  
25 TTTGTGACCGAAGCGCGCTGACCACTGTAACCGAGCCAGCCCAATCCTTTGATT  
TGATGTTGATATAGATCAAAATCAGCAACCGCCGACAGCGAGTGCCAAAGTGTGTTC  
AATCGGCACTCGGTACGACGCGCAGCAGGGGTTGATGTTGCGGTAATGCCCTGCCATA  
CCATCGCGCAGCAATCGACCGGCAGCATATCCATCGGTTTCATCAGAAAAATCAGACAA  
ACAGGCTCAGACCCAAACCGCGCGACGCGCTTTCTAGACTTTTCGTTGTAATGATGCTCT  
30 TACACATATCTGCCACAACTCAACAAAGATTTCCACTGCGGCTGGAAACGTCGCGGAA  
CGCCTGCGCTCGCTTTTTTTCACCGCGCCACACAGAAAGCTGCCGATTAGCGCCAA  
GGACGGCAAAAAAGACGGCATCAAGTTAATAAAGCAAAAAATCAGCAATGTTTTCAGTC  
CCTGACCTGAGTAACATCCGACAACTGGTCAAGCTCTGCAAGTGGTGCTTGATGTAGT  
CGGCAAGCGTAAATGGTTTCACTGCGCATATCTTCACTCTCAACATATCAAAAAAAC  
35 AAATGGCTGACACCGAGCAGCCCCATCAGAAACGGGGGCAACACGAGGATTGATGCCAT  
ATTGCAAAATACGGCAAGCATGGACACAGCGACAGCACTACTTTTAAATCTCTCCGAAG  
ACGAACATCTGCTTTTCAGGAAGGGGTTTCCCTGAAAGATTTTAAAGTAAATCTGCA  
ACAAACGTTGGGAAGCAGTAGGACAAACCGCCACCGACCGCGGAAGGAATCCGGCAAA  
CCCATACAGCAAGGCAACTGCGCGCATATGGACAATACGGCGAATGTAGATGATTAG  
40 ATCTGCTTCATAAAGGAATGTTTCGCGCTCGGATTTGGGCGCGGCTAATAATATTGA  
AAGCCTTATTACGTCAAGCGACAGTTAATCTTTGTGAACCAACGATCCCATATCGCGC  
GCTCGCGGCTGAATAACGGGCGACAGGTGTCATTCTAACACACATACATATTAATTACAG  
GATATTACGGAGTTTGTCCGCAATTTCTTACATTTTAAATGTTCTTACGTGATTGTTT  
GCTTTACGTGGAATAATAAAAAATCAACCGGAATTTGATGAGTATTTCGCTCGGATTG  
45 TCGGAGCTTTGGGGAATTTGCTCAATAAATAAAGAGTTCGTCTGAAATATTTTACAGACG  
CCTTTTCCGAATAAAGGATTAGCAACTGCCTGCCGCTTTAAGCAAGCATTTGCAATGACT  
TTTGCTCTTTGTGCTTCCGCTCCCAACAAATTTGCATCGGAAGTGGTAACGCGGATT  
GCTGATTACACTGGTAACATAGCATTGGCTACGCGCTTACCACAGTTGCGGTAAAGTT  
GATGGGATGCTCTCAATTGTTGGGTTGCTGATTTTACGGCAITTTGGGCTGACGCCAA  
50 GGCACACCGGCGCAGTCTCCTGAAGTTTCTAGTGGAAACGGTTACATTAATGATTGAGCC  
GCAACCTGCTAATGCCAACGCAACGACGAGCGGAAACGATGATGCGTGTGTTCAATAT  
TTCTCTGAAAAATAAAAATGAAACAGGAAAAACGATTTTACGTGAAGCAGAAAAATGT  
CAATAGAAATATATTTCCCACTTAAATCTGGAAAGCATTTCTCTATATTTACAGCGGTA  
TATCCCCCAAAATTAAGGCGGTAATCTATGCCCAAGCTGCTCCAGCAGGTGGCGCAAGCT  
55 TPCAGGCGTATCGAAATACAGGACAACTCTGCTTTTTTGTGGTTGGCGGTTTTGACTTC  
AGCGTTGACACCCAGTTTTTCAGTCAGCAAACTATTACGGCGCGCATGTCGCGCGCGG  
AGTCTTTTGGGCTCGGACGTTTGTGTTTGAAGGGCGGCTGGCTGCGGCGTTCGACTTC

GCGCACCAGCAGCCGTTTTTGTACGGCTTTTGCGCCAATTGAGCTGTTGACGAGTTT  
TCGGAGAGGACCATGCGCGGCGTGCCCAATTC

- 5 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 5>:

**gnm\_5**

CAGACATTACCGTGTACAACGGCCAACAAACGAAGCAGCACAGCGTTGCGAGTGC  
TTTACCCGGGCTACCGGCATCAAGTCACTCAACAGCGCCACACGGCAGCAGCTTGGC  
GGTCAAAATCAAAGAAGAAGCAGCGAAGCCCGCCGACGTATTCTATTCCGAACAAATC  
10 CCGGCACCTCGCCACCCTTTCCGCCGCCAACCTCCTAGAGCCCTGCCCGCTCCACCATC  
AAGCAAAACAGCGCGCAGGGCGGTGCGGGTTGCCGCCAAAAAGACTGGGTGGCAGTGC  
GGACGTTGCGCGCTCGTCGTTTACGACACCGCAAACTGTCTGAAAAAGATTGGAAAAA  
TCCGTCCTGAATTACGCCACGCCGAATGGAAAAACCGCATCGGTACGCCCCCACTTCC  
GGCGCGTTCTTGGAACAGGTTGTGCGCATCGTCAAACTGAAAGCGGAAGCGCGCGCATTTG  
15 AAATGGCTCAAAAGGTCTGAAAGAATACGGCAAGCCTTACGCTAAAAACTCCGTGCGCCCT  
CAAGCGGTTGAAAAAGCGCAAAATCGATGCGCCCTCATCAACAACACTACTACTGGCAGCT  
TTTGGCGGTGAAAAAGCGCTACAAAATGTCCACACCGCGCTGAATTCGTCCGCCACAGA  
GATCCCGCGCACTCGTTACCTATTCCGGCGCAGCGGTGTTAAAACTCCCAACAAACAG  
GATGAGGCGAAAAAATTCGTGCGCTTCTCGCCAGCAGGAAGGACAGCGCGCCTTACC  
20 GCCCTCGGTGCCGAATATCCTTTGAATCCGACGTGGTATCCACTTTCAATTTGGAACCC  
ATCGCCAAAGTTGGAAGCACCCCAAGTGC CGCCACCACTGTTCCGAAAAAACAACCGCC  
ACCGGGCTGCTTGAGCAGCGGATGAATAAGCGGTTTTCGGATTGTCAAAACGGGTGG  
CAATTTATACGTGCGCCGTTTTGCGGATAAAAAACACTATGTCCTCAAAAAAATACCC  
CATTTGGCTTACCGGCTCATCTACTGATTGCCCTACCGCTTACCCTGCCTTTTTTATA  
25 TGTCTGATTCGGTTTCGTGGCAGGTGCGCATCAACCGCGCGTGAACATGTTGTTCCGCGC  
CGGTATGTGGGATTTGCTCTCCACACCTTGACGATGATGGCGGCGGTTACCCTGATTTTC  
CATTTGTTTTGGGCATTGCTGCGCCCTTTTGTTCACAGCTTACCGCTTCTTCGGCAAAAC  
CTTTTTTCAGACGGCAATCACCTGCCTTTGTGCATCCCGCATTTGTGAGTGTTCAC  
CTGGATCAGCCTGACCTTCCGTGTGCAAGGCTTTTGGGGACAGTGATGATTAAGAGCT  
30 GTCTCCTGTTCCCGCTCGCCTACCTGCCGTCGAGGGCGCACTCAAAACGATCAGCCTGTCT  
TTACGAAGAAGTCAGCCTGCTCTTGGCAAAAGCCGCTGCAACCTTTTTTTCGCCCAT  
CCTCCCGCATCAAAACCGCCATCGGCAGCAGCGTGTACTGATTGCCCTGCATATGCT  
GGTCGAATTTGGCGCGGTATCCATTTTGAATACCCCACTTTTACCACCGCCATTTTCCGA  
AGAATACGAAATGTCTACACAACAATACCGCGCGCTGCTTTCCGCTGTTTTTAAATGGC  
35 GGTGTGGCGCATCGTCTGATTTTGGAGAAGCATATTTCCGGGCAAGCGCAAGATTACCA  
CAGCGGCAAAAGCGTTGCCGCTCTATCCGTCAAAAACCTCAAACTGCCCGTCAGAT  
TGGCGGATTTGTTTTTAAAGCAGCTTGTGACTTTGGGCATTATATCCCCTTTGGCGT  
ATTGATACATTGGATGATGGTGGCAGCTTCCGGCATTCGCGCTCGTATCCGTTATTGA  
TGCTTTTATCCGTTCTTAAAGCATATCGGCTTTAGTGGGATTTTGAATATATTATGTGC  
40 CTTGCCCTTGTGTTGGGCATCGGTTGCTATCGCAATTTTAAACGTTTGGATAGACAG  
GCTGCGGTTTTTACTGCACGCGCTCCCGGTTTGGTTATCGCCCTATCCTTGGTTTATTT  
CAGCATCAACTACACCCCTGCGGTTTACCAAACTTTATCGTCGTCATCCTTGCCATTTT  
CATGCTTTTACCTGCGGATGGCGCAAAACCCCTGAGGACTTCCTTGGAAACACTCCCAAA  
AGGATGGAACAGGTGCGCGCAACATTTGGGCGCGGACACTTCTTATTTTCAGGACGTT  
45 GGTATCGCGCTCCATCTGCCCGCATTACCGCGCATTCGCATCGTCTTCTCTCAAACT  
GATGAAGAAGCTGACCGCCACCTGCTGCTGACCAACGACGATGCCACACACTCTCCAC  
CGCGGTTTGGGAATACACATCGGACGCAATACCGCGCGCACCCCTTACCGGCTGAT  
GCTGGATTTATTTTCCGGCATCCCGGTATTCCTGCTGAAGAAATACGCTTCAAAATACA  
GCTTTGAGGAAGTACCGCATGACCGCGCCCTGCACATCGGACACTGTCCAAAAGTTTT  
50 CAAACACCCAGTTTTAAACGACATTGCTCAGCCTCGACCGGGCGAATCCTCTTT  
ATCGTCGGCGCGCTCGGCTCGGCAAAACCACTTTTACGCTGCTTCCGGTTTGA  
CAACCCGATTTTGGCGAAATTCGCTTCCGGCAGAACCATCTTCTCGAAAAATACCAAC  
CTCCCGTCCGGAAACCGCGTTTGGTTATGCTGACAGGAAGGTGCTGTTCCCCAC

CTGACCGTTTACCGCAACACCGCCTACGGGCTGGGCAACGGCAAGGCAAGACGGCGCAA  
 GAGCGGCAGCGCATCGAAGCTATGTTGGAATTGACCGGCATTTCGGAACCTTGGCGGACGC  
 TATCCGCAAGAACTTTGGGCGGACAGCAACAGCGCTCGCCCTCGCGCGCGCCTTCGCA  
 CCGCATCCCGAACTGATTTGTTGAGCAACACCTTCAGCGCGCTGGACGGAACAGTTGGCG  
 5 CGCCAGATTTCGCGAAGACATGATTGCCGCCCTGGCGGCCAACGGCAAACTCTGCCGTTTTG  
 GTACGCCACGACCGCGAAGAACCCCTGCAATACGCCGACCGGATTGCGGTGATGAACAGT  
 GGGCGCATCTCTCAAACCTGCAAGCCCTACAGAAATTGTACCGACAACCTGCCGACCTTTAAT  
 GCCGCCCTGTTTATCGCGGAAGGCATGCTGTCCCGCGCGCGCTCAACGCCGACGGCCACC  
 GCGGATTTCGGGATTGGCGCGCTGCCGCTTCAAAGCGGCGACCCGAGGCACACGCGCG  
 10 ACACCTGCTCATCGCTCCGGAACAGTTGAGCCTTCACCCCCATTCCGACCCACCGCCTCC  
 ATTACGCGCGTGGTTCTCAAACACGCCCCAAAGCGCGGCATACCGAAATCAGCCTCGGG  
 GTCCGACAAACCGTCTCAAGCTCAACCTCCCTTCGCGCCCCACCTGTACAGACGGCATT  
 TCGCGCTCTCTCAATTGGACGGTCCGCGCCTGTTCTTCCCGGAAATACCTCTGAAAG  
 GCGGCAGCATCCACAAGCCTGCGGATATTATCTTTGGAACAGAAATTTGTTTGTCTAT  
 15 ATTCACCTGCGCGCCTCAAGCCAAACAGCGCACGCGACGCGACGAGGAGCGGTTTTCTG  
 CCTATATGCGCGCCCTTCCAACACATATGCCGCACACCGCAGCATACGAAAGGATATAT  
 CATGGCAAAAGTACTCATGCTACCGTATCTGCCGGAATGGACGCTTCGCGCGCCGACACA  
 AGCCTTTGCAAAAGCACTGGACGCACAAATTTTCAAGCCGTTGACGCAACCTGCCCGGAAAC  
 CCTGCTCGCGCAAGGCAAAAGCAGCAGTGGTTCGACGCACTGGTCGGCAAAAGTTGCCCG  
 20 ACTCGATGCGCGCAACCTCTCATCGAAGGCATCGCGCCGATGCCGACAAATCTACCT  
 CGCGAGCAAAACGTCGAACCTGGCATTGTCCTTGACGGCGGACCGCTTTCGCGCTCGG  
 TTCCGACAAACCGCGATGCCGACGAACCTGCAAAATCGGCTGAACCTTGCCAAACAGTTTCT  
 CGCGCGCGCGCGGGCGTATTGGAAGTTTGTGCTGGACGGCGCGGAGCCTTCGTTGC  
 CGAAGCGGCGACCGCAAAACACCGCCTGACCTTCTTCGTTTCGACGCGACGCGCTGAAAGA  
 25 CGTATTCGCTATTGSCAGGCGCGAAGCAAAACGCTGTGCCGCGCGCAATTCGCGTACAAA  
 CCTGATCGACTTCGCGCGCAAGCGCGCAAAACGCAATGCTGCTGCTGAGGCGCGCAAGCC  
 CGCGAGCTCCAAGCGCGCGCATCTGCCACGAAAGCATTGCCGCTCGCTGCTGCTGCTGCT  
 TGCCAAACGCGAAGAGTGAAGCGCTTGCCAAAGAACGCGGCATCAGCTGTCGCCGACTC  
 TTTGGAATATCATGATCCGCGCTCATTGGTCGAACAAATACGTCGAGCGGATGTGCGGAAT  
 30 GCGCAAAATCCAAAGGCTGACACCGAAGACGCGCGCAAGCACTGCAAGACACCGTGGT  
 ACTCGGTACGATGATGGCGCAAAATGATGTGGACGGTTTGGTATCCGTTGCGGTTCA  
 CACACCGCCAAACACCATCCGCGCCGCTTTGCAACTGATTAACACGCAACCGGCGCAG  
 CCTCGTGTCACGCGTATTTTATGTGCTGCCAACCAAGTCTCGTCTTCGCGGACTG  
 CGCGGTTAATCCGAACCCGACCGCGCAACAGCTTGCGCACATCGCATCCAGTCTCCGCA  
 35 TTCGCAAAAGCCTTCGCGCATCGACCGCAAGTGGCGATGATTTCTACTCCACCGTCAA  
 CTCGCGAGCGCGCCGATGTCGATACCGTCAAGCAACCAACAACTTCCCGCGGCTTCA  
 ACGCCCGACCTCGCCATCGACGGCCCGTGCATATGATCGCGCAACCGTGCCTGGGTGT  
 TGGCAAACTCAAAGCTCCGCGCAACCGCGTGGCAGGCAAGCAACCGTTTGGCATTTCCC  
 CGAAGCTGAACACCGCAACTGCACCTATAAAGCGCTCAACGCAACCGCAACGCTCTTAAG  
 40 CAGTGGCGCGCTGCTGCAAGCGCTGGCTAAACCGGTCAACGACCTCTCCGCGGCGGACT  
 GGTAGAAGATATCGTGTATACCATCGCCCTGACTGCCGTTTCAGGCAAAACAAATGGAAG  
 CTGCAAAACGGCTTTCGGGGTTTAAACCCATGCGCGTCTGAAGACAGACTCCGTTTCTCA  
 GACGCGATTTTTATCAGCAGCGCACATTTGTTGTAAAAATCGAGGCATATTGCAAAAA  
 AAGAGGAGGAAGCATGCAAAACGCCATTATCGATTACGGTATGGGCAACCGCATTCGG  
 45 TATTGAAATCCGTCCGACGCGCGGCGACGTTGCCGGAATAATACCGAAATCTTTTAA  
 GCGCGCACCCGACCGCGTGTCCGCGCGCAAAAGTCATTTTCCGGTTCAGGCGCGCA  
 TGCCGACTGTATGGCGGCATTAAACGAGACGCTTTGGACGAGGCAGTCAAGATGCGT  
 TAAAAACAAACCGTTTTCGGAATCTGCGTCCGCGCGCAACTTTTATTCGACCAAGT  
 AAGAAGGAACACCGACCGCTTGGGCTGGTTCGCGCGCAAAAGTCAGACGCTTGAAGCGG  
 50 ACCTCCGCGACCCGAGGGATGCCGCTGAAAGTCCCGCATATGGGCTGGAACACCGTGT  
 GCCAAACCAAAACACCGCTGTTTAAAGATATTTCCCAAGACACGCTTTTACTTCG  
 TCCACAGCTACTATTTCGCCCGCGAAATCCGAAACCATATTGGGCGAAAGCGACTACC  
 CGTCCCGCTTGGCTGCATGCTCGGCAAGACACAGTATTCGCGACGAAATTCACAGCG  
 AAAAAAGCGACGATGCCGGGCTGACGATGTTGAAAAACTTTTAAACTGTGAAGCGGAC  
 55 ACGCGCCCGCACAGGAGAAAAATATGCTGCTGATACCGGCATCGATTGGAAGAAGAG  
 ACGCTGCTCGCGCTGAAACAGGGCTGATGGAAGAGGCGACCGCTTTTCGGAATTGCC  
 CGCCGAACCGCGCTGCACTGGTTCAAACCAAGCGCGCGCGCTGCATCTGGTAGATT

5 GAAACGGCGGCTTTGCCGGCGTTCCGCAAAACCTGCCCGCCATCAAAGACATCCTTGCCGG  
 TGTCCGCAAAAGACATCCCCGTACAGCTCGGCGCGGCATACGCGATTTGAAAACCATCGG  
 ACATATTTTGGATTTGGGCTTAAACGACGTGATTATCGGCAGCGCGCGGTCAAAGAACCC  
 CGACTTCGTGCGCGAGGCGTGCAAAAGCCTTCCCGGGCAGGATTATTGTCCGGCTGGATGC  
 10 CAAGAAGCGGTATGGCGGCCATCGACGGCTGGGCAACCGTAACCGGCATCATGTGTAATTGA  
 TTTGGCAAAACGCTTTGAAGACGACGGCGTCAACAGCATCATCTACACCGACATCGGGCG  
 CGACGGTATGATGAGCGCGGTGAACATCGACGCGACGGTCAAACCTGCCCAAAACCGTCCG  
 CATTCGCGTCATCTCTCCGSGGACGTACCGGCTTGGACGACATCCGCGCCTGTGTGC  
 CGCCGAAAACATGGCGTAGCAGGCGCGATTACCGGCCGCGGATTTCAGGCGTAGCAT  
 15 CGATTTTGCCCAAGCGCAGCAACTGGCAGATTCCCTCGACTAAAGGCATCCGATTATGGC  
 ACTGGCAAAACGCATCATCCCTGTCTCGACGTAAAGAGCGGGCGCTCGTCAAAAGCGGT  
 GAACCTTCATCGGTTTGGCGACGCGGGCGACCCCGTGAAGCGCGCAACGCTACAAACGG  
 CGAAGCGCGGACGAATTGACCTTCTCGACATCACCGCTCATCCGACAAACCGCGACAC  
 CATCTCGACATCATCGAAGAGGTTGCCGGACAAGTCTCATCCCCCTGACCTGCGCGG  
 20 CGCGCTACGCACCGTTGCCGACATCCGCGCCTGTCAATGCCGGCGGGCAAAAGTCAG  
 CATCAACACGCGCGCGTTACCCGTCCCGATTAAATTGACGAAGCCCGCGATTTCGCG  
 TTTCCGAAGCCATCGTCGCCGCCGTGATGCCAAAGCGCGCAACCCGAAAAACACACGCTG  
 GGAATCTTTTACCACGGCGGGCGAAATCGACCGGTTTGGATGCGGTGGAAATGGGCGGT  
 CGAAATCGAAAAACGCGCGCGGGCGAAATCCTGTCAACCGTATGGACAGGGACGCTAC  
 25 GAAACAGSGGTTCAACCTGCCGCTGACCGCGCGTTGCCGAAGCCGTGCACATCCCGGT  
 CATCGCTCCGCGGGGTCGGCAATGTCCGGCACTGATTGAAGGCATACCGAAGCGAA  
 AGCCGATGCCGACTTGGCGCGCGCATTTTCCATTCGGGGAATCGCCATCCGCGAAGC  
 CAACCGCGCTATGCCGGAAGCGCGCATCGAAGTGCCTCTGACCGCTCGCATTCGCG  
 30 TTTGAAAGGAAATATGGAATAAAACCTGCTTGAAGCCGTCAAATTTGACGAAAAGGTTT  
 GGTTTGCCCATCGCCCAAGATGCCGAAACCAAACGTATTTAATGGTGGCGTGGATGAA  
 CGCCGAAGCCCTGCAAAAAACCGTCGAAACCGGCTTTGCCCACTATTACAGCCGTTCGGC  
 CAAAAACAATGGATGAAGGGCGAAGAGTCGGGACACACGCAAAAGTCCGCGCATCGCG  
 CTTGACTCGGACGGCGACGCCATTGTGATGCTCATCGCCAAAAACGCGCGCATCGCTGT  
 CCACACCGGGCGAGAAAGCTGCTTTTCAAAAGTTCGGCTGGCAGCGCTGGGAACACCGC  
 35 CGATCGCTCTCGAAAGACGAAAAGAGATTACGGCAGCAGCACTGACCGCTCCCAAC  
 ATGTAATTATCAGGCATTTTGTACAAATTCGCGCTCTCAAACTGTCCGGGCGCT  
 TGAAGAGCGGCTGAACCTTTTGCAGAAAGAAACATGTCCTCAAGAAATCCTCGAACCAAG  
 TGGCGCGCGCGCGACGTTTGGCATCATCTCCACCCCTGACGAGGTAAACACAGCTTGA  
 40 CTGAAAACCTTTGCTGTTTTCGGGCGCGATTACAGCGCGGGTACGGTAAAAAGCGAAGA  
 AAACCGGCAATTCGCCACTTCCGACTGGATGGAAATCAGAAAGCAGCGCGGCATTTCCG  
 TGGCATCAAGTGTGATGCAGTTCGATTACAAAGACACACCGCTCAACCTCTTGGACACGC  
 CGGGACCAAGACTTCTCGAAGACACCTACCGCGTTTAAACCGCGTGGACAGCGCAT  
 45 TTAATGTCATCGACGCGGCAAAAGCGGTGGAAGCGCAAAACCATCAAGCTCTTAAAGCTCT  
 GCGCGCTCGCGATACACCGATTGTTACGTTTATGAACAAATACGACCGGAGTTCGCGG  
 50 ATTCCCTGGCAACTTTTGGACGAAGTGGAAAAATTTTAAAAATCCGCTGCGCGCGCTTA  
 CCTGCGCGATCGGTATGGGCAAAACTTCAAGGCGGTGTACACCATCTGAACGATGAAA  
 TTTATCTCTTTGAAGCTGGCGCGCAAGCCTGCCGACAGGTTCGACATCATCAAGGCA  
 TCGAATCTCTGAATTTGGAACACGCTTCCGTTGGAAATCCAGCAGTTGCGCGAGCGAAA  
 55 TCGAATTTGGTGAAGCGGCTTCCAACGAGTTTAATCTCGACGAATTCCTCGCGCGCGAAC  
 TCACCGCGTATTCTTCGGCTCTGCGATTAAACACTTCGGTATTCAGGAAATCTCAATT  
 CATTGATTGACTGGGCGCCGCGCGCAAAACGCGCGACGCGACCTGACGTATGTCGAGC  
 GCGACGAGCGAAGTTTTCGGGATTATCTTCAAAATCCAAGCCAATGAGACCCGAAAC  
 ACCGCGACCGTATTGCTTCTTGGCGGTCTGTCCGCGCAATTCGAGCGCGGCATGAAGA  
 TGAACACCTTGGTATCAACCGCGAAATCGCGCGCTCCAGGCTGTTTACCTTCATGTCCG  
 60 ACAGCCGCGAGCTGTTGAAGAGCCTACGCGCGCGACATTCATCGCATCCCGAACCCAG  
 GCAACATCTCAATCGCGCACGCTTCTCCGAAGCGCAACACTGGCGCTCACCGGCATCC  
 CATCTTCGACCCGAACCTGTTCCGCGAGCTACGCATCAAAACCCGCTGAAATCAACG  
 AACCTCAAAAGGCTTGCAACAGCTCGGCGAAGAGGCGCGGTGACGAGTTGTTCAACCGCA  
 TGAGCGCGCGGATTGATTATTTGGGCGGGTGGCGGTTCGAGTTTGAAGTCGTTACCT  
 65 CGCGCTCGCCCAACGAATACGCGGTAGAAGCGGTGTCGACAGCGCATCCATCTGGTCGG  
 CGCGCTGGGTATCGTGGCAGCAAGAAAAAATCGCTGAATTTGAAAAGCCACGCGGG  
 GCAACCTCGCATCGACGACGCGCGCAACTCGCTACCTCGCCCCAACCGCGTGAATT





GGAGGGGGTTTGGGCGCGGTATCGTTCCGCGCGCCAGCGAGTCAAGGCGAGGCTCAG  
 GATTGCCGCCGCCACAGTGTTTTTTCATGGTTTTTCAGACTTTTCGTTCAAAAAATAAAA  
 ACATTGCGAGGACGGACGGCGCGCTGCATCGGAAGCTGTGGGGGCGCGCGTTCGGCTTT  
 CTGGCGCCTTGTGCGACGAAGGTTTGCAATTAACAGGCAAAAACAGCGGGGGCGCAACCGT  
 5 TAATTTTACCAGGTTTGGCCTTCCGGTCCCGATCGGGCGGTAAATCGGGACATTTGTTCC  
 GCCTCGTAAAAATGCGCTCTGAAGCCTCGCGCGCTTTCAGACGGCATCGGGCGGACGG  
 CATCAGTTGCTCAACACGTCCACGCTTTGGGCGGGTAAACTTGAACGCGCCGCGGATG  
 AGTTGGGATTTGTTATTAACCCGCGAACTGATGAGGTTTGGTTGCCGAAGCTGTCT  
 TTAAGCTGCATGGCGCGAGGTTGCCGCTTTGAAGCCGATCGCGATGTATTTGGTAGCCG  
 10 CGCTGTTTGGCTTTGGGCGTTGCCAGCACATAATCGATGCCGTTGGACGAACCGTCTCT  
 TTCAGCTGTAGCTGCTTTCGAGGGCGGTTTTGTTGCACAGGATGGCGCGGGGCTGCCG  
 CCTATGGCTTGGCTTGGGACGACTTGTCTACTGTGCCAGATCAACATCGTAGAGCCAA  
 ACGGTTTGACCGTCGCGGACGATGTTTGCCTGTAAAGTTTGGTGATTCCCATTTGAAA  
 AGCGCCGTCGCGAGGATTTGAACGTGCCGTGCCGCGTTTGGGTTTTCTTTTGGCTTGG  
 15 ACGGTTTGGGTGAAGCTGCCGTGTATACCGTCGCGCATCGTTGTTGAATTGCTTAAGCGCG  
 TCTACCGCGCCCGCTGTGCGGAAGCGACGCGACGCTAGGAGCAAAACGGCGAGGAAT  
 TGGAAACGTTGTGCGGTTTTCATATTATTTTCTTGTGCGGATGAGTGTGGCGTAAAG  
 TATCGCGCGACAAAACAATCATACGGCGCGGTTACGGGCGGTTTGCATTTTGCAAAAC  
 CGGTTTTCCGAGGGCTGATTTTTTGCCCAACCGGAAAAGCGCGCGCCACGCTGCCCTTT  
 20 AATGTGTCGCGCTTATAGTGGATTAACAAAAATCAGGACAAGGCGACGAAGCGCGACGAC  
 AGTACAATAAGTACGGAGCGATTACCTTGGTGCTTCAGCACCTTAGAGAATCGTCTCT  
 TTGAGCTAAGGCGAGGCAACACCGTACTGGTTTTTGTTAATCCACTATATTGACGGTTT  
 GGGCGCGGAATGCCGAATCGCGGAGATTATATGCTCATCTTGTTTTTTTAAACGCTAT  
 25 AATATTTGTTTTCCGAACACGGCGGACTTGAGATGAAACCGGATATTATGCTTTGCTGG  
 AACCGCCCTGCTTTTCGGGCGACAGGATGAAAAGGACGGCTGACGGATGAGCGGTTTG  
 GCGCGCTTCAAAAATCGGACGCGGCGGAAACAAACGACCCGCGGCGGACTTCCCCCGCG  
 CGGGACGACCGGACGAAGCCTGTTTTGGTGCGCCGTGCGAGCTGACGCCACGCAAAATGA  
 ACACAAACGAAGGCTATGCGGCGATGCTGCACGCGATTGCGCATATCGAATTCACGCCA  
 TCAACTGCGCTTTGGAACGCGGCATACGCTTTCCGCAAGCTGCCGTTTCAGTTTGTCCGCG  
 30 ACTGGGTGAAAGTGGCGAAGCAAGAGGTGTACCATTTCCGCCCTGATGCGCGAAAGSCTGC  
 GCGCTTTCCGCTTCGATTACGGCGATTTTGAAGCACACAATCATTTATGGGATATGGCAT  
 ACAAACCCGCTACGATCCTTTGTTGGGTATGGCTTAGTGCCGCGGTTTTTGAAGCGC  
 GCGGGCTGGACGTTACGCCCGCATACGCGGGAAGTGGCGACGCGCGGTGATTCGGGAAA  
 35 CCTGCGCGGTGTTGGACATCATTTACCGCGAGAAGTGGGACACGTCGCCATCGGCAACC  
 GGTGTATCAACACCTTTGCCGCGAACGCGGTTTGAAGCTGTGCCCTGTTTCGCGAGCC  
 TGATTGCCGTTACGATATGTTTATCTTCGGGGCTATGTGAACATCGAAGCGCGGAAA  
 AAGCAGGCTTCAGCGCTTTGAATTTGGATATGTTTGAAGATTTCGACGAGGTTTGAAC  
 40 AAAATAAATATGCGCTGTGAACCCCTTCGTCCCGACTTTATAAAAAAGGAACACACTG  
 ATACAGCCGCTATTGTTGCAGCTCGATGGCAGCGTCGCCGACACCCGCTAGACCTCGCG  
 GCGCACTCAACACCTGCTGCCGCCACGGACTACTGCAAAAAGCATGGACGAATCT  
 CGCACCACAAGCAGCCAGCGCGCGGAGGACTGATCAAGCTCGCGCAGGCATCACCCCC  
 GACCATCCGACTATGCCGATGGCGCACCGAATACCTTGACGAATACGACGACCGGCTAC  
 45 GCCCAAGACACCCCTCTCGACGGGTAAACGAACCTATCGCCGAACCTCGGAAGAAGC  
 GGCAATCAATGGGGCATCATACCAACAACCCATGCGCTTCACCGACAACCTCGTCCGCC  
 AAACCTCGGCTTATCATCCACCCCGCGCTCGTGTGACGGCGACACTCGCGCGAGCCCC  
 AAGCCACGCTCAAAACCATGCTGTATGCTGCGGCAAAATCCACGCCGACCCGCAACAC  
 ACACCTCTGAGCTCGCGGACGCGGAACGATATACAGGCGGGGCGCAACGCCGATGAGC  
 50 ACCGTCCTGCCGAATGGGCTTACATCGCTCCGAAGACGATACCGGCTCATGGCAGGCG  
 GATTTCACATCCGACGCGCACTCGATCTGCTCGAATGCTGGACAAAATACAGCCCTGA  
 AAAATATCCGCCCCAACAATATAGTGGATTAACAAAAACAGTACGGGCTGTGCTGCG  
 55 TTTATGCTCAAGAGAACGATTCTCTAAGGTGCTGAACCAACCAAGTAACTCGGCTCGGTAC  
 TATTTGTAAGTGTGCGGCTTCGTGCGCTTGTCTGATTTTTTGTAAATCCATATAAACC  
 TGCCGCTGAAACCTGATTTTCAGACGGCAGTTCCGCGCTTCAACCGGAATCAAGGCGGTC  
 AAAACCTGCGTTTTGAGCTTGCACGCTGAAGGATGTGTCAGCCCAATTCCTCAACGCACT  
 ATTCGCTGATTTGCAAAACGGAATCCCATGCGGCTGTAACATATCTTCGGCGTTCGCCCA  
 CCTCGCTGGGATGATGATCGATTTTGGCATAAAGTTGAATTCGGGCGGCGCTTTCGCGGA  
 TGGCTTGAACAGTTTCGGCTGGATGCTCAACCCGAACAGCTTATCCCTATAAGGCTTGA

CCATACGCGGCAGATCGGCCGATTCCAAATCGTCGGGAATCAGCGGATAGTTTGCCGCAC  
GGATCGCGTATTGCAGGCGAGGTAAGGCGAGTCGGCGTTTGCCCGAACCGGATACAC  
CCATCAAGATTACATCGCGTTCTCGAAGGTTCTTATCGCTGACCCGCTCGTCGGTTC  
AAGAAAAATTGACCGCTTCCATACGCGCATCATAAACGTTTGGTATTACCGATCATGTGAT  
5 GCGGCTGCGCGGATGCGCTGGCTTCGGTATTGAGTTCCCTTCTCAACAGTCCCAAAAAAG  
TCTCAAGAAATTAATCTGAAAAAGCATCGGCCCTTGTATAATCCGACGGATTTCGTAT  
CAACCACACTGCAAAACGCAATCGGACGCTGACCGTTTCTCGCGGCTCCGATTGACT  
TCTCCACCACCGCGCGGCGCTTTCCGGCGTATCGCAAAACGGATGCGTATGGCGTTTGA  
ACGACAGATTGCCAACTGGTTACGAAACGCTCGCGCATATTCTCAGCATCGACCCG  
10 TACGCTCGGAAATGTAAACACATGGCGCGGACTGCTCATCTTCCATCTTAAAAACACAG  
GTTTAAATCCCATATAACAGCAGCAGCAGACAGGAAAGCACCOCGAGCACACCTA  
CTCCGGATTACACCCAAACAGACACAATATAATTTTGAATAAAAATTATTATATAAAGT  
ATTTTTTGGCAGAAAAATTTAAAAAATAAACAAAAAATCAAAACAGAAAAACATTAACC  
TATTCAAACCACTGTTTTACAAAGAAAAATACCCAAAAAAGAAATATACCGGCTGTAA  
15 TTTCAACCGCTACACACGCGGAAACCGCAATTTTCAGACGGCATCATGATTTTAAAC  
GGATAAAACACATGACAGCAGAGGAACGAATCGCTTAAATAAGCACGCGGATTTGTTTC  
TTTTTTAACTATTTTGATTGGACACACAAATGGCGGACAACTACGTAATCTGGTTTGA  
AAACCTGCGTATGACAGATGTTGAACGCGTGGGCGTTAAAAACGCTCGCTGGCGGAAT  
GATCAGTCAGCTGACCGAAAAAGGCGTTCCGGTCCCGCGGCGTTTCCACCACCGCCGA  
20 AGCCTACCGCGCATTCCTCGCACACACGCTCGAGCGAACGCATTTCCGCGCGCATGGC  
AAAATTGGATGTCGAAGACGTTGCGCAACTGGCAGCGTCGGCAAGAAATCGCCCAATG  
GATTTTGGATACGCGCTTCCCGGAACAGCTCGATGCGCGAAATCGAAGCGCATGGAACAA  
AATGGTTGCGGATGCGCGCGGTGCGGACATTTCCGTTTGGCGTACGTTTCCGCAACTCG  
CGAAGACCTGCCGGACGCATCATTCGCTGGACAACAGGAAACCTTCTTGAACATCAACGG  
25 CTTGGATAACGTTAAAGAAGCGTAGCACATGATTTCGCTTCCCTGTATAACGACCGTGC  
CATTTCTTACCGTTCCACAAGGCTTCGAACACGACATCGTCGCGCTTCCGCGCGGCT  
TCAACGATGTTGCGGTTCCGACAGCGCGCATCAGGTGTGATGTTCAACCTCGACACGGA  
ATCGGCTACGATCAAGTCGTTTGTGTACCTCCTTACGGCTCGGGCGAAAACTGCGT  
ACAAGGTGCGGTCAACCCGACGAATTTATGTGTCAAAACCACTCAAAGCGGCA  
30 GCCCGCATCCTGCGTAAACCATGGGTTCAAAACACATCAAAATGATTTTACCGACAA  
AGCAGAAGCGGTAATCCGTAACCAACGTCGATGTCCCGAGGAAGACCGCAACGCTT  
CTCCATTACCGACGAAGAAATTAAGTGTGGCGCATACGCACCTGACCATCGAAACAA  
CTACGCGCGCGGATGGATATCGAATGGGACCGGACGCGTTGGACGGCAAACTCTACAT  
CCTGCAAGCCCGTCCCGAAACCGTAAATCCCAAGAGAGGCAACCGCAACCTTCGCGC  
35 CTTGCCCATCAACGGCGACAAAAACCGTATTATGCGAAGGCCGCGCCATCGTGACAAAGT  
CGGTGAGGCGAAGGTGCGCTGATTAAAGATGTTCCGAGATGGATTCCGTCGAAGCGG  
CGACGTACTCGTTACCGACATGACCGATCCGGATTGGGAACCGGTGATGAACGTTGCTTC  
TGCCATCGTTACCAACCGCGCGCGCGTACCTGCCAGCGGCCATCATCGCGGTGAATT  
GGGCATTCCTGCCGTGTGCGGTCGGCGAATGCAACGGAATTCGTGAAAAACCGTCAAGA  
40 AGTTACCGTATCCTGTGCGGAAGCGATACCGGCTTTATCTATCCGCGTCTGTTGAGCT  
ACAGATTACCGATGTGCGCTTAGACAAATATGCTTAAGCACCTGTAAAGTCATGATGAA  
CGTCGGCAATCCGGAATCGCATTCAGCTTCGCCAACCTGCCACGGAAGGACATCGGCTT  
GGCGCGATTGGAATTTATCATCAACCGCAAAATCGGTATCCACCCCAAGCCTTTGTGGA  
ATTTGCAAAACAGACGCAATTAAGGCGGAAATTAACCGCGGTATCGCGGTTTACG  
45 GTCCCTGCTGCATTTCTACGTGATAAAATCGCGAAGGCGTGGCGACATTTGGCCGACAT  
GGTTTATTCGCGTAAAACCATCGTCGATGTTCCGACTTCAAAATCAACGAATACGCCAA  
CTGTGTGCGCGGCAACGATATACGAACCGCATGAAGAAAAACCGGATTTGGGCTTCGCTG  
TGCGGCGGCTTATGTCGCCGACAACTTCAAAGCATGTTTCGCTTGAATGCAAGGCTT  
GAAACCGCTCCGCGATGAAATGGGTTGACCAACGTTGAAATCATGATTCCGTTCTGTCG  
50 CACTTGGCGAAGCGCAAGCGGTTGTCAAAGCCCTGAAGAAAAACCGGTTGAAACGCGC  
CAAAAAACCGCTGCGGCTGATTATGATGTGCGAGCTGCCGAGCAACCGGCTATTGGGGA  
ACAATTCCTGCAATACTTCGACGGCTTCTCCATCGGCTCGAACGACATGACCCAACTGAC  
CCTCGGCTTCGACCGCGCAGCGGCTTGGTATCCGAATCGTTGACGAACGCAACCTCGG  
CGTCAAGTGTGCTGCACCTTGCATCTCCGCTCGCGCAAGCAGAACAAATATGTCGG  
55 CATTCGGGTCAAGGCCGCTCCGACCATCCGACTTCGCCAAATGGCTGGTGGAGGAGG  
CATTGAAGCGTTTCCCTGAACCCGGATACGTCATCGAAATTTGGCTATATTGCGGAA  
TGAATTGAACAAATAATCAATGCCATACCCCGAGCCTGAAAAAGCGCGGGGTATTTTT

TTCCAAGCAGCTCCGCTCAGACGGCATTTCCTGCCGATGCCCGTCCGCGATAATATTG  
 ACACCCACGCCGCGACTGCCATACAATTCGCCCTCCCGGAGCAACCGGCAACGGTCAGCT  
 TCTCTCTTCAGACGGCATCTGCTGTCTTTTCTCTTCAAAATACATCATTATTATGCA  
 5 CGTCTCCGAATTACAAACCTGCACATTTCCAAACCTCTAGAATTGGCGGAAGAACCGG  
 CATCGAAAACGCCAACCGATTTCGCGAAACAGACCTCGTATTTGCCATCGTCGCCCAGAT  
 GATGAAAAGAGCGAGGGTTTCACCTGCTCCGGCAGCGTTGAAATCCTGCCCGACGGTT  
 CGGCTTCTCCGACGGCGGACAGCTCCTATTTCGGCGGCCGACGACATCATGTCTC  
 GCCACCCCAATCCGCGCTTCAACTGCATACGGGCGACACCATCGAAGGAAGCGTGGC  
 CGTCCCAAAAGACAACGAACGCTATTTGCCCTGGTCAGGCTTGATACCATCAACGGCGA  
 10 CCACCCGGGAAGTATGCCGCATAAAATCCTGTTTGAACCTGACCCGCTGTTTCCGAC  
 CGAACAGTTGAAGCTGGAACGCGACTTAAAGTCGGAAGAAAACCTGACCGGACGTGCCAT  
 CGACCTGATTTCCCTATCGGCAAGGTCAGCGGCCCTCTTGGTTGCCCGCCCAAAAG  
 CGGTAAACCGCTGATGCTGCAAAACATTGCCACGCCGTACCGCCAACTATCCCGAAGT  
 CGAAGCTCATGCTCCTCTTGATTGACGAACGTCGCGAAGAGTAACGAAATGAGCGCGTC  
 15 CGTCCGTGGCAGAGTAGTCTCTCCACCTTTGACGAGCGGCTCAACGCCACGTTCCAAGT  
 TGCCGAATGGTGCTTGAAAAGCCAAAGCGTATGGTGGAAACAAAAAGACGTGGTCACT  
 CCGTCTGGATTGATTACCGGCTTGGCGGCGCTACAATACCGCTGCTGCTACCTCGGG  
 CAAATCTTCGACCGGCGGTGCTGATGCCAACGCGCTGCATCGTCCAAAGCTTTCTTCGG  
 CGCGCGCGCAACGCTGGAAGAGCGGCTCGCTGACCATCATGCCACCAGCTTGGTTGA  
 20 AACCGGCAGCCGTATGAGCAGATGTGATTTACGAAGAAATCAAAGGCACCGCAATATGGA  
 ATTGCACCTTGACCGCGATAGGCGGAAAACGCCCTTCCCGGCATCAACATCAACAA  
 ATCCGCGACGCGCGCGAGAGAGCTGCTTGTCCCAACACGACAGTTACAACGTATGTGCT  
 CTTACGCAAGTTCTTGACCCGATGGACGAATTCGAGGACGCCGAATTTTAAATCGGGAA  
 AATCAAAAGCTCTAAAAACAACGACGATTCTTTGAACATGATCGCGGCAAAATAACCGC  
 25 CGCGCCGCAATTAATGCGAAATGCGCTGTAAGCCTGAAATCGGTTTCAGACGGCACTT  
 TCAATTCACAGCGTCGCGCAGCTCCTCCTCCCGCGTTTAAACGGCGCAACCGTCGCGACT  
 TCCGCTGCTCCGCTTGGCGAAGCGCGGCTTTGCAAGCGCGCTTGAACGCTACCGTACC  
 GGCAATGAAACCGATCGGGGAACCTTGATTCAAGGTTGCGCGCAACCGCCTCATTTTGA  
 30 TATAAATTCGGGCTGTCTAGATAACTAGGGAATTAATTAAGTTAGATTGAGCTTGCCCT  
 ATGAGAAAAATTCGTCTAAGCCGTATAAACAATAAATCACTATTGAAGCTTTGTGCGCA  
 GGTGTAAGTGAAGAACAGCAGCAGAGTTAGTAGGCGTTAATAAAGTACCTCAGCCTAT  
 TATTTTCATCGTTTACGATTACTTATTTATCAAAACAGTCGCAATTTGAAATGTTTACG  
 35 GGCGAAGTAGAAGCAGATGAAAGTTATTTGCTGAACGACAAAACCATATCAATGGAATT  
 GGGAACTTTTGAACCGGGCAAAACGTCATTACGCAAGTTTGAACGCTTCCCAACGCG  
 CATTTGAGCTGATTAAAGGGTAGCAACGAGCTTTTAAACAACGAGAGATAAAAGTT  
 CAAATTTCCATTTTAAACAATTAGTAAATCGAGTTTATCCTAGTTATCTAGGACAGCC  
 CCATAAATTTTATAGTGGATTAAACAAAACAGTACGGCGTTGCTCGCTAGCTACCA  
 40 AGAGAACGATTCTCAAGTGCTGAAGCACCAAGTGAATCGGTTCCGTACTATTGTACT  
 GTCTCGGCTTCGTGCGCTTGCTCGATTGTTTGTAAATCACTATATTCCCAATAAAAA  
 TTTTATATATATTAACTAATAATTAATTTTATAAATAAAAAATATTGCAACAATATT  
 TGGCTTATCGCCCAACCTCTGTATATTTTCTACAGTAAATGTTGACAAATCCATACGC  
 CCACATATGCGCGCCTAAGGATAAATCCTCCGCGGACAAACGGGTGCAAGGGATCGGA  
 45 TGCGATATTCCATATTCAAAACAGGATTTGGCGGCACATCGGCAAAATCCCGCGCGCG  
 CCGGCTCCGCGAGGCTTGGCTCCCTCCCGGACAAGCCCGACCCCGCTTCCGAAAGA  
 CGGCGTCAACCATTAAGGAACTTTAGTCAAAATGAAAAAACACATATTGGGCGCACTCT  
 TGCTGCGCGCATCCCTATCGGCAGAACCTTTAAACTGGTGGAGGCTTATTCGCGCGTCA  
 ATTGCGGCGATACCGGCTGGTGATGACTGCGGCTGCTTGGTACTGTTGATGACGCTTC  
 50 CGGGCTTGCTTTATTCACGGCGGTATGGTGGGAAAAAAACCTGCTCTGACGATGCA  
 TGCACAGCTTTTCCATCGGCACATTGGTGGGCATCCTTTGGTGGCGCGTGGGTATCTCT  
 TAGCGTTACGCGCGGAAATGCTTTATCGGCGGTTTGGGCGCGCTATTTTAAAGCGGA  
 TGCAGATAGACGCTACCGCACAGATGCTGACCGGTGCGCCCAATGCGCGACGTGTTCCG  
 55 AACCGGTTATATGTTTTTCAGATGACGTTTGGCATATTTCGACCGGCATTTATACCG  
 GCGGCTTGCCGAACGGATGAAATATTCGGAATGATGCTGTTTGGGCAATATGGTTT  
 TATTTGTTTATGTCGCGGCGCGCATTTGGGTGCGGCGCGGCTTTATGAGCAAGGGCG  
 GCGTATTTGATTTATGCGCGCGGTACGGTGGTGACATCAATGCGGATATCGCGGACGTC  
 TCGCGGCTTGGTTTGGGCGAGCGCATAGGCTACGGGCGCGAGGCGATGCTCCGCA  
 ATATGCGCATGACACTGATCGGCGCGCAATGTTGTGGTTCGCTGGTTTGGCTTAAACG

CCGGATCGGCGCTTGC GGCGAGACGCGGCGGCGSGTATGGCGATGGCGGTAACGCAAGGTGT  
 CGGCGGTATTCCGCGCGGCGAGGCTGGCTTGGCTGCGCAAAAAATAGCGGGACACAAACCTT  
 CGGCTTTGGGGGTGGCTTCGGGCGSGTTTCGGGTCTGGTCGGCATCACCCCTCGCGCGCG  
 GCTTTACCGGCGCGTGGGCGGCGCGGCCATCGGTATATTGACTCGCGCGCGCGTGTCTTTG  
 5 TGTGCGCTCACCGTCGTCAAACACAATTCGGTTACGATGATCTTTGGACGCTTCGCGCA  
 TACACGGAATTCGGGCGGCTGGTGGGCGGAATATTGACCGGCATCTTTTCGACAAACCGCA  
 TTTTCGGCGGGGATCGGCGACTTTCGACGAGCTTGGGATACAGGTAAAGACGGGGTGCT  
 TTATGCGGCGATACAGCGGCTTAATGAGTTGGGCGAATTTGAAGGTCGTGGGGAATACTC  
 CGCGCGCGCTCGCGCTCGGCAAGGATGTCGAACGCGAAGGTTTGGATCTGAATATCCACG  
 10 GCGAACCGCTGGAAATAGGCGCGCTATGCCGCTCTGAAGCTGAAAATCGGGTTTCAGACG  
 GCATTTTTCACGTTTTCGGCGCGATGGATAAACATATAGTGGATTAAACAAAATCAGGACA  
 AGGCGACGAAGCCGACAGAGTACAGATAGTACGGAACCGATTCACTTGGTGGTTTCAGCA  
 CCTTAGAGAAATCGTTCTCTTTGAGCTAAGCGAGGCAACGCCGTAAGTGGTTTGTGTAAT  
 CCACATACTAGCTCGCTCGGACGCTTAACGGCTGTCTTTCCACTGATAATATTTCGAGCGGAG  
 15 GAAAGAACCGAGTTTTCGCAAAAAAGGTTGCAGGATAAATATTTCGGCTGGCGCAACCGCTC  
 AAACGGCTTCAGACGGCATTCGTCCCTAAATTTGCTTCGGCAACCGCGACGCTCGAAT  
 CGCTGTTATCGCCATCCGCTGTCGCGAATAACCTTTCGCGATAAAAAACATTCGGGGCTAA  
 ACGTCCGAAATCGGGACAGGTTGGCGGTATGTCGCACTCCCGCCCAACGATCAATTTTC  
 GATTTTGACATCGGCAAGCTTCGCGAAAACTTTAAGCATATCTTCGGCGGACAGCTCGGT  
 20 CATACGCTCAGGATTGTGATAAACTCGTTATCTTACC GCGAAAGCACTTCGCGCTC  
 CGCGCTGAGCGGTAATAATCCAAAAATATGGCGGTTGTCGCATCTGCCATATTGTTACG  
 GATAAGCCCTTTTCGGCGCGCGCCCAAGGGTTTCGGTCGCAATATAAGGTGCTGACAGC  
 AATCGGCTTGGCTTCAAAGGCGGGAATATCGGGTCAAACCTGCATAAGTATTGACAGC  
 ATAGACACATATTTGCACTCGACGCTGCTTCGGGCGGTGTAACACGACCAACCGCTTTG  
 25 ATGCGGTTTCGATGCACTGTCATCGGCGATTGCTCGAAAAATTCGCGCACCGGCTTCGGCAG  
 GCGACGCGGATGCGCAAGGTGTAAGTGAGCGGATGCAAGGTGTCGCGGATAAGGGGTCGAA  
 TTGTGCGCTTGGTACATATCGCTGTCAAGCTGCTGTTCACTCGGCTTTATTCGCAAG  
 TTGATAATGACTCGCACCGTAAATGCCGTTGGGCGTGTTCATGCCACTGCTGCAACTCTTC  
 CCAATGCTCGGACGGACGGCAACCGTGGCATAACCGCGCTGCCAATCACAATCGACGGC  
 30 ATGTTTGGCGACGCGTTCGTCCACAGTTCGACGCGCTGCAAGACTGTTCGCAAAAACTA  
 TTGCGCTGCTCCAAGCCGACTGTTTTCAAATTTCCCCCATACCGACGCGTAACTCGCT  
 GATAACCTGCCCGCCATCCGTCCCGACGCGCGCAAAACCGATACGCGCGGCTTCCAAAC  
 AACCGTTTCACTGCTCCGTCCGCCAAGGGCAATGCAGTGCACAAACACCCCAATCCGCG  
 35 GCCGATGATACAGGTATCGGTTTTCAGACGGCATGAACTTTCGGATAAACAGTATGAGG  
 ATTAACCGCAACTGAAATAATAAGTAGCGAGATATTCTTGAAAAATCAGGCGGAATCAATTG  
 GTTTGCTTTATCAGGTGATTTTTCGACGGAATGATACAGGCTGTCGGGCGCATATCGTCC  
 AAACGAGAAATCGGTTGAAGAAAACAGGCTGACCAATCATCGCGTCAAGCTGCCTTATT  
 AATTAATTTGCTTTCTCGGACGCCAATTTTCCTAGGCGGTAGGCTTCGCGCGCTTCGCG  
 40 TCACGCTTGGTTGCTGCTCATCATCCAATTAATGACGATGATGACCAATGTTCGCGAT  
 ATGCGGATAGGATGGTGCCTGCAAGACATTCATCTGAGGATCGAGACCACTGATTTTTCG  
 GAGAAATCACTCGCGCAATGTGGATGACCGGGCGGAGAGGAATGAGGTAAATCACC  
 AAATCATCAAAGACAGGTAATGCCAGCAGAAAGCTGAAGCGATGGCAGGGGCAATC  
 AAAGGCAAAAGTGATGACAAAAAGATTTTCAGCGGCGCGCGCCCAATCCATTCGGCGCT  
 45 TCTTCGAGCGACTGGTCAAGCTCAACGACAGCGGAACGGGATAACAACGGTAATGTACGCG  
 ATACACAGCGTCTGATGTCGAGGAAGATGGTGAAGAGCGACGATCAAAGTAGAGATGT  
 GTGAACCATTCGCTGCCCTGCAAAAAATATCTGTACCTGAATAATCAGCAGCAGCATAGAC  
 AGACCGGTAATCAGCTCGGCGCATCACCATAGGTGCGGAAATCATGCCAGCGCAAGAGTA  
 CTGCCCGCAAAACGTTTAATCTCGCGCCATCGCATAGCTGCGCAGCGTGCCCAAAACGACG  
 50 CGGCAAGCGAAGACACAAACGGCAATCCGACGACGACGCAAGCGCTTCGAAAGTGTG  
 TCGTTTTCAGCAATGCGCGCTACCACTTGGTCGAAAGCGCCGCCCAACGGTTTACCAGC  
 TTGATTCGTTTAAACGAATAGATGACCAAAAAACACGCGGGATATACAGAAACCGCAGC  
 GACAGTGCCACATCACTTTCAGAACCAAGATAATTTGATTTCTGCATTAATTGGCTC  
 CTTCTTCCAAATTCGGGTTTTCATAATGCTGAACACGGCAATCGGCAACGACCGACGCG  
 55 CGACCATTCAGACGGCGACGCGGAAGCCAGCGCGCTGTTGTTTATCGAAGAACCGCT  
 GCCACAGACTTTTACCAATCATCAGTTTTCGGAACCGCGACGAGCTCGGGAATGAGCA  
 ACTCGCGACAGCAGGACGAAACACGACTGGAGCGCTGCAATTAATGGCGGTTTCGACA  
 AAGCAGGGTAATCGTCAAGACGATTTCGACGCGCCCGCGGCCCAATTCGGAAGCCGCTT

CRAAGCAGCGGTTGTGCGAGTTTACCAGTTGCGGTGTATAGCGGCAGAATCATAAACGGCA  
 GATAGGCGTAAACCATCACCAATTAGGCGA/AAGGCATTGTAGAACAAATCCAAAGGCT  
 CGCTGATAATACCCATTTTAATCAACAGGTTGTTTCAATGCCGTATGCGCGAGCAGAC  
 CCATCCAGCATAGACGCGCAACAGGAACGATGTCCAAAAGGCCAGCATATGCGGAACGA  
 5 GCAAAACCATTCGCGACAGAAAGGATTGGCACGAGAAATCGCATAGGCGGTCCGATTAACCGA  
 CCAACAGACAAATATCCGTCGTAGTCAGCGCAGCTCTTAATTGAAGACCAATAAGTCA TCA  
 GATAGATTGCTGTTTTCACCGTCGCCGAACGGATTGAGCGTACTCCAAAATTTTGA  
 AGATTCTGCATAATTTTGGTAGCTGACAGCAATATTGACAGCACCCTCAATCTCATCTTA  
 TCGTCGTTTAAAGGAGTAAACGCGCGGATGCGGATTCTGTTCGGCAAGCTGATTCTCA  
 10 GCACGATGCGGAACGGAATCAGAAACAGCACCAAAAGCCAAATATACGGTACGCGCAATCA  
 CGCGACCGCTGCCCGSACGCGGGAACAGCTTTGTTTTTCAGTTTATTAAGGTTTACATGCA  
 TCCCTTTAAATCAACGGAAACACGGAGTCGGTTGGTTTTCCGGCCAGCTGATATAGACGG  
 TTTCTGCCAAAGTCGCGCGGTGTAATGTTGCGCACATACCGATAAGGGGCGGGGACTTTGGC  
 TTTTGACGACGCGCCCGTTGCCGAGCTTGATATGGTAAATGGCGAAGCTGCCCAAATAGG  
 15 CGATTCTCTTTACCGTGCCCTTTCCGCCAGTTGTAGTCGCCCAAATATTCGGGTTTTCTT  
 TATATAAATCAATATCCTCTGGTCGAATACTAACCCAAAGGTCCTGCTCGCTCGGACAC  
 CCAAACCGTGATCGATGCGGACGTGGTTTTCCAAACCTTCGCATTGATAACGCGCATAGT  
 CGGCATGATCTTCAATCACCACACCGCTCAAAGATGTTGGTTTTCCGCGATAAACCTGCCAG  
 TGAAGCGGCTGTTGGGATAGTCGTACACGTCGCTGGGTGTGCCGACTTGCTGCACCTGAC  
 20 CGTACAGACATAATGGCGATGCGGGTGCACCTGCTCATCGCCTCTTCTGCTGTCGTAA  
 CCAATAACAGSTTACGCGGACTTGTTCAGCGTATTGACCAACTCAAGCTGGGTTTGTG  
 GGCGCAGTTTTTTGTCCAATGCACCGAGGGGCTCATCCAGCAGTAGAATTTGCGACGTT  
 TTGCGACAGTCGCTGCCAAAGCAATGCGCTGCTGTCAGCCGCGGACAATTTGTCGCGGT  
 TCGCTTTAGCAAAATTTGGTCATCTGAACGAGCGGAGCAATTTCTCGACGCGCGCGGCA  
 25 TTTGCGCTTTAGGCAATTTGTCTGTTTCAGACGGAAGGCAATGTTTGTCTACAGGTCA  
 TATCGGAAAAGCGCGTAACCTTTGGAACATCATATTGATGGGCGCATATAGGGTGCAA  
 TTTGGTAAATCTCTGACCATCAAGGATAATTTTCCCTGATTGGGACTTTCCATACCGC  
 CGACATAGTCGACGAGTGTAGATTTCCGCTGCCGGAACCTGCCCAAAGGGCGAAGATT  
 CGTGTGATAAATGTCCAAGTCGATGTTATCGACAGCGTAATTGTCAACCAACTTTTTCA  
 30 CCAAACTTGGATTTGAGATAAGGTTTGGCTGAAGACGCAAGTGTGCGGTCATAATGG  
 CAATCTCCAATAAAAAGACGAGTACCGCAAAAACGGAATTTTCAATGGGTGATAAAAAG  
 CTGTTTGATTGCTGGCGGGAGTTAAACGTTTGATGCCGTCGAAACTCTTTGAAGCGCA  
 CGGGCAGCATGAATGGAACAAGATTCCAAAGAACTTTATATATATAGTTTATGCGGT  
 TTTCCGGCAATATAGTGGATTAATTTAAACCAAGTACAGCGTTGCGTGCCTTCGCGTAC  
 35 TATTTGACTGTCTGCGGCTTCGTCGCTTGTCTGATTAAATTTAATCCATATAAAT  
 ATGGATTGAGCTTGTGCGAAAGCAACAGAAAGAAAACCCGCCATTTTTCTGGGCGG  
 TGTGCGAAAGCGTAATTTATTACGACAGCCCAAGCGGGTAAATCAACGCGCGCATACGTA  
 GCGCTGGGTACGCGGCAAGTAGGCGACGAGCGCGCGGCTTGGCTGACCATTTGCAACG  
 CGCCGACCGGCTGTGGTGGTCTTTGGGGTTGGCTTTGAAGTGGGGGTCAGGTCGTGAT  
 40 GCGGAAGATCAACAGAGCGACTTGTACTTCGGAAGAGCCGGTGTGCGCTTCTTGGCTGT  
 GAAATCTTTAACGATTTGTGCTTTTGTCTACGCGTCACTGCCATATGAAGAACTCCAAA  
 AATATAGAATCCCATAGGATTTCAGACAAGTTTGCCAAAGCTGAAAGACAACGGCAAC  
 TCCCTATTGCCAAGATAGGACAACGTGGCATTATGACACAATTCGCCATTCTGCACAA  
 TATTTAAGACCGTGAAGTAACCGTTAAAAATGCGCTCTGAAGCATTGTCTGCTTGAGA  
 45 CGGCAATGTTGACGCGCATATGCGCTTCAAACCAAGTTTCTTCTTCTTCGCGTT  
 TTTACGATATTGTCGCGGCTCAAACCGAATATAGCAGAAGCGGCTGGCAACCAATAC  
 GGAAGAAATAATGCCGAACAGATGCCAATGGTCAACGCCATAGAAAAGCGGTGCAAGGC  
 CGCACCGCGAACAACAGCATGGATACGACCATCGCTCGGTGCAACCGTGGGTAATGAT  
 GGTGCGGCTCATGTTGCGGTAATCGGTTGTGCGTACTTCGGGACGCGCATGTCGCGC  
 50 CATCGCGGCTTCGGGAAGTTTTCACGGATACGGTCGAAGCAGCAGCGGATTCGTTGCA  
 AGAATAGCCCAATACGCGAAGGATACCGCGCAAGCAGTACGGAATAATCCATTGAA  
 GAAAGCAAGCAGCGGAGAAATAATCAGATGCTGTCATATTGGCGATAATGGCAGATAC  
 GGCAAAACGCCATTCAAACCGCATGACAGGTAATAATGATGCCGATAACGCAAAAC  
 TAAAGCAATCAATCCATTACTTACCAATTCCTCACCAGCTTCGGGCGGATAAATTCAGC  
 55 TTGGCGCAAGGTAAAGTCGGGACTGTCTTTTTCAGCAAAATCCATAACCTGATTGGACA  
 CTGTGCGGAAGTAACACCTTCTTTGTGCGGACGGGATCATGATGCTTTGTTCGCTACC  
 CAATGGCTGAACCTGTACATACCTATTTTCAGCGTATCAGAGCGGTTCGCGCATCTTATT

GACATCCGCGACCTTGCTGATATTGGACATTCCATTACCGTACCGCGGGTAAATTGCGACAGA  
 GAAATTGAGACCTCTGGTAACCAAAAGAACCGGCGAGGATAACGTAAACCAACGAAAT  
 GAAGTGCCTCAGTTTGGCGGTAGCTCATAAACGGAATATCGCGTTTGATTTTAAAGAGTTT  
 CATAGCTTTACTCCTTGCGCTCCTGCCATTTCGGCTTTTCGGCTTCCACACCGAACCAATGGGA  
 5 AATATTCTGCAATTTGGCTCTGCGTACGACAGATTGACCAACGCGACGGAAATACGAC  
 GACGGATGAATACATCGAAGTCAGAATACCCAAACAGTGTACGACCGCAAAACCGCGGTAC  
 CAGGCGGGAACCGAATACCAAAAGCGCGATACCGGCAATCAGCGAAGTCAGGTTTCAATC  
 GCAATGGTGCGCCATCGCTGTTGGAAACCGAGATTGATTGCCTGCTCGCGCGGACCGCC  
 GGCACGAAATTTCTCGCGGATACGTTCTGTTAATCAGACAGTTGGAGTCGATTGCCATACC  
 10 CAAGCTCAACCGCAGCGCGGCCATACCGGTAACGTCAACGTTGCCTGCATGGCAGACAA  
 AATACCGATTAGGAACAGTATCTTGGCACTCAATGCAATGGTAGAAAAAGAAACCCATCAG  
 ACGGATGTAAACCCATGAATGCGACGACGATGGCAAAACCCATAAAGTCGAATGGAA  
 GCCTTTTTTCGATGTTCTCCTTACCCAAAGACGCGACGATGGTACGTTCTTCGCAATCTG  
 CATCGGTGCGGCAAGAGAACCGGCGACGCAACAGCAAGACGATATCATTGGCTTCGGCTGT  
 15 CGTCATGCTTCGGGAAATTTCCACGCGTCCGCGGTAATGGCAGTACGGATAACCGCGCG  
 GGTTACAACTCGGATTTCTTGGTCGATCAAAACCATCGCCATGCGTTTGGCGACATT  
 TCGCGCAGTCAGTTCGCCGAAAATGCTGCCGCCGCGCTGTCCAAGCTCAGACTCAGCGC  
 AGGTGCGGCCATTGGTGCAAACTCGTTGCGCATCGTTGATGTTGTCGCCGCTGACGGC  
 GACCTGTTGCTGATCAGCAGAAATTCGGGACGATCTCCGCGCTTGAAGACAGCTCATATA  
 20 ACCGCTCGGCGAGTTGCTTCCAATGCTTCGCGCACTTGGCAGGATCGTCTCCACAT  
 ACGCAATTCCAAAGTCGCGGTACGGCGATGATGCTTTTGCCTTGGCAGTATCCTGAAC  
 GCCCGGAAGCTGCACGAGGATACGGTCTGCACCGGACTGCTGGATGACGGGCTCGGCGAC  
 GCCCAACTCGTTACACGGTTTGTGACGGGTAGTGATGTTCTGTTTGACCGCTACGGAAAC  
 CACTTTATTGACCGCTTCTTCGAAAGCGTCAAGACGATATTGCTGCGCTCGAATTCAG  
 25 CGTTGCTTCAGAAACAGCTTGGCGCACTGCGCGAGAGCTTTTGCACATCACTCGCATCC  
 TGCAAAAGGACGCTCAGGCTGTTTCCAGCTGACGCAACCGTGCCTGCGGATTTTTCG  
 CGGCGGAGTTCGCGCGGATGTCGCCCGAATAACGTTCAAACTTTTTCGATCGTGTGCT  
 TCTATTCGACCTGCATGTTGAATGCAACGCGCGCGCAGGTCCAAACCCAAACATC  
 GGATTGGCTTTGATTTTCGCATCCATTTCGGGCTGTCCGCCAACAGGTTGAGCGCGGTA  
 30 ATATACCTTCGCCCAAAGTGTTCGATGACGTCGCGCGCTTAAGCTGCTGTTCTGTG  
 TCTTTGAAACGCACTTTCAGTGAATGTCCACAACAACTCCGCTCGGTCTGAATACCT  
 CGGTTTTTCAGCGCGCATCCACTTGAATTTGAGTCTGTTGCTGATGATGATGGCTTGT  
 CGGTTGGTCGATACCTGCACGCGCGGTGTTTGCCTGAATAGGTTGGGCGCGAATACACT  
 35 GCGGCAACCGCAATCGTGAACACAACTCAGCAGATATTTCCATAAAGGATAACGGTTTCATC  
 ATTGTCTCTTAATGGTTGAACCCACCCCTTCGTTGGTTCGGAATCGGCTATTTCAG  
 AAGAGCAAAAAACCTTCCAGCCAGGCAAGACGGAAGCGGCATCCTGAATATGCGCG  
 CCTCGCTGTCGGAACATGTCGAACCTTCGTTGGAATCAAAACAAGTGCCTGATTCG  
 40 GGTCTTCAGATGCGGCTTTCGCGCAAACTCAATCGACTTTTCGCGCAATCGCATTCG  
 TTCACTCGACCTCGATTTTGTACCTGTCGATATCCACGTTAAAAAAGCTGTTCCGC  
 GACTTCGTTTACCTTACCTTTGAAACCTGCGCGCAAGACCACTTTGTGCGGCACTTCAA  
 GCGCGCAAGCATTGCTGATGCGCTTTGAATTTCTTTTGTGCGGACGATGATCAGGAA  
 GTAGAACACCACCAATATCAACACTAAGGAGCAAAATGTGCACAGCTTGATCATAT  
 45 TTATCCGTTCTTTCTAATATGGTTGAAAATCGAGAGGGGTATATAATAACATAAGACGT  
 AAAACAATATATCGGGTTTGGCGTCGTAACGACGCTATACCGCAGCCTGCGCGTCCACAA  
 ACCATGCTCTTGACCGCTAATCTTGAATATCTATGCATGTTGCGGCTTTTTCGTTGGG  
 CAABAACGCGCGCACCGCATGGATTTGCAATCCGCGCTGTGCGGGGACGAACCGCGCG  
 50 AAACCATCCGATTTCGCCGACCGCATCTCTGCATCGACAGGCATTGCGCGCGCGCG  
 TATTTGGCAGCACTCCAAACCATAGAGCGGGAAGAAATCAGCGATACGCGCTCGCAT  
 GTGCCACTCGAGCAAAATATCTGAACCTTTGGAATCTTGCCTGCCCAAAAAGCAAGAT  
 TFCGCCCTGGATAACGACACTGCAATCAGCAGAGGATCGCTGTCTGCGCAGCGCTTTGCG  
 55 CGCGGCTTCGGCAGTTCAGGCAGTCGACATGGTCATGAACCGTAAGACGATGCGCT  
 TTGCGCGCGCGCGCGCGGACACCATCGGGCAGCGGCAAGACGCGCGGATTCTGCT  
 GCTGAACAACGTTGCGCGCGCGCTCATGCATGCCATTGCGGAATACCGCTGAAACGCAT  
 TGCGCTCATCGATTTGATGTCCACTACGCGACGGTACGGCAGAAATATTCACCAAGACA  
 TCCGCGCATCTGTTTTCACCTGTTGAAACCGACCTTTCCCTTCCCGCGAAACACA  
 CGATATGCGCCGACGCGGCAATATGGTGCACCTGCGCTTTCGCGCGAGAACCGGACGCG  
 CACATTCGCGGAACGCGTCCGACGGCAGTGCTACCCGCACTTTCGCGCATTCAAACCCGA

ACTGGTGTCTGCTGTGGCCGAGGATTGCAGCGCACACCGTCTAGACGAATCGGGCAGGCTCAA  
 CCTGCACGAGGCGGATTTTGCCTGGCTGACACACAAAATCATTGACAGCGCATCGGGCTG  
 CCCCAGCAAAATCATATCGGTACTCGAAGGCGGCTACACCGTTGAACCTCTGGGCACAATC  
 5 TGCTGCCGAGCATATCCGCGTGTGGCAGGGCTGGGCAAAATCCGATGCGCGCAACCGCCTA  
 TCAGAAAACTCTGGACCCCAACAAAAACGGTTTGGCAAAACCGAAAAACCGGACAGGTGGC  
 CCACCTACCCAATCCGACCGTTACGACATATAGTGGATTAAACAAAATCAGGACAAGGC  
 GACGAAGCCGACAGACAGTACAGATAGTACGGAACCGATTCTACTTGGTGGTGGACCACTT  
 AGAATACTGTTCTCTTTGAGCTAAGGCGAGGCAACCGTACTGGTTTGTGTTAATCCCA  
 TATAAATCCGCTCTGAAGCCGATTCCGTTTTCAGACGACATCATTATTGACCTGACGAC  
 10 AACGAAAAGCCTTCGCGCTGCTTAACACATCTCTTGAGACCTTTGCAAAAATAGTCTGT  
 TAACGAAATTTGACGCATAAAAAATGCGCCAAAAAATTTCAATTGCTCAAAACCTTCCTA  
 ATATTAGCAAAAAAGTAGGAAAAATCAGAAAAAGTTTTCGATTTTGAATAAGATTGAGC  
 ATAAAAATTTAGTAACCTATGTTATTGCAAAAGTCTCCTCTTGTAGTAAAAATATCTAAAC  
 AGATTCACTGGAAACGGTCAAGCTTCTTCAAGCCATTCCCATTTCAACCGCGCGCTGCC  
 15 AGATTGACAGCGTATTCTACTTGAACCAAGGAGCGTTACAATGAAAGCAGCACGTTT  
 TACGACAAAGGCGACATCCGCTCGAAGACATCCCGAACCGACCGTCGCCCCCGCGCAT  
 GTCGGCATCAATGTCGCTGGTGGCGCATCTCGGTAAGTACTGACCTGACGAATTCATGGA  
 GGCCGATTTTCATTCCGCTTGGCGTATCGCACCCGATTTCGGCGAGTTCGACGCC  
 GTAACGATGGGACAGAGTTCTCGCGCGTGGTCTATCCGCTCGCGCAAGCGTGGACGAC  
 20 ATCAAAGTCGGCCAACAGCTGGTGGTGAACCTACATCATCCGCGATGACGTACCGAC  
 GACGAAGGCGCAACTACCACTCTCCAAAGATATGAACCTTATCGGCTGGGCGCGCTGC  
 GCGCGCGCTGTCTCGAAAAAATCGCGCTCAACCGCGTGGGTCATCCGATTTCGCGAC  
 AAAATCCCGTTGGATCAAGCCGTTTGTGCAAGCCGCTGTCTGTGCGACACACAGCGCTAT  
 25 GTACGACGCGCGCGCAAGAAAGCGCAGCTCGCATTTGGTGGCGGTGCAGGTCCGATCGGT  
 TTGCTTTGGCTGCCGTGTTGAAGCCCAAGGCGATCAAAAGTCAATCATCACCGAGTTGAGT  
 AAGACGCGCAAGACAAAGCGCGCAATCCGCGTTGGCGACTACATCTCGACCGCTGCC  
 GAAGTCGATGTTGTTGCAGAAAGTGAAGAACTGACCAACGCGCAAGCGGTGGACGTGGCA  
 TTTGAGTGCACAGCGTCAACAAAGTTGTTGATACTTTGGTGAAGCCTGCAAACTGCC  
 GCCAATTTGGTTATCGTATCCATCTGGAGCCACCCGCGCACCATCAACGTCACACGCTG  
 30 GTGATGAAGAGTTGGACGTGCGCGCGCAGGATTGCTTACTGCAACGACCAAGCGCGAAACC  
 ATCAAATCTGTCGAAGAAGGCAAAATCAACCTTGAGCCTTTTCATCACCACGCGCATCAAG  
 CTGGACGAGCTGTTTCCAAAGGCTTCGAGCGTCTGATTCAACAACGAATCCGCGCTT  
 AAAATTTATGTGAGTCCAAACCTCTAAGCAAAATACATTTGCAACAGCACAAATGCGCTC  
 TGAAACCGCTCAGACGGCATTTTCCAAAGCGCAACAGCGGTATTGCCCCGAGAGCAGCC  
 35 GTTTAGCCTATCATTCGCAACAAACAGAAACAAACAGAAAGGAAAATCATGGGAGATTCCG  
 TACTATCCGCCATCCAACAAACCATCACCCAGCGAAAAATTCGCCAATCCGTCGGAATCTT  
 ACGTCGCACAGCTCTTGATTAAGGCGCAAGCAAAATCTCAAAAAAGTGATTGAAGAG  
 CGCGCAAGAGTGTGATGGCATCCAAAGACAAAAACCCGTCGCCACTGGTTTACGAAGTTG  
 CCGACTTATGGTTTACACCATGATTCTTCTGACACCAACGACCTGAAGGCGCAAGAGCG  
 40 TATTGGACGAATTGCGCGCGTCAGGCGGCTGCGGGCTGGTTCGAAAAAGCGCCTCGCA  
 CAGAATCTGAATTTATATTAATAACCGCACTTTCCACATTCATCCGCTGACGCGCTT  
 TTCAGACGGCATCGGAGCGGTTATGGACAACCTGATTTTCTGCAAAATCGCGCGCAAG  
 CATTCGCGCGCAACCGTCTATGAAGACGGCAAAATGGTTTGTTCAGAGAACTGCAACC  
 45 CGCTGCTCGGTTTCATCTGCTGCTGATTCCCAAGTCCATTTCGATTGCTTGGCACAACG  
 CGCGCCCGCAACATCAGATGCTGCTGGGCAAAATGATGTTGAAAGTTCCCGAAGTCGCGCA  
 AGCGCGAGGACTGGCAGACGGCTTCAAACCTGATCAATACCGGAAAAGCGCGCGGACA  
 AGAGGCTTCCACCTGCATATACACATCATGGGTACACCGTATAAACCGCTTATTTCACA  
 ATCAACCCCTAATCTTACTTAAGGATACATCATGGGACGTTTCTCTGACGACCTGGA  
 50 TTATCGTACTGATTATCGTCGTTTGATATTGCGGACCAAAAACTGCGCAAGCTGGCA  
 AAGACCTTCGCGGTCGCGTTTCATGACTTCAACAGGGGCTGAACGAAGGTACAGACGGCA  
 AAGAAGCCCAAAAGACGATGTAATCGAACCAAAAAAGACGAAGAACAAGCGCTAATTTC  
 TGTGTTGATTTCGGTTTGGCGAGCTGGTTTGTGCGGCATTATCGCCCTGATTGCTCTCG  
 GCGCCGACGCGCTGCCGAGGCGCGCGCACCGCGGACGGCTCATTCGGCAGGCTGCAAC  
 55 GCTTTTGTGCGGACGCTCAACAGGAATTTGACACTCAATGAACTGGAAGAACTGAGGA  
 AGGCAAAAGCAGGAATTTGAAGCTCGCGCGCTCAGGTCGAGACGCTCAAGAAACCCG  
 GTACGGATATGGAAGGCAATCTGCACGACATTTTCCGACGCTGTAAGCTTGGCAAAAAAC  
 TGCCCGAACAGGGGACACTGCCGATTTTCGGTGTGATGAAACGGCAATCCGCTTCCCG



ATGCGGCAAAACCCCTATCAGACGGCATTTCGACGTTATGCCGTCCGAACGTTCTCATG  
 CTTTCGCGCGAAACCCCTTGGGGACAGCGGGCAACCGGCGATACAGCCGCAACCCGCGGAAA  
 CGGACCAAGACC GCGCATGGCGGGAATACCTGACTGCTTCTGCGCGCGCACCCGTCGTAC  
 AGACCGTCGAAGTCAGCTATATCGATAGCTGTTGAAACGCCCTGTTCCGCACACCACTT  
 5 CCTCGGCAAAACAGGCAATAAGCCGCAAAACGCGATTTCGTCCGAACACCGCGCCAAAC  
 CTAATTTGCGCGTCCGTAATCATAAAGAGAGCAATCCGGTGTCCGAACACAAACAGAA  
 AACCCTGTCACCGCTGTGTCGAGCATCTCATCGAGCTGCGCCGCGCTGATGTGGAG  
 GTTGTCCGATCTTAGTCTGCTTTTTCGCGCTAATGCGGTTTGCCCAACAACTCTATACT  
 TTTATCGCGACCCGCTGATGGCAAACTTGCCCAAAAGACACAGCATGATTGCCACCGAT  
 10 GTCATCGCACCATTTTTCTGTCGCGGTCAAAGTTACCTGATGGCGCATTTTTAAATTTGCT  
 TCGCGCATACGCTCTACCAATCTGGGCATTTCGTGCGCCCGCACTCTACCAAAACGAA  
 AAACGCCGTGATTACGCCGCTCGTCTCTCCAGCGTCAGCTGTTTTCATCGGCATGGCA  
 TTTGCTCTACTTTTTGGTTTTCCCGCTCATTTTCAAATTCCTTGCCAGCGTTACCCCTGTC  
 GGTGTCAAATATGGGCACAGACATCGACAAATACCTCTCCTCATCTTGGGGATGTTTGT  
 15 GCGTTCGGCACACGTTTGAAGTCCCATTTGTCGTATCCTGTTAAACAAAATTTGGTGTG  
 GTAACACCCGGACAGCTCAAACGCGCCCGCCCTATGTGATTGTGCGCGCTTTTGTCAAT  
 CGCGCCATCATCAGCCGCCGATGTGATTTCACAAACCCGTGCTGCCATTCGCGTGATT  
 CTCTTATACGAAGCAGGTATTTGGTTCGGACGCTTTTTCAGGCCAGTTCAAGAACAGGAT  
 GCGGACATACGCCGCTGCAACAACTGACACTATGCCGTCCGAACCTCGGCTCATAC  
 20 CGCAACAGATTAAAGAAATACCTTTGAATACCCCTCTATTAGGTTCAAACAGCCCGCGCCG  
 AATGGAAATCCTGACACAGTTGGGCTACCGCGTCATCAACTGCCTGCCGCGATCGACGA  
 ATCCGTTAAAGCCGGCGAAACACCTTTCGCTTACGTTCAAAGGATGGCAGAAGAAAATAA  
 CGGAACCGCCCTGACCTCTTTTTCGAAACCAACGCGCAATGCCGATTTCCCGCTGAT  
 TACCGCCGACACCTGCGTCGTTTTCAGACGGCATCATATTGGGCAAAACCCGCTCCCAAGC  
 25 CGAAGCAATCGAATTTTAAACCGATTGTCGCGCAAAACAAACATACCGTCTGACTGCTGT  
 CTGATTCTATTCGCGGCAAAACGTCGAAGCCGCTGCAAAACCAACCGCGTCGTTTTCAA  
 GCCCTCGAGTTCGGAAGAAATTTCCGCTATGTGCAAGCGCGGAGCGGATGGACAAAGC  
 CGGTGCGCTACGCCGTACAAGGCATAGCGGCATCTTTATCCAATCTATCGAAGCGAGCTT  
 CAGCGCCATATGGGACTGCCGCTTTATGAACCGTTTCGATGTGACGATTGGGATTA  
 30 CGCTCCCGCTTGTCCGCGCTTAAACCGTAAAGACCGCGTGAACAGACAAACCGCTTAC  
 CTCTTGGCTCTTTTCAGCCTGATCGCATGATAATCCTGTCCCTTTCTCGGGAACATGTGG  
 ATTGCACCGTTGCGCCCGGGCGCTCGTGGCTCGCGCTCAAAGCCCTCCCGCTCTGTGCTG  
 CGCGTTTCAGGCATCTTGAAGAAAGAAATCTATACTTACCAATACAGCTCCATGCTGTTT  
 CTGATTTACTTTGCGGAAGCGCTGATGCGCGCTTTCGACGCTATCCCGCAAGACAGATT  
 35 TGCGCGCGCTTTCGCGAGTATTCAGCATCATCTTCTCATATCCTGCTGCGTTCGTC  
 AAACAATACAAGGAAACAAACAATGCCGCTGAAACGACCGTATCCGCGCGCACACCCGCG  
 CGCCAAACTGCCGATTACATCCTGCCCTGCTTCTTTGGATAGGCATCGTCCCTCTGAC  
 CTTCGCGCTCAAACCTGAAACCGCTGCGCCGACTTTTACCAGATGCCCGCGCGACGCGG  
 CCTGATTGTCCTGTTGTTCTCAGCGCAGGAAAAAATGTTTGATGTCAAAATCCCGCG  
 40 CATCAGCTTCTCTGTTTGAATGGCGCGCTTTTGGTATCTTCAGGCACCGCTGATGAA  
 CCTGATTTACCCCGGTATGACGACATCGTCTCTTGGATTTTCATCTTGTGTCGCGTGA  
 CGCGTGGGCTGCCGAGCTTGGTCGCACATCTCGGACAAGAACGCATCTGTGACCTGTT  
 TGCTGGTCTGCTGCTTATCGGCTCCGTCTCAATCTGATCTGTCGTCATCCAGTTTGC  
 CGGCTGGGAAGACACCCCTCTGTTTCAAAACATCATCTGTTTACAGCGGGCAAGGCGTAA  
 45 CGACACATCTGGGACGCGCAACAACCTCGGACATACCTCATGTGGGCGATCTCGCGCG  
 CGCTTACCTCAACGGCAACGAAAAATCCCGCGCGCCCTCGGCGTAACTGCTGATTTG  
 GCAGACCGCGCTTTTAGGTTTGGTCAACTCGCGCACCATCTTGACCTACATAGCGCGCAT  
 CGCCCTATCCTCTCCTTCTGGAATTTCCGTTCCGACAAATCAACAGGCGGACATGCT  
 CGGATGACCGCGAGCGTATTCCTTACCAGCGCTGTTTCCAATTTTCCATGAACACATCT  
 50 GGAACCTTTACTGGCATCCGCTACGAAACTGCCGTGGAACGCGTGCACAGCGGCTT  
 CACAGACTTGCCGCGCAAACTGCAATGGAATAAGCCCTTGCGGCTTCCAGTCCGCGCC  
 GATATTCCGGCACGGCTGGAACAGTTTGGCCCAACAACCTTCTCATCAATGCGCAACA  
 GCAACAATACAGCAACCTCTCAGCAAGCTTGTTCACCCATTCCCAACAATCGTCTCT  
 CCAACTCTTTGCAGAGATGGGAATCAGCGGACGCTTCTGTTTGGCGCAACCTGCTGAC  
 55 GGTGATTTCCGGGCTGCTTAAACGCCCTGACCCCGCATCGCTTTTCTAATCTGCAC  
 CGCTTGGCGTCAGTATGTGCCACAGTATGCTCGAATATCCTTTGTGGTATGCTCTTCT  
 CATCCCTTCGGGATGATGCTTCTCTGTCGCCCGCAGAGGCTTCAGACGGCATCGCCTT

CAAAAAGCCCAATCTCGGCATCTGACCGCTCCGCCCATATTGCGAGGATTGCT  
 GCATTTGACTGGACATACACCCGGCTGGTTAACGCCTTTCCCGCCCACTGACGACAG  
 TCCGAAAACCTCAACCGGAAATCAACGAGTTGCGCTATATTTCGCAAAACAGTCGAGT  
 5 GCTGTCCTTTTATGCCGACTTCTCCCTCGTAACTTCCGCTGCCGGAATACCCCGAAAC  
 CTAGACTTGGCGGGAAGAAGCAACCTCAATCACTAAAATACCGCCCACTCCGCCAC  
 CTACGCGATCGCCCTCTACCTGATGCGGCAAGGCAAGTTGCAAGAGCAAAACATGGAT  
 CGCGGCGACACAGTCTTATTACCCGTACCTGTATGCCCGGATACGCCGAGAAATCCGCA  
 ACTGCCGCTATGGGCGCCGCTGCTACCCGAACCTGCTCAAAGACTGCAAAGCCTTCGCCGC  
 CGCGCCCGGTCATCCGGAAGCAAAACCTGCAATGACCCGCGCGCGCGGATGCGGATAC  
 10 CGCCGCAATGTAAGCTCCATGCAAGACATTGCAAAAACAGCAAAACCGTAGGGAAT  
 ACCTTATCAAAAAACATTGCAGCGGTGTTAAGATAAACCGTCAAAACATCTTTTCACaGc  
 CCGCCCGAAACAGGGTCGGGCATACCTTTACGAAAGGAAACACCATGAGCCGCGTAT  
 TACTCGTAGATGACGATGCCCTGCTAACCGAACTGCTGACCGAATACCTGAGCGCGAAG  
 GTCTGAACCTCCGACGCGTTCCGACGGGGAAGCAGCGGTACAGGAAATCCTGAGCGGGC  
 15 AGTACGATGTAGTCGATTGGATCCATGATGCCAAAATGAACGGCTTGGATGCTCTGA  
 AAAACGTACGCGCCGAGACACCGTCCCATCATCATGCTGACCGCAAAGCGACGACA  
 TCGACCGAATCATCGGCTTGGAAATGGGCGGGACGACTATGTCGCCAAACCTGCAACAC  
 CACGCGCACTCTTGGCAGCATCAATGCCATCCTGCGCGCGGACAAACAGCGGCGAATC  
 AGAACACGCAACCAACAGCATCTCGTCAGCGATGTCGCTCTGACCCCGCAAAACGGC  
 20 AGGCATCCGTCAAAGACATGCCGCTCGAATGACGAGCACCAGATTCAACCTGCTCGAAG  
 TCCGTAGTGGCCATGCCGGACAGGTAGTCAGCAAGAAACCTGTCCGTGGAAGCATCG  
 ACCGCAAGCTGGCAAAATTCGACCGCAGTATGCACGTACACATCTCCAGCATCGGCCAC  
 AGTTGGCGATGCCTCTCTGATTCAACCGTACGCGGCTTGGGCTACCTGTTTGTCAAAA  
 ACTGAAATAAACAGATAAATAAACTGTTCCAAACGCATTTCCGCCAATTTTGGCGGGT  
 25 ATCGCTCTGTGCATCTTTGTGGCAGTTTCTTCTTGCTGGTGTGAGAAACACCTTTGCC  
 GAAACCAAGTTCAACCAACGCGCACCATCGAAACCACTTTGATGGGACGATCATTTCC  
 GATTCGCGGACGCGGGGACGCGGGTGGCGCGGAATCCTGACGGAATGGAATGGAAGC  
 CCGCTCTCATCGGGCGGTGACGTATATACGGGCGACGAGAAAAAGATATCCTGAACCGG  
 TATATCGACAGCTATACCATCGAACGCGCCCGCTTTTCGCCCGCGGACACCGGCATCC  
 30 AACCTCGTCCATATCGAATACGACCGCTTCGCCGAAGAATACCTGTTCTTCAACCAAGAC  
 TGGGCAACACTCCAGCGCGCGCGCTGCCAGCGCCCTGTTGATCCCGGCGCTGCGCTG  
 GCCCGATTTGGACGAACCTCATATATTGTCCTCATCATCATCGTCGGACTCGTGATG  
 GCATATATCTCGCCGGCAACATTGCCAAACCATCAGAATCTTAGGCAACCGCATGGAC  
 AGGGTGGCAACCGGAGAATCTGAACCCGATATCTCCAAACAGGTGACGACCGCGACGAC  
 35 GAATTTGCCATCTTGCCATCCAATTGCAGAAATGGTGGAAAACTCGAAAAACTCGTT  
 GCCAAAGAACGCGCACCTGCTCCATCAGCTCTCCATGAAATGCGTTCTCCCTTTGGCGGC  
 ATGACGGCAATTTGTCGACTGATTGAGGCGCAGCCCCAAAAACAGGAGCAATATCTCAAA  
 CGGCTGGAAGGCGAACTGACCCGATGGATACGCTGGCGGGAACTGTTAAACCTGTGCC  
 CGTCTCGAAACTTCCATATGCGCTTGGAAAAAGAAAGCTGAAACTCTCGCCCTTCCTG  
 40 GGCAACCTGCTAGAAGACAACTCAAAGCATTCGCAAAAAACGGCAACCGGTTACCTG  
 TCTGCCGACGAAAAATCCCCGAAAAACACCACTCCTTGGCAACGAAAGCTACCTGTATC  
 CGCGCCTTCGACAACGTCATCCGCAACGCGCTCAACTACAGCTCCGGAAGGCGACGACAT  
 CTGATCAACATCGGACAAGACCAAAACACTGGAATATCGACGTTACCGCAACGCGCCC  
 GCGCTGGACGAAATGCAGCTCCCGCATCTTCAACCGCTTCTACCGCTGACGACTCCAGT  
 45 GCCAACAAACCCGGAACAGGACTGGGCTTGCAATTGACCAACATATATTGACAGACAC  
 TGCGGCAAAATCATCGCGAAAAACATCAACCGCAACGGTCTGCGGATGCGCTTTATCTG  
 CCAAGAAAAAAACCGGTTCCAAAACAGAAAAAGTGCAGACTGACCATATACGCGTGC  
 AACCGCTTCAGACGGCATTGCAACAAAGTATACCCCAAAACCAACACAGCGGCGTGC  
 TCTCCAAAAATCAGCGACATACCGTCCGCAAGGAATATATCATGTGCGCAACCGGAT  
 50 CCGGGTACTTCTTCATGCCCAACACATCATCTGATAGGCGCGAGCGAACAACCGTAC  
 AGCTGGGCGAAGCTGTACTCAGCAACCTGCTGAGTACGCGCTTTCAAGGAAAAATCACC  
 CCGCTAAACCGCGCCACACACCATAGCGCGGACTGCCCGCTACACGAGCTCAACAAA  
 ATCCCGCGCAATGCAGACCTGATTATTCGCGTTACCTACCCGACAGTTACGACACCGCT  
 TTTCAAAACCTGCCGAAAAAGCAGCTCGGACACATCATCTCATACGAGCTGGGACAAAC  
 55 CTGCTGCGCGAGAACTGCACACGCGCAAACTGCCATCGGCAACACACGCGCAACGGA  
 CTCAACTCACCGCTGCACACGCGAGGACATCAACTGCGCTCACTCGGACTCAACATC  
 AGTACCCAAAGACGGATACGCGCAGGCCATACCGCATACTGACCGGCAATGCGCGCTC

AGCGCGCAAAATCGACAACATCTGAAACAACTCCGTCAAGGCATCCCGGCCACATCAGC  
 CTGCATCCCGGCATCAGCCCATCAGATCCGCGGATTGGCTCAACCGCTTCGGACACAGC  
 CTGCACACCAAAACCGCGCTCTACACCAACCCCTGAAGAGGATCAGCGAAACTGTTCT  
 AGCGCAATCCGCCAATTTACCCGGCATACGCCGCTGATTCTCCATCATCCTCGCGCAGC  
 5 ACAGAAACCGACCGTGGCGTACTGCACTGCTCGCCGACACTGCAACTTCTCTGTGAGT  
 TTCAACCGCGACGACCTCGAAGCGCATGCGCGCCCACTGTCCGACCTTCCACCCCTG  
 TCCGCACTGCACATCTGTCCGACACGCTGCGGAATGGCTGCACGCGCACGCGCCAA  
 AACCTCACCTCCACTTTCCCAACTTTCCCAACACATCCGCAACGGACACCTGACCGGC  
 ACACCCACACCTCAATCTGCCAGGACATCGCCTCAGCTCAGCTTGCCCAACCCGACAC  
 10 CAAGCCGCTCTAACCATCTCAGTCCCTCCGACACGAGGATTACAAAAAACAGCACGC  
 GCGCTTATCGCGCTGTCCGAACAGACCGCAAAACCCCTGCTCGTCAGCAGCCCTTTTCA  
 CAGCGCATTAACCATTTTCGACACCCCACTCAGGCAATCCGACCCCTTCTACCGCAAC  
 ACCGCGCGCGCTTGAAACAGGCACAGCTCGACATTTGCACCGCGCAGCATGCGGCTGT  
 AAAACACCGCAACCCCAAAACATCAAAAAAGCCCTTGACGCGCAACCCCTCCTGCTC  
 15 GCGGAAGCCTGCACCTCCCGCCCTACCGGCACACACCCATAACGCGGTACAAATCCAA  
 TTTGACAGCCACCCCTCTATGGCGACATCCTGACGCACTGCAACGGAACAAACCACT  
 GCGGTACTCCGCGCTTTACCACTGCTGCACGCGCCACCTTGCCGCTTTGCCGAATC  
 CAGCGCACAAACCTCGACCACTTCTGCACTGACCTGACCGTCAATCCGGAATACCGC  
 CAACACATTTCTCGGCATCACCCTCAACCTCAACGCGGGACAAATCAGCAGCGATTTCCTC  
 20 TTAAGACACCGCAACACAGGACAGCGCCAAACCGAAGAACACAGGCAAGCGCGCCAA  
 ACCCTCGAATCATCGCGCGCAAAATGCGAGGTGCGCGCATACCTGAACACAAACAC  
 CGGACAGCGCGCAATTTCTCGCGCACACAGCGAAGCGCGCGCAGAACTGCTCGGCAAC  
 AAAACCGAAACCGGAGCAGCGCTACCAACGTAATTTGCCCTATCCCGAGCATACCC  
 25 AAAACATGTCCTTAAGAAACACACGACCGTTACCATACCCCATTTTGCCGGAAGAC  
 GCAGAGCCAAACAGCAGTTCTGTCGCGACGCTCGGTCGGAAGCACGTCACAGCCTTC  
 ATGACCCACACCAAGCACTGCGCGAGCCAGTTGGCAGCCTGTGCAACCCCGATTAC  
 CACTGTGAAGCGCATGGACGCAAGGATGCGGACAGCAACATGCTGCGCTGCTCGC  
 CACAGCGCCTGAATGCAAGCAATGCGAATTCGGCATCACACTGCGGGAACATATGCGC  
 GCGAGCGACTGGCACAGAAATGATGGAATCATATCAAAACCGCGCAGCAGCAAGC  
 30 TACCGGACTATGAGTGCCGACATTTCTCAAAACCAATACCCCATGATCAAACTTGCTGAA  
 AAATCAGGATTTACCTCAAGGAATCGGACACCGAAAAAACCTGTACCGCGCATATCTG  
 AACCTTGGCGCAGACAAAACACAGAAAAACAAATAAAACTTGCGCACCGACCAACAA  
 ATAACCTAAATCGCGAGTTTCCATATATCGATTCTTCAAAAGGACTCAAAATGGTAT  
 TATCGTTTGGCACGCGCGGCTCGAAACACCGCCCTTCTACACGTCACTGTTACTG  
 35 ACTCACGCGCGCGCGCAGCGCGCTTCATCGAAGCGGTAGGCTTCTACAACCCCGTAG  
 CCAACGAAACAAAGAGCGCTCGCGCTCAATGCAGACCGCTGAACCATGGATTGAC  
 AAGCGCGCAAGTCAGCGACTCGGTTGCAAACTGATTAAGAAACAAAGCGCGCTAAT  
 CGGCATTGGCGCATGACAGACACTCAAAACCGGCTAGCCATGGGCTACATCAAGGCG  
 TATTCCGCAATAAAGGCTGGTTGAATTTGCCGCCAACCCGAATATTCCGACAGCCTTT  
 40 TGGACTACCCGAGTGGCATTTGGTCAAGGACGGCAAAACCATCAGCGTTACCTTTGAAG  
 CCGGAARAAGTCGTCAACGCGCAACTCCAGTCAAAATCGAAGGCATTAACGACCGGACT  
 TGGCATTTCTATTGCGCGGTTACACCATCGAAATACCCCGTGAAGCATTCGCCCGCAGC  
 AAGAAGACGAATACTACTGACAGACTTGGTCGGCATGACCGTTGTCAACAAAGACATA  
 CGGTTTTAGGCAAGGTAAGCAACCTGATGGAACCGCGCAACACGATATTGATGATTG  
 45 ACGGAGAACACGGGAGATTCTGATTCCGTTGTTTCCAAATATATGAAACCGCTGATA  
 CCGGACAGCAAGACCATTAATGCCGACTGGGTTTGGACTACTGATGCTTATCCAGGACT  
 TACCATTTTCCCGCAATGTTGCAGACATTACCGCTACGCGTAACGGGAGCGCGGAA  
 CAGACGGAATCTGGCAGTTGAAGCAGTCAATCCCGAAAGTTTGGCGCAACAGATT  
 GGGCTACATCGACGACCGCGGTTGGCGCGCGCGGGAATGATTATGATGGCTCGCCG  
 50 GCTTCATCGCGCAATAGAACACGCCAAACACCAATCTCCCAAGCTGCAAAAGTCATCTA  
 CCTACGCCCCCAAGGAAACCGCTTGACACACCAAAAGCGGTGAAGCTGGCAGAACTTC  
 CGCATCTGATTCTGCTGTGCGGACGTTATGAGGGCATAGACGAAAGGCTTCTGCAAGGA  
 CGGTCGATGAAGAAATCAGCATCGGAGACTTCGTTGTTCCGCGCGGAGGCTTCCCGCA  
 TGATGCTGATGGATGCGGTATTGAGGCTCGTACCGCGGTATTGGGCGATATGCACTG  
 55 CCGAACAGGATTCGTTCTCAAGCGGCATTTTGGACTGCCCCACTACACCAAAACCTTAG  
 AATTTCAAGTATGCGTGTTCGGAAGTATTGCGTTCCGGCAATCATGGCTGATAGCGG  
 AATGGCGGTTGGAACAACTCGCTGCGCGCACCTTGGAGCGCAGACCGGATCTTTTGAA

AGCGCGTTTTAATCCCAAAGGAATCCCGCCTTTAGAAACCATCCGGCAAGAGCAACGGG  
 AATCCCAATCATAATTTAGGAAAAAAACAATGAACCTGATTCAACAGCTCGAGCAAGAAG  
 AATTTGCCCGCCTGAATAAAGAAATCCCGAATTTCGCACCGGGCACCGTAGTCGTAT  
 CCGTACGCGCTGTGGAAGGTACCCGACGCGCTCTGAAGCCTCAAGAGCGTGGTTATTG  
 5 CCGGTGCAACCGTGGTCTGAACAGCAACTTCATCGTCGCAAAATCTCCAGCGGGGAAG  
 GTGTTGAACGTACTTTCCAACGTACTCTCCGACCGTCGAAAAAATCGAAGTCAACCGCC  
 GTGGCAGCTACGCGGTGCCAACTGTACTACCTGCGCGGCTGACCGTAAAGCTGCAC  
 GCATCAAGAAAAATCGCTGCACGCAAGGTTGATTCAACCGTTTTCCCCCAATGCGC  
 TCTGAACCTTCAGACGGCATTCTTATTGCTGCGATGCGCGCAAGTCAACGATAGCTG  
 10 CCCTCATCCACCTTGATTAAACAATCACTCCCGCTATTCAAGCATAAATTACAGACCAA  
 ACCTATACAGATCATATCAGCCATATAACGATAAACGCTTTACCGCTTCCTTTCAA  
 AACCGCAATCATCATGACACCTTCCTTTTACTATCAGGATTGACCTTCCGCTCATCC  
 TTGCCCTGATTGCCGTATCCCTTTTATGGGGCGTTTACTTTTGGGACGATACCGCATGAG  
 CATCATTTGCAAAACCTGACCGTCAGTACCGCGCCGACCTGCGGTGCACATGTGGA  
 15 CATTACTTTGAAGACATAGTATGTGGCGGTTTCGTCCTCAACGCGCGCAGGGAATC  
 CACCTTTCTCAAATCCTTGATGGGATTGACGCTATCGATACAGGCAGCATCCGGCTGGA  
 CGGATTGACCGCTCAGAACATCGCCTACCTTCCCGACGAGTCCGATATCGACCGCTCCCA  
 GCCTATGACCGTTTTGCACTTGGCGCAATGGGGCTATGGTATGAATTCGGCTTCAA  
 AGGGATAAATACCGCTCAAAACACCGCGTTCAGGAAGCCTTGGAGCGGTGGAATGCA  
 20 ACGGTTTTGCCGACCGTCAGATTGCTATCTCTCAAAACGGACAATTCACGCTGTCTTTT  
 TGCCGGAATGCTGGTTCAAATGCAAAATTCCTGCTCGACGAACCTTCAATGCCGT  
 TGATGACGAGCAACCTACGAGCTTCTCGACGATTGACGAATGCCATTGCGCGGGACA  
 CGCCATCATCGCCGTACTGACAGATTACGAACAAGTCCGTGCTTCTTCCCAATACCTC  
 25 CTGCTCGCCCGCGAAAAAATTGCGCGAGCGCAACCGAGACCATTCGACAGAACCTTA  
 CTTGCGCCCAAGCCAACGCCAAAATGCAGCAACAGGAAGCCCGACTGGTGGCGCTGATA  
 AATGCCGTCTGAAACCGAAAAACCATGAATCTCTACGACCTGCTCCTTGCCTGCTTGA  
 GAATTCGACTTATGCGCTACGCCCTCGCATCCGTCTTCTGCTGTCCCTCATGAGCCGCA  
 CCGCTCGGCGTATCTCTGCTATGCGCGGTATGAGCCTGATAGGCGACGATGAGCCAC  
 GCGCTCTGCGCGGTGCGCGCGTGGCTACATGTTTGGCGCTGAGCCTGCCCGCATC  
 30 GTTGTGGCGGGCTAGCCGACGGCATGCTATGGCATGCTTGGCGGCTGCTGACGCCG  
 TTTACCAACCTGAAAGAAGATGCCAATTTGCGGCTTTTATCTACGACGCTCGCCATC  
 GGCCTAGTCTGCTCGTCAGCAAAAACGGGAGCAGCGTGGATTGCTCCACCTCCTTTTCGGC  
 TCTGTACTTGGCGTCGATATTCTGCGCTGACGCTCATCGCCGCGCTCTCCAGCCTCAGC  
 35 CTCATTACCTTTGGCGTCATCTACCGCCGCTGCTACTCGAAAGCATCGACCCCGTGT  
 CTCAAATCCGTCGGCGGCAAAAGCGGGCTTTGGCAGCTCCTCTTCTGCTCCTGGTCTG  
 ATGAACCTCGTATCCGGCTTTCAAGCCTCGGCACATCATGCTCGGACTCATGATG  
 GTGCCAGCATTAACGCCCGCTGTGGGCGAAGCATATGGGCGCACTCATCTCTATCC  
 GTTCTGACAGCCCTGCTGTGCGGCTTGAGCGGACTGCTATTCTCAACCATGCAAAAT  
 CCTTCCGGTCCCGCATCATCTCTGTGTCAGCGTCTCTTATCTCTTTTCGCTCATACTC  
 40 GGCAAGAAAGCGGCATTCTGACCGG

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 6>:

#### gnm\_6

GTTATGATATGTTTCGATATGTAACATTTATAGGTTTGGAGCGATAAAACATGAATGCA  
 45 GTCTAGTGTGCGTAATCGTTATGCTGGTCTGTGCGTGTGCGCGTGCAGTGGTATTG  
 AGCCTGACGCTGCGCGGTTTGTGCGCGCGCGGTGGCGGGTATCCGCTGCAAAACAT  
 GCCGATCGGCGGGACAGGTCACTGAGCGGGGATTATCCCGGTGTTCAACAAAGGTTG  
 GAAGCGGGTGCAGAGATTGCGCTTTCTTATGCGATGCTCGGCGCTTGTGAATGGCGATT  
 ACCCATTCGCGCTTCCGCGACGACTTTCGCGCGGCTGTCGCAAGCTGAACCGGGG  
 50 GGTATGCCCGACAGCGTGCCTTTCGGGCGAGGCGCGGTCAAATGGCTGCTGCTTCCATC  
 ATCCTTGATGGGCATGATGAGTCAGAACATCATCCCATCCACATGCTCTTATCCCG  
 ATGATTGTTCCGCGCTGCTTTGGTGTTCACCGCTGAAATGACGCGCGCGCTGATT  
 GCGTGCCTCATACTTTCGGGCTGGTACGACTATATGTTCTGCTTACGGCTTCGGC

GC GATTTTTTTGAACGAAATCCTGTTGGGCAACATCCATTCCGCGCGCCGCGAGCTTGAT  
GTGAAAAACATTAACGTGATGGCGCAATGGCGATTCCGCGGTTGGGAATGCTGGCCGGA  
CTCTCTGCTGGCGTTTGTCCATTACCGCAAAACCGCGCTGTACCAAAACAACTATGCGCAT  
5 AC GGGCGGGCAACGCCGATGTCGGCAACACGTCGCGACCGCTCCGCCATACCGAGCCTGGCC  
GCCGCCGTGGCCATTGGCGTATGCTTTGCCATCCAGTTGATGTATGAAGACTGCGCTGGTG  
TTGGGCGCGATGCTCGGTTTTCGCCGTATTATGATGTTGGGGGTTCATTAAACCGGCAACAG  
GCAAACGACGTATTTCGGCGAAGGTATCAAGATGATGGCATGTTGGCTTTCATTATGATT  
GCCGCGCAGGGTTTGGCCCGTGTATGAATGGACCGGGCATATTACGCCGTGCTGGTGGAA  
AGCAGTATGGCGATATTCCGCAACAGCAAAGGTATGCGCGCATTTGGCGATGCTGGTGGTG  
10 CGGCTTTTGGTAACGATGGGCATCGGTTCTGTCCTTTTCCACTTTGCCGATATTGCGCGG  
ATTATATGTCCTTTGTGTGTCGGTTTGGGTTTTTTCGCCGCTTGGCACCGTGCCTATTGTCT  
GGCACGGCGGGGGCGTTGGGCGATGCCGGTTTCGCTGCGTCCGATTCCACGCTGGGCGCC  
ACGATGGGGCTGAACGCCGACGGGCGACGACCCACATCCGCGATTCCGTTATCCCGACCC  
TTCTATCCACTACAACATCCCGCTGCTGATTGCCGGCTGGATTGCCGCGATGGTGCTGTAA  
15 ATGACGCGGTTCAAGAGTTGGAACGCCGTATTGTGCAACTGGAATCCAATCCGCGCTT  
CAGGAGGACGTAATCGCCGCCCTGAACGCGATGGTGGCGGAATTGCGGCGAGACCTGGAT  
TTGACGACGCTCAGTTGAGGCTGCTGTATCAAAAAATGCAGGACAGGAATCCCGACCGCG  
CAAGAGCGCTGATTCCCTGCGCGACGAGATTCCGCGCATTTATGATGCCCGCGATCTCC  
GGATTTCCTTAAAAAGGCTGTGTTTGAATATTCCGCGATGCAAACTAAGATATATAG  
20 TGGATTAACAAAAAACAGGCAAGGCGAGCAAGCCGACAGACAGTACAAATAGTACGGAAAC  
CGATTCACTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGCGAGCGCAAA  
CGCTGTACTGGTTTTTGTAAATCCACTATAACTTTAATCAGTCGGCAAAATGCGCTTTTAT  
TCCGATGGGAACCGTTTTCCGCCGCAACGGAATTAAGCGCTTCCCGCTGCAAACTGAT  
AAAAACCAACCGGTTATCAACACAGCCAAAAAAGCGCTCCGAACCCAAAGGGGACAGAT  
25 AC GGGCAAAACACATTACGGGGAAACGTTTTACTCAATGAGTCTGCGAAACACAGATTGC  
TAAACCAATTGCAATTATAAGGTAAGTTATTTTTTTTTTTTTTTTTTTTGAAGAAATG  
TAAATTTTTTAAATTTTAAACCGCTTCGCGCGCATCCGTTTGGATGCGCTCTGAACCGCG  
GGCAGGGTTTATCGCGCTGTGCCGCAACCGGGCATTCAGGGTTGGCGGCGAGGTCGAA  
TATTGCCACGCCCTTCCAAGGCAAGTAAACCGCCAGCTTCGCGTGCAGCGTTTCGCC  
30 GCATCCAGCAGGATTTTCAGAGCCTCGCGCGCTTGGGTACTGCCGATGATGCCGACCAGC  
GGCGAGAACACGCCGAAGAGAGAACAGATGCCGCTGTAAGCCGATCCGCGCTCAAAACAGG  
CAGGCGTAAACCGCGAGTCGGGCAAGTCGGGACGGTACACGGCAAGTTGCCCTTCAAAG  
CGTACCGCCGCCCTGAAACACGAGCGGTGTTTTCGTTTGCACGCGAGGACGGTTGACGGCT  
TGCCGCTGGCGTAGTTGTGCAACAGCTCAAAACGATGTGCGCGCTTGAACCAAAACCG  
35 GTCAGCGCGCAGCGCTCGAGTTTTTCGTTGACGCGCGGACGTTGACGGTATGGTTGATG  
CGTTTTCAGCGCGGCTGCCAAGGCTTCGGTTTTGAGTTTGGCGACATCGGCCCTCGTCAAA  
CGCATTTGGCGTTGCGAGTTGTGCAAGTTGACCGGTGTCGGAATCGGCTATGGTCAGCGTG  
CGCACACCCGAAGCGGCAAGGTAGGGCAGTGCAGCGGCAACCCAAACCGCCGCGCAGC  
ACCAAAATATGCGCGGCGGAAAGTTTCTGCTGCCCTTCGATGCCGATTTGCTCCAGAGAG  
40 ATGTGGCGGCTGTACCGCAGCAGGAATGCATCTGCTGTTGCTGCTTCGCTGCTGGTCTATG  
ATGATGTTGCGAAAAAACAGTTGCGGGCGATTGTAAACGCTGCCGTGCGGCGCGGCTTCAA  
CTTCAGACGGCATTTCCGGACACGGCGGTTAAAGTGTGAACGGTTTGGCACGGATGGCGG  
CATTTTGGGTACATTTACAAATATTACGGCAGCAGAGAGAGAAAAATCATGCAACTGCAT  
ATTCTGAACAAATCCAAAGGACCGGGCTTTGGCGGCGGACCGGGAATTTCTGAAACAAATCC  
45 CTGTTCAACCTCCTGCACGAAGACCTCGCGCTTGGTTTTCGAAACAGTCAAACTCTTG  
TCCACTTCGACGACAGCGCGGCTGATTGTAAGAAAGTATTGCCGCAATTGGACAGAACAA  
CAAAACCCAGGATTAACTTTGGCTTGGCGGCTTTCGCCAGATTGTAACATGCGCCGAA  
GACGTGCACCACGAACGCCGCCGCAATCCACGAAGAACCGGACGCGGCGCGCGGAA  
GGCAGCTGACGGAACCGTCCGAGGCTCAAAAGCGGGGAAGCCAGCGCAATCGGTG  
50 CAGCGGCAGTTGGACAATACGTCGTTACCGCGTTTTGACCGCGCACCCGACCGAAGTG  
CAACGCCCAACCGTCTTAAGCTTCAACCGCGCATCCGCGCACTGTTGCCGCAACCGTAA  
CGCTGCACCAATGCCGACGCGCTGGCACGGCTGCGCGCGGAAATCGACACTATCTGTCTG  
GGCTTGTGGCAGACAGCGAAACGCCGCCGCAAACTCAGCGTCAACGACGAAATCAAC  
AACGCGCTGTCCATCTTCGCGATGAGCTTTTTCGAAGCGCTGCCAAGCTCTACCGCGAA  
55 ATGGAACACGACTTTCAGACGGCTATCCCGGCGTCCGCGTTCCGAGCATCTTCAAAATC  
GGCGGCTGGATGCGCGGCGACCGGACGCGCAATCCGTTTGTTCGCGCAACCGCTGCGC  
TTTGCTTTCCGCCGCCACGCCGATGCCGTGTTCCGCTTCTATCGCGGCGAATCGACAAA

CTCTACCGCGAATGCCGCTCTCCATCCGCCGCTCAAAGTCAACGGCGATGTAACGGCG  
TTGTCGCCACAATCGCCCGACGAAGAAATCGCCCGCGCGCAAGAACCTTACCCGCCGCGC  
ATCGCCTACATTATGGCGCGCGCTATGGGCAAGCGCGCGCGCTCGGTTTGGGTATGGG  
TGCAAATTTCGGCTTTCTCGAGCCTTATGCTTCGGCACAGAGTTTCTGGATGATTGGAA  
5 AATTTGCAACGTTCCCTTATCGACAACGGCAGCGCTCTGTTGCCGAAGCCGTTTGGCA  
GACCTCATCCGTTCCGTATCCGTGTTCCGCTTTCACATGATGCCGCTCGACTTGGCGCAA  
ACGCGAGCGAAACACGCCGATGTGGTTGCCGAGCTTTTCCAAACACGAGCTTGGGAAGC  
TACAACCCGCTGAACGAAGAGCAAAAACAAACCGCCCTGTTGCGCGAATTGAGCCATCAA  
CGTCTCTGTACAGCCCGTTATCACATACAGCGACCATACCCGCCACGAAGCTGGCAATT  
10 TTCAACGAAGCGCGCAAAATCAAAGACGAATTTGGCGAAGATGCCGTAAACAAAGCATT  
ATTTCCAACCTGCGAAACACCCAGCGACCTGCTCGCCTTGGCATTGCTGCTGAAAGAAAC  
GGCCTGTTGGCGGTGGAAAACGGCAACCGCACAGCGCATCAATATCGTGCCGCTGTTT  
GAAACCATTTGAAGCGTTGGAAGACGCTGTCCGCTCATGGAACCATGTTCCGCTCGAC  
TCGTACGATGCACGTCTCGAAGCCGTGGAAACATCCAAAGATCATGCTCGGCTATTCC  
15 GACTCCAACAGGACGGCGGTACGTTACAGCTCATGTTGCTCTATCAGGCGGAATTG  
GGCTTGGTCGAACCTTCAAAAAATACGATGTCGATGCGCTGTTCCACGAGACGGCG  
GGCAGCGTAGGTCCGGCGCGCGCCCTTCTTACCAGCCATTCTCGCCCAACCGCGCGCG  
AGCGTGGCGGGAACAAATCCGCATCACGGAACAGGCGAAGTCATTACCGCCAAATACGCG  
GACCCCGGCAATGCCCAACGCAACTTGGAAACCTTGGTTCGCCGACTTTGGAAGACGAG  
20 ATCTTGGCGGATAAAAAGACCTGATGCCAACTGATGACGCGATTGTGCGGACGTATGC  
TTTCAAACTACTACCGCAACTGATTACCCATCCGACTTCTCATGACTACTTTTCTGCAAAAC  
AGCCCGATTTCAGGAAATCGCCACCTCAACCTAGGCGAGCGCTCCCGCAGCGCGCAAAAC  
TTGGCGCGGATTACGAGCTTGGCGCGGATTCGCTGGGTATTTCTGGATGCAGAACCGC  
CTCATGCTCGCGGCTTGGTACGCTTTCGGCAGCGCGGTGGAAACCTTGTGCGAAGACAAA  
25 CCGCAAGCGCTCGCGCCCTGCGCGACACCGCCAAAGCAACCGCTTCTCCAGGCCATG  
CTCTCCAATATGGAACAGTGATGGCGAAAACCGACATCACCTCGCGGAAAATCTAGCC  
GGCTTGGTCGAATCGCCCGATAAGCAAAAATCATCTTCGGGATGATTAAAGAGAATATG  
CGCCCGAGCGCAAGACACTGCTCGACCTACTGCAAAACGAAGAGCTTTTGGCGCAAC  
CGCAGCCTCGCCGCTTGGCTCGCTTTGAGGATTCCTACCTGAACGCGCTCAACGCTTTG  
30 CAAGTCGCATGCTCAACGCGCTGCGTAAAGAACCGCAACTCCGACGCGCTTCTGATG  
GTGCACTGACCATCAACGGCGTGGCGCAAGGTTTGGCGAATACAGGCTGATAGTGCCG  
ATCGGGGCAAAATGCCGTCTGAACGCTTTCAGACGCAATTCCTGACCGCACTTCGAG  
AGAAACACCGATTGTTTAAAGTGAACGGCAGTGATATGTTGAAGACGACCAATGAA  
TTACCGTTATCGGCGCAGGTTCTGTTGGGTACGCGCTCGCCCTGCAATTTTCCCAACACG  
35 GCAACCGCGTATCCCTGTGGACGCGCAACGACAGCAAGTCCGTCAAAATGCAGGAAGCGC  
GTGAAAACAAACGCGGACTGCCCGGCTTTCTTCTCCGAAAACCTTGAAGTGTGTGGG  
ATTTGGCAGACGCGCTCAAGACAGCGGACTTGTCTTATCGTAACCTCCGTTGGCGGAT  
TGAGAACAGCGCGAGAGCTGCTCAAAACAGTACGCGCGCGGACCTTCGCCCTCGCG  
CCTGCAAGGATTTCAGACAGGATACCGGCTGCTGACCTTTCAAGTCTTGAAGAGATG  
40 TGCCGCAATTAAGAAAATCGCGCTACTTTCCGCGCCGAGTTTTCGACAGGAACCTCGCCA  
AACAACTGCCCTGCGCGTCTGCTTGGCTCCGAAAACCAAGAGTGGATTGAAGAACTCG  
TACCGCAGCTCAACACGACGCTCATGAGGCTTACGCGAGTACCGATGTTATCGCGGTGG  
CGGTTGGCGGCGCGTAAAAAATGTTATGGCGATTGCCACCGGATTGTCGACGCGCTAG  
AGTACGGGCTTAAACGCCGCTGCGGCACTGGTTACGCGCGGATAGCTGAAATCACCCGCG  
45 TTGCTTCCGAATGGGCGCACAGCCCAAAACCATGATGGGGCTGGCAGGATCGCGGAC  
TCATCTTCACTGCACCGCGGCACTTTCGCGCAACCGCGCGCTCGGCTTGGGTTTGGACG  
AAGCGAAGGAATGCATCAGGTGCTGCTGGAATCGGACGCTTCCGAAGGGTGCAGCA  
CGATAGAGAGAGTCTTCACTACTGCTTGAAGTACCAATCGACATGCCGATTACCCAA  
CTCTGCTCAACTCATCCGCAAGAAATGACCCCGCAACAGGTTGTGCAAGAGCTGATGG  
50 AAGCGAGCGCGGTTTTGAATAAACACAGACAGATGCCGCTTGAAGCCTTCAGACGCGCA  
TACGGACAGGTAAAGTTATGAACAAAATATCGAAAACCTCGAAAGCAGCGCTTATAGCT  
TGGTACAAAATTCGAAACCTCTGTCAGCGAAAACCGCCGCTCAAAGAACCTGCGCG  
AACTCAAAACGGCGCACGAGCGGCAAAAACCTGCAACACGAAACCGCGCTCGACGAAC  
TCA  
CGAAGCCCTGCTCGTCCAAGTCGGCAAACTCAAAGAACCTGCAAAACAAAATTGACA  
55 GCTTGACAGGAAAAATCACGATACCGCAGCTGCTGCAACAGAGCAGGGAATAATGCA  
CGCACTGCGAGCGGCTTCCCAATGGCAGGAACGCAAGCAATAAGGATTAAAGGATG  
AACATCGAACAGTCCACATCGAAGTCATGTCAGCGCGGCTGACCGTCAACACGCGCGCA

GAAGAAAAAGACACTGTTGCAGGCAGTCGGAATGCTCAACGGCAAAGCCGAAGCCATC  
 CGCGAAGGCGGACGCGTCGCGGACAGCGAAAAAATCGTCATTATGGCCGCGCTCAACGCTC  
 GTCCACGACCTGTTGAAACCTCCCTGAACGGCGCGATTGGCAATCGGCGATTTTGGC  
 CGTAAATATAGCCGATATGGACACGCTGCCAAAAAGCACTATCCGCTTGGCGAGGAA  
 5 TAACCTCTTTTTCCCTGCGGTGTGCGCGAAGGCATATATTCCTTGAACCAATAAGTTCG  
 CTTTAAGGTTGCCGGGAGCAGTAGTGGGCGCAGCGCTCCTTTGCGGAGCAGCCCGAACT  
 ACCGCGAGCGCGCTTGTACGACAGGTTCAAGCGGATTGCGCCGAACGCGCTCTCGG  
 GGGATTCCCAATCAAACCGCATGCAAGCATGCGGTTTTCACATTGGCGCGCGCCCCG  
 CCCGAAAAAGCAGTATGCAGTCTGCCAAATCCGGAATAATCCTCCGTAAACGCGTAATG  
 10 CGATTGACAAAAATCGAATCTGTCTTTAAATTTACAACCTTTCTATATCTATCTGGATT  
 CCACATTAAGAACCTTTTCAGCGAAACCCAGAGGTGAAGCGCGAATGGTTGCTATCG  
 ATGCCAAGACAAAAGTCTTGGGTGCGGTTGCGGCGGAAGTCGCCAGCGCTCTGCGTGGA  
 AACCAAACTGAATACACCCCCACGTCGATACCGGCGATTACATCATTGTTATCAATG  
 CGGACAAATCGCGTGAACCGGTGCCAAATTCGAAGATAAAAAATCTCCGCCATTCCG  
 15 GTTCCCAAGGCGGTATCTACGAAGCAGCTTCCGCGAAATCAAGAGCAATTCGCCGGCC  
 GCGCTTTGGAAACAAGCTGTAAAGGTATGCTGCCAAAGTCTCTGGGTACGCCATGA  
 TTAATAAACTGAAAGTGATGCGGGTGCGGAACAGCCCATGCTGCGCAACAACCCAAAG  
 TTTTGGAACTGAAATGAAGACGCGACATGAACGTAATACTACTACGCGACAGCCGCC  
 GCAAAAGTTCAGTGGCTCGTGATTCTCTGATTAAAGTACAGGTCAAATCATCGTAAACG  
 20 GTCTCCCGTTGACGAATCTTCGCACGGGAACACCGAATGGTTGTTGCCCAACCT  
 TGGTCTGACTGAAACGCGCAATCTTCGACATCAAAGTCAATGTTGTTGGCGGGCGG  
 AAACCGCGCAGTCGGGCGCAATCCGCCACGGCATTACCGTGCCCTGATCGACTTCGATG  
 CGCGCTTGAACCCGCGCTTGCTCAAGCTGGTTTTGTTACCGCGATGCCCGAAGTCG  
 ACGTGAATAAACCGGGCTGCGCAAGACAGCGCTGCAAAACAAATCTCCAAACGTTAAT  
 25 GTTGAAATTCAAAAACCTGCTTATATCGCAGGGTTTTTATTTGTAGTAGACGGTTTC  
 TCTGGCAATCTAAAGATTACAGATTGGGCAAAATCAAAACAGTATAGTGGATTAAACA  
 AATACTAGGACAGGCGACGAAGCCGACAGCAGTACAAATAGTAGGCAAGGCGAGGCA  
 CGCGTACTGGTTTTGTAAATCCACTATACATGAAAAATAGAAAACTGCCGGGTATG  
 GTTGAATAAGGGGTGACAGCGGTTCCAGTTGCTGACTCGGCGCAATCTGCAAAACCGC  
 30 GTTCGGTATGATTGGCAAAATTTGTGAGATAGCTCTGTCCGTATCTTCGGTACGGA  
 TGGCGCATACAGTTTCTTTGCAAGTCCGTGCGCAGTAATTTGGCGGTGGACGACATAGC  
 CTTTTTCAAGGTAGGCGATGACTGTCAATAGGGAAGGCGGCAATGCCACGCTTCTGAGT  
 CAACCAGTTGGATAATGGCAGTGGTCAGCTCGCTGTGTGCGGCGCGCGGGTTGATGTTT  
 TCGGAATCAGGATTTTTTTGGCAAAATCCAGCATCTCGTCGGGAACGGGATAAGTAACTA  
 35 CGGTTTTCCCGATAAAGTCTTCCGCGTCCAAACGTTTTTGGCGCGAAGCGGATGGTCTG  
 GTGCGAAATGCGGACCATTTCTGATAGGCAACAGCGGTTGGAAGAAATACCGTTTTGTT  
 TTTCCGCTTCGGAACAATGGCAAGGTGCGCAGCGTTGTGACGAGCAGTCCGACGGGAT  
 CGCTTTGGAATCCGATACGATATCCAATTGCACTTGGGGCCATCGGCGCGGCAATCGC  
 CCATGGCGGCATCAGCAGTCGAAACAGGTATGGCATTCGACGGCAATCCGAGCTCTC  
 40 CGCGCTCTCCTTCGCTGATTGCGCGCAATCCCAATTCGCAACAGCACTTGAGGTATAA  
 GTTCGTGGGCGAGGCGCAGCAGCTTTCCGCCACCGGGGTAAGCGCAAGGGCGTGATT  
 TGCCTTGAACAGCGCGCTGCGCTAGTGGTTTTTCGAGCATACGGATCTGGTGGGAAAGGG  
 CGGATTGGTGAAGGAAACCGTTTGGCGGCAAGGAGACGCTGCCGGTTTTCTCAAGTG  
 CCAGCAGGGTTTTGAGGTGGCGCAATTCGATAATGGAATCCATGGGGCTTCAGACGGCAT  
 45 ATTGAACCGGCGCATATTAATAATATTATATGCGGTTGCAAAATCGGAAAAATGTGAATT  
 CCGGACATTTGCGATTAGAATGCCCGCTGTTTAAAGCGATTAGGAAAAAAGATGGTAT  
 TGTACAGGATTTTTCTGACTTGGTGAATGAACATTCGACAGCGCTGTTTAAAGATT  
 ACGCCCCTAACGGTTGCAAGTTGAAGGAGGGAATATATCGGAAAAATCGTTACGTCGG  
 TAAGCGCAAGCAGGCGAGCGATTGATTGTTGCTGTGAGCAGAAGGCAGATTGCTTTTGG  
 50 TACATCACGGTATGTTCTGAAAAACAGCTTGCAGACGTTACTGCTTGAATAAAGAAC  
 GGATTGCGCAGCTTTACGGCAGCAGCATCAATATGGCAGGCTACCATCTGCCCTGGATG  
 CACATCCCACACTGGGCAACATGCCCAACTCGCCGACAGATTGGTTTTGCGACAGAAA  
 AACGGTTTGGCGAACAACCTGCTCACTCGGCGAGCTGAAACAAGCCAGACACTCG  
 GCGATTGCGGCGCATATTGAACAGTTTTGCAACGTAAAGCTGTGCTATTCGGCAATC  
 55 CGAGACGCGAAATCCGACGGTTGCATGGTGCAGCGCGGCGCGCAGGGGTTTTTTCAGA  
 CGGCAATAGACGAAGGTGTCGATCTGATTGACGGGGGAAATCTCTGAAGCCCAATACC  
 ACCTTGCCAATGAACGGGTACGGCTTCATTTCGCGCAGGCGATCAGCGCAGCAACGTT

ACGCGCTACGCGCGCTGGCAGAAATCGGCGCGAGAGGTTTTCCGGTTGGAAAGTGTGCCATT  
 TTGACGAAAACAATCCGGCTTGAAGTCTTGAGAAATATCATAAACCTTACCTTTATTTAA  
 ATAAATGCTTTGAGTATCACTGCAAACTGGGTAAAAATGCAACGTTTAAATGGCTCGGTATT  
 CCCCAAAATATTAGGACGACTGAATATGGATATATCAAGAAATCAACAACGGCCCGCGCG  
 5 TTTCCTGACACTCGCGACTCGCGCGCGGGCGGAGTGGCAGCATTTGGGTGTGGCAACGCG  
 GTTTGTGGCCAGTTTTTCCCTTCGGAAAAAGCCAAGCCGCGGTGCTGCGCTGAGGT  
 GGAATGTCAGTAAATCGAAGCGGTGAGTGTCTGACCGCGAGTGGCAAGGCAACCGAT  
 TTGGGTGCTCAACCGTCAGATCAGAGCTTAAGACCTGAAAGGCGCTGAACGCGCAACT  
 TACGATCCCAATTCCGATCGGGAACAGCAGCGGAGTATGCTAAAAACGAGACCGGTTC  
 10 GATTAAAGCCGAACATCCTTGTGCGCATCGGTATCTGCACCCATTGGGGCTGCTCGCCAC  
 CTTCCGTCCGACATTTGCCCGCGCGATTGGGTGACAGACTGAAAGCGCGCTTCTTCG  
 CCGCTGCGACGGTTGCAAAATCGACTTGGCGCGCGCGTATATAAGGTGTTCTCGTCCCG  
 GACCAACCTGGTTGCCCGCATATAAATACTTGAGCGACACAATACTTGGTGGGCGA  
 AGACTAAGAATAAGGAACGATTAATATGGCAAAACCAACAATAGCAAAAGCAAAAGCATT  
 15 GTTAGGCTGGGTAGATGCCGTTTTCCATTAAAGTAAATGTGGAAGAGCATCTGTCTGA  
 ATACTATGGCGCTAAAAACTTCAACTCTGGTATTCTTCGGCTCATTTGCTATGCTGGT  
 GCTGGTGAATCAAATCGTCAGCGGTATTTTCCTGACCATGAACTACAAACCGGACGCGAA  
 CCTTAAGCGCTACCATCTGCTGCTGCTTACCGCAGTAGAGTACATCATGCAAGGAGCT  
 GTCCGGCGGCTGGATTATCCGCTATATGCACTCTACCGCGCATCTTCTCTTCATCGT  
 20 CGTTTATCTGCACATGTTCCGTGCTGATTTACGSTTCGTACAAAAACCGCGCAATT  
 GGTGTGGATTTCGGTTCCCTGATTTCTTGGCATTGATGGCAGAAGCCTTATTGGGCTA  
 CTTGCTGCCCTGGGGTCAAAATGTCCTTCTGGGTGCGCAGGTAAATTATTAACCTGTTCTC  
 CGCATCCCTGTTATCGSTCTGATTGTCCACTTGGATCGCGGTGACTTCAACGTTTC  
 CGATGTTACTTTGAACCGATTCTTCGCGCTGACGTTATCGCTGACTTTGGTATTGCT  
 25 CGGCTTGGTTGTGGCTCATATCATTTGCCCTTGCATGAAGTGGGTTCCAACAACCTGAOGG  
 GTGAGAAATCAAAAGCTGAAGAAGTAAAAACGGTGTCCCTCTAGATGGCATACCTTTTT  
 TCCGCTATTATGTTGTGATGATATATTGGCAGTAAAGATATTCTGATTGTTCTGTGCG  
 CGTGATGTTCTTTCGACCTGAAGCGCGCGGTACTTCTTGAAGCGCAAACTTCATGCG  
 AGCAATGCGCTGAAAAACCTTCGACATTTGCGCGGCTATGGTACTTCACTCCGTTCTA  
 30 CGCAATCTGCGTGCATTCCTTCTTTCGCGGTACTCAGGTATGGGGTGTAAATCGGTAT  
 GGGTGCAGCAGTTGACTGATCGCTTGTGCTGCTTGGTATGAAGGCGAGGTTAAATC  
 TGTCCGCTATCGCGGCCCAATCTTCAAAACCGCATTTGGTCTGTCATCTTGCTCTCAT  
 CGGTTTGGGTATTTTGGGTGCAATGGTAGCAACTGATACGCGTACTTTGGTTCACGTAT  
 CCTGTCTTTCGCTACTTTGCATTCTTCTGGGTATGCGGTTCTATACCAAACTGGATAC  
 35 CAACAACCAAGTTCCTGAACGCGTAACCATGAGCACTACTAAACAAAAAATATGTTCTT  
 TGTTTACGTCGGTATTACCGTTGTTGGTGCTTACTTTTGTGCAACCAATATCTGATGAGG  
 CGACGCAAAATGAACAAACTCTGAAAACTGGTTTGTGCTTATTGCTGGCAGTGCCT  
 ATGAGTGCAGCGCTCGCCAGCGCGCGCGCACTACGAAAAAGTCGATATCGACCTGGCT  
 GACCAGTCAGCCTGCAGCAGCGTGGCGCAATCTTTACAACTACTGTTGTCTTGCAC  
 40 TCTGCAAGCGGTATGCGCTTCAACCGTCTGAAGAAGCACTGGTTGACTGACGAAGAATC  
 AAAAAAACCTGATGTTTACCAACGATATATCGGCGATGTCATGCATTCGGCGATGAAC  
 CGSAAAGATCGGCAAAATGTTTTGSGTCTGCTCCGCGGATTTGACGTTGATTGCGCGT  
 TCCAAAGGTGCACTACCTTTTACGCTATATGCGCGCTTCTATAAAGATCCGACCGGT  
 CGGAGCGGTGGAACAATCTGTATTGATTAAGTCGGTATGCCCCACCGGTTGTGGGAG  
 45 CAACAAGGTGTTCAAGCGTTGAGTTGGATGCCAAAGGTGACGCGGTTATGGTAAAGAC  
 GAACAGCGGAGATGAAGCCTAAGCTGTATTGGGAATCTACCGGTTTGACAGCGCGCGC  
 CTGCTTAACGGCAAAAGTATCCAAAGAGATGACAGCATATGACGCGATTGTCAT  
 TACCTTGTGTACATGGGCGAACCCTGCACAATCTGCAACGAAAGTATAGGCTATGTCGTG  
 ATGATTTTCTATTTCGGGTTATGCTGCTTTGSGTTACTTCTCTAAATAAGATATTTGG  
 50 AAACAGCTACACTAAGCGTTTGGAAACAAAGGGCAACTCTTTAGGGTTTGGCCTTTTTT  
 CATTTCGCTGCCGTTTGAAGCGCTGAATCCGATGCGGCTGCAACATAGCTGCAACAT  
 TTCAGACGCGCATCTTTAAAAATGTGACAGCATCGGGAACCTTAATCAGGGTTTGTGGCAG  
 ATTGATATTGAATTAGGAAAAAGTCTGAAACCGCAAGCAGCATGGTAAGCGGATGTGCA  
 CAGGTTTAAAGCCAATCCGCTATATTTTGGAGCTATGTCGAACAAACAGGATGAGATCG  
 55 GAATTAAGCGCGGTTTTGTCCGGTGTGAAATGTTTGAATATTAGGATAATTGATGGAAC  
 TGAATGAGCTGTTTGTGCTTTCGCGGCTGGTGTGCGGCGGTGTTTACTATGGTTGC  
 TGATGAAGGGCGGTTTTACGGCGAGTTTCCGGGTTTGAACGCGCACCTGCGCGAAAAAG



CGGCAAGATGTGATTTTGTGCAACAGGCACACGGCAAAACCGTGTGCGAATTGGCGGTGT  
 TGGACGGGAAATACCGGCATTTCAGGACGCAAAATATGCTTTGGGCAACCGTTTTCGCG  
 CAGCGGAAAAGCAGATTGCCATTTCAGGAAAAGAGGCGGAGTCGGCGCGGTGAAGC  
 AGTCGTATATCGAGTTGCAGGAAAAGGCACAGGTTTGGCGGTTGAAAACGCAACGTTTG  
 5 CAGCGCAGCTCGGACAGGAACGGAAGCGTTTGGCGACCAATATGCTTGGAAACGCCAAA  
 TCCGCCAAGAATCGAAACCGGATTGGAAAGAAAGCCGCCAACTGTCGCGCAGCTGCAAA  
 ACGACCTTTTCGATGTCGGCAACCGTTTGGCGCAGCGGAAAACAGATTGCCCATTTGC  
 AGGAAAAGAGGCGGGAAGCGGAGCGGTTGAGGCAGTCGCATACCGAGTTGCAGGAAAAG  
 CACAGGTTTGGCGGTTGAAAACGAACGTTTGGCAACGCCAAATCGAACAGGAACGCCCTTG  
 10 CTTCTGAAGAGAAGCTGTCCTTGTCTGGCGAGGCGGCCAAAAGTTTGAGCGATCAGTTTC  
 AAAATCTGGCCAACGATTTTGAAGAAAAAAGCCGCGTTTACCAGAGCAGAACCGCG  
 AGCAGCTCCATCAGGTTTGAACCCGCTAAACGAACGCATCCACGTTTCCGCGAGTTGG  
 TCAAGCAACCTATGATAAAGAATCGCGGAGCGGTGACGTTGGAAAACGAAATGAAC  
 GGCTTCAGGGTTGAACGCGCAGCTGCACAGCGAGGCAAAAGGCCCTGACCAACGCGCTGA  
 15 CCGGTACGCAGAAATAGGTTCAGGGCAATTGGGGCGAGATGATTCTGAAAACCGTTTGG  
 AAAATTCGCGCCTTCAGAAAAGGCGGGAATATGTGTTACGGCGGCATCCGTCGAAAAG  
 AGGAAGACGGCGGCACGCGCGCTCCAGCCGACGTTTGGTCAACTGCCCGACAGCA  
 AGCAGATTGTGATTGATTCGAAGTCTCGCTGACAGCTTATGTGGCTACGACGAGCGG  
 CGGATCGGATACGGCGGCACGCGAATGGCGGCACAGTTGCCAGCATCCGTGCACACA  
 20 TGAAGCGTTGCTCGCTGAAGGATTACACCGATTTGAAGCTGTAACACATTTGGATTTCG  
 TCTTTATGTTTATCCCTGTGCAACGCGCCTACCTGTTGGCGTTGCAGAATGACGCGGCT  
 TGTTCAGAGAGTGTTTCGCAAAACGGATTATGCTGTTGGCGCCAGTACGCTGTCTGGCCA  
 TTTTCGAGACGGTGGCGAATATTGGCGCAACGACAGCAAAATCAGAACGCACTGGCGA  
 25 TTTGCGGCAAGAGCGCGCAAGCTGTACGACAAGTTTTCGCGCTTCGTACAGACGCTCGAAA  
 GCGTCGGCAAGGCATCGATCAGCGCGCAAGCAGTTTTCAGACGGCATTCGAAGCACTTG  
 CCGAAGGCGCGCGGGAATCTGTGTCGACGCGCGGAGAACTGCGCTCTTTGGCGGTGA  
 GCGAGGCAAAACAACTTCAACGGGATTGTGTCGAGCGTTTCCAAATGAACACAGCGGTGTG  
 GGAATCTTTGAATACGCGGCGAAGATGAAGCAGCTGACTTGTGCGCGAAAATATTGT  
 30 TTCAGCGCGGGCGGGAATGCGAAAAGCGCGGCGTAAGTCTACTGTTCTGATTTTGGGTT  
 TTTTGTGTTGAAGTACTTACCAAAGCCTTGTCCGCGAGGTACACCGCGAAGCGCGCGGT  
 GTCTGAGCCTTTTGTGTTTCAGACGGCATCAGTCGAGATGATCCGCTCTGAAGACCGTAG  
 GGAAGGCGGTTAGAAAACGGATTGTGCCGCTTTTCGTGTCCGATGGAAGTCATACGCC  
 35 GTGTCCGCGCACACTTGCACGCTTTCGGGAAGGTTGAATAATTGTTCGGGATATTATT  
 GATTAAAGTCGCGGTGTTGCCGCGGGAATTCGTTCTCGCTATGGTTTCGTAAAACAG  
 CACGTCGCGCGCAATCAGCAATTTCGCGCTCGGCACAAATAAAGACGATATGTCCGCGCT  
 ATGGCCGGAAATATGCAGCACTTGAAGGCATAGCTCCGACCGTGAGCGTTTCGCGCTTC  
 40 TTCGAGCCAAACGTTTCGCGCAAAAGGCGGCGGAGACGGGAAATCCGATTTCGCGCGTGT  
 TTGCGGACGCGATTGGAGCAGGAATTACGTCGCGATCGCGCGCGAGGACAGGAGATT  
 ATGCGTTTCAACATTTCGACACGCGCGCGCGTGATCGAGATGGCCGTCGCTCAGGCCA  
 GATTGCCGTTGAGCTGAAGTTTGGCGTTTGGCAACGCTTTCGACAGGACGACGCGCTGCC  
 45 GCGCATCTGGTCAGGACGGCTTCCCGCTTTCGTCGTCCCAAAATCAGGGTCGAGTTTGG  
 GCGGAAGGGGTAACGGGGAAGATTTCGTAAGCTAGGGTCATCGGCGGTGTTCTCAAACGG  
 TTTTTCAGACGGCATCGGTTTTCGCGTTTGTGTTTATGGCGGTTTTCGCGCGTTTGTATA  
 TTTGGGGAATCAGATGATTAAAGAACAATCGGCGGCATCATACCGATTTTTACCGCGGT  
 50 TTTATCGCTGCATCAGCAGGCGCGCGCGGATTGATGTCGGCGCAGGAATACAAAGGCA  
 GGATATTGCCGCTGGGCGATGAGCGAANAATCGACGCGCTGCGCGCTATTGGGACGG  
 AAAGCACTGATGAGCGCTCAGGCGTACGCGTTTGTCTCGCGCAAGGTTTACCCGCTCA  
 GTTTCGCGCTTATCTTTGGACGGCGAATTGTATAGCGGACGTGGTCAGTTTCAGGACAGAT  
 55 TTTCCGCTACCGTGCGTTCTGTGTTTCTCAGACTGGCGGCGCATCCGCTGCACGTTTTCGA  
 TGTACCCAAAGGCGCAGGGCAACCTCTACCAACGTTTGGCAGTCGCAACGCAAGGGCTGAA  
 AACGCTCCGAAGCGCGCGATTACCATCATCCCGCAAAATCAAAGTGCGGACCGGACGA  
 CGCATGGACTTTTAAACAAATCGAAGCGCAGGCGCGCAAGGCGTGATGCTGCGTCA  
 GCGCAATCCCGTTACAGCGGCGGCGAGGACGCAATATTGAAGCTGAAAAGCGCAATA  
 CGACGACGAATGCACGGTAACGCGGCACTATGAGGCGAAAGGGCGAAAGCCGAGCGGCT  
 GGGCGCGGTGGCTGCAAAAACCGGCACGGCGAATTCGCGATCGGCGAGCGGTTTCAAGA  
 TAAACCGCGCGCAACCGCGCCAAAATCGGCACACTGATTACCTACCGTTACCGTGCGTT  
 TACGCGGAAAGGACGCGCGAATTTGCCCACTTGTGCGCGTGCATACGACCGCTGAGC

AGGACAGTTTCAGACGGCATCCGATACTTTGGTTTATAATTTTCCTTTTACCGACCGATTCC  
 CGACATATGACCGGATTTAGAAAAACAAACGCTTTGAAACACAGGCGATGCTTGAAGAACGCC  
 GATCTTTTGGTTTCGACCAAGGCCAATGCCGTGCCCACTGCAAAAAGTGGCGGAGCAGAGATT  
 5 ACCTGGTGATTGGGCGGCAAAATATCCGCTGCTGCTGCCCGGATGATGGGCGGCGGGTGGTG  
 TTTACGGGGCAGTTGCTGCCGCTGTTGCGTTTCCCTTAGATTGTTGATTATGTTCCAGGTT  
 TCCCGTTACGGCGACAAGCTGGAGGGCGCGCGCTCAACTGGAAGCGATAGCCCGATAGCG  
 GAACAAATCCGGGGCAGGCACGTCGTGCTGGACGATATTTGGACGAAGGCGCATAGC  
 ATGTCCGCGATTCAAGCCAAACTTTTGGAAATGGGTGCGCGAAGCTGCCGTGCGGCGGGT  
 TTCGCCAACAAAGCTGATTGACAAACCAAGCCTATCCGAGCGGATATGTCCGACTGGAT  
 10 TTGCCCAACCGTTATGTTTTCCGTTACGGCATGGATGCGGCGGGCTGCTGGCGCAATCTG  
 GCGAGATTACGCATTGGGCGGAAAAAAGGGCGCGATGCCGCTCTGAAGGCTGTTCAGA  
 CGCATCCGCGGCATACGCCGCGCAGGATAATGAGGAACAGGACGCATAATATGATAGGGC  
 TTTTAATCATCACACAGAAACCATAGGCGAAGCTACCGCAAGCTGGCGCATATTTTT  
 TCCGGCGCGACTGCTTGA AAAACGTC CGCATACTCGGCGTGACGCCGACGGAAGACCAAG  
 15 ACGACATCAACAAACGCCATTGCCGCGCTTACGGAATTTCCGACAAACGACGCGCGTGC  
 TGATTATGACCGATATTTTCGGTGCACCCCCCTGCAATGCCGCCGCCGCTCTGTCGCG  
 AAAACAAATCGCGATTGACCGGGCTGAACGCGCGATGATGGTTAAGGCGGTCCCAAT  
 ATTCGCGGCGCGGGAAGACCTTGCGCCTTTACCGAATGGCTCAGGAGGCGCGCGGTAA  
 AAGGCATTTCGCCATCAGCTCCGCGCCGAAGATTGTTGTGCCGCGCAGCGCGGATG  
 20 CCGCTGGAAGAAGCGGCGAGGCGAGGAAAAATTAAACGGCGCTGCTGCCGATATACA  
 TACACGGGAATCGAAATGCTCAAAACATCCATCGAAATCATCAACAAATCGGACCTCCA  
 CGCCGCGCGTCCAACAAGTTACCCAAACCGCGTCCCAATTCAAAAGCGAAGCTGTGGGT  
 TAGCAAAAACGACAGCGCGGTCAACGGCAAAAAGCATTTGGGGCTGATGATCTGCCGCG  
 CGCCAAAGGTCAGGTCATCGAACTGGAGACGGACGCGCGGACGAGGCGGAAGCGATGCG  
 25 CGCCTACCGCACTTAATCAACGGCTACTTCGGCGAGGGCGAATAATGATGATCGTGCT  
 CACGGGCTGGCGGCGGGCAAGGCATTGCCGTCGGTTGCGCCCACTGATTGCGCGCGGT  
 ACGGAGGAAGTGCAGCATATGATGTTGCGGAGGCGGACCCGATGCCAAGCGGAAGT  
 TTCGATCGCCCGTCAAAGCCACGCGCAAGAGTTGGAACAGCTCCGACGCGCATTTCCC  
 GAAAACGCCCGCAACGAGTTGGGCGGTTTCATCTCGCTACACCTGATGCTCTTGACCGAT  
 30 GTTACCTTTGCCGCGGAACCGTTCGATATTTAAGGGAACAAAAATCAACGCCGAGTGG  
 GCATTGAAGCAGCAGACGCAAACTCGCCGCCCAATCGACATATGGACGATGCTCAT  
 TTGCGCGAACGCAAGCAGGATATGCTGCAAGTCGTCGCCCGCATCCACAACCACTGTGC  
 GGGCAGGCAACGAGTTGGAAGTTGCCGACAACCTGTTTACGAAACCGGTTCTGATTGCA  
 AACGACCTTTCCGCCGCCGACACGGTTTGTTTAAAGAGCAGCGCATGCGCGCTGCGCGC  
 35 ACCGATGCCGCGGCCCCACCGGCATACGGCGATTTGGGCGAGGCTTGGACATCCCG  
 TCCGTGCTGGGGCTGCACAACGCGCGCAAACTGATTACCGAAGGCGAAACGCTATTGTG  
 GACGGTATCAACGCGGTGTTGATTATCGCGCCGGATGAGTCGGTGTGAACGAATACCGC  
 CGCGCTGCCCGCAATACCGCACGCCAACAACGCGATTGGAACAGCTCAAAAACCGCCGCC  
 CGCGCCACCGCGACGCGGCTCTGCATCGAGCTTGTGGGCAATATAGAATCGCGCAAGAC  
 40 GTGAAAACGCTGCACAACCTCGGCGCAGACGCGCATCGGCTGTTCCGACGCGAGTTCTT  
 TACCTGAACCGCGATACGATGCCCTCTGAAGACGAGCAGTACGAAGTGTACAGCGCGAT  
 GTCAAAAAGTGAAGGCAAAAGCGTAAAGATACGACGACGTCGATTAGGTGTGGACAAA  
 AACCCCGCTGGTTTCGGGAAAAACAGCACGCCCCAACCGCACCTCAACCCCGCTGGGC  
 ATGACGGGCATCCGCTGTGCCCTTGCCGAACCGGTATGTTCCGACCCAGATGCGCGCC  
 45 ATCCTCGTCGCGCGGTACAGCGGCCGCTGCGGATGATGTGGCGGATGATTACCTCGGTA  
 TCCGAAGTCGCGCAGTGCTCATCCACTCTGACACCGCGCAACCGCAGCTTGC CGAACGCG  
 GCGCATGCCCTTCGGTAAAGTCGGCATCGGCTGTATGATTGAAATTCGCTGCCGCGGCTG  
 ACCGTGCGCAGTATTTGAAACTGGTCGATTTCATCTCGTCGGTACCAACGACCTGATT  
 CAATACATCTTGTCCGTCGATCGCGCGACGACAGCGTCAGCACCTCTACGAGGCGGCG  
 50 CATCCCGCGTGCTGAAAAATGCTGCACAACGCTCATCCGTACCGCAACCGCATGGAACAAA  
 GACGTATCCGATGCGCGGAGATGGCGGCGATACCGCGTTTACCGCGGTTTTATTTGGGT  
 ATGGGGCTGCGCGGTTTTTCCATGAACCCCAACACATCTGCCGCGTAAAAACATCAT  
 CTGCACAGCAATGTCGACAGCTCGAAAGTGATATTGTGAAAGTCATCCGCTGCGAAGAC  
 GAAGAGAAGTTCGAAAGCTGATCAACACAGATGAACAGCGGTGCTGTGCGGGAAGAACGC  
 55 GACTTCAAGGGGCGGAAATAATACGCGAGTAAAAAATAGAAATACTTTAAACATGCCCG  
 CAATCTGAAATTTTGCCATTCTGCAAAAATAGAAAACCGAAACAGAAACCCAAATTCGCG  
 CATTCCCTCAAAAACGAAAACCAAAATCAGAAACCTAAAATCCGTCATTCCCGCGCAGG

CGGGAATCTAGGTTTTCGCGCACGGAACTTATCGGGAAAAACGGTTTCTTTAGATTTTA  
 CTTTCTAGATTCCCGCTTCGCGGGGAATGACGATGAAAAGATTGTTGTCGCTTCGGATAA  
 AGTTTTCGGCTGTTGGGTCTAGATTCCCGCTTTCGCGGGATGACGCGAGAGTGGTTTC  
 AGTTGCTCTCGATAAATGCCGCCATCTCAAGTCTCGTCATTCCCTTAAAAACAGAAAACCG  
 5 AATCGAAGAACCTAAAAATCCCGTCATTCCGCGCAGGCGGGAACTAGTCTCTGTCGGCAC  
 AGAACTCTGTCGGGAAAAACGGTTTCTTTAGATTTTACGTTCTAGATTCCCGCCTGCGGG  
 GGAATGACGATGAAAAGATTGTTGTCGCTTCGGATAAATTTTGTGCGTGGGTTCTAG  
 ATTCCCGCTTTCGCGGGAATGACGCGAGAGTGGTTCTGTTGCTCCGATAAATGCCCGC  
 ATCTCAAGTCTCGTCATTCCCTTAAAAACAGAAAACCGAAATCAGAAACCTAAAAATCCCGT  
 10 CATTCGCGCAGGCGGGGAATCTAGGTTTGTGCGGTGCGGAAACTTGTGAAAACTTTGCA  
 AAATCCCTCAAAATCCCACCAAGACATTAGGAGATTTCATGAGCACCTTCTTCCAGC  
 AAACCGCACAGGCATGATTGCCCAACACATCAACCGTTCCCGCTATTGAAGTTGGATC  
 AAGTGATTGATTGGCAGCGGATCGAACAATACCTGAACCGTCAAAAAACCGGTTACCTTC  
 GAGACCACCGCGGCGCTCCCGCTATCCGCTGCTGCTCATGTTCAAAGCCGCTGCTGCTCG  
 15 GACAAATGGCAGCAGCTTCCGATCCCGAATCGAACACAGACCTCATTACCCGCAATCGACT  
 TCAACCTGTTTTCGCGTTTCGACGAACTGAGCATCCCGATTACAGCACCTTATGCCGCT  
 ACCGCAACTGGCTGGCGCAAGACGACACCTGTCGGAATGCTCAAATGATCAACCCGCC  
 AACTGACCGAAAAAGGTTTAAAGTAGAAGAACCTCCGCCCGCTATTGACCCACCA  
 TTAATTACAGCCGCCGACGCAACAGCGCTCAGGCCATAGAAGTCGATGAAGAAGGACAAG  
 20 TCAGCGGCCAAACCCACGAGTAGAGGACAGCGATGCGCGTTGGATCAGAAAAACGGCC  
 TCTCAAACTCGGTTACAAACAACTATCCCGCACCGATGCGGAAGGCTATATCGAGAAAC  
 TGCACATATAGTAGATTAAATTTAAATCAGGACAAGGCGACGAAGCCGACAGACATGACA  
 GATAGTACGGAAGGCGAGGCAACGCCGTACTGGTTTAAATTTAATCCACTTATATGCG  
 25 GCAAGGCTCGCGCAACCGTCCGCTGACGAGGCGCAACCAACGCAACCGATTTTGT  
 CGAAGACCCCTTATGTGTCGAAACAGAGCTTCGGTACGCTGCACCGTAAATTCGCTACG  
 CCCGGCGAGCCTATTTCGGACTGATTAAAGTGAAGTGGCGCAAGGCCATCTGAAGCGGATGT  
 GTTTGAACCTGTTGAAGACCGCAACAGGCTAAGTGGCGCCGCTGCCGCTTAAAGGCGCA  
 CCGGATGCTGATTATCGGGATCCGGGGAGGATTAAAGGGGATTTTGGGTAGAAATTAGG  
 AGGTATTTGGGGCAAAATAGACGAAACCTGTGTTGGGTTTCGCTGTTGCGAGGAA  
 30 AGGAATTTTGCAGAGGCTCAGATTGTTGTCGCTTCGGATAAATTTTTCGCGCTTGGGT  
 TCTAGATTCCCGCTTTCGCGGAATGACGCGAGGGTGGTTTCAGTTGCTCCGATAAATG  
 CCGCATCTCAAGTCTCGTCATTCCCTCAAAAAACAGAAAACCAAAATCAGAAACCTAAAA  
 TCCCGTCATTCCCGCGCAGGCGGGAAATCTAGGTCTGTCGGCACAGAAACTTGTCCGGAAA  
 AACCGTTTCTTAGATTTTACGTTCTGGATTCCCGCTGCGCGGAATGACGATGAAGAA  
 35 ATTGTTGTCGCTTCGGATAAATTTTTCGCGCTTGGGTTCTAGATTCCCGCTTTTTCGCGG  
 AATGACGCGAGGGTGGTTTCAGTTGCTCCCGATAAATGCCGCATCTCAAGTCTCGTCAT  
 TCCCTCAAAAAACAGAAAACCAAAATCAGAAACCTAAAAATCCCGTCATTCCCGCGCAGGCGG  
 GAATCTAGGTTCTGTCGCGCAGGAACTTATCGGGAAAAACGGTTTCTTAGATTTTACGTT  
 TCTAGATTCCCGCTGCGCGGGAATGACGATGAAAAGATTGTTGTTGTTTCGGATAAAT  
 40 TTTGACGCCCTGATAAAAAAATATGCTGCTTGGTAAAAAATGCCGCTCGAAGAAAT  
 TCAGACGGCATTTTGTTTTAAAGACATCAGCGGAAGCGGACGATTTCGCGTTCTTCGA  
 TATGGATGCGTACCGTATCTTTCGCGATACGCGCCCGGCTGCGGCATATCAGAGGTTCA  
 GCCACAGGATGCCGTTTCGCGATGGAGGACGGAAGGCTGAACGATTCCGGCAACACAGG  
 TACGGGATAATACGCGGCACTCCATGCCGCTTGGTGCAGAACGACCGCATGTTGCGGAA  
 45 TATGGCGGTTATCGTCGGTATTGGGCAACCCATCAGTTCGCGGACCTGCATCAGAGATG  
 GTGTTTTCGCAATGTTTCGGGCGTACCGTATTGAGAATCCTCCCTTATGATCAGCG  
 CGATTCTGCTGCGCTCGTACAGGCTTCTTCGGGCGAATGCGTTACCAAAACGCGCAGGGA  
 TGCCGCGCTTTCGGATACGTTCCGCGATCATACGCGCAGCGTCCCGCGCAATGCGTGT  
 CCAAACTGGAAACGATTCTGTCACACAGCAGCAGGGAAGGGCGGACAACCAAGCGCGCG  
 50 CCAACGCGGACCGTGTCTTCGCTCCGGAAGTTTTCAGGCTTCGCGGTGCCCTCGT  
 TTTCCAGTCCGACTTCGGCAAGTCCGCCATGCGGAGGCGTTCGCGTTTCGCGTTTCGGCA  
 TTTTTCGATTTTCAAACGGAATGCGCGATTTCACGCGCACTCATATGGGAAACACGCG  
 CGTAATCTTGAAACATCAGCGAGATACGGCGTTTTCGGGCGGCATCAGGGTAATGTTT  
 CTCGCTTCAGCCATATTTCCCGCGCTTCGCGCGGACATCCCGCAATTTATATTCAGCA  
 55 GGGTGGATTTTCGCGAGCCGACCGCCCAAAACGCGCAGTATTTTCGCGCGCGCCAGC  
 TCAGGACGATGTTGTCGCGCAGCGTTTATTCGCGAGAGCTTTCGAGAGTCCGTCAGTT  
 CAAGCATGCGCGCATCTTATAAACGTATGCCCTCCACGCCATCCGACAGCGGATGGGCGCG

ATCAATCAGACCGTAACGGCAAAACGCGTCCAGCGTAACCAAGTTGCGCGTGTGCATCAT  
 GTTTCGCCGACACATGGCATCCAAACAGACCGCGCATGTCCATTTTCTCAAAACCCGCCAC  
 TTGCCATCCCTGATTTTCAGGCAGGAAGGTTTCGGGCAGGACGGCATCGAATACATACAG  
 5 GTTCTCATTTGTGTACACCCCGGCTGACGGAGCGCAGGCTGTGCAGCTGCGATACCGGGCG  
 GATTGAGCGGAAGCAGCGTTTATCCAAACCGGCTCTTCGCTGCTTTCGCGACACACGGC  
 TTCAGACGGCATTTCCGCGCCGGAACACCGCGCGCGCAGTATTGTGCGATTGTTGTTGGG  
 ATCGACTGCTTTGTGCGACTGCGCCTGCTATCCAGAAATGCCATCGCGCGTCCGATTC  
 GGTCAAGCCGTTGAGATGGACGGCGCGGCTGAGCAGTCCGAAGGACGGAACGGCGGCG  
 TTCGAGCGTTGAACAAGGGTTGCCGCCGCGTGTGCTCAGGTCSAAACATCTGTTCGCCCA  
 10 GCGCTCCAAAGCCCCGCACAGTGGCCAACCGAGCGGAGTGCTGTAAAGCTCCGCCCAT  
 ATCAGCCGACCGCTCCGATTCAGAAAAATGCGCTCTGAAGACTCCGAGCAGCTTGCCCTC  
 CAGGCTCTTTTGTACGCGTTCCACCCATTCCGGCGACAGGTTGCCAAAGGCAGACGCTT  
 CAGATACAGCGTTTCCAGCAACTTCTGCACCGTAACCTGCTTTTGCCCACTCGAACAG  
 AGCATCAAGGTCTTGTGTTGCTGACGATTCCGTAACACGAGCGTCCGATGGTTGGCTT  
 15 TCTTGAAGACAATGCGGAAGATTGTAGCAAACTGCTGTAATTTGCAACCGCAACAGAGC  
 GGCGGTCTGCCGTTCCGATATTGCGGCGGGAAGGAAAAATCCGGCAAAAAACGAGGCGCG  
 AGGAAACAGGAAACAGGAACAGGCAAAACAAACCCCTCGGCATTGAACCGAGGGGTTT  
 GATTAATTTGGTTGCGGGAGCAGGATTGCAACCTACGACCTTCGGGTTATGAGCCGACGAG  
 CTCACATGCTGCTCCATCCCGCTCAGAAATGAAACTATACGGCAGATTTTATGTTG  
 20 TCAAACTACTTCCGCAAAAAATCATAAAATTTTGGCTCCGCGGCTTATGCTGATT  
 TGAATATATTATTTCTTCAAAAAGTTTCACTGTTGCTGATTAAATTTTGGTTAACTGAA  
 ACAGGGGTGCTGCTGATGTTTAGCGGCTGAGAAATACCCTTTACACCCGATCGGGATA  
 ATACTGCTGGGGAGTTTTCAGGATTCTGCTTTTCAGACGGCATTTGGTTTTCAAATGC  
 CGTCTGAAACGCAAAACGCTCCTGTTTCTTAATTTCAAACGAGAAACAGGAGCAATTT  
 25 TTTTATGACTACGCCAAAAAAAACCGCAAAACTTCGGCAACGAGCGCGGAGCTTCG  
 CGACTTGAGCGAAGACATCGGCATCTGCTTTAAATATCCGAACCTCGGAACGCGTGATATT  
 CGAAGGACGCGCGACGACATCCGCGTGCTTTGCGGAAATCCGTCAGGACGACACTTA  
 CACGGCGCAAGGTACGGAAGCCAATCCGCGGATTCGCGTCAACGACCGCGCGGTGA  
 CGCGGACCCGCGGCGCATATCGACCTGAACCAAGGCTCGCGCACATCCGACCGCGGTG  
 30 GCTGGCAACGCGCGGATACCGAAATCTGCCAAGCTCTCCAGCGAATACGGCATCGA  
 ACGGGACACAGATCCGAAACCGGCCATCTGCGTTTCAACCAAATCAACCGCCGCGGCT  
 CGCGAAAAGCGCGACGAACCTAACCCAGCTTCACTACGCGCGCAAGGCATTAACGCGC  
 CGAAATGGAGTTTGTCCGCATACGCGAAGCTTAAAAATTAGACGAATGTGCCAAAAACG  
 35 GGAATACGCCAAACTCTTGAACAGCAGCGCGGGGCAAGTTTCGGTGCGAATCCCGAC  
 CCATCCGACCAAATCAACGCCGAATTCGTGCGCAAGAAATCGCGCGCGGACGCGCAT  
 TATTCCGCGCAACATCAACCAACCCGAACCTCGAACCGATGATTATCGCGCCGCAACTTTCG  
 TGTCAAAATCAACGCGAACTTGGGCACTCCGCGTCACTCCAGCTGACCGAAGAAAT  
 TCGAAAAATGGTGTGGTGTGCTGCTTGGGCGCGGACAGGATTATGGATTTCGAAACG  
 40 CGCGCACATCCATGAACGCGCGAATGGATTATCCGCAACGCGCGCTCCCCATCGGCAC  
 CTGCGCGATTACCAAGCGTTGAAAAAACCGCGGCGATCGCGCAAGATTGACTTGTGGGA  
 TTTGTTCCGCGACCCCTCATCGAACGCGGAGCAAGCGCTGAGCTATTTCACCATACA  
 CGCGGGGCTGTGCTGCTTATGTGCGATGACGCGCAACCGGCTCACCGGCATCGTCTC  
 GCGGCGGCTTCGATTATGGCGAAATGGTGTTCGCAATCATCGGAAAAATTTCTCTA  
 CACGCTATTCCAGCAAAATCTGCGAAATTTGAAGAGCGTATGAGCTATCGTCAGCCTCGG  
 45 CGAGCGGCTCGCGCCCGGCTGCATTGCCGATGCCAACGCAAGTCCCAATTCGCGGAAC  
 GCACACTCTGGCGAATTGACCGATAAAGCGTGGAAACATGAGCTACAAGTCATGATCGA  
 AGGCGCCGCGCATGTGCGCGTCAACGCGTCAAGAAAAACATGACCGAAGAGCTGCAAC  
 CTGCTTTGAAGCACTTTTACAGCGCTCGGCGCGCTCGTTACCGACATCGCACCCCGCTA  
 CGACCACATCACTTCGGGCATAGGCGCGGCAATATCGGCTGGTACGGCAGCGCGATGCT  
 50 TTTGTACGTTACCCGGAAGAGCAATTTGGGCTGCCGACAAAGAGCGTGGCGACGCG  
 CATCATCACTCAAACTCGCGCGCAACCGCGCGATCTCGCAAGGCTGGCGCGGCGG  
 ACAATTAAGTGTACAACCGCTGAGCAAGCGCGCTTTCAGATTCCGCTGGCGCGACCAATT  
 TCGCTTTAAGCCTCAACCTGAACGTGCCGAGAGCTTCCACGACGAAACCGCTGCTGCGGA  
 55 AGGCGCGAAAAATCGCCCACTTCTGCTGATGTGGCGCCCAAAATCTGCTCGATGAAAAAT  
 CACGCGAAGATGCGGACTACGCGCAGCAAGCAAAAGCCCAACGGCAGGCGATGGAGGA  
 AAAAGCGGCTGAGTTTCTCAAAAAGGCGCGAAGATTACAGTTAAACCTCAAGCAAAAAA  
 ATGCGCGTCTGAAACCGGAAAAAAGGCTTCAGACGGCATTCTTTCGCTGTGAAAAATATA

GTGGATTAAACAAAATCAGGACAAGGCGACGAAGCCGAGACAGTACAGATAGTACGGAA  
 CCGATTCACTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGCGGAGGCA  
 ACGCCGTACTGGTTTTTGGTTAATCCACTATAATTTTAAAAATTTTATATTCACATAGAT  
 GGGGATGATGGGATTAGGATTCTGATTTTGGTTTTGAGAGAATGAAGGATTATGAGATT  
 5 TGGGCGGATTATCGGAAAAATAGATCTTTCCGCCGTATTCCCGCGAGCGGGGAATC  
 TAGACATCTAATGCTAAGGCAATTTATCGGGAATGACTGAAACTCAAAAACTAGATTCC  
 CACTTCTGCGGGAATGACGGGATTAAGTTTCAAAATTTATTCTAAATAGCTGAAACTCA  
 ACGCACTGGATTCCCGCTCGCGGGGAATGACGAAGTGAAGTTACCCGAACCTTAAAC  
 AAGCGAAACCGAAGCACTAGATTCCCACCTTTCGTGGGAATGACGCGAGCGGGATTCTG  
 10 TTGCTCCCGATAAATCCGCAACCTCAAAATCCCGTCATCCCGCGAGCGGGGAATCTAG  
 GTCTCTCGGTGCGGAACTTATCGGGTAAACGGTTTCTTGAGATTTCGCTCCTGGATT  
 CCCACTTTCTGCGGAATGACGGGATTAAGTTTCAAAATTTATTCTAAATAGCTGAAACT  
 CAACGCACTAGATTCCCGCTCGCGGGGAATGACGGCATATTTTGACATTGAATAAAAA  
 GACTAAAAACAGAAAAAGCCAAACAGAAAAAGCCAAACAGAAAAAGCCAAACAGAAAA  
 15 ACAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGAAAAACAGCGAAACAGAAAA  
 ACAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGAAAAAGCCAAACAGAAAAACAG  
 AAGCAACAGAAAAAGCCGTGTCTGGGACAGGCTTTTGTGTATCAAACTCTTTGTCAG  
 ATTAGAATTTGTGGCGAGACGACACCGCGGCGAGTCGCTACGAATTTGTTTCCGCTT  
 TGCTTCTTGCAACCAACCGGCGAGAAACCAAGGCGAAGTCGCTTTGGAGAAGTCGTATT  
 20 CCGCACCGCAACCACTTGGTCGTATTCTGTGCTATGCTGCACTCATCAACCAACCTT  
 TGAAGCCGTGGGCGTAAGAACTCGGGCGTTACGTTGCGGAAGCGGTATGCCAAGGTCG  
 CGCACTCTCGGTTTGAGAGTTGTGCGAATTGGAAGCATCAGTCAGTTTCGCGCTTGT  
 GCTGTACGGCTACGGAAGCGTACAGGCGATCATTGTGCTAACCGCTGACCAACGCTGAA  
 CTCGTGTTATCTCAATATTCAGGCCCTCTTGCACTTGATGATGTCTTTTATAGGCAACG  
 25 CATATTGCACAGAAAGCCACGTTTTGTAGTTGAAGCCGGCGGTGTGAAGTCGCTGT  
 TATGTCGCTCATTGTCTGTTAAGCGCATTTAGCGCTGCGCGTGAAGGCGCGCAAAAT  
 CAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGAAAAAGCCAAACAGAAAAACAG  
 CCAATAGTCGCTTTGCTATCCCAAGGATTGATGTGCGCGGTGCTTTTACAGACGCTG  
 TCAACAGACCGACGCGCAATTTACCGAAGCGGCTTTACGCGGATGAAGGATTGCGGCT  
 30 TGCCCAACCGGAGTCAGTACGCGGATAGATGCTTTTGTCAACCTGCCAAATGGCTT  
 TCAGGCGGTTACCGAGGCTCTCTTGGCCTTTGAAGCCGATTTCGAACCCAAATCAACGA  
 TGCCGATACGCGTTGTAACTTCAGTAACCTTGCGCGTTTGGTGAATACAGAGCGGAAG  
 TTTCTACCGCGGCTTGATGGTCCGCTACAGGGTAACGTCAGCCATTGCTGCAACAGGAA  
 GGGCTGCCAAAGTCAGGCAATCAGGGATTTTTTCATTGCTGATTCCTTTTGTGGTTAA  
 35 GAAATTTAAGCGCGCGGGCTTCCAAGCGCTTAGCTTTGCATTTACCGCGACGCTTTT  
 CGGCGATTCCATGTCTGAACTATAGATGTTCTGTCTGAAAAACAACTTCTGCTGTG  
 TTTTGTGTGAATTCGATGTGATTTTGAAGGCGGATAGAGATATTATGGGATTAATTTT  
 GTTTTATAACATATGGTTATTTAAATTTTAAAGATTGCAATTTTACAACCTTACTCG  
 GGAGGGTATTGGAGGGCATTGCAAAACCGGGGTTATAAAGACGCGCAAAAACGCGACGT  
 40 GGTTCCTTCGGAACGCGGGATGCAAAACCCGCCCTCGCGCAGGAGATAGTGATTAA  
 CAAAATCAGGACAAGCGACGAAGCGCAGACAGTACAAATAGTACGGAACCGATTAC  
 TTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGCGAGGCAACGCTAAC  
 GTCATTCCCGCACTTTTCGTCACTCCCGCTCAGCGGGGAATCTAGAATCTCGGACCTT  
 AGATAATCTTTGAATATTGCCGCTGCCTTAAGGTCGGATTCCCGCTCGCGGGGAATGA  
 45 CGGCTGACAGTCCCGACGCTCTTTAGAGTGGATTAAACAAAATCAGGACAAGCGGACGA  
 AGCGCAGACAGTACAAATAGTACGGAACCGATTCACTTGGTGCTTCAACACCTTAGAGA  
 ATCGTCTCTTTGAGCTAAGCGGAGGCAACGCTAACCGCTCATTCCGCGCACTTTCTGCT  
 TCCCGCTCAGGCGGAATCTAGATCTCGGACTTCAGATAATCTTTGAATATTGCTGT  
 TGTTCTAAGGCTAGATTCCGCGCTCGCGGGGAATGACGAATCCATCCGACGGAACCT  
 50 ATATCCGCTCATTCTACGAACCTAGATCCGCTCATTCCCTCAAAAACAGAAAACCAAAA  
 TTAGAAACCTAAAAATCCCGTCATTCCCGCGCAGCGGGAATCCAAATCTGTCCGCAAGGA  
 AAATTTACGATAAAACGGTTTTTATAGTTCCAGTTCTAGATTCCCGCTCGCGGGGAA  
 TGACGAATCCATCCGACGGAACCTATATCCGTCATTCTTACGAACCTACATCCCGCT  
 ATTCCTCAAAAACAGAAAACCAAAATTTAGAAACCTAAAAATCCCGTCATTCCCGCGGAGG  
 55 CGGGAATCTAGGTCGTGCGGTGCGGAACTTATCGGTTAAACCGGTTCTTTAGATTCCA  
 GCTTCTAGATTCCCGCTCGCGGGGAATGACGGCTCAGATGCCCAGCGGTCTTTATAG  
 GGATTAAACAAAATCAGGATAAGGCGACGAAGCGCAGACAGTACAAATAGTACGGAAC

-67-

5 GATTCACTTGGTGCTTCAACACCTTAGAGAATCGTTCCTTTGAGCTAAGCGGAGGCAAC  
 ACCGTACTGGTTTAAAGTTAATCCACTATAATGAACAATCCATTACAGACTTCAATC  
 AGGCAACATCTCCTGCAATCTGAAACAGTTTTTCAGCCGTACTGTTGCTCTAAATTGC  
 CAAGATGTTTACCAATCCGGCTTTATCCACAGCCCTAATCTGTTGGGCAAAAGCCAAC  
 10 CGTCTTATCTGAAAGCGGACATTGACGGGAACGGGCGAGGCGCTTCCGCTCGTCA  
 TGGGAACGATCAGCACAGCTTTGAGATAGTTGTCTATTTACAGGAGGAGAGACTACGACAC  
 AAGGACGTGTCTTTTGTATTTCGCTTCTACGGTCGGGTCTAAGGAGACAGATAGATT  
 CGCCGGGTACTACCATATCCATTCTTTATCGCTCTGTTTTCAATTCGGAATAAATG  
 15 CTCTCGTCTGGTTTCGACAAGCATTGCGGCAGCTTCTGCCCATCCCTCGGAACGGTAGG  
 ACAGCTTAAATAATATTGCCCTTTTCAACTGTAACAGCCAAGCTGTCTACTGCCCTAT  
 TTGACCCAATAATGATTTGGGCAGAAATCACGCTTGGCAGTTTCCCATTTTGCCTATGTT  
 GAGAAATCATATACGTACCATTACCTGTTTATGTAATAACAATGTTAGTACCTTGATG  
 AGGTAGTGTCAACATGGAAAAAGATTGCCTGACAGTTTGTCCGATTTCAAATCTCCGCG  
 ACAAAGCATGTTTTAAAGCCATTGCGGGATTTGGGGCGGATGATGCCGTATGCCCTCGGGA  
 20 TAGTGCAGCCGGTCAGGTAAAGTCCGTCGGGCATGAAGTGCAGCGGGCTTTGAGGCGG  
 CTGCGTCTTGAATCAGTCCGGCGAAGCCTTCGACGCTGAGTCTGCCGCTCCGCAATAA  
 ACGAGCGGCCCATGATGTTGCGTACCATTGGTGCMAAmAgCGCTTGCCTGCAAAATCG  
 AGGCGGACGAGTCTGAGCTTTGGGTAAAGTTTCGGCGGGTAGATGGTTTTGACGGGGGA  
 25 TTTTGCTTGGCATTGCGCGGCGGGAAGCTGGAGAAGTCTTGTTCGCCACCAATAAAGC  
 GGCAGCTGCCGATCTGCCGATGTGCGAGTTTGAAGTGTGTCAGGCTGCCCTGTTTT  
 GAGCAGGGGGGAACGACGCGGGCGGATTGACGAGTAGTCGGTAGTGCCTGCGATGCG  
 GTCAAAATCGTGCAATGAAATTCGGGGGCGACCTGTGCGGGCTGCAAAACGGCAATGCGCTT  
 GGGCAGGTGGGCAATTTACGCGCGCACCCATGCTGTTGGGACGGGCGGAGTTGTGTC  
 GAAGTGGACGACTTGGGCGGTGCGATGCAGCCGGTGTGCGTCTGCCGGCAACGGTGTG  
 30 GGAACGCGCTTCCCTGCTATTGGGCGAGCGGGTTTCCAATGCCCTGAACGGCTCGG  
 TACGCGCTCAGCCTGTTCTGCGACCGTAAAGCGGCTGCCCTCATAGGATAGGGTTAT  
 TGCCCAACGGTTGTTTTGTGCGGATCCATCGGATTTGGGATTCGGATAAATGTTTCAGC  
 TGCAATGATCGAGATTTTGCAGGGAAACGCAACGCCAGGCGGCGAGCGGCTGTTT  
 35 GGGGAGTGTGTTGGGGGGGGGATGCAAGTTGCTACGAATCGCTATCCTGTGAATTTACCC  
 GTGCAGGAGTCCCGAATCGTCATTCCCGCGCAGGCGGGAATCTAGGACGTAAATCTAA  
 AGAAACCAATTTATAGTGGAATTAACAAAACAGTACAGCGTTGCCTCGCTTTAGCTCAA  
 AGAGAACGATTCTCTCAGGTGCTGAAGCACCAAGTGAATCGGTTCCGTAATTTTGTACT  
 GTCTCGCGCTTCGTGCGCTTGCTGATTTTTGTAAATCCACTATATCCGATAAGTTTCC  
 40 GCACGGACAAAATAGATTCCCACTTTCGTGGGAATGACGGGATCAGGTTTCGTGGGAAT  
 GACGCGAAGCAAACTCAATCCCGTATTCCCGCGCAGGCGGGAATCTAGACCTTAGA  
 ACAACGCAATATTCAAAGATTATCTGAAAGCTTGGGATCTGGAATCCCACTTCGTGG  
 GAATGACGGAATGTAGGTTCTGAGGAATGACGGGATGCAGGTTCCGTATGGAATGGAATC  
 GTCATTCCCGCGCAGGCGGGAATCTAGGTTCTGTCAGTGCAGGAATCTATCGGATAAAAGC  
 45 GTTCTCGAGATTTTCTGCTCGGATTTCCCACTTTCGTGGGAATGACGCGGTGAGGTTT  
 CCGTATGATGGAATTCGTATTCCCGCGCAGTGGGGAATCTAGACATCAATGCTAAGCG  
 ATTTTATCGGAATGACTGAAACTCAAAAACCTGGATTTCCCACTTTCGTGGGAATGACG  
 GATGCAGGTTTCTTAACCCCGGTTCTAGATTCCCACTTTCGTAGGAATGACGGCGGTA  
 GATTTGCGAGATGCGGCGGATTTCGGCAGGTTCTCAACCATCTCAATCCACCTGACCG  
 50 CCTTTACGAATCCGCGCGCATCTGCGGAACGCAAAAAAATGCGCTCCGAAAAACCTT  
 CAGACGGCATTTTCGCGGGCAAACTCAGTAAAGACTTCGCTCAGCTTAAGCGTTTCAAT  
 45 CCGCAGCTCGGACCGGCGGGTTTCGGGTTTCGGAAGAGCGGTGTGAATGAAGAACCGGC  
 AGACGCGGTGTGCGGCCCATCTCTGCCCGAACCGCGGCAAGCGTATCGCGGTTTGA  
 ATCGGCGGGCGGTGCTGTTTCGGCACGAGTCCGCTCTGAAGCGGGCGGTGCTCGG  
 55 CTCGCGCTCAGCCTAAGCGGAAAGTTCCCTCGCGTGGATTTTGAAGCACTGTTTTCGCT  
 TGGCGGTGTAGGGGCGAAGCGCGGGGTGAGTTCCCAAAAGCGGGGCTGTGGTCGGAT  
 GCGCGAGGTGCGAGATTTCGTGTATGACAGCATAGTCGGCAACGCTATTCCGCTGCGCGGA  
 CAGCGCCGCAATGAAGCGTATGCTCTGTGTTTTCGGCACACGCCCCAGAAAGTTTGG  
 CAGAGTCAAGCGAGGAGAGCGGCGGGAACAGTTGTGTGTCGCGGCTGGGCTTCGAGGC  
 GGGGAATCAGTAACTGTGCGCCTGCGGTTCCAAAAAGTCCCGCAGCAGCGCAAGCTGTT  
 60 TTTTCGGGTGCGCTTCGGGAACACGGATTTTCAGACGGCATCAGCAGGATTTCGCTGTCT  
 GATGGGCGGTGAGGCAAGCTGTCTGCGGTGGAAGAGGATGGATTTCGGGCGCGGTTTT  
 CGGCAAGTTTCGCGCGCGGTGTTTTTCGCGAGTGTTCGCCAGCAGCGGCTTCGTTTTCAT

ACAGCCAGCGGTTTAGAGCGGAGACGGAGAAGCAGGGTGGGACGCTGATGCGGACGGTAT  
 GTGTGCCGCGGGGGCGGATAATCAGGTTTTCTTGGCAGCGGCTGATTTCGACGGTCA  
 GTTCCATGCGCTCTGAAAGGGTGTGGACAAAGCGCGTACATGCGGTTTCAGACGGCATTTT  
 GCGGCCAAACGGGCGCTGCGCCGGAATAAGCGGTTGTTCGCTTCATGAGATGTTTCGCA  
 5 TTTTCCATCAATTTCGGCTTCGCTGCGCGTTGCGTGCGGGATGTCGACAGATGACGAC  
 GGTGATTTCCCGGGATATTTCAGAAAGGAGTTTTTCGGCCAAATTCGCGCGTGTTCGAG  
 GCGCAGCGGGACGATGTCATCTCAAACATTTCCGCTACGCGCGCGCGAGTTTGTA  
 TTTGCCGCGTTTTCCGGGCGCAAGGCGCGTGCTTCGGGGAAAATGGTAATCCAATAGCC  
 TTTGCTTTTTCGCAACCAACCCCTGTTTTATGAGCTGCTCGTTGGCTTCGCGCGGGTGT  
 10 GCGGTCTATGCCCTATGTTTTGACACAGTTTCAAGCCCCAGCCGAAAAGGGGATTTTGAA  
 CAATCGCGTTTGGCAACGTAACCTGCGCGCGGAAAAATGCTCTGAAGGGCGAGCGTTTC  
 CCAGCGCGCTTTGGTGTTCGCGCAGATGACGGCGGGCGGTGCGGGATGTTTTCCGCGCC  
 GATGATGCGGATTTGAGCCCGACGATGTGTTTGAAGCAGCGTTGAGAAATGCCGACCA  
 GACCGCGCCATCTTGTGCGCCCGTCCCGGAAAGGCGAGGCGAGCAGCATAAAGGGA  
 15 GAGGAAAATCAGGGTGGAAACAGAGATACGACGAGTAATCAGGTTGCGGATGATGAGCAT  
 GCTTTTCCTTTCGGAATGCGGTATGTTTCAGTCGCGTTGCGGTGCGGTGTTTTCTCGCA  
 TGATGTATTGTGAGAAATCGAGCAGGATACGAAACCTGTGTGTGTTTCGGGCAATTGCT  
 TGCCTGTTCGGAGAGCGTTTTTTTGCCTTTCCGCTCAGAACACGCGCGGGTTTCGCGC  
 CGACGCGCATGATTGCTGCAAAATCGCGCAGGCTGTCCGCGACGACGCGGTTTCGAGG  
 20 CTTGGGCGTTGAAGCGTCCGATGATGCTTCAATCATACCCGGTTTGGCGTTTCGGGAGAT  
 TGCAGTTTCGCGCATCGGTGTGCGGCGAGAACGAGATGCGGTGATTTTCGCGCGCTGCT  
 GACGGACGAGCGCGTGCAATTTGGCGTGCAATTCGCTAAGGTTTTGAACGGTAAAAATTT  
 TGGCGCGAGTCCGGGATTTGGTTGGTGGCAACGGCGACGGTGTAGCCTGCTGCGCAGAA  
 25 ATGCCACCGCATCCATGCTGCTTCGACAGGATACCACTCGTCAACGGATTTGACGAGAT  
 CGTCCGGCTCTGATTGATGACGCGCTGCGCGTCSAGAAATGATGAGTTTCATCGCGTTTC  
 CTTTGGATTGGGGCAGGTGCGGGGTGGCATTATATCTGAATATCGGTGGAAATGCGCGCT  
 TGGCGCGGATAACGCGCTGTTCCGCGCAACCCGTTGCAATGCGCGGATCGCGCTTTTCG  
 GGGCGGTTGCGGATGTTTTCTGCTGCTGCTCCTGCAACGCGGATTTCTGCGCGGACGTA  
 30 TTTTCGCTGCAAAAGTCTCGGCGCGGAAGTTCGGGGCAATGCGGTTTGGGAGCGCGGT  
 CAGGCGGCAAGCATTTCAAGAATCAGCCGATGTGTTTGTCTAAAGCCGGGTTGTAGTTC  
 AGTGC CGCATCGGTCGGACAGCGCGGTGTCGCGCTGTTTTTAAGCTGACGCGTTTG  
 GCAACGGTTGCGCCAGGTTTTCCGGGTTTTGGCGTGAGAAAAAGAACCGCGCTTCTTCG  
 TTCATGACCTCTGATACATGCCATGTTTTTCGAGAGGACGACGCGTGTGCCCATAGGACG  
 35 GATTTCGACGCGGACGAGCCGGAAGGTTTCGTACAGGGAAGCCATAATGTAAGATCGGCG  
 GCGCGTAGAGTTTCGGGCATATCGGTGCGAAGCCAGTCCGACGACGTTTTTCATAGGG  
 CGGGGAGCGGGGAGCCGACAAACGCGGAGCTTGACGGGCGAGCTGGTATGTTGCAAAAAG  
 TCGGCAAGCAGTTCCAGACCTTTGCGCGTGTGGCGGTCGATGGGAACAGGAAAACGGT  
 TCATGTCGCGCAAGCGTATTTGGCGCGCAGGTGCGCAGTTTTCTCGGGTTGTGGAAG  
 40 AAGCGTTCGATCTGCGGGGGGGGGGGCGACTTGGATTCCTTCAGGGGGAACGCGGTA  
 CAGTCGACCAAGTTTCGCGCCGATCATATGGGAATGCGCCATAATCAGTTTGGCGGTGGC  
 GTAGTTGCTGCGGTTGCGGCGATGCGGAGGCGGTCGAGCAGGTTTCGTTTTTCGCGCAT  
 ATGTGCGAGGTAGCCCAAGTGTGTGCGCGCGAGATGAGGAGTTCGCGTATTCGCGCGTG  
 TGGCAGCAATCAGTTTGGCGGCACTGTTTTTTCGTTTTCGAGCGAGCGCGCTTGAAAA  
 45 GAGGAATGAGCGTATTTTTTCAGCGTCCGCTGTGATGCAAGAATGGGGTTTCGATTAG  
 GCGGATTCAGGAATGCTGTGATCAAAATTCGTCGCAATAAACGGCGCGTGTGATGTTTTG  
 TCTGTTTCAGACCTTTACCAAAATCCAATGTGTAGCGTTTCGCTGCGCGCGCGTGTGTTGA  
 GTGTTGTTGTCGAATGCTATTTGAGCTTCATCATTTGTCCTTTATGTTGCGTCCGCG  
 TTTGTCGGGCGGATTTGTGCTGAGGGGCGAGGTAATGCGCTGTGTGCGCGAATACGG  
 50 TTTGCCGTTTGTTCGGCAATGCGCTCTGAAGCGCGCGCGGGCTTCAGACCGCATTTTTCG  
 CTTATCTCTTAAATACGGGGACGAGTTCCATTTGGCTCAATACCTGTGCGCGCATGTTG  
 ACAGTCGGAAAGGAAGACCAAAACATCAGCCACAGCGCGGTAACCTTTATAGGTTT  
 TTGCTGCGCGCAATTTTTTTCGCGCAACGGTAGACGACATGCGCGGGATGATCGTTGTC  
 CAGACGCTTTCGCCACAGGCGACGTAGCCGATGCGGTAACGAAGCGGTGGGGAAGAGC  
 55 AGGCAAGAAATCAGGGGCGCGAGGAAGTTCAGCGCGCGGTTTTGTTGCGCGCGGAGATG  
 CTGTGCTTCCATTTGAAGATGTCGCGGATGATGTCGAAGATGCGAGCGTTACGCGCTAAA  
 AACGAGGTGGCGATCGCCATATAGGAAAAACAGGGACATATTTGTCCATATTCGCGGTT  
 TGGGCGAATTTGACAGCGGTTTCGATGAGGACGGAGACTTGCCTTCGCGCGCATGACG

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

GGGGCGAATCGTTGCGCGGCAGGTTGCCTTGGATGGCGGTTTGCCAGAGGACGTAAATT  
ACCAGCGCAATCAGTGTGCCCGTCCAGATGGATTAGCCACTTTGGGCGCGTCGCCTTTA  
AAGTATTTGAGCAGGCTGGAGACGTTGCCGTGGAAGCCGAAGGAGCGGAGCGAGCGGGC  
AGGGCGGTTGGCGCGTAAATCCAGTAGTTTGTGCGCGCGGGGGCTTGGGTATCGAAGAGG  
ACGAGCGGCTTGGCATCGGCAATCAGCCGCGCGGCCCAAAATAAAGCTCAATACCATG  
CCGCGGATAAAGACCGCGGTGAAGCGGTGCACCAAGCGTGCGGATGCCATACGCAAAAG  
GCGAGGATCGCGAAGAAGACGAGTTGTCCGACGGTGAATGAAACGTGCCCGCTGCCGCG  
CTCGCTAAGCCTTTGCGGTCAGGTGCCGCGGCAAGATATAAGCGTAAGTAAAGCAG  
TATAAAGCAAGGCGAGCGCGATGCCGTTGATGATGTTCCAGCGCGTCCGAGCAGGTCT  
TTGACCATCGTTCGAAACTTGGCGCGTGCAGATAATGGTGTGACTTCCAAAATCAT  
AGSCCGCTGGAAGCATAGAAAACAGGTGTACAGCAACACGGCAGCGAGCGGTAAAC  
CATACCGCGGATGTGCGGTCGGGTTGCGGAGCATGCCTGCGCGATGACGCTGCCGCG  
ATAATCATCGCGCGCGCAACAGTGAAGGGGTTTTGTTGGGCATATTTGTCTTTCTGCC  
AGAAAAAGCGAGCCGCCATTTATGCCGTAAAGTGAAGGATTGTAAAGTATTTGCGCGC  
GCCGCCGAAAAGSCTTTCAGACGCGATTGTGTTCCATAGTATAATCTTGGGTTTTGGAG  
TGGCGGGTTTCGTAGATGCGAGGGAATGTCCGACMAAAAATAAATGTCCATGAGGGG  
GAAATCGCCAAATTCAGCGGATTCGCGACAAATGCTGGGCAAGTCCGCGAGTTCAAA  
ACCTTGCACGACATCAATCCGCTGCCGCTGGATTATATGACGCGACAGCGGATTTGTCG  
GGCAAAOCCGSTTTTGACGTGGGCTGCCGCGCGGCATCTTGGCGAAAGTATGGCGCGG  
CGCGGGCGCGGCTTTGTAAGGGCATCGACATGGCGGAGCAGTCTTGGAAACCGCCCGC  
CTCAGCGCGGCTTTGAACAATGTCCCGGATATCGAATACGAATGTATCCCGTGAAGAC  
CTTGGCGAGGCGAAACCGCATCGTTCGATGTGTTAACGTGCATGGAATGATGGAACAC  
GTCCCGCATCCCGCGCCATCGTGGTCTTGTGCCAATCTGTGCAACCGGACCGGACATG  
GTGTTTTTTCCACCATCAATAAAAACCCGAATCGTACCTGCATCTGATTGTGGCGGCG  
GAAATATCTGTGTAAGTTTGTCCCAAGGCGACGACGACTGGAAAAAATTCATCCGACCT  
CGCGAGCTGGCGGAATGTGCGCTCAGGCGAGGCTTGGATGTGGCGGATACGAAGGATG  
ACTTACCATGTGTTTCGCAAACTTATGCCCTGTGGATTCGACCGATGCAATTATATG  
TTTGCTTCCGCTCCGGCTTCTGACGCGGGTTTGCCCGTTTTTGAGCAAGTGAAGTGTAT  
ATGCTGTCTATACCAAGTGTTCGATGATGAATGCGCGGCTTCTGAGCGGTTACGAT  
TTGGGGGAATTTGTTCCCTCGAGGGCATCGCGAGGGGATTACCAACAGCAATATTTTT  
CTGACGACGACTTCGGGACGTTATGTGCTGACCGTGTGTAAGTGTGAAACAGGAAGAG  
CTCCGCTTTTTCTGGAGCTTAACCGGCATTTAGTATGAAGGGCGTGGCGGTTGCCGCG  
CCGTTTGGCGCAAAAGACGCGCGGCTTGATTCGCTTTTGGCGGGTAAGCCTGCCCTGCTG  
GTTGCTCGCTGAAAGGTTGCGATACCGCGCTGCCGAGGCTGAGCAGTGTTTTATACC  
GGTGGCATGTTGGCGAAAATGACACTTGGCGCGCGGATTCCTTTTGGAAATGGAAGAAC  
CCGCGTTACAAATGCGTGGTGGACGGAGGCGTGCGCCGCGCTGCTGCCGCTCTGTGCA  
GAGCATGGCGCACTGCTGTGTTCCGAAATCGATGCGTGAAGGCAAACTCTCGGCATCAT  
CTGCCTTCGGGCATCATCCATGCCGATCTGTTTAAAGACAATGTTGCTTGACGCGGT  
CAGGTATCGGCTTCATCGATTCTATTACGCTTCCGCGGCAATTTTATGTATGACTTG  
GCGATTTCGGTCAACGATTGGGCAAGGACGGCGCAATAAGTTGGATGAGGCGTTGAAA  
AAGCGGCTTTATCGCGGTTATGAGGGCGTGCGCCCTTGAGTGGCGAAGAAAGCGGAT  
TCTCCGACCGCCCAACGTCGCGGCTGCATCCGTTTTTGGGTGTGCGCGCTGTGGATT  
CATTTTCCGCGAGGCGGCGAGATGACGTTTATCAAGACCCGAACGCGTTCCGCAACCTG  
CTGTTGAGTTTGGGTTGAGTGGTCCGCGCTTTGACAGAAATGCCGCTGTAAGGGGTTTC  
AGACGGCATTTTATGGCTGATTAAACGAAATAGACGATAGCCGGGATTTTCCATT  
TTATAGTGATTAACAAAATCAGGACAAGGCGACGAAGCCGACAGTACAGATAGG  
CGGAAGGATTCACTTGGTGCTTCAGCACTTAGAATCGTTCTTTCGAGCTAAGGCG  
AGGCAACGCTGACTGGTTTTGTTAATCCATATAAATCAATGTAATCCATTCTGTCC  
CGATGTTTATCGCGTCTGAAACCCATCCTGTGCGGCTTCAGACGCGATATTGCTTCAA  
AGCAGGTTTCCGAGGCAACCCAGTTCAAGAAATCGGCTTCGACCGCTTCCGCGCTGCGG  
GGGTTGGCGATTTCGACCCGATATTCGCGCTTCGCCAGTTCCTCGAGGATTTCCAGTTGC  
GATTCGAGCATCCCTGCTTTCATGTAATGTCTTTTGGCGACATCATGCGCTCGAGGTTG  
ATGCTTTCGCGCGGACTGAGGTGATGAAGGCAGCTTTGCGCTTCGCTCCGCGCAGAAATG  
TCCGCTTAGCCCGGTTTGGGCGGAACAGGTTACGATGGTGTGGTTCCGACCTTTTGC  
GCTGTGCGTTCATCCAGTCGCGCAGATTGCCCAACACCGGATAGCGGCTTTCATCGGTC  
AGCGGAATACCGCGCCCATCTTGTGCGGTTGGCTTGGGTGGGAGTGGAACTCGCGCTTCG  
GCATAGGACATGACCGAGGTGTTTTCGAGGACAGCGCGCGGTTGCTTCCCGCAG